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Preface 
Embryonic stem cells have immense therapeutic potential, but for cell therapy these
pluripotent cells will have to be differentiated towards cells of interest before 
transplantation. Controlled, robust differentiation processes will require knowledge of
the signalling pathways and mechanisms which will obviously be unique for each
differentiated cell type. There are a tremendous variety of approaches and techniques, 
and this book, Embryonic Stem Cells - Differentiation and Pluripotent Alternatives and its 
companion, Embryonic Stem Cells - Basic Biology to Bioengineering, serve as a snapshot of
many of the activities currently underway on a number of different fronts. 
This book is divided into eight parts and provides examples of the many tissue types 
that embryonic stem cells are being pushed towards, as well as alternative sources for 
pluripotent stem cells.
Part 1: General Differentiation
Chapters 1-3 present a number of different aspects of embryonic stem cell
differentiation including signalling pathways, epigenetic factors, bioactive lipids and
retinoid signalling.
Part 2: Neural and Retinal Differentiation
Chapters 4-7 examine how neural cell types are generated from embryonic stem cells,
including looking at some interesting imaging techniques and a review of stem cell 
therapy for retinal diseases. 
Part 3: Cardiac and Other Myogenic Differentiation 
Chapters 8-12 present a number of aspects of cardiomyocytes differentiation including
detailed characterization of the differentiated cells. In addition the use of ESC-derived
myogenic cells for neuromuscular diseases is discussed. 
Part 4: Endothelial Differentiation 
Chapters 13-14 describe endothelial differentiation with a focus on the signalling
transduction pathways involved.
Part 5: Hepatic Differentiation
Chapters 15-16 examine another interesting application of embryonic stem cells for 
hepatic tissue engineering.
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Part 6: Osteogenic Differentiation 
Chapter 17 looks at osteogenesis and the developmental path from pluripotent cells to 
osteoblasts. 
Part 7: Pluripotent Alternatives Induced Pluripotent Stem Cells (iPSCs) 
Chapters 18-21 discuss induced pluripotent stem cells (iPSCs) starting with a great 
review of the iPSC story to date. The next chapters present new techniques to generate 
iPSCs including from cord blood cells. An interesting application of iPSCs in the 
modelling of neurological diseases is described as an example of one of the many uses 
of these cells. 
Part 8: Pluripotent Alternatives Other Cell Sources 
Chapters 22-25 describe alternative sources of pluripotent stem cells. These include 
very small embryonic/epiblast like stem cells, multipotent dental stem cells, 
pluripotent stem cells from testis and amniotic fluid stem cells. 
In the book Embryonic Stem Cells - Differentiation and Pluripotent Alternatives, the story 
begins with a foundation upon which future therapies and uses of embryonic stem 
cells can be built. 
I would like to thank all of the authors for their valuable contributions. I would also 
like to thank Megan Hunt who provided me with much needed assistance and acted 
as a sounding board for early chapter selection, and the staff at InTech, particularly 
Romina Krebel who answered all of my questions and kept me on track during the 
entire process.  
Calgary, Alberta, Canada, September 2011  
 
Michael S. Kallos  
Pharmaceutical Production Research Facility (PPRF),  
Schulich School of Engineering, University of Calgary, Alberta,  
Canada  
Department of Chemical and Petroleum Engineering,  
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Role of Signaling Pathways and Epigenetic 
Factors in Lineage Determination During Human 
Embryonic Stem Cell Differentiation 
Prasenjit Sarkar and Balaji M. Rao 
Department of Chemical and Biomolecular Engineering,  
North Carolina State University, Raleigh, NC,  
USA 
1. Introduction 
Human embryonic stem cells (hESCs) are culture-adapted cells that were originally derived 
from the inner cell mass (ICM) of the blastocyst-stage embryo [1]. HESCs are pluripotent 
cells that can be propagated indefinitely in culture, while retaining the in vivo properties of 
ICM cells; they can give rise to all tissues of the three germ layers (ectoderm, mesoderm and 
endoderm). Due to their pluripotency, hESCs have been the subject of intense research since 
they were initially isolated in 1998. HESCs can serve as model systems to study early human 
development, in addition to providing a potentially unlimited source of functional tissues 
for use in drug evaluation and regenerative medicine. Nevertheless, despite major advances, 
the exact molecular mechanisms that govern the self-renewal and differentiation of hESCs 
remain unclear. Indeed, a mechanistic understanding of the molecular processes regulating 
hESC fate can elucidate early events in human development and enable the development of 
protocols for efficient generation of functional tissues. Here we review the molecular 
mechanisms that regulate hESC fate; specifically, we focus on the role of signaling pathways 
and factors regulating epigenetic changes, in hESC self-renewal and lineage-specific 
differentiation. 
In hESCs, as in embryos, differentiation is triggered by developmental cues such as 
morphogens or cytokines that are present in the extracellular space. These morphogens or 
cytokines bind to their cognate plasma membrane-bound receptors and activate specific 
signaling pathways inside the cell. Activation of signaling pathways involves a sequence of 
phosphorylation events that eventually result in the regulation of specific transcription 
factors. These transcription factors, in turn, can recruit other co-factors and directly cause 
transcription of downstream genes. Furthermore, transcription factors can recruit histone 
modifying and chromatin remodeling enzymes to reshuffle the epigenetic structure, such 
that pluripotency genes become inaccessible for transcription and are repressed, whereas 
lineage-specific genes become accessible and are activated. This sequence of events finally 
leads to expression of lineage-specific proteins such as transcription factors and structural 
proteins, causing a morphological change in the cell. Also, pluripotency associated 
transcription factors and other pluripotency-associated genes are permanently repressed, 
thereby completing the process of differentiation. Thus, the process of differentiation is a 
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rather complex cascade of events, controlled by signaling pathways, transcription factors, 
epigenetic factors and lineage-specific proteins. While significant understanding of each of 
these functional groups (i.e., signaling pathways, transcription factors, epigenetic factors 
and lineage-specific proteins) has been gathered in isolation, very little is known about the 
interactions amongst these groups, particularly in the context of hESC differentiation. In 
part, interactions amongst these groups confer lineage specificity to the process of 
differentiation and mediate the development of specific tissues upon exposure of hESCs to 
certain morphogens. In this review, we focus on the role of signaling pathways, 
transcription factors and epigenetic factors in the context of lineage-specific differentiation 
of hESCs and summarize the various links between these groups. Our goal is to present a 
mechanistic overview of the sequence of molecular events that regulate the differentiation of 
hESCs along various lineages.  
2. The signaling pathways 
As briefly described earlier, the self-renewal and differentiation of hESCs is governed by 
several developmental cues. The most well known among these are cytokines that trigger 
specific signaling pathways. These extracellular ligands initiate signaling through 
interactions with ligand-specific cell surface receptors. Receptor-binding typically results in 
association of multiple receptor subunits and activation of the kinase domains of receptors 
or other receptor-bound effector proteins. This triggers a sequence of phosphorylation 
events involving various other proteins, finally resulting in the activation or inhibition of 
transcription factors. These transcription factors in turn are directly responsible for 
activating or repressing their target genes. Thus, a group of signaling pathways is usually 
responsible for modulating gene expression in hESCs, leading to control of the 
transcriptome, the proteome and ultimately cellular physiology. In this section, we 
summarize key signaling pathways that have been implicated in the maintenance of 
undifferentiated hESCs and their lineage-specific differentiation.  
2.1.1 The transforming growth factor-β pathway 
The transforming growth factor  (TGF-) pathway is well known for its involvement in 
embryonic development and patterning, as well as in epithelial-to-mesenchymal 
transformations and carcinogenesis [2-3]. This pathway (extensively reviewed elsewhere [2, 
4-5]) is divided into two branches: the Activin/Nodal branch and the Bone Morphogenetic 
Protein (BMP) branch. The Activin/Nodal pathway is activated by ligands such as Activin, 
Nodal and TGF1. These ligands bind to their Type II receptor, which then recruits the Type 
I receptor. The Type II receptor phosphorylates the intracellular domain of the Type I 
receptor, creating a binding site for SMAD2 and SMAD3 transcription factors. Upon 
binding, SMAD2/3 is phosphorylated by the Type I receptor, leading to subsequent 
dissociation of SMAD2/3. Phosphorylated SMAD2/3 then associates with SMAD4 and can 
enter the nucleus to modulate gene expression. The BMP branch is activated by the BMP 
ligands; binding of BMP ligands results in phosphorylation of the type I receptor by the type 
II receptor, and subsequent intracellular binding and phosphorylation of SMAD1/5/8. 
Phosphorylated SMAD1/5/8 forms a complex with SMAD4 and subsequently enters the 
nucleus. Unlike ligands in the Activin/Nodal branch, the BMPs have high affinities for the 
type I receptor and bind weakly to the type II receptor; Activin/Nodal bind with high 
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affinity to their type II receptors and do not directly interact with their type I receptors. 
Numerous other proteins can modulate the localization and activity of SMADs (reviewed in 
[6-8]). Additionally, the activated TGF pathway receptors can also activate the Mitogen 
Activated Protein Kinase (MAPK) Pathway [9]. 
2.1.2 Role in lineage determination 
The TGF pathway plays a significant role during embryogenesis across many species 
including flies, fishes, amphibians and mammals (reviewed in [10]). Specifically among 
vertebrates, Nodal is expressed throughout the epiblast [11] and is required for specification 
of mesoderm and endoderm from the epiblast [12]. Low levels of Nodal lead to mesoderm 
formation whereas high levels lead to endoderm formation [13]. Absence of Nodal signaling 
through active inhibition leads to ectoderm formation [12, 14]. Within the ectoderm, high 
levels of BMP cause formation of epidermis while low levels cause neural plate formation 
[15]. Intermediate levels of BMP lead to neural crest formation at the borders of the neural 
plate, although this a necessary but not a sufficient condition [16].  
Not surprisingly, in vitro protocols for differentiating hESCs resemble in vivo conditions 
present during embryogenesis. Specifically, Activin causes endoderm differentiation from 
hESC cultures, while Activin and BMP simultaneously lead to mesoderm formation [17-21]. 
Inhibition of both Activin/Nodal and BMP causes neural differentiation [22] and this 
differentiation proceeds through an epiblast-like intermediate. Intriguingly, some amount of 
Activin/Nodal signaling is essential for hESC pluripotency; the pluripotency factor Nanog 
is a direct target of Smad2/3 [23-25] and inhibition of Activin/Nodal causes upregulation of 
BMP and subsequent trophectoderm differentiation [26]. Short term BMP treatment causes 
mesoderm formation [27] whereas long term BMP treatment leads to trophectoderm 
formation [28]. The disparity of BMP treatment leading to trophectoderm differentiation and 
not epidermal differentiation, as during embryogenesis, can in part be attributed to the fact 
that hESCs are derived from ICM cells and not epiblast cells. Thus, even though in vivo 
embryogenesis serves to provide guidelines for carrying out in vitro differentiation of 
hESCs, major challenges still remain. The biggest of these challenges is perhaps the 
heterogeneity in lineages of differentiated cells obtained through most in vitro protocols. 
This is primarily because most differentiation protocols rely on embryoid body (EB) 
formation which results in a heterogeneous environment for cells within the EB, and leads 
to heterogeneity in the lineages obtained after differentiation. Another challenge is the 
inability to form an absolute mechanistic link between the culture conditions used to 
differentiate hESCs, and the differentiation behavior seen in hESCs. This is mostly because 
the composition of serum, B27, serum replacer, conditioned medium and other components 
of media used for differentiation studies, are unknown [29].  
2.2 The Fibroblast Growth Factor pathway 
The Fibroblast Growth Factor (FGF) pathway is also known for its involvement in 
embryonic development and patterning, as well as in regulation of cell growth, proliferation 
and motility (extensively reviewed in [30-34]). The FGF pathway is activated when the FGF 
ligands, which have a strong affinity for Heparan Sulfate Proteoglycans (HSPGs), bind to 
FGF Receptors (FGFRs) forming a 2:2:2 combination of FGF: FGFR: HSPG on the cell 
surface. The ensuing receptor dimerization causes transphosphorylation of tyrosine residues 
in the intracellular domains of FGFRs through their tyrosine kinase domains. The 
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rather complex cascade of events, controlled by signaling pathways, transcription factors, 
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nucleus. Unlike ligands in the Activin/Nodal branch, the BMPs have high affinities for the 
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affinity to their type II receptors and do not directly interact with their type I receptors. 
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mesoderm formation [27] whereas long term BMP treatment leads to trophectoderm 
formation [28]. The disparity of BMP treatment leading to trophectoderm differentiation and 
not epidermal differentiation, as during embryogenesis, can in part be attributed to the fact 
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phosphorylated tyrosines of FGFRs cause recruitment of the GRB2/SOS complex and its 
subsequent activation. SOS then activates RAS, which triggers the MAPK cascade, finally 
leading to the activation of extracellular-signal related kinases (ERKs). Activated Erk1/2 can 
phosphorylate and control the activity of a wide range of proteins [35]. Notably, Erk1/2 can 
phosphorylate the linker region of SMAD1 and inhibit BMP signaling [36-37]. Additionally, 
activated FGF receptors can also recruit FRS2/GRB2 and activate them, leading to 
recruitment of GAB1. GAB1 activates the Phosphatidylinositol 3-kinase (PI3K) pathway. 
Thus, FGF can also activate the PI3K pathway in a cell-specific context. 
2.2.1 Role in lineage determination 
The FGF pathway is needed for proper embryonic development in vertebrates. Experiments 
in mice have shown that FGF4 is required for ICM proliferation and maintenance [38-39], 
and for trophectoderm and primitive endoderm development [40]. FGF4 is secreted by the 
ICM and supports trophectoderm maintenance [41]. Interestingly, activation of HRas1 
which is a component of the MAPK pathway, in mouse embryonic stem cells (mESCs) 
caused upregulation of Cdx2, a trophectoderm marker, and trophectoderm stem cells were 
derived from these mutants [42]. FGF4 secreted by ICM also causes primitive endoderm 
differentiation [43]. Further along the developmental timeline, FGF signaling is required for 
the induction of paraxial mesoderm and for maintenance (but not induction) of axial 
mesoderm [44-46]. FGF is required for primitive streak formation and cell migration during 
gastrulation [45, 47]. Inhibition of FGF is required for blood development [48-50], whereas 
activation of FGF signaling is required for neural differentiation [51]. However the 
mechanism by which FGF aids in embryonic neural differentiation is not fully understood 
[52-53]. In vitro studies have mimicked the role of FGF signaling in hESC maintenance and 
differentiation. FGF2 is required for maintaining hESCs in a pluripotent state [24, 54-55]. 
FGF signaling is also required for maintenance of mouse trophectoderm stem cells which 
are derived from the trophectoderm tissue of mouse embryos [56]. While there are no 
specific studies which delineate the inductive and maintenance/proliferative roles of FGF 
during hESC differentiation, work with mESCs have given ambiguous results, some 
showing that autocrine FGF2 is essential for neural differentiation [57] while others showing 
that FGF2 has a role in maintenance rather than induction of neural differentiation [58-59]. 
However, FGF signaling does seem to be necessary for inducing the posterior nervous 
system in vertebrate embryos [53, 60].  
2.3 The Wnt pathway 
The Wnt pathway is widely implicated during various stages of embryonic development, 
homeostasis as well as in cancer. This pathway (reviewed in [61-62]) has canonical and non-
canonical branches. The canonical Wnt pathway is activated by binding of Wnt ligands to 
the Frizzled receptors and low-density lipoprotein receptor-related protein 5/6 (LRP5/6) co-
receptors leading to the recruitment of Dishevelled to the Frizzled receptor. This causes 
recruitment of Axin to the receptor complex, causing the subsequent deactivation of Axin. In 
the absence of Wnt signaling, Axin associates with GSK3, adenomatous polyposis coli 
(APC), casein kinase 1 (CK1) and -catenin. CK1 and GSK3 phosphorylate -catenin 
causing it to be degraded. Upon Wnt activation, Axin is inhibited and -catenin becomes de-
repressed, and subsequently enters the nucleus to function as a transcription factor. Various 
co-factors associate with -catenin and control its promoter specificity, thus dictating the 
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target genes activated or repressed by -catenin [63-64]. The non-canonical Wnt pathway 
acts independently of -catenin and is also required during embryogenesis. The details of 
this Ca2+-dependent pathway are reviewed in [62]. 
2.3.1 Role in lineage determination 
The canonical Wnt pathway is activated during gastrulation [65] and mutation of Wnt3 
blocks primitive streak formation resulting in lack of mesoderm and endoderm [66] (the 
primitive streak-specific transcription factor Brachyury is a direct target of Wnt3a signaling 
[67]). Similar defects are seen in Lrp5/6 double mutants and -catenin loss-of-function 
mutants [68-69]. Interestingly, expression of Cripto, a co-receptor for Nodal signaling, is 
missing in -catenin loss-of-function mutants [70]. Also, -catenin is indispensable for 
endoderm formation and loss of -catenin causes definitive endoderm to change into pre-
cardiac mesoderm [71]. Although loss of Wnt signaling leads to loss of mesoderm 
formation, inhibition of Wnt signaling is required for a cardiac fate [65, 72], once pre-cardiac 
mesoderm has been induced. Remarkably, similar reports for the role of Wnt signaling have 
been obtained through in vitro differentiation studies in hESCs. Over-expression of -catenin 
in hESC cultures lead to primitive streak formation [73]. Inputs form Activin/Nodal and 
BMP pathways are necessary for further lineage specification into mesoderm/endoderm. 
Blocking BMP signaling abolishes mesoderm and leads to endoderm formation, whereas 
Activin/Nodal is required for endoderm formation [73]. Wnt is required for mesoderm 
differentiation but must be inhibited thereafter for cardiac mesoderm formation [74]. 
2.4 The Phosphatidylinositol-3Kinase pathway 
The Phosphatidylinositol-3Kinase (PI3K) pathway regulates cell survival, apoptosis and has 
been implicated in cancer. The pathway as well as its role in cancer is reviewed in [75-78]. It 
also has been, in select cases, implicated in lineage-specific hESC differentiation [79]. The 
pathway is activated when PI3K is phosphorylated; this can happen through binding of 
Insulin to the Insulin receptor or of Insulin-like growth Factor (IGF) to Insulin-like Growth 
Factor Receptor (IGFR), or as previously discussed, by recruitment and activation of GAB1 
by FGFR. Activated PI3K phosphorylates Phosphatidylinositol (4, 5)-biphosphate to 
Phosphatidylinositol (3, 4, 5)-triphosphate and creates a docking site for proteins with a 
pleckstrin homology (PH) domain, such as Akt. Once Akt is properly docked, it is 
phosphorylated and activated by protein-dependent kinase 1 (PDK1). Akt can then 
dissociate and activate/repress numerous proteins by phosphorylating them [80]. The PI3K 
pathway has not received much attention during vertebrate embryogenesis, though some 
recent studies have emerged to show that it is necessary for normal embryo development 
[81-82]. Homozygous null mutations in the p110β subunit of PI3K cause embryonic lethality 
before formation of the blastocyst [83]. Thus, in vivo studies do not implicate PI3K signaling 
in differentiation of cells, but rather in maintenance of cell viability [82]. It has been 
hypothesized that growth factors maintain PI3K signaling during embryogenesis to guard 
against ectopic or metastatic growth of cells, since such ectopic/metastatic cells do not 
receive enough growth factors and enter the default apoptotic pathway [84]. In contrast, in 
vitro studies with hESCs have shown some supportive role for the PI3K pathway in 
definitive endoderm differentiation. Inhibition of PI3K signaling enhances definitive 
endoderm differentiation by Activin [85]. Other conflicting reports show that PI3K signaling 
stabilizes -catenin during definitive endoderm formation [73]. A major challenge in 
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elucidating the possible role of this pathway during differentiation is the inability to 
decouple its role in cell viability. Therefore, careful studies need to be designed to assess the 
extent of its role in causing differentiation. 
2.5 The Hippo pathway 
So far we have focused on developmental cues in the form of morphogens, i.e. protein 
ligands that physically diffuse through the embryonic tissue and pattern the embryo. 
Another developmental cue that has recently emerged to be of significant importance 
during embryogenesis is cell-cell contact. An increase in cell-cell contact is sensed by the cell 
through the activation of the Hippo pathway (reviewed in [86-87]). The Hippo pathway is 
important for organ size control, tumorigenesis, epithelial-to-mesenchymal transformation 
and cell-cell contact inhibition. Although the molecular mechanisms of cell-cell contact 
sensing are not fully understood, an increase in cell-cell contact is known to ultimately lead 
to phosphorylation of MST1/2 kinases. They then associate with SAV1 and phosphorylate 
the LATS1/2 kinases. Upon phosphorylation, LATS1/2 kinases recruit MOB1 and 
phosphorylate YAP and TAZ, both of which are homologues with non-redundant functions 
[86, 88]. Phosphorylation of TAZ and YAP leads to their association with 14-3-3 proteins and 
subsequent cytoplasmic retention [89-90]. YAP and TAZ act as co-factors for various 
transcription factors such as TEADs, RUNX, PAX3 and SMAD1/2/3/7 and modulate their 
nuclear localization and/or activity [91-96]. Additionally, TAZ can associate with DVL2 and 
inhibit its phosphorylation by CK1, thus possibly inhibiting -catenin activation by Wnt 
factors [97]. Therefore, the nucleocytoplasmic shuttling of YAP and/or TAZ can lead to 
changes in the activity levels of associating transcription factors, leading to differentiation 
[93]. Indeed, low cell-cell contact at the periphery of the embryo leads to Yap activation, 
which in concert with Tead4, leads to trophoblast differentiation in mouse blastocysts [98]. 
The inner cell mass and epiblast tissues show predominantly cytoplasmic and weakly 
nuclear localization for Yap, Taz and phospho-Smad2 [98-99], in agreement with the fact 
that Taz controls Smad2 localization [93]. While cells of the mouse ICM continue to 
differentiate, in vitro cultures derived from ICM (i.e. mESCs) maintain high levels of Yap. 
Yap is downregulated during in vitro mESC differentiation and upregulated in mouse and 
human induced pluripotent stem (iPS) cells [100]. Ectopic Yap expression maintains mESC 
phenotype even under differentiation conditions. Though it remains to be seen whether 
downregulation of Yap/Taz is the cause of differentiation of ICM cells in vivo, experiments 
with hESCs show that downregulation of TAZ initiates neural differentiation [93]. Tead and 
Yap suppress terminal neuronal differentiation and maintain neural progenitor populations 
in the vertebrate neural tube [94]. Tead2 and Yap activate Pax3 expression during neural 
crest formation [101]. Tead1/2 and Yap also maintain the notochord which is formed from 
the axial mesoderm [102]. Thus the co-activators YAP and TAZ are important for the activity 
of many transcription factors during embryogenesis. However, further studies are needed to 
uncover the specific inductive/maintenance roles of these co-factors and their 
responsiveness to Hippo signaling in these tissues. 
2.6 Crosstalk between signaling pathways 
There is a vast amount of crosstalk between the various pathways described here, thus 
adding additional complexity in the regulation of downstream transcription factors [103]. 
As described earlier, the TGF-β pathway can activate the MAPK pathway directly 
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downstream of receptor activation [9]. Both TGF-β and FGF pathways can activate the PI3K 
pathways directly at the receptor level [9, 30]. However, the crosstalk between pathways is 
cell-specific, since the available pool of interacting proteins depends on the cell-type. Also, 
the promoter accessibility of downstream genes is dependent on cell-type. Therefore, here 
we restrict our discussion to crosstalk events identified specifically in hESCs. Activin/BMP 
signaling induces Wnt ligand expression in hESCs [74]. Also, Activin regulates FGF, Wnt 
and BMP pathways in hESCs [104]. Inhibition of Activin/Nodal signaling causes 
downregulation of Wnt3, FGF2, FGF4 and FGF8 expression [26] and upregulation of BMP 
signaling [26] while activation of Activin signaling causes upregulation of Wnt3 and FGF8 
expression [104]. Interestingly, upregulation of Activin signaling also causes upregulation of 
Nodal and Lefty expression. Cerberus1, an inhibitor of Nodal signaling, is a downstream 
target of both Wnt and Nodal pathways in hESCs [105]. Expression of Cripto, a co-activator 
of Nodal signaling, is upregulated by FGF signaling in hESCs [24]. As described earlier, 
YAP, which is regulated by the Hippo pathway, controls the nuclear localization of Smad2 
in hESCs [93]. Thus, it can be seen that hESCs exhibit considerable endogenous signaling 
wherein, signaling pathways not only control their own ligand expression but also the 
expression of ligands of other pathways.  
3. Other regulators of differentiation 
While morphogens and other developmental cues act as the environmental input to hESCs 
and trigger the process of differentiation, the molecular mechanisms responsible for 
carrying out differentiation inside the cell are complex and require many key factors. These 
factors are required for the following: 1) to bring about a change in gene expression which 
causes the cell to transition into the new lineage-specific physiology, 2) to reshuffle the 
epigenetic structure of the genome, and finally 3) to make the new epigenetic structure 
permanent, lending stability to the newly formed cellular physiology. We will now discuss 
these intracellular factors that mediate various aspects of the differentiation process. 
3.1 MicroRNAs 
MicroRNAs (miRNAs) have emerged as a new paradigm for regulating gene expression at 
the post-transcriptional level. The role of miRNAs in embryogenesis, stem cell fate and 
cancer is reviewed in [106-108]. Transcription factors regulate promoter regions of miRNAs, 
which upon synthesis can target many mRNAs and lead to downregulation of protein 
synthesis. MiRNAs, which upon transcription are called pri-miRNAs, fold into secondary 
structures with characteristic hairpin-loops. These are recognized by Drosha, which cleaves 
the hairpin-loop structures to generate pre-miRNAs. Pre-miRNAs are then exported to the 
cytoplasm and recognized by Dicer, which cleaves one of the strands and incorporates the 
other into the RNA-induced silencing complex (RISC). Once incorporated into RISC, the 
single-stranded miRNA recognizes target mRNAs (usually many different mRNA targets) 
through partial sequence complimentarily, and causes down-regulation of protein synthesis. 
It is now known that miRNAs play an important role in embryogenesis [109] and lineage-
determination, and that many lineages have their characteristic miRNA expression patterns, 
akin to characteristic mRNA expression patterns [110]. The role of miRNAs in 
embryogenesis is evident from the fact that Dicer mutant mouse embryos die during 
gastrulation [111], while Dicer deficient zebrafish embryos do not develop beyond day8 
[109]. The role of miRNAs in embryonic stem cell pluripotency and differentiation has also 
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the axial mesoderm [102]. Thus the co-activators YAP and TAZ are important for the activity 
of many transcription factors during embryogenesis. However, further studies are needed to 
uncover the specific inductive/maintenance roles of these co-factors and their 
responsiveness to Hippo signaling in these tissues. 
2.6 Crosstalk between signaling pathways 
There is a vast amount of crosstalk between the various pathways described here, thus 
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As described earlier, the TGF-β pathway can activate the MAPK pathway directly 
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downstream of receptor activation [9]. Both TGF-β and FGF pathways can activate the PI3K 
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signaling [26] while activation of Activin signaling causes upregulation of Wnt3 and FGF8 
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been demonstrated recently [107]. Dicer deficient mESCs fail to differentiate in vitro as well 
as in vivo [112]. Over-expression of miR-302 leads to reprogramming of human hair follicle 
cells and human skin cancer cells to form iPS cells [113-114]. During mESC differentiation, 
miR-134, miR-296 and miR-470 target and downregulate the transcription factors Nanog, 
Sox2 and Oct4 [115]. MiR-200c, miR-203 and miR-183 target and repress Sox2 and Klf4, both 
of which are involved in maintaining pluripotency in mESCs [116]. Similarly, during hESC 
differentiation, miR-145 targets and represses OCT4, SOX2 and KLF4 [117]. Sall4, another 
pluripotency-related transcription factor, is positively regulated by the ESC cell cycle 
regulating (ESCC) family of miRNAs and negatively regulated by the let7 family [118]. 
Additionally, miRNAs are also implicated during later stages of differentiation. The muscle-
specific miR-1 controls cardiomyocyte differentiation and proliferation in mice by targeting 
the Hand2 transcription factor [119]. miR-181 controls hematopoietic differentiation in mice 
[120] and miR-143 regulates adipocyte differentiation [121]. MiR-196 is involved in HOX 
gene regulation [122-124] and the miR-200 family regulates olfactory neurogenesis [125]. 
MiRNAs have also been implicated in skin morphogenesis [126]. Most intriguingly, 
transfection of muscle-specific miR-1 or brain-specific miR-124 into human HeLa cells shifts 
the mRNA expression profile towards that of muscle or brain cells, respectively [127].  
The expression of miRNAs is regulated by transcription factors which bind promoter 
regions of genes harboring miRNAs; more than half of known mammalian miRNA genes 
are within host gene introns and are spliced after transcription [128]. For example, Activin A 
signaling regulates the expression of ~12 miRNAs in hESC cultures [129]. OCT4, NANOG 
and SOX2 occupy the promoter regions of ~14 miRNAs in hESCs [130]. Additionally, 
miRNAs can be regulated directly by signaling pathways. In smooth muscle cells, BMP4 or 
TGF-β signaling causes increased processing of pri-miR-21 and pri-miR-199a [131] and 
regulates the processing of numerous other miRNAs [132]. The MAPK/ERK pathway can 
regulate miRNA maturation in the cytosol by controlling phosphorylation of TRBP, which 
functions with Dicer [133]. However, it is largely accepted that miRNAs do not trigger 
differentiation but rather, are required for carrying out the process of differentiation [107]. It 
is hypothesized that miRNAs are required to dampen the stochastic noise in mRNA 
transcription levels of genes during the process of differentiation. Thus, miRNAs add 
another layer of complexity to gene regulation during the process of differentiation, by fine-
tuning active mRNA levels of a gene. 
3.2 Epigenetic factors 
Our discussion on signaling pathways focused on how a change in gene expression during 
differentiation is initiated; while miRNAs are most probably required to stabilize the mRNA 
levels against stochastic perturbations during differentiation. However, to provide long-
term stability to the new gene expression pattern, the epigenetic structure of the genome 
needs to be changed. Epigenetic factors are responsible for modulating the epigenetic 
structure of hESCs, while it is pluripotent (reviewed in [134]) as well as while it goes 
through differentiation. The epigenetic structure of the genome dictates the promoter 
regions that would be accessible to transcription factors for initiating transcription; the 
heterochromatin, being densely packed, is inaccessible whereas the euchromatin is loosely 
packed and readily accessible. The epigenetic structure of hESCs is different from that of 
differentiated cells. The epigenetic structure also differs across various lineages of 
differentiation. Thus, epigenetic factors are involved in changing the epigenetic structure of 
the genome in a lineage-dependent fashion. 
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Epigenetic factors comprise broadly of histone modifying enzymes and chromatin 
remodeling complexes. The concerted action of both is needed to bring a stable change in 
the epigenetic landscape. Histone modifying enzymes are enzymes that modify histones 
post-translationally and create an epigenetic code of various acetylations, ubiquitinations 
and methylations throughout the genome (the histone code hypothesis [135-136]). This code 
is then recognized by chromatin remodeling enzymes, which alter the higher order structure 
of nucleosomes by creating heterochromatin and euchromatin. By controlling the formation 
of heterochromatin and euchromatin, these epigenetic factors control promoter accessibility 
and gene expression during differentiation. Differentiation is thought to proceed through 
activation of lineage-specific genes and repression of pluripotency genes [137]. This requires 
epigenetic factors to create repressive histone modifications on pluripotency genes (which 
were hitherto active) and reciprocally, to create activating histone modifications on lineage-
specific genes (which were hitherto repressed). Permanent modification of histones also 
allows for epigenetic stability of the differentiated cell, which now becomes locked in this 
lineage. There is also some feedback from chromatin remodeling enzymes back to histone 
modifying enzymes. This means that certain chromatin remodeling enzymes can recruit 
back specific histone modifying enzymes for changing the histone code further. This is 
thought to provide more robustness to this system of epigenetic modification, thus lending 
further stability to the differentiated phenotype. 
3.2.1 Histone Acetyltransferases 
Of the various histone modifications, acetylation and methylation are critical for regulating 
the chromatin structure and gene expression [138]. These histone modifications, which 
create the genome-wide histone code, are regulated by Histone Acetyltransferases (HATs), 
Histone Deacetylases (HDACs), Histone Methyltransferases (HMTs) and Histone 
Demethylases. Histone Acetyltransferases are further classified into five families [139-140]: 
the Gcn5-related HATs (GNATs); the MYST (MOZ, Ybf2/Sas3, Sas2 and Tip60)-related 
HATs; p300/CBP HATs; general transcription factor HATs; and nuclear hormone-related 
HATs. In humans, the identified GNAT-related HAT complexes are PCAF, STAGA and 
TFTC. All three complexes have the chromatin-binding bromodomain which targets these 
complexes to chromatin. The bromodomain specifically recognizes and binds acetylated 
histones [141-142]. In mammals, the identified MYST-related HATs are Moz, Qkf, Mof, 
Tip60 (homologue of yeast NuA4 [143]) and Hbo1. The TIP60 complex contains the 
chromatin-binding chromodomain. The chromodomain of yeast SAGA HAT complex has 
been shown to recognize methylated histones [144] raising the possibility that TIP60 may 
also be recruited to methylated histones in humans. Together with the case of the 
bromodomain containing complexes, this implies that HATs may be recruited to specifically 
tagged histones and may function in a signaling cascade to modify the epigenetic map of the 
genome [145]. Mof homozygous null mice lack H4K16 acetylation and arrest at blastocyst 
stage [146]. Homozygous null Tip60 mutant mice also die during blastocyst stage[147]. Tip60 
has also been implicated in pluripotency of ESCs [148]. Qkf is required for normal 
development of neurons of the cerebral cortex [149], whereas Moz is required for normal 
hematopoietic stem cell development [150-152]. 
3.2.2 Histone Deacetylases 
The family of Histone Deacetylases is classified into four groups [153-155]: the Class I 
HDACs (yeast Rpd3-like) comprising of HDAC1/2, HDAC3 and HDAC8; the Class II 
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HDACs (yeast Hda1-like) comprising of HDACs4-7, HDAC9 and HDAC10; the Class III 
HDACs (Sir2-like) comprising of SIRT1-7; and the Class IV HDACs (HDAC11-like) 
comprising of HDAC11. Of these, HDAC1 and HDAC2 have been identified in numerous 
complexes [156], namely: the SIN3 co-repressor complex, the nucleosome remodeling and 
deacetylase (NuRD) complex, the CoREST complex, the Nanog and Oct4 associated 
deacetylase (NODE) complex and the SHIP1 containing complex. HDACs complexes 
become associated with transcription factors through mediator proteins such as Sin3, NCoR, 
SMRT, CtBP and TLE [157]. Hdac1 and Hdac2 are important for embryonic development, 
especially during myogenesis, neurogenesis, haematopoiesis and epithelial cell 
differentiation [156]. The HDAC complexes NuRD and SIN3 are critical during different 
stages of embryonic development [158]. Mice embryos lacking Mbd3 or p66α, components 
of the NuRD complex, die during embryonic development [159-160]. Mbd3 null mice show 
normal segregation of trophoblast and primitive endoderm, but fail to develop embryonic 
ectoderm and extraembryonic ectoderm [161]. ICM cells of these embryos continue 
expressing Oct4 and the primitive endoderm marker Gata4 and fail to expand in number. 
Further, even though the primitive endoderm is present, the visceral endoderm fails to form. 
Analogously, the ICM cells derived from Mbd3 null mice did not expand ex-vivo and mESCs 
could not be formed [161]. Mbd3 null mESCs could initiate differentiation but could not 
commit to the differentiated lineages [162]. Mbd3 was also shown to suppress trophoblast 
commitment of mESCs [163]. P66α, however, was not required for proper blastocyst formation 
and implantation, and p66α null mice died later during embryogenesis [160]. Mi-2β, another 
component of the NuRD complex, is important for haematopoiesis, lymphopoiesis and skin 
development [164-167]. Similar to Mbd3 and p66α, Sin3a null mice embryos also die after 
implantation [168-169]. The ICM derived from these embryos shows severely retarded 
proliferation ex vivo [168]. Sin3b null embryos show defects in erythrocyte and granulocyte 
maturation and in skeletal development [170]. The Class III HDACs, known as Sirtuins (SirTs), 
are also implicated during differentiation and mammalian development [171]. SirT1 is highly 
expressed in ESCs and decreases during differentiation [172]. During late development, SirT2 
modulates skeletal muscle and SirT1 modulates white adipose tissue differentiation [173-174]. 
Under oxidative stress, SirT1 causes astroglial differentiation in mouse neural progenitor cells 
[175]. SirtT2 controls gametogenesis in mice embryos [176]. 
3.2.3 Histone Methyltransferases 
Various Histone Methyltransferases (HMTs) exist in the mammalian genome and many 
putative HMTs are yet to be discovered [177]. The major mammalian HMTs include Ash1l, 
Dot1l, Ezh1-2, G9a, GLP, Mll1-5, Nsd1, Prdm1-6, Prdm8-16, PrSet7, Setd1-7, Setdb1-2, 
Setmar, Smyd1-5, Suv39h1-2, Suv4-20h1-2 and Whsc1/l1. Their requirement during specific 
stages of mammalian development is comprehensively reviewed in [177]. These HMTs are 
associated with specific histone methylation activities on H3 and H4 histones. Although 
most of identified methylation marks are promiscuous and need further study, some histone 
methylation marks correlate well with gene activity. Transcriptionally active genes display 
H3K4me3 on their promoter region and H3K36me3 across the gene body, while repressed 
genes are enriched in H3K27me3 over the gene body, with some amount of H3K9me3 and 
H4K20me3 [178-180]. H3K4 methylation, which is associated with gene activation, is 
induced by Mll1-5, Setd1a/b and Ash1l. Therefore, these HMTs are critical during 
mammalian development. Mutations in Mll1 lead to embryonic lethality in mice [181-182] 
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and cause aberrant regulation of Hox genes. Generation and/or expansion of hematopoietic 
stem cells, is abrogated in these embryos [183]. Mll2 null mice are capable of blastocyst 
formation and normal implantation without any lineage-specific growth abnormalities, but 
die later during embryonic development [184]. Very few genes are misregulated in Mll2 null 
mESCs, though Mll2 is needed for spermatogenesis [185]. Mll3 mutant mice show impaired 
differentiation towards the adipocyte lineage [186], while Mll5 mutant mice show impaired 
hematopoietic development [187]. H3K27 methylation, which is associated with gene 
repression and is important for embryonic development, is caused by the Ezh1-2 HTMs. 
Again, Ezh2 knockout causes early embryonic lethality in mouse embryos [188]. These 
embryos fail to complete gastrulation. Ezh2 is also shown to regulate epidermal and 
hematopoietic differentiation during embryogenesis [189-191]. H3K9 methylation is also 
associated with gene repression, and is induced by G9a, GLP, Prdm2, Setdb1 and Suv39h1-
2. No gene targets for the Suv39h enzymes have been discovered though Suv39h double 
mutant mice display impaired viability as well as sterility [192]. In contrast, Setdb1 knockout 
causes early embryonic lethality in mouse embryos due to aberrant blastocyst formation, 
and mESCs cannot be derived from these mutant blastocysts [193]. Setdb1 also controls the 
switch between osteoblastogenesis and adipogenesis from bone marrow mesenchymal 
progenitor cells [194]. Similar to Setdb1, both G9a and GLP null mice also show embryonic 
lethality, including aberrant somitogenesis and aberrant neural tube formation [195-196]. 
G9a inactivates ~120 genes during mESC differentiation including Oct4 and Nanog, in 
concert with DNA Methyltransferases Dnmt3a/b [197-198]. G9a is also implicated for 
genomic imprinting in the mouse placenta [199]. 
3.2.4 Histone Demethylases 
In humans, the identified histone demethylases include the KDM (Lysine (K) Demethylase) 
families of demethylases (KDM1-6), the PHF family and the JMJD6 family (reviewed in [200-
201]). As with histone methyltransferases, histone demethylases are critical for embryonic 
development. The KDM1 family comprises of KDM1A and KDM1B. Homozygous deletion 
mutants of Kdm1a are early embryonic lethal and do not gastrulate [202]. Kdm1a null ES cells 
are pluripotent but do not form embryoid bodies and do not differentiate [202]. Kdm1b 
mutant mice embryos are maternal embryonic lethal and defective in imprinting [203]. The 
KDM2 family comprises of KDM2A and KDM2B, of which, KDM2B is implicated in 
osteogenesis from mesenchymal stem cells [204]. The KDM3 family consists of KDM3A, 
KDM3B and JMJD1C. KDM3A is required for spermatogenesis [205-206]. KDM3A is 
positively regulated by Oct4 and depletion of KDM3A from ES cells leads to differentiation 
[207]. The KDM4 family consists of KDM4A, KDM4B, KDM4C and KDM4D, of which, 
KDM4C is also positively regulated by Oct4 [207]. Depletion of KDM4C causes 
differentiation in ES cells and KDM4C also positively regulates Nanog expression [207]. The 
KDM5 family comprises of KDM5A, KDM5B, KDM5C and KDM5D, of which, KDM5A has 
been implicated in differentiation [208]. The KDM6 family consists of KDM6A, UTY and 
KDM6B. KDM6A and KDM6B are shown to regulate HOX gene expression during 
development [209-210]. KDM6B also controls neuronal differentiation and epidermal 
differentiation [211-213]. The PHF family includes JHDM1D, PHF2 and PHF8, while the 
JMJD6 family includes only JMJD6. JHDM1D is required for neural differentiation in mESCs 
and knockdown of Jhdm1d blocks neural differentiation [214]. 
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and cause aberrant regulation of Hox genes. Generation and/or expansion of hematopoietic 
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repression and is important for embryonic development, is caused by the Ezh1-2 HTMs. 
Again, Ezh2 knockout causes early embryonic lethality in mouse embryos [188]. These 
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KDM6B. KDM6A and KDM6B are shown to regulate HOX gene expression during 
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3.2.5 DNA Methyltransferases 
The DNA Methyltransferases (DNMTs) in humans include DNMT1, DNMT2 and DNMT3 
(reviewed in [215-216]). The identified isoforms of DNMT1 are DNMT1s, DNMT1o, 
DNMT1b and DNMTΔE3-6. Members of DNMT3 are DNMT3a, DNMT3b and DNMT3L, of 
which, DNMT3a has isoforms DNMT3a1-4 and DNMT3b has isoforms DNMT3b1-8. Dnmt1 
null mice embryos die after gastrulation, before the 8-somite stage [217]. Double 
homozygous null mutations in Dnmt3a and Dnmt3b in mice embryos also caused similar 
phenotypes, with defects in neural tube closure and embryonic lethality at presomite stage 
[218-219]. During normal development, Dnmt3b is expressed in ICM, epiblast, embryonic 
ectoderm and spermatogonia of mouse embryo, whereas Dnmt3a is expressed throughout 
the embryo after E10.5 [220-221]. Dnmt3b is also expressed in progenitor population during 
hematopoiesis, spermatogenesis and neurogenesis [222]. During terminal neuronal 
differentiation, expression shifts to Dnmt3a [222]. Dnmt3l is required for genomic 
imprinting and female homozygous Dnmt3l null mice die during embryogenesis due to 
imprinting defects [223]. These mice show reduced spongiotrophoblast differentiation and 
excess trophoblast giant cell formation. Male homozygous Dnmt3l null mouse embryos 
show impaired spermatogenesis, but are viable [224]. Dnmt3a is also required for 
imprinting and spermatogenesis [225-226]. Curiously, triple homozygous knockout of 
Dnmt1, Dnmt3a and Dnmt3b causes no change in ESC self-renewal [227]. However, Dnmt1 
null ESCs with extremely low CpG methylation levels do not differentiate [228]. Similar 
blockage of differentiation is also observed in dual Dnmt3a/Dnmt3b homozygous null 
mutants [228]. 
3.2.6 Chromatin remodeling enzymes 
Chromatin remodeling enzymes are involved in controlling the higher order structure of 
chromatin by creating heterochromatin and euchromatin, and utilize the energy of ATP to 
do so. Chromatin remodeling enzymes thereby control cell fate during differentiation of 
ESCs (reviewed in [229]). During in vivo development, chromatin remodeling enzymes have 
been shown to be important for myeloid differentiation, erythropoiesis, T-cell development, 
adipogenesis, neurogenesis and myogenesis (reviewed in [230]). Mammalian chromatin 
modeling enzymes are categorized into three families: SWI/SNF, ISWI and CHD. The 
SWI/SNF family is characterized by the presence of either Brg1 or Brm as the catalytic 
subunit, and is further categorized into two subfamilies: Baf and Pbaf [231]. Brg1 
homozygous null mice die at peri-implantation stage and their ICM as well as trophoblast 
tissues die [232]. Similar phenotypes are observed homozygous mice null for Snf5, another 
subunit of SWI/SNF complexes [233]. However, downregulation of Baf60c causes late 
embryonic lethality due to defects in cardiac and skeletal muscle development [234]. Similarly, 
ablation of Baf180 leads to defects in heart development and placental trophectoderm 
development, and subsequent embryonic lethality [235] However, homozygous null 
mutations in Baf155 caused early embryonic lethality due to failure of ICM cells, though 
trophoblast giant cells were found to be normal [236]. Heterozygotes null for Baf155 showed 
defective brain development. In mESCs, knockdown of Brg1 leads to loss of self-renewal and 
impaired ability to differentiate to ectoderm and mesoderm [237]. Inactivation of Baf250b has 
been associated with reduced self-renewal and increased differentiation [238]. Interestingly, 
ablation of Baf250a caused failure of mesoderm formation in mouse embryos as well as in ESC-
based embryoid body cultures [239]. However, primitive endoderm differentiation and 
neuronal differentiation could be established in these cells. Brg1, Baf47, Baf155 and Baf57 are 
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required to suppress Nanog expression during differentiation and knockdown of Baf155 or 
Baf57 lead to de-repression of Nanog levels during differentiation [240].  
The ISWI family of chromatin remodelers is characterized by the presence of the Snf2h or Snf2l 
ATPase subunits that interact with unmodified histones. Snf2h is a part of the RSH, WICH, 
NoRC, CHRAC and ACF chromatin remodeling complexes. Snf2l is a part of the NURF and 
CERF complexes. Similar to Brg1, Snf2h homozygous null mice die at peri-implantation stage 
and both ICM and trophectoderm tissues degenerate [241]. Cecr2, a component of CERF, has 
been implicated in neural tube formation in mice [242]. Human NURF has also been 
implicated in neuronal development [243]. Interestingly, homozygous mice null for Bptf, a 
component of NURF, fail to form the visceral endoderm [244]. Bptf is required for ectoderm, 
mesoderm and both definitive and visceral endoderm development from ESCs in embryoid 
body cultures. Association between NURF complex and Smad transcription factors are 
necessary for endoderm formation [244]. The CHD family of chromatin remodelers is 
characterized by the presence of two chromodomains, with affinity for methylated histones. 
The CHD family is categorized into three subfamilies: family I with CHD1-2, family II with 
CHD3-4 and family III with CHD5-9. Downregulation of Chd1 in ESCs leads to impaired 
pluripotency, such that the cells are incapable of primitive endoderm and cardiac mesoderm 
differentiation and become prone to neural differentiation [245]. CHD3 and CHD4 are also 
found in NuRD histone deacetylase complexes described previously. Mutations in Chd7 are 
embryonic lethal, showing that Chd7 is also important for embryonic development [246]. 
3.2.7 Regulation of epigenetic factors by transcription factors 
Significant literature has been accumulated concerning the regulation of epigenetic factors 
by transcription factors. Transcription factors lie downstream of signaling pathways, raising 
the possibility that signaling pathways can control the recruitment of epigenetic factors to 
specific promoter regions. The vast number of interactions between the Smad transcription 
factors and epigenetic factors is extensively reviewed in [157]. Smads 1-4 can directly 
interact with HATs p300 and CBP [247] while Smads 2-3 can also interact with PCAF [248]. 
Smads 1, 2, 3 and 5 can interact with the HAT GCN5 [249] while Smad5 can also interact 
with the histone methyltransferases Suv39h2 [250]. Smad7 is acetylated and protected from 
degradation by p300 [251]. Smads 6 and 7 can also bind and recruit HDACs [252]. As 
discussed before, “bridging” proteins such as NCoR, Sin3, SMRT, CtBP and TLE can also 
help epigenetic factors to associate with transcription factors. Smad6 can directly bind CtBP 
[253]. Smads 3 and 4 can interact with NCoR and Sin3 through Dach1 [254]. Smad1 can also 
associate with Sin3a through Dach1 [255]. Smads 2, 3 and 4 can recruit NCoR as well as 
Sin3/HDAC through Ski [256-257]. Smad3 can associate with Hdac1 through TGIF2 [258]. 
Similarly, the transcription factor β-catenin can recruit epigenetic factors and influence the 
epigenetic state of cells (reviewed in [64]). β-catenin can associate with the HATs p300 and 
CBP [259-260] as well as TIP60 [261]. β-catenin can also associate with the chromatin 
remodeling factors Brg1 and ISWI [64]. Additionally, β-catenin can interact with the histone 
methyltransferases Mll1/Mll2 [261]. The Erk kinase, which is downstream of the MAPK 
pathway, can phosphorylate CBP [262], Smads 1-4 [263-265] as well as Brg1 and Brm [266]. 
Similarly, the Akt kinase, which is downstream of PI3K signaling, can associate with 
SWI/SNF components Ini1, Baf155 and Baf170, and can phosphorylate Baf155 [267]. Akt can 
interact with the histone methyltransferases Setdb1 [268] and Ezh2 and can phosphorylate 
and inhibit Ezh2 [269]. Akt can also phosphorylate and activate p300 [270]. Interestingly, the 
pluripotency factor Oct4 has also been shown to associate with numerous epigenetic factors 
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modeling enzymes are categorized into three families: SWI/SNF, ISWI and CHD. The 
SWI/SNF family is characterized by the presence of either Brg1 or Brm as the catalytic 
subunit, and is further categorized into two subfamilies: Baf and Pbaf [231]. Brg1 
homozygous null mice die at peri-implantation stage and their ICM as well as trophoblast 
tissues die [232]. Similar phenotypes are observed homozygous mice null for Snf5, another 
subunit of SWI/SNF complexes [233]. However, downregulation of Baf60c causes late 
embryonic lethality due to defects in cardiac and skeletal muscle development [234]. Similarly, 
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trophoblast giant cells were found to be normal [236]. Heterozygotes null for Baf155 showed 
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required to suppress Nanog expression during differentiation and knockdown of Baf155 or 
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implicated in neuronal development [243]. Interestingly, homozygous mice null for Bptf, a 
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differentiation and become prone to neural differentiation [245]. CHD3 and CHD4 are also 
found in NuRD histone deacetylase complexes described previously. Mutations in Chd7 are 
embryonic lethal, showing that Chd7 is also important for embryonic development [246]. 
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Significant literature has been accumulated concerning the regulation of epigenetic factors 
by transcription factors. Transcription factors lie downstream of signaling pathways, raising 
the possibility that signaling pathways can control the recruitment of epigenetic factors to 
specific promoter regions. The vast number of interactions between the Smad transcription 
factors and epigenetic factors is extensively reviewed in [157]. Smads 1-4 can directly 
interact with HATs p300 and CBP [247] while Smads 2-3 can also interact with PCAF [248]. 
Smads 1, 2, 3 and 5 can interact with the HAT GCN5 [249] while Smad5 can also interact 
with the histone methyltransferases Suv39h2 [250]. Smad7 is acetylated and protected from 
degradation by p300 [251]. Smads 6 and 7 can also bind and recruit HDACs [252]. As 
discussed before, “bridging” proteins such as NCoR, Sin3, SMRT, CtBP and TLE can also 
help epigenetic factors to associate with transcription factors. Smad6 can directly bind CtBP 
[253]. Smads 3 and 4 can interact with NCoR and Sin3 through Dach1 [254]. Smad1 can also 
associate with Sin3a through Dach1 [255]. Smads 2, 3 and 4 can recruit NCoR as well as 
Sin3/HDAC through Ski [256-257]. Smad3 can associate with Hdac1 through TGIF2 [258]. 
Similarly, the transcription factor β-catenin can recruit epigenetic factors and influence the 
epigenetic state of cells (reviewed in [64]). β-catenin can associate with the HATs p300 and 
CBP [259-260] as well as TIP60 [261]. β-catenin can also associate with the chromatin 
remodeling factors Brg1 and ISWI [64]. Additionally, β-catenin can interact with the histone 
methyltransferases Mll1/Mll2 [261]. The Erk kinase, which is downstream of the MAPK 
pathway, can phosphorylate CBP [262], Smads 1-4 [263-265] as well as Brg1 and Brm [266]. 
Similarly, the Akt kinase, which is downstream of PI3K signaling, can associate with 
SWI/SNF components Ini1, Baf155 and Baf170, and can phosphorylate Baf155 [267]. Akt can 
interact with the histone methyltransferases Setdb1 [268] and Ezh2 and can phosphorylate 
and inhibit Ezh2 [269]. Akt can also phosphorylate and activate p300 [270]. Interestingly, the 
pluripotency factor Oct4 has also been shown to associate with numerous epigenetic factors 
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including components of the NuRD HDAC complex (Chd4, p66α, p66β, Mbd3, Mta1-3 and 
Hdac1), chromatin remodeling proteins (Brg1, Baf155 and ISWI) and DNA 
methyltransferases (Dnmt3a and Dnmt3l) [271]. 
3.3 Cell polarity 
Cell polarity is a feature of cellular physiology exhibited by epithelial cells. It refers to 
uneven spatial distribution of proteins across the cell, causing different parts of the cell to 
have different morphology and functions. Cell polarity can be classified as apical-basal 
polarity (epithelial cells), anterior-posterior polarity (neurons) and planar polarity (cochlea). 
In mammals, the apical-basal polarity of epithelial cells is regulated by three distinct protein 
complexes: the Crumbs/PALS1/PATJ complex, the Par3/Par6/aPKC complex and the 
Scribble/Dlg/Lgl complex. A detailed review of these complexes and their function in 
controlling epithelial architecture, cell migration and tumorigenesis can be found in [272]. 
The apical-basal polarity is lost during epithelial-to-mesenchymal transformation (EMT), a 
process that changes epithelial cells to mesenchymal cells with no apical-basal polarity and 
occurs during embryogenesis, fibrosis and cancer metastasis. Importantly, recent findings 
have indicated that epithelial cell polarity is required for early mouse embryogenesis and 
may be the driving factor for differentiation of certain early lineages. For example, the cell 
polarity regulator Par6 is required for proper trophectoderm formation in mouse embryos 
[273]. Downregulation of Par3 or aPKC drives blastomeres towards ICM instead of 
trophectoderm [274]. Interestingly, the Crumbs polarity complex has been found to interact 
with components of the Hippo signaling pathway [99], and the Hippo has been implicated 
in trophectoderm formation as discussed in the review. It will therefore be interesting to 
study whether cell polarity proteins indeed control trophectoderm differentiation during 
early stages of embryogenesis. 
4. Conclusions 
The development and morphogenesis of the embryo is under strict control by a rather small 
set of signaling pathways. However, the presence of multiple ligands and multiple receptors, 
numerous transcription factor-binding partners and significant crosstalk between pathways 
gives rise to vast complexity within this small set of signaling pathways. Further, lineage-
specific differentiation is also controlled by complex regulation of various histone 
acetyltransferases, histone deacetylases, histone methyltransferases, histone demethylases, 
DNA methyltransferases and chromatin-remodeling enzymes. A detailed and molecular-level 
understanding of the determinants of lineage specificity of differentiation has only recently 
begun to emerge through studies of the signaling pathways and their downstream factors. We 
have summarized the signaling pathways and miRNAs associated with differentiation to 
various lineages in Table 1. Along similar lines, various histone modifying proteins and 
chromatin remodeling proteins associated with various lineages are summarized in Table 2. 
Even though these tables present a concise mechanistic linkage between various regulators of 
ESC differentiation, questions regarding how lineage-specific transcription factors are 
regulated and how a balance between opposing factors, such as HATs and HDACs, or HMTs 
and histone demethylases, is achieved in the cell remain largely unanswered. Further, the 
possible role of lineage-specific transcription factors in the recruitment of epigenetic factors 
also remains largely unknown. Thus, our understanding of the lineage-specificity of 
differentiation is still rudimentary and requires significant additional research. 
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[273]. Downregulation of Par3 or aPKC drives blastomeres towards ICM instead of 
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with components of the Hippo signaling pathway [99], and the Hippo has been implicated 
in trophectoderm formation as discussed in the review. It will therefore be interesting to 
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specific differentiation is also controlled by complex regulation of various histone 
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DNA methyltransferases and chromatin-remodeling enzymes. A detailed and molecular-level 
understanding of the determinants of lineage specificity of differentiation has only recently 
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have summarized the signaling pathways and miRNAs associated with differentiation to 
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Even though these tables present a concise mechanistic linkage between various regulators of 
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and histone demethylases, is achieved in the cell remain largely unanswered. Further, the 
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Table 1. Summary of signaling pathways, their link with lineage-specific transcription 
factors and micro-RNAs during embryogenesis and during hESC differentiation  
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1. Introduction 
Bioactive lipids are lipids with cell signaling functions. In the last two decades, they have 
become increasingly important in many fields of biology. They are the main diffusible 
mediators of inflammatory responses in tissues and regulate the polarity of cellular 
membranes. They are also critical for cell fate decisions during stem cell differentiation by 
inducing apoptosis or sustaining cell survival and polarity. The bioactive lipids discussed 
here belong to the classes of phospho- and sphingolipids. Mainly three different types of 
lipids and their function in stem cell differentiation will be reviewed in detail: 
phophatidylinositols (PIPs), lysophospholipids and eicosanoids, and the sphingolipid 
ceramide and its derivative sphingosine-1-phosphate (S1P).  
2. Biological Function of bioactive lipids in stem cell differentiation 
2.1 Phosphatidylinositols  
The phosphatidylinositols PI(3,4)P2 and PI(3,4,5)P3 generated by class I 
phosphatidyinositol-3-kinase (PI3K) upon induction of tyrosine receptor kinases or G-
protein coupled receptors (GPCRs) are known to be the major activators of the Akt/PKB cell 
signaling pathway for cell survival and differentiation (Callihan et al., 2011; Frebel &Wiese, 
2006; Layden et al., 2010; Paling et al., 2004; Storm et al., 2007; Umehara et al., 2007). The 
phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a lipid phosphatase 
that catalyzes the hydrolysis of PIP3 to PIP2, which leads to inactivation of the Akt/PKB cell 
signaling pathway and loss of pluripotency in stem cells (Groszer et al., 2001; Korkaya et al., 
2009; Otaegi et al., 2006). PTEN is a tumor suppressor mutated in many types of cancer and 
it is critical for the controlled growth of embryonic tissue and ES cells.   
PTEN converts PIP3 into PIP2 (Fig. 1). Since PIP3 activates the Akt/PKB cell signaling 
pathway, thus PTEN catalyzing PIP3 hydrolysis is a negative regulator of Akt/PKB. 
Consistent with this function, deletion of PTEN activates Akt/PKB-dependent cell signaling 
pathways (Groszer et al., 2001). PTEN mutations are often found in human cancers such as 
glioblastoma, prostate cancer, and breast cancer. Loss of function of this tumor suppressor 
gene results in the up-regulation of the Akt/PKB-to-β-catenin pathway (Fig. 2A) (Korkaya et 
al., 2009). Akt/PKB phosphorylates and therefore, inactivates glycogen synthase-3β (GSK-
3β), a protein kinase in the Wnt signaling pathway that phosphorylates β-catenin (Doble 
&Woodgett, 2003; Ikeda et al., 2000; van Noort et al., 2002). The oncogene β-catenin is an 
important adhesion protein and transcription factor for genes involved in proliferation. 
When phosphorylated by GSK-3β, β-catenin (in a protein complex with adenomatous 
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phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a lipid phosphatase 
that catalyzes the hydrolysis of PIP3 to PIP2, which leads to inactivation of the Akt/PKB cell 
signaling pathway and loss of pluripotency in stem cells (Groszer et al., 2001; Korkaya et al., 
2009; Otaegi et al., 2006). PTEN is a tumor suppressor mutated in many types of cancer and 
it is critical for the controlled growth of embryonic tissue and ES cells.   
PTEN converts PIP3 into PIP2 (Fig. 1). Since PIP3 activates the Akt/PKB cell signaling 
pathway, thus PTEN catalyzing PIP3 hydrolysis is a negative regulator of Akt/PKB. 
Consistent with this function, deletion of PTEN activates Akt/PKB-dependent cell signaling 
pathways (Groszer et al., 2001). PTEN mutations are often found in human cancers such as 
glioblastoma, prostate cancer, and breast cancer. Loss of function of this tumor suppressor 
gene results in the up-regulation of the Akt/PKB-to-β-catenin pathway (Fig. 2A) (Korkaya et 
al., 2009). Akt/PKB phosphorylates and therefore, inactivates glycogen synthase-3β (GSK-
3β), a protein kinase in the Wnt signaling pathway that phosphorylates β-catenin (Doble 
&Woodgett, 2003; Ikeda et al., 2000; van Noort et al., 2002). The oncogene β-catenin is an 
important adhesion protein and transcription factor for genes involved in proliferation. 
When phosphorylated by GSK-3β, β-catenin (in a protein complex with adenomatous 
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polyposis coli or APC) is proteolytically degraded and thus, adhesion lost and proliferation 
reduced. Consistent with this function, deletion of β-catenin results in loss of pluripotency 
and early embryonic death of the respective knockout mouse (Haegel et al., 1995). Likewise, 
deletion of PTEN results in increased β-catenin levels and increased pluripotency or 
malignancy (Groszer et al., 2001). Therefore, the PTEN vs. PI3K-to-Akt/PKB antagonism is 
interesting in two biological contexts with respect to stem cell differentiation: maintenance 
of pluripotent stem cells and tumorigenesis of cancer stem cells. In the first context, 
inhibition of PTEN, activation of PI3K and Akt/PKB, or inhibition of GSK-3β will be useful 
to maintain pluripotent ES cells. In the second context, activation of PTEN, inhibition of 
PI3K and Akt/PKB, or activation of GSK-3β may be a useful strategy to eliminate cancer 
stem cells.  
In the cultivation process of ES cells, elevated expression of the transcription factors Oct-4 
and Nanog is essential for maintenance of pluripotency (Bhattacharya et al., 2003; Sato et al., 
2004). It has been shown that two cell signaling pathways are critical for this regulation: the 
janus kinase/signal transducer and activator of transcription 3 (Jak/Stat3) and the Akt/PKB 
signaling pathways (Fig. 2A) (Kelly et al., 2011; Paling et al., 2004). In the cultivation of 
mouse ES cells, the most important growth factor activating Stat3 and Akt/PKB is LIF 
(leukemia inhibitory factor), an interleukin 6 class cytokine binding to LIF receptor α 
(LIFRα) (Cartwright et al., 2005; Niwa et al., 1998; Okita &Yamanaka, 2006; Schuringa et al., 
2002; Takao et al., 2007). In vitro, LIF is added to the medium when cultivating 
undifferentiated mouse ES cells on feeder fibroblasts and in feeder-free culture. In vivo, LIF 
is generated by the trophoectoderm from where it penetrates the inner cell mass, the source 
of pluripotent ES cells in the pre-implantation embryo. In human ES cells, the role of LIF as 
“guardian” of pluripotency is taken over by fibroblast growth factor (FGF) (Lanner 
&Rossant, 2010; Li et al., 2007) (Fig. 2A).  Binding of FGF-2 to the FGF receptor 2 (FGFR2) 
activates similar cell signaling pathways in human ES cells as stimulated by LIF in mouse ES 
cells: Jak/Stat3, mitogen-activated protein kinase (MAPK), and Akt/PKB (Lanner &Rossant, 
2010; Li et al., 2007). However, FGFR-dependent signaling is very diverse and it depends on 
individual receptor protein complexes which specific response is elicited by FGF. For 
example, in mouse ES cells, FGF-2 is used to maintain the multipotent neuroprogenitor 
stage and to prevent further neuronal differentiation. In human ES cells, supplementation of 
the serum-free cell culture medium with FGF-2 is critical to prevent apoptosis and to 
maintain pluripotency.  
The role of lipids as the key factors in the PI3K-to-Akt/PKB-to-β-catenin cell signaling 
pathway is obvious since phosphatidylinositols (PIPs) are lipids by provenance. 
Unfortunately, PIPs are not applicable as exogenous factors that can be simply added to 
stem cell media since these lipids are part of an intracellular cell signaling cascade not easily 
accessible to the outside of the cell. However, there are other lipid-regulated pathways that 
are dependent on the activation of cell surface receptors, which is of tremendous advantage 
if one attempts to use lipids as exogenously added growth or differentiation factors (see 
section 2.2). The two receptors involved in maintenance of pluripotency, LIFRα and FGFR2 
are both tyrosine receptor kinases which are not directly activated by lipids, although 
indirect regulation by so-called “lipid rafts” has been discussed (see section 2.4) (Lee et al., 
2010b; Yanagisawa et al., 2004b, 2005).  
In addition to using natural lipids as ligands, stem cell differentiation can also be modulated 
by pharmacologic reagents that are either lipid analogs, inhibitors of enzymes in lipid 
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Fig. 1. Metabolism of phosphatidylinositols in the PI3K-to-Akt/PKB cells signaling pathway 
for ES cell pluripotency. PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin 
homolog deleted on chromosome 10 
metabolism, or drugs targeting downstream effectors of lipid-regulated cell signaling 
pathways. Two drugs that are inhibitors of protein kinases in the LIFRα and FGFR2 
pathways have been tested on their effect on pluripotency: LY294002 and indirubin-3-
monoxime, two inhibitors specific for PI3K and GSK-3β, respectively (Chen et al., 2006; 
Chen et al., 2000; Ding &Schultz, 2004; Ding et al., 2003; Lyssiotis et al., 2011; Otaegi et al., 
2006; Paling et al., 2004; Sato et al., 2004). The PI3K inhibitor LY294002 has been shown to 
reduce the capacity of mouse and human ES cells to self-renew and to undergo subsequent 
steps of lineage specification and differentiation (Paling et al., 2004). These effects are likely 
to involve differentiation stage-specific (contextual) other cell signaling pathways 
downstream (or parallel) to the PI3K-to-Akt/PKB signaling axis. While it may not be 
desired to interfere with ES cell pluripotency, LY294002 and other PI3K and Akt/PKB 
inhibitors are currently tested for cancer treatment, in particular for targeting cancer stem 
cells (Bleau et al., 2009; Plo et al., 1999). If one desires to sustain self-renewal of ES cells, 
GSK-3β inhibitors such as indirubin-3-monoxime or BIO are attractive candidates. BIO has 
been successfully used to maintain pluripotency in human ES cells (Sato et al., 2004). 
Additional effectors targeting GSK-3β are synthetic agonists of the Wnt receptor Frizzled, 
however, their use in stem cell differentiation is not yet sufficiently investigated (Lyssiotis et 
al., 2011).  
Interestingly, inhibitors of the mitogen activated protein kinase (MAPK) pathway such as 
the MAPK kinase (MEK) inhibitor PD98059 have been used with mouse ES cells to promote 
self-renewal or pluripotency (Buehr &Smith, 2003; Li et al., 2007). This appears paradoxical 
since LIFRα as well as FGFR2 are known to activate MAPK, which suggests that activation 
of MAPK is involved in pluripotency. However, only transient MAPK activation to promote 
G1 re-entry is useful for self-renewal while prolonged activation will promote 
differentiation (Fig. 2B). Therefore, a combination of LIF with the MAPK-kinase (MEK) 
inhibitor PD95059 activating PI3K-to-Akt/PKB while inhibiting MAPK signaling has been 
successfully used to promote pluripotency in mouse ES cells, but also to enhance the 
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malignancy (Groszer et al., 2001). Therefore, the PTEN vs. PI3K-to-Akt/PKB antagonism is 
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of pluripotent stem cells and tumorigenesis of cancer stem cells. In the first context, 
inhibition of PTEN, activation of PI3K and Akt/PKB, or inhibition of GSK-3β will be useful 
to maintain pluripotent ES cells. In the second context, activation of PTEN, inhibition of 
PI3K and Akt/PKB, or activation of GSK-3β may be a useful strategy to eliminate cancer 
stem cells.  
In the cultivation process of ES cells, elevated expression of the transcription factors Oct-4 
and Nanog is essential for maintenance of pluripotency (Bhattacharya et al., 2003; Sato et al., 
2004). It has been shown that two cell signaling pathways are critical for this regulation: the 
janus kinase/signal transducer and activator of transcription 3 (Jak/Stat3) and the Akt/PKB 
signaling pathways (Fig. 2A) (Kelly et al., 2011; Paling et al., 2004). In the cultivation of 
mouse ES cells, the most important growth factor activating Stat3 and Akt/PKB is LIF 
(leukemia inhibitory factor), an interleukin 6 class cytokine binding to LIF receptor α 
(LIFRα) (Cartwright et al., 2005; Niwa et al., 1998; Okita &Yamanaka, 2006; Schuringa et al., 
2002; Takao et al., 2007). In vitro, LIF is added to the medium when cultivating 
undifferentiated mouse ES cells on feeder fibroblasts and in feeder-free culture. In vivo, LIF 
is generated by the trophoectoderm from where it penetrates the inner cell mass, the source 
of pluripotent ES cells in the pre-implantation embryo. In human ES cells, the role of LIF as 
“guardian” of pluripotency is taken over by fibroblast growth factor (FGF) (Lanner 
&Rossant, 2010; Li et al., 2007) (Fig. 2A).  Binding of FGF-2 to the FGF receptor 2 (FGFR2) 
activates similar cell signaling pathways in human ES cells as stimulated by LIF in mouse ES 
cells: Jak/Stat3, mitogen-activated protein kinase (MAPK), and Akt/PKB (Lanner &Rossant, 
2010; Li et al., 2007). However, FGFR-dependent signaling is very diverse and it depends on 
individual receptor protein complexes which specific response is elicited by FGF. For 
example, in mouse ES cells, FGF-2 is used to maintain the multipotent neuroprogenitor 
stage and to prevent further neuronal differentiation. In human ES cells, supplementation of 
the serum-free cell culture medium with FGF-2 is critical to prevent apoptosis and to 
maintain pluripotency.  
The role of lipids as the key factors in the PI3K-to-Akt/PKB-to-β-catenin cell signaling 
pathway is obvious since phosphatidylinositols (PIPs) are lipids by provenance. 
Unfortunately, PIPs are not applicable as exogenous factors that can be simply added to 
stem cell media since these lipids are part of an intracellular cell signaling cascade not easily 
accessible to the outside of the cell. However, there are other lipid-regulated pathways that 
are dependent on the activation of cell surface receptors, which is of tremendous advantage 
if one attempts to use lipids as exogenously added growth or differentiation factors (see 
section 2.2). The two receptors involved in maintenance of pluripotency, LIFRα and FGFR2 
are both tyrosine receptor kinases which are not directly activated by lipids, although 
indirect regulation by so-called “lipid rafts” has been discussed (see section 2.4) (Lee et al., 
2010b; Yanagisawa et al., 2004b, 2005).  
In addition to using natural lipids as ligands, stem cell differentiation can also be modulated 
by pharmacologic reagents that are either lipid analogs, inhibitors of enzymes in lipid 
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Fig. 1. Metabolism of phosphatidylinositols in the PI3K-to-Akt/PKB cells signaling pathway 
for ES cell pluripotency. PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin 
homolog deleted on chromosome 10 
metabolism, or drugs targeting downstream effectors of lipid-regulated cell signaling 
pathways. Two drugs that are inhibitors of protein kinases in the LIFRα and FGFR2 
pathways have been tested on their effect on pluripotency: LY294002 and indirubin-3-
monoxime, two inhibitors specific for PI3K and GSK-3β, respectively (Chen et al., 2006; 
Chen et al., 2000; Ding &Schultz, 2004; Ding et al., 2003; Lyssiotis et al., 2011; Otaegi et al., 
2006; Paling et al., 2004; Sato et al., 2004). The PI3K inhibitor LY294002 has been shown to 
reduce the capacity of mouse and human ES cells to self-renew and to undergo subsequent 
steps of lineage specification and differentiation (Paling et al., 2004). These effects are likely 
to involve differentiation stage-specific (contextual) other cell signaling pathways 
downstream (or parallel) to the PI3K-to-Akt/PKB signaling axis. While it may not be 
desired to interfere with ES cell pluripotency, LY294002 and other PI3K and Akt/PKB 
inhibitors are currently tested for cancer treatment, in particular for targeting cancer stem 
cells (Bleau et al., 2009; Plo et al., 1999). If one desires to sustain self-renewal of ES cells, 
GSK-3β inhibitors such as indirubin-3-monoxime or BIO are attractive candidates. BIO has 
been successfully used to maintain pluripotency in human ES cells (Sato et al., 2004). 
Additional effectors targeting GSK-3β are synthetic agonists of the Wnt receptor Frizzled, 
however, their use in stem cell differentiation is not yet sufficiently investigated (Lyssiotis et 
al., 2011).  
Interestingly, inhibitors of the mitogen activated protein kinase (MAPK) pathway such as 
the MAPK kinase (MEK) inhibitor PD98059 have been used with mouse ES cells to promote 
self-renewal or pluripotency (Buehr &Smith, 2003; Li et al., 2007). This appears paradoxical 
since LIFRα as well as FGFR2 are known to activate MAPK, which suggests that activation 
of MAPK is involved in pluripotency. However, only transient MAPK activation to promote 
G1 re-entry is useful for self-renewal while prolonged activation will promote 
differentiation (Fig. 2B). Therefore, a combination of LIF with the MAPK-kinase (MEK) 
inhibitor PD95059 activating PI3K-to-Akt/PKB while inhibiting MAPK signaling has been 
successfully used to promote pluripotency in mouse ES cells, but also to enhance the 
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A B 
Fig. 2. Cell signaling pathways for ES cell pluripotency. Elliptic circles label enzymes that 
promote pluripotency, while diamonds label enzymes that reduce pluripotency and 
promote differentiation. MAPK shows both, pro-pluripotency or pro-differentiation activity 
in human or mouse ES cells, respectively.   
generation of induced pluripotent stem (iPS) cells (Li et al., 2007; Lyssiotis et al., 2011). The 
situation in human ES cells, however, is different. In contrast to mouse ES cells, inhibition of 
the MAPK cell signaling pathway reduces the potential of undifferentiated human ES cells 
to self-renew, indicating that FGFR2-mediated activation of Ras/Raf-to-MEK-to MAPK is 
critical for human ES cell pluripotency (Ding et al., 2010). A similar role has been found for 
Bmp4, which promotes pluripotency in mouse and differentiation in human ES cells 
(Bouhon et al., 2005; Zeng et al., 2004; Zhang et al., 2010). It is quite possible that this 
difference depends on which other pathways for pluripotency are co-activated such as 
Jak/Stat3 in mouse or Activin in human ES cells. Bioactive lipids are important in that they 
co-regulate several cell signaling pathways critical for pluripotency and differentiation of ES 
cells, in particular MAPK and PI3K downstream of ClassA/Rhodopsin-like GPCRs, which 
will be discussed in the next section. 
2.2 Lysophospholipids and eicosanoids 
Lysophospholipids (LPLs) are lipids generated by hydrolytic cleavage of fatty acid from 
glycerophospholipids, which is catalyzed by phospholipases. Distinct phospholipases cleave 
off either one of the two (PLA1 and PLA2) or both (PLB) fatty acid residues, or they cleave 
off the phosphate-containing head group (PLC) or the alcohol (PLD) (Gardell et al., 2006; 
Hla et al., 2001; Hla et al., 2000; Lin et al., 2010; Meyer zu Heringdorf &Jakobs, 2007; 
Okudaira et al., 2010; Radeff-Huang et al., 2004; Tigyi &Parrill, 2003; Ye et al., 2002). PLA2 
generates arachidonic acid, the precursor for the generation of eicosanoids, a group of 
inflammatory mediators including prostaglandins and leukotrienes (Funk, 2001; Jenkins et 
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al., 2009; Khanapure et al., 2007; Lambeau &Gelb, 2008; Szefel et al., 2011; Wymann 
&Schneiter, 2008). Similar to the PLD reaction, lysophospholipase D or autotaxin generates 
lysophosphatidic acid (LPA) from lysophosphatidylcholine (Nakanaga et al., 2010; Okudaira 
et al., 2010; Samadi et al., 2011). LPA receptors are critical in cell proliferation and 
tumorigenesis and have recently been shown to promote proliferation of human neural 
precursor cells (Callihan et al., 2011; Hurst et al., 2008; Lin et al., 2010; Pebay et al., 2007; 
Pebay et al., 2005; Pitson &Pebay, 2009).   
Arachidonic acid, generated by PLA2 from phospholipids such as phosphatidylcholine (Fig. 
3A) is converted to a variety of pro-inflammotory eicosanoids among which prostaglandins, 
thromboxanes, and leukotrienes are the most important signaling lipids (Fig. 3B). The effect 
of eicosanoids on ES cells is not well understood and research is mostly limited to results 
with mouse ES cells. Interestingly, lysophospholipids such as LPA and eicosanoids such as 
prostaglandin E2 (PGE2) appear to activate similar downstream cell signaling pathways, 
mainly the PI3K-to-Akt/PKB, MAPK, and Wnt/GSK-3β pathways (Callihan et al., 2011; 
Goessling et al., 2009; Logan et al., 2007; North et al., 2007; Pebay et al., 2007; Pitson &Pebay, 
2009; Yun et al., 2009). In contrast to LIFRα or FGFR2, however, stimulation of Akt/PKB by 
PGE2 has not been reported to sustain pluripotency, but is rather anti-apoptotic/cell 
protective and promotes stem cell proliferation. This may not be surprising since generation 
and conversion of arachidonic acid is often a response to hypoxic insults, which can damage 
mitochondria and induce apoptosis. Notably, inhibition of eicosanoid biosynthesis reduces 
the potential of mouse and human ES cells to self-renew, indicating a role of eicosanoids in 
stem cell maintenance or pluripotency (Yanes et al., 2010). Thromboxane has not been 
described to play a role in stem cell differentiation, maybe because its main function is 
rather confined to platelet aggregation. In contrast, prostacyclin, a similar eicosanoid in 





Fig. 3. Biosynthesis pathways in lysoposphatidic acid (LPA) and eicosanoid metabolism 
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generation of induced pluripotent stem (iPS) cells (Li et al., 2007; Lyssiotis et al., 2011). The 
situation in human ES cells, however, is different. In contrast to mouse ES cells, inhibition of 
the MAPK cell signaling pathway reduces the potential of undifferentiated human ES cells 
to self-renew, indicating that FGFR2-mediated activation of Ras/Raf-to-MEK-to MAPK is 
critical for human ES cell pluripotency (Ding et al., 2010). A similar role has been found for 
Bmp4, which promotes pluripotency in mouse and differentiation in human ES cells 
(Bouhon et al., 2005; Zeng et al., 2004; Zhang et al., 2010). It is quite possible that this 
difference depends on which other pathways for pluripotency are co-activated such as 
Jak/Stat3 in mouse or Activin in human ES cells. Bioactive lipids are important in that they 
co-regulate several cell signaling pathways critical for pluripotency and differentiation of ES 
cells, in particular MAPK and PI3K downstream of ClassA/Rhodopsin-like GPCRs, which 
will be discussed in the next section. 
2.2 Lysophospholipids and eicosanoids 
Lysophospholipids (LPLs) are lipids generated by hydrolytic cleavage of fatty acid from 
glycerophospholipids, which is catalyzed by phospholipases. Distinct phospholipases cleave 
off either one of the two (PLA1 and PLA2) or both (PLB) fatty acid residues, or they cleave 
off the phosphate-containing head group (PLC) or the alcohol (PLD) (Gardell et al., 2006; 
Hla et al., 2001; Hla et al., 2000; Lin et al., 2010; Meyer zu Heringdorf &Jakobs, 2007; 
Okudaira et al., 2010; Radeff-Huang et al., 2004; Tigyi &Parrill, 2003; Ye et al., 2002). PLA2 
generates arachidonic acid, the precursor for the generation of eicosanoids, a group of 
inflammatory mediators including prostaglandins and leukotrienes (Funk, 2001; Jenkins et 
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al., 2009; Khanapure et al., 2007; Lambeau &Gelb, 2008; Szefel et al., 2011; Wymann 
&Schneiter, 2008). Similar to the PLD reaction, lysophospholipase D or autotaxin generates 
lysophosphatidic acid (LPA) from lysophosphatidylcholine (Nakanaga et al., 2010; Okudaira 
et al., 2010; Samadi et al., 2011). LPA receptors are critical in cell proliferation and 
tumorigenesis and have recently been shown to promote proliferation of human neural 
precursor cells (Callihan et al., 2011; Hurst et al., 2008; Lin et al., 2010; Pebay et al., 2007; 
Pebay et al., 2005; Pitson &Pebay, 2009).   
Arachidonic acid, generated by PLA2 from phospholipids such as phosphatidylcholine (Fig. 
3A) is converted to a variety of pro-inflammotory eicosanoids among which prostaglandins, 
thromboxanes, and leukotrienes are the most important signaling lipids (Fig. 3B). The effect 
of eicosanoids on ES cells is not well understood and research is mostly limited to results 
with mouse ES cells. Interestingly, lysophospholipids such as LPA and eicosanoids such as 
prostaglandin E2 (PGE2) appear to activate similar downstream cell signaling pathways, 
mainly the PI3K-to-Akt/PKB, MAPK, and Wnt/GSK-3β pathways (Callihan et al., 2011; 
Goessling et al., 2009; Logan et al., 2007; North et al., 2007; Pebay et al., 2007; Pitson &Pebay, 
2009; Yun et al., 2009). In contrast to LIFRα or FGFR2, however, stimulation of Akt/PKB by 
PGE2 has not been reported to sustain pluripotency, but is rather anti-apoptotic/cell 
protective and promotes stem cell proliferation. This may not be surprising since generation 
and conversion of arachidonic acid is often a response to hypoxic insults, which can damage 
mitochondria and induce apoptosis. Notably, inhibition of eicosanoid biosynthesis reduces 
the potential of mouse and human ES cells to self-renew, indicating a role of eicosanoids in 
stem cell maintenance or pluripotency (Yanes et al., 2010). Thromboxane has not been 
described to play a role in stem cell differentiation, maybe because its main function is 
rather confined to platelet aggregation. In contrast, prostacyclin, a similar eicosanoid in 
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cells (Chillar et al., 2010; Xu et al., 2008). In addition to prostacyclin, leukotriene of the LTD4 
type has been used in several studies to promote proliferation and cardiovascular 
differentiation of mouse ES cells (Finkensieper et al., 2010; Funk, 2001; Kim et al., 2010). 
The effect of prostaglandins and other eicosanoids on ES cells is worth discussing in an 
important aspect of human health care. Inhibitors of cyclooxygenase 2 (Cox-2), the enzyme 
critical for PGE2 production, are taken by nearly everyone to ease up head ache, back pain, 
and inflammation. The Cox-2 inhibitor aspirin is one of the most successfully administered 
drugs world-wide. A recent study on the negative effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) such as aspirin on the differentiation of human ES cells suggests that one 
has to be careful with the use of NSAIDs when human ES cells are to be transplanted for 
heart tissue repair (Chillar et al., 2010). These observations suggest that eicosanoids are 
important in cardiogenic/cardiovascular differentiation of ES cells.  
The eicosanoid as well as lysophospholipid receptors belong to the family of Class A 
Rhodopsin-like GPCRs (Callihan et al., 2011; Hla et al., 2001; Kostenis, 2004; Lin et al., 2010; 
Pitson &Pebay, 2009; Radeff-Huang et al., 2004). They mediate the activation of downstream 
cell signaling pathways through different types of GTPases, mainly Gi, Gq, and G12/13,   
 
 
Fig. 4. GPCR-dependent cell signaling pathways with similar function for ES cell 
pluripotency and differentiation. DAG, diacylglycerol; PLC, phospholipase C; EP, 
eicosanoid receptor. 
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acting upon PI3K-to-Akt/PKB (Gi), Ras-to-ERK (Gi, Gq) Rho (G12/13), and PLC-to-PKC 
(Gq) cell signaling pathways for pluripotency and cell survival (Akt/PKB), proliferation 
(Rho and PKC), and differentiation/specification (MAPK) pathways (Fig. 4). Hence, 
combinations of particular cell signaling lipids with cytokines or growth factors such as LIF 
or FGF-2 activating similar effectors have been found to be useful in directing stem cell fate 
toward pluripotency, proliferation, or differentiation, respectively (Hurst et al., 2008; 
Kilkenny et al., 2003; Layden et al., 2010; Pebay et al., 2007; Radeff-Huang et al., 2004). There 
are five GPCRs for each LPA and sphingosine-1-phosphate (S1P) expressed in mouse and 
human ES cells.  
2.3 Ceramide and sphingosine-1-phosphate  
Sphingolipids are acyl (fatty acid) derivatives of the amino alcohol sphingosine. They 
encompass sphingosine, ceramide, and ceramide derivatives such as sphingomyelin, 
ceramide-1-phosphate, S1P, and glycosphingolipids (Fig. 5A for structures) (Bartke 
&Hannun, 2009; Chalfant &Spiegel, 2005; Chen et al., 2010; Futerman &Hannun, 2004; 
Hannun et al., 2001; Hannun &Obeid, 2002, 2008; Lebman &Spiegel, 2008; Merrill et al., 
1997; Spiegel &Milstien, 2003; Strub et al., 2010; Takabe et al., 2008). Important biological 
functions of sphingolipids are cell signaling for inflammation, apoptosis, cell cycle 
regulation, and autophagy (Bartke &Hannun, 2009; Basu &Kolesnick, 1998; Bieberich, 2004, 
2008a; Futerman &Hannun, 2004; Gulbins &Kolesnick, 2003; Haimovitz-Friedman et al., 
1997; Hannun &Obeid, 2008; Morales et al., 2007). Most recently, particular sphingolipids 
have also been implicated in ES cell differentiation and cell polarity (Bieberich, 2004, 2008a, 
b, 2010; Bieberich et al., 2003; Bieberich et al., 2001; Bieberich et al., 2004; Gardell et al., 2006; 
Goldman et al., 1984; Harada et al., 2004; Hurst et al., 2008; Jung et al., 2009; Pebay et al., 
2007; Pebay et al., 2005; Pitson &Pebay, 2009; Salli et al., 2009; Walter et al., 2007; Wang et al., 
2008a; Wong et al., 2007; Yanagisawa et al., 2004a). Ceramide has been shown to induce 
apoptosis specifically in residual pluripotent stem (rPS) cells that cause teratomas (stem cell-
derived tumors) after stem cell transplantation. S1P has been found to promote 
oligodendrocyte differentiation (see section 3.2. for discussion).  
Ceramide is the precursor of all bioactive sphingolipids. It is synthesized in three different 
metabolic pathways.  Figure 5B shows that sphingolipid metabolism is integrated into 
phospholipid (i.e., PC), one carbon unit (i.e., choline), fatty acid (i.e., palmitoyl CoA for de 
novo biosynthesis and other fatty acids in the salvage pathway), and amino acid (i.e., serine 
in de novo biosynthesis) metabolism (Bartke &Hannun, 2009; Bieberich, 2004, 2008a; Chen et 
al., 2010; Futerman &Hannun, 2004; Futerman &Riezman, 2005; Gault et al., 2010; Hannun et 
al., 2001; Luberto &Hannun, 1999). In cell cultures, plenty of these precursors are provided 
in the medium, which may not necessarily reproduce the metabolic situation of stem cells or 
other cell types in vivo.  Recently, our group has found that neural crest-derived stem or 
progenitor cells are sensitive to alcohol due to ethanol-induced elevation of ceramide and 
induction of apoptosis (Wang &Bieberich, 2010). Apoptosis can be prevented by 
supplementing the medium with CDP-choline, This effect can be explained by providing 
excess of substrate required to drive conversion of ceramide to SM using the interconnection 
of the Kennedy pathway for phospholipid biosynthesis and the SM cycle (Fig. 5B). Choline 
can also be replenished from the one carbon unit metabolism, which establishes the 
interconnection of sphingolipid metabolism with this metabolic pathway.  
The fatty acid metabolism interconnects with sphingolipid biosynthesis twice, in the de 
novo and salvage pathways. The de novo pathway uses palmitoyl CoA and serine for a 
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cells (Chillar et al., 2010; Xu et al., 2008). In addition to prostacyclin, leukotriene of the LTD4 
type has been used in several studies to promote proliferation and cardiovascular 
differentiation of mouse ES cells (Finkensieper et al., 2010; Funk, 2001; Kim et al., 2010). 
The effect of prostaglandins and other eicosanoids on ES cells is worth discussing in an 
important aspect of human health care. Inhibitors of cyclooxygenase 2 (Cox-2), the enzyme 
critical for PGE2 production, are taken by nearly everyone to ease up head ache, back pain, 
and inflammation. The Cox-2 inhibitor aspirin is one of the most successfully administered 
drugs world-wide. A recent study on the negative effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) such as aspirin on the differentiation of human ES cells suggests that one 
has to be careful with the use of NSAIDs when human ES cells are to be transplanted for 
heart tissue repair (Chillar et al., 2010). These observations suggest that eicosanoids are 
important in cardiogenic/cardiovascular differentiation of ES cells.  
The eicosanoid as well as lysophospholipid receptors belong to the family of Class A 
Rhodopsin-like GPCRs (Callihan et al., 2011; Hla et al., 2001; Kostenis, 2004; Lin et al., 2010; 
Pitson &Pebay, 2009; Radeff-Huang et al., 2004). They mediate the activation of downstream 
cell signaling pathways through different types of GTPases, mainly Gi, Gq, and G12/13,   
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acting upon PI3K-to-Akt/PKB (Gi), Ras-to-ERK (Gi, Gq) Rho (G12/13), and PLC-to-PKC 
(Gq) cell signaling pathways for pluripotency and cell survival (Akt/PKB), proliferation 
(Rho and PKC), and differentiation/specification (MAPK) pathways (Fig. 4). Hence, 
combinations of particular cell signaling lipids with cytokines or growth factors such as LIF 
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ceramide-1-phosphate, S1P, and glycosphingolipids (Fig. 5A for structures) (Bartke 
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novo and salvage pathways. The de novo pathway uses palmitoyl CoA and serine for a 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 40
condensation reaction that is the first step in ceramide biosynthesis. Since serine is used as 
the second substrate, de novo biosynthesis ties into the amino acid metabolism as well. The 
salvage pathway uses a variety of activated fatty acids for re-attachment to sphingosine (Fig. 
5B). While supply with precursors for lipid metabolism may not be critical in vitro, 
specialized tissues or cells such as astrocytes providing nutrients and metabolic precursors 
to neurons or neural stem cells in vivo maybe more sensitive toward lipid imbalances as 
observed in fetal alcohol syndrome and Alzheimer’s disease (Adibhatla &Hatcher, 2008; 
Cutler et al., 2004; De Vito et al., 2000; Hirabayashi &Furuya, 2008; Jana et al., 2009; Jana 
&Pahan, 2010; Muscoli et al., 2010; Riboni et al., 2002; Satoi et al., 2005; Wang et al., 2008b). 
In particular, neural stem cells are confined to distinct morphological cell complexes which 
tightly control the interaction with other cells and therefore, comprise “metabolic niches” 





Fig. 5. Structures of ceramide precursors and derivatives with cell signaling function and 
interconnection of ceramide metabolism with other lipid and amino acid metabolism. N-
oleoyl serinol (S18) or FTY720 are analogues of ceramide or S1P, respectively. Box shows 
common structural motif.  
Regulation of sphingolipid metabolism by its interconnection with other lipid metabolic 
pathways has a direct impact on lipid-dependent cell signaling. Ceramide is the precursor of 
S1P, which is a ligand for five distinct S1P receptors (S1P1-5) on the cell surface and also 
binding partner/co-factor for at least three intracellular proteins, histone deacetylase 1 and 2 
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(HDAC 1 and 2) in the nucleus, the E3 ubiquitin ligase TRAF2, and prohibitin in the 
mitochondria (Alvarez et al., 2010; Callihan et al., 2011; Hait et al., 2009; Hait et al., 2006; 
Hurst et al., 2008; Pitson &Pebay, 2009; Radeff-Huang et al., 2004; Sanchez &Hla, 2004; 
Spiegel &Kolesnick, 2002; Strub et al., 2011) . The effect of intracellular S1P on stem cell 
differentiation is not known. However, there is solid experimental evidence that S1P has 
profound effects on ES cells and ES cell-derived neural progenitors via S1P receptors, which 
will be discussed in section 3.2.  
2.4 Terpenoids, sterols, glycosphingolipids, and lipid rafts 
The previous sections discussed bioactive lipids that are known to act through lipid 
receptors or binding proteins. There are many more lipids that regulate cell signaling 
pathways through a mechanism known as “lipid rafts” or “lipid microdomains” (Bieberich, 
2008a; Lee et al., 2010b; Lingwood &Simons, 2010; Miljan &Bremer, 2002; Ohanian 
&Ohanian, 2001; Yanagisawa et al., 2005). Lipid rafts are areas in the cell membrane (or 
intracellular membranes) that emerge from the self-assembly of lipids in an ordered 
structure. They are believed to show high affinity to specific cell signaling proteins such as 
growth factor or cytokine receptors, which leads to clustering and activation of these 
receptors. Therefore, bioactive lipids can affect stem cell differentiation in two different 
ways: direct interaction with lipid receptors such as GPCRs and lipid raft-dependent 
activation of growth factor or cytokine receptors such as LIFRα or FGFR2 (Bieberich, 2008a; 
Bryant et al., 2009; Gutierrez &Brandan, 2010; Lee et al., 2010b; Yanagisawa et al., 2005). 
Lipids that form rafts are sphingomyelin, cholesterol, and glycosphingolipids. In addition, 
signal transduction proteins such as Ras can be modified with fatty acids (palmitoylation) or 
terpenoids (farnesylation, geranylation) and glycophosphatidylinositol (GPI anchor), which 
tremendously increases membrane binding and raft association (Levental et al., 2010; 
Lingwood &Simons, 2010; Resh, 2004; Roy et al., 2005). It has been shown that particular 
glycosphingolipids termed gangliosides can regulate ES cell differentiation by the activation 
of FGFR2 and other receptors in lipid rafts (Bieberich, 2004; Yanagisawa et al., 2005). An 
example for this mechanism is the corrective activity of the ganglioside GM1 on the effect of 
the fungus toxin fumonisin B1, which causes neural tube defects by inhibiting sphingolipid 
biosynthesis (Gelineau-van Waes et al., 2005; Marasas et al., 2004). It has also been 
demonstrated that the activity of sonic hedgehog, a morphogen critical for germ layer 
formation is functionally dependent on palmitoylation and modification with cholesterol 
(Gofflot et al., 2003; Guy, 2000; Incardona &Roelink, 2000; Karpen et al., 2001; Kelley et al., 
1996; Lewis et al., 2001; Li et al., 2006). Inhibition of cholesterol biosynthesis with statins 
leads to aberrant embryo development. Although these are impressive examples of the 
effect of lipid modification and lipid raft formation on stem cell differentiation and embryo 
development, it is presently not known how to specifically utilize this mechanism in 
controlling the differentiation of ES cells. It is also not clear, which differentiation potential 
cholesterol has besides being critical for lipid raft formation. There is a plethora of steroid 
hormones such as estrogen or progesterone that are bioactive lipids activating nuclear 
receptors critical for embryo development. Progesterone is a particularly curious case since 
it is added to most of the supplements (e.g., N2, B27) found in defined media used for the in 
vitro maintenance and differentiation of ES cells. The use of this and other bioactive and 
synthetic lipids for the in vitro differentiation of ES cells will be discussed in the following 
section. 
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profound effects on ES cells and ES cell-derived neural progenitors via S1P receptors, which 
will be discussed in section 3.2.  
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The previous sections discussed bioactive lipids that are known to act through lipid 
receptors or binding proteins. There are many more lipids that regulate cell signaling 
pathways through a mechanism known as “lipid rafts” or “lipid microdomains” (Bieberich, 
2008a; Lee et al., 2010b; Lingwood &Simons, 2010; Miljan &Bremer, 2002; Ohanian 
&Ohanian, 2001; Yanagisawa et al., 2005). Lipid rafts are areas in the cell membrane (or 
intracellular membranes) that emerge from the self-assembly of lipids in an ordered 
structure. They are believed to show high affinity to specific cell signaling proteins such as 
growth factor or cytokine receptors, which leads to clustering and activation of these 
receptors. Therefore, bioactive lipids can affect stem cell differentiation in two different 
ways: direct interaction with lipid receptors such as GPCRs and lipid raft-dependent 
activation of growth factor or cytokine receptors such as LIFRα or FGFR2 (Bieberich, 2008a; 
Bryant et al., 2009; Gutierrez &Brandan, 2010; Lee et al., 2010b; Yanagisawa et al., 2005). 
Lipids that form rafts are sphingomyelin, cholesterol, and glycosphingolipids. In addition, 
signal transduction proteins such as Ras can be modified with fatty acids (palmitoylation) or 
terpenoids (farnesylation, geranylation) and glycophosphatidylinositol (GPI anchor), which 
tremendously increases membrane binding and raft association (Levental et al., 2010; 
Lingwood &Simons, 2010; Resh, 2004; Roy et al., 2005). It has been shown that particular 
glycosphingolipids termed gangliosides can regulate ES cell differentiation by the activation 
of FGFR2 and other receptors in lipid rafts (Bieberich, 2004; Yanagisawa et al., 2005). An 
example for this mechanism is the corrective activity of the ganglioside GM1 on the effect of 
the fungus toxin fumonisin B1, which causes neural tube defects by inhibiting sphingolipid 
biosynthesis (Gelineau-van Waes et al., 2005; Marasas et al., 2004). It has also been 
demonstrated that the activity of sonic hedgehog, a morphogen critical for germ layer 
formation is functionally dependent on palmitoylation and modification with cholesterol 
(Gofflot et al., 2003; Guy, 2000; Incardona &Roelink, 2000; Karpen et al., 2001; Kelley et al., 
1996; Lewis et al., 2001; Li et al., 2006). Inhibition of cholesterol biosynthesis with statins 
leads to aberrant embryo development. Although these are impressive examples of the 
effect of lipid modification and lipid raft formation on stem cell differentiation and embryo 
development, it is presently not known how to specifically utilize this mechanism in 
controlling the differentiation of ES cells. It is also not clear, which differentiation potential 
cholesterol has besides being critical for lipid raft formation. There is a plethora of steroid 
hormones such as estrogen or progesterone that are bioactive lipids activating nuclear 
receptors critical for embryo development. Progesterone is a particularly curious case since 
it is added to most of the supplements (e.g., N2, B27) found in defined media used for the in 
vitro maintenance and differentiation of ES cells. The use of this and other bioactive and 
synthetic lipids for the in vitro differentiation of ES cells will be discussed in the following 
section. 
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3. Bioactive lipids and their use for in vitro differentiation of embryonic stem 
cells 
3.1 Induction of apoptosis in teratoma-forming stem cells by ceramide analogs 
The reliability and safety of current stem cell differentiation protocols is still a matter of 
controversy. Many studies have shown that even when using similar protocols for the in 
vitro differentiation of ES cells, transplantation can lead to the formation of teratomas 
(Baker, 2009; Bieberich, 2008b; Blum &Benvenisty, 2008; Fong et al., 2010; Fujikawa et al., 
2005; Lee et al., 2009; Vogel, 2005; Wang et al., 2010). Teratomas are stem cell-derived 
tumors that are fatal if they grow in the brain or heart. Teratomas may arise from any type 
of pluripotent cells, including induced pluripotent stem (iPS) cells. Therefore, they are a 
major safety concern, in particular when using larger numbers of ES or iPS cell-derived 
cells. Our studies have shown that teratomas arise from a particular type of residual 
pluripotent stem (rPS) cells that maintain the expression of the pluripotency transcription 
factor Oct-4 and fail to differentiate or undergo apoptosis (Bieberich, 2008a, b, 2010; 
Bieberich et al., 2003; Bieberich et al., 2004). However, we have also found that they co-
express prostate apoptosis response 4 (PAR-4), a protein that sensitizes cells toward 
ceramide-induced apoptosis. Using a water-soluble ceramide analog termed N-oleoyl 
serinol or S18, which was for the first time synthesized in our laboratory, we were able to 
rid stem cells grafts of teratoma-forming rPS cells (Bieberich et al., 2002; Bieberich et al., 
2000). We have shown that S18 promotes binding of atypical PKC (aPKC) to PAR-4, which 
inhibits the aPKC-activated NF-κB cell survival pathway and induces apoptosis in rPS 
cells (Bieberich, 2008a; Krishnamurthy et al., 2007; Wang et al., 2009; Wang et al., 2005). 
These cells are eliminated because they are sensitive to S18. Neural progenitor cells will 
survive and undergo further differentiation because they show no or only low level 
expression of PAR-4.  
3.2 Induction of oligodendrocyte differentiation by S1P and S1P analogs 
It has been shown that S1P and the S1P prodrug analog FTY720 promote cell survival and 
differentiation of primary cultures of oligodendroglial precursor cells (OPCs) (Bieberich, 
2010; Coelho et al., 2010; Jung et al., 2007; Miron et al., 2008a; Saini et al., 2005). We have 
found that teratoma-forming rPS cells do not express the S1P receptor S1P1, which makes 
them vulnerable to ceramide or S18-induced apoptosis (Bieberich, 2008b, 2010; Bieberich 
et al., 2004). In contrast, ES cell-derived neural progenitor cells express S1P1. Our studies 
have shown that in the presence of S18 and FTY720, neural progenitor cells will survive 
and undergo oligodendroglial differentiation because they are insensitive to S18 (PAR-4 is 
not expressed). At the same time, OPC differentiation is promoted by FTY720 or S1P 
(S1P1 is expressed). Implantation of S18 and FTY720-treated neural progenitors does not 
result in teratoma formation and leads to integration of the grafted cells into highly 
myelinated areas of the brain such as the corpus callosum (Bieberich, 2010). Therefore, a 
combined treatment with ceramide analogs and S1P analogs or S1P receptor agonists is a 
promising strategy to control ES cell differentiation toward OPCs that are useful for 
treatment of de- or dysmelination diseases such as multiple sclerosis. Interestingly, the 
addition of S1P analogs to the ceramide analog S18 resulted in a shift of predominantly 
neuronal differentiation (as promoted by S18 alone) of ES cells toward oligodendroglial 
lineage, which is an impressive example for the impact of bioactive lipids on stem cell 
differentiation. 
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3.3 Synthetic lipids as small molecular effectors for ES cell differentiation 
The use of defined media supplemented with small molecule effectors that control the in 
vitro differentiation of stem cells is a promising strategy to generate transplantable 
progenitor cells that have not been in contact with animal-derived products such as serum. 
Currently, there are more than twenty compounds available that specifically induce 
differentiation of ES cells toward progenitors of bone, heart, muscle, or brain tissue. 
Although most of these compounds are not considered bioactive lipids because they are 
synthetic drugs not found in biological organisms, almost all of them are lipids with respect 
to their chemical structure. One of the first synthetic lipids used a small molecule effector for 
ES cell differentiation is a bioactive lipid with critical function in brain development: retinoic 
acid (Dinsmore et al., 1996; Guan et al., 2001; Hu et al., 2009; Jiang et al., 2010; Lee et al., 
2010a; Liour et al., 2006; Mayer-Proschel et al., 1997; Mummery et al., 1990; Murashov et al., 
2005; Osakada &Takahashi, 2011; Plachta et al., 2004). Mouse and human ES cells respond to 
a brief exposure to retinoic acid by accelerating differentiation into motoneurons, 
interneurons, and even oligendendrocytes when combined with specific growth factors such 
as FGF-2 or platelet-derived growth factor (PDGF). Another bioactive lipid used for in vitro 
differentiation of mouse and human ES cells, in particular toward oligodendroglial lineage 
is thyroid hormone (T3) (Glaser et al., 2007; Kang et al., 2007).  
In addition to these naturally occurring lipids, synthetic lipids have been isolated from 
chemical libraries using various bioassays for ES cell differentiation. Indirubin-3-oxime type 
compounds for maintenance of pluripotency have already been discussed in section 1. A 
more detailed discussion of these small molecule effectors can be found in the following 
articles (Ding et al., 2003; Lyssiotis et al., 2011; Zhu et al., 2010).  The advantage of these 
compounds emerges from their lipid-like structure, which allows for penetration of the 
blood brain barrier. Provided that toxicity issues do not prevent the use of these compounds 
in vivo, bioactive and synthetic lipids are likely to develop into powerful pharmacologic 
drugs that can be used for in vitro differentiation of ES or iPS cells and then after 
transplantation, for further treatment of the patient to enhance the in vivo differentiation of 
the grafted cells. One of the first drugs with this dual potential of in vitro and in vivo use is 
FTY720 (Bieberich, 2010; Coelho et al., 2007; Lee et al., 2010a; Miron et al., 2008a; Miron et al., 
2008b; Napoli, 2000). It is quite expectable that many of these “dual use” drugs will play an 
important role in the clinical application of ES and iPS cells.   
4. Conclusions and perspectives 
The goal of this chapter was to review current knowledge on bioactive lipids in embryonic 
stem cell differentiation. One of the important results of this analysis is the insight into the 
interconnection between lipid metabolism and signaling function. Unlike most proteins, 
lipids can be converted into derivatives that either complement or antagonize each other’s 
cell signaling function. For example, conversion of PC to LPA and eisosanoids has similar 
effects on enhancing pluripotency. On the other hand, conversion of ceramide to S1P can 
have opposite functions, in particular with respect to apoptosis and survival of pluripotent 
stem cells. Another important insight is that most bioactive lipids cooperate with cytokine 
and growth factor receptors providing the possibility to combine these factors with the 
respective lipids in defined media for controlled stem cell differentiation. For example, FGF-
2 can be combined with the ceramide analog S18 to promote neuronal differentiation, or 
with S18 and FTY720 to enhance specification to oligodendroglial lineage. This provides the 
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3.3 Synthetic lipids as small molecular effectors for ES cell differentiation 
The use of defined media supplemented with small molecule effectors that control the in 
vitro differentiation of stem cells is a promising strategy to generate transplantable 
progenitor cells that have not been in contact with animal-derived products such as serum. 
Currently, there are more than twenty compounds available that specifically induce 
differentiation of ES cells toward progenitors of bone, heart, muscle, or brain tissue. 
Although most of these compounds are not considered bioactive lipids because they are 
synthetic drugs not found in biological organisms, almost all of them are lipids with respect 
to their chemical structure. One of the first synthetic lipids used a small molecule effector for 
ES cell differentiation is a bioactive lipid with critical function in brain development: retinoic 
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2010a; Liour et al., 2006; Mayer-Proschel et al., 1997; Mummery et al., 1990; Murashov et al., 
2005; Osakada &Takahashi, 2011; Plachta et al., 2004). Mouse and human ES cells respond to 
a brief exposure to retinoic acid by accelerating differentiation into motoneurons, 
interneurons, and even oligendendrocytes when combined with specific growth factors such 
as FGF-2 or platelet-derived growth factor (PDGF). Another bioactive lipid used for in vitro 
differentiation of mouse and human ES cells, in particular toward oligodendroglial lineage 
is thyroid hormone (T3) (Glaser et al., 2007; Kang et al., 2007).  
In addition to these naturally occurring lipids, synthetic lipids have been isolated from 
chemical libraries using various bioassays for ES cell differentiation. Indirubin-3-oxime type 
compounds for maintenance of pluripotency have already been discussed in section 1. A 
more detailed discussion of these small molecule effectors can be found in the following 
articles (Ding et al., 2003; Lyssiotis et al., 2011; Zhu et al., 2010).  The advantage of these 
compounds emerges from their lipid-like structure, which allows for penetration of the 
blood brain barrier. Provided that toxicity issues do not prevent the use of these compounds 
in vivo, bioactive and synthetic lipids are likely to develop into powerful pharmacologic 
drugs that can be used for in vitro differentiation of ES or iPS cells and then after 
transplantation, for further treatment of the patient to enhance the in vivo differentiation of 
the grafted cells. One of the first drugs with this dual potential of in vitro and in vivo use is 
FTY720 (Bieberich, 2010; Coelho et al., 2007; Lee et al., 2010a; Miron et al., 2008a; Miron et al., 
2008b; Napoli, 2000). It is quite expectable that many of these “dual use” drugs will play an 
important role in the clinical application of ES and iPS cells.   
4. Conclusions and perspectives 
The goal of this chapter was to review current knowledge on bioactive lipids in embryonic 
stem cell differentiation. One of the important results of this analysis is the insight into the 
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lipids can be converted into derivatives that either complement or antagonize each other’s 
cell signaling function. For example, conversion of PC to LPA and eisosanoids has similar 
effects on enhancing pluripotency. On the other hand, conversion of ceramide to S1P can 
have opposite functions, in particular with respect to apoptosis and survival of pluripotent 
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and growth factor receptors providing the possibility to combine these factors with the 
respective lipids in defined media for controlled stem cell differentiation. For example, FGF-
2 can be combined with the ceramide analog S18 to promote neuronal differentiation, or 
with S18 and FTY720 to enhance specification to oligodendroglial lineage. This provides the 
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opportunity to generate bioactive lipids or lipid analogs that can be applied for in vitro 
differentiation of stem cells and then for further treatment of the patient who has received 
the stem cell graft. These “dual use” bioactive lipids will be of tremendous value for the 
therapeutic application of stem cells.   
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1. Introduction 
Although the beneficial effect of certain foods, such as liver, egg or carrot is known from 
ancient remedies, one of the common active substances, called Vitamin A, was not identified 
until 1913, when it has been independently discovered by Elmer McCollum at the 
University of Wisconsin–Madison, and Lafayette Mendel and Thomas Burr Osborne at Yale 
University. Since then numerous studies have come to light documenting the effect of 
vitamin A on the health of the individual from birth to adult age. Hale has demonstrated 
among the first that deprivation of vitamin A during pregnancy induces congenital ocular 
malformation (Hale, 1933). Wilson and Warkany later described several other congenital 
malformations that occurred in fetuses from vitamin A-deficient (VAD) rats affecting the 
genito-urinary tract, heart and great vessels, ocular and respiratory system (Wilson and 
Warkany 1947; Wilson and Warkany 1950; Warkany 1954). 
In 1968 Saunders and Gasseling have shown that grafting a posterior margin zone (called 
zone of polarizing activity, ZPA) of a chick embryo limb bud to the anterior side is able to 
induce an extra set of limb structures (Saunders 1968). It suggested that the ZPA region 
contains a diffusible morphogen. Surprisingly, retinoic acid (RA), a derivative of vitamin A, 
has been found to have the same effect on the anterior side of the bud (Tickle, Alberts et al. 
1982). There was a doubt that retinoic acid is responsible in vivo for the phenomenon, but in 
1987 Thaller and Eichele demonstrated the graded distribution of endogenous retinoic acid 
from posterior to anterior in the limb bud (Thaller and Eichele 1987). This was the time 
when retinoic acid became known as the first morphogen. Part of the truth that later RA was 
found to act indirectly, via induction of sonic hedgehog (Shh), and actually Shh is the true 
morphogen signal peptide produced by the ZPA (Riddle, Johnson et al. 1993). 
Our understanding on how vitamin A and its derivatives (called retinoids) are able to have 
such morpho-regulatory effect on the body has dramatically increased in parallel with the 
evolution of molecular biology methodologies. Development of cloning strategy, 
establishment of cDNA library made possible the identification of a receptor for the active 
derivative of vitamin A by the Evans and Chambon laboratories (Giguere, Ong et al. 1987; 
Petkovich, Brand et al. 1987). This opened the way to clarify the role of retinoids in 
embryonic development. Several aspects of the retinoid signaling have been described in the 
last two deacades using genetically modified mice. Excellent reviews are available 
summarizing these in vivo results (Duester 2008; Dolle 2009; Mark, Ghyselinck et al. 2009). 
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At the same time, in vivo system did not make it possible to understand the molecular 
mechanism in details. Thus, different cell lines were used, including embryonic carcinoma 
(EC) and embryonic stem (ES) cells. ES cells have the ability to resemble normal embryonic 
development much closer than any other cell lines and allow one to study the molecular 
mechanisms in the context of differentiation. 
In this chapter we will focus on recent studies using embryonic stem cells as a model 
system to deconvolute the retinoid signaling in depth. The first section ‘Retinoid signaling 
pathway’ will introduce briefly the present accepted molecular mechanism of retinoid 
action. We will then go through the retinoid field in the context of ES cell pluripotency 
and in context of early differentiation. Unconventionally, we will discuss a set of genes 
that were identified in high-throughput methods as potentially retinoic acid regulated 
genes in ES cells, including many that were previously not implicated in RA regulation. 
The chapter intends to serve as a starting point to the better orientation in retinoid field 
and embryonic stem cells.  
2. Retinoid signaling pathway 
There are two sources of dietary vitamin A. Retinoids are immediately available to the body 
from intracellular stores. In contrast, precursors (such as carotenoids, mainly found in 
plants) first must be converted to active forms. The predominant retinoid present in the 
mammalian fasting circulation is the retinol. Retinol is bound to a 21 kDa retinol-binding 
protein (RBP4) since it is not soluble in aqueous environments (Noy 1992). Two active 
derivatives, all-trans retinoic acid (atRA) and 13-cis-retinoic acid can be also found in the 
fasting plasma (Horst, Reinhardt et al. 1995), however at much lower concentration (for 
instance, atRA is 7.3-9 nmol/l in rats) (Cullum and Zile 1985). Retinol is transported into the 
cytoplasm of the target cell through RBP receptor Stra6 (Kawaguchi, Yu et al. 2007). Cellular 
retinol binding proteins (CRBPI and II) are able to bind this cytosolic retinol in many cell 
types, functioning as storage of retinol. For biological effects retinol must be converted into 
its active forms, and that process involves two steps. Alcohol dehydrogenases (ADHs) and 
retinol dehydrogenases (RDHs) are catalyzing the first step, the oxidation of retinol to 
retinaldehyde (retinal). The second step is the oxidation of retinaldehyde to retinoic acid 
(RA) that is catalyzed by retinaldehyde dehydrogenases (Aldh1a1, Aldh1a2 and Aldh1a3). 
Retinoic acid is not produced by all cell of the body. Cells without active RA synthesis may 
have access to it, since it can be also taken up from the environment. RA can chemically exist 
as several different isomers including atRA, 9-cis-RA, 11-cis-RA, 13-cis-RA, etc, showing 
some tissue specific distribution. In the cytoplasm RA binds to intracellular retinoic acid 
binding protein 2 (Crabp2) and delivers to the nucleus where it serves as a ligand for the 
retinoic acid receptor – retinoid X receptor heterodimer (RAR:RXR) (reviews in (Blomhoff 
and Blomhoff 2006; Duester 2008; D'Ambrosio, Clugston et al. 2011). 
RA acts via the activation of RAR:RXR heterodimer. RAR (RARα, RARβ and RARγ) and 
RXR (RXRα, RXRβ and RXRγ) are two families of nuclear receptors that bind DNA and 
directly regulate transcription (review in (Chambon 2005)). RARs and RXRs exhibit the 
conserved structure of nuclear receptors, including DNA-binding domain (DBD) and C-
terminal ligand binding domain (LBD) (review in (Bain, Heneghan et al. 2007)). RARs bind 
atRA, and the RXR partner bind 9-cis-RA. However, 9-cis-RA is normally undetectable 
except when retinol is present in excess (Mic, Molotkov et al. 2003). When RA binds to the 
RAR partner of RAR:RXR heterodimers it binds to a regulatory DNA element, called RA 
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response element (RARE) (Umesono, Giguere et al. 1988; Glass 1994). The excess of RA is 
further oxidized and degraded by Cyp26 enzymes (Cyp26a1, b1 and c1) (Figure 1). 
During embryonic development RA acts as a morpho-regulator, forming an anterior-
posterior (A–P) concentration gradient (Casci 2008) and cross-talks with other key 
embryonic signals, especially fibroblast growth factors (FGFs) and sonic hedgehog (Shh) 
(Niederreither and Dolle 2008). Production by Aldh1a1-a3 and elimination together determine 
the local concentration of RA. Cells can read their position in the RA gradient (considering the 
gradient of other morphogenes) and differentiate accordingly to these signals. Knockout of 
both Aldh1a2 and Cyp26a1, the two key enzymes responsible to determine the local RA 
concentration, lead to early morphogenetic defects and embryonic lethality, indicating the 
importance of the precise regulation of RA concentration along the body (Niederreither, 
Subbarayan et al. 1999). Interestingly, Cyp26a1 expression itself is inducible by RA (Ray, Bain 
et al. 1997), and has two identified RARE (Loudig, Maclean et al. 2005), suggesting a negative 
feedback mechanism to control the RA concentration. After all, Cyp26a1 is not expressed 
posteriorly, where RA is the highest, raising the possibility that Cyp26a1 is controlled by 
another signals as well. Fibroblast growth factor (FGF) is one of the candidates that can be 
responsible for RA independent regulation. Accordingly, the elimination of FGF signaling was 
found to shift the expression of Cyp26a1 posteriorly (Casci 2008).  
Present model proposes that unliganded RAR heterodimerizes with RXR and binds to DNA. 
In the absence of ligand the heterodimer is often complexed with corepressor proteins (such 
as SMRT, NCoR, etc.) (Nagy, Kao et al. 1997) and inhibits gene expression. Indeed, RA 
receptors are present not only where RA signaling is active, but also in anterior regions in 
which RA is fully absent. This is, as we will show later, true for undifferentiated embryonic 
stem cells, as well. Unliganded RAR:RXR thought to have a repressor function. Such active 
repression of RAR signaling has important regulatory role, for instance it is required for the 
proper head formation (Koide, Downes et al. 2001). Ligand binding stimulates a cascade of 
events resulting the release of corepressor complexes, recruitment of transcriptional 
coactivators (NCoA, CBP/p300, etc.) and thus initiation of transcription (Figure 1) (Glass 
and Rosenfeld 2000; Rochette-Egly 2005). Alternatively, ligand dependent repression of 
target genes is also known (Horlein, Naar et al. 1995). 
Strikingly, while in embryonic carcinoma (EC) or HL60 cells RA induces cell cycle arrests 
and differentiation (Flynn, Miller et al. 1983; Mummery, van Rooijen et al. 1987) in 
hepatocytes RA promotes cell proliferation (Ledda-Columbano, Pibiri et al. 2004). Cell-type 
specific expression of coregulators may resolve this contradiction and provide an additional 
context-dependent level of RA-signaling control. Little is known about the expression of RA 
coregulators in ES cells and early differentiation. Gudas recently showed an example for the 
complexity of mechanism that control RA-mediated transcription in fibroblasts versus stem 
cells. It was found that while RARβ2 is induced in both cell types by RA; Hoxa1 and 
Cyp26a1 are induced only in F9 stem cells, but not in fibroblasts. Coactivators and RNA Pol 
II recruitment are following this pattern. Strikingly, recruitment of Suz12 (a polycomb 
protein), H3K27me3 (repressive epigenetic modification), H3K9 and K14 acetylation 
(activation) and methylated CpG islands are just partly able to explain this phenomenon 
(Kashyap and Gudas 2010). Thus, simple gene expressional studies are not enough to clarify 
the context-dependent role of coregulators in cell fate commitment. Combination of single 
cell analysis and genome-wide screen will be required to unexplore this level of regulation. 
Potential applications and an outlook will be discussed briefly at the end of this chapter, in 
the “Future directions”. 
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response element (RARE) (Umesono, Giguere et al. 1988; Glass 1994). The excess of RA is 
further oxidized and degraded by Cyp26 enzymes (Cyp26a1, b1 and c1) (Figure 1). 
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(Niederreither and Dolle 2008). Production by Aldh1a1-a3 and elimination together determine 
the local concentration of RA. Cells can read their position in the RA gradient (considering the 
gradient of other morphogenes) and differentiate accordingly to these signals. Knockout of 
both Aldh1a2 and Cyp26a1, the two key enzymes responsible to determine the local RA 
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feedback mechanism to control the RA concentration. After all, Cyp26a1 is not expressed 
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Strikingly, while in embryonic carcinoma (EC) or HL60 cells RA induces cell cycle arrests 
and differentiation (Flynn, Miller et al. 1983; Mummery, van Rooijen et al. 1987) in 
hepatocytes RA promotes cell proliferation (Ledda-Columbano, Pibiri et al. 2004). Cell-type 
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protein), H3K27me3 (repressive epigenetic modification), H3K9 and K14 acetylation 
(activation) and methylated CpG islands are just partly able to explain this phenomenon 
(Kashyap and Gudas 2010). Thus, simple gene expressional studies are not enough to clarify 
the context-dependent role of coregulators in cell fate commitment. Combination of single 
cell analysis and genome-wide screen will be required to unexplore this level of regulation. 
Potential applications and an outlook will be discussed briefly at the end of this chapter, in 
the “Future directions”. 
 




Fig. 1. Overview of retinoid signaling. Retinol is taken up from the serum by the cells via 
retinol binding protein (Rbp) receptor Stra6. Intracellular retinol is reversibly oxidized to 
retinal by retinol dehydrogenases (Rdh) and further oxidized to biologically active RA by 
retinal dehydrogenases (Aldh).  Alternatively, cells can take up RA from the environment. 
Depending on the cell necessities the unwanted RA is eliminated by Cyp26 enzymes or 
transported into the nucleus and activate the transcription via RAR:RXR. According to the 
present model, unliganded RAR:RXR bind corepressor complexes while activating ligands 
replace them to coactivators and promote transcriptional activation. 
3. Retinol in ES pluripotency 
In standard mammalian cell cultures blood derived fetal bovine serum (FBS) or fetal calf 
serum (FCS) are widely used in 1-20% to supplement the basal media providing essential 
factors for the cells. Media for embryonic stem cell culturing contains notable, typically 15% 
FBS and other factors, provided by the feeder cells. Due to the requirement of these 
components, ES-cell self-renewal was thought to be dependent on multifactorial 
stimulations. However, serum-free condition and feeder-independent cultures have been 
developed in recent years with success. These cultures require addition of Bmp4 and LIF 
(Williams, Hilton et al. 1988; Qi, Li et al. 2004). LIF can act via activation of Jak-Stat3 
signaling pathway, however a complex interplay of different signaling pathways and 
transcription factors, such as Nanog, Oct3/4, Fgf4, Sox2, etc. are all together responsible for 
the pluripotency. Recently, it was shown that inhibition of FGF receptor tyrosine kinases 
and the inhibition of ERK cascade in combination with LIF addition are able to maintain 
cellular growth capacity and self-renewal of ES cells, providing a ground state to ES cells 
(Ying, Wray et al. 2008). These studies excluded the requirement of other extrinsic signals, 
such as FBS content. However, developing embryo is in direct contact with the serum, thus 
further studies of FBS will help us to better understand its role in embryogenesis. 
Certification of defined sera usually does not include the information of its retinol content. 
According to our data, an ES-qualified serum contains notable retinol (Simandi, Balint et al. 
2010). It is questionable whether this high retinol content of serum is playing any role in 
maintenance of normal phenotype of undifferentiated ES cells. Jaspal S. Khillan and his 
research group have focused on whether retinol affects any key signaling pathways in ES 
pluripotency. Interestingly, they found that it can suppress the differentiation of ESCs by 
up-regulating the expression of Nanog (Chen, Yang et al. 2007). The activation of Nanog by 
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retinol appears to be independent of previously described LIF/Stat3, Oct3/4-Sox2, bone 
morphogenic proteins (BMPs), and Wnt/beta-catenin pathways. Importantly, forced 
constitutive expression of Nanog was shown to sufficiently prevent ES cell differentiation 
and render self-renewal constitutive even in the presence of active FGF/Erk signaling 
(references in (Silva and Smith 2008)). 
The ability of retinol to influence gene expression and cell fate commitment is thought to 
make possible by enzymes controlling the conversion steps of the biologically active forms. 
In other words, only that cell is able to respond to the retinol which is expressing the 
necessary enzymes and receptors, listed above in section ‘Retinoid signaling pathway’. 
Using global gene expression analyses we found, that only RDHs, Crabp1, RARs (Rarγ, 
Rarβ) and RXRs (Rxrα, Rxrβ) are expressed unambiguously detectable levels in ES cells. 
RBPs, ALDHs and Cyp26s are present at very low mRNA levels in undifferentiated 
embryonic stem cells (Simandi, Balint et al. 2010). These results suggest that endogenous 
production of RA from the retinol content of serum is unlikely to take place in 
undifferentiated ES cells. Indeed, it has been demonstrated by HPLC analysis that retinol is 
not metabolized to RA in ES cells in the presence of LIF (Lane, Chen et al. 1999). Thus, 
presence of retinol in the serum is not in contrast with the importance of RA in 
differentiation, since endogenous RA synthesis is not taking place to induce retinoid 
signaling and differentiation. The fact, that RBP neutralizing antibody fail to prevent retinol-
mediated up-regulation of Nanog, suggests a new and independent retinol mediated 
pathway. Indeed, retinol can activate PI3kinase directly via insulin-like growth factor-1 
(IGF-1) receptor/IRS-1 (Chen and Khillan 2010). The exact mechanism by which retinol 
interacts with IGF-1 receptor is not clear at this stage. As the authors hypothesize, retinol 
may be required to preserve the integrity of stem cells in early-stage embryos before the 
lineage restricted differentiation is determined. Verifying this striking mechanism, IGF-
1/IGFBP-1 has been already shown to facilitate the establishment of a stem-cell line (Lin, 
Yen et al. 2003). Further studies confirming the positive effect of retinol on stem cell culture 
may raise the adaptation of purified retinol in routine stem cell culturing and it may further 
revise the composition of serum-free media. 
However active ligand of RAR is not produced in undifferentiated ES cells, important to 
note, that as the circulating serum, the FBS may also contain active derivatives of retinol, 
such as atRA or 13-cis RA in low but detectable concentration. AtRA, although fully ionized 
in free solution at pH 7.4, is uncharged when within a lipid environment (Noy 1992). 
Uncharged atRA is able to traverse the membrane and enter the cell (Figure 1) (Chen and 
Gudas 1996). It was discussed above that even ES cells express RARs and RXRs and Crabp, 
minimally required to respond for a stimuli. In our study we could detect atRA content of 
the cell culture serum and we could detect atRA by LC-MS in the cells, suggesting that atRA 
is taken up by the cells. Furthermore, we found that it has impact on basal gene expression 
level which could be inhibited by BMS493, an inverse RAR agonist (Simandi, Balint et al. 
2010). In conclusion these data suggest that the artificial combination of retinol and RAR 
antagonist may enhance the quality of ES cultures. 
4. Retinoid receptors in undifferentiated ES cells 
Even in undifferentiated ES cells Rarγ, Rarβ, Rxrα and Rxrβ are expressed, however their 
function is not clear at this moment. According to the “unliganded receptor-repression” 
model their DNA binding influences the expression of adjacent genes. The binding site of 
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retinol appears to be independent of previously described LIF/Stat3, Oct3/4-Sox2, bone 
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and render self-renewal constitutive even in the presence of active FGF/Erk signaling 
(references in (Silva and Smith 2008)). 
The ability of retinol to influence gene expression and cell fate commitment is thought to 
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embryonic stem cells (Simandi, Balint et al. 2010). These results suggest that endogenous 
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1/IGFBP-1 has been already shown to facilitate the establishment of a stem-cell line (Lin, 
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may raise the adaptation of purified retinol in routine stem cell culturing and it may further 
revise the composition of serum-free media. 
However active ligand of RAR is not produced in undifferentiated ES cells, important to 
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such as atRA or 13-cis RA in low but detectable concentration. AtRA, although fully ionized 
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is taken up by the cells. Furthermore, we found that it has impact on basal gene expression 
level which could be inhibited by BMS493, an inverse RAR agonist (Simandi, Balint et al. 
2010). In conclusion these data suggest that the artificial combination of retinol and RAR 
antagonist may enhance the quality of ES cultures. 
4. Retinoid receptors in undifferentiated ES cells 
Even in undifferentiated ES cells Rarγ, Rarβ, Rxrα and Rxrβ are expressed, however their 
function is not clear at this moment. According to the “unliganded receptor-repression” 
model their DNA binding influences the expression of adjacent genes. The binding site of 
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the RAR:RXR heterodimer on the DNA is the so called RA response element (RARE). RARE is 
consisting two consensus half-sites separated by a variable length of DNA. The sequence of 
this consensus half-site is most typically 5’-AGGTCA-3’ (Balmer and Blomhoff 2005). 
According to the relative direction of the half-sites, direct repeat, inverted repeat and everted 
repeat can be distinguished (Honkakoski and Negishi 2000). Type II nuclear receptors, such as 
RARs and RXRs typically bind to a direct repeat (DR), separated by 1, 2 or 5 nucleotides (called 
DR1, DR2, DR5, respectively). The RAREs tipically located in target genes, however large 
number of DR2-type elements are present within Alu repeats (Vansant and Reynolds 1995) 




Fig. 2. RARE elements of well-known RA target genes. RAR binding occurs most typically 
on DR5 (Hoxa1, Cyp26a1, RARβ2) and DR2 (Hoxb1) elements. 
Chromatin immunoprecipitation (ChIP) is a powerful and widely applied technique for 
detecting the association of individual proteins with specific genomic regions. ChIP can be 
combined with microarray technology to identify the location of specific proteins on a 
genome-wide basis (called ChIP-chip) (Aparicio, Geisberg et al. 2004). A recent study has 
performed ChIP-chip on mouse embryonic fibroblasts and ES cells overexpressing tagged 
Rarγ (Delacroix, Moutier et al. 2010). Rarγ is the dominantly expressed subtype of RAR in 
ES cells, thus it confirms the biological relevance of this analysis. 354 target loci bound by 
the RAR were identified in MEFs and 462 loci in undifferentiated ES cells. These sites 
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obviously do not cover the full repertoire, but as this was the first large-scale study, it served 
many striking results. First, it was found that only a minority of the 354 MEF loci were 
present in ES cells, suggesting cell-specific occupancy of RAR binding. This can be an 
important mechanism contributing to the distinct of retinoid signaling seen in different cell 
types. Not unexpectedly, in ES cells RAR was found to occupy genes with a wide variety of 
functions: pluripotency (Oct3/4, Lin28, or Utf1), differentiation (Lefty1, Lefty2), important 
signaling pathways (Nodal, Notch4, sonic hedgehog pathway components, several FGF), a 
more systematic discussion of regulated genes will be provided in the next section. In MEF 
cells RAR occupancy (ChIP-chip data) and RA regulation (microarray) has been analyzed 
together, showing that only small subset of RAR bound genes were regulated by RA. In 
undifferentiated ES cells such dataset is still not available. It cannot be completely excluded 
that formaldehyde cross-linking or overexpression of Rarγ gives its artificial detection by 
ChIP. However, many of those RAR bound, but not regulated genes were found to be 
regulated by RA in other cell types, suggesting the good source of data and a highly cell 
type and context dependent regulation. Moreover, part of the genes, bound by unliganded 
RAR, showed H3K4me3 (associated with active chromatin) and expression. Data is lacking 
to show whether there is a partial repression in case of these genes or unliganded RAR 
binding do not influence their expression at all. Latter would suggest that unliganded RAR 
silences only small subsets of bounded target genes. This is at least partly in contrast with 
the previously mentioned “unliganded RAR – corepressors recruitment” model (shown on 
Figure 1) and confute one at this moment to unambiguously predict which gene and which 
cell type will respond to the stimuli. In the same study the sequence of RAR-bound loci has 
been compared. Interestingly, majority of the loci did not contain consensus DR1, -2 or -5 
elements, rather compromised one or several anomalously spaced consensus half sites. 
Strikingly, there was no correlation between the presence/absence of recognizable DR 
elements and RA regulation. Bioinformatic analyses are considering the sequence diversity 
of RAR binding sites and the varying distance between the direct repeats only in a limited 
level. Genome-wide RAR binding studies in different cell types combined with advanced 
bioinformatic analysis of target loci may help to build a better prediction model and further 
investigate the biological aspects of different binding sites and the potential role of 
epigenetic state of these regions. One of such pioneer study (Mahony, Mazzoni et al. 2011) 
will be discussed in the next section. 
5. Retinoic acid induced downregulation of stem cell pluripotency and 
differentiation induction 
The moment that we revoke LIF from the media of undifferentiated ES cells results in the 
spontaneous differentiation of cells. This can be further induced by allowing them to form 
aggregates, called embryoid bodies (EB). We have looked for the early changes during the 
four day embryoid body formation using genome-wide expressional analysis and found 
~1000 genes to be regulated. Important genes involved in retinoid signaling, such as Stra6, 
Aldh1a2, Rarβ, etc. are not among them, only the expression of the RA induced-RA 
eliminator Cyp26a1 is elevated, suggesting that RA signaling is not activated yet in this 
stage and the incidental RA level is actively cleared away. This is in correlation with the 
findings that presence of RA decreases the viability of blastocyst (Huang, Shen et al. 2003) 
and explain the importance of uterine Cyp26a1 activity in the maintenance of pregnancy, 
especially during the process of blastocyst implantation (Han, Xia et al. 2010). Potentially, an 
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RA-independent, FGF signaling controlled Cyp26a1 expression may be responsible for this 
for RA clearance in day 4 EBs. This explains why Cyp26a1 could upregulate in the presence 
of RAR inverse agonist BMS493. In contrast, following the post-implantation RA is sorely 
needed. Absence of RA in this stage cause serious malformations, including axial rotation, 
shortens along the anterioposterior axis, disturbed limb bud development, finally resulting 
early embryo death (Niederreither, Subbarayan et al. 1999). 
Currently, the effector molecules and cascade signaling of the early retinoid signaling in the 
vertebrate embryo are barely known. Mechanistic studies showed that RA is not just 
initiating the differentiation, but also actively decrease the pluripotency via binding to 
RARE in Oct3/4 promoter (Pikarsky, Sharir et al. 1994) and regulation of LIF-signaling 
(Tighe and Gudas 2004). Indeed, Oct3/4 is not changing significantly between day 0 and 
day 4 in our data, but it is actively down-regulated following RA-treatment. In the same 
time, neural marker DCX becomes upregulated (Simandi, Balint et al. 2010). This suggests 
clearly the importance of retinoic acid-free (but not retinol-free) environment to the 
undifferentiated embryonic stem cells. The importance of RA in pluripotency can be studied 
from a different viewpoint, namely, whether retinoid signaling is able to influence the cell 
reprogramming. Yamanaka and contributors have shown that introduction of four factors 
(Oct3/4, C-Myc, Klf4 and Sox-2) into mouse embryonic fibroblast (MEF) cells induce the  
reprogramming of the differentiated cells and driving back them to embryonic stem cell-like 
cells, called induced pluripotent stem cells (iPSC) (Takahashi and Yamanaka 2006). A recent 
study has investigated how different nuclear receptors influence the iPS generation from 
MEFs. This screen included 19 nuclear receptors, among them Rarα, Rarγ and Rxrα. 
Surprisingly, none of the overexpressed retinoid receptors influenced significantly the 
obtained iPS colony numbers (Heng, Feng et al. 2010). Importantly, this study did not use 
ligands or antagonists to activate (or repress) the overexpressed receptors. 
More is known about the ES differentiation promoting effect of RA. Over the years, many 
RA-regulated differentiation pathways have been discovered first in embryonic carcinoma 
(EC) and then adopted to ES cells as well. The most studied mouse EC cell lines include F9 
cells, which can be induced by RA to differentiate into primitive, parietal, and visceral 
endodermal cells; and P19 cells, which can differentiate to endodermal and neuronal cells 
upon RA treatment. ES cells can be induced to differentiate into a number of different cell 
types; many of which require RA treatment (Soprano, Teets et al. 2007). 
To understand in depth how retinoic acid is able to drive a given differentiation pathway, 
one should identify a set of regulated genes by high-throughput methods. Here, a very 
important issue is the applicable concentration of retinoic acid. Typically, a regulated gene 
shows dose dependent effect. From this dose dependent curve one can determine the half 
maximal effective concentration (EC50) of the given gene. This value may vary in case of 
other target genes. Thus, it can happen that with the application of lower retinoic acid 
concentration one will induce only the most responsiveness genes (lower EC50). A solution 
for this problem can be a high RA concentration that will give the maximal response 
(saturation). However, this posing is just partly correct. First, in the embryonic development 
RA grade has very important effect in the anterior-posterior patterning and deep impact on 
cell fate commitment. This can be true for stem cell differentiation as well. Strikingly, there 
is no systematic study available using different concentration of RA comparing sets of 
regulated genes genome-wide. Theoretically, a low concentration of RA results in the 
expression of “gene A”, a higher concentration will also express “gene B”, which may 
negatively affect the expression of “gene A” by a negative feedback mechanism.  
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Limited number of studies demonstrated the dose-dependent effect of RA on a given 
pathway. For instance, it was shown that higher concentrations of RA induce a dorsal 
phenotype, while lower concentrations of RA induced a more ventral phenotype during RA 
induced neural differentiation (Okada, Shimazaki et al. 2004). Not only the concentration, 
but also the timing of RA signal might be very important. According to the established 
protocols, different cell types (such as adipocyte, pancreatic cell, neural cells, primordial 
germ cells, etc.) requires RA signal in various time-points during their differentiation (Bost, 
Caron et al. 2002; Bibel, Richter et al. 2007; Eguizabal, Shovlin et al. 2009). 
The exact molecular events that lead from a pluripotent stem cell to a fully differentiated cell 
following RA treatment are yet to be determined. Considering the above discussed time- 
and dose-dependent effect, gene expressional studies can determine the early signaling 
pathways induced by retinoic acid. We have performed such a study on 4 day-old embryoid 
bodies treated with 5 µM ATRA for 12 hours and identified 70 annotated genes that were 
regulated at least 2-fold. At first glance it seems a low number of genes, but another 
independent study could detect similarly only 96 significantly differently expressed genes 
(Mahony, Mazzoni et al. 2011). Gene expressional studies cannot clearly classify sets of 
genes that are directly regulated by RAR. A new method, namely ChIP-Seq, combines 
chromatin immunoprecipitation (ChIP) with parallel DNA sequencing to identify global 
binding sites for any protein of interest (Johnson, Mortazavi et al. 2007). A recently 
published paper investigated the ligand-dependent dynamics of RAR binding during early 
differentiation using ChIP-Seq. In the absence of RA, ChIP-Seq enrichment could be 
detected at 1822 sites in embryoid bodies. After 8 hours of exposure to RA this number did 
not really changed (enrichment at 1924 sites). The most frequent motifs were DR2 and DR5. 
Confirming the previously discussed ChIP-chip dataset, only 507 sites bound constitutively 
RAR. This is further query the accepted model of constitutively binding RARs. More 
strikingly, in the same study they could detect a ligand-dependent shift in RAR’s preference 
from DR0 and DR1 (absence of ligand) to DR5 (presence of ligand).  
6. Retinoic acid driven signaling pathways in embryonic stem cells 
Vitamin A-deficient and genetic animal models revealed the importance of retinoic acid 
signaling in embryonic development and organogenesis. In early development, RA 
participates in the organization of the trunk by providing an instructive signal for posterior 
neuroectoderm, foregut endoderm and a permissive signal for trunk mesoderm 
differentiation. At later stages, RA contributes to the development of the eye and other 
organs (reviewed in (Duester 2008). Presumably, in vitro experiments in stem cell cultures 
are able to reveal the in vivo molecular targets of retinoid action during the development. 
Indeed, we will show hereinafter that genes identified in cell culture experiments match in 
vivo findings. However, one should assume that these in vitro cultures are not able to 
perfectly mimic the spatio-temporal events. 
Binding of RA to its receptor induces differentiation mainly via one of the following 
mechanisms: 1) Initiate changes in interaction of RAR:RXR and co-regulators (SMRT, NCoR, 
NCoA, CBP/p300, etc.), resulting transcription of primary target genes; 2) Induces 
expression of transcription factors (Hox, Cdx, etc) and other signaling molecules, resulting 
transcription of secondary target genes. Regulation of non-coding RNAs may serve as 
additional level of retinoid action (Rossi, D'Urso et al. 2010); 3) Alters interactions with 
proteins involved in epigenetic regulation (Kashyap, Gudas et al. 2011). Furthermore, there 
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are proteins that bind at or near RAREs resulting a more complex mechanism of retinoid 
action (for review, see (Gudas and Wagner 2011). 
In the followings we will discuss the potential role of genes identified in ChIP-chip study of 
ES cells (Delacroix, Moutier et al. 2010), in day 2 EBs by ChIP-Seq study (Mahony, Mazzoni 
et al. 2011) or in our microarray study (Simandi, Balint et al. 2010), focusing especially on 
those which were found in more than one of these studies. In fact, the overlap between the 
results is remarkable. The results of these experiments provide a list about genes that are 
primary (ChIP-chip, ChIP-Seq) or secondary response to RA (microarray) considering the 
technical limitation of such experiments. Based on the published biological functions, we 
divided arbitrarily some of the genes into functional subgroups. An asterisk (*) mark genes 
where previously identified or predicted RARE could be identified. Following the gene 
name, an arrow marks the atRA effect for the expression of the given gene (↑, ↓), up and 
down, respectively. 
6.1 Regulators of RA metabolism 
The following genes are well known players in the retinoid metabolism (see Figure 1 and 3). 
At the same time many of them are involved in the proper eye function, and very likely 
important in its development. For more details about retinoid signaling in embryonic eye 
development look for recent reviews in (Duester 2009), (Cvekl and Wang 2009). 
Cyp26a1* (cytochrome P450, family 26, subfamily a, polypeptide 1) (↑) 
Cyp26 enzymes have been shown to restrict the availability of RA to the transcriptional 
machinery (review in (Pennimpede, Cameron et al. 2010). HPLC and LC-MS-MS identified 
4-OH-RA, 4-oxo-RA and 18-OH-RA and other oxidized products formed as metabolites by 
Cyp26a1 (Chithalen, Luu et al. 2002). Cyp26a1 expression is directly regulated by RA, and 
presumably independently regulated by FGF (Casci 2008). Microarray analyses revealed 
that RA-treated Cyp26a1 −/− ES cells exhibited lower mRNA levels than wild-type ES cells 
for genes involved in differentiation, particularly in neural and smooth muscle 
differentiation (Langton and Gudas 2008). One intriguing possible role of Cyp26a1 is to 
regulate the formation of waves or pulses of RA during the dynamic development of some 
structures, most notably the hindbrain (Sirbu, Gresh et al. 2005). 
Dhrs3 (dehydrogenase/reductase (SDR family) member 3), also known as retinal short-
chain dehydrogenase/reductase (retSDR1) (↑) 
It has been first described in cone photoreceptors suggesting its possible responsibility for 
reduction of all-trans-retinal in photoreceptor outer segments that serve as the first step in 
the regeneration of bleached visual pigments (Haeseleer, Huang et al. 1998). Furthermore, it 
was found to be expressed also in placenta, lung, liver, kidney, pancreas, and retina; many 
of these tissues known to actively metabolize retinol. Thus, it suggests that Dhrs3 acts as a 
generic all-trans-retinol dehydrogenase in many tissues, ensuring that deleterious levels of 
all-trans-retinal do not accumulate. It was later demonstrated that Dhrs3 is induced by RA 
in a wide array of cell lines derived from different human tissues and a recent study has 
shown that Dhrs3 respond oppositely to RA antagonists. Using morpholino knockdown and 
mRNA over-expression, this study demonstrated that Dhrs3 is required to limit RA levels in 
the embryo, primarily in the central nervous system (CNS) (Feng, Hernandez et al. 2010). 
These together suggest that Dhrs3 is an RA-induced feedback inhibitor of RA biosynthesis, 
and it acts very similarly than Cyp26a1. Whether the RA function is direct or indirect in 
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Dhrs3 regulation remained to be undetermined. Both ChIP-chip and ChIP-Seq analysis 
could identify Dhrs3; however typical binding site was not identifiable. 
Rarb* (retinoic acid receptor, beta) (↑) 
The various RAR subtypes (α, β, γ) are widely but differentially expressed during murine 
embryonic development, and most tissues express one or more of the subtypes and isoforms 
during development in different combinations (Dolle 2009). The expression of Rarβ gene is 
spatially and temporally restricted in certain structures in the developing embryo 
(segmented brain (r7), hypothalamus, ventricular neuroepithelium, pigmented epithelium, 
proximal bronchi, myocardium, etc.), suggesting that Rarβ could play specific roles during 
morphogenesis. In contrast, mice lacking all isoforms of Rarβ develop normally and there is 
no obvious alteration in the spatial pattern of expression of Hox genes (Luo, Pasceri et al. 
1995). These experiments demonstrate that Rarβ is not absolutely required for embryonic 
development, maybe due to the redundancy in their role among the RAR isoforms.  
Rbp1* (retinol binding protein 1, cellular), also known as CRBP1 (↑) 
As it was discussed previously, retinol and retinaldehyde in the cytoplasm are associated 
with cellular retinol-binding proteins (CRBPs). CRBP1 is the most widespread, but it 
displays some tissue specificity (Dolle, Ruberte et al. 1990). Functional analysis of CRBP1 
suggested its role in retinol storage and release where high levels of RA are required for 
specific morphogenetic processes (Ghyselinck, Bavik et al. 1999). However, CRBP1-deficient 
mice did not show any morphological defects, did not result altering organogenesis and 
CRBP1 ablation did not change RA-dependent gene expression, indicating that absence of 
CRBP1 is not life-threatening, at least under conditions of maternal vitamin A dietary 
sufficiency (Ghyselinck, Bavik et al. 1999). 
Stra6 (stimulated by retinoic acid gene 6) (↑) 
Existence of a cell-surface receptor for RBP has been predicted since the mid-1970s. In 2007, 
Kawaguchi and coworkers could identify Stra6 that acts as a high affinity cell surface 
receptor for RBP (Kawaguchi, Yu et al. 2007), however Stra6 is not expressed in all retinoid 
metabolizing tissues. Interestingly, cell culture experiments have shown that Stra6-
expressing cells, preloaded with retinol, are able to release more retinol into the culture 
medium than cells without expresson of Stra6 (Isken, Golczak et al. 2008), suggesting that 
Stra6 acts as a bidirectional transporter of retinol. Potentially, Stra6 depending on 
intracellular retinol/retinoic acid concentration, coordinate retinol uptake /removal, thus 
avoiding cells to take up toxic amount of retinol. Stra6 mutation was found to lead severe 
congenital abnormalities in humans, including congenital heart defects, mental retardation 
and lung hypoplasia (Pasutto, Sticht et al. 2007). 
6.2 Regulators of body axis patterning 
Retinoic acid has been described as a first morphogen (Slack 1987). Indeed, it is responsible 
for the regulation of several genes implicated in body axis determination. However, the 
embryonic axis formation is a very complex process, regulated by additional factors, such as 
Wnt, Shh, Bmp and FGF signaling (Meyers and Martin 1999; Diez del Corral and Storey 
2004). Final outcome of the differentiation is the resultant of these signaling pathways. Most 
of the following genes are well known RA signaling targets, the reason for listing them here 
is to demonstrate the role of RA in body axis determination. 
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Fig. 3. Effect of all-trans retinoic acid treatment on the retinoid pathway in EBs. Addition of 
atRA induce its removal via multiple pathway (in red). Stra6 may responsible to eliminate 
the intracellular retinol, Crbp1 may hold back the retinol from further steps, Dhrs3 
participates in retinal removal, while Cyp26a1 can degrade the produced RA. These 
mechanisms may have a role to protect the blastocyst from the toxic effect of retinoids. 
Cdx1* (caudal type homeobox 1) (↑) 
The Cdx genes (Cdx1, 2 and 4) are relatives of Hox genes (see below) and believed to derive 
from a common ProtoHox ancestral cluster (Chourrout, Delsuc et al. 2006). Cdx regulate 
anterior-posterior (AP) vertebral patterning, at least in part, through direct regulation of 
Hox gene expression via Cdx-binding sites, which are often found in clusters  throughout 
the Hox cluster (Gaunt, Drage et al. 2008). Prior work has shown that Cdx1 is target of Wnt, 
RA and FGF signaling, suggesting that Cdx1 is responsible to convey the activity of these 
signaling molecules to Hox genes. Indeed, RARE and Lef/Tcf-response elements (LRE) has 
been identified in the proximal promoter of Cdx1. Interestingly, mutation of LRE greatly 
reduce the induction of Cdx1 by RA, demonstrating a requirement for Wnt signaling in the 
regulation of this gene by retinoids (Beland, Pilon et al. 2004). Retinoic acid plays a key role 
in early stages of Cdx1 expression at embryonic day 7.5. Surprisingly, Cdx1 -/- mice are 
viable and fertile, however showing anterior homeotic transformations of vertebrae 
(Subramanian, Meyer et al. 1995). These abnormalities are concomitant with posterior shifts 
of Hox gene expression domains in the somitic mesoderm. 
In ES cell derived EBs Cdx1 expression is increasing, peaking between day 2 and day 3 
which is the reported window of hemangioblast and blood fate specification (day 3 to day 4 
of EB differentiation). Ectopic expression of Cdx1 in differentiating EBs up-regulated Hoxa 
and Hoxb posterior cluster genes (Hoxa6, Hoxb8, Hoxb9) (McKinney-Freeman, Lengerke et al. 
2008). 
Hox (homeobox) genes (* in the text) (↑) 
Hox genes are organized in gene clusters (Hoxa, Hoxb, Hoxc, and Hoxd) and show a strict 
coordinated expression, reglated by among others Cdx genes. Retinoic acid is not only 
through the regulation of Cdx, but also directly a well-established regulator of Hox genes 
along the anterior-posterior axis in higher animals. Genes in the 3’ ends of Hox clusters are 
induced by RA, while 5' Hox genes are not induced by RA (Langston and Gudas 1992; 
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Langston, Thompson et al. 1997). Indeed, microarray and ChIP-Seq studies identified 
several members of the Hox family (Hoxa1*, a2*, a3*, a4, a5*, a10 and Hoxb1*, b2*, b3*, b4*, 
b5*, b6*, Hoxc4 etc.). Hoxc and Hoxd clusters are not induced upon RA treatment in ES cells 
and day 2 or day 4 old EBs. Several RARE has been identified in the Hox cluster by ChIP-
Seq, many of them have been described in previous publications (Popperl and Featherstone 
1993; Dupe, Davenne et al. 1997; Packer, Crotty et al. 1998; Huang, Chen et al. 2002). 
Lefty1 (left right determination factor 1) (↑) 
A distinctive and essential feature of the vertebrate body is a pronounced left-right 
asymmetry (review in (Mercola and Levin 2001). Left-right asymmetric signaling molecules 
in mammals include three transforming growth factor beta (TGFbeta)-related factors, Nodal, 
Lefty1 and Lefty2 that are responsible for the mirror-image anatomy. They are all expressed 
on the left half of developing mouse embryos. Nodal acts as a left-side determinant by 
transducing signals through Smad and FAST and by inducing Pitx2 expression on the left 
side. Lefty proteins are antagonists that inhibit Nodal signaling (Hamada, Meno et al. 2001). 
Nodal and Lefty are expressed in the pancreas during embryogenesis and islet regeneration. 
In vitro studies demonstrated that Nodal inhibits, whereas Lefty enhances, the proliferation 
of a pancreatic cell line (Zhang, Sterling et al. 2008). 
Meis1 and Meis2* (myeloid ecotropic viral integration site) (↑) 
Homeodomain proteins of the Meis subfamily are expressed dynamically in several organs 
during embryogenesis and exert potent regulatory activity through their interaction with 
Hox proteins and other transcription factors. Meis1-deficient embryos have partially 
duplicated retinas and smaller lenses than normal. They also fail to produce 
megakaryocytes, display extensive hemorrhaging, and die by embryonic day 14.5 (Hisa, 
Spence et al. 2004). In addition, Meis1-deficient embryos lack well-formed capillaries, 
although larger blood vessels are normal. Definitive myeloerythroid lineages are present in 
the mutant embryos, but the total numbers of colony-forming cells are dramatically reduced 
(Azcoitia, Aracil et al. 2005). 
Pbx2* (pre B-cell leukemia transcription factor 2) ((-), see in the text) 
It has been found that Pbx2 -/- embryos are born at the expected Mendelian frequencies and 
exhibit no detectable abnormalities in development and organogenesis (Selleri, DiMartino et 
al. 2004), however they show limb abnormalities (Capellini, Di Giacomo et al. 2006). 
Supporting its role in this phenomenon, its elevated expression in limb buds after RA 
treatment has been demonstrated. Retinoic acid response element in the promoter of Pbx2 
has been identified in both ChIP-chip and ChIP-Seq study, even without ligand activation. 
However it seems to be not regulated by atRA in ES cells or EBs according to the microarray 
data, suggesting a more context dependent regulation of this gene by RA. As Pbx proteins 
have been shown to dimerize with Hox proteins and act as a cofactor, we included here 
(Moens and Selleri 2006). Pbx2 is believed to be involved in the control of proximodistal axis 
formation in mouse (Capellini, Zewdu et al. 2008).  
Tshz1 (teashirt zinc finger family member 1) (↑) 
Tshz1 is detected from E9.5 in the somites, and also present in the spinal cord, limb buds 
and branchial arches. Tshz1 -/- mice exhibit Hox-like vertebral malformations and homeotic 
transformations in the cervical and thoracic regions, suggesting that Tshz1 and Hox genes 
are involved in common pathways to control skeletal morphogenesis (Core, Caubit et al. 
 




Fig. 3. Effect of all-trans retinoic acid treatment on the retinoid pathway in EBs. Addition of 
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Cdx1* (caudal type homeobox 1) (↑) 
The Cdx genes (Cdx1, 2 and 4) are relatives of Hox genes (see below) and believed to derive 
from a common ProtoHox ancestral cluster (Chourrout, Delsuc et al. 2006). Cdx regulate 
anterior-posterior (AP) vertebral patterning, at least in part, through direct regulation of 
Hox gene expression via Cdx-binding sites, which are often found in clusters  throughout 
the Hox cluster (Gaunt, Drage et al. 2008). Prior work has shown that Cdx1 is target of Wnt, 
RA and FGF signaling, suggesting that Cdx1 is responsible to convey the activity of these 
signaling molecules to Hox genes. Indeed, RARE and Lef/Tcf-response elements (LRE) has 
been identified in the proximal promoter of Cdx1. Interestingly, mutation of LRE greatly 
reduce the induction of Cdx1 by RA, demonstrating a requirement for Wnt signaling in the 
regulation of this gene by retinoids (Beland, Pilon et al. 2004). Retinoic acid plays a key role 
in early stages of Cdx1 expression at embryonic day 7.5. Surprisingly, Cdx1 -/- mice are 
viable and fertile, however showing anterior homeotic transformations of vertebrae 
(Subramanian, Meyer et al. 1995). These abnormalities are concomitant with posterior shifts 
of Hox gene expression domains in the somitic mesoderm. 
In ES cell derived EBs Cdx1 expression is increasing, peaking between day 2 and day 3 
which is the reported window of hemangioblast and blood fate specification (day 3 to day 4 
of EB differentiation). Ectopic expression of Cdx1 in differentiating EBs up-regulated Hoxa 
and Hoxb posterior cluster genes (Hoxa6, Hoxb8, Hoxb9) (McKinney-Freeman, Lengerke et al. 
2008). 
Hox (homeobox) genes (* in the text) (↑) 
Hox genes are organized in gene clusters (Hoxa, Hoxb, Hoxc, and Hoxd) and show a strict 
coordinated expression, reglated by among others Cdx genes. Retinoic acid is not only 
through the regulation of Cdx, but also directly a well-established regulator of Hox genes 
along the anterior-posterior axis in higher animals. Genes in the 3’ ends of Hox clusters are 
induced by RA, while 5' Hox genes are not induced by RA (Langston and Gudas 1992; 
 
Retinoid Signaling is a Context-Dependent Regulator of Embryonic Stem Cells 
 
67 
Langston, Thompson et al. 1997). Indeed, microarray and ChIP-Seq studies identified 
several members of the Hox family (Hoxa1*, a2*, a3*, a4, a5*, a10 and Hoxb1*, b2*, b3*, b4*, 
b5*, b6*, Hoxc4 etc.). Hoxc and Hoxd clusters are not induced upon RA treatment in ES cells 
and day 2 or day 4 old EBs. Several RARE has been identified in the Hox cluster by ChIP-
Seq, many of them have been described in previous publications (Popperl and Featherstone 
1993; Dupe, Davenne et al. 1997; Packer, Crotty et al. 1998; Huang, Chen et al. 2002). 
Lefty1 (left right determination factor 1) (↑) 
A distinctive and essential feature of the vertebrate body is a pronounced left-right 
asymmetry (review in (Mercola and Levin 2001). Left-right asymmetric signaling molecules 
in mammals include three transforming growth factor beta (TGFbeta)-related factors, Nodal, 
Lefty1 and Lefty2 that are responsible for the mirror-image anatomy. They are all expressed 
on the left half of developing mouse embryos. Nodal acts as a left-side determinant by 
transducing signals through Smad and FAST and by inducing Pitx2 expression on the left 
side. Lefty proteins are antagonists that inhibit Nodal signaling (Hamada, Meno et al. 2001). 
Nodal and Lefty are expressed in the pancreas during embryogenesis and islet regeneration. 
In vitro studies demonstrated that Nodal inhibits, whereas Lefty enhances, the proliferation 
of a pancreatic cell line (Zhang, Sterling et al. 2008). 
Meis1 and Meis2* (myeloid ecotropic viral integration site) (↑) 
Homeodomain proteins of the Meis subfamily are expressed dynamically in several organs 
during embryogenesis and exert potent regulatory activity through their interaction with 
Hox proteins and other transcription factors. Meis1-deficient embryos have partially 
duplicated retinas and smaller lenses than normal. They also fail to produce 
megakaryocytes, display extensive hemorrhaging, and die by embryonic day 14.5 (Hisa, 
Spence et al. 2004). In addition, Meis1-deficient embryos lack well-formed capillaries, 
although larger blood vessels are normal. Definitive myeloerythroid lineages are present in 
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2007). Previous studies suggested Tshz1 as an RA regulated gene, however direct evidence 
was not shown yet. 
6.3 Testis development, spermatogenesis, female fertility 
Generation of putative primordial germ cells (PGCs) has been reported during the 
differentiation of mouse and human ESCs in in vitro systems using RA (reviewed in (Zhou, 
Meng et al. 2010)). In vivo PGCs come from the proximal epiblast and migrate subsequently 
into the mesoderm, the endoderm and the posterior of the yolk sac (Bendel-Stenzel, 
Anderson et al. 1998). The mechanisms responsible for the pluripotent epiblast cells to 
become PGCs involve bone morphogenetic protein 2 (Bmp2), Bmp4, Bmp8b, Prdm1 and 
Prdm14 (Ying and Zhao 2001; Edson, Nagaraja et al. 2009). Migration of PGCs requires 
interferon-induced transmembrane proteins 1 and 3, Kit ligand and Cxcl12 (Molyneaux, 
Zinszner et al. 2003). Germ cells continue to proliferate by mitosis upon arriving in the 
genital ridge. Spermatogonial lineage does not enter meiosis before puberty, and the 
proliferation is inhibited by androgens. In contrast, germ cells in the female gonad continue 
to proliferate by mitosis and enter meiosis. These are raising the evidence of testicular 
meiosis-preventing and ovarian meiosis-inducing factors. Initiation of meiosis in the fetal 
ovary has been suggested to require retinoic acid (Bowles, Knight et al. 2006). Germ cells fail 
to enter meiosis and remain undifferentiated in embryonic vitamin A-deficient ovaries, 
suggesting that retinol regulates the initiation of meiosis I (Li and Clagett-Dame 2009). 
Another study revealed, that RA-degrading enzyme Cyp26b1 in fetal testis is responsible to 
delay meiosis until postnatal development (Koubova, Menke et al. 2006). However, RA acts 
too widely in mammalian development to account, by itself, for the cell-type and temporal 
specificity of meiotic initiation. The following RA regulated genes have been found related 
to germ cell development; many of them only partly characterized yet. 
Agpat3* (1-acylglycerol-3-phosphate O-acyltransferase 3) also known LPAAT3 (↑) 
Agpat3 was shown to have both lysophosphatidic acid acyltransferase (LPAAT) and 
lysophosphatidylinositol acyltransferase (LPIAT) activities. It is mainly expressed in the 
liver, kidney, and testis. Present studies suggest its role in PI (phosphatidylinositol) 
production of the testis. Interestingly, expression of Agpat3 in the testis is enhanced 
significantly in an age-dependent manner (Yuki, Shindou et al. 2009). 
Nrip1 (Nuclear receptor interacting protein 1) also known as RIP140 (↑) 
A nuclear protein that specifically interacts with the hormone-dependent activation domain 
AF2 of nuclear receptors. Mice null for Nrip1 gene are viable, but females are infertile 
because of complete failure of mature follicles to release oocytes at ovulation stage. 
Heterozygous females are only partially affected (White, Leonardsson et al. 2000).  
Rec8* (REC8 homolog (yeast)) (↑) 
Gene expression of Rec8 is strictly confined to spermatocytes and spermatids in male mouse 
and oocytes in female mouse. Restricted expression pattern of Rec8 mRNA implies its 
essential role in meiosis in both sexes of mammals (Lee, Yokota et al. 2002). It was found 
that Rec8 is a key component of the meiotic cohesin complex. During meiosis, cohesin is 
required for the establishment and maintenance of sister-chromatid cohesion, for the 
formation of the synaptonemal complex, and for recombination between homologous 
chromosomes. Importantly, Rec8 -/- mice are born in sub-Mendelian frequencies and both 
sexes have germ cell failure causing sterility (Xu, Beasley et al. 2005).  
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Stra8* (stimulated by retinoic acid 8) (↑) 
Encodes a protein that is crucial for mammalian germ cells to enter into pre-meiotic stages. 
Microarray analysis of whole murine embryonic ovary and postnatal testis time course data 
revealed a single peak of Stra8 expression in each organ at the onset of meiosis; at E14.5 in 
the ovary and 10 days postpartum in the testis (Hogarth, Mitchell et al. 2011). Stra8 is 
specifically expressed in mammalian germ cells before their transition from mitosis to 
meiosis and its expression is observed only in the postnatal testis. Stra8 associates with DNA 
and possesses transcriptional activity (Tedesco, La Sala et al. 2009). Stra8 mRNA and protein 
were induced in cells treated by all-trans and 9-cis retinoic acids in P19 embryonal 
carcinoma cells (Oulad-Abdelghani, Bouillet et al. 1996), however using Aldh1a2 -/- mice 
(lacking RA synthesis) it was found that Stra8 expression is detectable even in the absence of 
RA (Kumar, Chatzi et al. 2011). 
The following genes are also regulated by atRA and could be detected with ChIP-chip or ChIP-
Seq. They are related to fertility, testis or germ cells, but due to the limited available data, they 
are not discussed here in details: Wdr40b (↑), Nr0b1 (↑), Cxcl12 (↑), Kit (↑), Tcp11 (↑). 
6.4 Neuroectodermal cell fate commitment 
Other chapters of the book prominently construe with the neural differentiation of stem 
cells. Present protocols are widely using RA to induce the neural differentiation of stem 
cells; however the exact mechanisms remained largely unknown yet. The fact that 
endogenous RA is starting to synthetize in mouse embryo after forebrain and midbrain 
neuroectoderm induction is raising the possibility that RA is actually not required for neural 
induction (Duester 2008). However, RA induced Hoxa1 activity is clearly essential for the 
neuronal differentiation (Martinez-Ceballos and Gudas 2008). 
The following genes were found to be related to the neural differentiation or functioning. 
They may have role in the neural specification only. Some of them are putatively involved in 
the eye development as well. 
Ankrd43* (ankyrin repeat domain 43) (↑) 
Very limited information is available for this gene. It is among those seven genes which 
were found to be differentially expressed in progenitors in the lateral and medial ganglionic 
eminences (LGE and MGE). LGE progenitors produce striatal projection neurons and 
olfactory bulb interneurons, whereas MGE as well as caudal ganglionic eminence (CGE) 
progenitors produce cortical and hippocampal interneurons. Thus, its RA regulation 
suggests the role of RA in neural specialization (Tucker, Segall et al. 2008). 
Glra2 (glycine receptor chloride channel, alpha 2 subunit) (↑) 
This gene mediates inhibitory neurotransmission in the spinal cord, brainstem and retina. 
During development, Glra2 is expressed in the retina, in the spinal cord, and throughout the 
brain. Mice with a targeted deletion of Glra2 show no gross morphological or molecular 
alterations in the nervous system. (Young-Pearse, Ivic et al. 2006). 
Gpr124 (G protein-coupled receptor 124) (↑) 
GPR124 is highly expressed in central nervous system (CNS) endothelium. Its deletion 
resulted embryonic lethality through CNS-specific angiogenesis arrest in forebrain and neural 
tube. Conversely, GPR124 overexpression throughout all adult vascular beds produced CNS-
specific hyperproliferative vascular malformations (Kuhnert, Mancuso et al. 2010). 
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6.5 Adipocyte differentiation 
Adipogenesis is a complex process by a multifaceted transcriptional regulatory cascade. In 
recent years data have emerged indicating a role of retinoids in adipose tissue. Retinoids has 
been shown to inhibit preadipocyte to adipocyte differentiation by repressing Pparγ and Rxrα 
activities (Ziouzenkova, Orasanu et al. 2007), however we should note that the embryonic stem 
cell derived adipogenesis requires RA in the very beginning (Bost, Caron et al. 2002). The role 
of such early RA signal in adipocyte differentiation remained largely unknown. 
Cidea (cell death-inducing DNA fragmentation factor, alpha subunit-like effector A) (↑) 
Cidea-null mice are lean and resistant to diet-induced obesity and diabetes, indicating a role 
for Cidea in energy balance and adiposity (Zhou, Yon Toh et al. 2003). Thus, Cidea can be a 
potential RA regulated gene in ES cell that influence the adipocyte differentiation. 
Nrip1 (discussed also in “Regulators of RA metabolism” section) (↑) 
Knockout male and female mice are smaller than wild-type littermates. Nrip1-null cells 
show elevated energy expenditure and express high levels of the uncoupling protein 1 gene 
(Ucp1), carnitine palmitoyltransferase 1b, and the cell-death-inducing DFF45-like effector A 
(Cidea) (Christian, Kiskinis et al. 2005). 
Rbp1* (retinol binding protein 1, cellular), also known as CRBP1 (discussed also in 
“Regulators of RA metabolism” section) (↑) 
Interestingly, a recent study showed that CRBP1-deficient mice fed with high-fat diet (HFD) 
lead to increased adiposity. Similarly, suppression of CRBP-I expression in vitro enhanced 
adipocyte differentiation (Zizola, Frey et al. 2010).  
Rarb* (discussed also in “Regulators of RA metabolism” section) (↑) 
Rarβ activation has been shown that both sufficient and necessary to trigger commitment of 
mES cells to adipocytes (Monteiro, Wdziekonski et al. 2009). 
7. Future directions 
Microarray completed with ChIP-chip or ChIP-Seq is useful to determine sets of RA 
regulated genes and map the binding sites of RAR:RXR heterodimer. We have shown that 
RA treatment of ES cells or EBs induces expression of genes involved in retinoid 
metabolism, body-axis regulation, gonad development and neural differentiation. Other 
recently introduced methods, such as RNA-Seq (Wang, Gerstein et al. 2009) and Gro-Seq 
(Core, Waterfall et al. 2008), still have not been used in retinoid research, and may serve 
more detailed picture about the direct effect of RA (detailed description of genome-wide 
approaches in aspect of stem cell research is reviewed in (Zhang and Huang 2010). Future 
experiments should be complemented with studies investigating the co-occupancy of RAR, 
RXR, RNA Pol II and coregulators (SMRT, NCoR, NCoA, CBP/p300, etc.) genome-wide to 
get information about the direct gene regulation and its temporal dynamics. Development of 
data processing methods and integration of system biology will be also required for 
analyzing the complexity underlying the regulatory networks in stem cells and during cell 
fate commitment (Macarthur, Ma'ayan et al. 2009).  
There are other technical challenges limiting our recent possibilities. Several cell-type specific 
differentiation protocol has been published, many of them resulting heterogeneous cell 
population. This is mainly due to our poor understanding on interactions of different signal 
cascades. Uncontrolled content of FBS, heterogeneity during EB formation, not adequate 
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ligand treatment may also affect the quality of cell culture. For instance, embryonic stem cell 
derived embryoid bodies often show heterogeneity in their size that may have impact on cell 
fate commitment (Mansergh, Daly et al. 2009). Adherent monolayer cultures have been used to 
get more homogenous differentiation. It has been successfully used for neural differentiation 
(Pachernik, Esner et al. 2002), however many of the lineage differentiation is still require the EB 
formation, implying the importance of a three-dimensional structure. Replacement of EBs by 
scaffolds can provide such three-dimensional environment in which cells have access to 
nutrients and space to grow. Recent studies are using scaffolds to induce high organization of 
stem cells during differentiation. For instance, one of the most recent study reported the 
dynamic, autonomous formation of the optic cup structure from a three-dimensional culture of 
mouse embryonic stem cell aggregates (Eiraku, Takata et al. 2011). 
During development, morphogens are secreted locally and presented to embryonic cells in a 
spatially and temporally controlled manner to direct appropriate differentiation and tissue 
formation. This seems to be true for RA production as well. In vitro addition of RA to the 
media of differentiating EBs does not accurately replicate this process. In addition, the 
diffusion of RA into EBs may be restricted by the formation of an exterior shell composed of 
collagenous matrix and tight E-cadherin mediated cell–cell adhesions at the EB surface. 
Biodegradable microspheres to deliver morphogens directly within EBs may enable 
production of more homogeneous populations of differentiated cells (Bratt-Leal, Carpenedo 
et al. 2010). A study examined ESC differentiation in response to microsphere-mediated 
delivery of RA  (Li, Davidovich et al. 2011). The authors found that after 10 days of 
differentiation, the RA microsphere-containing EBs formed large cystic structures that 
comprised the majority of the EBs. Genome-wide analysis revealed more pronounced up-
regulation in visceral endoderm, epiblast, and early primitive streak markers and down-
regulation in mesoderm and definitive endoderm differentiation. Thus, in the existing stem 
cell differentiation protocols we need to revisit the usefulness of cytokine/ligand delivering 
microspheres. 
Finally, important to note that RT-PCR, western blot or even microarray analysis are able to 
reveal only the average response of the cell population to a given signal (Figure 4). This is 
clearly giving only limited information. Single cell analyzing methods will bring us closer to 
understand the dynamics of cell fate commitment. This field is expected to accelerate soon 




Fig. 4. Population measurements can obscure the heterogeneity of the cells within the 
embryoid body. For instance, western blot or RT-PCR are not able to determine whether 
only a few cell are expressing the gene of interest on high level (A), every cell on middle 
level (B) or there is a polarity (C).  
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activities (Ziouzenkova, Orasanu et al. 2007), however we should note that the embryonic stem 
cell derived adipogenesis requires RA in the very beginning (Bost, Caron et al. 2002). The role 
of such early RA signal in adipocyte differentiation remained largely unknown. 
Cidea (cell death-inducing DNA fragmentation factor, alpha subunit-like effector A) (↑) 
Cidea-null mice are lean and resistant to diet-induced obesity and diabetes, indicating a role 
for Cidea in energy balance and adiposity (Zhou, Yon Toh et al. 2003). Thus, Cidea can be a 
potential RA regulated gene in ES cell that influence the adipocyte differentiation. 
Nrip1 (discussed also in “Regulators of RA metabolism” section) (↑) 
Knockout male and female mice are smaller than wild-type littermates. Nrip1-null cells 
show elevated energy expenditure and express high levels of the uncoupling protein 1 gene 
(Ucp1), carnitine palmitoyltransferase 1b, and the cell-death-inducing DFF45-like effector A 
(Cidea) (Christian, Kiskinis et al. 2005). 
Rbp1* (retinol binding protein 1, cellular), also known as CRBP1 (discussed also in 
“Regulators of RA metabolism” section) (↑) 
Interestingly, a recent study showed that CRBP1-deficient mice fed with high-fat diet (HFD) 
lead to increased adiposity. Similarly, suppression of CRBP-I expression in vitro enhanced 
adipocyte differentiation (Zizola, Frey et al. 2010).  
Rarb* (discussed also in “Regulators of RA metabolism” section) (↑) 
Rarβ activation has been shown that both sufficient and necessary to trigger commitment of 
mES cells to adipocytes (Monteiro, Wdziekonski et al. 2009). 
7. Future directions 
Microarray completed with ChIP-chip or ChIP-Seq is useful to determine sets of RA 
regulated genes and map the binding sites of RAR:RXR heterodimer. We have shown that 
RA treatment of ES cells or EBs induces expression of genes involved in retinoid 
metabolism, body-axis regulation, gonad development and neural differentiation. Other 
recently introduced methods, such as RNA-Seq (Wang, Gerstein et al. 2009) and Gro-Seq 
(Core, Waterfall et al. 2008), still have not been used in retinoid research, and may serve 
more detailed picture about the direct effect of RA (detailed description of genome-wide 
approaches in aspect of stem cell research is reviewed in (Zhang and Huang 2010). Future 
experiments should be complemented with studies investigating the co-occupancy of RAR, 
RXR, RNA Pol II and coregulators (SMRT, NCoR, NCoA, CBP/p300, etc.) genome-wide to 
get information about the direct gene regulation and its temporal dynamics. Development of 
data processing methods and integration of system biology will be also required for 
analyzing the complexity underlying the regulatory networks in stem cells and during cell 
fate commitment (Macarthur, Ma'ayan et al. 2009).  
There are other technical challenges limiting our recent possibilities. Several cell-type specific 
differentiation protocol has been published, many of them resulting heterogeneous cell 
population. This is mainly due to our poor understanding on interactions of different signal 
cascades. Uncontrolled content of FBS, heterogeneity during EB formation, not adequate 
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ligand treatment may also affect the quality of cell culture. For instance, embryonic stem cell 
derived embryoid bodies often show heterogeneity in their size that may have impact on cell 
fate commitment (Mansergh, Daly et al. 2009). Adherent monolayer cultures have been used to 
get more homogenous differentiation. It has been successfully used for neural differentiation 
(Pachernik, Esner et al. 2002), however many of the lineage differentiation is still require the EB 
formation, implying the importance of a three-dimensional structure. Replacement of EBs by 
scaffolds can provide such three-dimensional environment in which cells have access to 
nutrients and space to grow. Recent studies are using scaffolds to induce high organization of 
stem cells during differentiation. For instance, one of the most recent study reported the 
dynamic, autonomous formation of the optic cup structure from a three-dimensional culture of 
mouse embryonic stem cell aggregates (Eiraku, Takata et al. 2011). 
During development, morphogens are secreted locally and presented to embryonic cells in a 
spatially and temporally controlled manner to direct appropriate differentiation and tissue 
formation. This seems to be true for RA production as well. In vitro addition of RA to the 
media of differentiating EBs does not accurately replicate this process. In addition, the 
diffusion of RA into EBs may be restricted by the formation of an exterior shell composed of 
collagenous matrix and tight E-cadherin mediated cell–cell adhesions at the EB surface. 
Biodegradable microspheres to deliver morphogens directly within EBs may enable 
production of more homogeneous populations of differentiated cells (Bratt-Leal, Carpenedo 
et al. 2010). A study examined ESC differentiation in response to microsphere-mediated 
delivery of RA  (Li, Davidovich et al. 2011). The authors found that after 10 days of 
differentiation, the RA microsphere-containing EBs formed large cystic structures that 
comprised the majority of the EBs. Genome-wide analysis revealed more pronounced up-
regulation in visceral endoderm, epiblast, and early primitive streak markers and down-
regulation in mesoderm and definitive endoderm differentiation. Thus, in the existing stem 
cell differentiation protocols we need to revisit the usefulness of cytokine/ligand delivering 
microspheres. 
Finally, important to note that RT-PCR, western blot or even microarray analysis are able to 
reveal only the average response of the cell population to a given signal (Figure 4). This is 
clearly giving only limited information. Single cell analyzing methods will bring us closer to 
understand the dynamics of cell fate commitment. This field is expected to accelerate soon 




Fig. 4. Population measurements can obscure the heterogeneity of the cells within the 
embryoid body. For instance, western blot or RT-PCR are not able to determine whether 
only a few cell are expressing the gene of interest on high level (A), every cell on middle 
level (B) or there is a polarity (C).  
 




Embryonic cells are widely used model system to understand the early steps of embryonic 
development. Over the last years, many RA-regulated pathways have been discovered in 
EC and ES cells using a diverse set of techniques. In this chapter we have summarized the 
results of recent studies using high-throughput approaches (microarray, ChIP-chip, ChIP-
Seq) to understand the mechanistic of retinoid signaling in early embryonic development. 
However, many questions remained to be unanswered. We should face the new technical 
challenges to be able to work out these issues.  
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1. Introduction  
Embryonic stem (ES) cells are derived directly from inner cell mass (ICM) of mouse or human 
preimplantation embryos (Evans & Kaufman 1981, Martin 1981, Thomson et al., 1998). They 
are pluripotent, once they are able to differentiate in vitro and in vivo into derivatives of the 
three embryonic germ cell lines: mesoderm, endoderm and ectoderm (Fig. 1). The 
establishment of protocols for direct in vitro differentiation of pluripotent stem cell (PSC) into 
desirable cell type is extremely important for their use in therapies, for the studies of human 
diseases, and also for biochemical, toxicological and pharmacological studies (Pederson 1999, 
Sukoyan et al., 2002, Wobus & Löser 2011). Therefore, focusing on the PSCs use in these 
studies, many efforts have been devoted to the establishment of stem cells models with a 
particular emphasis to their in vitro differentiation into mature and functional neurons.  
The nervous system is the most complex system in the organism and its formation usually 
involves four stages: specification of the neural cells identity (neural or glia), neural 
migration and axon formation, synapse formation (with target neurons, muscle or gland 
cells) and synaptic connection refinement (elimination of axons branches and cells death) 
(Müller 2006). It is well-known that many genes are involved in the process of neuronal 
stem cells fate specification (Aiba et al., 2006). This process depends on the specific 
environment during organogenesis, after birth and during adult life. The temporal and 
spatial factors are essential for neuronal differentiation, due to the multilayer nature of 
cortex (Müller 2006). Although numerous publications have reported PSCs differentiation 
toward neurons, many important questions are not answered yet, especially in respect to the 
equivalency of the in vitro PSCs model and in vivo central nervous system (CNS) 
development. Accomplishments in these directions would represent a crucial starting point 
for the stem cell therapies and drug discovery. A number of important protocols have been 
set up for the differentiation of PSCs into neurons, which mainly lead to the coexistence in 
the culture of differentiated neurons and non-neural cells, together with neural precursors 
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and undifferentiated PSCs (Okabe et al., 1996, Li et al., 1998, Mujtaba et al., 1999, Baharvand 
et al., 2007). Most of these protocols are short-lasting, which therefore does not allow a 
careful analysis of the neurons maturation, aging, and death processes.  
In this chapter, we describe principal methods of PSCs differentiation into neurons in vitro. 
Next, we present a method developed by our group, which established a long-term culture 
of committed neuronal precursors and functional neurons from mouse embryonic stem 
(mES) cells. In addition, using this long-term protocol we demonstrated the temporal and 
spatial localization of microtubule-associated proteins, such as, Lis1 (Lissencephaly-1) and 
Ndel1 (nuclear distribution element-like) in neuronal precursors and differentiated neurons. 
These both proteins have been shown to be essential for neuronal differentiation during the 
CNS development. Regardless of the relevance of these proteins for neuronal differentiation, 
their expression during PSCs differentiation was marginally explored.  
 
 
Fig. 1. ES cell isolation and differentiation. 
2. Pluripotent stem cells as a model of in vitro differentiation 
ES cells are powerful biological model, which can provide important information for our 
knowledge regarding the cell commitment and differentiation during development process 
(O’Shea 1999, Wobus & Boheler 2005). Multiple methods have been developed in order to 
induce in vitro PSCs differentiation and to obtain the desirable cell phenotype (Baharvand et 
al., 2004, Keller 2005). It has been found that ES cells are able to differentiate spontaneously 
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within cell aggregates, when feeder layers and required factors to maintain pluripotency are 
removed. These aggregates, denominated embryoid bodies (EBs), resemble early post 
implantation embryos, although chaotically organized inside. It is assumed that EBs 
formation initiates spontaneous differentiation of ES cells to the three embryonic germ 
layers (Evans & Kaufman 1981). Innumerous studies have addressed the issue of cell specific 
differentiation of ES cells. In Figure 2 we summarize the main cell phenotypes, which can be 
induced to differentiate from ES cells in vitro under specific culture conditions. Those 
accomplishments are the result of a dynamic interaction between knowledge of embryonic 
development and empirical testing, targeted at reproducing in vitro cell specification 
conditions found in the developing embryo. 
 
 
Fig. 2. ES cell differentiation in vitro. ES cells are isolated from the ICM of the blastocyst. 
These cells can be induced to form EBs, which are structures that contain representatives of 
the three embryonic germ layers. Under the appropriate culture condition, the EBs can be 
induced to differentiate into several types of cells in vitro. 
2.1 Mesoderm specification 
Mesoderm is the germ layer responsible for the development of muscle, bone, cartilage, 
blood, and connective tissue. Blood and endothelial cells are the first cell types to form in the 
developing vertebrate embryo at around six days of gestation. This event leads to the 
formation of the yolk sac, an extraembryonic membrane composed of adjacent mesodermal 
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and primitive (visceral) endodermal cell layers, which give rise to blood and endothelial 
cells (Baron 2001). In vitro differentiation of ES cells in EBs allows the generation of blood 
islands containing erythrocytes and macrophages (Doetschman et al., 1985), whereas 
differentiation in semisolid medium is efficient for the formation of neutrophilis, 
macrophages, and erythroid lineages (Wiles & Keller 1991). In an attempt to identify 
potential inducers of the hematopoietic lineage, researchers indicated Wnt3 (Proto-oncogene 
protein) as an important signaling molecule that plays a significant role in enhancing 
hematopoietic commitment during in vitro differentiation of ES cells (Lako et al., 2001). The 
hematopoietic cells derived from ES cells have been characterized by specific gene 
expression patterns and by cell surface antigens (Wiles & Keller 1991, Wang et al., 1992). 
However, the most important aspect was to characterize these cells in the functional 
capacity, by demonstrating long-term multilineage hematopoietic repopulating properties 
in an animal model (Palacios et al., 1995). 
Cardiomyocytes readily differentiate from aggregates composed of mES cells in the 
presence of high concentration of serum (around 20%), and display properties comparable 
to those observed in vivo: they express similar cardiac gene expression patterns, present 
sarcomeric structures, and demonstrate contractility triggered by cardiac-specific ion 
currents, as well as the expression of membrane-bound ion channels. This type of 
differentiation can develop spontaneously or be induced by differentiation factors including 
dimethyl sulfoxide (DMSO) and retinoic acid (RA), or small molecules, such as Dynorphin B 
and cardiogenol derivatives (Fassler et al., 1996). Human ES cells also hold the ability to 
differentiate into cardiomyocytes, which show similar properties to those derived from mES 
cells (Kehat et al., 2001). Furthermore, it is well established that ES cells can efficiently 
differentiate into several other mesodermal cells types, including mesenchymal cell-derived 
adipogenic (Dani et al., 1997), chondrogenic (Kramer et al., 2000), osteoblast (Buttery et al., 
2001), and myogenic cells (Rohwedel et al., 1994). In all of these experiments, the cell type 
derivation was induced by specific differentiation factors. 
2.2 Endoderm specification 
Endoderm is responsible for deriving the pancreas and liver. Regarding the therapeutic 
interest for the treatment of hepatic failure and diabetes mellitus, hepatic and pancreatic 
cells are of special interest. Thus, since these cells could be derived from ES cells new hope 
has emerged (Soria 2001). These in vitro derived cells showed hepatic-restricted transcripts 
and proteins, and were able to integrate and to function in a host liver following 
transplantation (Chinzei et al., 2002). Recently, researchers demonstrated that hepatocyte-
like endodermal markers were also detected in ES cell derivatives (Yamada et al., 2002). 
The potential use of ES cells for treatment of diabetes was enhanced by the perspective of 
deriving insulin-producing pancreatic endocrine cells. Researchers at NovoCell, Inc., a 
biotechnology company in the USA, have developed an in vitro differentiation process that 
mimics pancreatic organogenesis. By directing cells through stages resembling definitive 
endoderm, gut-tube endoderm, pancreatic endoderm and endocrine precursor, they were 
able to convert human ES cells to endocrine cells capable of synthesizing the pancreatic 
hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin (D’Amour et 
al., 2006). Moreover, in pre-clinical trials, the same group showed that those ES-derived 
pancreatic cells efficiently generated glucose-responsive endocrine cells after implantation 
into mice, and those insulin producing cells, in turn protected animals from streptozotocin-
induced hyperglycemia (Kroon et al., 2008).   
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2.3 Ectoderm specification  
The embryonic ectoderm is an embryonic germ layer, which can produce various cell lineages 
during development. Of particular interest, the differentiation of ES cells into neuronal cells 
was published independently by three groups in 1995 (Bain et al., 1995, Fraichard et al., 1995, 
Strubing et al., 1995). Gene expression and electrophysiological studies of cell derivatives from 
PSCs indicated the presence of the all three major cell types of the brain: astrocytes, 
oligodendrocytes, and neurons (dopaminergic, GABAergic (gamma-aminobutyric-acid-
releasing), serotonergic, glutamatergic and cholinergic neurons) (Lee et al., 2000, Rolletschek at 
al., 2001, Aubert et al., 2002) (Fig. 3). Thus, these studies opened first perspectives regarding ES 
cell models for the study of neurodegenerative disorders. Human ES cells are also able to 
generate the neural epithelium (Thomson et al., 1998, Reubinoff et al., 2000, Zhang et al., 2001). 
However, although neural progenitors derived from ES cells could be enriched and directed to 
differentiate into mature neurons, astrocytes, and oligodendrocytes (Carpenter et al., 2001), 
experimental data obtained until recently could not demonstrate the formation of a given 
neuron subtype  (Lee et al., 2000, Rolletschek at al., 2001, Aubert et al., 2002). The possibility of 
generating neurons in vitro signals for a first step towards exploring the therapeutic potential 
of ES cells for Parkinson’s disease (Svendsen, 2008). 
 
 
Fig. 3. All three major cell types of CNS derivative from PSCs: oligodendrocytes, astrocytes, 
and neurons. 
2.3.1 Three dimensional (3-D) model of PSCs differentiation 
Currently, common protocol comprises three steps: EBs (3-D model) formation, derivation of 
primitive neuroepithelial cells from EBs and generation of differentiated neural cell types. The 
most widely used method to induce neuronal differentiation is to enzymatically or 
mechanically lift the PSCs colonies and place them into low-adherence culture dishes or flasks 
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without substrate, feeder cells, or mitogens, where they form EBs (Carpenter et al., 2001, 
Colombo et al., 2006, Baharvand et al., 2007). The culture media formulations for EBs vary 
significantly between different works (Ng et al., 2005, Yoon et al., 2006). Next, EBs are 
transferred to serum-free culture media and are plated onto laminin (poly-lysine)-coated 
dishes in order to generate an adherent culture and to differentiate into neuroepithelial cells. 
The EBs undergo spontaneous differentiation and the formation of clusters of small elongated 
cells surrounding a central zone, free of cells, so-called neural rosettes was showed (Pankratz 
et al., 2007, Pankratz & Zhang 2007). These rosettes resemble the morphology of the primitive 
neural tube and express early neural marker antigens such as Nestin (type VI intermediate 
filament (IF) protein) and Musashi-1 (RNA-binding proteins expressed in the CNS), but not 
markers of more mature neural cells. These rosettes were observed in majority of the studies of 
induction of neural differentiation of PSCs. PSCs neuroepithelial differentiation method are 
widely used to generate neural progenitors and mature neural  cell types. The neuroepithelial 
cells obtained by this approach express the neuroepithelial transcription factors, such as PAX6 
(Paired box gene 6), Sox1 (Sex determining region Y-box 1), and Sox2 (sex determining region 
Y-box 2), in about 90% of the total differentiated progenies (Li et al., 2007, Pankratz & Zhang 
2007). Neuronal differentiation can also occur without EBs formation. In this case, specific 
growth factors or the co-culture of PSCs with cells of a particular origin that have been found 
to produce factors of neuronal cell specification are used to accelerate the differentiation 
towards one cell type or lineage of interest.  
RA is an important regulator of the nervous system development, regeneration and 
maintenance (Zhang 2006, Maden 2007). Although, rosette formation occurrs during 
spontaneous in vitro differentiation of PSC-derived EBs, addition of RA enhances 
significantly the yielding of rosettes and mature neurons. Therefore, the predominant 
number of studies uses RA alone or in combination with other factors, e.g. bFGF (basic 
fibroblast growth factor). Additionally, neural differentiation can also be induced by the 
withdrawal of bFGF/EGF (epithelial growth factor) and exposure to BDNF (brain-derived 
neurotrophic factor), NGF (neuronal growth factor) or other factors into the culture medium. 
The above described protocol and its modifications commonly produce mixed population of 
neuronal cells, which contain precursors, neurons and glial cells. This mixed population needs 
the application of further protocols for selection and enrichment, in order to obtain almost 
pure population of precursors or neurons, suitable for pharmacological screening or 
therapeutic applications.   
2.3.2 Bi-dimensional (2-D) model of PSCs differentiation  
Primary neural stem cells (NSC) can proliferate in vitro, forming multicellular floating 
spherical clusters, commonly referred as neurospheres, which are mainly composed by 
committed progenitor cells. When adhered on substrate, these neurospheres differentiate 
into functional neurons (Reynolds & Weiss, 1992; Chojnacki & Weiss, 2008). Our group 
aimed at developing a protocol for PSCs differentiation into neurons, which resemble the 
differentiation pattern of NSC-derived adherent neurosphere (AN). This protocol comprises 
five steps: EBs formation, culturing of floating EBs in the presence of RA, EBs adherence, 
formation of AN (2-D model), composed by commuted neuronal precursors and generation 
of neurons from AN. We further referred adherent EBs as ANs. It is worth mentioning that 
this protocol avoids the formation of rosettes.  
The details of 2-D protocol are presented in Figure 4. An enzymatic digestion with trypsin of 
mES cells were used in order to obtain a feeder-free cell suspension. The mES cells were 
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plated in culture flask, which allows rapid adherence of feeder cells. The EBs were obtained 
in low serum (5%) basal culture medium, following routine protocol of hanging drop 
method. Next, EBs were transferred into low-adherence culture dishes without substrate 
that allows adherence, and the neuronal differentiation was induced by the addition of RA 
(at final concentration of 0.1 µM). The EBs were maintained under non-adherent serum-free 
culture conditions (neurobasal (NB) medium supplemented with B27), for additional 4 days. 
Next, RA was removed and the EBs was transferred to poly-lysine treated plastic dishes in 
order to form ANs. The ANs were maintained in serum-free conditions for additional 7 
days. At this moment of neuronal differentiation, outgrowth of neuron-like cells on the 
periphery of ANs was clearly observed (Fig. 5). These ANs were caught in small pieces and 
mechanically transferred into another Petri dish. After 3-4 days, these small ANs start to 
produce outgrowth of neurons. This process of ANs mechanical splitting and transfer can be 




Fig. 4. Differentiation of ES cells towards neurons. 1-2: EBs formation; 3-6: 3-D model; 7-11:2-
D model. (1) Pluripotent ES cells in basal culture medium. (2) EBs formation using 
suspension cell culture or hanging drop protocol. (3-5) Adherence of EBs, in serum-free 
medium with or without RA, production of neuroepithelial cells, (4) rosette formation, (5) 
neurons (white-brilliant) and glial cells (black) production. (6-11) culture of floating EBs in 
serum-free medium in the presence of RA, (7, 9, 10) RA removal, EBs adherence and ANs 
formation, production of neuronal precursor and mature neurons, (8, 10) ANs mechanical 
splitting and transfer using glass pipette. White arrows showed in (2) EBs (phase contrast), 
in (3) rosette (Hematoxylin & Eosin staining) in (5) neurons (phase contrast), in (7, 9, 11) AN 
with outgrowing neurons (phase contrast). 
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without substrate, feeder cells, or mitogens, where they form EBs (Carpenter et al., 2001, 
Colombo et al., 2006, Baharvand et al., 2007). The culture media formulations for EBs vary 
significantly between different works (Ng et al., 2005, Yoon et al., 2006). Next, EBs are 
transferred to serum-free culture media and are plated onto laminin (poly-lysine)-coated 
dishes in order to generate an adherent culture and to differentiate into neuroepithelial cells. 
The EBs undergo spontaneous differentiation and the formation of clusters of small elongated 
cells surrounding a central zone, free of cells, so-called neural rosettes was showed (Pankratz 
et al., 2007, Pankratz & Zhang 2007). These rosettes resemble the morphology of the primitive 
neural tube and express early neural marker antigens such as Nestin (type VI intermediate 
filament (IF) protein) and Musashi-1 (RNA-binding proteins expressed in the CNS), but not 
markers of more mature neural cells. These rosettes were observed in majority of the studies of 
induction of neural differentiation of PSCs. PSCs neuroepithelial differentiation method are 
widely used to generate neural progenitors and mature neural  cell types. The neuroepithelial 
cells obtained by this approach express the neuroepithelial transcription factors, such as PAX6 
(Paired box gene 6), Sox1 (Sex determining region Y-box 1), and Sox2 (sex determining region 
Y-box 2), in about 90% of the total differentiated progenies (Li et al., 2007, Pankratz & Zhang 
2007). Neuronal differentiation can also occur without EBs formation. In this case, specific 
growth factors or the co-culture of PSCs with cells of a particular origin that have been found 
to produce factors of neuronal cell specification are used to accelerate the differentiation 
towards one cell type or lineage of interest.  
RA is an important regulator of the nervous system development, regeneration and 
maintenance (Zhang 2006, Maden 2007). Although, rosette formation occurrs during 
spontaneous in vitro differentiation of PSC-derived EBs, addition of RA enhances 
significantly the yielding of rosettes and mature neurons. Therefore, the predominant 
number of studies uses RA alone or in combination with other factors, e.g. bFGF (basic 
fibroblast growth factor). Additionally, neural differentiation can also be induced by the 
withdrawal of bFGF/EGF (epithelial growth factor) and exposure to BDNF (brain-derived 
neurotrophic factor), NGF (neuronal growth factor) or other factors into the culture medium. 
The above described protocol and its modifications commonly produce mixed population of 
neuronal cells, which contain precursors, neurons and glial cells. This mixed population needs 
the application of further protocols for selection and enrichment, in order to obtain almost 
pure population of precursors or neurons, suitable for pharmacological screening or 
therapeutic applications.   
2.3.2 Bi-dimensional (2-D) model of PSCs differentiation  
Primary neural stem cells (NSC) can proliferate in vitro, forming multicellular floating 
spherical clusters, commonly referred as neurospheres, which are mainly composed by 
committed progenitor cells. When adhered on substrate, these neurospheres differentiate 
into functional neurons (Reynolds & Weiss, 1992; Chojnacki & Weiss, 2008). Our group 
aimed at developing a protocol for PSCs differentiation into neurons, which resemble the 
differentiation pattern of NSC-derived adherent neurosphere (AN). This protocol comprises 
five steps: EBs formation, culturing of floating EBs in the presence of RA, EBs adherence, 
formation of AN (2-D model), composed by commuted neuronal precursors and generation 
of neurons from AN. We further referred adherent EBs as ANs. It is worth mentioning that 
this protocol avoids the formation of rosettes.  
The details of 2-D protocol are presented in Figure 4. An enzymatic digestion with trypsin of 
mES cells were used in order to obtain a feeder-free cell suspension. The mES cells were 
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culture conditions (neurobasal (NB) medium supplemented with B27), for additional 4 days. 
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order to form ANs. The ANs were maintained in serum-free conditions for additional 7 
days. At this moment of neuronal differentiation, outgrowth of neuron-like cells on the 
periphery of ANs was clearly observed (Fig. 5). These ANs were caught in small pieces and 
mechanically transferred into another Petri dish. After 3-4 days, these small ANs start to 
produce outgrowth of neurons. This process of ANs mechanical splitting and transfer can be 
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Fig. 5. Differentiation of PSC-derived adherent neurospheres. A) AN (black) producing a 
network of connected neurons. B) AN (white) after mechanical splitting and transfer. 
Migration of neurons also can be observed. Light microscopy (phase contrast).  
These ANs present expression of the neural progenitor cell markers, such as Sox1 and 
Nestin just after plating. Following differentiation, the inner part of the AN, continuously 
expressed Sox 1 and Nestin proteins, while outgrowing neurons, which form an extensive 
neurite net around the AN expressed beta III-tubulin (neuron-specific marker) (Fig. 6).  
 
 
Fig. 6. Expression of neuroepithelial and neuronal markers in AN. A) Expression of Sox 1 
protein (red), which express in the nucleus of progenitor cells localized in the inner part of 
AN. B) Expression of beta-III tubulin protein (green) at the periphery of AN and in 
outgrowing neurons. C) Higher magnification of extensive neurite net in (B) showing 
interconnected neurons. 
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The expression of other neuron-specific proteins, such as MAP2 (microtubule-associated 
protein 2), NF-M (neurofilament medium protein), Tau (a microtubule-associated protein), 
NeuN (neuronal nuclei marker), GABA and 5-HT (5-hydroxytryptamin), was observed in 
neurons derived from ANs each time after splitting and mechanical transfer, which was 
maintained during three months. Electrophysiological analysis, by using the patch-clamp 
technique, in long-lasting culture of AN-derived mature neurons, showed the presence of 
ionic channels and membrane electrical potentials typical of electrically excitable cells, 
which is a characteristic feature of functional CNS neurons. 
This method of mechanical splitting and transfer of ANs is advantageous because it avoids 
the trauma associated to the trypsin treatments and mechanical dissociation and, so forth, 
may improve the survival of committed precursors able to differentiate into neurons. It is 
well-known that CNS precursors are localized in stem cell niche of organisms, which 
guarantees their continuous growth and renewing, and also the production of differentiated 
cells. In our model, ANs provide a constant microenvironment (in vitro niche) for the 
neuronal progenitor cells, which can be maintained for at least twelve weeks in culture, 
following repetitive mechanical splitting and transfer. Since expression of GFAP (Glial 
fibrillary acidic protein) gene has not been detected, it seems that AN direct the fate of non-
committed precursors toward the neurons generation. 
2.3.3 Importance of lineage selection for transplantation studies in regenerative 
medicine 
A majority of available protocols for neural differentiation result in the generation of multiple 
cell types of committed neural precursor to a fully differentiated, post-mitotic neural cell. The 
selection and expansion of ES-derived neural precursors is a material for transplantation 
studies focusing on diseases as Parkinson’s or Alzheimer’s disease, or neural damage 
following stroke or injury. Such protocol is important due to the elimination of PSCs from the 
transplanted cell population, which can generate teratocarcinomas (Zhang et al., 1996, 
Deacon et al., 1998, Bjorklund et al., 2002). Commonly genetic engineering methods are used 
for lineage selection on differentiating ES cells to purify neural precursors. These techniques 
rely on the introduction of a reporter/selection cassette into a locus with restricted expression 
in the desired cell type by homologous recombination. Thus, to address lineage selection of 
neuronal precursor one copy of the pan-neural gene Sox1 has been replaced by the dual 
selection/reporter cassette egfpIRESpac in ES cell line, which confers cell-autonomous green 
fluorescence and puromycin resistance to cells that express Sox1. This gene is not expressed 
in ES cells. Its expression is limited to neuroectodermal cell, and undifferentiated ES cells are 
not fluorescent. Upon neural differentiation, Sox1 is activated and the cells produce green 
fluorescence enabling further purification of both neural and non-neural cells generated 
during differentiation. Fluorescence-activated cell sorting (FACS) is used for the isolation of 
both Sox1–GFP-positive and -negative cells allowing further analysis (Li et al., 1998, Pevny et 
al., 1998, Wood et al., 1999, Ying et al., 2003).  
The comparison of AN and the above described techniques demonstrated that we succeeded 
to establish very simple and long-term protocol for generation of Sox1 positive cells. It is 
useful to note that 3 months of several mechanical splitting, Sox1-positive cells maintain the 
expression and continuously produce outgrowing beta III-tubulin-positive cells, while 
expression of GFAP gene has not been detected (Hayashi et al., 2010). Quantification of 
precursors and mature neurons demonstrated stable production of both Sox1 and beta III-
tubulin proteins during the first 2 months. At the end of the third month, Sox1-nestin-
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maintained during three months. Electrophysiological analysis, by using the patch-clamp 
technique, in long-lasting culture of AN-derived mature neurons, showed the presence of 
ionic channels and membrane electrical potentials typical of electrically excitable cells, 
which is a characteristic feature of functional CNS neurons. 
This method of mechanical splitting and transfer of ANs is advantageous because it avoids 
the trauma associated to the trypsin treatments and mechanical dissociation and, so forth, 
may improve the survival of committed precursors able to differentiate into neurons. It is 
well-known that CNS precursors are localized in stem cell niche of organisms, which 
guarantees their continuous growth and renewing, and also the production of differentiated 
cells. In our model, ANs provide a constant microenvironment (in vitro niche) for the 
neuronal progenitor cells, which can be maintained for at least twelve weeks in culture, 
following repetitive mechanical splitting and transfer. Since expression of GFAP (Glial 
fibrillary acidic protein) gene has not been detected, it seems that AN direct the fate of non-
committed precursors toward the neurons generation. 
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cell types of committed neural precursor to a fully differentiated, post-mitotic neural cell. The 
selection and expansion of ES-derived neural precursors is a material for transplantation 
studies focusing on diseases as Parkinson’s or Alzheimer’s disease, or neural damage 
following stroke or injury. Such protocol is important due to the elimination of PSCs from the 
transplanted cell population, which can generate teratocarcinomas (Zhang et al., 1996, 
Deacon et al., 1998, Bjorklund et al., 2002). Commonly genetic engineering methods are used 
for lineage selection on differentiating ES cells to purify neural precursors. These techniques 
rely on the introduction of a reporter/selection cassette into a locus with restricted expression 
in the desired cell type by homologous recombination. Thus, to address lineage selection of 
neuronal precursor one copy of the pan-neural gene Sox1 has been replaced by the dual 
selection/reporter cassette egfpIRESpac in ES cell line, which confers cell-autonomous green 
fluorescence and puromycin resistance to cells that express Sox1. This gene is not expressed 
in ES cells. Its expression is limited to neuroectodermal cell, and undifferentiated ES cells are 
not fluorescent. Upon neural differentiation, Sox1 is activated and the cells produce green 
fluorescence enabling further purification of both neural and non-neural cells generated 
during differentiation. Fluorescence-activated cell sorting (FACS) is used for the isolation of 
both Sox1–GFP-positive and -negative cells allowing further analysis (Li et al., 1998, Pevny et 
al., 1998, Wood et al., 1999, Ying et al., 2003).  
The comparison of AN and the above described techniques demonstrated that we succeeded 
to establish very simple and long-term protocol for generation of Sox1 positive cells. It is 
useful to note that 3 months of several mechanical splitting, Sox1-positive cells maintain the 
expression and continuously produce outgrowing beta III-tubulin-positive cells, while 
expression of GFAP gene has not been detected (Hayashi et al., 2010). Quantification of 
precursors and mature neurons demonstrated stable production of both Sox1 and beta III-
tubulin proteins during the first 2 months. At the end of the third month, Sox1-nestin-
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positive cells were maintained at a similar level as before (~83%), whereas the number of 
immature neurons (~45%) decreased 1.5-fold, suggesting delay of the maturation process 
(~32%). Moreover, we showed that under the described conditions, dopaminergic, 
GABAergic, and serotonergic neurons can be produced. Therefore, generation of 2-D model 
is of great importance because allows expansion of neural progenitor without genetic 
modification from primary ES cell culture. Our AN protocol is especially advantageous for 
the future of regenerative medicine and treatment of neurodegenerative diseases, which will 
provide more tools for a safety clinical protocol with the advantage of lacking the 
intermediate effects from non-neural cells. 
2.3.4 Importance of microtubule associated proteins for neuronal differentiation 
Neuronal migration has been studied extensively in diverse mammalian species and the 
sequence of events that occurs during cortical development is shared by all mammals. 
(Gleeson & Walsh 2000, Walsh & Goffinet 2000). During neurogenesis, neural precursors are 
generated, which proliferate and differentiate into immature postmitotic neurons. These 
immature cells migrate from the ventricular zone (VZ) to preplate, a layer at the surface of 
the developing cerebral cortex, splitting the preplate and forming the cortical plate, which 
further develops into the cortex. Following immature neurons migration from the VZ, 
cortical lamination is established in an inside-out fashion. In the deep of the cortex, the 
earliest-born neurons end up, while later-born neurons localize at more superficial layers of 
the cortex residing near the pial surface. Synaptogenesis and apoptosis of neurons occur at 
the final stages of cortical development. Indeed, the migration of neurons requires the same 
steps, which is necessary for migration of any cell type. The signals of environment for 
attraction and repulsion; the nucleus dislocation from central position to the periphery, a 
process called nucleokinesis; and a mechanism for migration end up. Microtubule 
associated proteins (MAPs), for instance, Lis1 and Ndel1, have been shown to be essential 
for neuronal differentiation and cell migration during the CNS development and also in the 
adult nervous system.  
2.3.4.1 Lis1 and Ndel1 
Haploinsufficiency of Lis1 results in lissencephaly, a human neuronal migration disorder 
(Reiner et al., 1993, Saillour et al., 2009). Patients with type 1 Lissencephaly disorder, have a 
reduction in brain folding, and aberrant distribution and orientation of neurons in several 
brain regions. Lis1 binds with high affinity to a protein called Ndel1. Both proteins can 
complex with cytoplasmic dynein, the retrograde microtubule motor. Lis1 and Ndel1 are 
proposed to be important for the regulation of dynein-related events in mitosis and 
migration (Shu et al., 2004, Yamada et al., 2008, Youn et al., 2009, Hippenmeyer et al., 2010, 
Zyłkiewicz et al., 2011). Thus, PSCs can provide an important model to study migration 
defects related to MAPs. 
Lis1 is a central component of a protein complex, evolutionarily conserved from fungus to 
human that regulates nuclear migration (Morris, 2000). Lis1 is able to regulate neuronal 
migration efficiency in a dose-dependent manner (Gambello et al., 2003). Reduced Lis1 
activity results in severe defects in the radial migration of multiple types of neurons, 
including neocortical projection neurons (Tsai et al., 2005).  
Ndel1 is important for normal cortical development and it is involved in microtubule 
organization, nuclear translocation, and neuronal positioning, in concert with various other 
proteins, including Lis1 (Shu et al., 2004, Youn et al., 2009). Mutations in the mammals Lis1 
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gene result in neuronal migration defects (Reiner et al., 1993, Youn et al., 2009, Saillour et al., 
2009), while knockdown or ablation of cortical Ndel1 function also results in impaired 
migration of neocortical projection neurons (Sasaki et al., 2005, Youn et al., 2009). Lis1 and 
Ndel1 co-localize predominantly in the centrosome in early neuroblasts, and later, 
redistributes to axons during neuronal development (Shu et al., 2004, Guo et al., 2006, 
Bradshaw et al., 2008, Hayashi et al., 2010). Thus, Lis1 and Ndel1 are essential for normal 
cortical neuronal migration and neurite outgrowth. 
Currently, Lis1 and Ndel1 were shown to have additional, important functions in the 
cytoplasmic dynein pathway. They participate in nuclear and centrosomal transport in 
migrating neurons (Shu et al., 2004, Tsai et al., 2005). Additionally, they influence a centrosome 
positioning in migrating non-neuronal cells (Dujardin et al., 2003, Stehman et al., 2007, Shen et 
al., 2008) as well as chromosome alignment, and mitotic spindle orientation (Faulkner et al., 
2000, Siller et al., 2005, Liang et al., 2007, Stehman et al., 2007, Vergnolle & Taylor 2007). 
McKenney and co-authors (2010), using biochemical and biophysical approaches, 
investigated whether and how Lis1 and NudE (Ndel1) affect dynein motor activity. Results 
obtained in this work apparently explain the requirement for Lis1 and NudE in the transport 
of nuclei, centrosomes, chromosomes, and the microtubule cytoskeleton. Additionally, they 
provide new insight into the molecular basis for lissencephaly, and the mechanism of action of 
these proteins in a broad range of biological functions.  
2.3.4.2 Expression of Lis1 and Ndel1 in ANs  
Regardless of the relevance of these proteins for neuronal differentiation, their expression 
during PSCs differentiation is not well explored yet. Our group was the first to analyze 
intracellular localization of both proteins in mES cells, undifferentiated and during in vitro 
neural differentiation (Hayashi et al., 2010). The expression of both Lis1 and Ndel1 proteins 
was observed in undifferentiated cells, which presented co-localization within the 
perinuclear region (Fig. 7). At early stages of differentiation, just after formation of ANs, 
Lis1 expression was observed in the cytoplasm, while Ndel1 was in the perinuclear region of 
committed cells. Following differentiation, when ANs grow in size, the expression of both 
proteins was no more observed in the area of committed cells. Both Lis1 and Ndel1 proteins 
were visualized in outgrowing neuritis. Additionally, they co-localized with Tau, which is a 
marker of MAPs, involved in the microtubule assembly and stabilization. In the same way, 
Ndel1 and MAP2 were also co-localized. In non-rosette MAP2 positive neurons, Lis1 and 
Ndel1 proteins co-localized in neuronal cell body and growing axons (Fig. 7). 
In attempt to mimic the development of cortical layers in vitro and to study the cell 
migration during the differentiation process, which can be assessed by the analysis of the 
expression pattern of these proteins, the ANs were allowed to grow for 15 days without 
splitting. Significant variation in spatial distribution of Lis1 and Ndel1 proteins were 
observed within 2-D ANs. The expression of Lis1 was observed in the inner part of ANs, in 
the cells presenting rosette morphology. Unexpectedly, Ndel1 was not expressed in rosette 
forming cells. Both proteins were co-localized in the cytoplasm of the cells showing 
neuroblast-like morphology, which were found close to the periphery of AN. Lis1 protein 
was expressing in the cells very closely localized to Ndel1 expressing cells, which, in turn, 
were close to the region of outgrowing neurons. Co-localization of Lis1 and Ndel1 
expression was detected in cells from upper layer of ANs. Ndel1 was found to interact with 
centrosomes, suggesting that these cells are early neuroblasts (Fig. 8).  
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for neuronal differentiation and cell migration during the CNS development and also in the 
adult nervous system.  
2.3.4.1 Lis1 and Ndel1 
Haploinsufficiency of Lis1 results in lissencephaly, a human neuronal migration disorder 
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gene result in neuronal migration defects (Reiner et al., 1993, Youn et al., 2009, Saillour et al., 
2009), while knockdown or ablation of cortical Ndel1 function also results in impaired 
migration of neocortical projection neurons (Sasaki et al., 2005, Youn et al., 2009). Lis1 and 
Ndel1 co-localize predominantly in the centrosome in early neuroblasts, and later, 
redistributes to axons during neuronal development (Shu et al., 2004, Guo et al., 2006, 
Bradshaw et al., 2008, Hayashi et al., 2010). Thus, Lis1 and Ndel1 are essential for normal 
cortical neuronal migration and neurite outgrowth. 
Currently, Lis1 and Ndel1 were shown to have additional, important functions in the 
cytoplasmic dynein pathway. They participate in nuclear and centrosomal transport in 
migrating neurons (Shu et al., 2004, Tsai et al., 2005). Additionally, they influence a centrosome 
positioning in migrating non-neuronal cells (Dujardin et al., 2003, Stehman et al., 2007, Shen et 
al., 2008) as well as chromosome alignment, and mitotic spindle orientation (Faulkner et al., 
2000, Siller et al., 2005, Liang et al., 2007, Stehman et al., 2007, Vergnolle & Taylor 2007). 
McKenney and co-authors (2010), using biochemical and biophysical approaches, 
investigated whether and how Lis1 and NudE (Ndel1) affect dynein motor activity. Results 
obtained in this work apparently explain the requirement for Lis1 and NudE in the transport 
of nuclei, centrosomes, chromosomes, and the microtubule cytoskeleton. Additionally, they 
provide new insight into the molecular basis for lissencephaly, and the mechanism of action of 
these proteins in a broad range of biological functions.  
2.3.4.2 Expression of Lis1 and Ndel1 in ANs  
Regardless of the relevance of these proteins for neuronal differentiation, their expression 
during PSCs differentiation is not well explored yet. Our group was the first to analyze 
intracellular localization of both proteins in mES cells, undifferentiated and during in vitro 
neural differentiation (Hayashi et al., 2010). The expression of both Lis1 and Ndel1 proteins 
was observed in undifferentiated cells, which presented co-localization within the 
perinuclear region (Fig. 7). At early stages of differentiation, just after formation of ANs, 
Lis1 expression was observed in the cytoplasm, while Ndel1 was in the perinuclear region of 
committed cells. Following differentiation, when ANs grow in size, the expression of both 
proteins was no more observed in the area of committed cells. Both Lis1 and Ndel1 proteins 
were visualized in outgrowing neuritis. Additionally, they co-localized with Tau, which is a 
marker of MAPs, involved in the microtubule assembly and stabilization. In the same way, 
Ndel1 and MAP2 were also co-localized. In non-rosette MAP2 positive neurons, Lis1 and 
Ndel1 proteins co-localized in neuronal cell body and growing axons (Fig. 7). 
In attempt to mimic the development of cortical layers in vitro and to study the cell 
migration during the differentiation process, which can be assessed by the analysis of the 
expression pattern of these proteins, the ANs were allowed to grow for 15 days without 
splitting. Significant variation in spatial distribution of Lis1 and Ndel1 proteins were 
observed within 2-D ANs. The expression of Lis1 was observed in the inner part of ANs, in 
the cells presenting rosette morphology. Unexpectedly, Ndel1 was not expressed in rosette 
forming cells. Both proteins were co-localized in the cytoplasm of the cells showing 
neuroblast-like morphology, which were found close to the periphery of AN. Lis1 protein 
was expressing in the cells very closely localized to Ndel1 expressing cells, which, in turn, 
were close to the region of outgrowing neurons. Co-localization of Lis1 and Ndel1 
expression was detected in cells from upper layer of ANs. Ndel1 was found to interact with 
centrosomes, suggesting that these cells are early neuroblasts (Fig. 8).  
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differentiation of PSCs. In undifferentiated ES cells, both Lis1 and Ndel1 show a perinuclear 
co-localization. In neuronal precursors, Lis1 presents a cytoplasmatic and Ndel1 a 
perinuclear localization. In neurons, at the periphery of ANs, both Lis1 and Ndel1 co-
localize in the outgrowing neurites. In non-rosette neurons, these proteins co-localize in 
neuronal body and neurites. 
 
 
Fig. 8. Schematic presentation of Lis1 and Ndel1 expression in different layers of AN. Lis1 
(green) expression was observed in the inner part of AN in the cells organized in rosettes. 
Intermediate layer (yellow) is composed by the neuroblast-like cells, which express both 
proteins, Lis1 (green) in the cytoplasm and Ndel1 in centriolos (red) and less in cytoplasm. 
Upper layer is composed mainly by Lis1 and at the periphery of AN by Ndel1 expressing 
cells. Proteins expression is also demonstrated by immunofluorescence within AN located 
on both sides of schematic presentation (Confocal microscopy + Fluorescence).  
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Interaction of Lis1 and Ndel1 with other cytosolic proteins had been well studied using 
cultured non-neuronal and/or neuronal cells and the expression of both Ndel1 and Lis1 
genes in early neuroblasts derived from embryonic and adult tissues was observed (Sasaki 
et al., 2000, Shu et al., 2004). Our data demonstrated an expression of only Ndel1 without 
Lis1 expression in the centrosome region in neuroblast-like cells within differentiated AN. 
Variation of spatial distribution of Lis1 and Ndel proteins expression was also observed. The 
ES cells isolated from, for instance, Lis1 or Ndel1 knockout mice, followed by their 
differentiation into neuronal cells using the present protocol, will permit the elucidation of 
the real role of each protein during the neuronal differentiation process. Our data suggest 
that further analysis involving other important MAPs are necessary to allow a better 
comprehension of the migration mechanism(s) and of the specification fate of neuronal cells 
during differentiation. 
3. Conclusions 
PSCs have the capacity to differentiate in vitro into neuronal cells spontaneously through 
EBs formation or in monolayer culture. EBs 3-D model is shown to be more efficient model, 
which can be improved using serum-free culture conditions and inductors of differentiation 
(e.g. RA). Following this protocol, neuroepithelial cells could be obtained, which formed 
rosettes. Further selection and enrichment protocols are needed to isolate culture of 
committed neuronal precursor, neurons and/or glial cells. This 3-D model provides short-
term culture of neuronal cells, which did not allow analysis of neurons migration and 
survival. It is of note that these AN can be maintained even in the absence of growth factors, 
without lacking the capacity to produce functional neurons. 
Our study demonstrated that ANs is a long-term protocol, which can be used to analyze the 
process of neuronal differentiation in dynamics. Plating of intact ANs also provides a 
window of time to the precursor cells for establishing their fate in a 2-D environment. ANs 
model avoid a stage of rosettes formation directly producing committed progenitors and 
non-rosette neurons, mimicking process of differentiation of neurospheres form CNS. 
Mature neurons, obtained from ANs, display ionic channels and membrane electrical 
potential, which are typical of electrically excitable cells and are also a characteristic feature 
of functional CNS neurons.  
Following mechanical splitting and transfer, these ANs grow continuously, confirming their 
auto-renewing properties similarly to progenitors of CNS. When maintained untouched 
during prolonged period (at least 15 days), progenitors inside growing ANs undergo further 
cell specification. As we demonstrated by the analyses of expression of Lis1 and Ndel1 
proteins, both presented differential spatial distribution within the ANs. The discrepancy 
between patterns of expression of these proteins in neuroblasts isolated from embryonic or 
adult mouse neuronal tissues, and in those AN-derived cells was observed. AN-derived 
neuroblasts demonstrated only Ndel1 location in centrosome region, instead of showing the 
location of both proteins in this region. This indicates that miss expression of proteins, 
which are responsible for neuronal cells division and migration, can occur during in vitro 
differentiation.  
Thus, our protocol provides an efficient experimental model for studying neuronal in vitro 
differentiation mimicking early development, as well as it represents a novel source of 
functional cells that can be used as tools for testing the effects of drugs on functional 
neuronal cells. 
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1. Introduction 
The nervous system development is of tremendous fundamental importance, but it is 
immensely challenging because of the complexity of both its architecture and function (Staii 
et al., 2011). Understanding the formation of this ordered complexity is one of the greatest 
challenges of modern science. Mechanisms by which progenitor cells differentiate and 
acquire their cell identity are just beginning to be fully understood (Gilbert, 2000; Lai & 
Johnson, 2008). 
A potent tool for studying differentiation and development in vitro has been offered to 
researchers by the isolation of mouse embryonic stem (ES) cells derived from the inner cell 
mass of blastocyst-stage embryos  more than 20 years ago (Evans & Kaufman, 1981; Martin, 
1981). Two unique characteristics distinguish them from all other organ-specific stem cells 
identified to date. First, they can be maintained and expanded as pure populations of 
undifferentiated cells for extended periods of time retaining normal karyotypes. Second, 
they are pluripotent, capable to generate every cell type in the body. The pluripotent nature 
of mouse ES cells was formally demonstrated by their ability to contribute to all tissues of 
adult mice, including the germline, following their injection into host blastocysts (Bradley et 
al., 1984). In addition to their developmental potential in vivo, ES cells display a remarkable 
capacity to form all differentiated cell types in culture (Keller, 2005). 
In vitro differentiation of embryonic stem (ES) cells recapitulates early events in the 
development of the mammalian nervous system: ES cells can both generate and respond in 
vitro to signals that normally regulate embryonic development (Fraichard et al., 1995; Keller, 
2005). This knowledge has been transported in vitro designing several different protocols 
that have evolved to promote neuroectoderm differentiation (Cai & Grabel, 2007; Keller, 
2005). Each of the three major neural cell types of the central nervous system—neurons, 
astrocytes, and oligodendrocytes—can be generated, and relatively pure populations of each 
can be isolated when cultured under appropriate conditions (Okabe et al., 1996; Barberi et 
al., 2003). In addition to the generation of these different neural populations, conditions 
have been established for the development of different subtypes of neurons. Thus neurons 
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development of the mammalian nervous system: ES cells can both generate and respond in 
vitro to signals that normally regulate embryonic development (Fraichard et al., 1995; Keller, 
2005). This knowledge has been transported in vitro designing several different protocols 
that have evolved to promote neuroectoderm differentiation (Cai & Grabel, 2007; Keller, 
2005). Each of the three major neural cell types of the central nervous system—neurons, 
astrocytes, and oligodendrocytes—can be generated, and relatively pure populations of each 
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of different parts of the neural tube were successfully generated including spinal 
motoneurons, midbrain dopaminergic neurons, spinal cord interneurons, Purkinje and 
granule cells of cerebellum, hypothalamus and finally cortical pyramidal cells (Gaspard & 
Vanderhaeghen, 2010). 
These neurons do not only have the correct morphology and express specific markers but 
they are also functional: electrophysiological data from ES-derived neurons with different 
protocols validate their functional differentiation in vitro and there are evidence of the 
formation of synapse between ES-derived neurons or between an ES-derived neuron and a 
mature neuron in organotypic slices as well as integration of ES-derived neurons in vivo. 
Moreover, networks formed by ES-derived neurons display functional properties 
remarkably similar to those of hippocampal neurons (Ban et al., 2007 and references herein). 
The isolation of human ES cells in 1998 (Thomson et al., 1998) dramatically elevated the 
interest in the therapeutic promises of ES cells differentiation, in particular for brain repair. 
Therefore ES have emerged as a powerful tool in neurobiology, helping address 
longstanding questions in an entirely novel way (Gaspard & Vanderhaeghen, 2011). 
If the cell is to become a neuron, the next decision is what type of neuron it will be. After 
fate is determined, still another decision gives the neuron a specific target (Gilbert, 2000). 
Neurons find their targets by protruding axons driven by the motile apparatus of growth 
cones. The surface of growth cones contains receptors for extracellular guidance cues that 
integrate this information into directional movement towards the target cell (Grzywa et al., 
2006). Filamentous (F)-actin is the primary cytoskeletal element that maintains the growth 
cone shape and is essential for proper axon guidance, whereas microtubules are essential for 
giving the axon structure and serve an important function in axon elongation (Dent & 
Gertler, 2003). Thus growth cones act as sensors, signal transducers and motility devices and 
understanding their fate is a key question. 
While the role of guidance molecules (Dickson, 2002) for growth cone movements, 
underlying signalling of both the F-actin and microtubules is well established (Dent & 
Gertler, 2003; Schaefer et al., 2002), relatively little is known about the three-dimensional 
structure of growth cones, which is difficult to determine in vivo in the mouse embryo and 
impossible in the human embryo (Keller, 2005). 
Cellular three-dimensional structures can be analyzed with different imaging techniques. 
Despite the enormous advancements brought about by electron and scanning probe 
microscopy, about 80% of all microscopy investigations in the life sciences are still carried 
out with conventional lenses and visible light. Taking advantage of the optical transparency 
of cells, light microscopy uniquely provides noninvasive imaging of the interior of cells 
(Hell, 2007). 
Discovered and first patented in 1957 by Marvin Minsky, confocal microscope, a 
predecessor to today's widely used confocal laser scanning microscopy (CLSM) has 
allowed a major advance in biological imaging of cell structure and physiology in thick 
specimens, in three dimensions and in time. CLSM offers high-quality three-dimensional 
fluorescent images over conventional wide-field optical microscopy, due to its ability to 
control the depth of a focal plane to eliminate out-of-focus light or glares in specimens and 
its capability to collect serial (i.e., z-stack) optical images for thick specimens without the 
need for physical sectioning of the tissue. In this way, thin, optical sections with greater 
resolution and contrast and with greater sensitivity than conventional, wide-field 
microscopes are produced (Dailey et al., 1999; Park et al., 2010; Pawley, 2006). 
Characterization of Embryonic Stem (ES)  
Neuronal Differentiation Combining Atomic Force, Confocal and DIC Microscopy Imaging 
 
101 
Confocal laser scanning microscopy (CLSM) utilizes the optical pathway of a regular optical 
microscope and in combination with immunofluorescence histochemistry has been widely 
used to simultaneously map the distribution and localization of different cellular 
components (extracellular and intracellular macro-molecules, including proteins, nucleic 
acids and lipids, as well as intracellular ions such as calcium) helping to understand 
intracellular mechanisms (Dailey et al., 1999; Rajwa et al., 2004). Moreover, it is possible to 
monitor the process and dynamics of living cells with high temporal resolution (Hell, 2007; 
Park et al., 2010). 
The 200 nm resolution limit of the CLSM is restricted by the diffraction limits of the 
microscope objective and does not permit accurate evaluation of the sample height. The z-
resolution of CLSM for any given wavelength is always at least 2 times less than the 
corresponding xy-resolution thus restricting a detailed structural image that can be achieved 
when exploring biological samples (Doak et al., 2008; Rajwa et al., 2004).  
Great advances in optical microscopy such as near field scanning optical microscopy 
(NSOM), stimulated emission depletion microscopy (STED), photoactivated localization 
microscopy (PALM), and stochastic optical reconstruction microscopy (STORM) have been 
achieved to overcome the optical diffraction limit (Hell, 2007 and 2009; Schermelleh et al., 
2010), but there are still constraints for realizing time-resolved dynamics or three 
dimensional imaging (Park et al., 2010). These techniques provide an excellent spatial 
resolution in the xy plane also in live specimens but relying on the presence of fluorophores 
cannot provide information on the overall morphology of cells. 
State-of-the-art transmission and scanning electron microscopy techniques are technically 
demanding, relatively costly, and time-consuming. Moreover, the possibility to specifically 
label and visualize multiple cellular structures or components in one specimen is still 
limited. Furthermore, chemical fixation, contrasting procedures and/or physical sectioning 
can cause artifacts and exclude the option to observe living cells (Schermelleh et al., 2010). 
With the discovery of Atomic force microscopy (AFM), amazing progress has been made in 
the imaging of biomolecules with sub-nanometer resolution (Binnig et al., 1986; Engel et al. 
1997; Fotiadis et al., 2002; Kasas et al, 1993; Lal & John, 1994; Müller et al., 1999), comparable 
to scanning electron microscopy. To date, AFM has been used increasingly and is 
progressively becoming a usual benchtop technique. The volume of scientific publications 
citing AFM increases continuously and papers with a biological emphasis reached more 
than 21% of total publications (as in 2006) (Parot et al., 2007). 
AFM is a scanning probe device, which generates an image by systematically scanning a sharp 
tip mounted on the end of a flexible cantilever over the samples’ surface. The tip interacts with 
the surface causing the cantilever to bend. A laser beam acting as an optical lever is deflected 
from the end of the cantilever to a position sensitive photo-diode that measures the cantilever 
deflection. In this way a topographic map of the surface is generated (Doak et al., 2008). 
AFM can be used in ambient air or under liquid and provides an unprecedented way to 
image the morphological structure of the surfaces of cells and other biological samples, i.e. it 
images the surfaces where most of the regulatory biochemical and other signals are directed 
(Lal & John, 1994). By functionalizing the cantilever tip with appropriate molecules, (Reddy 
et al., 2004; Li et al., 2006), it is possible to localize specific molecules on the surface of the 
cell and to obtain a high resolution map of their localization. Furthermore, AFM, by 
measuring forces within and between biological molecules, can provide additional 
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biophysical information on molecular characteristics by acting as a sensor that quantifies the 
interaction forces between the tip and sample as they are brought into and out of contact 
(Butt et al., 2005, as cited in Doak et al., 2008). 
In the case of neurons, the majority of AFM imaging has focused on the cell body, axon, and 
synaptic vesicles, whereas less attention has been paid to the growth cone and its 
underlying cytoskeletal structures (Grzywa et al., 2006; Laishram et al., 2009; McNally et al., 
2005; Parpura et al., 1993; Xiong et al., 2009; Yunxu et al., 2006). In particular the 
morphological characterization at nanometer scale of ES-derived growth cones with AFM is 
largely unexplored.  
As a stand-alone technique, AFM can provide unique biophysical and ultra-structural 
information on a sample, but a limitation is the difficulty in correlating structural or 
mechanical features with functionality (Kellermayer et al., 2006; Doak et al., 2008). Therefore 
it is necessary to combine AFM imaging with other techniques to obtain functional 
information. In particular, with fluorescent confocal microscopy specific subcellular 
components can be stained allowing functional studies.  
AFM microscopy is a scanning method and therefore cannot be used to investigate the 
motion of large biological samples at a high temporal resolution, which are better viewed 
with conventional video imaging with CCD cameras (Cojoc et al., 2007; Niell and Smith, 
2004; Schaefer et al., 2002) or time-lapse confocal microscope (Dailey et al., 1999; Fishell et 
al., 1995). It is possible to follow moving biological structures with AFM only when small 
details such as filopodia are imaged (McNally et al., 2005), or the temporal resolution is 
substantially decreased (Yunxu et al., 2006).  
Here we describe how combining three different imaging techniques (time-lapse DIC 
imaging, AFM on both fixed and living neurons and fluorescence confocal microscopy) used 
separately, at different times, on different instruments - but on the same samples it was 
possible to provide a morphological characterization of ES-derived growth cones related to 
their movement (Ban et al., 2011) and hypothesize a possible functional role of the 
fragmented structures observed only in a fraction of growth cones. 
2. Combined AFM, confocal and DIC imaging for characterization of  
ES-derived neuronal growth cones 
2.1 Morphological characterization of ES-derived growth cones 
AFM imaging on more that one hundred fixed cells (n=119) revealed different morphologies 
of ES-derived growth cones, as shown in Figure 1. 
ES-derived neuronal precursors were obtained using the protocol described previously (Ban 
et al., 2007). Cells were plated on coverslips and induced to differentiate for 24 hours. 
During this period of culture, ES-derived neurons extended neurites with growth cones 
moving forward, retracting and exploring the environment with their filopodia. The 
structure of the differentiating growth cones was analyzed by AFM in contact mode in 
liquid. Cells were plated at a density of 3x104 cells/cm2 in order to obtain isolated growth 
cones to avoid overlapping structures. This low density, however, is sufficient for the 
neuronal survival in culture. 
At this stage of differentiation, very different structures were observed with the diameter of 
growth cones that varied from 1.5 to 28 m and height that varied from 65 to 593 nm. They 
could be classified in three different morphological groups: in the first one (Figure 1D-I) they 
appeared swollen and smooth, with several filopodia spreading from the central domain. The 
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height differed substantially from one growth cone to another but in this group (68% of 
growth cones analyzed) it always exceeded 200nm. In the second group (21% of cases) growth 
cones were flat with few or no filopodia (Figure 1A-C) and their height was consistently below 
200nm. In the third group (11% of cases) growth cones showed a ruffled and fragmented 
structure with several holes (Figure 1J-L). The height of these growth cones was also below 
200nm, and their thickness almost vanished in some regions. All these structural details were 
not recognizable with optical microscope due to their small dimensions. 
 
 
Fig. 1. High resolution AFM images of ES-derived growth cones fixed after 24 h of 
differentiation. Growth cones could have flat and rough (A-C), swollen and smooth (D-I) or 
fragmented (J-L) structures. Scale bar, 2µm. 
Although during image acquisition the AFM tip interacts with the cell surface and could 
modify or damage the cell membrane, we demonstrated that the fragmented structures were 
not an artifact of AFM scanning by acquiring a series of images of a compact growth cone at 
increasing tapping forces of 200, 1000 and 3000 pN respectively. In 4 independent 
experiments performed, the height profile of the growth cones at varying forces showed a 
decrease in height caused by a compression of the cell structures, probably due to the 
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residual cell elasticity, after the fixation procedure. However, when the imaging force was 
restored to the initial value of 200pN, the cell morphology was exactly the same as in the 
first scan and no damage was introduced (Ban et al., 2011). 
Holes and fragments of growth cones were not fixation artefacts. In fact, using three 
different fixation methods both fragmented and compact growth cones were present on the 
same coverslip and sometimes on neighbouring cells. Fragmented structures were also 
observed in growth cones of living neurons analyzed by AFM: in 6 out of 23 imaged cells 
the growth cones retracted leaving behind fragments with variable dimensions. In 3 cases 
holes in the growth cones were observed and in one case the holes were already present at 
the first scan. The physiological dynamics was poorly affected by AFM scans and the 
cantilever tip did not damage the growth cones since in majority of cases (14 out of 23 
imaged cells) their compact structure was preserved during the scanning period even 
though cycles of protrusion and retraction were observed. Moreover, fragmentation 
observed under living conditions (13% of cases) had comparable proportion in respect to 
what observed with fixed cells (11% of cases). Altogether, these observations suggested that 
the fragments observed on the fixed cells were originated before fixation and that 
fragmentation is a physiological phenomenon (Ban et al., 2011). 
We hypothesized that the different morphologies observed in the growth cones might 
correlate with different types of movement. For doing so we took advantage of the 3 
techniques described to study the motion of living growth cones and trying to correlate it 
with structure and expression of specific subcellular components. 
2.2 Preparation of coverslips  
To be able to collect images with all these techniques (each of them with different 
performaces, resolution and collection modes) but from the same cell it was necessary to 
have a position marker on the sample. 
In our case we prepared a home-made coverslips on which ES-derived neuronal precursors 
were plated and induced to differentiate. But commercial coverslips with numerical grid 
could serve the same purpose.  
Coverslips with printed markers were prepared by optical lithography and metal 
evaporation on 24mm diameter glass coverslips. A polymeric photoresist was deposited on 
one side of the coverslips by spin coating. The indexed pattern was produced by UV 
exposure through a patterned optical mask. A 20nm titanium layer was finally deposited 
and stripped by lift-off techniques (Figure 2A). 
In the free space between printed markers the movement of neurons and their growth cones 
could be clearly monitored (Figure 2B). Time-lapse DIC and AFM imaging can be performed 
on living cells while immunofluorescence assays (Figure 2C) and high resolution AFM 
(Figure 2D) can be done at very different time intervals after fixation (from few hours up to 
many months if samples are kept at +4°C in paraformaldehyde). 
2.3 Correlation between movement and structure/function 
Theoretically movement and structure could be analyzed imaging living cells with AFM.  
When performing AFM on living cells images could be obtained in tapping mode at 0.6 scan 
line per second and with a maximum of 256 scan lines. In this way the acquisition of AFM 
images required several minutes and, due to the movement of growth cones and to the 
fluidity of the membrane, a high resolution AFM image could not be achieved. Giving 
higher temporal resolution, time-lapse differential interference contrast (DIC) imaging was 
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used. Images with resolution between 512x512 and 1024x1024 pixels were acquired every 10 
seconds, for a total of 80 frames (total duration 13 minutes and 20 seconds) and the motion 
of more than 100 growth cones was collected.  
 
 
Fig. 2. (A) An example of a coverslip with printed markers and numbers. Scale bar, 100 m. 
(B) ES-derived growth cone (inset) imaged with DIC using a confocal microscope. Scale bar, 
25 m. (C) Confocal image (1024x1024 pixels) of a growth cone stained for with an antibody 
against neural cell adhesion molecule (NCAM). Scale bar, 10 m. (D) AFM image (1024x1024 
pixels) of the same growth cone. Scale bar, 5 m. Color bar from 0 to 350nm (From Kondra 
et al., 2009, Journal of Neuroscience Methods, ELSEVIER). 
From the time-lapse analysis 4 different types of movements were observed: exploring 
(43/104), growing (16/104), retracting (17/104) and stasis (28/104). 29 of these cells were 
imaged with AFM. Cells were fixed immediately after video imaging, AFM with a 
resolution between 512x512 and 1024x1024 pixels was performed followed by staining with 
appropriate antibodies. 
Filopodia of exploring growth cones (9 out of 29 cells) moved with a velocity up to 80 nm s-1 
with an average value of 25±7 nm s-1 exploring very efficiently the surrounding free space 
independently in all directions. Some filopodia were continuously extending and retracting, 
changing rapidly in their length, while some others were freely exploring maintaining their 
shape. AFM imaging revealed a smooth and compact surface. The growth cones had 
average height of 852 ± 235 nm and their filopodia had a height varying between 67 and 219 
nm (n=40; average height 98.8 ± 48.3nm). 
Neurites of growing growth cones (5 out of 29 cells) could grow by 1-5 m in 2-10 minutes 
and in two cases a neurite grew up to 14 m in less than 2 minutes. As for exploring growth 
cones, in all cases AFM showed a compact and smooth surface. Filopodia height reached 
almost 2 m and their average length was 3.5 m (n=20).  
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used. Images with resolution between 512x512 and 1024x1024 pixels were acquired every 10 
seconds, for a total of 80 frames (total duration 13 minutes and 20 seconds) and the motion 
of more than 100 growth cones was collected.  
 
 
Fig. 2. (A) An example of a coverslip with printed markers and numbers. Scale bar, 100 m. 
(B) ES-derived growth cone (inset) imaged with DIC using a confocal microscope. Scale bar, 
25 m. (C) Confocal image (1024x1024 pixels) of a growth cone stained for with an antibody 
against neural cell adhesion molecule (NCAM). Scale bar, 10 m. (D) AFM image (1024x1024 
pixels) of the same growth cone. Scale bar, 5 m. Color bar from 0 to 350nm (From Kondra 
et al., 2009, Journal of Neuroscience Methods, ELSEVIER). 
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imaged with AFM. Cells were fixed immediately after video imaging, AFM with a 
resolution between 512x512 and 1024x1024 pixels was performed followed by staining with 
appropriate antibodies. 
Filopodia of exploring growth cones (9 out of 29 cells) moved with a velocity up to 80 nm s-1 
with an average value of 25±7 nm s-1 exploring very efficiently the surrounding free space 
independently in all directions. Some filopodia were continuously extending and retracting, 
changing rapidly in their length, while some others were freely exploring maintaining their 
shape. AFM imaging revealed a smooth and compact surface. The growth cones had 
average height of 852 ± 235 nm and their filopodia had a height varying between 67 and 219 
nm (n=40; average height 98.8 ± 48.3nm). 
Neurites of growing growth cones (5 out of 29 cells) could grow by 1-5 m in 2-10 minutes 
and in two cases a neurite grew up to 14 m in less than 2 minutes. As for exploring growth 
cones, in all cases AFM showed a compact and smooth surface. Filopodia height reached 
almost 2 m and their average length was 3.5 m (n=20).  
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Retracting growth cones (7 out of 29 cells) moved with a velocity ranging from 80 to 135 
nm/sec, retracting their filopodia and the whole neurites from the original position. After 
fixation, AFM scanning revealed the presence of fragments near the tip of fast retracting 
growth cones. The confirm that these fragments were actual parts of the growth cone left 
behind by the neuron came from AFM imaging of living neurons. In all 6 retracting growth 
cones observed, fragments with an average diameter of 85 ± 27 nm and an average height of 
75 ± 28 nm were detected.  
Growth cones were classified as static (8 out of 29 cells) when the external contour of the growth 
cone remained in the same position and the length of their neurite did not change during DIC 
observation. These growth cones had an apparently intact shape when viewed with time-lapsed 
DIC images (Figure 2B), but their 3D shape was highly fragmented when viewed with AFM 
(Figure 2D). Static growth cones were thinner and rarely reached 200nm height. 
When the same growth cone was analyzed with immunofluorescence - with actin and 
tubulin to follow cytoskeletal component underlying growth cone movement or neural cell 
adhesion molecule (NCAM) to visualize cell membrane contours - the two images were 
difficult to compare due to the different resolution (Figure 2C and D). Moreover, AFM and 
CLSM images contain different information: every pixel at location (x,y) in the AFM images 
provides a direct measurement in nm of the sample height while fluorescence images 
acquired with a confocal laser scanning microscope characterize the emitted fluorescence at 
the same location. 
In order to integrate the information derived from AFM and immunofluorescence analyses 
it is important to properly align or superimpose these different images. This problem has 
been extensively studied in Computer Vision, where it is referred as “Registration“ of 
different images (Kondra et al., 2009). 
2.4 Image registration 
Image registration is the process of overlaying two or more images of the same scene taken at 
different times, different viewpoints, and/or by different imaging modalities. Differences 
between images are introduced because of different imaging conditions, such as different 
viewing points or light conditions or because of the use of two different microscopes, as in the 
case under consideration. Registration transforms one image – usually the sensed image – so 
that it becomes aligned to the reference image. Image registration is a crucial step in image 
analysis and can be solved using methods used in computer vision (Trucco & Verri, 1998), in 
which the final information is obtained by integrating various data sources like in image 
fusion (Zitova & Flusser, 2003). Images taken from different modalities may undergo a linear 
deformation in scale, translation, rotation and sometimes shearing i.e. affine deformation.  
The word registration is used with two different meanings (Hill et al., 2001). The first 
meaning is to determine a transformation of one image so that features in the sensed image 
can be put in a one-to-one correspondence to features in the reference image. The symbol T 
is used to represent this type of transformation. The second meaning of registration enables 
also the comparison of the intensity at corresponding positions. The symbol Ti is used to 
describe this second meaning of registration, which incorporates the concepts of re-
sampling and interpolation. 
T is a spatial mapping. The more complete mapping Ti maps both position and associated 
intensity value from image A to image B. Therefore Ti maps an image to an image, whereas 
T maps between coordinates of image A into coordinates of image B. To overlay two images 
that have been registered, or to subtract one from another, is necessary to know Ti, not just 
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T. Ti is only defined in the region of overlap of the image fields of view, and has to take into 
account of image sampling and spatial resolution. 
Before doing the registration, it is necessary to select the correct type of transformation 
required for the images under consideration. The most widely used transformations are 
Linear, Affine and Projective. The linear transformation is used when shapes in the sensed 
image are unchanged, but are distorted by some combination of translation, rotation, and 
scaling. Straight lines remain straight, and parallel lines are still parallel. This is the case of 
the same biological sample viewed by two microscopes using different objectives and 
imaging systems, such as an AFM (Figure 2D) and a CLSM (Figure 2C). Registration using 
affine transformation is necessary when shapes in the sensed image are distorted also by 
shearing or a linear deformation. In this case, straight lines remain straight, and parallel 
lines remain parallel, but rectangles become parallelograms. Projective transformation is 
used when the scene appears tilted. Straight lines remain straight, but parallel lines 
converge toward vanishing points that might or might not fall within the image. 
If we consider two images of the same biological sample, the first one acquired using AFM 
and the second using a CLSM, the two imaging systems differ because of different scale 
factors, by a rigid translation of their origin and a possible rotation of their axis. It is 
assumed that the two imaging systems do not introduce any deformation. Registration of 
the two images consists in the determination of the transformation parameter by aligning 
properly the two images.  
The unknown parameters in the transformation matrix can be estimated either by matching 
a selected number of points or landmarks in the two images or by matching entire contours 
in the two images. The first method is used when it is possible to identify in the two images 
enough points corresponding to the same physical structure, such as the tip of a dendrite, or 
a small vesicle. The second method is used in presence of rounded biological structures, 
with no obvious marks and it is more convenient to put in correspondence two contours 
than isolated points. 
 
 
Fig. 3. Snapshot of the graphical user interface (From Kondra et al., 2009, Journal of 
Neuroscience Methods, ELSEVIER). 
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To apply these methods to the images derived from different microscopes we have 
implemented our Registration program using Matlab7.1 (The MathWorks Inc. 
http://www.mathworks.com) a standard tool common in the computer vision and 
biomedical community for statistical analysis and production of figures and images of 
analyzed data and results.  
For a more detailed mathematical description of the different transformations and 
description of the program see Kondra et al., 2009, Appendix 1, 2 and 3). 
Corresponding points or contours in AFM image and confocal image were marked by hand 
using a friendly graphical user interface developed for this particular purpose (Figure 3). 
Registration by points selection method is illustrated in Figure 4. The operator identifies N 
(minimum 3) points in the AFM image (Figure 4A) that are put in correspondence with N 
points in the confocal image (Figure 4B). Corresponding points in Figure 4A and B are 
indicated by the same number. By using these correspondences the parameters determining 
the transformation T are obtained by solving a system of linear equation and the confocal 
image can be registered. In this way same physical points in the original AFM and in the 
new registered confocal image, shown in Figure 4C, have the same location.    
To make more user friendly the selection of points, confocal image can be rotated in a 
sequence of 90 degrees and/or flipped to make a approximate alignment with AFM image 
(compare Figure 2C with Figure 4B). Control Point Selection Tool in Matlab was used to 
mark the control point pairs in the image to be registered, the input image (Figure 4B), and 
the image to which you are comparing it, the base image (Figure 4A) corresponding points 
were initially specified by pointing and clicking in the input and base images so that each 
point specified in the input image had a match in the base image. 
 
 
Fig. 4. Example of registering images using points selection method. (A) AFM image of ES-
derived growth cone. Color bar from 0 to 350nm. (B) Confocal image of the same ES-derived 
growth cone. Scale bar, 10 m. (C) Registered confocal image (From Kondra et al., 2009, 
Journal of Neuroscience Methods, ELSEVIER). 
The advantage of this tool is that, after the first three pairs are selected, it is sufficient to 
select a point in the input image and the Control Point Selection Tool estimates its match 
point in the base image or vice versa automatically, based on the geometric relationship of 
the previously selected control points. Another advantage of this tool is that if the image is 
not registered properly, it is possible to change the position of control points to get the exact 
superimposition. 
The alternative method is registration by aligning contours with Procrustes Analysis. 
Procrustes was a robber in Greek mythology. He would offer travellers hospitality in his 
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road-side house, and the opportunity to stay the night in his bed that would perfectly fit each 
visitor. As the visitors discovered to their cost, however, it was the guest who was altered to fit 
the bed, rather than the bed that was altered to fit the guest (Hill et al., 2001). Let us consider 
that the AFM image is like the bed and is the guest. So using the Procrustes’ method means 
that confocal image is altered by scaling and/or rotating it to approximately fit AFM image. 
The number of landmarks available depends on the structure of the image, and there may 
be differences in opinion between scientists as to which landmarks are consistent and 
locatable. Marking of the corresponding points thus becomes difficult when there are few 
corners in the structure, and thus exact location of the points is impossible and can differ 
from observer to observer. This problem can be solved by marking many points along the 
contour of the structure in both images. The contours are then interpolated so that both of 
them contain the same number of equally spaced points (for mathematical description of 
transformation see Kondra et al., 2009). 
An example of this method is illustrated in Figure 5. A contour was marked by continuously 
clicking on points following the borderline of the structure of interest in AFM image (Figure 
5A) and in the confocal image as well (Figure 5B). As a consequence of Procrustes analysis, 
confocal image was properly transformed and put in correspondence with AFM image 
(Figure 5C).  
 
 
Fig. 5. Example of registering images using Procrustes Analysis. (A) AFM image of ES-
derived growth cone. Scale bar, 10m. Color bar from 0 to 2200 nm. (B) Confocal image of 
the same ES-derived growth cone stained for neural cell adhesion molecule (NCAM). Scale 
bar, 10m. (C) Registered confocal image of membrane protein NCAM (From Kondra et al., 
2009, Journal of Neuroscience Methods, ELSEVIER). 
2.5 Identification of nanometric structures and subcellular component in static 
fragmented growth cones 
With registration of confocal and AFM images it was possible to further analyze the 
composition of fragments characteristic of static and retracting growth cones. Their structure 
seemed compact when viewed with time-lapsed DIC images (Figure 6A), instead AFM 
(Figure 6B) revealed highly fragmented 3D shape. Profiles of AFM images of static growth 
cones showed isolated fragments with height that varied from 50 to 150 nm (Figure 6E). 
Registered confocal images demonstrated that they contain actin filaments but not tubulin 
and they are positive for neural cell adhesion molecule (NCAM) indicating that fragments 
left behind by growth cones are formed by chunks of actin filaments enveloped by the cell 
membrane (Figure 6C and D). 
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Height of fragments and of filopodia had a similar distribution varying from less than 30 nm 
up to 300 nm (Ban et al., 2011). Immobile growth cones not only were surrounded by detached 
fragments, but they also had holes. Growth cone regions surrounding these holes had a height 
varying from 20 to 90 nm and holes had an area varying between 0.03 to 0.650 m2. Fragments 
had a height varying from 40 to 400 nm with an area varying between 0.4 to 6m2. 
During the time-lapse DIC imaging none of the neurons with static growth cones showed 
signs of membrane blebbing or cell shrinking typical of apoptotic cell indicating that the 
observed fragmentation was not associated with apoptosis. Moreover, nuclear staining by 
Hoechst revealed that none of the eight cells that were also analyzed by AFM and 
immunofluorescence after fixation had an apoptotic nucleus. We can therefore conclude that 
growth cone fragmentation is not part of the apoptotic process. 
 
 
Fig. 6. Static growth cones. (A) DIC, (B) AFM topography and (C) registered confocal image 
of the same growth cone stained for F-actin (green), NCAM (red) and -tubulin III (blue). 
Scale bar, 5 m. (D) Confocal image of the inset shown in C. (E) Height profile along the 
white line shown in D. 
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Three different imaging techniques used separately, at different times, on different 
instruments - but on the same samples and the possibility to compare AFM and confocal 
images due to the development of the registration method (Kondra et al., 2009) allowed us 
to obtain a morphological characterization of ES-derived growth cones. 
Integrated AFM and CLSM instrument has been developed and it offers the advantage of 
parallel analysis of the same sample with nanometer-scale spatial resolution, frame/second 
temporal resolution, and chemical identification through fluorescence detection can be done 
simultaneously for live cells (Doak et al., 2008; Park et al., 2010).  
In addition to optical microscopy, AFM can be combined with other instruments and 
techniques, such as microfluidic liquid cell (Schoenwald et al., 2010), patch-clamp (Pamir et 
al., 2008) or ultramicrotome (Efimov et al., 2007) providing a novel insights to further 
understanding of cellular structure-function relationships getting down to the scale of single 
molecule.  
Although there are several studies where AFM is combined with confocal microscope (Doak 
et al, 2008; Moreno Flores & Toca-Herrera., 2009; Kassies et al., 2005; Owen et al., 2006; Park 
et al., 2010), our method is useful in cases where combined fluorescence (confocal) and 
atomic force microscope is not available. In addition, performing different assays separately 
permitted optimization of sample preparation for each experiment. For example, AFM on 
fixed cells was performed in contact mode, in liquid (phosphate buffer saline (PBS)) while 
for immunofluorescence assays, coverslips were mounted with commercial mounting 
medium, in order to reduce photobleaching during the repetitive number of confocal scans 
required to zoom in the region corresponding to the growth cone. Our AFM microscope was 
provided with fluorescence setup and we collected some fluorescent images while 
performing AFM. However, in PBS the samples bleached rapidly and the resulting images 
had poor definition. 
The combination of AFM and fluorescence confocal microscopy on fixed cells, and of time-
lapse DIC and AFM imaging on living cells allowed us to correlate morphology of ES-
derived growth cones  to their movement prior fixation providing therefore both structural 
and functional insights. 
Growth cones actively exploring the environment before fixation had a smooth external 
surface. In contrast, growth cones which were immobile before fixation revealed a 
fragmented shape, composed of several nanoscale structures either partly attached or 
completely isolated from the rest of the growth cone. In addition, by using AFM on live 
specimen, fragmentation was observed in some of the retracting growth cones. Therefore 
the morphology of ES-derived growth cones depends on their overall motility.  
Growth cones with micrometric size holes of retinal ganglion cell axons were previously 
observed in vivo (Godement et al., 1994; Mason & Erskin, 2000). They appear in the spread 
growth cones and are predicted to form from the fusion or contact of lamellar extensions of 
the growth cone as they enfold radial glial processes. However, although morphologically 
similar, these two findings reflect a different biological phenomenon: first because our 
observations were the result of a technical approach measuring at nanometric level and 
second, because we never found fragmented structures in growing growth cones.  
The fragmentation can be related to growth cones pruning that occurs during the early 
development of the central nervous system, where an excessive outgrowth of projections 
need to be refined to achieve precise connectivity (Faulkner et al., 2007). The selective 
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of the same growth cone stained for F-actin (green), NCAM (red) and -tubulin III (blue). 
Scale bar, 5 m. (D) Confocal image of the inset shown in C. (E) Height profile along the 
white line shown in D. 
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Three different imaging techniques used separately, at different times, on different 
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to obtain a morphological characterization of ES-derived growth cones. 
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parallel analysis of the same sample with nanometer-scale spatial resolution, frame/second 
temporal resolution, and chemical identification through fluorescence detection can be done 
simultaneously for live cells (Doak et al., 2008; Park et al., 2010).  
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techniques, such as microfluidic liquid cell (Schoenwald et al., 2010), patch-clamp (Pamir et 
al., 2008) or ultramicrotome (Efimov et al., 2007) providing a novel insights to further 
understanding of cellular structure-function relationships getting down to the scale of single 
molecule.  
Although there are several studies where AFM is combined with confocal microscope (Doak 
et al, 2008; Moreno Flores & Toca-Herrera., 2009; Kassies et al., 2005; Owen et al., 2006; Park 
et al., 2010), our method is useful in cases where combined fluorescence (confocal) and 
atomic force microscope is not available. In addition, performing different assays separately 
permitted optimization of sample preparation for each experiment. For example, AFM on 
fixed cells was performed in contact mode, in liquid (phosphate buffer saline (PBS)) while 
for immunofluorescence assays, coverslips were mounted with commercial mounting 
medium, in order to reduce photobleaching during the repetitive number of confocal scans 
required to zoom in the region corresponding to the growth cone. Our AFM microscope was 
provided with fluorescence setup and we collected some fluorescent images while 
performing AFM. However, in PBS the samples bleached rapidly and the resulting images 
had poor definition. 
The combination of AFM and fluorescence confocal microscopy on fixed cells, and of time-
lapse DIC and AFM imaging on living cells allowed us to correlate morphology of ES-
derived growth cones  to their movement prior fixation providing therefore both structural 
and functional insights. 
Growth cones actively exploring the environment before fixation had a smooth external 
surface. In contrast, growth cones which were immobile before fixation revealed a 
fragmented shape, composed of several nanoscale structures either partly attached or 
completely isolated from the rest of the growth cone. In addition, by using AFM on live 
specimen, fragmentation was observed in some of the retracting growth cones. Therefore 
the morphology of ES-derived growth cones depends on their overall motility.  
Growth cones with micrometric size holes of retinal ganglion cell axons were previously 
observed in vivo (Godement et al., 1994; Mason & Erskin, 2000). They appear in the spread 
growth cones and are predicted to form from the fusion or contact of lamellar extensions of 
the growth cone as they enfold radial glial processes. However, although morphologically 
similar, these two findings reflect a different biological phenomenon: first because our 
observations were the result of a technical approach measuring at nanometric level and 
second, because we never found fragmented structures in growing growth cones.  
The fragmentation can be related to growth cones pruning that occurs during the early 
development of the central nervous system, where an excessive outgrowth of projections 
need to be refined to achieve precise connectivity (Faulkner et al., 2007). The selective 
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elimination of neuronal cell processes, or neurites, is an essential step during normal 
development and occurs through retraction, degeneration, or a combination of both (Franze 
et al., 2009).  
This phenomenon resembles the growth cone collapse induced by several factors like 
mercury (Leong et al., 2001), X-ray (Al-Jahdari et al., 2008) or semaphorin in the absence of 
growth factors (Tamagnone & Comoglio, 2004). The fragmentation of the growth cone we 
observed is a local phenomenon, similar to what observed for Lysophosphatidic acid (LPA) 
induction of collapse in vitro which, in contrast with other collapsing treatments, is 
reversible and not toxic (Saito, 1997). However, to our knowledge, this is the first time that 
this collapse-like phenomenon was observed to occur spontaneously.  
Previous investigations have shown the formation of migration tracks resulting from the 
release of cellular material onto glass surfaces and artificial matrices for a number of cell 
types (Fuhr et al., 1998; Kirfel et al., 2004; Richter et al., 2000; Zimmermann et al., 2001). 
Macroaggregates left behind migrating keratinocytes contain high amounts of 1 integrin 
and parts of the fibronectin and laminin receptors. They lack, however, of any cytosolic 
proteins including actin and of the adhesion complex constituents talin and vinculin. In our 
experimental conditions, fragments left behind by growth cones are composed of cell 
membrane but also of cytoplasmic proteins such as F-actin, as it was reported for other 
migrating cells (Fuhr et al., 1998). Fragments could correspond to filopodia originally 
present on the growth cone in that position also because the height distribution of filopodia 
and fragments was similar, suggesting that they may be composed of similar 
building/dismantling blocks. The existence of building blocks could agree with a previous 
study (Parpura et al., 1993) where it was found that the height of an hippocampal growth 
cones corresponds to a multiple of the heights of individual filopodia possibly due to 
overlying actin bundles arising from different filopodia. 
The release of a fragment might be energetically advantageous for faster retraction and/or 
change in growing direction compared to recycling of distal elements. However it cannot be 
excluded that fragments might act as guidance signals for neighboring neurons. 
Vertebrate semaphorins are either secreted or associated with the cell surface. In vitro and in 
vivo experiments have implicated semaphorins in the guidance of elongating axons and 
dendrites, as well as in axon branching, pruning and degeneration (Tamagnone & 
Comoglio, 2004). The primary role of Sema 3A in the nervous system is to repel growth 
cones from inappropriate areas and to help steer both axons and migrating cells along the 
correct trajectory (Brown & Bridgman, 2009). When added in bath, they cause rapid collapse 
of growth cones, followed by axon retraction (Kolpak et al., 2009). 
The fragmentation of growth cones that have not established contact or by pruned contact 
here observed could therefore serve as a migrating track for other neurons, by exposing 
semaphorins or other membrane proteins that act as receptors and/or ligands for axon 
guidance. 
4. Conclusion 
The combination of AFM and fluorescence confocal microscopy on fixed cells, and of time-
lapse DIC and AFM imaging on living cells allowed us to obtain a morphological 
characterization of ES-derived growth cones related to their movement providing both 
structural and functional insights. 
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In particular the registration method allowed to superimpose images taken from different 
modalities. Registration, however, is not restricted to confocal and AFM images but is a 
versatile tool for combined studies. The main advantage is that there is no need for 
sophisticated and combined microscopes but with conventional instruments and AFM, 
structural information at nanometer scale is combined with functional studies.  
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1. Introduction  
Oligodendrocytes (OL) are cells of the glial lineage which play a critical role in the central 
nervous system (CNS) by producing the multilamellar protein, myelin. Oligodendrocytes 
extend processes which wrap around the axons of several neurons. This myelin sheath 
increases neuronal conduction by decreasing ion leakage and capacitance of the axonal 
membrane and increasing saltatory conduction. Damage to oligodendrocytes results in loss 
of myelin and consequent functional impairment due to loss or decay of neuronal 
conduction. Demyelination in the CNS is the hallmark of conditions such as spinal cord 
injury (SCI), transverse myelitis and multiple sclerosis – resulting in functional impairment 
across the sensory, motor and cognitive domains. Current research on treatment of SCI 
focuses on the implantation of oligodendrocyte progenitor cells (OPC) into the injured 
region to achieve remyelination of the spared axons and potentially repair the sensory and 
motor pathways. However, this approach requires a large and relatively pure population of 
OPCs, which are differentiated from other multipotent cell lineages. Human embryonic 
stem cells have been used in several studies for this purpose and hence, it is important to 
understand the molecular mechanisms regulating the differentiation of pluripotent hESCs to 
oligodendrocytes. Elucidation of such mechanisms may lead to the development of more 
efficient differentiation protocols and the derivation of cells with improved myelination 
potential for implantation in injured spinal cords.  
While the molecular basis for hESC differentiation into OL lineage cells is not completely 
understood, several recent studies have filled some of the gaps in our knowledge of the 
field. The journey from a pluripotent state to commitment to the OL fate is characterized by 
a complex interplay between genetic regulation and epigenetic modifiers such as histone 
modification, DNA methylation and microRNAs (miRNAs). Global miRNA expression 
profiling of OL differentiation from hESCs has revealed that a significant number of the 
differentially expressed miRNAs have targets hypothesized to be involved in myelination 
and OL development. Such studies are complemented by histone modification analyses in 
ESCs which show that specific histone acetyltransferases (HATs) and histone deacetylases 
(HDACs) are up- or down-regulated during different time points in OL differentiation to 
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guide myelin production. This review focuses on the role of miRNAs in oligodendrocyte 
development from human embryonic stem cells and elucidates a new protocol developed to 
obtain oligodendrocytes from human embryonic stem cells with high yield and purity. 
2. MicroRNA regulation of oligodendrocyte development 
To date, many studies have attempted to unravel mechanisms of stem cell fate 
determination by studying gene expression by measuring messenger RNA (mRNA) 
expression. However, in the early-mid 90’s a novel class of RNA molecules was discovered 
that regulated gene expression at the level of translation in C. elegans. These RNAs were 
shown to regulate the translation of a target mRNA, by directly base-pairing to its 3'-
untranslated region (3' UTR) (Lee, Feinbaum & Ambros 1993, Wightman, Ha & Ruvkun 
1993). Nevertheless, the broad significance of these small RNAs was not fully appreciated 
until only a few years ago when many similar molecules were further identified in C. 
elegans, Drosophila, and in some mammals (Lee, Ambros 2001, Lagos-Quintana et al. 2001), 
and these newly recognized regulatory RNAs were termed microRNAs (miRNAs or miRs). 
To date, sequencing libraries of cloned small RNAs and bioinformatic analyses of genomic 
sequences have led to the identification of ~500 verified mammalian miRNAs while studies 
exploiting the high degree of conservation of miRNAs across mammalian genomes have 
suggested that as many as 1000 human miRNAs are likely to exist (Berezikov et al. 2005, 
Bentwich et al. 2005). Despite these great advances in the identification of miRNAs, our 
understanding of their roles in cellular processes remains at a very early stage although 
there is evidence suggesting that miRNA dysfunction contributes significantly to 
oncogenesis and stem cell self-renewal. 
MiRNAs are found in plants, viruses and animals and are generated via a multi-stage 
process. In mammals they are first transcribed as long precursor transcripts (~60-80 
nucleotides) known as primary (pri)-miRNAs containing a hairpin loop (Lee et al. 2002). Pri-
miRNAs are then processed into shorter hairpin shaped precursors (pre)-miRNAs in the 
nucleus and transported to the cytoplasm. There, the RNase-III enzyme Dicer performs a 
second cleavage to generate a double-stranded 21-23 nucleotide RNA molecule (Bernstein et 
al. 2001, Grishok et al. 2001, Hutvágner et al. 2001, Ketting et al. 2001, Knight, and Bass 
2001). A large protein complex known as the RNA-induced silencing complex, or RISC, 
associates with this RNA duplex and unwinds it. Generally, only one strand is stably 
incorporated into RISC while the other is discarded and rapidly degraded (Meister et al. 
2004). After the RISC is formed the miRNAs guide it to the target mRNA that is 
subsequently cleaved or translationally silenced. The degree of complementarity between a 
miRNA and its target dictates the mechanism of silencing (Meister et al. 2004, Hutvágner et 
al. 2004, Brennecke et al. 2003) 
While degradation occurs predominantly in plants, in mammals the predominant 
mechanism appears to be through imperfect base-pairing between a miRNA and its target, 
resulting in translational silencing through a complex mechanism that appears to involve 
inhibition of both translation initiation and elongation (Pillai, Bhattacharyya & Filipowicz 
2007).  
MiRNAs are attractive candidates for regulating stem cell identity, which includes self-
renewal and cell fate decisions, as their ability to simultaneously regulate many targets 
provides a means for coordinated control of gene action (Chen et al. 2007). Although direct 
functional roles in stem cell biology are just emerging, corroborating evidence from 
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expression patterns, predicted targets, and from overexpression studies suggests miRNAs 
are key regulators (Cheng et al. 2005). For example, the loss of Dicer1 in mice has been 
demonstrated to cause embryonic lethality as well as loss of stem cell populations 
implicating a role for miRNAs in stem cell self-renewal (Bernstein et al. 2003, Murchison et 
al. 2005). Based on several reports from mouse and human studies, distinct sets of miRNAs 
are expressed specifically in pluripotent stem cells and not in adult tissues further 
implicating their role in stem cell self-renewal. In addition, Argonaute family proteins, 
which are key components of the RISC complex, have also been shown to be required in the 
maintenance of germline stem cells in different organisms (Carmell et al. 2002). 
The role of miRNAs in oligodendrocyte fate determination has been a recent field of 
research and a few studies have reviewed the state of the current knowledge on the subject 
(He et al. 2011, Emery 2010, Dugas, Notterpek 2011).. This chapter aims to review the 
advances made in understanding oligodendrocyte fate determination by miRNAs and 
elucidate a novel protocol to derive OLs from embryonic stem cells in vitro to study their 
development.  
2.1 MicroRNAs in glial fate determination 
Zheng et al first reported that miRNAs were essential for the “developmental switch from 
neurogenesis to gliogenesis” (Zheng et al. 2010). The authors deleted Dicer, a protein 
necessary for functional miRNA synthesis, in the mouse ventral spinal neuroepithelium, 
where embryonic gliogenesis occurs. Neural patterning and motor neuron development 
occurred even in the absence of miRNA formation, showing that they are probably not 
involved in neuron maturation. However, oligodendrogenesis in the ventral spinal cord was 
blocked in the absence of Dicer, as confirmed by the complete absence of PDGFRα+ cells 
and a huge reduction in Sox10+ cells in the spinal cord parenchyma of Dicer mutants. On 
similar lines, astrogliogenesis was also found to be miRNA-dependent, as the study found 
that Dicer deletion led to the complete block of the development of a subset of astrocytes 
from the ventral neuroepithelium. This was confirmed by the lack of GFAP immunostaining 
of a small region flanking the floor plate when compared to the control. However, this study 
did not implicate any specific miRNA species as being involved in the regulation of 
gliogenesis in the developing spinal cord.  
2.2 MicroRNAs in oligodendrocyte development 
A 2009 study by Shin et al definitively established that miRNAs were involved in epigenetic 
regulation of oligodendrocyte function. This was performed by the OL-specific knockout of 
Dicer in postnatal mice. The Dicer protein is essential for synthesis of functional miRNAs 
and it was found that its elimination in postnatal OLs led to demyelination, oxidative 
damage, inflammatory astrocytosis and microgliosis in the brain. This phenotype resulted 
primarily from the disruption of miR-217 and consequent upregulation of its target ELOVL7 
(elongation of very long chain fatty acids protein 7). Overexpression of ELOVL7 leads to 
lipid accumulation in the myelin rich regions of the brain and significant decrease in 
peroxisomal β-oxidation activity (Shin et al. 2009).  
In the first study to analyze the global miRNA expression pattern in oligodendrocytes, Lau 
et al identified 98 miRNAs expressed by developing oligodendrocytes in the postnatal rat 
brain and found that 37 of these have an mRNA bias (Lau et al. 2008). In addition, the 
predicted protein targets of 13 miRNAs were dynamically regulated during OL 
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guide myelin production. This review focuses on the role of miRNAs in oligodendrocyte 
development from human embryonic stem cells and elucidates a new protocol developed to 
obtain oligodendrocytes from human embryonic stem cells with high yield and purity. 
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1993). Nevertheless, the broad significance of these small RNAs was not fully appreciated 
until only a few years ago when many similar molecules were further identified in C. 
elegans, Drosophila, and in some mammals (Lee, Ambros 2001, Lagos-Quintana et al. 2001), 
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2004). After the RISC is formed the miRNAs guide it to the target mRNA that is 
subsequently cleaved or translationally silenced. The degree of complementarity between a 
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While degradation occurs predominantly in plants, in mammals the predominant 
mechanism appears to be through imperfect base-pairing between a miRNA and its target, 
resulting in translational silencing through a complex mechanism that appears to involve 
inhibition of both translation initiation and elongation (Pillai, Bhattacharyya & Filipowicz 
2007).  
MiRNAs are attractive candidates for regulating stem cell identity, which includes self-
renewal and cell fate decisions, as their ability to simultaneously regulate many targets 
provides a means for coordinated control of gene action (Chen et al. 2007). Although direct 
functional roles in stem cell biology are just emerging, corroborating evidence from 
 
Oligodendrocyte Fate Determination in Human Embryonic Stem Cells 
 
121 
expression patterns, predicted targets, and from overexpression studies suggests miRNAs 
are key regulators (Cheng et al. 2005). For example, the loss of Dicer1 in mice has been 
demonstrated to cause embryonic lethality as well as loss of stem cell populations 
implicating a role for miRNAs in stem cell self-renewal (Bernstein et al. 2003, Murchison et 
al. 2005). Based on several reports from mouse and human studies, distinct sets of miRNAs 
are expressed specifically in pluripotent stem cells and not in adult tissues further 
implicating their role in stem cell self-renewal. In addition, Argonaute family proteins, 
which are key components of the RISC complex, have also been shown to be required in the 
maintenance of germline stem cells in different organisms (Carmell et al. 2002). 
The role of miRNAs in oligodendrocyte fate determination has been a recent field of 
research and a few studies have reviewed the state of the current knowledge on the subject 
(He et al. 2011, Emery 2010, Dugas, Notterpek 2011).. This chapter aims to review the 
advances made in understanding oligodendrocyte fate determination by miRNAs and 
elucidate a novel protocol to derive OLs from embryonic stem cells in vitro to study their 
development.  
2.1 MicroRNAs in glial fate determination 
Zheng et al first reported that miRNAs were essential for the “developmental switch from 
neurogenesis to gliogenesis” (Zheng et al. 2010). The authors deleted Dicer, a protein 
necessary for functional miRNA synthesis, in the mouse ventral spinal neuroepithelium, 
where embryonic gliogenesis occurs. Neural patterning and motor neuron development 
occurred even in the absence of miRNA formation, showing that they are probably not 
involved in neuron maturation. However, oligodendrogenesis in the ventral spinal cord was 
blocked in the absence of Dicer, as confirmed by the complete absence of PDGFRα+ cells 
and a huge reduction in Sox10+ cells in the spinal cord parenchyma of Dicer mutants. On 
similar lines, astrogliogenesis was also found to be miRNA-dependent, as the study found 
that Dicer deletion led to the complete block of the development of a subset of astrocytes 
from the ventral neuroepithelium. This was confirmed by the lack of GFAP immunostaining 
of a small region flanking the floor plate when compared to the control. However, this study 
did not implicate any specific miRNA species as being involved in the regulation of 
gliogenesis in the developing spinal cord.  
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A 2009 study by Shin et al definitively established that miRNAs were involved in epigenetic 
regulation of oligodendrocyte function. This was performed by the OL-specific knockout of 
Dicer in postnatal mice. The Dicer protein is essential for synthesis of functional miRNAs 
and it was found that its elimination in postnatal OLs led to demyelination, oxidative 
damage, inflammatory astrocytosis and microgliosis in the brain. This phenotype resulted 
primarily from the disruption of miR-217 and consequent upregulation of its target ELOVL7 
(elongation of very long chain fatty acids protein 7). Overexpression of ELOVL7 leads to 
lipid accumulation in the myelin rich regions of the brain and significant decrease in 
peroxisomal β-oxidation activity (Shin et al. 2009).  
In the first study to analyze the global miRNA expression pattern in oligodendrocytes, Lau 
et al identified 98 miRNAs expressed by developing oligodendrocytes in the postnatal rat 
brain and found that 37 of these have an mRNA bias (Lau et al. 2008). In addition, the 
predicted protein targets of 13 miRNAs were dynamically regulated during OL 
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development. In particular, the study identified miR-9 as a candidate miRNA with an 
important regulatory role during the transition from OPC (A2B5+/GalC−) to 
premyelinating OL (A2B5+/GalC+) and it was found that miR-9 downregulated the 
expression of the peripheral myelin protein (PMP) 22. PMP22 is expressed by Schwann cells 
and is a component of the compact myelin of the peripheral nervous system. Interestingly, 
miR-9 is not expressed by Schwann cells.  
Another study identified miR-23 and its target, Lamin B1 (LMNB1) as a regulatory 
component of OL differentiation (Lin, Fu 2009). Genomic duplication of LMNB1 has been 
implicated in autosomal dominant leukodystrophy (Padiath et al. 2006), a disease 
characterized by severe myelin loss in the CNS. Nuclear lamins such as LMNB1 interact 
with heterochromatin to regulate DNA synthesis and transcription and LMNB1 specifically 
regulates OL function; this was confirmed by the repression of transcription of OL-specific 
genes such as myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
oligodendrocyte glycoprotein (MOG) by overexpression of LMNB1. The Lin et al study 
showed that miR-23 downregulates LMNB1 in normal OLs and that downregulation of 
LMNB1 by miR-23 was important for the development of OLs from glial cell cultures (Lin, 
Fu 2009). The effect of LMNB1 on differentiation was confirmed by the observation that 
increased LMNB1 gene dosage caused an arrest in differentiation and led to the 
development of an MBP and PLP negative phenotype. This was hypothesized to be due to 
either faulty transcription of these genes or defective nuclear export.  
A 2010 study by Zhao et al identified miR-219 and miR-338 as OL-specific miRNAs. This was 
confirmed by the complete absence of these two miRNAs in the spinal cord of Olig1 mutant 
mice. Fluorescent in situ hybridization revealed that miR-219 and miR-338 positive cells were 
found only in the white matter of the spinal cord, which is where OLs reside. Further, it was 
found that these two miRNAs promoted OPC maturation in vitro and in vivo. Transfection of 
OPC-enriched cultures with these miRNAs led to a significant increase in the number of MBP+ 
cells (a marker of mature OLs) and a slight decrease in the number of PDGFRα+ OPCs. MiR-
219 and miR-338 were also found to be necessary for OL maturation. The study also identified 
Sox6 and Hes5 as potential protein targets of these miRNAs. These two transcription factors 
are inhibitors of OL maturation and have been shown to downregulate myelin gene 
expression and oligodendrocyte maturation (Kondo, Raff 2000, Liu et al. 2006). Sox6 and Hes5 
are downregulated by miR-219 and miR-338. The authors suggest that commitment to the 
oligodendroglial lineage would require downregulation of transcription factors which induce 
differentiation to other neural cell fates and this was confirmed by the observation that miR-
219 and miR-338 also downregulated other proneurogenic transcription factors such as 
NeuroD1, Isl1 and Otx2. In summary, these two miRs promote OL maturation by 
simultaneously inhibiting the inhibitors of OL differentiation and transcription factors which 
promote differentiation to non-OL neural cell fates.  
Another recent study confirmed the importance of miR-219 and miR-338 in OL 
differentiation and maturation (Dugas et al. 2010). In addition, it also found miR-138 to be 
strongly upregulated during OL differentiation. Among the three, miR-219 was found to be 
the strongest inducer of OL differentiation and its transfection in a purified OPC population 
increased the number of differentiated OLs expressing both early (CNP, MBP) and late 
(MOG) OL markers. OLs induced by transfection with miR-138 only expressed early OL 
markers. As expected, OL-specific miRNAs were found to target genes that are repressed 
during OL differentiation. In addition, this study also found that miR-219 downregulates 
inhibitors of OL differentiation. The validated targets of miR-219 were found to include 
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PDGFRα, Sox6, FoxJ3 and ZFP238. PDGF has been known to be an OPC mitogen for 
multiple decades (Besnard et al. 1987). ZFP238 and FoxJ3 had previously not been 
functionally characterized in OPCs and this study confirmed that FoxJ3 and ZFP238 are 
inhibitors of OL differentiation by constitutively expressing these genes in OPCs and 
observing significantly reduced differentiation to the mature OL stage.  
A study by Letzen et al was the first to perform a global miRNA analysis of cells isolated 
from 8 developmental stages from the pluripotent embryonic stem cell state to a mature, 
myelinating OL state (Letzen et al. 2010). Significantly, this study analyzed the expression of 
miRNAs in human cells as opposed to rodent models used in prior investigations. The study 
detected 183 miRNAs over the eight stages of oligodendrocyte maturation and also 
identified the highest differentially expressed miRNAs at each transition in the pluripotent-
to-mature OL differentiation scheme. These differentially-expressed miRNAs were then 
matched to potential protein targets which revealed proteins such as chromosome 11 open 
reading frame 9 (C11orf9), claudin-11 (Cldn11), myelin transcription factor 1-like (Mytl1), 
myelin-associated oligodendrocyte basic protein (Mobp), myelin protein zero-like 2 
(Mpzl2), and discoidin domain receptor tyrosine kinase 1 (Ddr1). The study focused on two 
miRNAs – miR-199a-5p and miR145, both of which show a decreasing expression level 
during the early to mid OP transition. C11orf9, which appears to be the human analog of the 
mouse myelin regulatory factor (MRF) was the target protein predicted for these 2 miRNAs. 
MRF has been shown to be necessary for myelination and OL maturation (Emery et al. 
2009). It is thought that the decrease in miR199a-5p levels during OPC maturation may be 
parallel to the observed increase in MRF expression during the same time window, 
implying that miR-199a-5p may be one of the regulators of myelination and OPC 
maturation. MiR-214 was also observed to be strongly downregulated during the early-to-
mid OPC transition and its predicted target is myelin-associated oligodendrocyte basic 
protein (MOBP), an important structural component of myelin.  
2.3 Oligodendrocytes, miRNA and disease 
Dysfunctional oligodendrocytes due to misregulation by miRNAs have recently been 
implicated in diseases of the central nervous system. For instance, mutations in several 
miRNAs have been discovered in the pathogenesis of multiple sclerosis (MS) (Junker, 
Hohlfeld & Meinl 2010). Specifically, miR-219 and miR-338 showed the maximum relative 
reduction in expression when the entire microRNAome of healthy, mature OLs was 
compared with chronic, inactivated MS tissue lesions (Junker et al. 2009). Other reports have 
also shown that miRNAs provide a mechanism for resistance against viral infection, and 
that miR-122 levels were significantly reduced in OLs infected with the Borna disease virus. 
This is significant as the Borna disease virus causes neurological disease in animals, and 
recent findings have implicated that it may also play a role in some human neurological and 
psychiatric conditions including bipolar disorder and depression (VandeWoude et al. 1990). 
In this case, overexpression of miR-122 inhibited viral protein synthesis and viral gene 
transcription and translation (Qian et al. 2010).  
In one study to examine the possible role of miRNAs in the development of schizophrenia, 
the expression levels of 435 miRNAs in postmortem brain samples of schizophrenic patients 
were compared with those of psychiatric healthy controls (Moreau et al. 2011). In this study, 
19% of the miRNAs analyzed showed misexpression in the schizophrenic samples, with 
these miRNAs mostly being downregulated compared to the healthy controls. On the other 
hand, a previous study identified differential expression of 28 miRNAs in the postmortem 
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PDGFRα, Sox6, FoxJ3 and ZFP238. PDGF has been known to be an OPC mitogen for 
multiple decades (Besnard et al. 1987). ZFP238 and FoxJ3 had previously not been 
functionally characterized in OPCs and this study confirmed that FoxJ3 and ZFP238 are 
inhibitors of OL differentiation by constitutively expressing these genes in OPCs and 
observing significantly reduced differentiation to the mature OL stage.  
A study by Letzen et al was the first to perform a global miRNA analysis of cells isolated 
from 8 developmental stages from the pluripotent embryonic stem cell state to a mature, 
myelinating OL state (Letzen et al. 2010). Significantly, this study analyzed the expression of 
miRNAs in human cells as opposed to rodent models used in prior investigations. The study 
detected 183 miRNAs over the eight stages of oligodendrocyte maturation and also 
identified the highest differentially expressed miRNAs at each transition in the pluripotent-
to-mature OL differentiation scheme. These differentially-expressed miRNAs were then 
matched to potential protein targets which revealed proteins such as chromosome 11 open 
reading frame 9 (C11orf9), claudin-11 (Cldn11), myelin transcription factor 1-like (Mytl1), 
myelin-associated oligodendrocyte basic protein (Mobp), myelin protein zero-like 2 
(Mpzl2), and discoidin domain receptor tyrosine kinase 1 (Ddr1). The study focused on two 
miRNAs – miR-199a-5p and miR145, both of which show a decreasing expression level 
during the early to mid OP transition. C11orf9, which appears to be the human analog of the 
mouse myelin regulatory factor (MRF) was the target protein predicted for these 2 miRNAs. 
MRF has been shown to be necessary for myelination and OL maturation (Emery et al. 
2009). It is thought that the decrease in miR199a-5p levels during OPC maturation may be 
parallel to the observed increase in MRF expression during the same time window, 
implying that miR-199a-5p may be one of the regulators of myelination and OPC 
maturation. MiR-214 was also observed to be strongly downregulated during the early-to-
mid OPC transition and its predicted target is myelin-associated oligodendrocyte basic 
protein (MOBP), an important structural component of myelin.  
2.3 Oligodendrocytes, miRNA and disease 
Dysfunctional oligodendrocytes due to misregulation by miRNAs have recently been 
implicated in diseases of the central nervous system. For instance, mutations in several 
miRNAs have been discovered in the pathogenesis of multiple sclerosis (MS) (Junker, 
Hohlfeld & Meinl 2010). Specifically, miR-219 and miR-338 showed the maximum relative 
reduction in expression when the entire microRNAome of healthy, mature OLs was 
compared with chronic, inactivated MS tissue lesions (Junker et al. 2009). Other reports have 
also shown that miRNAs provide a mechanism for resistance against viral infection, and 
that miR-122 levels were significantly reduced in OLs infected with the Borna disease virus. 
This is significant as the Borna disease virus causes neurological disease in animals, and 
recent findings have implicated that it may also play a role in some human neurological and 
psychiatric conditions including bipolar disorder and depression (VandeWoude et al. 1990). 
In this case, overexpression of miR-122 inhibited viral protein synthesis and viral gene 
transcription and translation (Qian et al. 2010).  
In one study to examine the possible role of miRNAs in the development of schizophrenia, 
the expression levels of 435 miRNAs in postmortem brain samples of schizophrenic patients 
were compared with those of psychiatric healthy controls (Moreau et al. 2011). In this study, 
19% of the miRNAs analyzed showed misexpression in the schizophrenic samples, with 
these miRNAs mostly being downregulated compared to the healthy controls. On the other 
hand, a previous study identified differential expression of 28 miRNAs in the postmortem 
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dorsolateral prefrontal cortex (Brodmanns Area) of schizophrenic individuals (Santarelli et 
al. 2011). 89% of these 28 miRNAs were upregulated and quantitative PCR was used to 
validate this finding for miR-328, miR-17-5p, miR-134, miR-652, miR-382, and miR-107. This 
elevation was linked to the observed upregulation of Dicer activity in these samples. The 
role of miRNAs in other neurological disorders has been reviewed (Xu, Karayiorgou & 
Gogos 2010). 
3. Methods of oligodendrocyte differentiation 
Unlike animal models, the study of oligodendrocyte development in humans has been 
generally limited in scope by the lack of models both in vivo and vitro that can be utilized to 
study this process. However, human embryonic stem cells provide an exciting model to help 
identify mechanisms that regulate the differentiation of oligodendrocytes. This includes 
elucidating the role of miRNAs in regulating the oligodendrocyte fate. This section describes 
a novel protocol for generating oligodendrocyte fated cells from human embryonic stem 
cells which have been developed in part from several published protocols (Nistor et al. 2005, 
Kerr et al. 2010). 
3.1 Materials 
3.1.1 Buffers and solutions 
PBS: Phosphate buffered saline, without Ca+2 and Mg+2, pH 7.0 (Invitrogen). 
Trypsin/EDTA: HBSS containing 0.05% trypsin and 0.53 mM EDTA (Sigma). 
Collagenase: 1mg/ ml collagenase IV (Invitrogen) in PBS, filtered. 
3.1.2 Culture media 
Basic culture medium for MEF: (Mouse embryonic fibroblast line PMEF-CF1 from 
Millipore): DMEM high glucose, supplemented with 10% Fetal Bovine Serum (Invitrogen), 2 
mM glutamax (Invitrogen), 5 U/ml penicillin–streptomycin (Invitrogen), and 0.1 mM non-
essential amino acids (NEAA). 
Basic culture medium for undifferentiated human embryonic stem cells: DMEM/F12 
(Invitrogen), supplemented with 20% Knockout Serum Replacement (Invitrogen), 2 mM 
glutamax (Invitrogen), 5 U/ml penicillin–streptomycin (Invitrogen), 0.1 mM non-essential 
amino acids and 3.5 µl β-mercaptoethanol supplemented with basic fibroblast growth factor 
(FGF2). 
Basic culture medium for neural and oligodendrocyte progenitors: Neural Basal Media, 
supplemented with 10% Bovine Serum Albumin in PBS, filtered (Gibco), 0.5% N2 
supplement (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma) and 25 ug/ml gentamicin 
(Invitrogen). 
3.1.3 Fixatives 
4% Paraformaldehyde: 4g paraformaldehyde in 100 ml PBS. To dissolve the 
paraformaldehyde, the PBS was preheated at 90°C and sodium hydroxide (NaOH) added 
drop-wise slowly until the solution turns clear. The solution was cooled down before use.  
3.2 Cell culture 
Human ESCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) in ESC 
growth media. Prior to differentiation, ESCs were separated from the feeder layer using a 
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solution of 1 mg/ml collagenase and plated on a 4% matrigel (BD Biosciences) substrate for 
5 to 7 days and fed feeder-conditioned media daily. Cells were subsequently differentiated 
into embryoid bodies (EBs), neural progenitors (NPC), glial restricted precursors (GPC), 
and oligodendrocyte precursors (OPC) and finally mature oligodendrocytes (OL). 
3.2.1 Preparation of MEF feeder layers 
MEFs were maintained in basic MEF culture medium. The feeder cells were prepared the 
day before ESCs are expanded.  The MEFs were plated at a density of 10 x 104 cells/cm2 onto 
0.1% w/v gelatin (Stem Cell Technologies) -coated culture dishes. Next morning, the feeder 
plates were γ-irradiated with a dose of 50 Gy (5000 rads) to induce cell cycle arrest. After 
irradiation, the culture medium was replaced. MEFs can also be mitotically-inactivated by 
treatment with mitomycin C (Sigma) at a concentration of 10 µg/ml for 4 hours at 37ºC. The 
ESCs were plated on top of the MEF feeder layer using collagenase as described below. The 
medium was replaced daily with fresh medium supplemented with growth factors. 
3.2.2 Human embryonic stem cells 
The derivation and maintenance of human embryonic stem cells has been covered at length 
and details can be found in the following reviews (Park et al. 2003, Draper et al. 2004, Lu et 
al. 2006, Suemori et al. 2006, Ludwig et al. 2006, Hoffman, and Carpenter 2005). In brief, a 
culture plate with mitotically inactivated MEF feeder cells was prepared 24 h before use 
with ESCs with MEF basic culture media. The medium was removed from a culture dish of 
ESCs and the dish was washed with PBS. ESC can be expanded using either collagenase or 
trypsin. In both cases, however, over trypsinization of the colonies should be avoided 
because it will reduce cell viability. This could occur by incubating cells too long with 
enzyme and/or over triturating. For one 10 cm plate of ESCs, 1 ml of collagenase or trypsin 
solution was added and placed in incubator at 37ºC for 5 to 10 min. The plate was removed 
from the incubator, the bottom of the plate scraped with a 5 ml pipette, making sure that all 
colonies had been lifted off, and then triturated slowly until only very small clumps were 
obtained. The colonies were not broken up into single cells as unlike their mouse 
counterparts, human ESCs do not survive well as single cells. The  cell suspension was 
transferred into a 15 ml conical tube, 10 ml complete medium added and centrifuged for 5 to 
10 min at 200 g at room temperature (RT). The pellet was resuspended in complete medium 
and placed onto mitotically-inactivated MEF feeder cell plate containing ESC complete 
medium with FGF2. The medium was replaced daily until ESC colonies reached optimal 
size for further passage. ESCs usually expanded by 5 fold after 5-7 days. 
3.2.3 Embryoid body formation 
Neural differentiation of ESCs was initiated via embryoid body (EB) suspensions. 
Embryonic stem cells were plated and dissociated onto 10 cm matrigel-coated tissue culture 
dishes as described above for passaging ESCs onto 10 cm plates with MEF. When ESCs were 
transferred onto matrigel they were grown in basic ESC culture media that had been 
conditioned on MEFs (live or irradiated) for 24 hours (12 ml of media per 10cm of confluent 
feeders), filtered and supplemented with 4 ng/ml FGF2. MEF-conditioned media was 
replaced on a daily basis until colonies were large and tight, almost near confluency in the 
wells.  
To generate embryoid bodies, the medium was removed from a culture dish of ESCs and 
the dish washed with PBS. For one six well plate of ESCs, the cells were incubated in 0.5 ml 
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dorsolateral prefrontal cortex (Brodmanns Area) of schizophrenic individuals (Santarelli et 
al. 2011). 89% of these 28 miRNAs were upregulated and quantitative PCR was used to 
validate this finding for miR-328, miR-17-5p, miR-134, miR-652, miR-382, and miR-107. This 
elevation was linked to the observed upregulation of Dicer activity in these samples. The 
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Gogos 2010). 
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solution of 1 mg/ml collagenase and plated on a 4% matrigel (BD Biosciences) substrate for 
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10 min at 200 g at room temperature (RT). The pellet was resuspended in complete medium 
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medium with FGF2. The medium was replaced daily until ESC colonies reached optimal 
size for further passage. ESCs usually expanded by 5 fold after 5-7 days. 
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dishes as described above for passaging ESCs onto 10 cm plates with MEF. When ESCs were 
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feeders), filtered and supplemented with 4 ng/ml FGF2. MEF-conditioned media was 
replaced on a daily basis until colonies were large and tight, almost near confluency in the 
wells.  
To generate embryoid bodies, the medium was removed from a culture dish of ESCs and 
the dish washed with PBS. For one six well plate of ESCs, the cells were incubated in 0.5 ml 
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of 1 mg/ml collagenase in PBS (avoid trypsinization as it can affect cell viability) and placed 
into the incubator at 37ºC for 5 to 10 min. After removing the tube from the incubator, the 
cells were scraped with a cell scraper or lifter. The cell suspension was transferred to a 
centrifuge tube very gently, 10 ml of neural basal media supplemented with 200 ng/ml 
noggin, 20 ng/ml FGF2, and 20 ng/ml FGF4 (all growth factors from R&D Systems) was 
added and centrifuged for 5 min at 200 g, (RT). The supernatant was removed and the pellet 
gently resuspended into complete medium and placed onto a non-adherent or low adhesive 
10 cm culture plate (Corning).  
Neural EBs were fed daily by sedimentation. This was performed by tilting the dish at a 45 
degree angle, waiting 5 minutes, and carefully aspirating with a 5ml pipette only half of the 
media so as to not discard the EBs floating in suspensions. EBs were grown for 10-25 days 
until they produced a transparent morphology. EBs were characterized by their loss of 
pluripotent markers, AP, OCT4, and NANOG and initiation of early markers of 
neuroectodermal fate including SSEA1, SOX1, PAX6 and Islet1 (Figure 1). The time may 
vary for different cell lines to reach this stage. Thus, the time at which is takes EBs to express 
these markers is dependent on the ESC line employed and so the cells should always be 
characterized at this point before proceeding forward. This can be performed by RT-PCR 
and by immunohistochemistry by freezing EBs in cryoprotectant mount media such as 
O.C.T. (Sakura Finetek TissueTek) and antibody staining (Table 1). The timeline provided 
here is based on our experiences using ESC lines H1 and H9 generated by Thomson et al 
(Thomson et al. 1998). 
 
 
Fig. 1. Timeline of oligodendrocyte differentiation from pluripotent human embryonic stem 
cells, showing the expression of relevant cellular markers at each stage. 
 




Fig. 2. Phase contrast images of various stages of oligodendrocyte differentiation. 
A. Pluripotent human embryonic stem cells on MEFs, B. EBs one day after being generated 
by the scraping method, C. NPCs sprouting from the periphery of a plated EB on matrigel 
after 24 hrs, D. OPC 9 days after 2 expansions in OPC inducing medium, and OLs one week 
after being exposed to OL inducing media. 
3.2.4 Neural progenitor cells 
10 cm tissue culture plates were coated with 3 ml of 4% matrigel in neural basal media for 
one hour prior to plating EBs. Human ESC Qualified Matrigel Matrix was thawed overnight 
at 4°C then diluted 1:24 (approximately 4% Matrigel) in cold neural basal medium.  
Afterwards, the matrigel was removed and EBs plated in 10 ml of neural basal media 
supplemented with 20 ng/ml FGF2 for 5 to 10 days. In this time, EBs spread over the plate 
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and became confluent. Most cells expressed neural fated markers including nestin and 
neural surface marker (A2B5) (Figure 1). NPCs at this stage were capable of deriving cells 
with both neuronal and glial fates. NPCs were fed daily. 
3.2.5 Glial progenitor cells 
NPCs were passaged in 1 to 3 splits for expansion using collagenase as described below 
(Passaging Cells) and replated on matrigel coated plates for differentiation into glial 
progenitor fate. Twenty-four hours after replating, media was changed to neural basal 
media supplemented with 20ng/ml EGF. Cells were fed daily for 10-14 days. GPCs began to 
express NG2, PDGFRα, and Olig1 (Figure 1). These cells can differentiate into either 
astrocytes or oligodendrocytes at this stage depending on the growth factors employed.  
3.2.6 Oligodendrocyte progenitor cells 
To promote differentiation into OPC, the media was supplemented with 20 ng/ml PDGF-
AA.  Cells were fed daily and begin to express OPC markers O1, O4, CNP, RIP, and GalC 
after one week (Figure 1). After 7–10 days the OPC morphology could be detected and was 
visible on the culture dish (Figure 2). By two weeks greater than 95% pure OPC could be 
obtained. Pure populations of OPCs can be obtained by FACs or MACs using O1 and O4 
antibody selection using standard procedures. Once an OPC line is derived, cells can be 
expanded using 1 mg/ml collagenase in PBS onto gelatin-coated plates for several months 
before they reach senescence. 
3.2.7 Oligodendrocytes 
Terminal differentiation to mature oligodendrocytes was initiated by the addition of 50 
ng/ml T3 (triiodothyronine, Sigma) and removal of PDGF-AA from the neural basal 
medium. Mature OLs demonstrate complex morphology after 3-5 days and express myelin-
associated proteins such as MAG, MOG, MOBP, and MBP (Figure 1). These cells do not 
survive as long as the progenitor cells and begin to die off after the first week. In total, their 
survival under these culture conditions is between 1-3 weeks after maturity.  
3.2.8 Passaging cells  
3 ml of 0.1% matrigel is placed on a 10cm tissue culture plate. The medium is removed from 
a culture dish of OL-fated cells and the dish washed with PBS. For one six well plate, the 
cells were incubated in 0.5 ml of 1 mg/ml collagenase in PBS (avoid trypsinization as it can 
affect cell viability) and cells placed into the incubator at 37ºC for 5 to 10 min. After 
removing the tube from the incubator, the cells were scraped with cell scraper or lifter. The 
suspension was mixed by gently pipetting up and down the cell clumps until a single-cell 
suspension was obtained. Importantly, to reduce cell mortality, the extent of cell disruption 
was controlled by pipetting only 5 to 10 times and with a 5ml pipette. The cell suspension 
was transferred to a centrifuge tube and centrifuge for 5 min at 200g at RT. The supernatant 
was removed and pellet resuspended in complete medium and placed onto the matrigel-
coated plates. Medium was replaced daily until the cells were confluent before passaging 
onto a larger culture dish plate. 
3.2.9 Freezing cells 
From one confluent 6-well ESCs, NPCs, GPCs or OPCs were dissociated using collagenase 
as described above. These were rinsed in neural basal media for neural cells and ESC media 
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for ESCs at 200g for 5 min. The supernatant was aspirated and the pellet resuspended in 
freshly prepared 1X Freezing Media (for neural cells: 50% Neural Basal Media, 40% FCS, 
10% DMSO; ESC freezing media: 50% Fetal Bovine Serum (Defined, Hyclone), 40% Neural 
Basal Media (Invitrogen) and 10% DMSO (Sigma), filtered).  1 ml of freezing media was 
added dropwise, mixing well after each addition. The suspension was transferred into 
sterile freezing vials, and placed into cryovessels. The cells were frozen overnight at -80oC, 
and then transferred to the liquid nitrogen freezer after 24 hours. 
3.2.10 Thawing out cells 
The vial of frozen cells was removed from the nitrogen freezer and transferred to a 37oC 
heat water bath to thaw by gentle shaking (thawing generally takes only 1-2 minutes). The 
suspension was transferred into 15 cc conical tube and 10 ml of culture media added and 
centrifuged at 200g for 5 min. The supernatant was removed, culture medium added, and 
plated directly onto a fresh matrigel coated plate for NPs, GPCs and OPCs or feeder plate 
for ESCs. 
 
Name Company Product Code 
Oct-4 BD Biosciences 611203 
Nanog EBioscience 14-5768-82 
Sox-2 Abcam ab15830-100 
Sox-1 Abcam ab22572 
Pax-6 Abcam ab5790 
Nestin Millipore mab5326 
Islet-1 DSHB 394D5 
A2B5 Millipore mab312r 
Sox-10 Santa Cruz Bio. sc17343 
Olig1 Millipore mab5540 
PDGFR-a Abcam ab61219 
NG2 Millipore ab5320 
O4 Millipore mab345 
O1 Millipore mab344 
RIP Abcam ab2035 
CNPase Millipore mab326r 
MBP Abcam ab7349-2 
Table 1. Specific antibodies for oligodendrocyte characterization 
3.3 Cell characterization 
The identity of a cell in the differentiation pathway from pluripotent embryonic stem cells to 
mature oligodendrocytes is most commonly studied by its morphology, its gene expression 
and by analyzing the expression of protein markers by immunodetection.  
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Morphologically, undifferentiated ESCs generate colonies on top of feeders, NPC are more 
columnar or cuboidal in shape while GPCs and OPCs generate bipolar cells. Mature OLs 
demonstrate a complex network of dendritic processes (Figure 2). 
Immunofluorescence (IF) staining of plated cells is more accurate morphology and the 
simplest method of analyzing protein expression to define the different stages of OL 
potential (Table 1 lists sources of reliable antibodies for OL characterization). Here we 
present a standard protocol for IF staining for OL fated cells. Figure 3 demonstrates staining 
at various stages of OL differentiation. 
Cells were plated onto 24-well culture plates. Before cells became confluent, cells were 
washed twice in PBS and the excess PBS was removed. Cells were fixed in 4% PFA in PBS 
for 10 minutes at RT. The fixative solution was removed and wells washed twice with PBS 
for 5 min each. Cells were permeabilized and blocked with PBS solution containing 0.2% 
(w/v) Triton X-100 and bovine serum albumin (BSA; Sigma) at a concentration 1% (w/v) in 
PBS and incubated for 5 minutes at RT (for cells surface markers this step was skipped). 
Primary antibody (1:50 dilution) was added after dilution in antibody dilution buffer (PBS 
with 0.1% (w/v) BSA) and incubated for 1 hr at RT. Sample was washed three times with 
PBS for 5 minutes each. Appropriate secondary antibody was added (Alexa488 or Alexa546 
conjugated antibodies, 1:200; Molecular Probes) in antibody dilution buffer and incubated in 
a humidified dark chamber for 1 hr at RT. Washed three times with PBS for 5 min each. 
Nuclei were stained with DAPI solution (Sigma) for 10 min at RT in a humidified chamber 
in the dark. DAPI solution was aspirated and 0.5 ml PBS was added to each well. Samples 
were examined under a fluorescence microscope with appropriate filters within 24 hrs as 
signal diminishes very rapidly. After 2 to 3 days most of the fluorescence signal is bleached. 
Sealant tape and aluminum foil was applied around the plates and stored in the dark at 4ºC 
(short term storage only). 
4. Results 
4.1 Morphological analysis of differentiated cells 
As shown in Figure 2, oligodendrocytes were successfully differentiated from human 
embryonic stem cells by our protocol described above. Embryoid bodies (Fig. 2b) were 
generated from pluripotent embryonic stem cells colonies (Fig. 2a). Plating these embryoid 
bodies on matrigel led to their adhesion and appearance of neural progenitor cells (Fig. 2c), 
which were then differentiated to glial progenitors (Fig. 2d) and subsequently 
oligodendrocyte progenitor cells (Fig 2e). Removal of all growth factors from the media led 
to the appearance of mature oligodendrocytes (Fig. 2e).  
4.2 Immunocytochemistry of differentiated cells 
EBs were characterized by their loss of pluripotent markers, AP, OCT4, and NANOG and 
initiation of early markers of neuroectodermal fate including SSEA1, SOX1, PAX6 and Islet1 
(Figure 1). Upon contact with matrigel, EBs spread over the plate and became confluent. 
Most cells expressed neural fated markers including nestin and neural surface marker 
(A2B5)(Figure 1). After 5-7 days in NP media and addition of EGF, GPCs appeared and 
began to express NG2, PDGFRα, and Olig1 (Figure 1). Subsequent addition of PDGF-AA 
after 7 days led to the appearance of OPC markers O1, O4, CNP, RIP, and GalC (Figure 1). 
Finally, mature oligodendrocytes express myelin-associated proteins such as MAG, MOG, 
MOBP, and MBP (Figure 1). 
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Fig. 3. Indirect immunofluorescence microscopy to examine differentiation of human ESCs 
into the oligodendrocyte lineage. The nuclei are stained blue by DAPI. Nestin (green) is 
shown for neural progenitors while NG2 (red), PDGFRa (green) O4 (red), RIP (red) and 
NOGO-a (green) are expressed by 5-day old oligodendrocyte progenitor cells.  
5. Conclusion 
In conclusion, a novel protocol adapted from previously published ones for oligodendrocyte 
development from pluripotent human embryonic stem cells has been developed. The cells 
express the established neural, glial and oligodendroglial markers as they advance along the 
differentiation timeline and we have confirmed this using indirect immunofluorescent 
microscopy.  
Also, we have reviewed the current state of knowledge about microRNA regulation of 
oligodendrocyte differentiation from pluripotent cells and myelination of CNS neurons by 
those cells. It is hoped that the protocol for obtaining OLs in high purity will aid in the 
unraveling of more mechanisms of miRNA regulation of myelination so that this knowledge 
can eventually be used for the development of a more efficient approach to the stem cell 
based therapy of spinal cord injuries and other demyelinating disorders.  
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Morphologically, undifferentiated ESCs generate colonies on top of feeders, NPC are more 
columnar or cuboidal in shape while GPCs and OPCs generate bipolar cells. Mature OLs 
demonstrate a complex network of dendritic processes (Figure 2). 
Immunofluorescence (IF) staining of plated cells is more accurate morphology and the 
simplest method of analyzing protein expression to define the different stages of OL 
potential (Table 1 lists sources of reliable antibodies for OL characterization). Here we 
present a standard protocol for IF staining for OL fated cells. Figure 3 demonstrates staining 
at various stages of OL differentiation. 
Cells were plated onto 24-well culture plates. Before cells became confluent, cells were 
washed twice in PBS and the excess PBS was removed. Cells were fixed in 4% PFA in PBS 
for 10 minutes at RT. The fixative solution was removed and wells washed twice with PBS 
for 5 min each. Cells were permeabilized and blocked with PBS solution containing 0.2% 
(w/v) Triton X-100 and bovine serum albumin (BSA; Sigma) at a concentration 1% (w/v) in 
PBS and incubated for 5 minutes at RT (for cells surface markers this step was skipped). 
Primary antibody (1:50 dilution) was added after dilution in antibody dilution buffer (PBS 
with 0.1% (w/v) BSA) and incubated for 1 hr at RT. Sample was washed three times with 
PBS for 5 minutes each. Appropriate secondary antibody was added (Alexa488 or Alexa546 
conjugated antibodies, 1:200; Molecular Probes) in antibody dilution buffer and incubated in 
a humidified dark chamber for 1 hr at RT. Washed three times with PBS for 5 min each. 
Nuclei were stained with DAPI solution (Sigma) for 10 min at RT in a humidified chamber 
in the dark. DAPI solution was aspirated and 0.5 ml PBS was added to each well. Samples 
were examined under a fluorescence microscope with appropriate filters within 24 hrs as 
signal diminishes very rapidly. After 2 to 3 days most of the fluorescence signal is bleached. 
Sealant tape and aluminum foil was applied around the plates and stored in the dark at 4ºC 
(short term storage only). 
4. Results 
4.1 Morphological analysis of differentiated cells 
As shown in Figure 2, oligodendrocytes were successfully differentiated from human 
embryonic stem cells by our protocol described above. Embryoid bodies (Fig. 2b) were 
generated from pluripotent embryonic stem cells colonies (Fig. 2a). Plating these embryoid 
bodies on matrigel led to their adhesion and appearance of neural progenitor cells (Fig. 2c), 
which were then differentiated to glial progenitors (Fig. 2d) and subsequently 
oligodendrocyte progenitor cells (Fig 2e). Removal of all growth factors from the media led 
to the appearance of mature oligodendrocytes (Fig. 2e).  
4.2 Immunocytochemistry of differentiated cells 
EBs were characterized by their loss of pluripotent markers, AP, OCT4, and NANOG and 
initiation of early markers of neuroectodermal fate including SSEA1, SOX1, PAX6 and Islet1 
(Figure 1). Upon contact with matrigel, EBs spread over the plate and became confluent. 
Most cells expressed neural fated markers including nestin and neural surface marker 
(A2B5)(Figure 1). After 5-7 days in NP media and addition of EGF, GPCs appeared and 
began to express NG2, PDGFRα, and Olig1 (Figure 1). Subsequent addition of PDGF-AA 
after 7 days led to the appearance of OPC markers O1, O4, CNP, RIP, and GalC (Figure 1). 
Finally, mature oligodendrocytes express myelin-associated proteins such as MAG, MOG, 
MOBP, and MBP (Figure 1). 
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Fig. 3. Indirect immunofluorescence microscopy to examine differentiation of human ESCs 
into the oligodendrocyte lineage. The nuclei are stained blue by DAPI. Nestin (green) is 
shown for neural progenitors while NG2 (red), PDGFRa (green) O4 (red), RIP (red) and 
NOGO-a (green) are expressed by 5-day old oligodendrocyte progenitor cells.  
5. Conclusion 
In conclusion, a novel protocol adapted from previously published ones for oligodendrocyte 
development from pluripotent human embryonic stem cells has been developed. The cells 
express the established neural, glial and oligodendroglial markers as they advance along the 
differentiation timeline and we have confirmed this using indirect immunofluorescent 
microscopy.  
Also, we have reviewed the current state of knowledge about microRNA regulation of 
oligodendrocyte differentiation from pluripotent cells and myelination of CNS neurons by 
those cells. It is hoped that the protocol for obtaining OLs in high purity will aid in the 
unraveling of more mechanisms of miRNA regulation of myelination so that this knowledge 
can eventually be used for the development of a more efficient approach to the stem cell 
based therapy of spinal cord injuries and other demyelinating disorders.  
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1. Introduction  
1.1  
Stem cell (SC) therapy is not a new concept. In the aftermath of the bombings of Hiroshima 
and Nagasaki in 1945, researchers discovered that bone marrow transplanted into irradiated 
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contains ganglion cell axons running to the brain and incoming blood vessels that open into 
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retina reveals that the ganglion cells (the output neurons of the retina) lie innermost in the 
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message that stimulates all of the succeeding neurons of the retina. The retinal message 
concerning the photic input and some preliminary organization of the visual image into 
several forms of sensation are transmitted to the brain from the spiking discharge pattern of 
the ganglion cells (Kolb, 2005). 
RPE cells support photoreceptor survival and are involved in, for example, ion and nutrient 
transport, formation of the blood-retina barrier and light absorption.  
They are also responsible for phagocytosis of the photoreceptor outer segments, which is 
important for the renewal of photoreceptor membranes. Interestingly, it has been 
demonstrated in a chicken model that, RPE in the postnatal stage of life is similar to that 
found in the embryonic retina with regard to specific gene expression.  
Furthermore, the generation and ex vivo expansion of RPE from human embryonic stem cells 
(hESCs) has been extensively studied and characterized. Moreover, hESC-derived RPE cells 
have been demonstrated to be functional in ex vivo conditions. More recently, the in vitro 
differentiation of RPE and photoreceptors from human induced pluripotent stem (iPS) cell 
cultures provid another potential tool for transplantation purposes and additionally enables 
avoidance of host immune reactions (Machalinska, 2009). 
1.3 Retinal diseases  
Age-related macular degeneration (AMD), glaucoma and diabetic retinopathy are the three 
most common causes of visual impairment and legal blindness in developed countries (Bunce, 
2006). One common denominator of these conditions is progressive loss of the neural cells of 
the eye [photoreceptors, interneurons and retinal ganglion cells (RGC)] and essential 
supporting cells such as the RPE. Retinal dystrophies [retinitis pigmentosa (RP), Stargardt’s 
disease, Best disease, Leber congenital amaurosis, etc.] all evolve with early loss of 
photoreceptors and subsequent loss of RGC. Recent years have seen enormous progress in the 
treatment options that stop the progression of AMD from a neovascular state to fibrosis, that 
slow down the progression of glaucoma by reducing intraocular pressure, and that prevent 
progression of diabetic retinopathy by optimizing glycemic control and treat retinal 
neovascularization early (Chakravarthy, 2010; Maier, 2005; O’Doherty, 2008; Mohamed, 2007). 
However, irreversible visual loss still occurs in a significant proportion of cases. Research is 
aimed at developing novel treatments using neuroprotective and regenerative strategies.  
SCs can potentially be used for both neuroprotection and cell replacement. Intravitreal 
delivery of neurotrophic factors slows down photoreceptor degeneration in rodent models 
of RP, RGC loss in glaucoma models and optic nerve and optic tract trauma, but the effect 
may be temporary. Slow-release preparations and gene therapy approaches used to induce 
retinal cells to secrete neurotrophic factors are two ways to induce longer-term effects. A 
third option is to use SC as long-term delivery agents, possibly encapsulated in a device, 
because many SC either secrete neurotrophins naturally or can be genetically engineered to 
do so (Otani, 2004; Dahlmann-Noor, 2010). 
Progress has also been made in the field of photoreceptor, RPE and RGC replacement by SC 
and progenitor cells, although long-term restoration of visual function has been confirmed. 
The recent discoveries that human fibroblasts can be ‘‘reprogrammed’’ to behave like 
embryonic SC and that adult eyes harbor retinal progenitor cells, also increase the potential 
availability of SC for transplantation, including autologous transplantation and stimulate 
intrinsic ‘‘self-regeneration, ’’ which could potentially overcome a lot of the problems 
associated with non-autologous transplantation in humans (Dahlmann-Noor, 2010).  
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2. Potential sources of stem cells for cell therapy in retinal diseases  
2.1 Bone marrow-derived stem cells 
Bone marrow-derived SCs have been proposed as a potential source of cells for regenerative 
medicine (Machalinska, 2009; Enzmann, 2009). This is based on the assumption that HSCs 
isolated from BM are plastic and are able to “transdifferentiate” into tissue-committed SCs 
for other organs (e. g., heart, liver or brain). Unfortunately, the concept of SC plasticity was 
not confirmed in recent studies and previously encouraging data demonstrating this 
phenomenon in vitro could be explained by a phenomenon of cell fusion or, as believed by 
our group, by the presence, of heterogeneous populations of SCs in BM (Müller-Sieburg, 
2002; Spangrude 1988). The identification of very small, embryonic-like SCs in BM supports 
the notion that this tissue contains a population of primitive SCs, which, if transplanted 
together with HSCs, would be able to regenerate damaged tissues in certain experimental 
settings. Cells from BM are easily and safely aspirated. After administering local anesthesia, 
about 10 mL of the BM is aspirated from the iliac crest using a sterile BM aspiration needle; 
subsequently mononuclear bone marrow SCs are separated using the Ficoll density 




Fig. 1. Sequence of photos showing the collection of bone marrow (A) and the initial 
separation of the mononuclear cells using Ficoll-Hypaque gradient centrifugation (B) (C) (D) 
(Siqueira RC 2010) 
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SC-based therapy has been tested in animal models for several diseases including 
neurodegenerative disorders, such as Parkinson disease, spinal cord injury, and multiple 
sclerosis. The replacement of lost neurons that are not physiologically replaced is pivotal for 
therapeutic success. In the eye, degeneration of neural cells in the retina is a hallmark of 
such widespread ocular diseases as AMD and RP. In these cases the loss of photoreceptors 
that occurs as a primary event as in RP or secondary to loss of RPE, as in AMD, leads to 
blindness (Machalinska 2009; Siqueira 2010).  
BM is an ideal tissue for studying SCs because of its accessibility and because proliferative 
dose-responses of bone marrow-derived SCs can be readily investigated. Furthermore, there 
are a number of well-defined mouse models and cell surface markers that allow effective 
studies of hematopoiesis in healthy and injured mice. Because of these characteristics and the 
experience of BM transplantation in the treatment of hematological cancers, bone marrow-
derived SCs have also become an important tool in regenerative medicine. The BM harbors at 
least two distinct SC populations: HSCs and multipotent marrow stromal cells (MSC).  
2.1.1 Hematopoietic stem cells 
HSCs are multipotent SCs that give rise to all the blood cell types including myeloid 
(monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, 
megakaryocytes/platelets, dendritic cells), and lymphoid lineages (T-cells, B-cells, NK-cells).  
HSCs are found in the BM of adults, which includes in femurs, hips, ribs, the sternum and 
other bones. Cells can be obtained directly from the hip using a needle and syringe (Figure 
1), or from the blood following pretreatment with cytokines, such as G-CSF (granulocyte 
colony stimulating factors), that induce cells to be released from the BM compartment. 
Other sources for clinical and scientific use include UCB and placenta (Ratajczak, 2004; 
Müller-Sieburg 2002).  
In reference to phenotype, HSCs are identified by their small size, lack of lineage markers, 
low staining (side population) by vital dyes such as rhodamine 123 (rhodamine-dull, also 
called rholo) or Hoechst 33342 and presence of various surface antigenic markers, many of 
which belong to the cluster of differentiation series: CD34, CD38, CD90, CD133, CD105, 
CD45 and also c-kit and SC factor receptor (Müller-Sieburg, 2002; Nielsen, 2009; Kuçi, 2009; 
Challen 2009 ; Voltarelli 2000; Voltarelli 2003). Otani (2004) demonstrated that whenever a 
fraction of mouse or human adult bone marrow–derived SCs [lineage-negative 
hematopoietic stem cells (Lin-HSCs)] containing endothelial precursors stabilizes and 
rescues retinal blood vessels that would ordinarily completely degenerate, a dramatic 
neurotrophic rescue effect is also observed. Retinal nuclear layers are preserved in two 
mouse models of retinal degeneration, rd1 and rd10, and detectable, albeit severely 
abnormal, electroretinogram recordings are observed in rescued mice at times when they 
are never observed in control-treated or untreated eyes. The normal mouse retina consists 
predominantly of rods, but the rescued cells after treatment with Lin-HSCs are nearly all 
cones. Microarray analysis of rescued retinas demonstrates significant upregulation of many 
antiapoptotic genes, including small heat shock proteins and transcription factors.  
Some reports have demonstrated the clinical feasibility of the intravitreal administration of 
autologous bone marrow-derived mononuclear cells (ABMC) in patients with advanced 
degenerative retinopathies (Jonas, 2008 and 2010). More recently, our group conducted a 
prospective phase I trial to investigate the safety of intravitreal ABMC in patients with 
retinitis pigmentosa or cone-rod dystrophy, with promising results (Siqueira, 2011).  
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2.1.2 Multipotent Mesenchymal Stromal Cells (Mesenchymal Stem Cells) 
Mesenchymal stem cells (MSCs) are progenitors of all connective tissue cells. In adults of 
multiple vertebrate species, MSCs have been isolated from BM and other tissues, expanded 
in culture and differentiated into several tissue-forming cells such as bone, cartilage, fat, 
muscle, tendon, liver, kidney, heart, and even brain cells.  
According to the International Society for Cellular Therapy ( Horwitz, 2005), there are three 
minimum requirements for a population of cells to be classified as MSCs. The first is that 
MSCs are isolated from a population of mononuclear cells on the basis of their selective 
adherence to the surface of the plastic of culture dishes, differing in this respect to bone 
marrow hematopoietic cells, a disadvantage of this method of identification is the possible 
contamination by hematopoietic cells and cellular heterogeneity with respect to the potential 
for differentiation. The second criteria is that CD105, CD73 and CD90 are present and that 
CD34, CD45, CD14 or CD11b, CD79, or CD19 and HLA-DR are not expressed in more than 
95% of the cells in culture. Finally, the cells can be differentiated into bone, fat and cartilage 
(Phinney, 2007).  
A number of studies have shown that bone-marrow-derived MSCs can differentiate into cells 
expressing photoreceptor proteins when injected into the subretinal space (Gong, 2008; 
Castanheira, 2008). Interestingly, it has been suggested that rat MSCs can be made to express 
photopigment (rhodopsin) in vitro simply by adding epidermal growth factor to the culture 
media (Zhang, 2008). Additionally, though other retina-relevant cell types have been 
engineered, a number of studies have shown that BM or adipose tissue MSCs are converted to 
RPE (Gong, 2008; Arnhold, 2006; Vossmerbaeumer 2009). As with work on other neuronal 
phenotypes, however, there has now been a reassessment of the ability of MSCs to 
differentiate into functionally useful retinal cells. Some studies have shown that transplanted 
bone marrow MSCs do not differentiate into neural retinal cells (YU, 2006). In an in vitro rat 
retina-explant model, untreated MSCs seemed to transdifferentiate into microglia109 in a way 
reminiscent of earlier work on MSC transplants in other neurological tissue (Azizi 1998). Some 
limited improvement was seen with pre-treatment with BDNF, NGF, and bFGF in terms of 
morphological differentiation into retinal neurons and expression of NF200, GFAP, PKC-
alpha, and recoverin, but these cells did not express Rhodopsin (Erices, 2000).  
In an ischemic retina rodent model, MSCs injected into the vitreous cavity have been shown 
to mature (with expression of neuron-specific enolase and neurofilament) and secrete CNTF, 
bFGF, and BDNF for at least 4 weeks (Li, 2009). Animal studies have also demonstrated that 
subretinal transplantation of MSCs delays retinal degeneration and preserves retinal 
function through a trophic response (Inoue, 2007). UCB-derived MSCs have also been 
shown to be neuroprotective of rat ganglion cells (Zwart, 2009). Very recently, the 
intravenous administration of bone marrow-derived MSCs was shown to prevent 
photoreceptor loss and preserve visual function in the RCS rat model of RP.  
A role for genetically-modified MSCs may emerge in the treatment of subretinal 
neovascularization. It has been shown that bone-marrow-derived MSCs accumulate around 
subretinal membranes induced by retinal laser burns. 
Intravenous injection of mouse bone-marrow MSCs genetically engineered to secrete 
pigment epithelium derived factor resulted in smaller neovascular complexes (Hou, 2010).  
2.2 Induced pluripotent stem cells 
Current methods of producing SCs from adult somatic cells offer an alternative cell source 
for transplantation. Induced pluripotent stem (iPS) cells are morphologically identical to 
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muscle, tendon, liver, kidney, heart, and even brain cells.  
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for differentiation. The second criteria is that CD105, CD73 and CD90 are present and that 
CD34, CD45, CD14 or CD11b, CD79, or CD19 and HLA-DR are not expressed in more than 
95% of the cells in culture. Finally, the cells can be differentiated into bone, fat and cartilage 
(Phinney, 2007).  
A number of studies have shown that bone-marrow-derived MSCs can differentiate into cells 
expressing photoreceptor proteins when injected into the subretinal space (Gong, 2008; 
Castanheira, 2008). Interestingly, it has been suggested that rat MSCs can be made to express 
photopigment (rhodopsin) in vitro simply by adding epidermal growth factor to the culture 
media (Zhang, 2008). Additionally, though other retina-relevant cell types have been 
engineered, a number of studies have shown that BM or adipose tissue MSCs are converted to 
RPE (Gong, 2008; Arnhold, 2006; Vossmerbaeumer 2009). As with work on other neuronal 
phenotypes, however, there has now been a reassessment of the ability of MSCs to 
differentiate into functionally useful retinal cells. Some studies have shown that transplanted 
bone marrow MSCs do not differentiate into neural retinal cells (YU, 2006). In an in vitro rat 
retina-explant model, untreated MSCs seemed to transdifferentiate into microglia109 in a way 
reminiscent of earlier work on MSC transplants in other neurological tissue (Azizi 1998). Some 
limited improvement was seen with pre-treatment with BDNF, NGF, and bFGF in terms of 
morphological differentiation into retinal neurons and expression of NF200, GFAP, PKC-
alpha, and recoverin, but these cells did not express Rhodopsin (Erices, 2000).  
In an ischemic retina rodent model, MSCs injected into the vitreous cavity have been shown 
to mature (with expression of neuron-specific enolase and neurofilament) and secrete CNTF, 
bFGF, and BDNF for at least 4 weeks (Li, 2009). Animal studies have also demonstrated that 
subretinal transplantation of MSCs delays retinal degeneration and preserves retinal 
function through a trophic response (Inoue, 2007). UCB-derived MSCs have also been 
shown to be neuroprotective of rat ganglion cells (Zwart, 2009). Very recently, the 
intravenous administration of bone marrow-derived MSCs was shown to prevent 
photoreceptor loss and preserve visual function in the RCS rat model of RP.  
A role for genetically-modified MSCs may emerge in the treatment of subretinal 
neovascularization. It has been shown that bone-marrow-derived MSCs accumulate around 
subretinal membranes induced by retinal laser burns. 
Intravenous injection of mouse bone-marrow MSCs genetically engineered to secrete 
pigment epithelium derived factor resulted in smaller neovascular complexes (Hou, 2010).  
2.2 Induced pluripotent stem cells 
Current methods of producing SCs from adult somatic cells offer an alternative cell source 
for transplantation. Induced pluripotent stem (iPS) cells are morphologically identical to 
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embryonic SCs, display similar gene expression profiles and epigenetic status and have the 
potential to form any cell in the body (Takahashi, 2006 and 2007; Yu, 2007). These cells have 
been employed to generate cells for the treatment of various diseases including diabetes, 
cardiovascular disease, sickle cell anemia, Parkinson's disease and hemophilia (Zhang, 2009; 
Hanna, 2007; Xu, 2009; Wernig, 2008). Meyer et al. 2009 recently showed that iPS cells can 
differentiate into retinal cell types whilst a paper by Buchholz et al. 2009 showed that 
human iPS cells can be differentiated into retinal pigment epithelial cells which display 
functionality in vitro.  
Carr (2009) demonstrated that iPS cells can be differentiated into functional iPS-RPE and 
that transplantation of these cells can facilitate the short-term maintenance of 
photoreceptors through phagocytosis of photoreceptor outer segments. Long-term visual 
function is maintained in this model of retinal disease even though the xenografted cells are 
eventually lost, suggesting a secondary protective host cellular response.  
While this particular line of iPS-RPE cells cannot be used as a direct therapy due to viral 
insertions of pluripotency genes, recent advances in iPS cell reprogramming technology, 
including the use of small molecules (Huangfu, 2008; Shi, 2008; Li, 2009), piggyBac 
transposition (Woltjen, 2009; Kaji, 2009), non-integrating episomal vectors (Yu, 2009) and 
manipulation of endogenous transcription factors (Balasubramanian, 2009) should eliminate 
the risks associated with the integration of SC genes into the genome. Furthermore, the 
finding that blood cells can be used to derive iPS cells (Loh, 2009) may remove the need for 
the invasive biopsies required to collect somatic cells and accelerate the ethical production of 
SC-derived tissue for therapeutic use.  
2.3 Human Embryonic Stem Cells 
The human embryonic stem cell (hESC) is defined as a cell that can both renew itself by 
repeated division and differentiate into any one of the 200 or more adult cell types in the 
human body. An hESC cell arises from the eight-cell stage morula. Outside of normal 
development, hESCs have been differentiated in vitro into neural cell types and even 
pigmented epithelium, although controlling their differentiation has proven challenging. 
Several hESC lines exist and are supported by public research funds. The use of hESCs has 
significant limitations, including ethical issues, and a risk of teratoma formation, but the 
chief problem is that we are still struggling to understand the developmental cues that 
differentiate hESCs into the specific adult cell types required to repair damaged tissues 
(MacLaren, 2007).  
Nistor et al. (2010) showed for the first time that three-dimensional early retinal progenitor 
tissue constructs can be derived from hESCs. Three-dimensional tissue constructs were 
developed by culturing hESC-derived neural retinal progenitors in a matrix on top of hESC-
derived RPE cells in a cell culture insert. An osmolarity gradient maintained the nutrition of 
the three-dimensional cell constructs. Cross-sections through hESC-derived tissue constructs 
were characterized by immunohistochemistry for various transcription factors and cell 
markers. Tissue constructs derived from hESC expressed transcription factors characteristic 
of retinal development, such as pax6, Otx2, Chx10, retinal RAX; Brn3b (necessary for 
differentiation of retinal ganglion cells) and crx and nrl (role in photoreceptor development). 
Many cells expressed neuronal markers including nestin, beta-tubulin and microtubule-
associated protein.  
Assessments of safety and efficacy are crucial before hESC therapies can move into the 
clinic. Two important early potential hESC applications are the use of retinal pigment 
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epithelium (RPE) for the treatment of age-related macular degeneration and Stargardt’s 
disease, an untreatable form of macular dystrophy that leads to early-onset blindness. Long-
term safety and function of RPE from hESCs in preclinical models of macular degeneration 
was demonstrated by Lu et al. (2009).  
They showed long-term functional rescue using hESC-derived RPE in both RCS rats and 
Elov14 mice, which are animal models of retinal degeneration and Stargardt’s disease, 
respectively. Good manufacturing practice-compliant hESC-RPE survived subretinal 
transplantation in RCS rats for prolonged periods (> 220 days). The cells sustained visual 
function and photoreceptor integrity in a dose-dependent fashion without teratoma 
formation or untoward pathological reactions.  
Near-normal functional measurements were recorded at > 60 days survival in RCS rats. To 
further address safety concerns, a Good laboratory practice-compliant study was carried out 
in the NIH III immune-deficient mouse model. Long-term data (spanning the life of the 
animals) showed no gross or microscopic evidence of teratoma/tumor formation after 
subretinal hESC-RPE transplantation.  
These results suggest that hESCs could serve as a potentially safe and inexhaustible source 
of RPE for the efficacious treatment of a range of retinal degenerative diseases.  
In 2010, the US Food and Drug Administration (FDA) granted Orphan drug designation for 
RPE cells of Advanced Cell Technology, Inc. (ACT) to initiate its Phase 1/2 clinical trials  
 
 
Fig. 1. Intravitreal injection of autologous bone marrow–derived stem cells in a patient with 
retinitis pigmentosa (Siqueira RC, 2010) 
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using retinal pigment epithelial (RPE) cells derived from hESCs to treat patients with 
Stargardt’s Macular Dystrophy (SMD). Moreover, in 2011 the company received a positive 
opinion from the Committee for Orphan Medicinal Products (COMP) of the European 
Medicines Agency (EMA) towards designation of this product as an orphan medicinal 
product for the treatment of Stargardt’s disease.  
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Table 1. Clinical and experimental studies using cell therapy for retinal diseases 
3. Conclusion  
Stem cells maintain the balance between somatic cell populations in various tissues and are 
responsible for organ regeneration. The remarkable progress of regenerative medicine in the 
last few years indicates promise for the use of stem cells in the treatment of ophthalmic 
disorders. Based on the above mentioned mechanisms, experimental and human studies 
with intravitreal bone marrow-derived stem cells have begun (Table 1). The history starts to 
be written in this very promising therapeutic field.  
4. Acknowledgment  
Júlio Cesar Voltarelli, André Marcio Vieira Messias, Rodrigo Jorge from São Paulo 
University - USP, Ribeirão Preto, SP, Brazil.  
5. References  
[1] Lorenz E, Congdon C, Uphoff ED, R. Modification of acute irradiation injury in mice and 
guinea-pigs by bone marrow injections. Radiology. 1951; 58:863-77.  
[2] Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal 
mouse bone marrow cells. Radiat Res. 1961; 14:213-22.  
[3] Lanza R, Rosenthal N. The stem cell challenge. Sci Am. 2004; 290:93-9.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 142 
using retinal pigment epithelial (RPE) cells derived from hESCs to treat patients with 
Stargardt’s Macular Dystrophy (SMD). Moreover, in 2011 the company received a positive 
opinion from the Committee for Orphan Medicinal Products (COMP) of the European 
Medicines Agency (EMA) towards designation of this product as an orphan medicinal 
product for the treatment of Stargardt’s disease.  
 
 
 Type of study Type of injury or 
illness 
Route used Type and source 
of cells 
Atsushi Otani et al. Experimental 
study in animals 









Wang S et al.  Experimental 
study in animals 
Retinitis pigmentosa Tail vein Pluripotent bone 
marrow-derived 
mesenchymal 
stem cells  
Li Na & Li Xiao-
rong & Yuan Jia-qin
Experimental 
study in animals 







Uteza Y, Rouillot JS, 
Kobetz A, et al.  
Experimental 
study in animals 
Photoreceptor cell 
degeneration in Royal 






Zhang Y, Wang W Experimental 








Tomita M Experimental 
study in animals 
Retinas mechanically 





derived stem cells 
Meyer JS et al.  Experimental 
study in animals 




Siqueira RC et al.  Experimental 
study in animals 
Chorioretinal injuries 





derived stem cells 
Wang HC et al.  Experimental 






derived stem cells 
Johnson TV et al.  Experimental 






stem cell  
Castanheira P et al.  Experimental 
study in animals 
Rat retinas submitted 






stem cell  
Jonas JB et al.  Case report Patient with atrophy 









Stem-Cell Therapy for Retinal Diseases 143 
 Type of study Type of injury or 
illness 
Route used Type and source 
of cells 
Jonas JB et al.  Case report Three patients with 
diabetic retinopathy, 
age related macular 
degeneration and 








Siqueira RC et al.  














Siqueira RC et al.  
Ethics committee of 
Brazil.  
Register: 16018 
Clinical trial  
Phase II 








Siqueira RC et al.  
Ethics committee of 
Brazil.  
Register 15978 
Clinical trial  
Phase I/II 












Clinical trial  
Phase I/II 







cells derived from 
human embryonic 
stem cells (hESCs) 
Table 1. Clinical and experimental studies using cell therapy for retinal diseases 
3. Conclusion  
Stem cells maintain the balance between somatic cell populations in various tissues and are 
responsible for organ regeneration. The remarkable progress of regenerative medicine in the 
last few years indicates promise for the use of stem cells in the treatment of ophthalmic 
disorders. Based on the above mentioned mechanisms, experimental and human studies 
with intravitreal bone marrow-derived stem cells have begun (Table 1). The history starts to 
be written in this very promising therapeutic field.  
4. Acknowledgment  
Júlio Cesar Voltarelli, André Marcio Vieira Messias, Rodrigo Jorge from São Paulo 
University - USP, Ribeirão Preto, SP, Brazil.  
5. References  
[1] Lorenz E, Congdon C, Uphoff ED, R. Modification of acute irradiation injury in mice and 
guinea-pigs by bone marrow injections. Radiology. 1951; 58:863-77.  
[2] Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal 
mouse bone marrow cells. Radiat Res. 1961; 14:213-22.  
[3] Lanza R, Rosenthal N. The stem cell challenge. Sci Am. 2004; 290:93-9.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 144 
[4] Mimeault M, Batra SK. Concise review: recent advances on the significance of stem cells 
in tissue regeneration and cancer therapies. Stem Cells. 2006; 24 (11):2319-45.  
[5] Ortiz-Gonzalez XR, Keene CD, Verfaillie C, Low WC. Neural induction of adult bone 
marrow and umbilical cord stem cells. Curr Neurovasc Res. 2004; 1 (3):207-13.  
[6] Trounson A. The production and directed differentiation of human embryonic stem 
cells. Endocr Rev. 2006; 27 (2):208-19. Review.  
[7] Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N. Effects of eight 
growth factors on the differentiation of cells derived from human embryonic stem 
cells. Proc Natl Acad Sci U S A. 2002; 97 (21):11307-12.  
[8] Siqueira RC, Voltarelli JC, Messias AM, Jorge R. Possible mechanisms of retinal function 
recovery with the use of cell therapy with bone marrow-derived stem cells.  Arq 
Bras Oftalmol. 2010 Oct; 73 (5):474-9.  
[9] Siqueira RC, Messias A, Voltarelli JC, Scott I, Jorge R. Autologous bone marrow-derived 
stem cells transplantation for retinitis pigmentosa. Cytotherapy. 2010; 12 Suppl 
1:58.  
[10] ClinicalTrials. gov. [Internet]. Autologous Bone Marrow-Derived Stem Cells 
Transplantation for Retinitis Pigmentosa. NCT01068561. [cited 2010 July 30]. 
Available at: http://clinicaltrial.gov/ 
[11] Siqueira RC. Autologous transplantation of retinal pigment epithelium in age related 
macular degeneration]. Arq Bras Oftalmol. 2009; 72 (1):123-30 
[12] Siqueira RC, Abad L, Benson G, Sami M. Behaviour of stem cells in eyes of rabbits with 
chorioretinal injuries caused by laser red diode 670N-M. In: Annual Meeting of the 
Association for Research in Vision and Ophthalmology (ARVO), 2008, Fort 
Lauderdale. Invest Ophthalmol Vis Sci. 2008; 49:536.  
[13] Siqueira RC. Cell therapy in ophthalmology diseases. Rev. Bras. Hematol. Hemoter. 2009, 
vol. 31, suppl. 1, pp. 120-127.  
[14] Kolb H. Simple Anatomy of the Retina.  The Organization of the Retina and Visual 
System [Internet]. Salt Lake City (UT): University of Utah Health Sciences Center; 
1995-. 2005 May 1.  
[15] Machalinska A, Baumert B, Kuprjanowicz L, Wiszniewska B, Karczewicz D, 
Machalinski B. Potential application of adult stem cells in retinal repair--challenge 
for regenerative medicine.  Curr Eye Res. 2009 Sep; 34 (9):748-60. Review.  
[16] Dahlmann-Noor A, Vijay S, Jayaram H, Limb A, Khaw PT. Current approaches and 
future prospects for stem cell rescue and regeneration of the retina and optic nerve.  
Can J Ophthalmol. 2010 Aug; 45 (4):333-41.  
[17] Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in 
England & Wales. BMC Public Health 2006; 6:58.  
[18] Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 2010; 
340:c981.  
[19] Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular 
hypertension and open angle glaucoma: meta-analysis of randomised controlled 
trials. BMJ 2005; 331:134.  
[20] O’Doherty M, Dooley I, Hickey-Dwyer M. Interventions for diabetic macular oedema: a 
systematic review of the literature. Br J Ophthalmol 2008; 92:1581–90.  
[21] Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic 
review. JAMA 2007; 298:902–16.  
 
Stem-Cell Therapy for Retinal Diseases 145 
[22] Enzmann V, Yolcu E, Kaplan HJ, Ildstad ST. Stem cells as tools in regenerative therapy 
for retinal degeneration. Arch Ophthalmol. 2009; 127 (4):563-71.  
[23] Crisostomo PR, Markel TA, Wang Y, Meldrum DR. Surgically relevant aspects of stem 
cell paracrine effects. Surgery. 2008; 143 (5):577-81.  
[24] Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-
mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005; 39 (2):363-76.  
[25] Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, Wee WR, Lee JH. The anti-inflammatory and 
anti-angiogenic role of mesenchymal stem cells in corneal wound healing following 
chemical injury. Stem Cells. 2008; 26 (4):1047-55.  
[26] Gomei Y, Nakamura Y, Yoshihara H, Hosokawa K, Iwasaki H, Suda T, Arai F. 
Functional differences between two Tie2 ligands, angiopoietin-1 and -2, in the 
regulation of adult bone marrow hematopoietic stem cells. Exp Hematol. 2010; 38 
(2):82-9.  
[27] Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into 
vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp 
Ophthalmol. 2009; 247 (4):503-14.  
[28] Markel TA, Wang Y, Herrmann JL, Crisostomo PR, Wang M, Novotny NM, et al. VEGF 
is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for 
defining the age threshold in adult and neonatal stem cell function. Am J Physiol 
Heart Circ Physiol. 2008; 295 (6):H2308-14.  
[29] Markel TA, Crisostomo PR, Wang M, Herring CM, Meldrum DR. Activation of 
individual tumor necrosis factor receptors differentially affects stem cell growth 
factor and cytokine production. Am J Physiol Gastrointest Liver Physiol. 2007; 293 
(4): G657-62 
[30] Harris JR, Brown GA, Jorgensen M, Kaushal S, Ellis EA, Grant MB, Scott EW. Bone 
marrow-derived cells home to and regenerate retinal pigment epithelium after 
injury. Invest Ophthalmol Vis Sci. 2006; 47 (5):2108-13.  
[31] Zhang P, Li J, Liu Y, Chen X, Kang Q, Zhao J, Li W. Human neural stem cell 
transplantation attenuates apoptosis and improves neurological functions after 
cerebral ischemia in rats. Acta Anaesthesiol Scand. 2009; 53 (9):1184-91.  
[32] Cheng AS, Yau TM. Paracrine effects of cell transplantation: strategies to augment the 
efficacy of cell therapies. Semin Thorac Cardiovasc Surg. 2008; 20 (2):94-101.  
[33] Harris JR, Fisher R, Jorgensen M, Kaushal S, Scott EW. CD133 progenitor cells from the 
bone marrow contribute to retinal pigment epithelium repair. Stem Cells. 2009; 27 
(2):457-66.  
[34] Tomita M, Adachi Y, Yamada H, Takahashi K, Kiuchi K, Oyaizu H, et al. Bone marrow-
derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells. 
2002; 20 (4):279-83.  
[35] Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, et al. Rescue of 
retinal degeneration by intravitreally injected adult bone marrow-derived 
lineagenegative hematopoietic stem cells. J Clin Invest. 2004; 114 (6):765-74. 
Comment in:J Clin Invest. 2004; 114 (6):755-7.  
[36] Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived 
stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. 
Nat Med. 2002; 8 (9):1004-10. Comment in: Nat Med. 2002; 8 (9): 932-4.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 144 
[4] Mimeault M, Batra SK. Concise review: recent advances on the significance of stem cells 
in tissue regeneration and cancer therapies. Stem Cells. 2006; 24 (11):2319-45.  
[5] Ortiz-Gonzalez XR, Keene CD, Verfaillie C, Low WC. Neural induction of adult bone 
marrow and umbilical cord stem cells. Curr Neurovasc Res. 2004; 1 (3):207-13.  
[6] Trounson A. The production and directed differentiation of human embryonic stem 
cells. Endocr Rev. 2006; 27 (2):208-19. Review.  
[7] Schuldiner M, Yanuka O, Itskovitz-Eldor J, Melton DA, Benvenisty N. Effects of eight 
growth factors on the differentiation of cells derived from human embryonic stem 
cells. Proc Natl Acad Sci U S A. 2002; 97 (21):11307-12.  
[8] Siqueira RC, Voltarelli JC, Messias AM, Jorge R. Possible mechanisms of retinal function 
recovery with the use of cell therapy with bone marrow-derived stem cells.  Arq 
Bras Oftalmol. 2010 Oct; 73 (5):474-9.  
[9] Siqueira RC, Messias A, Voltarelli JC, Scott I, Jorge R. Autologous bone marrow-derived 
stem cells transplantation for retinitis pigmentosa. Cytotherapy. 2010; 12 Suppl 
1:58.  
[10] ClinicalTrials. gov. [Internet]. Autologous Bone Marrow-Derived Stem Cells 
Transplantation for Retinitis Pigmentosa. NCT01068561. [cited 2010 July 30]. 
Available at: http://clinicaltrial.gov/ 
[11] Siqueira RC. Autologous transplantation of retinal pigment epithelium in age related 
macular degeneration]. Arq Bras Oftalmol. 2009; 72 (1):123-30 
[12] Siqueira RC, Abad L, Benson G, Sami M. Behaviour of stem cells in eyes of rabbits with 
chorioretinal injuries caused by laser red diode 670N-M. In: Annual Meeting of the 
Association for Research in Vision and Ophthalmology (ARVO), 2008, Fort 
Lauderdale. Invest Ophthalmol Vis Sci. 2008; 49:536.  
[13] Siqueira RC. Cell therapy in ophthalmology diseases. Rev. Bras. Hematol. Hemoter. 2009, 
vol. 31, suppl. 1, pp. 120-127.  
[14] Kolb H. Simple Anatomy of the Retina.  The Organization of the Retina and Visual 
System [Internet]. Salt Lake City (UT): University of Utah Health Sciences Center; 
1995-. 2005 May 1.  
[15] Machalinska A, Baumert B, Kuprjanowicz L, Wiszniewska B, Karczewicz D, 
Machalinski B. Potential application of adult stem cells in retinal repair--challenge 
for regenerative medicine.  Curr Eye Res. 2009 Sep; 34 (9):748-60. Review.  
[16] Dahlmann-Noor A, Vijay S, Jayaram H, Limb A, Khaw PT. Current approaches and 
future prospects for stem cell rescue and regeneration of the retina and optic nerve.  
Can J Ophthalmol. 2010 Aug; 45 (4):333-41.  
[17] Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in 
England & Wales. BMC Public Health 2006; 6:58.  
[18] Chakravarthy U, Evans J, Rosenfeld PJ. Age related macular degeneration. BMJ 2010; 
340:c981.  
[19] Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular 
hypertension and open angle glaucoma: meta-analysis of randomised controlled 
trials. BMJ 2005; 331:134.  
[20] O’Doherty M, Dooley I, Hickey-Dwyer M. Interventions for diabetic macular oedema: a 
systematic review of the literature. Br J Ophthalmol 2008; 92:1581–90.  
[21] Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic 
review. JAMA 2007; 298:902–16.  
 
Stem-Cell Therapy for Retinal Diseases 145 
[22] Enzmann V, Yolcu E, Kaplan HJ, Ildstad ST. Stem cells as tools in regenerative therapy 
for retinal degeneration. Arch Ophthalmol. 2009; 127 (4):563-71.  
[23] Crisostomo PR, Markel TA, Wang Y, Meldrum DR. Surgically relevant aspects of stem 
cell paracrine effects. Surgery. 2008; 143 (5):577-81.  
[24] Vandervelde S, van Luyn MJ, Tio RA, Harmsen MC. Signaling factors in stem cell-
mediated repair of infarcted myocardium. J Mol Cell Cardiol. 2005; 39 (2):363-76.  
[25] Oh JY, Kim MK, Shin MS, Lee HJ, Ko JH, Wee WR, Lee JH. The anti-inflammatory and 
anti-angiogenic role of mesenchymal stem cells in corneal wound healing following 
chemical injury. Stem Cells. 2008; 26 (4):1047-55.  
[26] Gomei Y, Nakamura Y, Yoshihara H, Hosokawa K, Iwasaki H, Suda T, Arai F. 
Functional differences between two Tie2 ligands, angiopoietin-1 and -2, in the 
regulation of adult bone marrow hematopoietic stem cells. Exp Hematol. 2010; 38 
(2):82-9.  
[27] Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into 
vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp 
Ophthalmol. 2009; 247 (4):503-14.  
[28] Markel TA, Wang Y, Herrmann JL, Crisostomo PR, Wang M, Novotny NM, et al. VEGF 
is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for 
defining the age threshold in adult and neonatal stem cell function. Am J Physiol 
Heart Circ Physiol. 2008; 295 (6):H2308-14.  
[29] Markel TA, Crisostomo PR, Wang M, Herring CM, Meldrum DR. Activation of 
individual tumor necrosis factor receptors differentially affects stem cell growth 
factor and cytokine production. Am J Physiol Gastrointest Liver Physiol. 2007; 293 
(4): G657-62 
[30] Harris JR, Brown GA, Jorgensen M, Kaushal S, Ellis EA, Grant MB, Scott EW. Bone 
marrow-derived cells home to and regenerate retinal pigment epithelium after 
injury. Invest Ophthalmol Vis Sci. 2006; 47 (5):2108-13.  
[31] Zhang P, Li J, Liu Y, Chen X, Kang Q, Zhao J, Li W. Human neural stem cell 
transplantation attenuates apoptosis and improves neurological functions after 
cerebral ischemia in rats. Acta Anaesthesiol Scand. 2009; 53 (9):1184-91.  
[32] Cheng AS, Yau TM. Paracrine effects of cell transplantation: strategies to augment the 
efficacy of cell therapies. Semin Thorac Cardiovasc Surg. 2008; 20 (2):94-101.  
[33] Harris JR, Fisher R, Jorgensen M, Kaushal S, Scott EW. CD133 progenitor cells from the 
bone marrow contribute to retinal pigment epithelium repair. Stem Cells. 2009; 27 
(2):457-66.  
[34] Tomita M, Adachi Y, Yamada H, Takahashi K, Kiuchi K, Oyaizu H, et al. Bone marrow-
derived stem cells can differentiate into retinal cells in injured rat retina. Stem Cells. 
2002; 20 (4):279-83.  
[35] Otani A, Dorrell MI, Kinder K, Moreno SK, Nusinowitz S, Banin E, et al. Rescue of 
retinal degeneration by intravitreally injected adult bone marrow-derived 
lineagenegative hematopoietic stem cells. J Clin Invest. 2004; 114 (6):765-74. 
Comment in:J Clin Invest. 2004; 114 (6):755-7.  
[36] Otani A, Kinder K, Ewalt K, Otero FJ, Schimmel P, Friedlander M. Bone marrow-derived 
stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. 
Nat Med. 2002; 8 (9):1004-10. Comment in: Nat Med. 2002; 8 (9): 932-4.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 146 
[37] Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural 
progenitors incorporate into degenerating retina and enhance survival of host 
photoreceptors. Stem Cells. 2006; 24 (2):274-83.  
[38] Binder S, Stanzel BV, Krebs I, Glittenberg C. Transplantation of the RPE in AMD. Prog 
Retin Eye Res. 2007 Sep; 26 (5):516-54. Epub 2007 Mar 6. Review.  
[39] Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R, Lund R. Long-term 
safety and function of RPE from human embryonic stem cells in preclinical models 
of macular degeneration. Stem Cells.  2009 Sep; 27 (9):2126-35.  
[40] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell. 2006; 126:663–676.  
[41] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. Induction of pluripotent 
stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861–872.  
[42] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Induced 
pluripotent stem cell lines derived from human somatic cells. Science. 2007; 
318:1917–1920.  
[43] Zhang D, Jiang W, Liu M, Sui X, Yin X, et al. Highly efficient differentiation of human 
ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009; 
52:615–621.  
[44] Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, et al. Functional cardiomyocytes 
derived from human induced pluripotent stem cells. Circ Res. 2009; 104:e30–41.  
[45] Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, et al. Treatment of sickle cell 
anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 
318:1920–1923.  
[46] Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, et al. Phenotypic correction of murine 
hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A. 2009; 106:80 
[47] Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, et al. Neurons derived from 
reprogrammed fibroblasts functionally integrate into the fetal brain and improve 
symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A. 2008; 
105:5856–5861.  
[48] Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, et al. Modeling early 
retinal development with human embryonic and induced pluripotent stem cells. 
Proc Natl Acad Sci U S A. 2009; 106: 
[49] Buchholz DE, Hikita ST, Rowland TJ, Friedrich AM, Hinman CR, et al. Derivation of 
Functional Retinal Pigmented Epithelium from Induced Pluripotent Stem Cells. 
Stem Cells. 2009; 27:2427–2434.  
[50] Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado 
A, Semo M, Smart MJ, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey PJ. 
Protective effects of human iPS-derived retinal pigment epithelium cell 
transplantation in the retinal dystrophic rat.  PLoS One. 2009 Dec 3; 4 (12):e8152.  
[51] Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. Induction of 
pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. 
Nat Biotechnol. 2008; 26:1269–1275.  
[52] Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, et al. Induction of pluripotent stem 
cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule 
compounds. Cell Stem Cell. 2008; 3:568–574. ] 
[53] Li W, Zhou H, Abujarour R, Zhu S, Joo JY, et al. Generation of Human Induced 
Pluripotent Stem Cells in the Absence of Exogenous Sox2. Stem Cells 2009.  
 
Stem-Cell Therapy for Retinal Diseases 147 
[54] Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, et al. piggyBac 
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 
2009; 458:766–770.  
[55] Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, et al. Virus-free induction of 
pluripotency and subsequent excision of reprogramming factors. Nature. 2009; 
458:771–775.  
[56] Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. Human Induced Pluripotent Stem 
Cells Free of Vector and Transgene Sequences. Science. 2009; 324:797–801.  
[57] Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic 
regulation of hematopoietic stem cell self-renewal and differentiation. Blood. 2002; 
100 (4):1302-9.  
[58] Balasubramanian S, Babai N, Chaudhuri A, Qiu F, Bhattacharya S, et al. Non Cell-
Autonomous Reprogramming of Adult Ocular Progenitors: Generation of 
Pluripotent Stem Cells Without Exogenous Transcription Factors. Stem Cells 2009.  
[59] Loh YH, Agarwal S, Park IH, Urbach A, Huo H, et al. Generation of induced 
pluripotent stem cells from human blood. Blood. 2009; 113:5476–5479.  
[60] Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse 
hematopoietic stem cells. Science. 1988; 241 (4861):58-62. Erratum in: Science. 
1989;244 (4908):1030.  
[61] Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J. Stem cell 
plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver 
and neural cells ‘hide out’ in the bone marrow. Leukemia. 2004; 18 (1):29-40.  
[62] Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic 
regulation of hematopoietic stem cell self-renewal and differentiation. Blood. 2002; 
100 (4):1302-9.  
[63] Nielsen JS, McNagny KM. CD34 is a key regulator of hematopoietic stem cell trafficking 
to bone marrow and mast cell progenitor trafficking in the periphery. 
Microcirculation. 2009; 16 (6):487-96.  
[64] Kuçi S, Kuçi Z, Latifi-Pupovci H, Niethammer D, Handgretinger R, Schumm M, et al. 
Adult stem cells as an alternative source of multipotential (pluripotential) cells 
inregenerative medicine. Curr Stem Cell Res Ther. 2009; 4 (2):107-17.  
[65] Challen GA, Boles N, Lin KK, Goodell MA. Mouse hematopoietic stem cell 
identificationand analysis. Cytometry A. 2009; 75 (1):14-24. Review.  
[66] Voltarelli JC, Ouyang J. Hematopoietic stem cell transplantation for autoimmune 
diseases in developing countries: current status and future prospectives. Bone 
Marrow Transplant. 2003; 32 Suppl 1:S69-71.  
[67] Voltarelli JC. Applications of flow cytometry to hematopoietic stem cell transplantation. 
Mem Inst Oswaldo Cruz. 2000; 95 (3):403-14.  
[68] Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans 
RJ, Krause DS, Keating A; International Society for Cellular Therapy. Clarification 
of the nomenclature for MSC: The International Society for Cellular Therapy 
position statement. Cytotherapy. 2005; 7 (5):393-5.  
[69] Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal 
cells: the state of transdifferentiation and modes of tissue repair-current views. 
Stem Cells. 2007; 25 (11):2896-902.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 146 
[37] Meyer JS, Katz ML, Maruniak JA, Kirk MD. Embryonic stem cell-derived neural 
progenitors incorporate into degenerating retina and enhance survival of host 
photoreceptors. Stem Cells. 2006; 24 (2):274-83.  
[38] Binder S, Stanzel BV, Krebs I, Glittenberg C. Transplantation of the RPE in AMD. Prog 
Retin Eye Res. 2007 Sep; 26 (5):516-54. Epub 2007 Mar 6. Review.  
[39] Lu B, Malcuit C, Wang S, Girman S, Francis P, Lemieux L, Lanza R, Lund R. Long-term 
safety and function of RPE from human embryonic stem cells in preclinical models 
of macular degeneration. Stem Cells.  2009 Sep; 27 (9):2126-35.  
[40] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic 
and adult fibroblast cultures by defined factors. Cell. 2006; 126:663–676.  
[41] Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. Induction of pluripotent 
stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131:861–872.  
[42] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. Induced 
pluripotent stem cell lines derived from human somatic cells. Science. 2007; 
318:1917–1920.  
[43] Zhang D, Jiang W, Liu M, Sui X, Yin X, et al. Highly efficient differentiation of human 
ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 2009; 
52:615–621.  
[44] Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, et al. Functional cardiomyocytes 
derived from human induced pluripotent stem cells. Circ Res. 2009; 104:e30–41.  
[45] Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, et al. Treatment of sickle cell 
anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 
318:1920–1923.  
[46] Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, et al. Phenotypic correction of murine 
hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A. 2009; 106:80 
[47] Wernig M, Zhao JP, Pruszak J, Hedlund E, Fu D, et al. Neurons derived from 
reprogrammed fibroblasts functionally integrate into the fetal brain and improve 
symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A. 2008; 
105:5856–5861.  
[48] Meyer JS, Shearer RL, Capowski EE, Wright LS, Wallace KA, et al. Modeling early 
retinal development with human embryonic and induced pluripotent stem cells. 
Proc Natl Acad Sci U S A. 2009; 106: 
[49] Buchholz DE, Hikita ST, Rowland TJ, Friedrich AM, Hinman CR, et al. Derivation of 
Functional Retinal Pigmented Epithelium from Induced Pluripotent Stem Cells. 
Stem Cells. 2009; 27:2427–2434.  
[50] Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado 
A, Semo M, Smart MJ, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey PJ. 
Protective effects of human iPS-derived retinal pigment epithelium cell 
transplantation in the retinal dystrophic rat.  PLoS One. 2009 Dec 3; 4 (12):e8152.  
[51] Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, et al. Induction of 
pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. 
Nat Biotechnol. 2008; 26:1269–1275.  
[52] Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, et al. Induction of pluripotent stem 
cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule 
compounds. Cell Stem Cell. 2008; 3:568–574. ] 
[53] Li W, Zhou H, Abujarour R, Zhu S, Joo JY, et al. Generation of Human Induced 
Pluripotent Stem Cells in the Absence of Exogenous Sox2. Stem Cells 2009.  
 
Stem-Cell Therapy for Retinal Diseases 147 
[54] Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, et al. piggyBac 
transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 
2009; 458:766–770.  
[55] Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, et al. Virus-free induction of 
pluripotency and subsequent excision of reprogramming factors. Nature. 2009; 
458:771–775.  
[56] Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, et al. Human Induced Pluripotent Stem 
Cells Free of Vector and Transgene Sequences. Science. 2009; 324:797–801.  
[57] Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic 
regulation of hematopoietic stem cell self-renewal and differentiation. Blood. 2002; 
100 (4):1302-9.  
[58] Balasubramanian S, Babai N, Chaudhuri A, Qiu F, Bhattacharya S, et al. Non Cell-
Autonomous Reprogramming of Adult Ocular Progenitors: Generation of 
Pluripotent Stem Cells Without Exogenous Transcription Factors. Stem Cells 2009.  
[59] Loh YH, Agarwal S, Park IH, Urbach A, Huo H, et al. Generation of induced 
pluripotent stem cells from human blood. Blood. 2009; 113:5476–5479.  
[60] Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse 
hematopoietic stem cells. Science. 1988; 241 (4861):58-62. Erratum in: Science. 
1989;244 (4908):1030.  
[61] Ratajczak MZ, Kucia M, Reca R, Majka M, Janowska-Wieczorek A, Ratajczak J. Stem cell 
plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver 
and neural cells ‘hide out’ in the bone marrow. Leukemia. 2004; 18 (1):29-40.  
[62] Müller-Sieburg CE, Cho RH, Thoman M, Adkins B, Sieburg HB. Deterministic 
regulation of hematopoietic stem cell self-renewal and differentiation. Blood. 2002; 
100 (4):1302-9.  
[63] Nielsen JS, McNagny KM. CD34 is a key regulator of hematopoietic stem cell trafficking 
to bone marrow and mast cell progenitor trafficking in the periphery. 
Microcirculation. 2009; 16 (6):487-96.  
[64] Kuçi S, Kuçi Z, Latifi-Pupovci H, Niethammer D, Handgretinger R, Schumm M, et al. 
Adult stem cells as an alternative source of multipotential (pluripotential) cells 
inregenerative medicine. Curr Stem Cell Res Ther. 2009; 4 (2):107-17.  
[65] Challen GA, Boles N, Lin KK, Goodell MA. Mouse hematopoietic stem cell 
identificationand analysis. Cytometry A. 2009; 75 (1):14-24. Review.  
[66] Voltarelli JC, Ouyang J. Hematopoietic stem cell transplantation for autoimmune 
diseases in developing countries: current status and future prospectives. Bone 
Marrow Transplant. 2003; 32 Suppl 1:S69-71.  
[67] Voltarelli JC. Applications of flow cytometry to hematopoietic stem cell transplantation. 
Mem Inst Oswaldo Cruz. 2000; 95 (3):403-14.  
[68] Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans 
RJ, Krause DS, Keating A; International Society for Cellular Therapy. Clarification 
of the nomenclature for MSC: The International Society for Cellular Therapy 
position statement. Cytotherapy. 2005; 7 (5):393-5.  
[69] Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal 
cells: the state of transdifferentiation and modes of tissue repair-current views. 
Stem Cells. 2007; 25 (11):2896-902.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 148 
[70] Gong L, Wu Q, Song B, et al. Differentiation of rat mesenchymal stem cells transplanted 
into the subretinal space of sodium iodate-injected rats. Clin Experiment Ophthalmol. 
2008; 36:666–671.  
[71] Castanheira P, Torquetti L, Nehemy MB, et al. Retinal incorporation and differentiation 
of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq 
Bras Oftalmol. 2008; 71:644–650.  
[72] Zhang ZQ, Dong FT. In vitro differentiation of rat mesenchymal stem cells into 
photoreceptors. Zhonghua Yan Ke Za Zhi. 2008; 44:540–544.  
[73] Vossmerbaeumer U, Ohnesorge S, Kuehl S, et al. Retinal pigment epithelial phenotype 
induced in human adipose tissue-derived mesenchymal stromal cells. Cytotherapy. 
2009; 11:177–188.  
[74] Arnhold S, Heiduschka P, Klein H, et al. Adenovirally transduced bone marrow 
stromal cells differentiate into pigment epithelial cells and induce rescue effects in 
RCS rats. Invest Ophthalmol Vis Sci. 2006; 47:4121–4129.  
[75] Yu S, Tanabe T, Dezawa M, et al. Effects of bone marrow stromal cell injection in an 
experimental glaucoma model. Biochem Biophys Res Commun. 2006; 344:1071–1079.  
[76] Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone 
marrow stromal cells implanted in the brains of albino rats—Similarities to 
astrocyte grafts. Proc Natl Acad Sci U S A. 1998; 95:3908–3913.  
[77] Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord 
blood. Br J Haematol. 2000; 109:235–242.  
[78] Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into 
vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp 
Ophthalmol. 2009; 247:503–514.  
[79] Inoue Y, Iriyama A, Ueno S, et al. Subretinal transplantation of bone marrow 
mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal 
degeneration. Exp Eye Res. 2007; 85:234–241.  
[80] Zwart I, Hill AJ, Al-Allaf F, et al. Umbilical cord blood mesenchymal stromal cells are 
neuroprotective and promote regeneration in a rat optic tract model. Exp Neurol. 
2009; 216:439–448.  
[81] Hou HY, Liang HL, Wang YS, et al. A Therapeutic strategy for choroidal 
neovascularization based on recruitment of mesenchymal stem cells to the sites of 
lesions. Mol Ther. 2010 Jul 20. [Epub ahead of print] 
[82] Jonas JB, Witzens-Harig M, Arseniev L, Ho AD. Intravitreal autologous bone marrow-
derived mononuclear cell transplantation: a feasibility report. Acta Ophthalmol. 
2008; 86 (2):225-6.  
[83] Jonas JB, Witzens-Harig M, Arseniev L, Ho AD. Intravitreal autologous bone marrow-
derived mononuclear cell transplantation. Acta Ophthalmol. 2010; 88 (4):e131-2.  
[84] Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of 
autologous bone marrow-derived mononuclear cells for hereditary retinal 
dystrophy: a phase I trial.  Retina. 2011 feb 2. [epub ahead of print] 
[85] Nistor G, Seiler MJ, Yan F, Ferguson D, Keirstead HS. Three-dimensional early retinal 
progenitor 3D tissue constructs derived from human embryonic stem cells. J 
Neurosci Methods.  2010 Jun 30; 190 (1):63-70. Epub 2010 May 4.  
[86] MacLaren R E, Pearson R A. Stem cell therapy and the retina. Eye (2007) 21, 1352–1359 
Part 3 
Cardiac and Other Myogenic Differentiation 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 148 
[70] Gong L, Wu Q, Song B, et al. Differentiation of rat mesenchymal stem cells transplanted 
into the subretinal space of sodium iodate-injected rats. Clin Experiment Ophthalmol. 
2008; 36:666–671.  
[71] Castanheira P, Torquetti L, Nehemy MB, et al. Retinal incorporation and differentiation 
of mesenchymal stem cells intravitreally injected in the injured retina of rats. Arq 
Bras Oftalmol. 2008; 71:644–650.  
[72] Zhang ZQ, Dong FT. In vitro differentiation of rat mesenchymal stem cells into 
photoreceptors. Zhonghua Yan Ke Za Zhi. 2008; 44:540–544.  
[73] Vossmerbaeumer U, Ohnesorge S, Kuehl S, et al. Retinal pigment epithelial phenotype 
induced in human adipose tissue-derived mesenchymal stromal cells. Cytotherapy. 
2009; 11:177–188.  
[74] Arnhold S, Heiduschka P, Klein H, et al. Adenovirally transduced bone marrow 
stromal cells differentiate into pigment epithelial cells and induce rescue effects in 
RCS rats. Invest Ophthalmol Vis Sci. 2006; 47:4121–4129.  
[75] Yu S, Tanabe T, Dezawa M, et al. Effects of bone marrow stromal cell injection in an 
experimental glaucoma model. Biochem Biophys Res Commun. 2006; 344:1071–1079.  
[76] Azizi SA, Stokes D, Augelli BJ, et al. Engraftment and migration of human bone 
marrow stromal cells implanted in the brains of albino rats—Similarities to 
astrocyte grafts. Proc Natl Acad Sci U S A. 1998; 95:3908–3913.  
[77] Erices A, Conget P, Minguell JJ. Mesenchymal progenitor cells in human umbilical cord 
blood. Br J Haematol. 2000; 109:235–242.  
[78] Li N, Li XR, Yuan JQ. Effects of bone-marrow mesenchymal stem cells transplanted into 
vitreous cavity of rat injured by ischemia/reperfusion. Graefes Arch Clin Exp 
Ophthalmol. 2009; 247:503–514.  
[79] Inoue Y, Iriyama A, Ueno S, et al. Subretinal transplantation of bone marrow 
mesenchymal stem cells delays retinal degeneration in the RCS rat model of retinal 
degeneration. Exp Eye Res. 2007; 85:234–241.  
[80] Zwart I, Hill AJ, Al-Allaf F, et al. Umbilical cord blood mesenchymal stromal cells are 
neuroprotective and promote regeneration in a rat optic tract model. Exp Neurol. 
2009; 216:439–448.  
[81] Hou HY, Liang HL, Wang YS, et al. A Therapeutic strategy for choroidal 
neovascularization based on recruitment of mesenchymal stem cells to the sites of 
lesions. Mol Ther. 2010 Jul 20. [Epub ahead of print] 
[82] Jonas JB, Witzens-Harig M, Arseniev L, Ho AD. Intravitreal autologous bone marrow-
derived mononuclear cell transplantation: a feasibility report. Acta Ophthalmol. 
2008; 86 (2):225-6.  
[83] Jonas JB, Witzens-Harig M, Arseniev L, Ho AD. Intravitreal autologous bone marrow-
derived mononuclear cell transplantation. Acta Ophthalmol. 2010; 88 (4):e131-2.  
[84] Siqueira RC, Messias A, Voltarelli JC, Scott IU, Jorge R. Intravitreal injection of 
autologous bone marrow-derived mononuclear cells for hereditary retinal 
dystrophy: a phase I trial.  Retina. 2011 feb 2. [epub ahead of print] 
[85] Nistor G, Seiler MJ, Yan F, Ferguson D, Keirstead HS. Three-dimensional early retinal 
progenitor 3D tissue constructs derived from human embryonic stem cells. J 
Neurosci Methods.  2010 Jun 30; 190 (1):63-70. Epub 2010 May 4.  
[86] MacLaren R E, Pearson R A. Stem cell therapy and the retina. Eye (2007) 21, 1352–1359 
Part 3 
Cardiac and Other Myogenic Differentiation 
 8 
Transcriptional Networks of Embryonic Stem 
Cell-Derived Cardiomyogenesis 
Diego Franco, Estefania Lozano-Velasco and Amelia Aránega 
Cardiovascular Development Group,  
Department of Experimental Biology,  
University of Jaén, Jaén 
Spain 
1. Introduction 
Embryonic stem cells are pluripotent cells that, if cultured under specific conditions, give 
rise to clusters of beating cardiomyocytes. Beating cardiomyocytes, also dubbed beating 
areas, display gene expression profiles and functional properties similar to adult 
cardiomyocytes.  In line with this, a wide heterogeneity has been observed in embryonic 
stem cell-derived cardiomyocytes, resembling thus the distinct characteristics of atrial, 
ventricular and conductive cardiomyocytes.  
It has been recently demonstrated that two distinct cardiogenic precursor cells contribute to 
the developing heart. The first heart field contributes to the cardiac linear straight tube while 
a second population of cells adds cells to both arterial and venous pole of the cardiac tube, 
delimiting thus the second heart field. As cardiogenesis advances the first heart field mainly 
gives rise to the left ventricle, whereas the second heart field contributes to the right 
ventricle, outflow tract and the atrial chambers. A third population of cells, with distinct 
gene expression fingerprint has been demonstrated to form the inflow tract, suggesting the 
possible existence of a third heart field.  
Over the last years we have gained insights about the transcriptional mechanisms that 
govern the distinct heart fields, however, our understanding about if such endogenous 
program is recapitulated in embryonic stem cell-derived cardiomyogenesis remains elusive. 
Within this review we elaborate about the current state-of-the-art of the transcriptional 
networks that operate during embryonic stem cell-derived cardiomyogenesis, with special 
emphasis on the development of heart field transcriptional networks. 
2. Cardiogenic potential of embryonic stem cells 
Embryonic stem cells are pluripotent stem cells derived from the inner cell mass of the 
developing blastocyst. In vitro culture of embryonic stem cells, if nurtured under specific 
conditions, can give rise to distinct cell types of endodermal, mesodermal and ectodermal 
lineages, including thus beating cardiomyocytes (Miller-Hance et al. 1993). Such capabilities 
have raised the possibility of using embryonic stem cells as a source to heal the damaged 
heart (Chinchilla & Franco, 2006; Franco et al., 2007). However, several constrains has 
obstructed this purpose. Leaving apart ethical concerns, mainly applicable to human 
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embryonic stem cells, technical and scientific obstacles also have contributed to slow down 
this quest. We shall update in this book chapter the state-of-the-art progress made to 
conquer the challenging aim of converting embryonic stem cells into beating 
cardiomyocytes as suitable therapeutical tools. 
It is incredible to observe that a subset of cells hunted from the inner mass cells of the 
developing blastocyst, set in appropriate cell culture conditions, are able to progressively 
proceed in vitro, differentiating into neurons, fibroblasts, cardiomyocytes as well as in 
several other cells types (Lanza et al., 2004). The real question is then; does this occur 
mimicking the early step of embryogenesis? Several studies have demonstrated that upon 
the initial phases of in vitro embryonic stem cells culture, the aggregating cells that form the 
embryonic bodies in the hanging drops acquire a rather well organized three-dimensional 
structure, by which externally located cells express ectodermal markers, while internally 
located cells express mesodermal and endodermal makers (Doetschman et al., 1985, Wobus 
& Boheler, 1999; Boheler et al., 2002). Thus, these findings support the notion that cell 
specification and determination of embryonic stem cells into a discrete cell type would 
mainly follow the endogenous signal pathways. Therefore, in order to understand how stem 
cells can lead to cardiomyocytes, efforts should be made to learn the natural routing of a 
mesodermal cell that will contribute to the heart.  In essence we need to learn how cardiac 
development is achieved.  
3. Transcriptional control of cardiac muscle development 
Over the last two decades, our understanding of the cellular and molecular mechanisms that 
govern cardiac development has greatly advanced. Initial steps of mesoderm commitment 
from the lateral plate mesoderm to the forming heart are mainly directed by interplay 
between Bmp, Fgf and Wnt signaling (Barron et al., 2000; Lopez-Sanchez et al., 2002; 
Marques et al., 2008). As soon as the cardiogenic mesoderm is committed, several 
transcription factors, such as Nkx2.5, Gata4, Srf, Hand2 and Mef2c are activated, which play 
crucial roles during cardiogenesis as revealed by loss-of-function experiments in mice 
(Lyons et al., 1995; Srivastava et al., 1995; Kuo et al., 1997; Lin et al., 1997). Cardiogenesis 
proceeds by the formation of two concentrical tissue layers, an external myocardial and 
internal endocardial layer. To date it remains elusive how each cardiogenic lineage is 
distinctly established and whether they share a common progenitor (Linask & Lash, 1993; 
Eisenberg & Bader, 1995) or, on the contrary, they are distinctly derived from separate 
precursors (Cohen-Gould & Mikawa, 1996; Wei & Mikawa, 2000). As the myocardium is 
configured, it has been recently demonstrated that two distinct cell populations contribute 
to the developing heart; the first heart field (FHF) will contribute to the linear heart tube and 
subsequently will give rise mainly to the left ventricle (Kelly & Buckingham, 2002), whereas 
a second population of cells is subsequently recruited, namely the second heart field (SHF), 
contributing to the rest of the developing heart (Kelly et al., 2001; Cai et al., 2001; Waldo et 
al., 2001; Kelly & Buckingham, 2002).  FHF derivatives express Nkx2.5 but are negative from 
islet-1, while SHF cells express both Nkx2.5 and islet-1. In addition, SHF derivates can be 
subdivided in two distinct regions, according to their entry site to the developing heart; a) 
anterior SHF leads to the formation of the right ventricle and outflow tract, and its 
contribution is governed by signaling emanating from Fgf8- and Fgf10-expressing cells 
(Watanabe et al. 2010), as well as contribution from Tbx1 signaling at the 
arterial/pharyngeal pole of the heart (Huynh et al., 2007; Liao et al., 2008), b) posterior SHF 
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will contribute to the atrioventricular canal as well as right and left atria, and its 
contribution is directed by Fgf10 signaling at the venous pole of the heart (Kelly et al., 2001). 
In addition, complex regulatory networks are operative in the embryonic heart providing 
differentiation cues to the developing myocardium, as illustrated by the complex expression 
pattern of T-box genes, including therein Tbx2, Tbx3, Tbx5, Tbx18 and Tbx20 (Singh & 
Kispert, 2010; Greulich et al., 2011), Hand1 and Hand2 providing systemic vs pulmonary 
cues (Srivastava et al.,  1995; Thomas et al., 1995) as well as left/right positional cues as 
illustrated by Pitx2 (Franco & Campione, 2003; Chinchilla et al., 2011).  Thus, shared and 
distinct transcriptional pathways are governing first and second heart field deployment, 
leading in both cases to activation of a core cardiac transcriptional regulatory network as 
illustrated in Figure 1. 
In addition, a third population of cells, with distinct gene expression hallmark as compared 
to first and second heart field cardiac precursors, has been demonstrated to form the inflow 
tract of the heart, suggesting the possible existence of a third heart field (Mommersteeg et 
al., 2010). Nkx2.5 /islet-1 negative cells, but positive for Tbx18, contribute to the formation 
of the caval veins (Mommersteeg et al., 2010). However, recent Cre-based lineage tracing 
experiments have challenged this notion, since all myocardial component of the venous 
pole, including the atrial appendages and the caval and pulmonary veins, have been 
reported to be derived from  islet-1 and Nkx2-5 positive cells (Ma et al., 2008).   
Concomitant with the deployment of the first and second heart field precursor cells, 
differentiation into distinct cardiomyocyte cell types is occurring, providing thus distinct 
working chamber and conduction system myocardium. Tbx2 and Tbx3 have been reported 
to play a fundamental role controlling gene expression pattern within the atrioventricular 
node (Bakker et al., 2008; Aanhaanen et al., 2009, 2011). Shox2, Tbx3 and Tbx18 have been 
demonstrated to play a crucial role on the sinoatrial node formation (Hoogaars et al., 2007; 
Wiese et al., 2009; Espinoza-Lewis et al. 2009).  Furthermore, cardiomyocyte subtypes 
progressively emerge during cardiogenesis, such as distinct atrial and ventricular chamber 
myocardium, although the transcriptional regulation of such cell identities remains rather 
elusive. In chicken, Irx4 plays a crucial role in this step (Bao et al., 1999; Bruneau et al. 2000), 
however such function is not conserved in mice (Bruneau et al., 2001), which might be 
partially taken by Coup-tfII (Pereira et al., 1999; Wu et al., 2011). Similar events also are 
applicable for the cardiac conduction system, in which nodal and bundle branch fascicles 
are developed, each of them with distinct functional capabilities, yet their transcriptional 
regulation remains rather unexplored (Franco & Icardo, 2001; Miquerol et al. 2011).  
In the adult heart, some of the developmental differences are progressively smoothened, in 
such a way that we can consider the adult heart being composed of two types of working 
myocardium (atrial and ventricular) and three distinct types of conductive cells (SAN and 
AVN node, His and bundle branches, and Purkinje fibers). Curiously, novel transmural 
differences emerge in the adult ventricular myocardium (Yan & Antzelevitch et al., 1996, 
1999; de Castro et al., 2005), which are crucial for correct function of the heart (Constantini et 
al. 2005).  
In its important to highlight that during cardiogenesis, the heart is progressively acquiring 
novel functional capabilities, which are reflected on the progressive onset of expression of 
contractile, conductive and cytoskeleton proteins. At the contractile level, sarcomeric genes 
such as myosins, actins and troponins, and cytoskeleton proteins as tropomyosin and 
actinins are differently expressed already at early stages of development (Lyons et al., 1990; 
Franco et al., 1998) providing functional heterogeneity to the developing myocardium, as 
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Fig. 1. Schematic representation of embryonic cardiac development. At gastrulation, 
nascent precardiac mesoderm listens to signal emanating from the surrounding ectodermal 
and endodermal tissues, committing the cells into the cardiogenic lineage, i.e. cardioblasts. 
Cardioblasts are characterized by the expression of core cardiac transcription factors, 
including Nkx2.5, Gata4 and Mef2c. Soon thereafter, cardiomyocyte and endothelial cell 
lineages emerged and within the cardiomyocyte lineage, two distinct populations of cells 
can be recognized, first heart field (FHF) and second heart field (SHF) cells. A third 
population of cells is originating soon thereafter, which lacks Nkx2.5 or islet-1 expression, 
yet, lineage tracing evidences using Cre/LoxP system suggested they have had a common 
ancestry (Cai et al., 2003; Zhou et al., 2008). FHF contributes mainly to the left ventricle and 
the atrioventricular canal (AVC). AVC will eventually be remodeled as septation proceeds, 
contributing therein to the formation of the atrioventricular node, which is characterized by 
Tbx2 and Tbx3 expression. Interestingly, SHF have two distinct components, an anterior 
SHF contributing to the outflow tract and right ventricle, listing to signal emanating from 
the pharyngeal arches domain, such as Fgf8 and Fgf10, and a posterior SHF leading to the 
right and left atrial chambers, listing to signals such as Fgf10. The “third” heart field 
contributes to the sinous venosus, forming therefore the caval veins and the sinoatrial node, 
and to the pulmonary myocardium which constitutes the atrial septa and the pulmonary 
veins (Franco et al., 2000). Importantly, almost all previously mentioned cardiac lineages 
listen to left/right signaling clues provided by the homeobox transcription factor Pitx2 
(Campione et al., 1999; Franco & Campione, 2003). 
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detailed in Table 1. Similarly, ion channels and gap junctional proteins are progressively 
expressed in distinct regions of the developing heart (Gros & Jongsma, 1996; Franco et al. 
2001; de Castro et al., 2005)(Table 1), providing the bases for the onset of a persitaltoid 
contraction in first instance and subsequently of synchronous contraction at late embryonic 
stage, displaying thus an apex-to-base pattern of activation. In essence, if we take thus as a 
reference our knowledge about cardiac development, it sounds reasonable that such 
information could be applicable to embryonic stem cells in order to obtain beating 
cardiomyocytes.  
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Table 1. Graphical respresentation of the expression profiles of cardiac-enriched 
transcription factors, sarcomeric proteins, ion channels and gap junctional proteins during 
embryonic heart development, in distinct regions of the embryonic/fetal heart. OFT, 
outflow tract; RV, right ventricle, LV, left ventricle, AVC, atrioventricular canal, RA, right 
atrium, LA, left atrium, SAN, sinoatrial node, CV, caval veins, PV, pulmonary veins. *AVC 
will lead in the adult heart to the atrioventricular node.  
4. Understanding transcriptional control of in vitro cardiogenesis 
The formation of beating cardiomyocytes from undifferentiated embryonic stem cell has 
been an important focus of scientific research, as it can be witnessed by the number of 
publication in this front. Several of the signaling pathways involved in in vivo cardiogenesis 
are also recapitulated in vitro, as depicted in Figure 2. Importantly, initial reports provided 
evidences that embryonic stem cell-derived cardiomyocytes display morphological, 
molecular and functional characteristics similar to adult cardiomyocytes, displaying 
therefore expression of sarcomeric and gap junctional proteins (Sachinidis et al., 2003; van 
Kempen et al., 2003; Fijnvandraaf et al., 2003ab). Additional experiments, demonstrated that 
most ion channels that are natively configure the cardiac action potential are also expressed 
during embryonic stem cell-derived cardiomyocytes (van Kempen et al., 2003). Furthermore, 
elegant spatio-temporal studies also nicely illustrate the progressive onset of the core 
transcriptional cardiac and ion channel expression during embryonic stem cell-derived 
cardiomyogenesis (Fijnvandraaf et al., 2003ab, van Kempen et al., 2003). However, several 
caveats were soon arising. Firstly, the fact that embryonic stem cell cultures, although 
capable of providing a source of cardiomyocytes, yield on average to a low percentage 
(<20%). Secondly, beating areas display distinct contraction rates, suggesting that large 
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heterogeneity was observed from beating area to beating area, which might have gone 
unappreciated since most studies were done using RT-PCR methods. Thirdly, it was unclear 
if all cells within a beating area were equally differentiated. Sorting out these key questions 
is compulsory before any therapeutical strategy could be envisioned since a large number of 
cardiomyocytes is required, which will need to be morphologically homogeneous in order 
to avoid the chance of generating arrhythmias, and sufficiently and adequately 
differentiated in order to limit the oncogenic propagation of undifferentiated or poorly 
differentiated embryonic stem cells.  
 
 
Fig. 2. Schematic representation of the signaling pathways involved in embryonic stem 
cell–derived cardiogenesis.  Pluripotency makers such as Nanog, Oct4, Klf4 and Sox2 are 
expressed in undifferentiated embryonic stem cells. As soon as differentiation is initiated, 
these makers are down-regulated and mesoderm specification genes such as Mesp1 are 
expressed. Soon thereafter, as the beating areas are conformed, core cardiac transcriptional 
regulatory genes are up-regulated, and progressively the nascent cardiomyocytes acquire 
sacormeric and ion channel proteins, as depicted in Table 2.   
First approaches to increase the efficiency of converting embryonic stem cells into 
cardiomycytes has been obtained by mimicking the inductive signals that naturally convert 
precardiogenic mesodermal cells into nascent cardioblasts (Hidai et al., 2003; Holtzinger et 
al., 2010). Bin et al. (2006) demonstrates that Bmp2 treatment of mouse embryonic stem cells 
increased the efficiency of obtaining beating areas, providing evidences that core 
transcriptional factor Nkx2.5 and structural proteins such as troponin-T and alpha-MHC 
were increased. Further evidences on the pivotal role of Bmp signaling in embryonic stem 
cell-derived cardiomyogenesis were reported by Rajasingh et al. (2007). More recently, Kim 
et al. (2008) provides similar evidences using human embryonic stem cells. However, other 
authors have reported that Bmp2 overexpression can also lead to induction of other 
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Table 1. Graphical respresentation of the expression profiles of cardiac-enriched 
transcription factors, sarcomeric proteins, ion channels and gap junctional proteins during 
embryonic heart development, in distinct regions of the embryonic/fetal heart. OFT, 
outflow tract; RV, right ventricle, LV, left ventricle, AVC, atrioventricular canal, RA, right 
atrium, LA, left atrium, SAN, sinoatrial node, CV, caval veins, PV, pulmonary veins. *AVC 
will lead in the adult heart to the atrioventricular node.  
4. Understanding transcriptional control of in vitro cardiogenesis 
The formation of beating cardiomyocytes from undifferentiated embryonic stem cell has 
been an important focus of scientific research, as it can be witnessed by the number of 
publication in this front. Several of the signaling pathways involved in in vivo cardiogenesis 
are also recapitulated in vitro, as depicted in Figure 2. Importantly, initial reports provided 
evidences that embryonic stem cell-derived cardiomyocytes display morphological, 
molecular and functional characteristics similar to adult cardiomyocytes, displaying 
therefore expression of sarcomeric and gap junctional proteins (Sachinidis et al., 2003; van 
Kempen et al., 2003; Fijnvandraaf et al., 2003ab). Additional experiments, demonstrated that 
most ion channels that are natively configure the cardiac action potential are also expressed 
during embryonic stem cell-derived cardiomyocytes (van Kempen et al., 2003). Furthermore, 
elegant spatio-temporal studies also nicely illustrate the progressive onset of the core 
transcriptional cardiac and ion channel expression during embryonic stem cell-derived 
cardiomyogenesis (Fijnvandraaf et al., 2003ab, van Kempen et al., 2003). However, several 
caveats were soon arising. Firstly, the fact that embryonic stem cell cultures, although 
capable of providing a source of cardiomyocytes, yield on average to a low percentage 
(<20%). Secondly, beating areas display distinct contraction rates, suggesting that large 
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heterogeneity was observed from beating area to beating area, which might have gone 
unappreciated since most studies were done using RT-PCR methods. Thirdly, it was unclear 
if all cells within a beating area were equally differentiated. Sorting out these key questions 
is compulsory before any therapeutical strategy could be envisioned since a large number of 
cardiomyocytes is required, which will need to be morphologically homogeneous in order 
to avoid the chance of generating arrhythmias, and sufficiently and adequately 
differentiated in order to limit the oncogenic propagation of undifferentiated or poorly 
differentiated embryonic stem cells.  
 
 
Fig. 2. Schematic representation of the signaling pathways involved in embryonic stem 
cell–derived cardiogenesis.  Pluripotency makers such as Nanog, Oct4, Klf4 and Sox2 are 
expressed in undifferentiated embryonic stem cells. As soon as differentiation is initiated, 
these makers are down-regulated and mesoderm specification genes such as Mesp1 are 
expressed. Soon thereafter, as the beating areas are conformed, core cardiac transcriptional 
regulatory genes are up-regulated, and progressively the nascent cardiomyocytes acquire 
sacormeric and ion channel proteins, as depicted in Table 2.   
First approaches to increase the efficiency of converting embryonic stem cells into 
cardiomycytes has been obtained by mimicking the inductive signals that naturally convert 
precardiogenic mesodermal cells into nascent cardioblasts (Hidai et al., 2003; Holtzinger et 
al., 2010). Bin et al. (2006) demonstrates that Bmp2 treatment of mouse embryonic stem cells 
increased the efficiency of obtaining beating areas, providing evidences that core 
transcriptional factor Nkx2.5 and structural proteins such as troponin-T and alpha-MHC 
were increased. Further evidences on the pivotal role of Bmp signaling in embryonic stem 
cell-derived cardiomyogenesis were reported by Rajasingh et al. (2007). More recently, Kim 
et al. (2008) provides similar evidences using human embryonic stem cells. However, other 
authors have reported that Bmp2 overexpression can also lead to induction of other 
mesodermal lineages such as smooth muscle cells (Blin et al., 2010) or condroblasts,  
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Table 2. Graphical respresentation of the expression profiles of cardiac-enriched 
transcription factors, sarcomeric proteins, ion channels and gap junctional proteins during 
embryonic stem cell differentiation. ESC, embryonic stm cells, EB, embryoid bodies, BA2, 
beating areas at 2 days of culture, BA7, beating areas at 7 days of culture, EB14, beating 
areas at 14 days of cultures. 
osteoblasts and adipoblasts, if cultures with supplementary co-factors (zur Nieden et al., 
2005). Thus, these data suggest that combinatorial treatments might even further enhance 
embryonic stem cell-derived cardiomyogenesis. In this context, Evseenko et al. (2010) has 
elegantly evaluated the initial stages of mesoderm commitment during human embryonic 
stem cell differentiation, demonstrating the presence of endogenous cardiogenic 
morphogens such as activin A, Bmp4, Vegf and Fgf2. Laflamme et al. (2007) demonstrate 
that Bmp4 treatment increased in vitro cardiomyogenesis using human embryonic stem cells 
and Paige et al. (2010) has elegantly shown a balanced interplay between activin A/Bmp4 
and Wnt/-catenin is needed to efficiently induce mesodermal lineage formation and 
subsequent cardiomyocyte development in human embryonic stem cells. Similar findings 
are also observed using mouse embryonic stem cells (Taha et al., 2006, 2007; Taha & 
Valojerdi, 2008; Takei et al., 2009; Verma & Lenka, 2010). In addition to the role of Bmp 
signaling, several studies have reported the pivotal role of Fgf signaling controlling mouse 
embryonic stem cell-derived cardiomyogenesis (Dell´Era et al., 2003; Ronca et al. 2009). 
Importantly, Fgf signaling, in conjunction with Bmp signaling enhances cardiomyocyte 
formation of other stem cell sources, such as bone marrow stem cells (Degeorge et al., 2008) 
or P19 carcinoma cell line (Hidai et al., 2003), reinforcing the notion that Fgf signaling is 
necessary (embryonic stem cells) and sufficient (other sources) to induce cardiomyocyte 
development. Curiously, novel signaling pathways, such as Sdf-1/Cxcr4 (Chiriac et al., 
2010) and Vegf (Chen et al., 2006) also play a determinant role in cardiogenesis, although 
their links to Bmp, Fgf and Wnt signaling remains unexplored.  
Understanding of the embryonic stem cell-derived cardiomyogenesis has also been largely 
unraveled by manipulation of several cardiac enriched transcription factors. Gata4 and 
Gata6 deficient mice suggested a pivotal role of this transcription factor in early 
cardiogenesis (Kuo et al., 1997; Xin et al., 2006). Gata4 deficient embryonic stem cells have 
been reported to disrupt visceral endoderm formation and thus hematopoiesis (Soudais et 
al., 1995; Bielinska et al., 1996, 1997; Morrisey et al., 2000; Pierre et al., 2009). Similar findings 
are also observed in Gata6 deficient embryonic stem cells (Pierre et al., 2009). Importantly, 
cardiomyogenesis is not affected in Gata4 deficient embryonic stem cells (Narita et al., 1997) 
but over-expression of Gata4 in embryonic stem cells enhances cardiogenesis (Grepin et al., 
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2005). Thus, these data suggest that combinatorial treatments might even further enhance 
embryonic stem cell-derived cardiomyogenesis. In this context, Evseenko et al. (2010) has 
elegantly evaluated the initial stages of mesoderm commitment during human embryonic 
stem cell differentiation, demonstrating the presence of endogenous cardiogenic 
morphogens such as activin A, Bmp4, Vegf and Fgf2. Laflamme et al. (2007) demonstrate 
that Bmp4 treatment increased in vitro cardiomyogenesis using human embryonic stem cells 
and Paige et al. (2010) has elegantly shown a balanced interplay between activin A/Bmp4 
and Wnt/-catenin is needed to efficiently induce mesodermal lineage formation and 
subsequent cardiomyocyte development in human embryonic stem cells. Similar findings 
are also observed using mouse embryonic stem cells (Taha et al., 2006, 2007; Taha & 
Valojerdi, 2008; Takei et al., 2009; Verma & Lenka, 2010). In addition to the role of Bmp 
signaling, several studies have reported the pivotal role of Fgf signaling controlling mouse 
embryonic stem cell-derived cardiomyogenesis (Dell´Era et al., 2003; Ronca et al. 2009). 
Importantly, Fgf signaling, in conjunction with Bmp signaling enhances cardiomyocyte 
formation of other stem cell sources, such as bone marrow stem cells (Degeorge et al., 2008) 
or P19 carcinoma cell line (Hidai et al., 2003), reinforcing the notion that Fgf signaling is 
necessary (embryonic stem cells) and sufficient (other sources) to induce cardiomyocyte 
development. Curiously, novel signaling pathways, such as Sdf-1/Cxcr4 (Chiriac et al., 
2010) and Vegf (Chen et al., 2006) also play a determinant role in cardiogenesis, although 
their links to Bmp, Fgf and Wnt signaling remains unexplored.  
Understanding of the embryonic stem cell-derived cardiomyogenesis has also been largely 
unraveled by manipulation of several cardiac enriched transcription factors. Gata4 and 
Gata6 deficient mice suggested a pivotal role of this transcription factor in early 
cardiogenesis (Kuo et al., 1997; Xin et al., 2006). Gata4 deficient embryonic stem cells have 
been reported to disrupt visceral endoderm formation and thus hematopoiesis (Soudais et 
al., 1995; Bielinska et al., 1996, 1997; Morrisey et al., 2000; Pierre et al., 2009). Similar findings 
are also observed in Gata6 deficient embryonic stem cells (Pierre et al., 2009). Importantly, 
cardiomyogenesis is not affected in Gata4 deficient embryonic stem cells (Narita et al., 1997) 
but over-expression of Gata4 in embryonic stem cells enhances cardiogenesis (Grepin et al., 
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1997) and visceral endoderm (Holtzinger et al. 2009) suggesting that Gata4 is not necessary 
but is sufficient to induce cardiomyocyte differentiation.  Nkx2.5 deficient mice display 
cardiac embryonic lethality (Lyons et al., 1995), supporting a pivotal role for Nkx2.5 in 
cardiomyogenesis. In this context, over-expression of Nkx2.5 in embryonic stem cells 
increases the expression of cardiogenic markers at the expenses of hematopoietic markers 
such as Gata-1 (Caprioli et al., 2011). Similarly, enhanced expression of Mef2c in embryonic 
stem cells increases cardiomyogenic differentiation (Puceat et al., 2003), in line with its 
determinant role during heart development as demonstrated by genetic deletion in mice 
(Lin et al., 1997). Comparable over-expression approaches in embryonic stem cells have been 
described for the homeobox transcription factor Pitx2, a left-right signaling pathway 
determinant (Campione et al., 1999, 2002). Enhanced expression of Pitx2 leads to increased 
expression of cardiac markers (Lozano-Velasco et al., 2011) supporting a role of this 
transcription factor in cardiogenesis. In addition, overexpression of Tbx5, a pivotal 
transcription factor associated with Holt-Oram syndrome (Li et al., 1997), in P19 embryonic 
carcinoma cells (Fijnvandraat et al., 2003abc) display similar findings.  Overall, these studies 
illustrate the pivotal role of distinct transcription factors with reported enhanced expression 
during cardiogenesis, as well as it also provides the entry to previously unknown 
transcription factors as key elements for cardiomyogenic lineage differentiation, as it is the 
case for the transcription factors hhLIM (Zheng et al., 2006) and Rb (Papadimou et al., 2005) 
or the GTPase Rac1 (Puceat et al., 2003).  
Importantly, although these reports provided evidence of enhancing cardiomyocte 
formation by the usage of discrete growth factors and/or transcription factors, and 
subsequently identifying cardiac specific molecular markers such as Nkx2.5, Gata4 and 
sarcomeric proteins (i.e troponin T and alpha-actinin), it remains elusive if cardiomyocyte 
heterogeneity in terms of lineage origin (FHF, SHF), gene expression (atrial/ventricular/ 
nodal) or function (working/conductive) is observed. We have recently reported that mouse 
embryonic stem cell-derived cardiomyocytes display a dynamic temporal expression of FHF 
and SHF makers which are reminiscent of the in vivo cell lineage deployment (Lozano-
Velasco et al. 2011). In addition, large heterogeneity in gene expression, displaying distinct 
atrial-, ventricular- and nodal-like patterns (Fijnvandraat et al. 2002, 2003abc) and functional 
heterogeneity (van Kempen et al., 2003) displaying distinct cardiac action potential 
configurations, have been extensively reported. In this context, is it important to highlight 
that overexpression of Pitx2 mainly directs the expression of SHF cardiomyocytes, since 
both islet-1 and Mef2c were up-regulated, whereas FHF marker Nkx2.5 was unaltered 
(Lozano-Velasco et al., 2011).  Furthermore overexpression of Pitx2 enhances Tbx5 
expression and thus Nppa (Anf) and Gja5 (Cx40)(Lozano-Velasco et al., 2011), in line with 
previous Tbx5 over-expression findings (Fijnvandraaf et al., 2003). Thus, it is plausible that 
enhance cardiomyocyte commitment by distinct inductive signals might generate cellular 
heterogeneity in a similar fashion as in the developing heart. If so, these observations might 
hindrance their therapeutical usage since,  for example, engrafting nodal-like cells in the 
ventricular chambers might lead to ectopic electrical foci and thus to arrhythmias.  In this 
context, searching for transcriptional factor cocktail which might homogenize the 
cardiomyocyte outcome is a plausible strategy, as recently reported to convert induced 
pluripotent fibroblasts into cardiomyocytes (Ieda et al. 2010) or hepatocytes (Huang et al., 
2011).  
Differentiation of embryonic stem cells into beating cardiomyocytes can therefore be naively 
observed by simply developing embryoid bodies or enhanced by supplementing these 
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embryonic stem cells and/or embryoid bodies with a subset of growth factors and/or 
transcription factors. Table 2 summarizes the current state of the art knowledge about the 
dynamic expression of distinct transcription factors, sarcommeric proteins, ion channels and 
gap junctions during embryonic stem cell-derived cardiomyogenesis. However, the question 
arising is: are all beating areas differentiated into cardiomyocytes or are there remaining 
non-differentiated embryonic stem cells or contaminating cells that might differentiate into 
other embryonic lineages? This is a crucial question if we aim to use them in vivo. We have 
recently reported that fine-dissection of beating areas have minor contamination of 
endodermal- or ectodermal cells (Lozano-Velasco et al., 2011) at distinct developmental 
stages. Thus, it seems that a rather homogeneously differentiated cluster of cells is normally 
achieved. It remains to be elucidated if undifferentiated embryonic stem cells remain in 
those areas. In vivo approaches suggest that indeed this might be the case, yet titering the 
number of engrafted cells results in absence of teratomas at the long run (Behfar et al., 2005, 
2007; Yamada et al. 2009).  
5. Conclusions and perspectives 
Over the last decade we have started to understand the molecular mechanisms that govern 
cardiac formation and we are translating these findings to the manipulation of embryonic stem 
cells opening promising avenues to enhance cardiomyocyte differentiation. We have learnt 
how to increase the number of cardiomyocyte produced, and we have learnt that embryonic 
development is faithfully recapitulated in vitro, including the onset of first and second heart 
field transcriptional programs. Manipulation of these transcriptional machinaries will be 
therefore the upcoming challenges for the next years to come in order to facilitate the 
generation of fully differentiated, structurally similar and functionally homogeneous 
cardiomyocytes. Searching for transcription factor cocktails or opening new strategies such as 
those emerging from the microRNA world (Ivey et al. 2008; Chinchilla et al., 2011) constitutes 
the next goals, as recently illustrated for miR-499 (Wilson et al., 2010). Thus, in summary, an 
important part of the route has been walked, and the way ahead seems promising with the 
reward of achieving therapeutically usable embryonic stem cell-derived cardiomyocytes. 
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Heart disease is one of the leading causes of mortality worldwide. Because adult 
cardiomyocytes (CMs) lack the ability to regenerate, malfunctions or significant loss of CMs 
due to disease or aging can lead to cardiac arrhythmias, heart failure, and subsequently 
death. Heart transplantation for patients with end stage heat failure is limited by the 
number of donor organs available. Cell-based therapies offer a promising alternative for 
myocardial repair, but there are significant challenges involved. The transplantation of 
human CMs, eg fetal CMs, is difficult for practical and ethical reasons, thus cells of non-
cardiac lineage, such as skeletal myoblasts (Murry et al., 1996; Menasche et al., 2003) and 
mesenchymal stem cells (Shake et al., 2002; Toma et al., 2002), have been considered as 
alternatives. Animal studies and clinical trials involving these cells have yielded conflicting 
results. Transplanted non-cardiac cells such as bone marrow-derived hematopoietic cells do 
not transdifferentiate into the cardiac lineage (Balsam et al., 2004; Murry et al., 2004). They 
also do not integrate into the host myocardium. For instance, the lack of electrical 
integration of skeletal myoblasts after their autologous transplantation into the myocardium 
resulted in the generation of malignant ventricular arrhythmias, which led to the premature 
termination of clinical trials involving skeletal myoblasts (Menasche et al., 2003; Smits et al., 
2003). Therefore, an alternative cell source is needed. 
2. Human embryonic stem cells and induced pluripotent stem cells 
Human embryonic stem cells (hESCs), isolated from the inner cell mass of blastocysts, can 
self-renew while maintaining their pluripotency to differentiate into all cell types (Thomson 
et al., 1998), including CMs (Kehat et al., 2001; Mummery, C. et al., 2002; Xu, C. et al., 2002; 
Xue et al., 2004; Mummery, C. et al., 2003). Therefore, hESCs may provide an unlimited ex 
vivo source of CMs for cell-based heart therapies. The laboratories of Yamanaka (Takahashi 
et al., 2007) and Thomson (Yu et al., 2007) showed that adult somatic cells can be 
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reprogrammed to become pluripotent hES-like cells (a.k.a. induced pluripotent stem cells or 
iPSCs) via the forced expression of four pluripotency genes (Oct4, Sox2, c-Myc, and Klf4 or 
Oct4, Sox2, Nanog, and Lin28) (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; 
Aasen et al., 2008). More recent studies have further demonstrated the successful use of less 
pluripotency factors (Huangfu et al., 2008; Kim, J. B. et al., 2008; Nakagawa et al., 2008) and 
non-viral methods (e.g., with synthetic modified RNA (Warren et al., 2010)) to reprogram 
somatic cells into iPSCs. Although concerns such as induced somatic coding mutations 
(Gore et al., 2011) have yet to be fully addressed, hiPSCs have morphology, gene expression 
profile, epigenetic status, in vitro and in vivo differentiation capacities similar to hESCs 
(Takahashi et al., 2007; Yu et al., 2007).  
3. Differentiation of hESC into CMs 
Previous studies studies have demonstrated that hESCs and hiPSCs can spontaneously 
differentiate into CMs when they aggregate in suspension to form embryoid bodies (Xu, C. 
et al., 2002; Zwi et al., 2009). Recent studies have focused on improving the yield and purity 
of CM differentiation. For instance, hESC differentiation into the CM lineage can be 
enhanced by coculture with visceral endoderm-like cells (Mummery, C. et al., 2003; 
Mummery, C. L. et al., 2007). Recently, an effective protocol for cardiac differentiation has 
been successfully developed by the Keller laboratory involving the stage-specific addition of 
growth factors, including BMP4, Activin-A, DKK, bFGF etc, to drive sequential 
differentiation into the epiblast, mesoderm and CMs, resulting in greatly increased yield of 
up to 50%, as gauged by the proportion of cells that express cardiac troponin T (Yang et al., 
2008). Other approaches have also been pursued, utilizing different extracellular matrices, 
serum (Passier et al., 2005) and insulin elimination (Xu, X. Q. et al., 2008). Besides improving 
the yield of CM differentiation, the isolation of a pure population of CMs is also important 
in order to prevent malignancy and arrhythmias. Various purification methods have been 
developed including Percoll gradient centrifugation (Xu, C. et al., 2002), optical signatures 
(Chan, J. W. et al., 2009) and genetic selection based on the expression of a reporter protein 
under the transcriptional control of a cardiac-restricted promoter (e.g., -myosin heavy 
chain (-MHC) (Anderson et al., 2007), ventricular myosin light chain (MLC-2v) (Huber et 
al., 2007; Fu et al., 2010)). 
4. Properties of hESC-derived CMs (hESC-CMs) 
4.1 Human ESC-CMs have molecular and structural properties of CMs 
Gene expression profiles have been examined for hESC-CMs cultured in different 
laboratories using different differentiation protocols and from different hESC lines (Kehat et 
al., 2001; Xu, C. et al., 2002; Snir et al., 2003; Norstrom et al., 2006). There is now consensus 
that hESC-CMs express transcription factors and structural proteins specific to human 
cardiomyocytes (Kehat et al., 2001; Xu, C. et al., 2002; Snir et al., 2003; Norstrom et al., 2006). 
Human ESC-CMs express cardiac-specific transcription factors such as NKx2.5, GATA4 and 
Mef-2 (Kehat et al., 2001; Xu, C. et al., 2002), which are expressed in the precardiac 
mesoderm but persist in the heart during development. Structural components of the 
myofibers can also be detected in hESC-CMs. These include , - and sarcomeric-myosin 
heavy chain (MHC), atrial and ventricular forms of myosin light chain (MLC-2a and –2v), 
tropomyosin, -actinin and desmin (Kehat et al., 2001; Xu, C. et al., 2002; Norstrom et al., 
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2006). Two members of the troponin complex, cardiac tropinin T, which binds to 
tropomyosin, and cardiac tropinin I, which regulates Ca2+-sensitive muscle contraction, are 
also present in hESC-CMs (Kehat et al., 2001; Xu, C. et al., 2002; Norstrom et al., 2006). At the 
ultrastructural level, hESC-CMs show clearly identifiable sarcomeres and intercalated discs 
(Kehat et al., 2001; Snir et al., 2003). Morphologically, single hESC-CMs show spindle, 
round, and tri- or multiangular morphologies, rather than the more defined rod shape of 
mature cells (Xu, C. et al., 2002). Sarcomeric striations are organized in separated bundles, 
reminiscent of the pattern seen in human fetal CMs, and rather than the highly organized 
parallel bundles seen in human adult CMs (Mummery, C. et al., 2003). These data suggest 
that hESC-CMs display molecular and structural properties consistent with immature 
human CMs.  
4.2 Human ESC-CMs have immature Ca2+ handling properties 
4.2.1 Mechanism of Ca2+-induced Ca2+-release and Ca2+ transient 
The contractile apparatus of CMs is dependent on the rise and decay of intracellular Ca2+, 
known as the Ca2+ transient. During an action potential (AP) of adult CMs, Ca2+ entry into 
the cytosol through sarcolemmal L-type Ca2+ channels triggers the release of Ca2+ from the 
intracellular Ca2+ stores (sarcoplasmic reticulum or SR) via the ryanodine receptors (RyR). 
This process, the so-called Ca2+-induced Ca2+-release (Bers, 2002), escalates the cytosolic Ca2+ 
([Ca2+]i) to activate the contractile apparatus for contraction. For relaxation, elevated [Ca2+]i 
gets pumped back into the SR by the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 
and extruded by the Na+-Ca2+ exchanger (NCX) to return to the resting [Ca2+]i level. Such a 
rise and subsequent decay of [Ca2+]i is known as Ca2+ transient. Given the central 
importance of Ca2+-induced Ca2+-release in cardiac excitation-contraction coupling, proper 
Ca2+ handling properties of hESC-CMs are crucial for their successful functional integration 
with the recipient heart after transplantation. Indeed, abnormal Ca2+ handling, as in the case 
of heart failure, can even be arrhythmogenic. 
4.2.2 Human ESC-CMs have functional SRs 
Dolnikov et al (2006) were the first to study the Ca2+-handling properties of hESC-CMs in 
detail (Dolnikov et al., 2006). They reported that Ca2+ transients recorded from spontaneously 
beating or electrically stimulated hESC-CMs respond to neither caffeine nor ryanodine; hESC-
CMs recorded as beating clusters also displayed a negative force-frequency relationship that is 
different from adult CMs. Based on these observations, the authors concluded that hESC-CMs 
are immature, do not express functional SRs, and that their contractions result from trans-
sarcolemmal Ca2+ influx (rather than Ca2+ release from the SR). Given the paucity of related 
data, our laboratory performed a comprehensive analysis to better define the Ca2+ handling 
properties of hESC-CMs by comparing Ca2+ transients from hESC-CMs and human fetal left 
ventricular (LV) CMs (16–18 weeks) (Figure 1, adopted with permission from Liu et al 2007 
Stem Cells Vol. 25, No. 12: pp.3038-3044). Upon electrical stimulation, all of hESC-CMs and 
fetal LV-CMs generated similar Ca2+ transients. However, caffeine induced Ca2+ release in 65% 
of fetal LVCMs and 38% of hESC-CMs. Ryanodine significantly reduced the electrically 
evoked Ca2+ transient amplitudes of caffeine-responsive but not -insensitive hESC-CMs and 
slowed their upstroke; thapsigargin, which inhibits SERCA, reduced the amplitude of only 
caffeine-responsive hESC-CMs and slowed the decay (Liu et al., 2007). The discrepancy 
between our findings and those of Dolnikov et al can be largely attributed to the newly 
identified caffeine-responsive population.  
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Fig. 1. Ca2+ handling properties of hESC-CMs 
A) Representative tracings caffeine-induced Ca2+ transients of hESC-CMs (HES2-, H1-CMs) 
and fetal (F) LV-CMs. B) % of caffeine-responsive and -insensitive cells. C) Expression of 
various Ca2+ handling proteins. -actin was used as the loading control. D) Immunostaining of 
RyRs. Adopted with permission from Liu et al 2007 Stem Cells Vol. 25, No. 12: pp.3038-3044.  
4.2.3 Differential expression of Ca2+ handling proteins 
While hESC-CMs express functional SRs, their Ca2+ handling properties are immature and 
are similar to those of fetal CMs. The functional immaturity of hESC-CMs may be attributed 
to the expression pattern of Ca2+ handling proteins (Figure 1C) (summarized in Table 1, 
adopted with permission from Kong et al 2010 Thromb Haemost Vol. 104, No. 1: pp.30-38).  
Compared to adult CMs, hESC-CMs express significantly lower levels of RyR, SERCA, 
phospholamban, calsequestrin and higher levels of calreticulin and NCX (Liu et al., 2007). 
The regulatory proteins junctin, triadin, and calsequestrin (CSQ) are expressed in adult LV-
CMs but are completely absent in hESC-CMs (Liu et al., 2007).  
 


























 hESC-CMs Fetal LVCMs Adult LVCMs 
RyR ++ ++ ++++ 
SERCA +++ +++ ++++ 
Phospholamban - ++ ++++ 
CSQ/Triadin/Junctin - + ++++ 
Calreticulin ++++ ++++ + 















Basal [Ca2+]i ++ +++ ++++ 
Amplitude ++ ++ ++++ 
Decay ++ ++ ++++ 
Upstroke ++ ++ ++++ 
Table 1. Ca2+ handling properties of hESC-CMs, fetal and adult LVCMs. 
Adopted with permission from Kong et al 2010 Thromb Haemost Vol. 104, No. 1: pp.30-38. 
4.2.4 T-Tubules are absent in hESC-CMs 
Transverse (t) tubules are invaginations in the sarcolemmal membrane that concentrate 
dihydropyridine receptors and bring them spatially close to RyRs residing on the SR 
membrane located deeper in the cytoplasm (Brette and Orchard, 2003; Brette and Orchard, 
2007). By physically minimizing the diffusion distance, RyRs in CMs can participate in Ca2+-
induced Ca2+-release without a lag. The result is a synchronized, faster, and greater transient 
[Ca2+]i increase from the peripheries to the center, creating a uniform Ca2+ wavefront across 
the transverse section with simultaneous recruitment of all SR. Fast and synchronized 
activation of RyRs translates into a greater Ca2+ transient amplitude, recruitment of more 
actin–myosin cross-bridge cycling, and generation of greater contractile force. The presence 
of t-tubules is therefore crucial to the mature Ca2+ handling of CMs. Lieu et al used 
fluorescent staining (Figure 2A and C, adopted with permission from Lieu et al 2009 Stem 
Cells Dev Vol. 18, No. 10: pp.1493-1500) and atomic force microscopy (Figure 2B and D) to 
detect the presence of t-tubules and showed that the latter is absent in hESC-CMs. 
Consistent with CMs deficient of t-tubules, hESC-CMs also exhibit a U-shaped Ca2+ 
wavefront that is caused by a delayed Ca2+ increase in the central region of the cell relative 
to the peripheral region (Lieu et al., 2009) (Figure 2E). 
4.2.5 Attempts to improve Ca2+-handling properties by genetic modification 
We hypothesize that the differential expression of key CM proteins underpins the 
immaturity of hESC-CMs relative to adult CMs. We tested this idea by overexpressing CSQ 
in hESC-CMs. CSQ is the most abundant, high-capacity but low-affinity, Ca2+-binding 
protein in the SR that is anchored to the RyR. The cardiac isoform CSQ2 can store up to 20 
mM Ca2+ while buffering the free SR [Ca2+] at ~1 mM. This allows repetitive muscle 
contractions without rundown. While CSQ is robustly expressed in adult CMs, it is 
completely absent in hESC-CMs (Liu et al., 2007). We hypothesized that forced expression of 
CSQ in hESC-CMs would induce functional improvement of SR. We tested this hypothesis 
by transduction of hESC-CMs with the recombinant adenovirus Ad-CMV-CSQ-IRES-GFP 
(Ad-CSQ) and demonstrated that Ad-CSQ significantly increased the transient amplitude, 
upstroke velocity, and transient decay compared with the control and a truncated mutant 
(Liu et al., 2009) (Figure 3, adopted with permission from Liu et al 2009 Am J Physiol Cell  
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Fig. 2. T-tubule imaging of a hESC-CM and a mature ventricular CM.   
Confocal microscopic images of a hESC-CM (A) did not show intracellular fluorescent spots 
like those in an adult guinea pig ventricular CM (C) suggesting the absence of t-tubules.  
The absence of t-tubules in ESC-CMs was further confirmed by atomic force microscopy 
imaging of an adult ventricular cardiomyocyte (D) showing regularly spaced pores in the 
sarcolemma that coincide with the Z-lines, while hESC-CM (B surface showed 
comparatively smoother topology with no presence of invaginations that are indicative of t-
tubules. E) Electrically induced Ca2+ transient in hESC-CMs. Top: Time progression 
linescans of pseudo-colored transient increase in intracellular Ca2+ across the mid-plane of a 
hESC-CM showed a U-shaped wavefront.  Bottom: Quantified Ca2+ transient of linescans of 
the top panel. Adopted with permission from Lieu et al 2009 Stem Cells Dev Vol. 18, No. 10: 
pp.1493-1500. 
Physiol Vol. 297, No. 1: pp.C152-159). These results showed that immature Ca2+-handling 
properties of hESC-CMs can be rescued by genetic modification and improved our 
understanding of CM maturation. 
4.3 Human ESC-CMs demonstrate immature electrophysiological properties similar to 
‘embryonic’ CMs 
He et al (2003) were the first to study the electrophysiological properties of hESC-CMs (He 
et al., 2003). They characterized the contractions and action potentials (APs) from beating EB 
outgrowths cultured for 40 to 95 days and showed that hESC can differentiate into a 
heterogeneous mixture of CMs, with APs classified as ‘nodal-like’, ‘embryonic ventricular-
like’ and ‘embryonic atrial-like’, analogous to CM specification into pacemaker, ventricular 
and atrial CMs. The latter two classes are considered ‘embryonic’ based on their Maximum 
diastolic potential and more depolarized resting membrane potential, and “slow” type APs 
based on low dV/dtmax. Unlike adult CMs, which are normally electrically silent yet are 
excitable upon stimulation, the majority of hESC-CMs fire spontaneously, exhibiting a high 
degree of automaticity. Our laboratory examined triggered activity and found that 
‘embryonic ventricular-like’ CMs exhibit delayed after depolarization, suggesting that 
hESC-CMs can be arrhythmogenic.  
 




Fig. 3. Effect of CSQ overexpression on hESC-CMs.   
A) Representative electrically-induced Ca2+ transient tracings for Ad-GFP (n=12) and Ad-
CSQ (n=29) and Ad-CSQ (truncated mutant) (n=14) transduced hESC-CMs. B) Bar graphs 
of amplitude.* P < 0.05, ** P < 0.01. Adopted with permission from Liu et al 2009 Am J 
Physiol Cell Physiol Vol. 297, No. 1: pp.C152-159. 
Subsequent studies were done to assess if hESC-CMs mature over time to acquire 
electrophysiological properties that are comparable to those of adult CMs and results are 
conflicting. Sartiani et al (2007) examined the AP of CMs over 3 months of culture and 
concluded that the molecular and functional expression of ion channels in hESC-CMs 
change over time, although they still do not reach the phenotype typical of adult VCMs 
(Sartiani et al., 2007). This is in contrast to findings by Pekkanen-Mattila et al (2010), which 
show that although one third of hESC-CMs exhibit a more mature phenotype, these changes 
are not correlated with time in culture (Pekkanen-Mattila et al., 2010). Taken together, these 
data suggest that hESC-CMs are functionally immature and present an arrhythmogenic risk. 
Therefore, facilitated in vitro maturation is important for the translation of hESC-CMs to the 
clinic and other applications (such as disease modeling, drug discovery and cardiotoxicity 
screening).  
Our group sought to define the immature proarrhythmic electrophysiological properties 
observed in hESC-CMs by examining the role of different currents in automaticity (Azene et 
al., 2005; Siu et al., 2006; Xue et al., 2007; Lieu et al., 2008; Chan, Y. C. et al., 2009). IK1 (the 
inward-rectifier K+ current encoded by Kir2.1), which stabilises a negative resting 
membrane potential, is important for suppressing automaticity and we hypothesize that its 
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Fig. 3. Effect of CSQ overexpression on hESC-CMs.   
A) Representative electrically-induced Ca2+ transient tracings for Ad-GFP (n=12) and Ad-
CSQ (n=29) and Ad-CSQ (truncated mutant) (n=14) transduced hESC-CMs. B) Bar graphs 
of amplitude.* P < 0.05, ** P < 0.01. Adopted with permission from Liu et al 2009 Am J 
Physiol Cell Physiol Vol. 297, No. 1: pp.C152-159. 
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data suggest that hESC-CMs are functionally immature and present an arrhythmogenic risk. 
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absence in hESC-CMs may underlie their immature phenotype. Consistent with this, forced 
Kir2.1 expression alone sufficed to render the electrical phenotype indistinguishable from 
that of primary adult ventricular cells (Lieu DK, Fu JD and Li RA, unpublished data). These 
proof-of-concept experiments show that developmentally arrested Ca2+ and 
electrophysiological phenotypes of hESC-CMs can be rescued. We are currently developing 
a non-genetic, non-pharmacologic method to drive global maturation, by targeting the 
microenvironmental niches and other non-cell autonomous means. 
5. The use of hESC-CMs for myocardial repair and bioartificial pacemakers 
Myocardial infarction is the major worldwide cardiovascular disorder in humans and is the 
leading cause of death in many parts of the world. Immediately after a heart attack, oxygen 
starvation of myocardial tissues leads to cell death, often resulting in irreversible and 
permanent damage to the heart. Despite some improvements in short term management of 
acute myocardial infarction, long term prognosis remains poor. Sudden cardiac death due to 
ventricular arrhythmias remains a leading cause of morbidity and mortality in the 
industrialised world, claiming well over 300,000 lives annually in the United States alone. 
After myocardial infarction, the heart undergoes hypertrophy in an attempt to compensate 
for loss of CMs, and cardiac fibroblasts secrete collagen and other extracellular matrix 
proteins during scar formation, leading to impaired cardiac function. Since terminally 
differentiated CMs have very limited potential for regeneration, transplantation is the only 
treatment for end-stage heart failure. However, this is hampered by the lack of suitable 
donor organs and tissues. Cell-based therapy is thus a promising option for myocardial 
repair. A range of cell sources have been considered, including bone marrow cells, skeletal 
myoblasts and smooth muscle cells, but their non-cardiac identity has presented major 
problems. They either do not differentiate into the cardiac lineage or they do not integrate 
well into the host myocardium (Menasche et al., 2003; Smits et al., 2003; Balsam et al., 2004; 
Murry et al., 2004). As discussed in previous sections, hESC-CMs have functional and 
structural properties very similar to human embryonic/fetal CMs and is therefore a very 
promising cell source. Transplantation of hESC-CMs to mouse/rat hearts showed that the 
cells survived, formed myocardial tissue and promoted functional improvement in rat 
models of myocardial infarction (Laflamme et al., 2007; Mignone et al., 2010). More detailed 
studies into the maturation of hESC-CMs, as well as the electropysiological consequences of 
hESC-CM transplantation are required before these early successes can be translated into 
clinical therapies. 
Normal rhythms originate in the SA node (SAN), a specialized cardiac tissue consisting of 
only a few thousands pacemaker cells. Malfunction of cardiac pacemaker cells due to 
disease or aging can cause rhythm generation disorders. Current treatments include 
pharmacological intervention and/or implantation of electronic pacemakers, but they are 
associated with significant shortcomings (e.g. increased susceptibility to infection, 
haemorrhage, lung collapse and death infection, finite battery life, patient discomfort related 
to the permanent implantation of a foreign device, and lack of intrinsic responsiveness to 
neural and hormonal regulation). Therefore ‘bioartificial-pacemakers’, made up of 
transplanted cells with pacemaker properties, may be a desirable alternative. 
There are two major strategies for creating bioartificial-pacemakers. The first is to confer 
pacemaker ability on cells that are normally silent. For instance, adult atrial and ventricular 
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CMs are electrically silent unless they are stimulated by signals transmitted from the SAN. 
This is due to the absence of If, encoded by the HCN channel family, and the presence of IK1. 
Several gene-based approaches have been pursued to induce pacemaker activity in these 
normally silent cells. Our group took a protein engineering approach to define criteria 
important for pacing and created a bioengineered construct of HCN (Lesso and Li, 2003; 
Tsang et al., 2004; Tsang et al., 2004; Tse et al., 2006; Xue et al., 2007). This engineered-
construct was shown to produce pacing in vitro and in vivo (Tse et al., 2006; Xue et al., 2007). 
In a sick sinus syndrome porcine model, pacing of the heart was restored and originated 
from the site of focal transduction in the left atrium with HCN-construct injection (Tse et al., 
2006). Somatic gene transfer to create such a gene-based bioartificial pacemaker significantly 
reduces the dependence on device-supported pacing by electronic pacemaker from 85% to 
15%. Alternatively, hESCs can be differentiated into pacemaker-like derivatives for 
transplantation to recreate a cell-based bioartificial pacemaker (Kehat et al., 2004; Xue et al., 
2005). Of note, the construction of cell-based bioartificial-pacemakers requires much fewer 
cells (several thousands) than myocardial transplantation (hundreds of millions). 
Furthermore, the spherical SAN is structurally less complex than the left ventricular 
myocardium. Our group is currently exploring the possibility of using nodal progenitors. 
We are also testing non-invasive catheter-based delivery techniques for implantation as well 
as long-term safety and efficacy. 
6. Creation of engineered cardiac tissue constructs  
The ventricular myocardium is a highly complex structure consisting of aligned, connected 
CMs, stromal cells and a vascular network systematically embedded in a mesh of 
extracellular matrix. Indeed, hESC-CMs differentiated in vitro lack the sub-cellular 
organization and higher order structural 2- or 3-dimensionality seen in adult heart. To more 
closely recapitulate the in vivo environment of the heart, various groups have used different 
approaches to manipulate the surface and geometry of the culture platform, cell and matrix 
composition. For instance, Luna et al used a tunable culture platform comprised of 
biomimetic wrinkles to simulate the heart’s complex anisotropic and multiscale architecture 
and showed that the hESC-CMs cultured on these ‘microgrooved’ substrates display the 
typical tropomyosin banding pattern consistent with organized sarcomeric structure 
patterns (Luna et al., 2011) (Figure 4, adopted with permission from Luna et al 2011 Tissue 
Eng Part C Methods Vol. 17, No. 5: pp.579-588). Quantitative assessment based on nuclei 
shape and actin organization show that the hESC-CMs exhibit increased alignment on 
microgrooved substrates compared with controls. Functionally, aligned monolayers of 
hESC-CMs display anisotropic conduction properties with distinct longitudinal and 
transverse velocities, a signature characteristic of the native heart, not seen in control 
randomly organized monolayers (Lieu, Wang, Khine and Li, unpublished data). In another 
approach to mimic the structure of the heart, the Costa lab was among the first to construct 
3-D engineered cardiac tissue constructs including cardiac papillary-like muscle strips as 
well as ventricle-like “organoid” chambers that exhibit key characteristics of cardiac 
physiology by ejecting fluid and displaying force-frequency and pressure-volume 
relationships (Kim, Do Eun et al., 2006; Lee et al., 2008). These studies were originally 
performed using rat cardiac myocytes but are now being applied to hESC/iPSC-CMs. 
Further optimization of hESC/iPSC-based cardiac tissue constructs will not only provide 
powerful tools for disease modeling, drug/cardiotoxicity screening and clinical translations, 
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organization and higher order structural 2- or 3-dimensionality seen in adult heart. To more 
closely recapitulate the in vivo environment of the heart, various groups have used different 
approaches to manipulate the surface and geometry of the culture platform, cell and matrix 
composition. For instance, Luna et al used a tunable culture platform comprised of 
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but physiologic 3D environment also promises to reveal novel insights not possible with 
conventional rigid 2D culture systems.  
 
 
Fig. 4. Confocal micrographs of hESC-derived CMs alignment on wrinkles.  
Human ESC-CMs were isolated and cultured on flat substrate (A) and wrinkle substrates  
(B) for 8 days. Green indicates tropomyosin staining, blue nuclear staining DAPI.  
C) Image processing was used to detect the orientation of the DAPI-labeled nuclei. D) 
Anisotropy analysis of control (black) versus green (on wrinkles) showing that 90° is 
direction of wrinkles. The thinner lines indicate the standard deviations. Adopted with 
permission from Luna et al 2011 Tissue Eng Part C Methods Vol. 17, No. 5: pp.579-588. 
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7. Pharmacological testing using hESC-CMs 
Adverse cardiac side effects is one of the most frequent reasons that cause drugs to be 
removed from the market. For instance, Vioxx, a once widely used COX-2 inhibitor 
prescribed to patients with arthritis and other conditions causing acute and chronic pain,  
was withdrawn from the market due to unexpected cardiotoxicity. Therefore, cardiotoxicity 
screening is necessary to test the efficacy and safety of new drug treatments. Cardiotoxicity 
arises from various mechanisms, including the modulation of signaling pathways and/or 
interference with the IKr current. The hERG channel, which produces the IKr current, is 
robustly blocked by a large class of drugs. This current has a major role in cardiac 
repolarization, so it affects the length of the action potential and the QT interval (the 
duration of ventricular depolarization and subsequent repolarization). QT prolongation 
may lead to arrhythmias, e.g. torsade de pointes, with potentially lethal consequences. Since 
adult CMs do not proliferate, animal CMs, isolated hearts or non-cardiac cells, which 
express cardiac ion channels are used although their non-human origin and instability in 
culture greatly limit their usefulness. Human ESC and hiPSC may provide an unlimited cell 
source for cardiotoxicity screening. Preliminary studies have already established that hESC-
CMs/hiPSC-CMs do express the hERG mRNA (Sartiani et al., 2007; Tanaka et al., 2009), and 
display an outward ‘IKr-like’ current that is sensitive to selective blockers of IKr and 
canonical long QT-inducing inhibitors including E4031, sotalol, and cisapride (Sartiani et al., 
2007; Caspi et al., 2009). When treated with a range of cardiac and non-cardiac drugs, hESC-
CM also exhibit dose responses predictive of clinical effects (Braam et al., 2010). These 
suggest that hESC-CMs may be a suitable model for cardiotoxicity testing, although issues 
of CM purity and maturation should be considered in the design of future experiments, as 
already discussed elsewhere. It is hoped that high-throughput pharmacological systems 
involving hESC/hiPSC-CMs will soon be developed.  
8. Human ESC-CMs/hiPSC-CMs as models of cardiovascular diseases 
The use of hESC-/hiPSC-CMs as models of cardiac disorders is an exciting area of research. 
Previously, transgenic mouse models were used to study human cardiac diseases, but these 
mouse models do not always fully recapitulate the same phenotypes as those seen in 
humans. For instance, electrophysiologically, mice also have shorter action potential 
duration and higher heart rate compared to humans (Danik et al., 2002), limiting their 
usefulness as models of some disorders such as arrhythmias. Human pluripotent stem cell 
derived CMs are therefore logical suitable alternative. Reprogramming technology 
pioneered by Yamanaka and Thomson has led to the creation of disease- or patient-specific 
iPSCs. The derivation of hiPSC from patients with a range of diseases including adenosine 
deaminase deficiency-related severe combined immunodeficiency, Shwachman-Bodian-
Diamond syndrome, Gaucher disease type III, Duchenne and Becker muscular dystrophy, 
Parkinson disease, Huntington disease, juvenile-onset, type 1 diabetes mellitus, Down 
Syndrome/trisomy 21, and the carrier state of Lesch-Nyhan syndrome has been reported 
(Park et al., 2008). More recently, Ebert et al (2009) reported the generation of hiPSC line 
from a patient of spinal muscular atrophy and these cells maintained the disease genotype 
and generated motor neurons that showed selective deficits compared to those derived from 
the patient’s unaffected mother (Ebert et al., 2009). Some advances have also been made in 
the area of cardiovascular research. For instance, hiPSC models of long-QT syndrome type 1 
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humans. For instance, electrophysiologically, mice also have shorter action potential 
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Syndrome/trisomy 21, and the carrier state of Lesch-Nyhan syndrome has been reported 
(Park et al., 2008). More recently, Ebert et al (2009) reported the generation of hiPSC line 
from a patient of spinal muscular atrophy and these cells maintained the disease genotype 
and generated motor neurons that showed selective deficits compared to those derived from 
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and type 2 were generated (Moretti et al., 2010; Itzhaki et al., 2011). CMs differentiated from 
these hiPSC recapitulated the electrophysiological features of the disorders such as 
prolongation of AP and arrhythmogenicity and enabled the groups to study the 
pathogenesis of the diseases. Itzhaki et al (2011) also used the hiPSC-CMs to evaluate the 
potency of existing and novel pharmacological agents that may either aggravate or 
ameliorate the long-QT syndrome type 2 disease phenotype. These studies illustrate the 
potential of human iPSC technology to model the abnormal functional phenotype of 
inherited cardiac disorders and to identify potential new therapeutic agents.  
9. Conclusion 
Adult CMs lack the potential to regenerate. Human ESC and hiPSCs, with their potential for 
unlimited self-renewal and differentiation, offer an exciting means of generating human 
CMs for research and regenerative medicine. Concentrated effort by research groups 
worldwide has resulted in higher efficiency of cardiogenic differentiation and better 
characterization of hESC-/hiPSC-CMs. Experiments using animal models have 
demonstrated functional improvement after hESC-CM transplantation. However, 
substantial hurdles have to be overcome before hESC-/hiPSC-CMs can be translated into 
clinical applications. For instance, hESC-CMs are functionally immature, limiting their use 
for transplantation and as disease models. More studies are required to evaluate the long 
term effect of hESC-/hiPSC-CMs transplantation. Nonetheless, there is much reason to 
believe that hESC and hiPSC technology will bring significant benefit to cardiac research 
and treatment.  
10. References 
Aasen, T., A. Raya, et al., (2008). Efficient and rapid generation of induced pluripotent stem 
cells from human keratinocytes. Nat Biotechnol Vol. 26, No. 11: pp.1276-1284. 
Anderson, D., T. Self, et al., (2007). Transgenic enrichment of cardiomyocytes from human 
embryonic stem cells. Mol Ther Vol. 15, No. 11: pp.2027-2036. 
Azene, E. M., T. Xue, et al., (2005). Non-equilibrium behavior of HCN channels: insights into 
the role of HCN channels in native and engineered pacemakers. Cardiovasc Res Vol. 
67, No. 2: pp.263-273. 
Balsam, L. B., A. J. Wagers, et al., (2004). Haematopoietic stem cells adopt mature 
haematopoietic fates in ischaemic myocardium. Nature Vol. 428, No. 6983: pp.668-
673. 
Bers, D. M., (2002). Cardiac excitation-contraction coupling. Nature Vol. 415, No. 6868: 
pp.198-205. 
Braam, S. R., L. Tertoolen, et al., (2010). Prediction of drug-induced cardiotoxicity using 
human embryonic stem cell-derived cardiomyocytes. Stem Cell Res Vol. 4, No. 2: 
pp.107-116. 
Brette, F. and C. Orchard, (2003). T-tubule function in mammalian cardiac myocytes. Circ 
Res Vol. 92, No. 11: pp.1182-1192. 
Brette, F. and C. Orchard, (2007). Resurgence of cardiac t-tubule research. Physiology 
(Bethesda) Vol. 22, No. 167-173. 
 
Human Pluripotent Stem Cells in Cardiovascular Research and Regenerative Medicine 
 
181 
Caspi, O., I. Itzhaki, et al., (2009). In vitro electrophysiological drug testing using human 
embryonic stem cell derived cardiomyocytes. Stem Cells Dev Vol. 18, No. 1: pp.161-
172. 
Chan, J. W., D. K. Lieu, et al., (2009). Label-free separation of human embryonic stem cells 
and their cardiac derivatives using Raman spectroscopy. Anal Chem Vol. 81, No. 4: 
pp.1324-1331. 
Chan, Y. C., C. W. Siu, et al., (2009). Synergistic effects of inward rectifier (I) and pacemaker 
(I) currents on the induction of bioengineered cardiac automaticity. J Cardiovasc 
Electrophysiol Vol. 20, No. 9: pp.1048-1054. 
Danik, S., C. Cabo, et al., (2002). Correlation of repolarization of ventricular monophasic 
action potential with ECG in the murine heart. Am J Physiol Heart Circ Physiol Vol. 
283, No. 1: pp.H372-381. 
Dolnikov, K., M. Shilkrut, et al., (2006). Functional properties of human embryonic stem cell-
derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic 
reticulum in the contraction. Stem Cells Vol. 24, No. 2: pp.236-245. 
Ebert, A. D., J. Yu, et al., (2009). Induced pluripotent stem cells from a spinal muscular 
atrophy patient. Nature Vol. 457, No. 7227: pp.277-280. 
Fu, J. D., P. Jiang, et al., (2010). Na+/Ca2+ exchanger is a determinant of excitation-
contraction coupling in human embryonic stem cell-derived ventricular 
cardiomyocytes. Stem Cells Dev Vol. 19, No. 6: pp.773-782. 
Gore, A., Z. Li, et al., (2011). Somatic coding mutations in human induced pluripotent stem 
cells. Nature Vol. 471, No. 7336: pp.63-67. 
He, J. Q., Y. Ma, et al., (2003). Human embryonic stem cells develop into multiple types of 
cardiac myocytes: action potential characterization. Circ Res Vol. 93, No. 1: pp.32-39. 
Huangfu, D., K. Osafune, et al., (2008). Induction of pluripotent stem cells from primary 
human fibroblasts with only Oct4 and Sox2. Nat Biotechnol Vol. 26, No. 11: pp.1269-
1275. 
Huber, I., I. Itzhaki, et al., (2007). Identification and selection of cardiomyocytes during 
human embryonic stem cell differentiation. FASEB J Vol. 21, No. 10: pp.2551-2563. 
Itzhaki, I., L. Maizels, et al., (2011). Modelling the long QT syndrome with induced 
pluripotent stem cells. Nature Vol. 471, No. 7337: pp.225-229. 
Kehat, I., D. Kenyagin-Karsenti, et al., (2001). Human embryonic stem cells can differentiate 
into myocytes with structural and functional properties of cardiomyocytes. J Clin 
Invest Vol. 108, No. 3: pp.407-414. 
Kehat, I., L. Khimovich, et al., (2004). Electromechanical integration of cardiomyocytes 
derived from human embryonic stem cells. Nat Biotechnol Vol. 22, No. 10: pp.1282-
1289. 
Kim, D. E., L. Eun Jung, et al. (2006). Engineered Cardiac Tissues for in vitro Assessment of 
Contractile Function and Repair Mechanisms,  Engineering in Medicine and Biology 
Society, 2006. EMBS '06. 28th Annual International Conference of the IEEE, 2006 
Kim, J. B., H. Zaehres, et al., (2008). Pluripotent stem cells induced from adult neural stem 
cells by reprogramming with two factors. Nature Vol. 454, No. 7204: pp.646-650. 
Kong, C. W., F. G. Akar, et al., (2010). Translational potential of human embryonic and 
induced pluripotent stem cells for myocardial repair: insights from experimental 
models. Thromb Haemost Vol. 104, No. 1: pp.30-38. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
180 
and type 2 were generated (Moretti et al., 2010; Itzhaki et al., 2011). CMs differentiated from 
these hiPSC recapitulated the electrophysiological features of the disorders such as 
prolongation of AP and arrhythmogenicity and enabled the groups to study the 
pathogenesis of the diseases. Itzhaki et al (2011) also used the hiPSC-CMs to evaluate the 
potency of existing and novel pharmacological agents that may either aggravate or 
ameliorate the long-QT syndrome type 2 disease phenotype. These studies illustrate the 
potential of human iPSC technology to model the abnormal functional phenotype of 
inherited cardiac disorders and to identify potential new therapeutic agents.  
9. Conclusion 
Adult CMs lack the potential to regenerate. Human ESC and hiPSCs, with their potential for 
unlimited self-renewal and differentiation, offer an exciting means of generating human 
CMs for research and regenerative medicine. Concentrated effort by research groups 
worldwide has resulted in higher efficiency of cardiogenic differentiation and better 
characterization of hESC-/hiPSC-CMs. Experiments using animal models have 
demonstrated functional improvement after hESC-CM transplantation. However, 
substantial hurdles have to be overcome before hESC-/hiPSC-CMs can be translated into 
clinical applications. For instance, hESC-CMs are functionally immature, limiting their use 
for transplantation and as disease models. More studies are required to evaluate the long 
term effect of hESC-/hiPSC-CMs transplantation. Nonetheless, there is much reason to 
believe that hESC and hiPSC technology will bring significant benefit to cardiac research 
and treatment.  
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1. Introduction 
Human pluripotent stem cells comprise embryonic and induced pluripotent stem cells. Both 
of these are able to give rise to all cell types of an individual, including heart muscle cells or 
cardiomyocytes. First stable human embryonic stem cell (hESC) lines were derived in 1998 
by James A. Thomson and his co-workers (Thomson et al., 1998). First cardiomyocytes 
derived from hESCs were made in 2001 by Kehat and co-workers (Kehat et al., 2001) and 
after that many research groups have derived and studied human pluripotent stem cell 
derived cardiac cells and their properties. In 2007 the first human induced pluripotent stem 
cells (hiPSCs) were produced by Shinya Yamanaka’s (Takahashi et al., 2007)  and James A. 
Thomson’s (Yu et al., 2007) groups from  dermal fibroblasts, and hiPSCs have  subsequently 
also been shown to be able to give rise to cardiomyocytes (Zhang et al., 2009, Zwi et al., 
2009). Pluripotent stem cell derived cardiac cells have a great potential for cardiotoxicity 
testing, for preclinical testing of new chemical entities for the pharmaceutical industry and 
hopefully in the future for cell therapy in myocardial infarction and heart failure. However, 
before these goals are achieved thorough characterization of the cardiomyocytes is needed 
to ensure their feasibility for these applications. 
2. Differentiation of cardiomyocytes from pluripotent stem cells 
Cardiomyocytes can be differentiated from pluripotent stem cells by multiple methods and 
the differentiation event is quite rapid, 10-20 days. However, all the differentiation methods 
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used also in production of other cell types such as neuronal cells, hematopoietic cells, 
adipocytes and chondrocytes (Pera & Trounson, 2004). For the whole existence of hESCs, EB 
differentiation has been widely used differentiation method for its relatively simple and 
inexpensive nature regardless the low differentiation rate. For example, if aiming at cardiac 
differentiation, under 10% of the EBs formed contain beating areas (Kehat et al., 2001). 
2.2 Differentiation with mouse visceral endoderm –like cells 
A little more directed way to differentiate cardiomyocytes from hESCs is in co-culture with 
mouse endodermal-like (END-2) cells (Figure 1B) (Mummery et al., 2003, Passier et al., 
2005). The differentiation inducing factors are secreted from END-2 cells and therefore 
END-2 conditioned medium can also be used in cardiomyocyte differentiation (Graichen et 
al., 2008). With END-2 methods, cardiogenic differentiation potential can be enhanced with 
serum-free medium supplemented with ascorbic acid (Passier et al., 2005) or adding 
cyclosporine A to the culture medium (Fujiwara et al., 2011). 
END-2 cells support the differentiation towards endodermal and mesodermal derivatives 
(Mummery et al., 2003, Passier et al., 2005, Beqqali et al., 2006). This is in accordance with 
embryonal development studies, which have shown that anterior visceral endoderm is 
essential in normal heart development (Lough & Sugi, 2000).  The specific mechanism or the 
specific factors inducing cardiac differentiation by END-2 cells are, however, not clearly 
known.  It has been suggested that removal of insulin by END-2 cells could have a role in 
this differentiation method. Insulin inhibits cardiac differentiation by suppressing 
endoderm and mesoderm formation and favouring ectoderm differentiation (Freund et al., 
2008) therefore the elimination of insulin from the medium by END-2 cells could favour the 
cardiac differentiation. Additionally, another more promising mechanism inducing cardiac 
differentiation by END-2 cells has been suggested to be prostaglandin I2 (PGI2) (Xu et al., 
2008). 
2.3 Cardiac differentiation with defined growth factors 
The combination of activin A and BMP-4  with matrigel has been used in differentiation 
protocols for cardiomyocytes (Figure 1C) (Laflamme et al., 2007). These factors enhance 
mesoendoderm formation, an early precursor cell lineage which gives rise to mesoderm and 
endoderm (Laflamme et al., 2007). Mesoderm is the origin of cardiac cells , but cardiac 
differentiation inducing signals are in large extent arising from endoderm (Lough & Sugi, 
2000). 
A stepwise differentiation protocol has also been developed by Gordon Keller's group (Yang et 
al., 2008, Kattman et al., 2011). This protocol involves induction of primitive streak-like 
population, in addition to formation of cardiac mesoderm and expansion of cardiac lineages. 
The protocol is based on EB differentiation and is comprised of three stages. Growth factors 
BMP-4, FGF, activin A, vascular endothelial growth factor (VEGF) and dickkoptf homolog 1 
(DKK1) were used in varying combinations. Mesoendoderm formation has also been induced 
by Wnt3A, an activator of the canonical Wnt/β-catenin signalling pathway (Tran et al., 2009). 
3. Characteristics of differentiated cardiomyocytes 
Cardiac differentiation can be followed by multiple markers at gene and protein expression 
levels. During early stages of differentiation mesoderm formation is detectable by the 
elevated mRNA level of Brachyury T. Brachyury T expression peak is detected at day 3 in 
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END-2 co-cultures (Beqqali et al., 2006, Pekkanen-Mattila et al., 2009) and a day later in EBs 
(Bettiol et al., 2007, Pekkanen-Mattila et al., 2010). The cardiac differentiation cascade can be 
 
 
Fig. 1. Differentiation methods for hESC derived cardiomyocytes (middle column) and 
characteristics of the differentiated cells (undermost column).  EB-differentiation can be 
performed in three ways, EBs can be formed either in hanging drops: enzymatically 
dissociated stem cells are pipetted in suspension into small drops on petri dish which is then 
inverted. EBs form in these drops and they can be plated down afterwards. EBs can be 
formed also in 96-well-plate wells, where single cell suspension is added and EB formation 
is forced by sentrifuging. Traditional was to EB formation is however the suspension method, 
where EBs form spontaneously in suspension from enzymatically dissociated hESCs. The 
picture A represents a 12-day old EB is attached to the bottom of cell culture dish. 
Differentiation with END-2-cells can be performed in two ways; hESC are plated onto END-2 
cell layer and differentiated as co-culture or hESC are differentiated as EBs in END-2 
conditioned medium. The picture B is taken from END-2 co-culture after one week of 
differentiation. Third way presented here is to culture hESCs on matrigel and initiate 
differentiation towrads cardiac lineage with growth factors, such as Activin-A and BMP-4. 
Differentiation is performed in a monolayer of cells (C). 
The first sign for differentiated cardiomyocytes is the formation of beating areas. hESC-CM 
have the ability to contract spontaneously and in addition to fire spontaneously action 
potentials (D). Differentiated cells are stained positively with troponin T (E) and connexin 45 
can be seen in the border areas of two troponin T positive cells (F). Electronmicroscopy (G) 
reveals sarcomere structures with Z-bands (marked with arrows) in the differentiated hESC-
CMs. 
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followed further by the expression of the cardiac regulatory transcription factors such as 
Islet-1 (ISL-1), Mesp 1, GATA-4, NKX2.5 and Tbx6 (Graichen et al., 2008, Yang et al., 2008).   
The first clear indication for emergence of cardiomyocytes is the formation of spontaneously 
beating aggregates or areas in the cell culture dish (Kehat et al., 2001, Mummery et al., 2003). 
The number of beating areas has been used in quantifying differentiation efficiency even 
though the beating areas contain varying numbers of cardiomyocytes (Passier et al., 2005, 
Pekkanen-Mattila et al., 2009, Pekkanen-Mattila et al., 2010). The amount of cardiomyocytes 
has also been quantitated using flow cytometry (Kattman et al., 2011).  Electron microscopy 
studies reveal that the differentiated cardiomyocytes contain myofibrils which are first 
organized randomly throughout the cytoplasm. However, organized sarcomeric structures 
occur at later stages of differentiation with A, I, and Z bands (Figure 1G). In the vicinity of 
the sarcomeres, mitochondria are also present. In addition, cells have intercalated disks with 
gap junctions and desmosomes  (Kehat et al., 2001, Snir et al., 2003, Pekkanen-Mattila et al., 
2009). Cardiac structural proteins such as troponin I, T or C (Figure 1 E), myosins and α-
actinin are also present in differentiated beating cells (Kehat et al., 2001, Mummery et al., 
2003). 
The beating function of heart muscle is the result of chain reactions between many ionic 
currents through cell membranes and sarcomeric proteins in the cytoplasm. Cardiomyocytes 
express ion channels and gap junction proteins on the cell membrane and these proteins are 
needed for transmission of electrical stimuli from cell to another (Figure 1 F) (He et al., 2003, 
Sartiani et al., 2007). Furthermore, there are intracellular channels such as ryanodine 
receptor 2 (RyR2) which are responsible for the calcium-induced calcium release (CICR) 
from the sarcoplasmic reticulum (Fabiato, 1983, Dolnikov et al., 2006, Satin et al., 2008). All 
these channels function in a cascade which results in synchronous contraction of the heart 
mediated by sarcoplasmic proteins.    
4. Cardiomyocytes during embryonic development and stem cell 
differentiation 
The development of the heart is composed of series of complicated differentiation events 
and morphogenetic changes (Buckingham et al., 2005). Additionally, electrical activities of 
cardiac cell change during development. For example, the average beating rate of human 
neonatal cardiomyocytes is ~140 beats per minute and in adult cardiomyocytes ~80 beats 
per minute (Huang et al., 2007).  The data of human cardiac embryology is, however, very 
restricted and, thus, most information is based on animal models. Microelectrode recordings 
from chick embryo revealed that the first contracting cardiomyocytes have pacemaker like 
action potentials. According to these measurements, the membrane diastolic potential in the 
first pacemaker like cells is in the range of -35 mV, action potential amplitude is relatively 
small and Ca2+ dependent action potential upstroke is slow (Sperelakis & Shigenobu, 1972). 
Similar postnatal development changes are seen in rabbit models. The beating rate decreases, 
action potential duration increases and the maximal diastolic potential (MDP) reaches more 
negative values during development (Toda, 1980). Allah and co-workers investigated in 
rabbits mRNA levels of several ion channels and Ca2+ handling proteins such as 
hyperpolarization activated cyclic nucleotide-gated potassium channel 4 (HCN4), NaV1.5, 
CaV1.3, NCX 1, KV1.5, ERG, KVLQT1 (also known as KCNQ1) and minK and they observed 
decreased mRNA levels of all these factors and suggested that this could explain the postnatal 
decrease in the beating rate and increase of action potential duration (Allah et al., 2011).   
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Ca-handling in cardiomyocytes also changes during embryonic development. According to 
ultrastructural studies, the sarcoplasmic reticulum is not completely developed at the early 
developmental stages and therefore neonatal cardiomyocytes are suggested to be more 
dependent on transsarcolemmal Ca2+ influx than sarcoplasmic Ca2+ release (Brook et al., 1983, 
Nakanishi et al., 1987, Nassar et al., 1987, Klitzner & Friedman, 1989). Therefore Na+/Ca2+ 
exchanger (NCX) have been suggested to have a important role in excitation-contraction 
coupling during the early developmental stages (Klitzner et al., 1991, Wetzel et al., 1991, 
Wetzel et al., 1991, Huynh et al., 1992) . Indeed, NCX gene and protein expression, in addition 
to NCX current have been shown to be enhanced at the early developmental stages (Artman, 
1992, Artman et al., 1995, Chin et al., 1997, Haddock et al., 1997, Gershome et al., 2011).      
Asp and colleagues compared the cardiac marker and ion channel expression of human 
embryonic stem cell derived cardiomyocyte (hESC-CM) clusters to human fetal, neonatal 
and adult atrial and ventricular origin heart tissue samples (Asp et al., 2010). They found the 
beating frequencies between hESC-CM clusters to vary substantially. They could identify 
two groups, one having slow (< 50 beats per minute[bpm]) and the other high (> 50 bmp) 
beating rate and they suggested these could represent ventricular and atrial type of cardiac 
cells, respectively. They also demonstrated that hESC-CMs had higher NKX2.5 and cardiac 
muscle actin mRNA expression levels than the heart samples. The NKX2.5 expression level, 
however, decreased over time in culture finally approaching that of the heart samples. 
Cardiac troponin T was more strongly expressed in ventricular samples and in hESC-CMs 
compared to atrial samples. The levels of cardiac troponin T mRNA also decreased over 
time in hESC-CMs. Phospholamban was expressed less in the atrial samples and hESC-CMs 
compared to ventricle samples. α-myosin heavy chain, which is normally mostly expressed 
in atrial tissue, was more strongly expressed in hESC-CMs with beat rates over 50 bpm and 
in adult atrial tissue samples whereas β-myosin heavy chain was more expressed in the 
ventricular heart samples and less in all the other heart preparations of hESC-CMs. The α-
myosin heavy chain mRNA levels increased with increasing age of the hESC-CMs. Across 
all the heart tissue and hESC-CM samples cardiac RyR2, L-type calcium channel, and NaV1.5 
sodium channel mRNA were similarly expressed. HERG mRNA expression in hESC-CMs 
was similar to neonatal and adult atrial samples. HCN2 was expressed in a more comparable 
way to the ventricular samples. Only HCN4 expression differed between the hESC-CMs, 
with those having the beating rate of less than 50 bpm having lower expression. Overall,  it 
was concluded that the difference between slow beating and fast beating hESC-CMs 
paralleled the human atrial and ventricular tissues (Asp et al., 2010). Despite small 
differences in expression levels, the conclusion from this study was that stem cell -derived 
cardiac cells share many similarities with human heart tissue and thus stem cell -derived 
cardiac cells are a good cellular model for human heart. 
5. Electrophysiology of human pluripotent stem cell derived cardiomyocytes 
The electrical properties of pluripotent stem cell derived cardiac cells have been studied 
principally either with patch clamp analysis of single cells or with microelectrode array 
(MEA) platform using beating cell aggregates. 
5.1 Patch clamp analysis 
Patch clamp method has been developed to study ion channels in excitable membranes. 
(Sakmann & Neher, 1984). In this technique micropipette is attached to the cell membrane 
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(Sakmann & Neher, 1984). In this technique micropipette is attached to the cell membrane 
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by a giga seal and this can be exploited to measure current changes and voltage across the 
membrane. This technique has been widely used in detailed electrical analysis of pluripotent 
stem cell derived cardiomyocytes. 
Key cardiac ion channel types (and respective currents in brackets) involved in the human 
ventricular action potential include NaV1.5 (INa), KV4.3 (Ito), CaV1.2 (ICa,L) KV11.1 (IKr), KV7.1 (IKs), 
and Kir2.X (IK1) (Pollard et al., 2010). These ion channels mediate the complex interaction 
between the currents and result in the characteristic action potential shape which can be 
divided into five different phases (Figure 2). Phase 0 of the action potential is the 
depolarization of the cardiomyocytes from the negative membrane potential to positive, 
called the upstroke. This is followed by phase 1, the short transient repolarization that is 
followed by phase 2, the plateau at slightly less positive membrane potential than the  
 
 
Fig. 2. Action potential phases and specification of cardiomyocyte subtypes. (A) Action 
potential (AP) parameters: Action potential amplitude (APA), maximum rate of rise of the 
action potential (dV/dtmax), action potential delay (ADP) and membrane diastolic potential 
(MDP). AP phase 0 is a rapid depolarization phase when the sodium channels are activated 
and membrane permeability is increased to Na+. Rapid depolarisation is followed by rapid 
repolarization phase 1 and plateau phase 2, where Ca2+ ions are entered to the cell throught 
L-type calcium channels. At phase 3, calcium channels are inactivated and repolarization is 
caused by outward potassium currents. Repolarization is due to the currents carried mainly 
by the slow Iks and rapid Ikr components of the delayed rectifier potassium channels. The 
Ikr current is produced by hERG channel (encoded by the human ether-à-go-go-related 
gene). By contrast, inward potassium current contributes to the maintenance of the resting 
membrane potential, phase 4. B-D. Classification of ventricular (B), atrial (C) an pacemaker-
like (D) action potentials. Ventricular action potential has a prominent plateau phase 
whereas atrial action potential is more triangularly shaped. Pacemaker-like cells are 
characterized by slower upstroke velocity and amplitude if compared to ventricular and 
atrial type of cells. 
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maximal upstroke value. Phase 2 is followed by phase 3, which is the repolarization back to 
the resting membrane potential. The resting state of the membrane potential is phase 4 
(Nerbonne & Kass, 2005). 
Sartiani and co-workers have investigated the expression of different ion channel proteins 
and respective ion currents with patch clamp technique in undifferentiated hESCs and in 
their early- (days 15 to 40) and late-stage (days 50-110) cardiomyocyte derivates using the 
EB differentiation method (Sartiani et al., 2007). Some ion currents were present readily in 
the undifferentiated cells (IKr, If, Ica,L). The properties of these currents were modified during 
hESC-CM development and some new currents (Ito and IK1) were introduced, so the 
cardiomyocytes achieved maturation over time. With regard to the Ito, transient outward 
potassium current, the two isoforms Kv1.4 and Kv4.3 were differentially expressed in the 
developing cardiomyocytes at mRNA level. The shorter Kv4.3 splice variant was expressed in 
over 57-days-old cardiomyocytes whereas the longer one was expressed in the earlier 
cardiomyocytes. The Kv1.4 isoform is expressed at least from day 25 onward. Despite Kv4.3 
mRNA expression in hESCs Ito current was not present in them. Ito could be detected using 
patch clamp on day 12 in the developing hESC-CMs and it was higher in later-stage (57 days 
old) cardiomyocytes compared to earlier ones (Sartiani et al., 2007).  
Another repolarizing current (IKr), encoded by the human ether-a-go-go related gene 
(HERG) channel is also expressed in hESCs as well as the developing cardiomyocytes. 
However, the shorter splice variant HERG1b mRNA was only expressed in the developing 
hESC-CMs. Using patch clamp an outward K+-current sensitive to E-4031, a selective blocker 
of the IKr current, could also be recorded in hESCs. HCN isoforms encode the If 
depolarization current. HCN1 and HCN4 were expressed more strongly in the 
undifferentiated hESCs and early cardiomyocytes than in late cardiomyocytes. HCN4 was 
also expressed in the adult heart, whereas HCN1 was not. HCN2 was expressed in the adult 
heart as well as strongly in hESCs and early and late hESC-CMs. Voltage clamp experiments 
revealed If currents in hESCs and early and late developing cardiomyocytes. However, 
during cardiomyocyte maturation, the If activation rate decreased. With regard to another 
depolarization current IK1, the Kir2.1 mRNA was already present in hESCs but the current 
could only be measured from the developing cardiomyocytes (Sartiani et al., 2007).   
Voltage-dependent Ca2+ current (ICa,L) is mediated by α1C subunit of the calcium channel in 
many tissues and this subunit is encoded by CACNA1C gene.  Sartiani and co-workers 
demonstrated mRNA expression of CACNA1C to be present both in undifferentiated hESCs 
and in the cardiomyocytes. Also, the ICa,L current could be recorded from hESCs as well as 
the hESC-CMs. During hESC-CM development the action potential upstroke velocity and 
action potential duration increased significantly. The beating rate on the other hand 
decreased during cardiomyocyte maturation and the diastolic depolarization rate flattened 
in the late cardiomyocytes. Pharmacological interventions also demonstrated intact ion 
channel function and expected responses were obtained with E4031 and BsCl2 (IK1 blockers), 
zatebradine (If blocker), and lacidipine (ICa,L blocker). Finally, stimulation with isoprenaline 
proved intact β-adrenergic signalling in the stem cell derived cardiomyocyte (Sartiani et al., 
2007).  
Taken together, the cardiomyocytes seem to achieve a more mature cardiac phenotype over 
time in cell culture, even though this has not been confirmed in all studies (Pekkanen-
Mattila et al., 2010). The Ito and IK1 currents could serve as markers for hESC cardiac 
differentiation (Sartiani et al., 2007) since they appear only later in cardiac differentiation. Ito 
current has also been shown to increase in postnatal rat cardiomyocytes (Guo et al., 1996, 
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maximal upstroke value. Phase 2 is followed by phase 3, which is the repolarization back to 
the resting membrane potential. The resting state of the membrane potential is phase 4 
(Nerbonne & Kass, 2005). 
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and respective ion currents with patch clamp technique in undifferentiated hESCs and in 
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the undifferentiated cells (IKr, If, Ica,L). The properties of these currents were modified during 
hESC-CM development and some new currents (Ito and IK1) were introduced, so the 
cardiomyocytes achieved maturation over time. With regard to the Ito, transient outward 
potassium current, the two isoforms Kv1.4 and Kv4.3 were differentially expressed in the 
developing cardiomyocytes at mRNA level. The shorter Kv4.3 splice variant was expressed in 
over 57-days-old cardiomyocytes whereas the longer one was expressed in the earlier 
cardiomyocytes. The Kv1.4 isoform is expressed at least from day 25 onward. Despite Kv4.3 
mRNA expression in hESCs Ito current was not present in them. Ito could be detected using 
patch clamp on day 12 in the developing hESC-CMs and it was higher in later-stage (57 days 
old) cardiomyocytes compared to earlier ones (Sartiani et al., 2007).  
Another repolarizing current (IKr), encoded by the human ether-a-go-go related gene 
(HERG) channel is also expressed in hESCs as well as the developing cardiomyocytes. 
However, the shorter splice variant HERG1b mRNA was only expressed in the developing 
hESC-CMs. Using patch clamp an outward K+-current sensitive to E-4031, a selective blocker 
of the IKr current, could also be recorded in hESCs. HCN isoforms encode the If 
depolarization current. HCN1 and HCN4 were expressed more strongly in the 
undifferentiated hESCs and early cardiomyocytes than in late cardiomyocytes. HCN4 was 
also expressed in the adult heart, whereas HCN1 was not. HCN2 was expressed in the adult 
heart as well as strongly in hESCs and early and late hESC-CMs. Voltage clamp experiments 
revealed If currents in hESCs and early and late developing cardiomyocytes. However, 
during cardiomyocyte maturation, the If activation rate decreased. With regard to another 
depolarization current IK1, the Kir2.1 mRNA was already present in hESCs but the current 
could only be measured from the developing cardiomyocytes (Sartiani et al., 2007).   
Voltage-dependent Ca2+ current (ICa,L) is mediated by α1C subunit of the calcium channel in 
many tissues and this subunit is encoded by CACNA1C gene.  Sartiani and co-workers 
demonstrated mRNA expression of CACNA1C to be present both in undifferentiated hESCs 
and in the cardiomyocytes. Also, the ICa,L current could be recorded from hESCs as well as 
the hESC-CMs. During hESC-CM development the action potential upstroke velocity and 
action potential duration increased significantly. The beating rate on the other hand 
decreased during cardiomyocyte maturation and the diastolic depolarization rate flattened 
in the late cardiomyocytes. Pharmacological interventions also demonstrated intact ion 
channel function and expected responses were obtained with E4031 and BsCl2 (IK1 blockers), 
zatebradine (If blocker), and lacidipine (ICa,L blocker). Finally, stimulation with isoprenaline 
proved intact β-adrenergic signalling in the stem cell derived cardiomyocyte (Sartiani et al., 
2007).  
Taken together, the cardiomyocytes seem to achieve a more mature cardiac phenotype over 
time in cell culture, even though this has not been confirmed in all studies (Pekkanen-
Mattila et al., 2010). The Ito and IK1 currents could serve as markers for hESC cardiac 
differentiation (Sartiani et al., 2007) since they appear only later in cardiac differentiation. Ito 
current has also been shown to increase in postnatal rat cardiomyocytes (Guo et al., 1996, 
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Shimoni et al., 1997) and IK1 current has been shown to stabilize the diastolic potential in 
myocytes (Silva & Rudy, 2003).  
With regard to the EB and END-2 co-culture differentiation methods our own experiments 
demonstrated that the EB method produces slightly more cardiomyocytes with consistent 
beating rate and more cardiomyocytes with ventricular type action potentials. The EB 
method also produced cardiomyocytes with significantly more hyperpolarized MDP 
(Pekkanen-Mattila et al., 2010). Low expression of IK1 current in developing hESC-CMs 
seems to be responsible, at least in part, for their low MDP (Sartiani et al., 2007). 
Cardiomyocytes produced with both methods did not differ in their upstroke velocity 
(Pekkanen-Mattila et al., 2010a).  
Dolnikov and colleagues studied mechanical functions of hESC derived cardiac cells. They 
found that hESC-CMs have a negative force-frequency relation, whereas mature human 
myocardium the relationship is positive (Dolnikov et al., 2005). They also found that 
blocking the ryanodine receptor or the sarcoplasmic-endoplasmic reticulum Ca2+ -ATPase 
did not affect the hESC-CM contraction as it usually does in mature cardiomyocytes. 
Furthermore, caffeine did not result in increase of intracellular calcium concentration. 
However, in subsequent studies caffeine-indused release of intracellular Ca2+  has been 
documented both in hESC and hiPSC -derived cardiac cells (Satin et al., 2008, Itzhaki et al., 
2011). Both RyR mediated release of intracellular Ca2+ stores as well as the reuptake of Ca2+ 
by SERCA into endoplasmic reticulum were reported to occur the same way as in cardiac 
tissue. These results indicate that Ca2+ handling in both hESC and hiPSC-derived cardiac 
cells are functional and further indicate the potential of these cardiac cells in the future 
applications in basic research as well as in translational cardiac research. 
5.2 Microelectrode array platform 
In addition to the more traditional patch clamp (Hamill et al., 1981) studies the MEA 
platform (Reppel et al., 2004) offers an easy and convenient medium-throughput technique 
to assess the electrical properties of the differentiated cardiomyocytes (Reppel et al., 2005). 
Action and field potential curves achieved by patch clamp and by MEA are represented in 
Figure 3. The MEA platform presents an advantageous additional tool for cardiac safety 
studies in addition to the more traditional Langendorff heart organ model, conventional 
patch clamp electrophysiology studies and heterologous expression systems of ion channels, 
especially the hERG potassium channel (Meyer et al., 2004)..  
The MEA system allows examination of multicellular cardiac syncythia, thus enabling 
electrocardiogram-like mapping of their field potential properties. Cardiac repolarization in 
hESC-CMs can be therefore investigated with MEAs and it has been demonstrated that drug 
effects can be investigated using this platform (Reppel et al., 2005). With MEA system, Caspi 
and co-workers were able to investigate drug effects on hESC-CMs. E-4031 is a compound 
that blocks IKr repolarizing current and this effect can be seen as prolongation of the cardiac 
field potential (FP) cycle in the electrocardiogram. The authors were able to demonstrate a 
dose-dependent effect where the field potential duration (FPD) prolonged by escalating 
concentrations of E-4031. Sotalol, a class III antiarrhythmic agent, also increased FPD as did 
quinidine and procainamide, both class IA antiarrhythmic agents. Cisapride, a 
gastrointestinal prokinetic drug that was withdrawn for the market due to adverse cardiac 
side effects, prolonged the FPD as well, as seen on the MEA recordings (Caspi et al., 2009, 
Liang et al., 2010).  
 




Fig. 3. Action and field potentials recorded from human embryonic stem cell –derived 
cardiomyocytes. Action potentials can be measured from single cardiomyocytes in current 
clamp mode using the patch clamp technique. Field potentials can be measured from a 
multicellular cardiac syncytium with microelectrode arrays. 
To assess the practicality of using hESC-CMs in conjunction with the MEA platform in 
pharmacotoxicological testing, Braam and colleagues investigated the effects of various 
drugs on the FPD of cardiomyocytes derived from human ES cells (Braam et al., 2010). They 
tested 12 compounds for their potential in prolonging repolarization (FPD) in hESC-CMs. 
Despite the relatively lower maturation of hESC-CMs compared to mature cardiomyocytes, 
they could be used in predicting the clinically observed cardiotoxic effects. Blocking of 
sodium, calcium and HERG potassium channels by lidocaine, nifidipine, and E-4031, 
respectively, had expected effects on hESC-CM field potential properties. Quinidine and 
sotalol, both used clinically to prolong repolarization, increased hESC-CM FPD at 
concentrations near the unbound effective therapeutic plasma concentration (ETCP 
unbound). They also tested drugs which have been known to prolong the QT interval in 
patients and noticed that the FPD prolongations too place at concentrations that were not as 
near the ECTP unbound range. The varying FP shapes in hESC-CM recordings did not affect 
the results, meaning that FPD changes in these cardiomyocytes can be reliably detected 
despite the large variety of FP shapes (Braam et al., 2010). The study provided, for the first 
time, data on the effects of large number of tested compound over a high concentration 
range on the FP properties of hESC-CM. 
6. Applications for pluripotent stem cell-derived cardiomyocytes 
6.1 Human model for development of cardiomyocytes and cardiac electrophysiology 
The amount of data about electrophysiological changes during human cardiac 
differentiation is limited. Data is mostly based on animal models, but due to the 
physiological differences between species this data cannot be always applied directly to 
humans. Human pluripotent stem cells differentiate into functional cardiomyocytes and 
these cells also mature in culture (Sartiani et al., 2007). Therefore they provide a good model 
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to study development of complex network of cardiac ion channels involved in signal 
transduction and cardiomyocyte contraction.  
6.2 Drug screening and safety pharmacology 
Many cardiac and also non-cardiac drugs have been withdrawn from the market because of 
toxic effects on heart and its function. Even though all new chemical entities (NCE) are 
tested according to requirements during drug development process, unforeseen effects such 
as syncope, arrhythmia, sudden death, polymorphic ventricular tachycardia (Torsade de 
pointes [TdP]) are occasionally seen only in clinical trials or when the drug is already on the 
market (Redfern et al., 2003, Roden, 2004, Lexchin, 2005). Pharmaceutical regulatory 
authorities have specified and expanded the requirements for safety testing and recommend 
that tests are done with two mammalian species, one rodent and other nonrodent species. 
Tests include electocardiographic recordings and also histological studies of the heart (ICH, 
2005, ICH, 2005, EMEA, 2008).  
With regard to proarrhythmic potential, the QT interval is the cornerstone of the guidelines 
for the assessment of new chemical compounds (ICH, 2005, ICH, 2005). A number of drugs 
can potentially prolong the QT interval (Fenichel et al., 2004, Roden, 2004), and it is also a 
leading cause for use restriction and market withdrawal (Roden, 2004), the International 
Conference of Harmonization has defined the evaluation of this risk for new chemical 
entities as standard preclinical process (Bode & Olejniczak, 2002, Cavero & Crumb, 2005). 
Delayed rectifier potassium current (IKr) is responsible in part for the repolarization of the 
action potential (Vandenberg et al., 2001, Pollard et al., 2008). Inhibition of this hERG 
channel (KV11.1) and the subsequent inhibition of the IKr, is the predominant basis of drug-
induced QT prolongation and TdP (Hancox et al., 2008; Redfern et al., 2003). Currently a 
number of preclinical models and assays have been employed by pharmaceutical companies 
(Carlsson, 2006, Pollard et al., 2008). These assays include in vivo QT assays, such as ECG 
telemetry of conscious dogs (Miyazaki et al., 2005), and in vitro assays, such as 
repolarization assay, which detects changes in the action potential delay (APD) of cardiac 
tissues (isolated animal Purkinje fibres, papillary muscles or cardiomyocytes) or the hERG 
channel assay where hERG current expressed in heterologous cell system (such as CHO or 
HEK293 cells) or  native IKr is characterized (Finlayson et al., 2004, Martin et al., 2004). 
However, current methods are not fully adequate (Redfern et al., 2003, Lu et al., 2008). They 
are costly and the in vivo assays are ethically questionable because of the large number of 
animals used. Therefore there is a need for an in vitro method based on human cardiac cells 
that would bring additional value and reliability for testing novel pharmaceutical agents. 
Cardiomyocytes derived both from hESC and iPS cells have many potential applications in 
the pharmaceutical industry including target validation, screening and safety 
pharmacology. These cells would serve as an inexhaustible and reproducible human model 
system and preliminary reports of the validation of hESC-CM system already exist (Braam 
et al., 2010, Mandenius et al., 2011).  
6.3 Disease modelling with induced pluripotent stem cell –derived cardiomyocytes 
The hiPSC technology (Takahashi et al., 2007, Yu et al., 2007) presents a great opportunity to 
investigate diseases in cell culture that would otherwise be challenging to study. Although 
the full potential of this method is still to be realized in cardiac research, some preliminary 
results provide encouragement to investigate this path further. 
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One condition that is challenging to study in patients in terms of underlying molecular 
mechanisms is the long QT syndrome (LQTS). This condition can be either genetic or 
acquired as a side effect of using certain therapeutic drugs. The first LQTS modelling using 
hiPSCs was reported in 2010 (Moretti et al., 2010). Pluripotent stem cells were 
reprogrammed from fibroblasts of two family members having LQTS type 1, and cardiac 
cells derived from these hiPSCs with LQT1 genotype had prolonged action potential.  
Additionally increased arrhythmogenicity could be demonstrated with isoproterenol. 
Similar findings have been reported about LQTS type 2 (Itzhaki et al., 2011, Matsa et al., 
2011).  
Cardiomyocytes have also been derived from hiPSCs from a patient with Timothy 
syndrome (Yazawa et al., 2011). These patients have mutation in the CACNA1C gene that 
encodes the CaV1.2 calcium ion channel in humans. The cardiomyocytes having Timothy 
syndrome genotype exhibited irregular contractions and excessive calcium influx as well as 
action potential prolongation, irregularities in the electrical activation and abnormal calcium 
transients in the ventricular-type cardiomyocytes (Yazawa et al., 2011). 
Taken together these results provide optimism for modelling different cardiac disease 
phenotypes in cell culture conditions. This allows for more detailed dissection of the 
pathological pathways and molecular interactions within and between the cells. An 
additional benefit is also the fact that these studies can be now carried out in patient-specific 
cells which provide suitable genomic backgrounds for more optimal comparison between 
the clinical disease phenotype and results obtained in vitro.  
7. Challenges in pluripotent stem cell research 
While human pluripotent stem cells represent a promising new tool for pharmacological 
and toxicological testing and hopefully also for regenerative therapies in the future some 
hurdles remain to be cleared before we can achieve those goals efficiently. With regards to 
hiPSC a question remains how close these cells are to hESCs in their properties. While they 
fulfil the criteria required for pluripotent stem cells, some recent studies suggest that they 
retain some aberrant epigenetic reprogramming compared to ES cells (Lister et al., 2011). 
Both cell types have similar global methylomes, but the reprogrammed iPS cell seem to 
retain some memory of the somatic cell DNA methylation patterns in addition to the 
methylation patterns that are specific for iPSCs (Lister et al., 2011). However, the 
cardiomyocytes differentiated from hiPSCs and hESCs seem to have very similar global 
transcriptomes (Gupta et al., 2010). 
Another issue with both, hESCs and hiPSCs, are the currently suboptimal differentiation 
protocols for desired differentiated cell types. Cardiomyocytes are no exception in this case 
and several protocols for more efficient differentiation have been experimented with. 
Recently, increased yields of cardiomyocytes have been obtained by stage-specific 
optimization of the activin/nodal and bone morphogenetic protein (BMP) signalling 
(Kattman et al., 2011). The directed differentiation protocol of hESC-CMs in a monolayer, 
with activin A and BMP4 supplementation, represents another step forward in creating 
more efficient differentiation methods (Laflamme et al., 2007). In hiPS reprogramming 
omission of c-Myc from the four factor Yamanaka cocktail has been shown to enhance their 
cardiogenic potential (Martinez-Fernandez et al., 2010).  
To achieve better cardiomyocyte differentiation efficiencies with pluripotent stem cells we 
need to gain more insight into the lineage-specification steps that govern the transformation 
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to study development of complex network of cardiac ion channels involved in signal 
transduction and cardiomyocyte contraction.  
6.2 Drug screening and safety pharmacology 
Many cardiac and also non-cardiac drugs have been withdrawn from the market because of 
toxic effects on heart and its function. Even though all new chemical entities (NCE) are 
tested according to requirements during drug development process, unforeseen effects such 
as syncope, arrhythmia, sudden death, polymorphic ventricular tachycardia (Torsade de 
pointes [TdP]) are occasionally seen only in clinical trials or when the drug is already on the 
market (Redfern et al., 2003, Roden, 2004, Lexchin, 2005). Pharmaceutical regulatory 
authorities have specified and expanded the requirements for safety testing and recommend 
that tests are done with two mammalian species, one rodent and other nonrodent species. 
Tests include electocardiographic recordings and also histological studies of the heart (ICH, 
2005, ICH, 2005, EMEA, 2008).  
With regard to proarrhythmic potential, the QT interval is the cornerstone of the guidelines 
for the assessment of new chemical compounds (ICH, 2005, ICH, 2005). A number of drugs 
can potentially prolong the QT interval (Fenichel et al., 2004, Roden, 2004), and it is also a 
leading cause for use restriction and market withdrawal (Roden, 2004), the International 
Conference of Harmonization has defined the evaluation of this risk for new chemical 
entities as standard preclinical process (Bode & Olejniczak, 2002, Cavero & Crumb, 2005). 
Delayed rectifier potassium current (IKr) is responsible in part for the repolarization of the 
action potential (Vandenberg et al., 2001, Pollard et al., 2008). Inhibition of this hERG 
channel (KV11.1) and the subsequent inhibition of the IKr, is the predominant basis of drug-
induced QT prolongation and TdP (Hancox et al., 2008; Redfern et al., 2003). Currently a 
number of preclinical models and assays have been employed by pharmaceutical companies 
(Carlsson, 2006, Pollard et al., 2008). These assays include in vivo QT assays, such as ECG 
telemetry of conscious dogs (Miyazaki et al., 2005), and in vitro assays, such as 
repolarization assay, which detects changes in the action potential delay (APD) of cardiac 
tissues (isolated animal Purkinje fibres, papillary muscles or cardiomyocytes) or the hERG 
channel assay where hERG current expressed in heterologous cell system (such as CHO or 
HEK293 cells) or  native IKr is characterized (Finlayson et al., 2004, Martin et al., 2004). 
However, current methods are not fully adequate (Redfern et al., 2003, Lu et al., 2008). They 
are costly and the in vivo assays are ethically questionable because of the large number of 
animals used. Therefore there is a need for an in vitro method based on human cardiac cells 
that would bring additional value and reliability for testing novel pharmaceutical agents. 
Cardiomyocytes derived both from hESC and iPS cells have many potential applications in 
the pharmaceutical industry including target validation, screening and safety 
pharmacology. These cells would serve as an inexhaustible and reproducible human model 
system and preliminary reports of the validation of hESC-CM system already exist (Braam 
et al., 2010, Mandenius et al., 2011).  
6.3 Disease modelling with induced pluripotent stem cell –derived cardiomyocytes 
The hiPSC technology (Takahashi et al., 2007, Yu et al., 2007) presents a great opportunity to 
investigate diseases in cell culture that would otherwise be challenging to study. Although 
the full potential of this method is still to be realized in cardiac research, some preliminary 
results provide encouragement to investigate this path further. 
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One condition that is challenging to study in patients in terms of underlying molecular 
mechanisms is the long QT syndrome (LQTS). This condition can be either genetic or 
acquired as a side effect of using certain therapeutic drugs. The first LQTS modelling using 
hiPSCs was reported in 2010 (Moretti et al., 2010). Pluripotent stem cells were 
reprogrammed from fibroblasts of two family members having LQTS type 1, and cardiac 
cells derived from these hiPSCs with LQT1 genotype had prolonged action potential.  
Additionally increased arrhythmogenicity could be demonstrated with isoproterenol. 
Similar findings have been reported about LQTS type 2 (Itzhaki et al., 2011, Matsa et al., 
2011).  
Cardiomyocytes have also been derived from hiPSCs from a patient with Timothy 
syndrome (Yazawa et al., 2011). These patients have mutation in the CACNA1C gene that 
encodes the CaV1.2 calcium ion channel in humans. The cardiomyocytes having Timothy 
syndrome genotype exhibited irregular contractions and excessive calcium influx as well as 
action potential prolongation, irregularities in the electrical activation and abnormal calcium 
transients in the ventricular-type cardiomyocytes (Yazawa et al., 2011). 
Taken together these results provide optimism for modelling different cardiac disease 
phenotypes in cell culture conditions. This allows for more detailed dissection of the 
pathological pathways and molecular interactions within and between the cells. An 
additional benefit is also the fact that these studies can be now carried out in patient-specific 
cells which provide suitable genomic backgrounds for more optimal comparison between 
the clinical disease phenotype and results obtained in vitro.  
7. Challenges in pluripotent stem cell research 
While human pluripotent stem cells represent a promising new tool for pharmacological 
and toxicological testing and hopefully also for regenerative therapies in the future some 
hurdles remain to be cleared before we can achieve those goals efficiently. With regards to 
hiPSC a question remains how close these cells are to hESCs in their properties. While they 
fulfil the criteria required for pluripotent stem cells, some recent studies suggest that they 
retain some aberrant epigenetic reprogramming compared to ES cells (Lister et al., 2011). 
Both cell types have similar global methylomes, but the reprogrammed iPS cell seem to 
retain some memory of the somatic cell DNA methylation patterns in addition to the 
methylation patterns that are specific for iPSCs (Lister et al., 2011). However, the 
cardiomyocytes differentiated from hiPSCs and hESCs seem to have very similar global 
transcriptomes (Gupta et al., 2010). 
Another issue with both, hESCs and hiPSCs, are the currently suboptimal differentiation 
protocols for desired differentiated cell types. Cardiomyocytes are no exception in this case 
and several protocols for more efficient differentiation have been experimented with. 
Recently, increased yields of cardiomyocytes have been obtained by stage-specific 
optimization of the activin/nodal and bone morphogenetic protein (BMP) signalling 
(Kattman et al., 2011). The directed differentiation protocol of hESC-CMs in a monolayer, 
with activin A and BMP4 supplementation, represents another step forward in creating 
more efficient differentiation methods (Laflamme et al., 2007). In hiPS reprogramming 
omission of c-Myc from the four factor Yamanaka cocktail has been shown to enhance their 
cardiogenic potential (Martinez-Fernandez et al., 2010).  
To achieve better cardiomyocyte differentiation efficiencies with pluripotent stem cells we 
need to gain more insight into the lineage-specification steps that govern the transformation 
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of pluripotent stem cells to committed progenitors and finally to mature differentiated 
cardiomyocytes. For example, ISL1+ cardiac progenitors are able to give rise to 
cardiomyocytes, smooth muscle, and endothelial cell lineages and these progenitor 
populations can be expanded in cell culture (Bu et al., 2009). KDR+ cells derived from 
human embryonic stem cells have also been shown to give rise to cardiac progenitor cells 
(Yang et al., 2008). 
8. Conclusion 
In conclusion, human pluripotent stem cell derived cardiomyocytes have very similar 
electrophysiological properties as human heart tissue and, thus, they have a great potential 
in the future to benefit pharmaceutical and toxicological industry.  Additionally, with these 
cells we are closer than ever before to individualized, patient-specific treatments.  However, 
a lot of basic research is still required before we can utilize the full advantage of human 
pluripotent stem cell –derived cardiac cells. 
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1. Introduction 
Myocardial infarction is one of the major causes of morbidity and mortality in many 
developed countries. A potential method for treatment of such disease is the cell 
replacement therapy which involves the transplantation of cardiomyocytes (CMs). 
However, CMs are of very limited supply. Embryonic stem cells (ESCs) isolated from the 
inner cell mass of blastocysts are capable of self-renewal and can differentiate into all cell 
lineages, including CMs (He et al., 2003; Kehat et al., 2002; Kehat et al., 2001; Moore et al., 
2008; Mummery et al., 2003; Ng et al., 2010; Thomson et al., 1998; Xu et al., 2002; Xue et al., 
2005). Therefore, ESCs can be an excellent source of CMs for regenerative medicine.  
Calcium (Ca2+) is a universal signaling molecule that regulates a wide variety of cellular 
functions. In CMs, intracellular Ca2+ concentration ([Ca2+]i) plays an important role in the 
contraction and relaxation of CMs. The [Ca2+]i is tightly regulated by many proteins, 
including ion channels, receptors, pumps, and exchangers that are located on the cell surface 
plasma membrane and on the sarcoplasmic reticulum (SR). The aim of this book chapter is 
to provide a thorough review on Ca2+ handling in ESC-derived CMs.  
For each protein of interest, some basic information on the protein was firstly presented. Then, 
changes in the expression of the protein and their contribution to the Ca2+ homeostasis and 
Ca2+ transient as described in human (h) and/or mouse (m) ESC studies were presented. In 
vivo data in mouse embryo studies were also presented for comparison purposes.  
The information reviewed in this chapter would be important not only for understanding 
the basic biology of early differentiating CMs, it would also be important for providing 
insights into the future uses of ESC-derived CMs for cell replacement therapies. 
2. Regulation of intracellular calcium level by voltage-operated calcium channels 
Voltage-operated Ca2+ channels are typically composed of five subunits, namely α1, α2, β, δ 
and  (Catterall, 1995; Catterall, 2000; De Waard et al., 1996; Dolphin, 2006; Moreno Davila, 
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Ca2+ transient as described in human (h) and/or mouse (m) ESC studies were presented. In 
vivo data in mouse embryo studies were also presented for comparison purposes.  
The information reviewed in this chapter would be important not only for understanding 
the basic biology of early differentiating CMs, it would also be important for providing 
insights into the future uses of ESC-derived CMs for cell replacement therapies. 
2. Regulation of intracellular calcium level by voltage-operated calcium channels 
Voltage-operated Ca2+ channels are typically composed of five subunits, namely α1, α2, β, δ 
and  (Catterall, 1995; Catterall, 2000; De Waard et al., 1996; Dolphin, 2006; Moreno Davila, 
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1999). The α1 subunit forms the ion conduction pore of the channels while the other subunits 
modulate the functions of the channels. The α1 subunit is itself a tetramer of proteins, each 
of which consists of six transmembrane segments (S1-S6). This subunit confers all of the 
major properties to voltage-operated Ca2+ channels in that it contains a voltage sensor at 
segment S4 and forms a Ca2+-selective pore at segments S5-S6. The other subunits are 
regarded as to providing ancillary functions to the channels. The α2 and δ subunits are two 
products of the same gene; the protein is cleaved into two peptides following translation. 
Subsequent disulfide bond formation anchors the extracellular α2 subunit to the membrane 
via the transmembrane δ subunit. The β subunit is a cytoplasmic protein; it contains an α1-
binding pocket, where specific amino acids in the linker region between segments S1 and S2 
of the α1 subunit bind (Richards et al., 2004). The  subunit is a monomer, which consists of 
four transmembrane segments (S1-S4). A diverse range of functionally distinct voltage-
operated Ca2+ channels are formed by the combinations of different isoforms that have been 
identified for each of these subunits. The α1 subunit is encoded by a family of ten distinct 
genes (the CaV gene family), which can be divided into three sub-families; CaV1 consists of 
CaV1.1-1.4, CaV2 consists of CaV2.1-2.3 and CaV3 consists of CaV3.1-3.3 (Catterall et al., 2005). 
The α2/δ and β subunits are each encoded by four genes; α2/δ1-4 and β1-4 respectively, while 
the  subunit is encoded by eight genes; 1-8 (Arikkath and Campbell, 2003; Yang et al., 2011). 
Voltage-operated Ca2+ channels function by regulating the entry of extracellular Ca2+ into 
cells. Two types of voltage-operated Ca2+ channels exist in adult CMs (Catterall et al., 2005; 
Ono and Iijima, 2005). These are T-type Ca2+ channels, which open in response to more 
negative membrane potentials at about >-70mV for very short durations of 0.5 to 2 
milliseconds (transient activation), and L-type Ca2+ channels, which open in response to less 
negative membrane potentials at about >-30mV for relatively longer periods of 0.5 to 10 
milliseconds (long-lasting activation) (De Waard et al., 1996). 
2.1 T-type calcium channels 
T-type Ca2+ channels could be the simplest type of voltage-operated Ca2+ channels known 
thus far. Its structure was initially predicted in silico by homology to other α1 subunits 
known at the time (Perez-Reyes, 2006). Since expression of the synthetic products was able 
to reproduce most of the electrophysiological properties observed in its native form, T-type 
Ca2+ channels were thought to consist of only one α1 subunit; the other ancillary subunits 
(α2, β, δ and ) were considered absent. Although later co-expression studies could describe 
a role for the other ancillary subunits in the regulating functions of T-type Ca2+ channels in 
vitro, presence of these subunits have not been validated in vivo (Dolphin et al., 1999; Dubel 
et al., 2004; Green et al., 2001; Hobom et al., 2000; Lacinova and Klugbauer, 2004). Therefore, 
further investigations will be required to ascertain the genuine structure of this type of 
voltage-operated Ca2+ channel. 
The α1 subunit of T-type Ca2+ channels is encoded by either one of the three CaV3 genes, 
among which CaV3.1 and CaV3.2 are expressed in sinoatrial (SA) nodal cells of the heart 
(Bohn et al., 2000; Perez-Reyes, 2003). The SA node is the primary site, where spontaneous 
rhythmic action potentials are initiated. At the beginning of each action potential in an SA 
nodal cell, an influx of extracellular Na+ into the cytosol, known as the funny current (If), 
first depolarizes the cell to about -50mV, at which T-type Ca2+ channels on the membrane 
open to allow an influx of extracellular Ca2+ into the cytosol. This produces a T-type Ca2+ 
current (ICa, T), which further depolarizes the cell to about -40mV. L-type Ca2+ channels on 
the membrane then open at this membrane potential to allow a greater influx of extracellular 
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Ca2+ into the cytosol and produce an L-type Ca2+ current (ICa, L) to a membrane potential 
until the threshold to produce an action potential is reached. Action potentials generated in 
the SA nodal cells are conducted to CMs within the working myocardium via gap junctions, 
ultimately resulting in regular contractions of the adult heart. 
CaV3.1 mRNA and protein were simultaneously detected as early as embryonic day 14 (E14) 
after the heart has fully matured in vivo within mouse embryos (Cribbs et al., 2001). In a 
separate experiment, the mRNA level of CaV3.1 was moderately reduced from E18 when 
compared to its expression at adult stage (Yasui et al., 2005). Ni2+ at a high concentration of 
100μM could be used to selectively block 50% of CaV3.1 T-type channels. The application of 
Ni2+ at this concentration was found to reduce ICa, T by about 40% in CMs derived from 
mouse embryos at E12.5, indicating that the CaV3.1 T-type channels were functional by this 
time-point (Cribbs et al., 2001). In addition, homozygous null CaV3.1-/- mice displayed 
bradycardia, i.e. a reduced rate of cardiac contraction (Mangoni et al., 2006). Expression of 
CaV3.1 has also been studied in vitro. Its mRNA could be detected as early as day 5 and 
generally increased up until its last measurement at day 15 post-differntiation in ht7 mouse 
ESC- (mESC-) derived CMs (Mizuta et al., 2005). In R1 mESC-derived CMs, however, CaV3.1 
mRNA could only be detected at two copies per cell by day 12, with its expression reaching 
the highest level at day 23 and declining by day 34 post-differentiation; the expression 
pattern reflected the amplitudes of ICa, T measured at these time-points. (Zhang et al., 2003). 
A reduction of about 46% in CaV3.1 expression from day 9.5 to day 23.5 post-differentiation 
was also reported in EMG7 mESC-derived CMs; this down-regulation was found to be 
associated with a decrease in the contraction rates of the CMs in that ICa, T was smaller in 
non-contracting myocytes at day 23.5 when compared to contracting CMs at day 9.5 and 
that the contraction rate at day 9.5 could be reduced via the application of 10μM efonidipine, 
an L- and T-type blocker, to the CMs (Yanagi et al., 2007). These data suggested a role for 
CaV3.1 in regulating the early contractions observed in the developing embryonic heart; by 
maintaining these contractions exclusively in developing pacemaker cells, other cells could 
then develop into non-contracting atrial or ventricular cells.  
CaV3.2 mRNA was detected as early as eight-week gestation in humans (Qu and Boutjdir, 
2001). In mouse, the expression of CaV3.2 was also measured at three time-points; its mRNA 
was detected as early as E9.5 and then its level was decreased by E18 until it was no longer 
detected at adult stage (Yasui et al., 2005). Again, CaV3.2 has been studied in vitro. Its mRNA 
was detected as early as day 5, but peaked at day 6 and gradually declined and was still 
detectable up until the last measurement at day 15 post-differentiation in ht7 mESC-derived 
CMs (Mizuta et al., 2005). In line with this finding, CaV3.2 mRNA level was also found to be 
down-regulated by about 24% from day 9.5 to day 23.5 post-differentiation in EMG7 mESC-
derived CMs (Yanagi et al., 2007). Ni2+ at a low concentration of <50μM could be used to 
selectively block 50% of CaV3.2 T-type channels. When Ni2+ was applied at 40μM to ht7 
mESC-derived CMs at day 8 post-differentiation, ICa, T was found to be evidently decreased 
by about 60%, which signified the presence of functional CaV3.2 T-type channels by this 
time-point. Homozygous null CaV3.2-/- mice showed no sign of cardiac arrhythmia, but 
cardiac fibrosis with age-dependent severity (Chen et al., 2003). These data suggested a role 
for CaV3.2 in regulating the growth and maturation of the developing embryonic heart.  
2.1.1 L-type calcium channels 
L-type Ca2+ channels are distinguished from other voltage-operated Ca2+ channels that open 
at high membrane potentials for long periods on the basis of their sensitivity to 1, 4-
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1999). The α1 subunit forms the ion conduction pore of the channels while the other subunits 
modulate the functions of the channels. The α1 subunit is itself a tetramer of proteins, each 
of which consists of six transmembrane segments (S1-S6). This subunit confers all of the 
major properties to voltage-operated Ca2+ channels in that it contains a voltage sensor at 
segment S4 and forms a Ca2+-selective pore at segments S5-S6. The other subunits are 
regarded as to providing ancillary functions to the channels. The α2 and δ subunits are two 
products of the same gene; the protein is cleaved into two peptides following translation. 
Subsequent disulfide bond formation anchors the extracellular α2 subunit to the membrane 
via the transmembrane δ subunit. The β subunit is a cytoplasmic protein; it contains an α1-
binding pocket, where specific amino acids in the linker region between segments S1 and S2 
of the α1 subunit bind (Richards et al., 2004). The  subunit is a monomer, which consists of 
four transmembrane segments (S1-S4). A diverse range of functionally distinct voltage-
operated Ca2+ channels are formed by the combinations of different isoforms that have been 
identified for each of these subunits. The α1 subunit is encoded by a family of ten distinct 
genes (the CaV gene family), which can be divided into three sub-families; CaV1 consists of 
CaV1.1-1.4, CaV2 consists of CaV2.1-2.3 and CaV3 consists of CaV3.1-3.3 (Catterall et al., 2005). 
The α2/δ and β subunits are each encoded by four genes; α2/δ1-4 and β1-4 respectively, while 
the  subunit is encoded by eight genes; 1-8 (Arikkath and Campbell, 2003; Yang et al., 2011). 
Voltage-operated Ca2+ channels function by regulating the entry of extracellular Ca2+ into 
cells. Two types of voltage-operated Ca2+ channels exist in adult CMs (Catterall et al., 2005; 
Ono and Iijima, 2005). These are T-type Ca2+ channels, which open in response to more 
negative membrane potentials at about >-70mV for very short durations of 0.5 to 2 
milliseconds (transient activation), and L-type Ca2+ channels, which open in response to less 
negative membrane potentials at about >-30mV for relatively longer periods of 0.5 to 10 
milliseconds (long-lasting activation) (De Waard et al., 1996). 
2.1 T-type calcium channels 
T-type Ca2+ channels could be the simplest type of voltage-operated Ca2+ channels known 
thus far. Its structure was initially predicted in silico by homology to other α1 subunits 
known at the time (Perez-Reyes, 2006). Since expression of the synthetic products was able 
to reproduce most of the electrophysiological properties observed in its native form, T-type 
Ca2+ channels were thought to consist of only one α1 subunit; the other ancillary subunits 
(α2, β, δ and ) were considered absent. Although later co-expression studies could describe 
a role for the other ancillary subunits in the regulating functions of T-type Ca2+ channels in 
vitro, presence of these subunits have not been validated in vivo (Dolphin et al., 1999; Dubel 
et al., 2004; Green et al., 2001; Hobom et al., 2000; Lacinova and Klugbauer, 2004). Therefore, 
further investigations will be required to ascertain the genuine structure of this type of 
voltage-operated Ca2+ channel. 
The α1 subunit of T-type Ca2+ channels is encoded by either one of the three CaV3 genes, 
among which CaV3.1 and CaV3.2 are expressed in sinoatrial (SA) nodal cells of the heart 
(Bohn et al., 2000; Perez-Reyes, 2003). The SA node is the primary site, where spontaneous 
rhythmic action potentials are initiated. At the beginning of each action potential in an SA 
nodal cell, an influx of extracellular Na+ into the cytosol, known as the funny current (If), 
first depolarizes the cell to about -50mV, at which T-type Ca2+ channels on the membrane 
open to allow an influx of extracellular Ca2+ into the cytosol. This produces a T-type Ca2+ 
current (ICa, T), which further depolarizes the cell to about -40mV. L-type Ca2+ channels on 
the membrane then open at this membrane potential to allow a greater influx of extracellular 
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Ca2+ into the cytosol and produce an L-type Ca2+ current (ICa, L) to a membrane potential 
until the threshold to produce an action potential is reached. Action potentials generated in 
the SA nodal cells are conducted to CMs within the working myocardium via gap junctions, 
ultimately resulting in regular contractions of the adult heart. 
CaV3.1 mRNA and protein were simultaneously detected as early as embryonic day 14 (E14) 
after the heart has fully matured in vivo within mouse embryos (Cribbs et al., 2001). In a 
separate experiment, the mRNA level of CaV3.1 was moderately reduced from E18 when 
compared to its expression at adult stage (Yasui et al., 2005). Ni2+ at a high concentration of 
100μM could be used to selectively block 50% of CaV3.1 T-type channels. The application of 
Ni2+ at this concentration was found to reduce ICa, T by about 40% in CMs derived from 
mouse embryos at E12.5, indicating that the CaV3.1 T-type channels were functional by this 
time-point (Cribbs et al., 2001). In addition, homozygous null CaV3.1-/- mice displayed 
bradycardia, i.e. a reduced rate of cardiac contraction (Mangoni et al., 2006). Expression of 
CaV3.1 has also been studied in vitro. Its mRNA could be detected as early as day 5 and 
generally increased up until its last measurement at day 15 post-differntiation in ht7 mouse 
ESC- (mESC-) derived CMs (Mizuta et al., 2005). In R1 mESC-derived CMs, however, CaV3.1 
mRNA could only be detected at two copies per cell by day 12, with its expression reaching 
the highest level at day 23 and declining by day 34 post-differentiation; the expression 
pattern reflected the amplitudes of ICa, T measured at these time-points. (Zhang et al., 2003). 
A reduction of about 46% in CaV3.1 expression from day 9.5 to day 23.5 post-differentiation 
was also reported in EMG7 mESC-derived CMs; this down-regulation was found to be 
associated with a decrease in the contraction rates of the CMs in that ICa, T was smaller in 
non-contracting myocytes at day 23.5 when compared to contracting CMs at day 9.5 and 
that the contraction rate at day 9.5 could be reduced via the application of 10μM efonidipine, 
an L- and T-type blocker, to the CMs (Yanagi et al., 2007). These data suggested a role for 
CaV3.1 in regulating the early contractions observed in the developing embryonic heart; by 
maintaining these contractions exclusively in developing pacemaker cells, other cells could 
then develop into non-contracting atrial or ventricular cells.  
CaV3.2 mRNA was detected as early as eight-week gestation in humans (Qu and Boutjdir, 
2001). In mouse, the expression of CaV3.2 was also measured at three time-points; its mRNA 
was detected as early as E9.5 and then its level was decreased by E18 until it was no longer 
detected at adult stage (Yasui et al., 2005). Again, CaV3.2 has been studied in vitro. Its mRNA 
was detected as early as day 5, but peaked at day 6 and gradually declined and was still 
detectable up until the last measurement at day 15 post-differentiation in ht7 mESC-derived 
CMs (Mizuta et al., 2005). In line with this finding, CaV3.2 mRNA level was also found to be 
down-regulated by about 24% from day 9.5 to day 23.5 post-differentiation in EMG7 mESC-
derived CMs (Yanagi et al., 2007). Ni2+ at a low concentration of <50μM could be used to 
selectively block 50% of CaV3.2 T-type channels. When Ni2+ was applied at 40μM to ht7 
mESC-derived CMs at day 8 post-differentiation, ICa, T was found to be evidently decreased 
by about 60%, which signified the presence of functional CaV3.2 T-type channels by this 
time-point. Homozygous null CaV3.2-/- mice showed no sign of cardiac arrhythmia, but 
cardiac fibrosis with age-dependent severity (Chen et al., 2003). These data suggested a role 
for CaV3.2 in regulating the growth and maturation of the developing embryonic heart.  
2.1.1 L-type calcium channels 
L-type Ca2+ channels are distinguished from other voltage-operated Ca2+ channels that open 
at high membrane potentials for long periods on the basis of their sensitivity to 1, 4-
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dihydropyridines (DHPs) (Hess et al., 1984). DHP-binding sites are contained within the α1 
subunit of L-type Ca2+ channels, which are encoded by either one of the four genes of the 
CaV1 sub-family. Among these, CaV1.1 is expressed predominantly in skeletal myocytes, 
CaV1.2 in adult CMs and CaV1.3 exclusively in SA nodal and atrial cells of the heart 
(Catterall, 2000; Qu et al., 2005). Unlike T-type, L-type Ca2+ channels are typical voltage-
operated Ca2+ channels, which are made up of five subunits. Together with one of each of 
the α2/δ1-4, β1-3 and 4, 6-8 ancillary subunits, CaV1.2- and CaV1.3-encoded α1 proteins form the 
functional L-type Ca2+ channels that are found within the adult heart (Freise et al., 1999; 
Hosey et al., 1996; Yang et al., 2011). 
CaV1.2 L-type Ca2+ channels are responsible for cardiac excitation-contraction coupling (E-C 
coupling), a mechanism by which an action potential is transformed into contraction in 
adult CMs. Upon the arrival of an action potential from SA nodal cells, L-type Ca2+ 
channels, which are clustered at transverse tubules (T-tubules), briefly open at the 
sarcolemma to allow an influx of extracellular Ca2+ into the cytosol of the CMs. This only 
accounts for about 30% of the increase in cytosolic Ca2+, which is maintained and magnified 
through a process known as calcium-induced calcium release (CICR) (Bers, 2002). CICR is 
mediated via ryanodine receptor (RyR) Ca2+ release channels, which detect the ICa, L and 
open to release Ca2+ from its intracellular stores within the SR into the cytosol of the CMs. 
This rise enhances binding of Ca2+ to troponin within the CMs, ultimately bringing about 
contractions of the adult heart. Conversely, CaV1.3 L-type Ca2+ channels are responsible for 
producing ICa, L, which constitutes one of the ionic currents to initiate action potentials at the 
SA node. Hence, these L-type Ca2+ channels contribute in maintaining the pacemaker 
activity of the adult heart (see ‘T-type calcium channels’ for details). 
Consistent with its role in E-C coupling in the adult heart, CaV1.2 mRNA was detected as 
early as eight-week gestation in humans, with its level culminating to its maximum at adult 
stage (Qu and Boutjdir, 2001). CaV1.2 mRNA was also present in vitro at <40 days post-
beating in H9.2 human ESC- (hESC-) derived CMs (Satin et al., 2008). In H7 hESC-derived 
CMs, Ca2+ transients that were detected at day 17 post-differentiation could be eliminated 
by the application of 10μM diltiazem, an L-type specific antagonist; this signified the 
functionality of L-type channels by this time-point (Zhu et al., 2009). Similar to humans, the 
expression of CaV1.2 was also up-regulated from its initial detection at E9.5 when the earliest 
contractions were observed by about three-fold at E15.5 when the heart has fully matured in 
mouse embryos; its protein was detected by E12.5 in mouse embryos (Acosta et al., 2004; Xu 
et al., 2003). In mESCs, patch clamp and Ca2+ imaging experiments indicated the functional 
expression of the ICa, L starting from differentiation day 7, even before the appearance of 
spontaneous contractions (Kolossov et al., 1998). The current density of ICa continued to 
increase to day 10, the day of beginning of spontaneous contractions in most differentiating 
embryoid bodies (EBs). Thereafter, similar current density was recorded on day 17, the last 
day of measurement (Kolossov et al., 1998). Homozygous null CaV1.2-/- mice died in utero by 
E14.5, probably due to an absence of CICR-regulated contractions, resulting in reduced 
oxygen supply to the embryos (Seisenberger et al., 2000). Despite the lethality observed, 
normal rhythmic contractions were sustained in the CaV1.2-/- mice until E12.5. For this 
reason, CICR was initially thought to be non-essential for regulating the early cardiac 
contractions observed before E12.5 until later time-points. This conclusion was further 
supported by the fact that both the contractions and Ca2+ oscillations of D3 mESC-derived 
CMs were insensitive to the application of 50nM nisoldipine, a specific L-type channel 
blocker, at days 8-11 post-differentiation (Viatchenko-Karpinski et al., 1999). In addition, 
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these cells were insensitive to the application of high K+ when compared to D3 mESC-
derived CMs at day 16 post-differentiation; exposure to high K+ at this stage would 
normally lead to immediate hyper-contraction and death of these cells. Albeit these findings, 
the notion that ICa, L was not required at earlier stages of development was overthrown 
when evidence for the existence of a compensatory mechanism emerged; the expression of 
CaV1.3 was eminently up-regulated at E9.5 and E12.5 by four fold to produce a DHPR-
insensitive ICa, L in CaV1.2-/- mouse embryos when compared to wild-type (Xu et al., 2003). 
This has not only reinstated the importance of ICa, L in maintaining cardiac contractions, even 
at the embryonic stage of the heart, but also appointed a new role for CaV1.3 to substitute for 
CaV1.2 and preserve its role in CICR for E-C coupling in its absence. In contrast with CaV1.2, 
CaV1.3 mRNA was detected by E9.5, with its level elevated only by a modest amount at 
E15.5 in mouse embryos. Its protein was also detected by E12.5 in mouse embryos (Xu et al., 
2003). Analogous to CaV3.1-/- mice, homozygous null CaV1.3-/- mice developed bradycardia, 
consistent with its primary role in regulating the pacemaker activity of the heart (Platzer et 
al., 2000; Zhang et al., 2002). In R1 mESC-derived CMs, the expression of L-type Ca2+ 
channels could be detected as early as day 7 post-differentiation; given that the application 
of 1μM nifedipine, an L-type channel-specific antagonist, could eliminate Ca2+ transients 
that were normally observed at early (days 9-11) and intermediate (days 13-15), but only 
partially inhibit those at late (18-21 days post-differentiation) stages, this indicated that L-
type channels were, in fact, playing a more dominant role at earlier developmental stages 
(Fu et al., 2006b). 
2.2 Regulation of intracellular calcium level by ligand-operated calcium release 
channels 
2.2.1 Ryanodine receptor (RyR) calcium release channels 
RyR-Ca2+ release channels of a molecular mass of greater than two Mega-Daltons probably 
form the largest ion channels known thus far (Lanner et al., 2010). RyR-Ca2+ release channels 
are composed of homo-tetramers of RyR proteins. Owing to its enormous size, structural 
elucidation of these channels has been a major challenge. Nonetheless, RyR-Ca2+ release 
channels have been predicted to be largely cytoplasmic, with an ion-conducting pore 
consisting of around four to twelve transmembrane segments. 
Three mammalian isoforms of RyRs exist; RyR1 is predominantly expressed in skeletal 
myocytes, RyR2 in CMs and RyR3 in astrocytes. The isoforms differ in three particular 
regions, which have been named domains D1-3 (Ma et al., 2004). As mentioned earlier in 
this chapter, RyR-Ca2+ release channels are induced to open in response to Ca2+ influx via L-
type Ca2+ channels to facilitate E-C coupling in muscle cells. In skeletal myocytes, E-C 
coupling takes place through direct physical interaction between RyR1 and the D2 region, 
which is located between segments S2 and S3 of the CaV1.1-encoded α1 subunit of L-type 
Ca2+ channels. In CMs, however, sequence divergence in the D2 domain between RyR1 and 
RyR2 means that RyR2 cannot physically interact with the CaV1.2-encoded α1 subunit of L-
type Ca2+ channels; E-C coupling can, therefore, only occur via CICR. RyR-Ca2+ release 
channels are, thus, organized into large arrays at junctions between the SR and the 
sarcolemma, in close proximity to the CaV1.2 L-type Ca2+ channels in adult CMs (Bers, 2004). 
Localized Ca2+ release events are referred to as Ca2+ sparks, which are collectively 
synchronized by ICa, L to produce large, whole cell Ca2+ transients in the CMs. 
Release of Ca2+ from the SR stores greatly increases the amount of cytosolic Ca2+ available to 
bind troponins in adult CMs. Adult CMs are mostly occupied by bouquets of thick and thin 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives  
 
208 
dihydropyridines (DHPs) (Hess et al., 1984). DHP-binding sites are contained within the α1 
subunit of L-type Ca2+ channels, which are encoded by either one of the four genes of the 
CaV1 sub-family. Among these, CaV1.1 is expressed predominantly in skeletal myocytes, 
CaV1.2 in adult CMs and CaV1.3 exclusively in SA nodal and atrial cells of the heart 
(Catterall, 2000; Qu et al., 2005). Unlike T-type, L-type Ca2+ channels are typical voltage-
operated Ca2+ channels, which are made up of five subunits. Together with one of each of 
the α2/δ1-4, β1-3 and 4, 6-8 ancillary subunits, CaV1.2- and CaV1.3-encoded α1 proteins form the 
functional L-type Ca2+ channels that are found within the adult heart (Freise et al., 1999; 
Hosey et al., 1996; Yang et al., 2011). 
CaV1.2 L-type Ca2+ channels are responsible for cardiac excitation-contraction coupling (E-C 
coupling), a mechanism by which an action potential is transformed into contraction in 
adult CMs. Upon the arrival of an action potential from SA nodal cells, L-type Ca2+ 
channels, which are clustered at transverse tubules (T-tubules), briefly open at the 
sarcolemma to allow an influx of extracellular Ca2+ into the cytosol of the CMs. This only 
accounts for about 30% of the increase in cytosolic Ca2+, which is maintained and magnified 
through a process known as calcium-induced calcium release (CICR) (Bers, 2002). CICR is 
mediated via ryanodine receptor (RyR) Ca2+ release channels, which detect the ICa, L and 
open to release Ca2+ from its intracellular stores within the SR into the cytosol of the CMs. 
This rise enhances binding of Ca2+ to troponin within the CMs, ultimately bringing about 
contractions of the adult heart. Conversely, CaV1.3 L-type Ca2+ channels are responsible for 
producing ICa, L, which constitutes one of the ionic currents to initiate action potentials at the 
SA node. Hence, these L-type Ca2+ channels contribute in maintaining the pacemaker 
activity of the adult heart (see ‘T-type calcium channels’ for details). 
Consistent with its role in E-C coupling in the adult heart, CaV1.2 mRNA was detected as 
early as eight-week gestation in humans, with its level culminating to its maximum at adult 
stage (Qu and Boutjdir, 2001). CaV1.2 mRNA was also present in vitro at <40 days post-
beating in H9.2 human ESC- (hESC-) derived CMs (Satin et al., 2008). In H7 hESC-derived 
CMs, Ca2+ transients that were detected at day 17 post-differentiation could be eliminated 
by the application of 10μM diltiazem, an L-type specific antagonist; this signified the 
functionality of L-type channels by this time-point (Zhu et al., 2009). Similar to humans, the 
expression of CaV1.2 was also up-regulated from its initial detection at E9.5 when the earliest 
contractions were observed by about three-fold at E15.5 when the heart has fully matured in 
mouse embryos; its protein was detected by E12.5 in mouse embryos (Acosta et al., 2004; Xu 
et al., 2003). In mESCs, patch clamp and Ca2+ imaging experiments indicated the functional 
expression of the ICa, L starting from differentiation day 7, even before the appearance of 
spontaneous contractions (Kolossov et al., 1998). The current density of ICa continued to 
increase to day 10, the day of beginning of spontaneous contractions in most differentiating 
embryoid bodies (EBs). Thereafter, similar current density was recorded on day 17, the last 
day of measurement (Kolossov et al., 1998). Homozygous null CaV1.2-/- mice died in utero by 
E14.5, probably due to an absence of CICR-regulated contractions, resulting in reduced 
oxygen supply to the embryos (Seisenberger et al., 2000). Despite the lethality observed, 
normal rhythmic contractions were sustained in the CaV1.2-/- mice until E12.5. For this 
reason, CICR was initially thought to be non-essential for regulating the early cardiac 
contractions observed before E12.5 until later time-points. This conclusion was further 
supported by the fact that both the contractions and Ca2+ oscillations of D3 mESC-derived 
CMs were insensitive to the application of 50nM nisoldipine, a specific L-type channel 
blocker, at days 8-11 post-differentiation (Viatchenko-Karpinski et al., 1999). In addition, 
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these cells were insensitive to the application of high K+ when compared to D3 mESC-
derived CMs at day 16 post-differentiation; exposure to high K+ at this stage would 
normally lead to immediate hyper-contraction and death of these cells. Albeit these findings, 
the notion that ICa, L was not required at earlier stages of development was overthrown 
when evidence for the existence of a compensatory mechanism emerged; the expression of 
CaV1.3 was eminently up-regulated at E9.5 and E12.5 by four fold to produce a DHPR-
insensitive ICa, L in CaV1.2-/- mouse embryos when compared to wild-type (Xu et al., 2003). 
This has not only reinstated the importance of ICa, L in maintaining cardiac contractions, even 
at the embryonic stage of the heart, but also appointed a new role for CaV1.3 to substitute for 
CaV1.2 and preserve its role in CICR for E-C coupling in its absence. In contrast with CaV1.2, 
CaV1.3 mRNA was detected by E9.5, with its level elevated only by a modest amount at 
E15.5 in mouse embryos. Its protein was also detected by E12.5 in mouse embryos (Xu et al., 
2003). Analogous to CaV3.1-/- mice, homozygous null CaV1.3-/- mice developed bradycardia, 
consistent with its primary role in regulating the pacemaker activity of the heart (Platzer et 
al., 2000; Zhang et al., 2002). In R1 mESC-derived CMs, the expression of L-type Ca2+ 
channels could be detected as early as day 7 post-differentiation; given that the application 
of 1μM nifedipine, an L-type channel-specific antagonist, could eliminate Ca2+ transients 
that were normally observed at early (days 9-11) and intermediate (days 13-15), but only 
partially inhibit those at late (18-21 days post-differentiation) stages, this indicated that L-
type channels were, in fact, playing a more dominant role at earlier developmental stages 
(Fu et al., 2006b). 
2.2 Regulation of intracellular calcium level by ligand-operated calcium release 
channels 
2.2.1 Ryanodine receptor (RyR) calcium release channels 
RyR-Ca2+ release channels of a molecular mass of greater than two Mega-Daltons probably 
form the largest ion channels known thus far (Lanner et al., 2010). RyR-Ca2+ release channels 
are composed of homo-tetramers of RyR proteins. Owing to its enormous size, structural 
elucidation of these channels has been a major challenge. Nonetheless, RyR-Ca2+ release 
channels have been predicted to be largely cytoplasmic, with an ion-conducting pore 
consisting of around four to twelve transmembrane segments. 
Three mammalian isoforms of RyRs exist; RyR1 is predominantly expressed in skeletal 
myocytes, RyR2 in CMs and RyR3 in astrocytes. The isoforms differ in three particular 
regions, which have been named domains D1-3 (Ma et al., 2004). As mentioned earlier in 
this chapter, RyR-Ca2+ release channels are induced to open in response to Ca2+ influx via L-
type Ca2+ channels to facilitate E-C coupling in muscle cells. In skeletal myocytes, E-C 
coupling takes place through direct physical interaction between RyR1 and the D2 region, 
which is located between segments S2 and S3 of the CaV1.1-encoded α1 subunit of L-type 
Ca2+ channels. In CMs, however, sequence divergence in the D2 domain between RyR1 and 
RyR2 means that RyR2 cannot physically interact with the CaV1.2-encoded α1 subunit of L-
type Ca2+ channels; E-C coupling can, therefore, only occur via CICR. RyR-Ca2+ release 
channels are, thus, organized into large arrays at junctions between the SR and the 
sarcolemma, in close proximity to the CaV1.2 L-type Ca2+ channels in adult CMs (Bers, 2004). 
Localized Ca2+ release events are referred to as Ca2+ sparks, which are collectively 
synchronized by ICa, L to produce large, whole cell Ca2+ transients in the CMs. 
Release of Ca2+ from the SR stores greatly increases the amount of cytosolic Ca2+ available to 
bind troponins in adult CMs. Adult CMs are mostly occupied by bouquets of thick and thin 
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filaments. Thick filaments are composed of myosin II molecules, while thin filaments are 
made up of troponin, tropomyosin and actin molecules. Troponin is itself a globular 
complex, which consists of three subunits, namely troponin T (TnT), troponin C (TnC) and 
troponin I (TnI). The TnT subunit binds tropomyosin, which coils around strands of actin 
molecules in the thin filament. Binding of Ca2+ to the TnC subunit induces a conformational 
change in the TnI subunit, thereby removing the steric hindrance on actin from 
tropomyosin. Binding of myosin II to actin can then occur, inducing a conformational 
change in the complex. This pulls the actin-associated thin filament pass the myosin II-
associated thick filament, resulting in a contracting phenomenon in the CMs. 
RyR2 protein was present as early as day 17 post-differentiation in H7 hESC-derived CMs 
(Zhu et al., 2009). In H9.2 hESC-derived CMs, the application of a puff of 10mM caffeine was 
able to induce Ca2+ release from the SR as early as day 2 post-beating; this signified the 
functionality of RyR-channels in these cells at this early time-point (Satin et al., 2008). In 
mouse embryos, RyR2 mRNA was detected as early as E8.5, the level of which continued to 
increase up until its last measurement at E16.5 (Rosemblit et al., 1999). Ca2+ release from the 
SR was inducible by the application of 10mM caffeine, indicating the functionality of RyR2 
channels by E8.5 in mouse embryos. In a different study, RyR2 protein was also detected at 
E18 and the detection persisted until adult stage (Liu et al., 2002). Homozygous null RyR2-/- 
mice died at E10, displaying morphological abnormalities in the heart tube (Takeshima et 
al., 1998). RyR2 expression has also been studied in vitro in mESC-derived CMs. RyR2 
mRNA and protein were detected as early as day 5 and day 9 post-differentiation in mESC-
derived CMs respectively (Boheler et al., 2002; Fu et al., 2006a). Immunohistochemistry 
revealed a continuous increase in RyR immunofluorescence intensity in differentiation day 
15-25 CMs compared with differentiation day 8-11 CMs, suggesting an increasing density of 
RyRs during cardiac differentiation (Sauer et al., 2001). The application of 10mM caffeine 
elicited Ca2+ transients, the amplitudes of which increased from day 8 to day 17 post-
differentiation in mESC-derived CMs (Kapur and Banach, 2007). Hence, RyR2 channels 
were functional by day 8 post-differentiation in mESC-derived CMs. RyR2-/- knockout R1 
mESC-derived CMs exhibited no difference in the amplitudes of Ca2+ transients but 
contractions at a reduced rate from early (days 9-11) to intermediate (days 13- 15) to late 
(days 18-21 post-differentiation) differentiation stages when compared with wild-type (Fu et 
al., 2006a; Yang et al., 2002). The applications of 10μM ryanodine and 10mM caffeine were 
able to inhibit and induce Ca2+ release from the SR respectively. Cardiac differentiation was 
not affected, as indicated by the number of contracting colonies present in the differentiating 
cultures. Both effects of ryanodine and caffeine were seen to increase with time post-
differentiation, indicating that SR Ca2+ loads increased during differentiation (Fu et al., 
2006a; Sauer et al., 2001). Altogether, these findings suggested a role for RyR to mediate SR 
Ca2+ release, thereby regulating the rate of the earliest contractions observed in the 
developing embryonic heart, and that this regulation increases with differentiation.  
2.2.2 Inositol 1, 4, 5-trisphosphate Receptor (IP3R) calcium release channels 
IP3R Ca2+ release channels represent a type of enigmatic intracellular Ca2+ channels in that 
both its structure and function(s) are not fully understood (Foskett et al., 2007; Taylor et al., 
2004; Taylor and Tovey, 2010; Yule et al., 2010). IP3R-Ca2+ release channels can be formed 
from either homo- or hetero-tetramers of IP3R proteins. Each subunit of IP3R proteins 
contains an IP3-binding domain at its N-terminus and six transmembrane segments (S1-6) at 
its C-terminus; the Ca2+-selective pore is formed at segments S5-6. Three mammalian 
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isoforms of IP3R exist, namely IP3R1, IP3R2 and IP3R3. These isoforms differ in their binding 
affinities for IP3, with IP3R2 being the most and IP3R3 being the least sensitive to the ligand 
(Iwai et al., 2007; Tu et al., 2005). All three IP3Rs are expressed in human adult CMs, but 
their subcellular localizations have not been studied (Nakazawa et al., 2011; Uchida et al., 
2010). In rat adult CMs, these are expressed at about 50-fold lower than those of RyRs; 
IP3R1s are localized around the nuclear envelope and SR, both of which are connected, 
while IP3R2s are dispersed throughout the cytosol in a punctate pattern (Bare et al., 2005; Li 
et al., 2005; Moschella and Marks, 1993). Thus far, the role of IP3Rs in the adult heart has not 
been defined, but an up-regulation in their expression has been associated with conditions 
of cardiac failure in that the mRNA levels of IP3R1 and IP3R2 were increased by 123% and 
93% respectively in failing compared with normal heart tissues (Ai et al., 2005; Go et al., 
1995). 
Activation of IP3R-Ca2+ release channels is regulated by both the concentration of cytosolic 
Ca2+ ions and the binding of IP3 to one or more of the IP3-binding domains (Iino, 1990; 
Taylor and Laude, 2002). Low concentrations of cytosolic Ca2+ ions are known to activate 
pore opening, while high concentrations inhibit it. IP3 is a second messenger that is 
generated via a G protein-coupled receptor-mediated signal transduction pathway. G 
protein-coupled receptors are transmembrane receptors that are able to sense external 
stimuli and relay these signals into the cell via their interactions with cytosolic G proteins. G 
proteins are heterotrimeric complexes, which consist of a GDP-bound Gα subunit and a Gβ 
dimer. G protein-coupled receptors are classified into different types according to the 
isoform of the Gα subunits contained within their G protein-interacting partners. Generation 
of IP3 involves the stimulation of a Gq type of G protein-coupled receptors. Upon 
stimulation with their agonists, a conformational change is induced in the Gq protein-
coupled receptors. This causes an exchange of GDP for GTP in the Gα subunits, which then 
dissociate from their Gq protein complexes. GTP-bound Gα subunits of Gq protein complexes 
are responsible for activating phospholipase C. It is this enzyme, which hydrolyses 
phosphatidylinositol 4, 5-bisphosphate (PIP2), a phospholipid component of the plasma 
membrane, to ultimately yield IP3 and another second messenger, diacylglycerol (DAG). IP3 
then binds to and activates IP3R-Ca2+ release channels. 
IP3R mRNA was present at detectable levels in D3 mESCs at the undifferentiated state 
(Yanagida et al., 2004). Application of 5μM ATP generated a Ca2+ transient in the 
undifferentiated D3 mESCs, which was inhibited by pre-treatment with 75μM 2-APB, an 
IP3R blocker. This verified the functionality of IP3R-channels in these cells. In H9.2 hESCs, 
immunostaining indicated that both IP3R1 and IP3R2 were expressed in hESC-dervied CMs 
(Sedan et al., 2010; Sedan et al., 2008); and the expression of IP3R2 was shown to gradually 
decline with maturation as revealed by quantitative RT-PCR (Satin et al., 2008). The 
expression of IP3R was also tested during development in vivo; its mRNA was first 
measured and detected as early as E5.5 in mouse embryos; it was present at high levels by 
E8.5 and continued to increase until E16.5 when its level started to drop (Rosemblit et al., 
1999). These were demonstrated to be functional at two time-points; application of 5μM of 
IP3 was able to induce Ca2+ release from the SR in CMs derived from mouse embryos at E5.5 
and E8.5. Application of 5μM xestospongin C, an IP3R antagonist, to mouse embryos at E10 
diminished its Ca2+ spiking; washing the drug out allowed slow recovery of this spiking 
activity (Mery et al., 2005). Likewise, application of 5μM xestospongin C also abrogated the 
Ca2+ spiking activity observed in CGR8 mESC-derived CMs at day 8-10 post-differentiation. 
In addition, during the whole course of cardiac differentiation of R1 mESCs, 2-APB 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives  
 
210 
filaments. Thick filaments are composed of myosin II molecules, while thin filaments are 
made up of troponin, tropomyosin and actin molecules. Troponin is itself a globular 
complex, which consists of three subunits, namely troponin T (TnT), troponin C (TnC) and 
troponin I (TnI). The TnT subunit binds tropomyosin, which coils around strands of actin 
molecules in the thin filament. Binding of Ca2+ to the TnC subunit induces a conformational 
change in the TnI subunit, thereby removing the steric hindrance on actin from 
tropomyosin. Binding of myosin II to actin can then occur, inducing a conformational 
change in the complex. This pulls the actin-associated thin filament pass the myosin II-
associated thick filament, resulting in a contracting phenomenon in the CMs. 
RyR2 protein was present as early as day 17 post-differentiation in H7 hESC-derived CMs 
(Zhu et al., 2009). In H9.2 hESC-derived CMs, the application of a puff of 10mM caffeine was 
able to induce Ca2+ release from the SR as early as day 2 post-beating; this signified the 
functionality of RyR-channels in these cells at this early time-point (Satin et al., 2008). In 
mouse embryos, RyR2 mRNA was detected as early as E8.5, the level of which continued to 
increase up until its last measurement at E16.5 (Rosemblit et al., 1999). Ca2+ release from the 
SR was inducible by the application of 10mM caffeine, indicating the functionality of RyR2 
channels by E8.5 in mouse embryos. In a different study, RyR2 protein was also detected at 
E18 and the detection persisted until adult stage (Liu et al., 2002). Homozygous null RyR2-/- 
mice died at E10, displaying morphological abnormalities in the heart tube (Takeshima et 
al., 1998). RyR2 expression has also been studied in vitro in mESC-derived CMs. RyR2 
mRNA and protein were detected as early as day 5 and day 9 post-differentiation in mESC-
derived CMs respectively (Boheler et al., 2002; Fu et al., 2006a). Immunohistochemistry 
revealed a continuous increase in RyR immunofluorescence intensity in differentiation day 
15-25 CMs compared with differentiation day 8-11 CMs, suggesting an increasing density of 
RyRs during cardiac differentiation (Sauer et al., 2001). The application of 10mM caffeine 
elicited Ca2+ transients, the amplitudes of which increased from day 8 to day 17 post-
differentiation in mESC-derived CMs (Kapur and Banach, 2007). Hence, RyR2 channels 
were functional by day 8 post-differentiation in mESC-derived CMs. RyR2-/- knockout R1 
mESC-derived CMs exhibited no difference in the amplitudes of Ca2+ transients but 
contractions at a reduced rate from early (days 9-11) to intermediate (days 13- 15) to late 
(days 18-21 post-differentiation) differentiation stages when compared with wild-type (Fu et 
al., 2006a; Yang et al., 2002). The applications of 10μM ryanodine and 10mM caffeine were 
able to inhibit and induce Ca2+ release from the SR respectively. Cardiac differentiation was 
not affected, as indicated by the number of contracting colonies present in the differentiating 
cultures. Both effects of ryanodine and caffeine were seen to increase with time post-
differentiation, indicating that SR Ca2+ loads increased during differentiation (Fu et al., 
2006a; Sauer et al., 2001). Altogether, these findings suggested a role for RyR to mediate SR 
Ca2+ release, thereby regulating the rate of the earliest contractions observed in the 
developing embryonic heart, and that this regulation increases with differentiation.  
2.2.2 Inositol 1, 4, 5-trisphosphate Receptor (IP3R) calcium release channels 
IP3R Ca2+ release channels represent a type of enigmatic intracellular Ca2+ channels in that 
both its structure and function(s) are not fully understood (Foskett et al., 2007; Taylor et al., 
2004; Taylor and Tovey, 2010; Yule et al., 2010). IP3R-Ca2+ release channels can be formed 
from either homo- or hetero-tetramers of IP3R proteins. Each subunit of IP3R proteins 
contains an IP3-binding domain at its N-terminus and six transmembrane segments (S1-6) at 
its C-terminus; the Ca2+-selective pore is formed at segments S5-6. Three mammalian 
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isoforms of IP3R exist, namely IP3R1, IP3R2 and IP3R3. These isoforms differ in their binding 
affinities for IP3, with IP3R2 being the most and IP3R3 being the least sensitive to the ligand 
(Iwai et al., 2007; Tu et al., 2005). All three IP3Rs are expressed in human adult CMs, but 
their subcellular localizations have not been studied (Nakazawa et al., 2011; Uchida et al., 
2010). In rat adult CMs, these are expressed at about 50-fold lower than those of RyRs; 
IP3R1s are localized around the nuclear envelope and SR, both of which are connected, 
while IP3R2s are dispersed throughout the cytosol in a punctate pattern (Bare et al., 2005; Li 
et al., 2005; Moschella and Marks, 1993). Thus far, the role of IP3Rs in the adult heart has not 
been defined, but an up-regulation in their expression has been associated with conditions 
of cardiac failure in that the mRNA levels of IP3R1 and IP3R2 were increased by 123% and 
93% respectively in failing compared with normal heart tissues (Ai et al., 2005; Go et al., 
1995). 
Activation of IP3R-Ca2+ release channels is regulated by both the concentration of cytosolic 
Ca2+ ions and the binding of IP3 to one or more of the IP3-binding domains (Iino, 1990; 
Taylor and Laude, 2002). Low concentrations of cytosolic Ca2+ ions are known to activate 
pore opening, while high concentrations inhibit it. IP3 is a second messenger that is 
generated via a G protein-coupled receptor-mediated signal transduction pathway. G 
protein-coupled receptors are transmembrane receptors that are able to sense external 
stimuli and relay these signals into the cell via their interactions with cytosolic G proteins. G 
proteins are heterotrimeric complexes, which consist of a GDP-bound Gα subunit and a Gβ 
dimer. G protein-coupled receptors are classified into different types according to the 
isoform of the Gα subunits contained within their G protein-interacting partners. Generation 
of IP3 involves the stimulation of a Gq type of G protein-coupled receptors. Upon 
stimulation with their agonists, a conformational change is induced in the Gq protein-
coupled receptors. This causes an exchange of GDP for GTP in the Gα subunits, which then 
dissociate from their Gq protein complexes. GTP-bound Gα subunits of Gq protein complexes 
are responsible for activating phospholipase C. It is this enzyme, which hydrolyses 
phosphatidylinositol 4, 5-bisphosphate (PIP2), a phospholipid component of the plasma 
membrane, to ultimately yield IP3 and another second messenger, diacylglycerol (DAG). IP3 
then binds to and activates IP3R-Ca2+ release channels. 
IP3R mRNA was present at detectable levels in D3 mESCs at the undifferentiated state 
(Yanagida et al., 2004). Application of 5μM ATP generated a Ca2+ transient in the 
undifferentiated D3 mESCs, which was inhibited by pre-treatment with 75μM 2-APB, an 
IP3R blocker. This verified the functionality of IP3R-channels in these cells. In H9.2 hESCs, 
immunostaining indicated that both IP3R1 and IP3R2 were expressed in hESC-dervied CMs 
(Sedan et al., 2010; Sedan et al., 2008); and the expression of IP3R2 was shown to gradually 
decline with maturation as revealed by quantitative RT-PCR (Satin et al., 2008). The 
expression of IP3R was also tested during development in vivo; its mRNA was first 
measured and detected as early as E5.5 in mouse embryos; it was present at high levels by 
E8.5 and continued to increase until E16.5 when its level started to drop (Rosemblit et al., 
1999). These were demonstrated to be functional at two time-points; application of 5μM of 
IP3 was able to induce Ca2+ release from the SR in CMs derived from mouse embryos at E5.5 
and E8.5. Application of 5μM xestospongin C, an IP3R antagonist, to mouse embryos at E10 
diminished its Ca2+ spiking; washing the drug out allowed slow recovery of this spiking 
activity (Mery et al., 2005). Likewise, application of 5μM xestospongin C also abrogated the 
Ca2+ spiking activity observed in CGR8 mESC-derived CMs at day 8-10 post-differentiation. 
In addition, during the whole course of cardiac differentiation of R1 mESCs, 2-APB 
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decreased both the amplitude and upstroke velocity of Ca2+ transients, with the inhibitory 
effect decreased as differentiation proceeded, suggesting that IP3R contributes to the Ca2+ 
transient and its effect decreases with differentiation (Fu et al., 2006b). In an attempt to 
discriminate between the roles of RyR- and IP3R2- channels, 50μM ryanodine was first used 
to block RyR-channels before the application of 5-20μM IP3-AM to CMs derived from mouse 
embryos at E10 (Rapila et al., 2008). This was able to induce a Ca2+ leak from the SR of the 
CMs in a concentration-dependent manner, whereby the slopes of the Ca2+ transients were 
elevated, despite its frequency stayed unchanged. In the absence of ryanodine, however, 
application of 10μM IP3-AM led to an increase in the frequency of Ca2+ transients and, 
hence, increased contractions in the CMs at E10. These data suggested a role for IP3R in 
regulating the rate of the earliest contractions observed in the developing embryonic heart, 
perhaps by providing a source of Ca2+ to bind RyRs so as to increase its open probability for 
greater Ca2+ release from the SR, as suggested by Rapila et al. (Rapila et al., 2008) In support 
of this finding, genetic knockdown of IP3R in CGR8 mESC-derived pacemaker cells resulted 
in weak and infrequent contractions, although differentiation was not affected, whilst mice 
over-expressing the IP3R2 gene developed mild cardiac hypertrophy by three months of age 
(Mery et al., 2005; Nakayama et al., 2010). 
2.3 Regulation of intracellular calcium level by exchanger and pump 
As previously mentioned, upon arrival of cardiac action potential, activation of L-type Ca2+ 
channel followed by CICR increases [Ca2+]i for the contraction process. Subsequently, the 
excess Ca2+ has to be removed in order to initiate relaxation. In CMs, this Ca2+ removal 
process is mediated by different Ca2+ extrusion mechanisms via the action of sodium-
calcium exchanger (NCX) and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). 
2.3.1 Sodium-calcium exchanger (NCX)  
NCX contains 9 transmembrane segments with a large loop at the cytoplasmic side 
(Philipson and Nicoll, 2000). Mutation experiments demonstrated the importance of -
helices in the transmembrane segments for the transport activity of NCX (Nicoll et al., 1996). 
The large intracellular loop is found to be not essential for the transport; however, it is 
important for catalyzing the ion translocation reaction and has important regulatory 
functions (Philipson and Nicoll, 2000). This loop consists of multiple regulatory sites, 
including the regulatory Ca2+ binding site and the exchanger inhibitory peptide (XIP) 
region. The activity of NCX is known to be regulated by at least 4 factors, including Ca2+ 
(DiPolo, 1979), Na+ (Hilgemann et al., 1992), PIP2 (Hilgemann, 1990), and phosphorylation 
(Iwamoto et al., 1996). Binding of Ca2+ to the Ca2+ binding site is required for activating the 
Na+-Ca2+ exchange activity (Giladi et al., 2010; Ottolia et al., 2004; Wu et al., 2010). On the 
other hand, the XIP region is responsible for the Na+-dependent inactivation and is involved 
in the elimination of the Na+-dependent inactivation process by PIP2 (Matsuoka et al., 1997). 
The activity of NCX is also regulated by phosphorylation, with stronger phosphorylation 
leading to higher NCX activity (Reppel et al., 2007a). Requirements of direct 
phosphorylation for up-regulation of NCX function by PKA and PKC are still in debate. A 
recent study by Wanichawan et al. demonstrated that the PKA phosphorylation site in full-
length NCX1 is inaccessible, suggesting that NCX1 is not a direct substrate of PKA 
(Wanichawan et al., 2011). On the other hand, another study showed that the activity of 
NCX1 is dependent on PKC, although direct phosphorylation by PKC is not required 
(Iwamoto et al., 1998). NCX exists in 3 different isoforms, namely NCX1, NCX2 and NCX3. 
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NCX1 is referred as the cardiac NCX isoform as it is highly expressed in CMs but only in a 
lesser extent in other tissues such as brain and kidney (Lee et al., 1994).  
NCX is classified as a secondary active transporter, which uses the energy stored in the 
electrochemical gradient in Na+ to extrude Ca2+ out of the cells, while the electrochemical 
gradient of Na+ is maintained by the Na+/K+-ATPase. Under normal condition, NCX 
operates in the forward mode in which it constitutively brings 3 Na+ into the cells and 
extrudes 1 Ca2+ in each translocation cycle. The forward mode is stimulated in response to a 
rise in [Ca2+]i, and it serves to bring [Ca2+]i back to normal level. In CMs, the primary role of 
NCX is to extrude Ca2+ after excitation under normal physiological conditions (Philipson 
and Nicoll, 2000). Some studies also showed that NCX functions in shaping the cardiac 
action potential. Application of NCX blocker KB-R7943 leads to shortening of plateau phase 
of cardiac potential (Spencer and Sham, 2003); similarly, CMs from NCX knockout mice also 
has a shorter AP when compare to wild-type mice (Pott et al., 2005), while induced over-
expression of NCX leads to a longer plateau (Wang et al., 2009). On the other hand, NCX 
also operates in the reverse mode in response to membrane depolarization in CMs. During 
the depolarization phase of action potential when the [Ca2+]i has not reached the peak of 
Ca2+ transients, the reverse mode is predominant (Sah et al., 2003). Ca2+ influx via the 
reverse mode of NCX has been suggested to act synergistically with Ca2+ influx via L-type 
Ca2+ channels to trigger Ca2+ release from the SR as ICa, L are small at depolarized membrane 
potential (Sah et al., 2003). In addition, NCX can positively regulate SR Ca2+ load via the 
reverse mode action (Hirota et al., 2007). Interestingly, under pathophysiological conditions 
such as cardiac failure, NCX also operates in the reverse mode to allow additional Ca2+ 
influx for contraction in order to compensate for the reduction in Ca2+ release from SR 
(Gaughan et al., 1999).  
NCX is found to be essential for embryo development. Several studies showed that NCX1 is 
expressed restrictedly in the embryonic heart during early development. NCX knockout are 
embryonic lethal at ~9-11 days post coitum with immature heart development (Cho et al., 
2000; Koushik et al., 2001; Reuter et al., 2003; Wakimoto et al., 2000). Molecular studies 
demonstrated that NCX mRNA expresses before the appearance of spontaneously beating 
mESC-CMs; the expression persists thereafter in the CMs (Fu et al., 2006b). It is suggested that 
expression of NCX at that early stage is essential for early EC-coupling as SR is not well-
developed at that stage, NCX is hence essential for maintaining the proper Ca2+ homeostasis 
even in the very early stage cardiac development (Reppel et al., 2007a; Reppel et al., 2007b).  
Two approaches were used to demonstrate the functional expression of NCX in ESC-CM. In 
Otsu et al. (Otsu et al., 2005), function of NCX was indirectly assessed by using high 
concentration of NCX blocker KB-R7943. Application of KB-R7943 induced sustained 
elevation of [Ca2+]i, and this elevation increased as differentiation of mESC-CMs proceeded 
(Otsu et al., 2005). Apart from using pharmacological blocker, direct measurement of NCX 
activity was performed by using patch-clamping. INCX was found to be increased as hESC-
CMs developed from day 7+40 to day 7+90 (Fu et al., 2010). However, CMs derived from 
murine embryonic heart at late stage (E16.5) showed a significantly lower INCX density when 
compared to CMs at early stage (E10.5) (Reppel et al., 2007a), probably due to the high 
phosphorylation status of NCX in early stage. Consistently, upon differentiation, the 
proportion of Ca2+ extrusion by NCX declined from day 9 to day 17 in mESC-CMs (Kapur 
and Banach, 2007). The discrepancy between different studies on the absolute functional 
expression of NCX as development proceeds is unknown. Nonetheless, it is clear that NCX 
is important for Ca2+ extrusion in differentiating CMs and the decreased contribution by 
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decreased both the amplitude and upstroke velocity of Ca2+ transients, with the inhibitory 
effect decreased as differentiation proceeded, suggesting that IP3R contributes to the Ca2+ 
transient and its effect decreases with differentiation (Fu et al., 2006b). In an attempt to 
discriminate between the roles of RyR- and IP3R2- channels, 50μM ryanodine was first used 
to block RyR-channels before the application of 5-20μM IP3-AM to CMs derived from mouse 
embryos at E10 (Rapila et al., 2008). This was able to induce a Ca2+ leak from the SR of the 
CMs in a concentration-dependent manner, whereby the slopes of the Ca2+ transients were 
elevated, despite its frequency stayed unchanged. In the absence of ryanodine, however, 
application of 10μM IP3-AM led to an increase in the frequency of Ca2+ transients and, 
hence, increased contractions in the CMs at E10. These data suggested a role for IP3R in 
regulating the rate of the earliest contractions observed in the developing embryonic heart, 
perhaps by providing a source of Ca2+ to bind RyRs so as to increase its open probability for 
greater Ca2+ release from the SR, as suggested by Rapila et al. (Rapila et al., 2008) In support 
of this finding, genetic knockdown of IP3R in CGR8 mESC-derived pacemaker cells resulted 
in weak and infrequent contractions, although differentiation was not affected, whilst mice 
over-expressing the IP3R2 gene developed mild cardiac hypertrophy by three months of age 
(Mery et al., 2005; Nakayama et al., 2010). 
2.3 Regulation of intracellular calcium level by exchanger and pump 
As previously mentioned, upon arrival of cardiac action potential, activation of L-type Ca2+ 
channel followed by CICR increases [Ca2+]i for the contraction process. Subsequently, the 
excess Ca2+ has to be removed in order to initiate relaxation. In CMs, this Ca2+ removal 
process is mediated by different Ca2+ extrusion mechanisms via the action of sodium-
calcium exchanger (NCX) and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA). 
2.3.1 Sodium-calcium exchanger (NCX)  
NCX contains 9 transmembrane segments with a large loop at the cytoplasmic side 
(Philipson and Nicoll, 2000). Mutation experiments demonstrated the importance of -
helices in the transmembrane segments for the transport activity of NCX (Nicoll et al., 1996). 
The large intracellular loop is found to be not essential for the transport; however, it is 
important for catalyzing the ion translocation reaction and has important regulatory 
functions (Philipson and Nicoll, 2000). This loop consists of multiple regulatory sites, 
including the regulatory Ca2+ binding site and the exchanger inhibitory peptide (XIP) 
region. The activity of NCX is known to be regulated by at least 4 factors, including Ca2+ 
(DiPolo, 1979), Na+ (Hilgemann et al., 1992), PIP2 (Hilgemann, 1990), and phosphorylation 
(Iwamoto et al., 1996). Binding of Ca2+ to the Ca2+ binding site is required for activating the 
Na+-Ca2+ exchange activity (Giladi et al., 2010; Ottolia et al., 2004; Wu et al., 2010). On the 
other hand, the XIP region is responsible for the Na+-dependent inactivation and is involved 
in the elimination of the Na+-dependent inactivation process by PIP2 (Matsuoka et al., 1997). 
The activity of NCX is also regulated by phosphorylation, with stronger phosphorylation 
leading to higher NCX activity (Reppel et al., 2007a). Requirements of direct 
phosphorylation for up-regulation of NCX function by PKA and PKC are still in debate. A 
recent study by Wanichawan et al. demonstrated that the PKA phosphorylation site in full-
length NCX1 is inaccessible, suggesting that NCX1 is not a direct substrate of PKA 
(Wanichawan et al., 2011). On the other hand, another study showed that the activity of 
NCX1 is dependent on PKC, although direct phosphorylation by PKC is not required 
(Iwamoto et al., 1998). NCX exists in 3 different isoforms, namely NCX1, NCX2 and NCX3. 
 
Maintenance Of Calcium Homeostasis in Embryonic Stem Cell-Derived Cardiomyocytes 
 
213 
NCX1 is referred as the cardiac NCX isoform as it is highly expressed in CMs but only in a 
lesser extent in other tissues such as brain and kidney (Lee et al., 1994).  
NCX is classified as a secondary active transporter, which uses the energy stored in the 
electrochemical gradient in Na+ to extrude Ca2+ out of the cells, while the electrochemical 
gradient of Na+ is maintained by the Na+/K+-ATPase. Under normal condition, NCX 
operates in the forward mode in which it constitutively brings 3 Na+ into the cells and 
extrudes 1 Ca2+ in each translocation cycle. The forward mode is stimulated in response to a 
rise in [Ca2+]i, and it serves to bring [Ca2+]i back to normal level. In CMs, the primary role of 
NCX is to extrude Ca2+ after excitation under normal physiological conditions (Philipson 
and Nicoll, 2000). Some studies also showed that NCX functions in shaping the cardiac 
action potential. Application of NCX blocker KB-R7943 leads to shortening of plateau phase 
of cardiac potential (Spencer and Sham, 2003); similarly, CMs from NCX knockout mice also 
has a shorter AP when compare to wild-type mice (Pott et al., 2005), while induced over-
expression of NCX leads to a longer plateau (Wang et al., 2009). On the other hand, NCX 
also operates in the reverse mode in response to membrane depolarization in CMs. During 
the depolarization phase of action potential when the [Ca2+]i has not reached the peak of 
Ca2+ transients, the reverse mode is predominant (Sah et al., 2003). Ca2+ influx via the 
reverse mode of NCX has been suggested to act synergistically with Ca2+ influx via L-type 
Ca2+ channels to trigger Ca2+ release from the SR as ICa, L are small at depolarized membrane 
potential (Sah et al., 2003). In addition, NCX can positively regulate SR Ca2+ load via the 
reverse mode action (Hirota et al., 2007). Interestingly, under pathophysiological conditions 
such as cardiac failure, NCX also operates in the reverse mode to allow additional Ca2+ 
influx for contraction in order to compensate for the reduction in Ca2+ release from SR 
(Gaughan et al., 1999).  
NCX is found to be essential for embryo development. Several studies showed that NCX1 is 
expressed restrictedly in the embryonic heart during early development. NCX knockout are 
embryonic lethal at ~9-11 days post coitum with immature heart development (Cho et al., 
2000; Koushik et al., 2001; Reuter et al., 2003; Wakimoto et al., 2000). Molecular studies 
demonstrated that NCX mRNA expresses before the appearance of spontaneously beating 
mESC-CMs; the expression persists thereafter in the CMs (Fu et al., 2006b). It is suggested that 
expression of NCX at that early stage is essential for early EC-coupling as SR is not well-
developed at that stage, NCX is hence essential for maintaining the proper Ca2+ homeostasis 
even in the very early stage cardiac development (Reppel et al., 2007a; Reppel et al., 2007b).  
Two approaches were used to demonstrate the functional expression of NCX in ESC-CM. In 
Otsu et al. (Otsu et al., 2005), function of NCX was indirectly assessed by using high 
concentration of NCX blocker KB-R7943. Application of KB-R7943 induced sustained 
elevation of [Ca2+]i, and this elevation increased as differentiation of mESC-CMs proceeded 
(Otsu et al., 2005). Apart from using pharmacological blocker, direct measurement of NCX 
activity was performed by using patch-clamping. INCX was found to be increased as hESC-
CMs developed from day 7+40 to day 7+90 (Fu et al., 2010). However, CMs derived from 
murine embryonic heart at late stage (E16.5) showed a significantly lower INCX density when 
compared to CMs at early stage (E10.5) (Reppel et al., 2007a), probably due to the high 
phosphorylation status of NCX in early stage. Consistently, upon differentiation, the 
proportion of Ca2+ extrusion by NCX declined from day 9 to day 17 in mESC-CMs (Kapur 
and Banach, 2007). The discrepancy between different studies on the absolute functional 
expression of NCX as development proceeds is unknown. Nonetheless, it is clear that NCX 
is important for Ca2+ extrusion in differentiating CMs and the decreased contribution by 
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NCX to Ca2+ extrusion as development proceeds may be explained by the gradual 
development of SERCA on the SR.  
In the study by Fu et al., the basal [Ca2+]i of mESC-CMs in both early and late developmental 
stages was increased after applying Na+-free solution, suggesting that NCX is functional in 
maintaining Ca2+ homeostasis (Fu et al., 2006b). Interestingly, Na+-free solution completely 
blocked the Ca2+ transients in CMs from late developmental stage but not the CMs from 
early developmental stage, suggesting that NCX starts to regulate Ca2+ transients only in the 
late developmental stage (Fu et al., 2006b). Similar results were obtained from hESC-CMs 
(Fu et al., 2010). Basal [Ca2+]i was marginally increased in CMs at day 7+90 after applying 
Na+-free solution, but the same was not observed in CMs at day 7+40. In addition, irregular 
Ca2+ transient pattern was observed in day 7+90 CMs treated with Na+-free solution (Fu et 
al., 2010). These suggested that the contribution of NCX to Ca2+ transients becomes more 
important as development proceeds in ESC-CMs.  
2.3.2 Sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) 
Details of the structure and function relationship of SERCA have been extensively reviewed 
(Periasamy et al., 2008; Periasamy and Huke, 2001; Toyoshima, 2008; Toyoshima and Inesi, 
2004; Wuytack et al., 2002). SERCA is a single polypeptide with ~1000 amino acid residues 
located on the ER/SR membrane. It consists of 10 transmembrane (M) domains and 3 
cytosolic domains, including actuator (A) domain, phosphorylation (P) domain, and 
nucleotide-binding (N) domain. A domain regulates the Ca2+ binding and release. N domain 
is connected to the P domain; it contains the adenosine binding site and forms the catalytic 
site. On the other hand, the -phosphate reacts with an amino acid residue in the P domain. 
SERCA utilizes the energy derived from ATP hydrolysis to pump Ca2+ against concentration 
gradient from the cytosol to the lumen of ER/SR. Two Ca2+ are transported by hydrolysis of 
one ATP in each catalytic cycle.  
Regulation of SERCA is mainly achieved by the action of SR membrane proteins 
phospholamban and sarcolipin (Asahi et al., 2003a; Edes and Kranias, 1987; MacLennan et 
al., 2002; MacLennan and Kranias, 2003; Simmerman and Jones, 1998; Traaseth et al., 2008). 
De-phosphorylated form of phospholamban interacts with SERCA and inhibits the 
pumping activities by decreasing the Ca2+ affinity of SERCA. Phospholamban exists in 
monomeric or pentameric form, while the monomeric form is inhibitory. Phosphorylation of 
phospholamban favors the formation of pentameric form, which in turns relieves the 
inhibitory effect on SERCA. Phosphorylation of phospholamban is regulated by cAMP-
dependent protein kinase (Schwinger et al., 1998) and Ca2+/calmodulin-dependent kinase (Ji 
et al., 2003). Sarcolipin is a shorter homolog of phospholamban (Hellstern et al., 2001). 
Unlike phospholamban, sarcolipin has no obvious phosphorylation site (Odermatt et al., 
1997); therefore, the effect of sarcolipin on SERCA inhibition is mainly controlled by altering 
the expression level of sarcolipin (Odermatt et al., 1998). Sarcolipin interacts directly with 
SERCA and inhibits its function by decreasing the Ca2+ affinity of SERCA. Sarcolipin can 
also exert its superinhibitory effect on SERCA by forming the tertiary complex 
phospholamban-sarcolipin-SERCA (Asahi et al., 2002; Asahi et al., 2003b). In addition, 
sarcolipin stabilizes the SERCA-phospholamban complex in the absence of phospholamban 
phosphorylation and also inhibits phospholamban phosphorylation (Asahi et al., 2004). 
SERCA plays a vital role in Ca2+ cycling between SR and cytosol, and this is important for 
EC-coupling. Over-expression of SERCA2a improved cardiac contractility by increasing SR 
Ca2+ loading and frequency of Ca2+ transients (Baker et al., 1998; He et al., 1997; Maier et al., 
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2005; Prasad et al., 2004). On the other hand, homozygous SERCA2a knockout mice are 
embryonic lethal (Periasamy et al., 1999), while heterozygous knockout mice are alive and 
able to reproduce (Shull et al., 2003). Ji et al. has reported that the content of SR Ca2+ stores 
and the amplitude of Ca2+ transients were decreased by 40-60% and ~30-40%, respectively, 
in heterozygous CMs (Ji et al., 2000). Interestingly, heterozygous CMs showed a reduced 
phospholamban expression, an enhanced phospholamban phosphorylation, and an 
upregulated NCX expression. However, these changes in Ca2+ handling proteins were not 
sufficient to compensate the effects on contractility by the loss of SERCA2a, indicating that 
SERCA2a is a critical regulator in controlling the E-C coupling of CMs (Ji et al., 2000). Apart 
from genetic manipulation of the expression level of SERCA, function of SERCA can also be 
assessed by using the pharmacological blocker thapsigargin. Acute application of 
thapsigargin caused the decrease in Ca2+ transient amplitude, rate of decay of Ca2+ 
transients, and duration of action potential in isolated ventricular myocytes (Kirby et al., 
1992), again suggesting the involvement of SERCA in the E-C coupling of CMs. 
In vertebrates, SERCA is encoded by three genes, including the SERCA1, SERCA2, and 
SERCA3. Alternative splicing of the transcripts from these genes produces more than 10 
SERCA isoforms. In CMs, SERCA2a and SERCA2b are expressed, with SERCA2a being the 
predominant form (Periasamy and Kalyanasundaram, 2007).  
SERCA2a mRNA is present before initial contraction of mESC-CMs, but has no obvious 
change in expression level during further differentiation (Fu et al., 2006b). From embryo 
studies, SERCA2 protein increased from E9.5 to E18 in mouse heart (Liu et al., 2002). In 
human, it was reported that SERCA2a protein level remained steady between 8 to 15th week 
gestation, and started to increase afterwards (Qu and Boutjdir, 2001). Role of SERCA in 
regulating Ca2+ transients in ESC-CMs has been studied by several groups. Zhu et al. 
demonstrated that SERCA inhibitors, including thapsigargin and cyclopiazonic acid, 
reduced ~70% amplitude of Ca2+ transients in hESC-CMs, but had no effect on the time of 
decay (Zhu et al., 2009). In case of mESC-CMs, thapsigargin reduced both the amplitude and 
decay of Ca2+ transients, but exerted similar inhibitory effect on CMs from the 3 
developmental stages (Fu et al., 2006a; Fu et al., 2006b). These findings are therefore 
consistent with the mRNA expression level of SERCA during mESC-CM differentiation. 
However, the contribution of Ca2+ removal by SERCA is estimated to be more important as 
differentiation proceeds based on Ca2+ imaging experiments (Kapur and Banach, 2007). 
Therefore, the role of other SR Ca2+ handling proteins cannot be neglected. For example, 
expression level of calsequestrin increases as SR matures (Fu et al., 2006a). This increases the 
capacity of SR Ca2+ load and may account for the requirement of greater contribution of Ca2+ 
removal by SERCA in later developmental stage of mESC-CMs. 
To summarize for the whole chapter, Figure 1 represents a summary of the relative 
contributions of different proteins responsible for regulating Ca2+ transients in early 
differentiating ESC-CMs as development proceeds.  
3. Conclusion 
In summary, early differentiating ESC-CMs have already developed a scheme for regulating 
their [Ca2+]i for E-C coupling. The relative contributions of the proteins that regulate Ca2+ 
transients alter upon the maturation of CMs. By comparing the regulation of [Ca2+]i in ESC-
CMs and that in adult CMs, we can obtain important insights into the potential strategies for 
‘fine-tuning’ ESC-CMs to better-suit different therapeutic and research purposes.  
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Fig. 1. Summary of the regulation of Ca2+ transients in CMs at early differentiation stage 
(EDS) and late differentiation stage (LDS). Number of a particular protein represents the 
relative changes in the expression level of that particular protein as differentiation proceeds. 
Thickness of the arrows represents the relative contribution of a particular path to the Ca2+ 
transients as differentiation proceeds.  
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to improve a patient’s quality of life. Nevertheless, cell therapy using embryonic or somatic 
stem cells is considered to offer the best potential for success, and many projects are now 
being undertaken to evaluate the therapeutic possibilities of this approach. 
Theoretically, due to their pluripotency, embryonic stem cells can give rise to any type of 
tissue, and raises the possibility of successfully treating many diseases. However, a simple 
injection of ES cells into various body locations in model organisms often leads to formation 
of undesirable teratomas and not to healthy new tissues. Accordingly, ES cells must be 
partially differentiated and selected prior to injection to increase the likelihood of 
implantation and growth of tissue exhibiting differentiation of the desired type. 
Although some modest advances have been achieved, to date the use of ES cells for therapy 
of neuromuscular disorders still remains a distant goal. In this review we mainly consider 
the role of embryonic stem cells in neuromuscular therapeutic approaches.  
2. Muscular dystrophies  
The neuromuscular disorders form a heterogeneous group of genetic diseases characterized 
by progressive loss of muscular strength caused by defects in or absence of muscle proteins 
and also to imbalance between rates of tissue degeneration and regeneration. There is great 
clinical variability, ranging from extremely mild to severe forms (Emery, 2002). 
More than 30 genetically defined forms are recognized, and in the last decade, mutations in 
several genes coding for the sarcolemmal, sarcomeric, cytosolic or nuclear muscle proteins 
have been reported. Deficiencies or loss of function of these proteins leads to variable 
degrees of progressive muscle degeneration, which in turn results in progressive loss of 
motor ability (Vainzof et al., 2003). The principle proteins involved occupy specific niches in 
muscle cells: dystrophin (Dmd), sarcoglycan (Sgca) and dysferlin (Dysf) are sarcolemmal or 
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extracellular matrix proteins; telethonin (Tcap) and actin alpha 1 (Acta1) are sarcomeric 
proteins; calpain 3 (Capn3) and FKRP (Fkrp) are cytosolic enzymes; and emerin (Emd) and 
lamin A/C (Lmna/c)are nuclear proteins (Figure 1). 
 
 
Fig. 1. Schematic representation of proteins involved in the process of muscle degeneration 
in neuromuscular disorders, localized at the sarcolemma, the sarcomere, the cytosol and the 
nucleus. The boxes contain the disease name associated with the protein. LGMD – limb-
girdle muscular dystrophy; EDMD- Emery-Dreifuss muscular dystrophy; FKRP – fukutin-
related protein; NOS – nitric oxide synthase. 
Defects in components of the dystrophin-glycoprotein complex (DGC) are known to be an 
important cause of different forms of muscular dystrophies (Ervasti & Campbell, 1993; 
Yoshida & Ozawa, 1990). The DGC is an oligomeric complex connecting the 
subsarcolemmal cytoskeleton to the extracellular matrix.  The DGC consists of dystroglycan 
(- and -DG), sarcoglycan (, -, -, - and -SG) and syntrophin/dystrobrevin sub-
complexes. The intracellular link of the DGC is the protein dystrophin that plays an 
important structural role in muscle fibers.  Mutations in the dystrophin gene cause the most 
common form of neuromuscular disorder, namely X-linked Duchenne muscular dystrophy 
(DMD) (Hoffman et al., 1987) with a frequency of 1 in 3000 males in most populations 
studied. Further, this disease epitomises the severe need for efficient treatment modalities, 
since 1/3rd of all patients arise from new mutations and the disease frequency can never be 
modulated efficiently by genetic counselling approaches. 
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Mutations in the genes coding the four SG proteins cause severe forms of limb-girdle 
muscular dystrophies type LGMD2D, 2E, 2C and 2F. The peripheral membrane glycoprotein 
-DG, a receptor for the heterotrimeric basement membrane protein laminin-2, binds to -
DG and so completes the connection from the inside to the outside of the cell (Straub and 
Campbell, 1997). Mutations in the Lama2 gene, encoding the 2 chain of laminin-2, cause 2-
laminin deficiency, and a severe form of congenital muscular dystrophy (CMD1A) linked to 
human chromosome 6q (Tomé et al., 1994). In addition, some forms of muscular dystrophy 
have recently been associated with genes encoding putative or known glycosyltransferases. 
Muscle protein analysis in these patients shows a hypoglycosilation of -dystroglycan and a 
consequent reduction of numerous ligands components of the extracellular matrix, such as 
laminin 2 (Muntoni et al., 2004).  Other milder forms of muscular dystrophy are caused by 
mutations in genes coding the enzyme calpain 3 (Capn3), the sarcolemmal protein dysferlin 
(Dysf), and the sarcomeric protein telethonin (Tcap) (Vainzof & Zatz, 2003). 
2.1 Animal models for neuromuscular diseases 
Several animal models, manifesting phenotypes observed in neuromuscular diseases have 
been identified in nature or generated in laboratory. These models generally present 
physiological alterations observed in human patients, and can be used as important tools for 
genetic, clinical and histopathological studies (Vainzof et al., 2008). 
The mdx mouse is the most widely used animal model for Duchenne muscular dystrophy 
(DMD) (Bulfield et al., 1984). Although it is a good genetic and biochemical model, 
presenting total deficiency of dystrophin in muscle, this mouse is not useful for clinical 
comparisons, because of its very mild phenotype. The canine golden retriever MD model 
presents a more clinically relevant model for DMD in humans due to the much larger size of 
the animals, significant muscle weakness progression and premature lethality.   
Models for autosomal recessive limb-girdle MD include the SJL/J mice that develop 
spontaneous myopathy resulting from a mutation in the Dysferlin gene, which is a 
specific model for LGMD2B (Bittner et al., 1999). For the human sarcoglycanopathies (SG), 
the BIO14.6 hamster is the spontaneous animal model for -SG deficiency, while some 
canine models with deficiency of SG proteins have also been identified (Straub et al., 
1998). More recently, using homologous recombination in embryonic stem cells, several 
mouse models have been developed with null mutations in each one of the four SG genes.  
All sarcoglycan-null animals display a progressive muscular dystrophy of variable 
severity, and share the property of a significant secondary reduction in the expression of 
the other members of the sarcoglycan subcomplex, and other components of the 
Dystrophin-glycoprotein complex.   
Mouse models for congenital MD include the dy/dy (dystrophia-muscularis) mouse, and the 
allelic mutant dy2J/dy2J mouse, both presenting a significant reduction of 2-laminin in the 
muscle and a severe phenotype. The myodystrophy mouse (Largemyd), harbors a mutation 
in the glycosyltransferase Large, which leads to altered glycosylation of -DG, and a severe 
phenotype (Grewal et al., 2001). 
Other informative models for muscle proteins include the knockout mouse for myostatin, 
demonstrating that this protein is a negative regulator of muscle growth (Patel & Amthor, 
2005).  Additionally, the stress syndrome in pigs, caused by mutations in the porcine Ryr1 
gene, helped to localize the gene causing malignant hyperthermia and Central Core 
myopathy in humans (Yang et al., 2006). 
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The study of animal models for genetic neuromuscular diseases, in spite of some differences 
with their equivalent human disease phenotypes, can provide important clues to 
understanding the pathogenesis of these disorders in humans and are also very valuable for 
testing strategies for cellular therapeutic approaches. 
3. Muscle development 
Activating key genes in a sequence similar to that occurring in the normal organism is a 
reasonable approach to obtain differentiated muscle cells in vitro. This depends on 
understanding the gene pathways leading to myogenic differentiation.  
Skeletal muscle development can be divided into a number of principal stages: 
determination of the cell fate (myoblast formation); myoblasts proliferation; alignment and 
fusion of myoblasts; formation of myotubes; maturation of myotubes and muscle fibre 




Fig. 2. Schematic of the myogenic cascade 
3.1 Anatomy of embryonic myogenesis – Myotome formation 
The majority of skeletal myogenic progenitors arise from somites, which are transitory 
condensations of paraxial mesoderm on either side of the neural tube and notochord. As the 
maturation of somites progresses, myogenic progenitor cells are confined to the epithelium 
of the dermomyotome, which give rise to the dermis and the skeletal muscle of the trunk 
and limbs (Buckingham, 2006). 
The dermomyotome is subdivided into the hypaxial dermomyotome – the source of the 
lateral trunk muscles and limb muscles – and the epaxial dermomyotome – the source of the 
deep back musculature (Parker et al., 2003). In this structure, it is possible to distinguish two 
lips: the hypaxial and epaxial lips, from which cells delaminate and migrate under the 
dermomyotome, forming the myotome, an intermediate structure (Buckingham, 2001) 
(Figure 3). 
3.2 Molecular markers and regulatory factors 
Pax3 and Pax7 are markers for cells derived from the dermomyotome and recently formed 
muscle masses. Pax3 expression is involved in progenitor muscle cell formation and is 
essential for the definition and migration of these cells to their proper location in the 
body. Pax3 acts mainly during embryogenesis, while Pax7 is more important in adult 
myogenesis. 
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Fig. 3. The origin of different muscles in the embryo. VLL – ventral lateral lip. DML – dorsal 
medial lip. (Adapted from Buckingham, 2001).  
The induction of myogenesis in the cells of somites is conducted by factors secreted by the 
notochord and neural tube: various members of the Wnt family and Shh, are responsible for 
the activation of MRFs (myogenic regulatory factors). Expression of Ctnnb1 (β-catenin) 
dependent Wnt6 signalling is important for the maintenance of the epithelial structure of the 
dermomyotome that is essential for the ordered progression of myogenesis. In epaxial 
muscle, Wnt family members are involved in Myf5 and MyoD regulation through a complex 
cascade of gene regulation that includes the action of Shh as a positive regulator of Myf5 
(Parker et al., 2003) (Figure 4 A). 
The MRFs concerned are MyoD, Myf5, myogenin and Myf6 (Mrf4) and each one has a 
defined role in regulating skeletal muscle development and differentiation, directing the 
expression of genes responsible for the formation of the contractile machinery of the muscle 
(Bryson-Richardson & Currie, 2008). All have a homologous bHLH domain, required for 
DNA binding and dimerization with transcription factors of the E-protein family. The 
complexes of MRF-E proteins bind to a specific consensus sequence found in the promoters 
of many muscle-specific genes.  
In hypaxial muscle, the MRFs are up-regulated by Pax3, which in turn, is regulated by 
family members of the sine oculis homeobox (Six) and eyes absent (Eya) genes (Bryson-
Richardson & Currie, 2008) (Figure 4 B). 
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Fig. 4. Gene regulatory networks in A- epaxial muscle (left) and in B- hypaxial muscle 
(right). 
Another important family of transcription factors is the myocyte enhancer factor-2 (Mef2), 
also involved in the expression of many muscle-protein genes in mouse (Naya & Olson, 
1999). The Mef2 family acts in conjunction with MRFs, especially Myf6 and Myog 
(myogenin), to coordinate myoblast terminal differentiation.  
3.3 Myogenesis in the adult – muscle regeneration 
The cells responsible for regeneration in adult muscle are the satellite cells, localized under 
the basal lamina of muscle fibers. The satellite cells are partially undifferentiated myogenic 
precursor cells capable of both self-renew and differentiation into new myogenic cells 
(Relaix & Marcelle, 2009). 
In response to injury, and under the stimulus of several myogenic factors, these cells are 
activated, start to proliferate and differentiate, fuse to pre-existing fibers (hypertrophy), or 
generate new fibers (hyperplasia) in a process recapitulating muscle development (Hawke 
& Garry, 2001). Myogenic determinants involve the components of the family of 
transcription factors called muscle regulatory factors (MRFs), include:  a) Myf5 and Myod1, 
responsible for muscle-cell type determination and satellite-cells activation; b) Myf6 (also 
called Mrf4) and Myog, responsible for muscle differentiation (Brand-Saberi & Christ, 1999). 
In addition to satellite cells, there are other cell types that contribute to muscle regeneration: 
bone-marrow derived cells (Ferrari et al., 1998), muscle side-population cells (Gussoni et al., 
1999), CD34+/Sca1+ cells (Torrente et al., 2001; Lee et al., 2000) and cells of vascular origin 
(Figure 5). 
The regenerative capacity of the satellite cells, however, is finite, and the exhaustion of the 
pool of precursor cells is an important factor contributing to the progressive muscle 
deterioration observed in human and murine muscular dystrophy. In fact, the exhaustion of 
satellite cells is the primary cause of onset of symptoms in Duchenne muscular dystrophy.  
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Fig. 5. Adult myogenesis and precursors cell types. Adapted from Parker et al., 2003. 
Thus, cell therapies for muscular dystrophies can also focus on the re-establishment of the 
muscle’s satellite cell pool, which reduces rapidly when there are excessive cycles of 
degeneration and regeneration.  
4. ES cells in myogenic differentiation 
Any attempt to direct the differentiation of ES cells must be designed so that the majority of 
cells will start to differentiate, as far as possibly, simultaneously into the desired cell type 
with avoidance of teratoma formation caused by non-committed pluripotent stem cells. 
Induction of appropriate myogenesis is a relatively difficult task given the unique 
architecture of muscle tissue. 
There are three main potential approaches to directed differentiation of ES cells into muscle: 
the use of muscle specific growth and differentiation factors, genetic modifications and use 
of genetically modified feeder cells (Grivennikov, 2008). The first two have already been 
tested for myogenic induction, but to date, there are no reports on the use of modified 
feeder cells for this purpose. 
For the differentiation of ES cells into different cell lineages, the cells must be cultivated in 
aggregates called embryoid bodies (EBs) by the hanging drop method (Figure 6), in which 
the 3-dimensional structure of the embryoid bodies, in combination with application of 
growth factors favouring myogenesis, encourages the stem cells to differentiate into 
myoblasts. The ES cells are first cultivated in drops of medium containing an exact number 
of cells leading to formation of EBs within 2 days, following which, the EBs are transferred 
into suspension cultures for some additional days resulting in adhesion of the EBs onto the 
bottom of tissue culture plates. The medium for EB cultivation is changed for one 
supporting myogenic differentiation at the time of EB adhesion. Studies suggest that the EBs 
need to be cultivated for five days in the suspension phase to obtain maximal differentiation 
into skeletal muscle cells. 
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Fig. 5. Adult myogenesis and precursors cell types. Adapted from Parker et al., 2003. 
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tested for myogenic induction, but to date, there are no reports on the use of modified 
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Fig. 6. Hanging drop method 
4.1 In vitro induction of myogenesis 
The use of chemical compounds to induce differentiation is a quite simple approach based 
on media supplementation. In some cases, different cell types can be obtained from the same 
compound according to the substance’s concentration. For instance, 1µM retinoic acid 
causes neuronal differentiation, while 25nM retinoic acid enhances skeletal myogenesis 
(Kennedy et al., 2009). 
One of the first reports of myogenic differentiation of ES cells was reported by Rohwedel et al. 
(1994), based on protocols developed by Wobus et al. in 1988 (2002), which depend on a prior 
differentiation in embryoid bodies followed by a posterior treatment with 1% DMSO 
(dimethyldisulfoxide) or 10-8M retinoic acid. The myogenic cells obtained in this work were 
identified as myoblasts and myotubes by hematoxylin-eosin staining. The first myosin-positive 
and desmin-positive skeletal muscle cells appeared four days after EB adhesion. Myogenin-
positive myocytes were identified after six days and fusion into myotubes on the seventh day. 
Neuronal cells also appeared mostly before the differentiation of skeletal muscle cells, which 
reached a maximum in nine days. However, some EB outgrowths containing ES cells, which 
decreased with prolonged time of differentiation. Using RT-PCR the authors detected 
expression of the myogenic regulatory factors myogenin, Myf5, Myf6 and Myod1, indicating 
that ES myogenic differentiation in vitro resembles myogenesis in vivo (Rohwedel et al., 1994).  
Retinoic acid (RA) is a derivate of vitamin A and has different roles in various processes in 
embryonic development and regulates the expression of several hundreds of genes 
(Blomhoff & Blomhoff, 2006), including MRFs. In stem cells and myoblast cells lines, RA 
enhances skeletal myogenesis at low concentrations (Edwards & McBurney, 1983; Halevy & 
Lerman, 1993; Albagli-Curiel et al., 1993, as cited in Kennedy et al., 2009). In the work of 
Kennedy et al. (2009), mouse ES cells and P19 cells (pluripotent embryonal carcinoma cells) 
were differentiated with various RA concentrations, ranging from zero to 50 nM and 
1%DMSO, that promotes skeletal myogenesis, but not cardiogenesis. They detected 
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increasing transcript levels of Meox1, Pax3 and Myod1 (all skeletal muscle markers) in the 
presence of various concentrations of RA by RT-PCR and showed that transcription peaked 
at a concentration of 25nM. 
Prelle et al. (2000) overexpressed the Igf2 gene (insulin-like growth factor 2) in mouse 
embryonic stem cells to evaluate this protein as a stimulator of myogenesis. Igf2 was 
identified as an autocrine differentiation factor in myoblasts (Stewart et al., 1996, as cited in 
Prelle et al., 2000). It is also a survival factor during the transition from proliferation to 
differentiation in myoblasts and overexpression of Igf2 in myoblasts results in enhanced 
differentiation characterized by accelerated expression of myogenin mRNA and extensive 
myotube formation (Stewart & Rotwein, 1996, as cited in Prelle et al., 2000). Embryoid 
bodies were formed by overexpression of Igf2 in ES cells and myocytes were observed three 
days after adhesion, with myotube formation four days later and commencement of 
myotube contraction after ten days. They also detected the expression of the myogenic 
proteins titin and sarcomeric Myhc (myosin heavy chain). On the last day of differentiation 
(day 23), the large contracting myotubes showed a regular sarcomeric organization of both 
titin and myosin proteins. 
By semi-quantitative RT-PCR, the expression onset and intensity of the skeletal muscle-
specific genes Myf5, Myod1 and Myog showed an increase in EB outgrowths overexpressing 
Igf2, with a similar pattern of expression to that occurring in vivo. Compared with non-
transformed cells, the cells overexpressing Igf2 showed an accelerated myogenic 
differentiation, associated with enhanced expression of MRFs, without effects in the 
sarcomeric structural organization. 
We recently tested different factors for differentiating murine embryonic stem cells into 
muscle. In terms of morphology, the cells obtained are very similar to myoblasts in primary 
culture. The cells obtained also express mRNA from some proteins typical of the process of 
myogenesis, but proteins of mature muscle were not detected. To induce myogenesis in 
mES cells, EBs were cultured in media with 1%DMSO or 5µL of 10-7M Igf2. After 13 days, 
cells were harvested for mRNA and protein analysis. Cells treated with Igf2 visually seemed 
to differentiate more rapidly and with a larger proportion of cells morphologically similar to 
myoblasts than the cells treated with DMSO (data not published) (Figure 7).  
 
 
Fig. 7. Embryoid body from mES cells treated with Igf2 twelve days after adhesion. Cells 
indicated by the arrows are similar in morphology to myoblasts. 
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4.2 In vivo experiments and potential of therapies for NMD  
Due to the lack of any available therapy for NMDs, cell therapy has been suggested as a 
promising alternative.  Several attempts to use adult stem cells have been carried out, but 
with limited results.  However, due to their greater pluripotency, ES cells show a greater 
potential for cell therapy, but can also form teratomas, when simply injected into the 
organism without predifferentiation, which must be avoided. Methods must be 
developed for inducing differentiation of the ES cells into the desired cell type before 
therapy, in such a way as to obtain a uniform population of differentiated cells, and, ideally, 
without the presence of undifferentiated ES cells.  
Although there are a reasonable number of articles describing derivation of cell lines with 
some skeletal muscle features, the functional results are far from ideal and more basic 
research into in vitro culturing procedures is required. The skeletal muscle tissue has a 
unique architecture, and it is very complicated to reproduce this in vitro, rendering it 
impossible to obtain totally differentiated cells prior to transplantation. Accordingly, 
transplants are best made with cells that are already committed to differentiating into the 
myogenic lineage but have not yet completed the process, which will occur in vivo following 
transplantation.  
Co-culturing of muscle stem/precursor cells from skeletal muscle with EB outgrowths can 
induce myogenic differentiation in vivo. This was achieved by Bhagavati & Xu, (2005) by 
obtaining muscle from normal mice and deriving ES cells by pre-plating muscle fragments 
and culturing EBs over them. The myogenic differentiation obtained in this manner is 
probably due to the myogenic stem/precursor cells being provided an optimal 
developmental environment by inductive signals for the EBs. Alternatively, it is possible 
that the occasional cell fusion between ES cells and myogenic precursor cells, results in the 
reprogramming of a limited number of ES cells. To test the potential of these cells to form 
skeletal muscle in vivo, the ES cells derived from co-culturing were injected into mdx mice 
via intramuscular injection. The muscles were analyzed after two weeks by 
immunohistochemical and in situ hybridization analyses. Dystrophin positive fibers that 
were lying on the surface of recipient muscle fibres were observed in 2 out of 8 injected 
mice. However, no functional evaluation was performed to test whether this newly derived 
muscle tissue was functionally normal (Bhagavati & Xu, 2005). 
Zheng et al. (2006) used three different media, and treatment with 10mM 5-azacytidine in 
some experiments, to induce myogenic differentiation in EBs derived from hES cells. The 5-
azacytidine treatment reduced cell proliferation and caused the cells to elongate. The 
expression analysis showed that the drug decreased the expression of Met and Pax3, but 
increased the expression of Pax7 and Myod1. The expression of Myf5, Des (desmin), Myhc, 
Tnni1 (troponin I), Ncam1 was observed under all culture conditions, but occurred in the 
absence of myotube and myofiber formation. This indicates that, although the treated cells 
had the potential to initiate myogenic gene expression, they were not yet committed to 
complete the process and form muscle cells. The transplantation of the human ES-derived 
precursors to NOD-SCID mice injured with cardiotoxin and irradiation resulted in the 
incorporation of approximately 28% of cells into host myofibers. In the adult environment, 
hES cells derived precursors followed the same sequence of muscle development as during 
embryogenesis: myoblasts expressed muscle-specific structural proteins, fused together to 
form myotubes and to mature into myofibers. Hybrid regenerated myofibers displayed 
striated myofibrils and expressed desmin, actinin, troponin I, dystrophin (human) and 
myosin heavy chain. The transplanted hES cells also gave rise to satellite cells, which can 
provide a semi-permanent source of donor cells (Zheng et al., 2006). 
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A mouse ES cell line (ZHTc6-MyoD) was established by Ozasa et al. (2007) by introducing a 
Myod1 transgene controlled by a Tet-Off system. This cell line is feeder-free, proliferates 
indefinitely and has the potential to differentiate almost exclusively into the myogenic lineage 
in the absence of doxycycline, and without pre-differentiation into embryoid bodies. To start 
the differentiation process, doxycycline is removed and a differentiation medium containing 
4% fetal bovine serum (FBS) is used. Although other FBS concentrations were tested, the best 
one for differentiation was found to be 4%. The morphology of ZHTc6-MyoD cells in an 
undifferentiated state is round, but after changing to differentiation medium, they became 
elongated. After seven days, they started to fuse into myotubes, and occasional light muscle 
contractions were observed. Besides Myod1 expression, the expression of desmin (day 4), 
myogenin (day 4) and dystrophin (day 8) was detected by Western blotting.  Pax7, Myod1, 
desmin, myosin heavy chain and dystrophin expression was assayed by immuno-
histochemical analysis. The cell’s potential to differentiate into myofibers in vivo was also 
investigated by intramuscular injections into mdx mice and clusters of dystrophin-positive 
myofibers were detected in the injected area (Ozasa et al., 2007). 
The use of hES cells in regenerative medicine requires pure cell populations, so that specific 
precursors are isolated; this is important to control cell differentiation into the desired 
lineage and avoid problems, such as teratomas. Barberi et al. (2007) developed a feeder-free 
induction system in monolayer culture to derive mesenchymal precursors from hES cells.  
The isolation of mesenchymal precursors was made using FACS (fluorescent activated cell 
sorting) of CD73+ cells, from which skeletal myoblasts were isolated by selecting for the 
expression of Ncam1 (neural cell adhesion molecule 1) in another round of cell sorting. 
When induced with N2 medium, these skeletal myoblasts underwent terminal 
differentiation and formed contractile myotubes. The majority of Ncam1+ cells expressed 
Myod1 and Myog in both undifferentiated and differentiated condition; however, the 
expression of mature muscle protein markers, such as myosin heavy chain 2a, desmin, 
skeletal muscle actin and sarcomeric myosin were present only in cells in terminal 
differentiation. After transplantation into a muscle injury model, long-term engraftment of 
hES cell-derived skeletal myoblasts was observed (Barberi et al., 2007). 
One of the reasons for the difficulty in obtaining skeletal muscle progenitors from ES cells is 
the scarcity of paraxial mesoderm formation in the embryoid body, due to the lack of signals 
from the neural tube and notochord that are only present in the embryo. Enhancement of 
paraxial mesoderm formation was  achieved by Darabi et al. (2008) by inducing Pax3 by 
doxycyclin and sorting EBs for the presence of the PDGF-α receptor (Pdgfr1) a paraxial 
mesoderm marker, and absence of Flk1 (synonymous with VEGFR in humans), which is a 
lateral plate mesoderm marker. The PDGFαR+Flk1- (Pdgfr1+/Flk1-) cell population is 
enriched under Pax3 induction for doxycycline, once paraxial mesoderm expansion is Pax3 
dependent in the embryo; this population shows proliferative capacity and myogenic 
potential. However, terminal muscle differentiation occurs only when Pax3 expression is 
removed and the cells exposed to a differentiation medium containing 2% horse serum. 
When transplanted into the tibialis anterior muscle of Rag2-/-γc-/- mice injured with 
cardiotoxin, the Pdgfr1+/Flk1- cells do not form teratomas and show muscle regeneration 
without the necessity of continuous Pax3 induction. In mdx mice, these cells exhibited 
significant engraftment and better functional properties (Darabi et al., 2008). 
The majority of transplantation experiments have been carried out in recessive models of 
muscular dystrophy, so it is unknown whether the same cellular therapies would produce 
equivalent results in dominant models. To address this question, Darabi et al. (2009) tested 
the therapeutic potential of the Pax3 induced Pdgfr1+/Flk1- cells in Frg1 transgenic mice, a 
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model for the dominant facioscapulohumeral muscular dystrophy (FSHD). Consistent with 
the results of the previous work, these cells showed appropriate engraftment and brought 
amelioration to muscle contractile properties, especially in males, perhaps due to gender 
differences. This work confirms the therapeutic potential of stem cells to treat both recessive 
and dominant forms of muscular dystrophy. 
According to Sakurai et al. (2008) the Pdgfr1+ population, when either positive or negative for 
Flk1, clearly consisted of paraxial mesoderm precursors, confirmed by the expression  Msgn1 
(mesogenin), Mesp2 and Tbx6. However, myotome and myogenic markers are not expressed 
by Pdgfr1+ cells, indicating that these cells have progressed to an early somatic stage, but are 
not yet completely committed to a specific lineage. When transplanted into the injured 
quadriceps femoris muscle of KSN nude mice, the Pdgfr1+ mesodermal progenitors are 
localized in the interstitial zone of muscles, adjacent to the myofibers. This localization 
suggests that these progenitor cells differentiated into satellite cells, which is confirmed by the 
expression of Pax7 and Cd34. Some progenitor nuclei are found in the center of myofibers, 
indicating the contribution of Pdgfr1+ cells to muscle regeneration (Sakurai et al., 2008). 
The culture of EBs in a differentiation medium composed by DMEM, 0.1 mM nonessential 
amino acids, 0.1 mM 2-mercaptoethanol, 5% horse serum and 10% fetal bovine serum, gives 
rise to cells expressing Pax7, but not Myod1, indicating the presence of quiescent satellite 
cells (Chang et al., 2009). These Pax7 positive cells were enriched by fluorescense activated 
sorting using the surface marker SM/C-2.6 antibody, typical of quiescent adult and neonatal 
mouse satellite cells. The SM/C-2.6 positive cells represented 15.7% of the EB derived cells. 
The SM/C-2.6 positive population showed myogenic potential both in vitro and in vivo 
experiments. In vivo, GFP+SM/C-2.6-positive cells were injected directly into cardiotoxin 
damaged muscles of mdx mice and were localized between the basal lamina and the muscle 
cell plasma membrane, which is the same location as satellite cells. After a second injury, a 
contribution of the injected cells to regeneration was observed, evidenced by the presence of 
GFP positive muscle fibers with central nuclei. In addition, the GFP+SM/C-2.6-positive cells 
were able to proliferate, and to replace recipient satellite cells that were still present 24 
weeks after transplantation, which is important for a continuous regeneration of the 
surrounding tissue (Chang et al., 2009). 
A summary of all published experiments to date are in table 1. 
 
 
Table 1. Summary of experiments testing the myogenic potential of ES cells. 
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5. Conclusion 
Several attempts to achieve appropriate differentiation of ES cells and implantation into 
model organisms have been tested with mixed results. The differentiation into the muscular 
lineage could be successfully obtained in vitro, as evidenced by the expression of myogenic 
markers.  However, despite attempts to direct in vivo differentiation, to date few reports 
have documented successful long term therapeutic results using these procedures. 
Strategies, such as selecting subpopulations of undifferentiated or partially differentiated 
embryonic stem cells before any kind of implantation treatment is undertaken, are emerging 
and should result in more homogenous cell populations and, diminish the frequency of 
maturation of stem cells into undesired cell types. In fact, the combination of several 
approaches, including cell sorting, genetic modification, and prior in vitro induction will 
probably be necessary to obtain successful therapeutic outcomes with ES cells. 
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model for the dominant facioscapulohumeral muscular dystrophy (FSHD). Consistent with 
the results of the previous work, these cells showed appropriate engraftment and brought 
amelioration to muscle contractile properties, especially in males, perhaps due to gender 
differences. This work confirms the therapeutic potential of stem cells to treat both recessive 
and dominant forms of muscular dystrophy. 
According to Sakurai et al. (2008) the Pdgfr1+ population, when either positive or negative for 
Flk1, clearly consisted of paraxial mesoderm precursors, confirmed by the expression  Msgn1 
(mesogenin), Mesp2 and Tbx6. However, myotome and myogenic markers are not expressed 
by Pdgfr1+ cells, indicating that these cells have progressed to an early somatic stage, but are 
not yet completely committed to a specific lineage. When transplanted into the injured 
quadriceps femoris muscle of KSN nude mice, the Pdgfr1+ mesodermal progenitors are 
localized in the interstitial zone of muscles, adjacent to the myofibers. This localization 
suggests that these progenitor cells differentiated into satellite cells, which is confirmed by the 
expression of Pax7 and Cd34. Some progenitor nuclei are found in the center of myofibers, 
indicating the contribution of Pdgfr1+ cells to muscle regeneration (Sakurai et al., 2008). 
The culture of EBs in a differentiation medium composed by DMEM, 0.1 mM nonessential 
amino acids, 0.1 mM 2-mercaptoethanol, 5% horse serum and 10% fetal bovine serum, gives 
rise to cells expressing Pax7, but not Myod1, indicating the presence of quiescent satellite 
cells (Chang et al., 2009). These Pax7 positive cells were enriched by fluorescense activated 
sorting using the surface marker SM/C-2.6 antibody, typical of quiescent adult and neonatal 
mouse satellite cells. The SM/C-2.6 positive cells represented 15.7% of the EB derived cells. 
The SM/C-2.6 positive population showed myogenic potential both in vitro and in vivo 
experiments. In vivo, GFP+SM/C-2.6-positive cells were injected directly into cardiotoxin 
damaged muscles of mdx mice and were localized between the basal lamina and the muscle 
cell plasma membrane, which is the same location as satellite cells. After a second injury, a 
contribution of the injected cells to regeneration was observed, evidenced by the presence of 
GFP positive muscle fibers with central nuclei. In addition, the GFP+SM/C-2.6-positive cells 
were able to proliferate, and to replace recipient satellite cells that were still present 24 
weeks after transplantation, which is important for a continuous regeneration of the 
surrounding tissue (Chang et al., 2009). 
A summary of all published experiments to date are in table 1. 
 
 
Table 1. Summary of experiments testing the myogenic potential of ES cells. 
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5. Conclusion 
Several attempts to achieve appropriate differentiation of ES cells and implantation into 
model organisms have been tested with mixed results. The differentiation into the muscular 
lineage could be successfully obtained in vitro, as evidenced by the expression of myogenic 
markers.  However, despite attempts to direct in vivo differentiation, to date few reports 
have documented successful long term therapeutic results using these procedures. 
Strategies, such as selecting subpopulations of undifferentiated or partially differentiated 
embryonic stem cells before any kind of implantation treatment is undertaken, are emerging 
and should result in more homogenous cell populations and, diminish the frequency of 
maturation of stem cells into undesired cell types. In fact, the combination of several 
approaches, including cell sorting, genetic modification, and prior in vitro induction will 
probably be necessary to obtain successful therapeutic outcomes with ES cells. 
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Blood vessels are essential for embryonic development and tissue homeostasis in adults 
(Coultas et al., 2005). They supply oxygen and nutrients and remove metabolic waste from 
tissues. Blood vessels also participate in intercellular communication. Secretion of 
growth/differentiation factors by blood vessels is essential for liver and pancreas 
organogenesis (Matsumoto et al., 2001; Lammert et al., 2001). Additionally, developing 
sympathetic neurons are guided by endothelins secreted by blood vessels (Makita et al., 
2008), and liver regeneration in adults is triggered by factors secreted by liver sinusoidal 
endothelial cells (Ding et al., 2010). 
In mice, vascular progenitor cells first develop in the posterior primitive streak in response 
to fibroblast growth factor-2 (FGF-2) and bone morphogenetic protein 4 (BMP4), and they 
are marked as vascular endothelial growth factor receptor 2 (VEGFR2)positive mesodermal 
cells (Fig. 1; Park et al., 2004; Flamme et al., 1995). These precursor cells are committed for 
development into the hematopoietic and/or vascular lineage (hemangioblasts or 
angioblasts), and they migrate into extra-embryonic sites including the yolk sac and 
allantois, as well as into intra-embryonic sites (Huber et al., 2004; Hiratsuka et al., 2005). In 
the yolk sac, these progenitors aggregate and form clusters known as blood islands. The 
outer cells of the blood islands differentiate into endothelial cells, whereas the inner cells 
give rise to hematopoietic progenitor cells. These cells subsequently form primary capillary 
plexuses (vasculogenesis). In contrast, intra-embryonic angioblasts do not form a plexus 
intermediately and directly assembles into the dorsal aorta or cardinal vein. The extra-
embryonic primary capillary plexuses then fuse with the intra-embryonic vessels to form a 
complete vascular network (angiogenesis). Angiopoietins and Tie receptors, along with 
vascular endothelial growth factor-A (VEGF-A) and Notch, are involved in this process 
(Thurston et al., 2003). Finally, mural cells that have differentiated in response to 
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transforming growth factor- (TGF-) are recruited to nascent vessels by platelet-derived 
growth factor (PDGF) secreted by endothelial cells (Betsholtz et al., 2005; Lebrin et al., 2005). 
This entire process ultimately leads to mature blood vessel formation. 
 
 
Fig. 1. Blood vessel formation during mouse development. EXE, extra-embryonic ectoderm; 
INE, intra-embryonic ectoderm; PPS, posterior primitive streak 
A number of extracellular signaling molecules are involved in vascular development, some 
of which, including FGF-2, angiopoietins, PDGF, and VEGF-A, transmit their signals 
through receptor tyrosine kinases (RTKs). Signal transduction pathways downstream of 
RTKs have been extensively studied, and most share downstream effector components such 
as the Ras-mitogenactivated kinase (Ras-MAPK) and the phosphatidylinositol-3’ kinase 
(PI3K) pathways. Intriguingly, these RTKs still transmit distinct signals and play unique 
roles that drive vascular development. The molecular basis for the observed signaling 
specificity remains unclear. To better understand this important process, we focused on 
signaling downstream of VEGFR2, a functional receptor for VEGF-A, using embryonic stem 
cellderived VEGFR2+ vascular progenitor cells (Suzuki et al., 2005; Kawasaki et al., 2008; 
Sase et al., 2009). VEGFR2-null mice demonstrate severe defects in vasculogenesis, and 
VEGFR2 signaling is thought to play crucial roles in embryonic blood vessel formation 
(Shalaby et al., 1995; Shalaby et al., 1997; see below for details). 
2. Use of differentiating embryonic stem cells for the study of lineage 
specification 
To elucidate the signaling pathways important for the endothelial differentiation of vascular 
progenitor cells, we employed an in vitro vascular differentiation system using mouse 
embryonic stem cells (ESC) (Hirashima et al., 1999; Yamashita et al., 2000). In vivo, vascular 
progenitor cells must migrate to the correct microenvironment where they receive a cue for 
endothelial specification and further proliferate. It is challenging to identify the 
contributions of distinct signaling pathways to each in vivo event that occurs during vascular 
development, but the use of the in vitro system has allowed us to focus on the signaling 
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events required for endothelial specification by providing well-defined supplements to the 
culture medium.  
We used ESC-derived vascular progenitor cells because it is practically impossible to 
prepare a sufficient amount of vascular progenitor cells from mouse embryos for 
biochemical study. In this in vitro system, ESCs are differentiated by culture on type IV-
collagencoated dishes in the absence of leukemia inhibitory factor (LIF) for four days, and 
during this time, mesodermal cells expressing VEGFR2 are induced. VEGFR2+ cells 
(comprising 510% of the total cell population) are then sorted by magnetic-activated cell 
sorting (MACS) and used as vascular progenitors. These cells differentiate into -smooth 
muscle actin-positive (SMA+) mural cells resembling vascular smooth muscle cells in the 
presence of PDGF-BB or serum, whereas they differentiate into platelet-endothelial adhesion 
molecule 1-positive (PECAM1+) endothelial cells in response to VEGF-A (Fig. 2; Yamashita 
et al., 2000; Ema et al., 2003; Watabe et al., 2003). Alteration of the differentiation fate of 
vascular progenitor cells was also examined by limiting dilution assay. VEGFR2+ cells were 
seeded at low density (90120 cells/cm2) and allowed to form single-cellderived colonies 
for four days. After immunostaining, the numbers of PECAM1+ or SMA+ colonies, which 
reflect the fate of differentiation, were counted. In the presence of VEGF-A, endothelial 
differentiation occurs at the expense of mural differentiation: stimulation with VEGF-A 
increases PECAM1+ colonies and decreases SMA+ colonies, while the total number of 
colonies remains constant. Thus, VEGF-A stimulation alters the differentiation fate of 
vascular progenitor cells. 
 
 
Fig. 2. In vitro vascular differentiation system (Yamashita et al., 2000) 
This in vitro system was originally established using CCE embryonic stem cells. However, 
we used MGZ-5 cells and MGZRTcH cells because they are more amenable to transgene 
expression. Accordingly, we first studied MGZ-5 cells expressing genes contained in the 
pCAGIP vector (Fujikura et al., 2002). MGZ-5 cells express polyoma large T antigen, and this 
allows the efficient episomal propagation of plasmids with a polyoma origin of replication 
such as pCAGIP. Thus, transgenes contained within the pCAGIP vector are stably expressed 
in MGZ-5 cells (supertransfection method, Gassmann et al., 1996). In later experiments, we 
used MGZRTcH cells derived from MGZ-5 cells (Masui et al., 2005) in which a target gene 
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can be knocked into the ROSA26 locus by homologous recombination using the Cre-loxP 
system, and gene expression is under the control of tetracycline (Tc) (tet-off system, Masui et 
al., 2005). Importantly, the ROSA26 locus is minimally affected by epigenetic silencing 
during cell differentiation (Zamobrowicz et al., 1997). Therefore, expression of a transgene 
knocked into this locus can be regulated by Tc during nearly any stage of differentiation. 
Using this in vitro system, we have successfully pursued two different lines of investigation 
of vasculogenesis: examination of downstream effectors of VEGFR2 signaling (Section 3) 
and screening of pharmacological inhibitors (Section 4). 
3. VEGFR2 transmits unique signals to induce endothelial differentiation 
VEGFR2, also known as Flk1 in mice and KDR in human, is a member of the VEGFR family 
of RTKs, which contains three members, VEGFGR1-3 (Fig. 3; Shibuya & ClaessonWelsh, 
2006). VEGFRs share characteristic structural features: they are composed of seven 
extracellular immunoglobulin-like domains, a transmembrane region, and an intracellular 
region with intrinsic tyrosine kinase activity. They have distinct expression profiles and 
different ligand specificities among VEGF family members.  
VEGFR1, also called Flt-1 (fms-like tyrosine kinase 1) is expressed in vascular endothelial 
cells, hematopoietic stem cells, macrophages, and monocytes. VEGFR2 is expressed in both 
vascular and lymphatic endothelial cells. VEGFR3, also called Flt-4 (fms-like tyrosine kinase 
4), is principally expressed in lymphatic endothelial cells. 
 
 
Fig. 3. VEGFR family members and their cognate ligands. The tyrosine kinase domains of 
VEGFRs are separated by the “kinase insert” of ~60 amino acid residues, a structural feature 
common to PDGF receptors and FGF receptors. The fifth immunoglobulin-like domain of 
VEGFR3 has an internal cleavage. The resultant N-terminal and C-terminal polypeptides are 
linked together by a disulfide bond. 
VEGF family members, including VEGF-A, -B, -C, -D and placenta growth factor (PlGF), 
regulate the development, growth and function of vascular as well as lymphatic endothelial 
cells (Ferrara et al., 2003). VEGF-A is bound by VEGFR2 and VEGFR1, which transmit 
signals essential for vasculogenesis and angiogenesis. VEGF-C and VEGF-D are bound by 
VEGFR2 and VEGFR3 and are both involved in lymphangiogenesis (Karkkainen et al., 2004; 
Baldwin et al., 2005). PlGF and VEGF-B signal through VEGFR1, and they contribute to 
pathological angiogenesis (Carmeliet et al., 2001; Mould et al., 2003) and endothelial fatty 
acid uptake (Hagberg et al., 2010). 
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3.1 Essential role of VEGFR2 during vasculogenesis 
Individual knock-out mice lacking VEGFR1, VEGFR2, or VEGFR3 all demonstrate vascular 
defects. VEGFR1-deficient mice exhibit disorganized vasculature secondary to endothelial 
cell overgrowth (Fong et al., 1995). VEGFR3 knockout mice have defects in vascular 
remodeling and develop fluid accumulations in the pericardial sac (Dumont et al., 1998). 
Blood vessel formation occurs in VEGFR1-/- and VEGFR3-/- mice. VEGFR1 and VEGFR3 are 
thus indispensable for angiogenesis but not vasculogenesis. In contrast, VEGFR2 plays 
essential roles during vasculogenesis. It is first expressed in the vascular progenitor cells at 
the posterior primitive streak. VEGFR2-deficient mice die in utero between 8.5 and 9.5 d.p.c. 
due to lack of organized blood vessels and hematopoietic cells. VEGFR2 signaling is 
required for the formation of blood islands at extraembryonic sites (Shalaby et al., 1995), 
where vascular endothelial cells and hematopoietic cells differentiate to form primary 
plexuses. In the absence of VEGFR2 signaling, vascular progenitor cells fail to migrate to 
extraembryonic sites from the posterior primitive streak (Shalaby et al., 1997). In the embryo 
proper, VEGFR2 signaling is required for endothelial specification of the vascular progenitor 
cells (Shalaby et al., 1997). Potential endothelial precursor cells are located at the correct 
anatomical niche, but they fail to complete the differentiation pathway. The identified roles 
of VEGFR2 signaling in vascular development in vivo include promoting the proliferation, 
migration, and differentiation of progenitor cells. Additionally, VEGF-A+/- mice have 
defects in vascular development (Carmeliet te a., 1996; Ferrara et al., 1996), but VEGF-C-/- 
mice and VEGF-D-/- mice exhibit lymphatic defects (Karkkainen et al., 2004; Baldwin et al., 
2005). Therefore, the VEGF-A/VEGFR2 axis appears to be essential for vasculogenesis.  
Because VEGFR2+ mesodermal cells can give rise to lineages other than endothelial and 
hematopoietic cells, including vascular mural cells, skeletal muscle cells, and 
cardiomyocytes (Motoike et al., 2003; Ema et al., 2006), differentiation of VEGFR2+ cells 
should be appropriately specified. We examined the nature of this unique and specific 
signaling.  
3.2 VEGFR2, but not VEGFR3, directs endothelial differentiation 
Although VEGFRs differ in their ligand-binding properties, their intracellular domains 
share structural similarities. However, the signaling properties of VEGFRs remain 
incompletely understood.  
VEGF-A, which initiates signaling from both VEGFR1 and VEGFR2, promotes the 
differentiation of endothelial cells from ESC-derived VEGFR2+ cells, whereas PlGF, a 
specific ligand for VEGFR1, fails to induce endothelial differentiation despite VEGFR1 
expression by precursor cells (Yamashita et al., 2000). Thus, VEGFR1 signaling does not 
direct endothelial differentiation. We then examined the ability of VEGFR3 to induce 
endothelial differentiation (Suzuki et al., 2005). While VEGFR3 is not expressed by VEGFR2+ 
vascular progenitor cells, we ectopically expressed VEGFR3 to examine whether VEGFR3 
signaling induces endothelial cell differentiation.  
3.2.1 VEGFR3 fails to induce endothelial differentiation 
VEGFR3 cDNA was introduced into MGZ-5 ES cells using the supertransfection technique 
followed by drug selection (Gassmann et al., 1996). VEGFR2+ vascular progenitor cells were 
then collected from the transfected cells after in vitro differentiation (Suzuki et al., 2005). 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 248 
can be knocked into the ROSA26 locus by homologous recombination using the Cre-loxP 
system, and gene expression is under the control of tetracycline (Tc) (tet-off system, Masui et 
al., 2005). Importantly, the ROSA26 locus is minimally affected by epigenetic silencing 
during cell differentiation (Zamobrowicz et al., 1997). Therefore, expression of a transgene 
knocked into this locus can be regulated by Tc during nearly any stage of differentiation. 
Using this in vitro system, we have successfully pursued two different lines of investigation 
of vasculogenesis: examination of downstream effectors of VEGFR2 signaling (Section 3) 
and screening of pharmacological inhibitors (Section 4). 
3. VEGFR2 transmits unique signals to induce endothelial differentiation 
VEGFR2, also known as Flk1 in mice and KDR in human, is a member of the VEGFR family 
of RTKs, which contains three members, VEGFGR1-3 (Fig. 3; Shibuya & ClaessonWelsh, 
2006). VEGFRs share characteristic structural features: they are composed of seven 
extracellular immunoglobulin-like domains, a transmembrane region, and an intracellular 
region with intrinsic tyrosine kinase activity. They have distinct expression profiles and 
different ligand specificities among VEGF family members.  
VEGFR1, also called Flt-1 (fms-like tyrosine kinase 1) is expressed in vascular endothelial 
cells, hematopoietic stem cells, macrophages, and monocytes. VEGFR2 is expressed in both 
vascular and lymphatic endothelial cells. VEGFR3, also called Flt-4 (fms-like tyrosine kinase 
4), is principally expressed in lymphatic endothelial cells. 
 
 
Fig. 3. VEGFR family members and their cognate ligands. The tyrosine kinase domains of 
VEGFRs are separated by the “kinase insert” of ~60 amino acid residues, a structural feature 
common to PDGF receptors and FGF receptors. The fifth immunoglobulin-like domain of 
VEGFR3 has an internal cleavage. The resultant N-terminal and C-terminal polypeptides are 
linked together by a disulfide bond. 
VEGF family members, including VEGF-A, -B, -C, -D and placenta growth factor (PlGF), 
regulate the development, growth and function of vascular as well as lymphatic endothelial 
cells (Ferrara et al., 2003). VEGF-A is bound by VEGFR2 and VEGFR1, which transmit 
signals essential for vasculogenesis and angiogenesis. VEGF-C and VEGF-D are bound by 
VEGFR2 and VEGFR3 and are both involved in lymphangiogenesis (Karkkainen et al., 2004; 
Baldwin et al., 2005). PlGF and VEGF-B signal through VEGFR1, and they contribute to 
pathological angiogenesis (Carmeliet et al., 2001; Mould et al., 2003) and endothelial fatty 
acid uptake (Hagberg et al., 2010). 
Dissecting the Signal Transduction Pathway that Directs Endothelial  
Differentiation Using Embryonic Stem Cell-Derived Vascular Progenitor Cells 249 
3.1 Essential role of VEGFR2 during vasculogenesis 
Individual knock-out mice lacking VEGFR1, VEGFR2, or VEGFR3 all demonstrate vascular 
defects. VEGFR1-deficient mice exhibit disorganized vasculature secondary to endothelial 
cell overgrowth (Fong et al., 1995). VEGFR3 knockout mice have defects in vascular 
remodeling and develop fluid accumulations in the pericardial sac (Dumont et al., 1998). 
Blood vessel formation occurs in VEGFR1-/- and VEGFR3-/- mice. VEGFR1 and VEGFR3 are 
thus indispensable for angiogenesis but not vasculogenesis. In contrast, VEGFR2 plays 
essential roles during vasculogenesis. It is first expressed in the vascular progenitor cells at 
the posterior primitive streak. VEGFR2-deficient mice die in utero between 8.5 and 9.5 d.p.c. 
due to lack of organized blood vessels and hematopoietic cells. VEGFR2 signaling is 
required for the formation of blood islands at extraembryonic sites (Shalaby et al., 1995), 
where vascular endothelial cells and hematopoietic cells differentiate to form primary 
plexuses. In the absence of VEGFR2 signaling, vascular progenitor cells fail to migrate to 
extraembryonic sites from the posterior primitive streak (Shalaby et al., 1997). In the embryo 
proper, VEGFR2 signaling is required for endothelial specification of the vascular progenitor 
cells (Shalaby et al., 1997). Potential endothelial precursor cells are located at the correct 
anatomical niche, but they fail to complete the differentiation pathway. The identified roles 
of VEGFR2 signaling in vascular development in vivo include promoting the proliferation, 
migration, and differentiation of progenitor cells. Additionally, VEGF-A+/- mice have 
defects in vascular development (Carmeliet te a., 1996; Ferrara et al., 1996), but VEGF-C-/- 
mice and VEGF-D-/- mice exhibit lymphatic defects (Karkkainen et al., 2004; Baldwin et al., 
2005). Therefore, the VEGF-A/VEGFR2 axis appears to be essential for vasculogenesis.  
Because VEGFR2+ mesodermal cells can give rise to lineages other than endothelial and 
hematopoietic cells, including vascular mural cells, skeletal muscle cells, and 
cardiomyocytes (Motoike et al., 2003; Ema et al., 2006), differentiation of VEGFR2+ cells 
should be appropriately specified. We examined the nature of this unique and specific 
signaling.  
3.2 VEGFR2, but not VEGFR3, directs endothelial differentiation 
Although VEGFRs differ in their ligand-binding properties, their intracellular domains 
share structural similarities. However, the signaling properties of VEGFRs remain 
incompletely understood.  
VEGF-A, which initiates signaling from both VEGFR1 and VEGFR2, promotes the 
differentiation of endothelial cells from ESC-derived VEGFR2+ cells, whereas PlGF, a 
specific ligand for VEGFR1, fails to induce endothelial differentiation despite VEGFR1 
expression by precursor cells (Yamashita et al., 2000). Thus, VEGFR1 signaling does not 
direct endothelial differentiation. We then examined the ability of VEGFR3 to induce 
endothelial differentiation (Suzuki et al., 2005). While VEGFR3 is not expressed by VEGFR2+ 
vascular progenitor cells, we ectopically expressed VEGFR3 to examine whether VEGFR3 
signaling induces endothelial cell differentiation.  
3.2.1 VEGFR3 fails to induce endothelial differentiation 
VEGFR3 cDNA was introduced into MGZ-5 ES cells using the supertransfection technique 
followed by drug selection (Gassmann et al., 1996). VEGFR2+ vascular progenitor cells were 
then collected from the transfected cells after in vitro differentiation (Suzuki et al., 2005). 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 250 
These cells differentiated into PECAM1+ endothelial cells in response to VEGF-C 
stimulation. Although VEGF-C is bound by both VEGFR2 and VEGFR3, it does not promote 
endothelial differentiation through endogenous VEGFR2 signaling, because it failed to 
induce endothelial differentiation of mock-transfected cells. We next examined the effect of 
VEGF-C(C152S), a mutant that selectively stimulates VEGFR3 (Kirkin et al., 2001). This 
mutant did not induce endothelial differentiation, but it caused vascular progenitor cell 
differentiation into mural cells (Suzuki et al., 2005). Thus, VEGFR3 signaling alone is not 
sufficient to induce endothelial differentiation. It remains possible that VEGF-C induces 
endothelial differentiation through heterodimer formation between ectopic VEGFR3 and 
endogenous VEGFR2 in these experimental conditions. Collectively, these findings indicate 
that VEGFR2 has unique properties among VEGFR family members even in this in vitro 
system.  
3.2.2 The intracellular domain of VEGFR2 can transmit signals for endothelial 
differentiation 
We next examined the intracellular events downstream of VEGFR2 that are required for 
endothelial differentiation. For this purpose, we constructed a chimeric receptor (denoted 
R32) that is composed of the extracellular and the transmembrane domains of VEGFR3 
fused with the intracellular domain of VEGFR2 (Fig. 4; Sase et al., 2009).  We then 
established ES cell lines expressing either R32 or VEGFR3 under the control of the Tc-
regulated promoter in MGZRTcH cells (denoted Tc-R32 and Tc-VEGFR3, respectively). 
  
 
Fig. 4. Schematic structure of the chimeric receptor R32  
VEGFR2+ vascular progenitor cells prepared from these cell lines differentiated into 
PECAM1+ cells following VEGF-A stimulation, indicating that these cell lines retain their 
ability to differentiate into endothelial cells. However, VEGFR2+ cells derived from Tc-R32, 
but not Tc-VEGFR3, differentiated into PECAM1+ cells upon stimulation with VEGF-
C(C152S). The PECAM1+ cells were also positive for other endothelial markers (VE-
cadherin, CD34, and endoglin) and appeared to be endothelial cells. Therefore, the 
differences in phenotypes between VEGFR2+ cells derived from Tc-R32 and Tc-VEGFR3 
cells are due to intrinsic properties of the intracellular domains of VEGFR2 and VEGFR3. 
The intracellular domain of VEGFR2 is sufficient to direct endothelial differentiation of ESC-
derived vascular progenitor cells. 
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3.2.3 Tyrosine 1175 of human VEGFR2 is required for endothelial specification of 
vascular progenitor cells and endothelial cell survival 
The role of signal transduction pathways downstream of VEGFR2 for cell proliferation, 
migration and survival have been well explored in mature endothelial cells. Five tyrosine 
residues (Y951, Y1054, Y1059, Y1175, and Y1214) have been identified in the intracellular 
domain of VEGFR2 as major phosphorylation sites (Matsumoto et al., 2005). Y1054 and Y1059 
are located in the activation loop of the kinase domain and are required for the activation of 
intrinsic kinase activity. The remaining tyrosine residues are located outside of the kinase 
domain and are required for recruitment of downstream effectors. Phosphorylation of Y1175 
leads to phospholipase C-activation, followed by protein kinase C (PKC) -mediated Raf 
activation to induce cell proliferation (Takahashi et al., 2000). Y1175 is also involved in the 
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Fig. 5. Signal transduction downstream of VEGFR2 
Y1173 in mouse VEGFR2 (corresponding to Y1175 in humans) is indispensable for blood 
vessel formation in vivo (Sakurai et al., 2005). VEGFR2 Y1173F knock-in mice died between 
E8.5 and E9.5, similar to VEGFR2-null mice. In Y1173F knock-in mice, VEGFR2+ vascular 
progenitor cells failed to migrate into the yolk sac to form blood islands, and, because 
vasculogenesis was aborted and progenitor cells did not receive specification signals, it 
remained unclear whether Y1173 is also important for endothelial specification of vascular 
progenitor cells. Therefore, we addressed this question using the in vitro differentiation 
system. 
3.2.3.1 Tyrosine 1175 of human VEGFR2 is required for endothelial differentiation 
To examine the roles of individual tyrosine residues in the induction of endothelial 
differentiation, we constructed three mutants of the R32 chimeric receptor (R32Y951F, 
R32Y1175F, and R32Y1214F) in which the indicated tyrosine residues were mutated to 
phenylalanine. After confirming the ability of these mutants to activate effective signals, we 
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These cells differentiated into PECAM1+ endothelial cells in response to VEGF-C 
stimulation. Although VEGF-C is bound by both VEGFR2 and VEGFR3, it does not promote 
endothelial differentiation through endogenous VEGFR2 signaling, because it failed to 
induce endothelial differentiation of mock-transfected cells. We next examined the effect of 
VEGF-C(C152S), a mutant that selectively stimulates VEGFR3 (Kirkin et al., 2001). This 
mutant did not induce endothelial differentiation, but it caused vascular progenitor cell 
differentiation into mural cells (Suzuki et al., 2005). Thus, VEGFR3 signaling alone is not 
sufficient to induce endothelial differentiation. It remains possible that VEGF-C induces 
endothelial differentiation through heterodimer formation between ectopic VEGFR3 and 
endogenous VEGFR2 in these experimental conditions. Collectively, these findings indicate 
that VEGFR2 has unique properties among VEGFR family members even in this in vitro 
system.  
3.2.2 The intracellular domain of VEGFR2 can transmit signals for endothelial 
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We next examined the intracellular events downstream of VEGFR2 that are required for 
endothelial differentiation. For this purpose, we constructed a chimeric receptor (denoted 
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fused with the intracellular domain of VEGFR2 (Fig. 4; Sase et al., 2009).  We then 
established ES cell lines expressing either R32 or VEGFR3 under the control of the Tc-
regulated promoter in MGZRTcH cells (denoted Tc-R32 and Tc-VEGFR3, respectively). 
  
 
Fig. 4. Schematic structure of the chimeric receptor R32  
VEGFR2+ vascular progenitor cells prepared from these cell lines differentiated into 
PECAM1+ cells following VEGF-A stimulation, indicating that these cell lines retain their 
ability to differentiate into endothelial cells. However, VEGFR2+ cells derived from Tc-R32, 
but not Tc-VEGFR3, differentiated into PECAM1+ cells upon stimulation with VEGF-
C(C152S). The PECAM1+ cells were also positive for other endothelial markers (VE-
cadherin, CD34, and endoglin) and appeared to be endothelial cells. Therefore, the 
differences in phenotypes between VEGFR2+ cells derived from Tc-R32 and Tc-VEGFR3 
cells are due to intrinsic properties of the intracellular domains of VEGFR2 and VEGFR3. 
The intracellular domain of VEGFR2 is sufficient to direct endothelial differentiation of ESC-
derived vascular progenitor cells. 
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3.2.3 Tyrosine 1175 of human VEGFR2 is required for endothelial specification of 
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established MGZRTcH ES cell lines expressing these mutant receptors (Tc-R32Y951F, Tc-
R32Y1175F, and Tc-R32Y1214F). VEGFR2+ vascular progenitor cells were prepared from 
these cell lines and examined for endothelial differentiation in the presence of VEGF-
C(C152S) (Sase et al., 2009).  
VEGFR2+ cells derived from Tc-R32Y951F and Tc-R32Y1214F differentiated into endothelial 
cells following treatment with VEGF-C(C152S) whereas those from Tc-R32Y1175F failed to 
do so. To exclude the possibility that signals associated with residues Y951 and Y1214 could 
compensate for one another to promote endothelial differentiation, we also established a cell 
line expressing a double mutant, Tc-R32Y951/1214F. VEGFR2+ cells derived from this cell 
line retained their ability to undergo endothelial differentiation. These findings indicate that 
signaling from Y1175 plays a central role in the endothelial differentiation of vascular 
progenitor cells, but residues Y951 and Y1214 are dispensable for this function.  
In this in vitro differentiation system, endothelial cells appear only when vascular progenitor 
cells are successfully specified into endothelial cells and when the differentiated endothelial 
cells are able to survive and proliferate (Fig. 6, top panel). Endothelial cells are unable to 
survive in the presence of serum alone, and they typically require growth factors such as 
VEGF-A or FGFs for survival and/or proliferation. We investigated whether signaling from 
Y1175 plays a role in specification, survival, or both processes. 
 
 
Fig. 6. VEGFR signaling and endothelial differentiation       
3.2.3.2 Tyrosine 1175 of human VEGFR2 is required for endothelial survival 
We first performed an endothelial survival assay (Fig. 7) with Tc-R32, Tc-R32Y1175F, and 
Tc-VEGFR3. ESC-derived VEGFR2+ cells were cultured with VEGF-A in serum-free medium 
for two days to induce mature endothelial cells, and the endothelial cells were then cultured 
in serum-free medium with or without VEGF-C(C152S) to activate the chimeric receptors.  
The number of endothelial cells cultured in the absence of VEGF-C(C152S) was considerably 
decreased within 12 h. VEGF-C(C152S)induced signaling from R32 led to a significant 
recovery in the number of cells, but VEGF-C(C152S) treatment of cells expressing R32Y1175 
failed to do so. Thus, Y1175 is involved in the transmission of survival signals to endothelial 
cells. As described in 3.2.1, VEGFR3 signaling is not sufficient for inducing endothelial 
differentiation from VEGFR2+ vascular progenitor cells. However, VEGFR3 signaling 
increased the survival of ESC-derived endothelial cells. We also found that LY294002, an 
inhibitor of PI3K, abrogated the effects of VEGFR3 on endothelial survival. These findings 
suggest that VEGFR3 signaling promotes endothelial survival despite its inability to direct 
endothelial specification (Fig. 6).  
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Fig. 7. Endothelial survival assay. When ESC-derived endothelial cells are cultured in 
serum-free medium, the cell number largely decreases within 12 h, while in the presence of 
an appropriate survival factor, the cell number is maintained.    
3.2.3.3 Tyrosine 1175 of human VEGFR2 is required for endothelial specification 
We next examined the involvement of signaling from Y1175 in the endothelial specification 
of vascular progenitor cells. Because R32Y1175F failed to transmit appropriate survival 
signals, we supplemented the cell cultures with a low dose of FGF-2 (0.5 ng/ml) to promote 
endothelial cell survival. VEGFR2+ cells derived from Tc-R32Y1175F failed to differentiate 
into endothelial cells upon stimulation with VEGF-C(C152S) although those derived from 
Tc-R32 successfully underwent differentiation. Thus, human VEGFR2 Y1175 is essential for 
the induction of endothelial cells from vascular progenitor cells through both specification 
of VEGFR2+ cells and their subsequent survival (Fig. 6). 
3.2.4 The VEGFR2-Y1175-PLC1 pathway is indispensable for endothelial 
specification 
In mature endothelial cells, Y1175 of human VEGFR2 primarily transmits cell proliferation 
signals through the recruitment of PLC and cell survival signals through the recruitment of 
Shb (Fig. 5). Intriguingly, PLC1 deficient mice are embryonically lethal secondary to a lack 
of vasculogenesis and erythrogenesis despite the presence of hemangioblasts (Liao et al., 
2002). Thus, PLC1 may be involved in the specification of vascular progenitor cells and/or 
subsequent survival of endothelial cells. We hypothesized that R32Y1175F failed to induce 
endothelial differentiation because it does not activate PLC1.  
3.2.4.1 Knockdown of PLC1 attenuated endothelial differentiation 
To elucidate the function of PLC1 in endothelial differentiation, we established a stable ES cell 
line in which expression of PLC1 can be knocked down by expression of pre-miRNA under 
the control of Tc (Tc-miRNA-PLC1) (Sase et al., 2009). We used this system to perform gene 
silencing studies because we had difficulty introducing siRNA oligonucleotides to VEGFR2+ 
vascular progenitor cells; we were able to easily introduce them into ES cells or differentiated 
endothelial cells, however (Kawasaki et al., 2008). It is likely that differentiating ES cells may 
be resistant to transfection at certain stages of development.   
Expression of the miRNA targeting PLC1 resulted in a modest decrease in PLC1 protein 
expression and decreased appearance of endothelial cells, indicating that PLC1 signaling is 
required for endothelial differentiation.  
3.2.4.2 Constitutively active PLC1 induces endothelial specification 
We next constructed a constitutively active form of PLC1, PalmPLC1, in which a sequence 
for myristoylation and palmitoylation was added to its N-terminus. This mutant protein is 
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failed to do so. Thus, Y1175 is involved in the transmission of survival signals to endothelial 
cells. As described in 3.2.1, VEGFR3 signaling is not sufficient for inducing endothelial 
differentiation from VEGFR2+ vascular progenitor cells. However, VEGFR3 signaling 
increased the survival of ESC-derived endothelial cells. We also found that LY294002, an 
inhibitor of PI3K, abrogated the effects of VEGFR3 on endothelial survival. These findings 
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constitutively localized at the plasma membrane. We then established a stable ES cell line 
harboring Tc-regulatable PalmPLC1 (Tc-PalmPLC1) or a negative control cell line (Tc-
empty) and examined the differentiation of VEGFR2+ cells derived from these cell lines.  
The induced expression of PalmPLC1 did not lead to the appearance of PECAM1+ cells 
from VEGFR2+ progenitor cells, and, after performing an endothelial survival assay, we 
found that PalmPLC1 did not transmit signals for cell survival in ESC-derived endothelial 
cells. We next examined endothelial differentiation of VEGFR2+ cells in the presence of a 
low dose of FGF-2 to support survival of endothelial cells. Stimulation with PalmPLC1 plus 
FGF-2 reconstituted signaling for endothelial differentiation although stimulation with only 
FGF-2 did not affect the number of differentiated endothelial cells. PalmPLC1-expressing 
progenitor cells treated with FGF-2 became positive for PECAM1, VE-cadherin, CD34, and 
endoglin, and these findings indicate that PLC1 signaling is involved in the endothelial 
specification of vascular progenitor cells but not in the survival of differentiated endothelial 
cells (Fig. 8). Consistent with this, VEGFR3, which transmits signals for endothelial survival 
but not endothelial specification, failed to activate PLC1 (Sase et al., 2009).  
At present, the signaling pathways downstream of Y1175 that mediate survival of 
endothelial cells remain to be elucidated. However, Shb may be a good candidate for a 
signaling effector because it activates the PI3K pathway. 
 
 
Fig. 8. Signaling from VEGFR2-Y1175 for induction of endothelial cells in vitro 
4. Ras signaling specifies endothelial lineage 
In addition to the chimeric receptor approach described above, we also used various 
pharmacological inhibitors to study endothelial differentiation (Kawasaki et al., 2008), and 
we found that temporally regulated Ras signaling plays a crucial role in endothelial 
specification downstream of PLC1. 
4.1 A farnesyltransferase inhibitor, FTI-277, inhibits VEGF-Ainduced endothelial 
differentiation of ESC-derived VEGFR2+ cells  
To determine the signaling components involved in VEGF-Ainduced endothelial 
differentiation from vascular progenitor cells, we screened various low molecular weight 
compounds targeting signaling molecules for their ability to inhibit endothelial 
differentiation in vitro. Among the compounds tested, we found that the farnesyltransferase 
inhibitor FTI-277 (Lerner et al., 1995) selectively affects endothelial differentiation. FTI-277 
interferes with the farnesylation of small G proteins and their subsequent association with 
the plasma membrane, thus abrogating their signaling functions. FTI-277 inhibited the 
appearance of VEGF-Ainduced PECAM1+ cells, but that of SMA+ was not. The effect of 
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FTI-277 was also confirmed in a limiting dilution assay. In the presence of FTI-277, the 
number of PECAM1+ colonies was decreased while SMA+ colonies were increased. 
Importantly, the total number of derived colonies was not significantly changed. These 
findings indicate that FTI-277 specifically inhibits the endothelial differentiation of ESC-
derived VEGFR2+ cells.  
We next performed an ex vivo whole-embryo culture assay to confirm the effects of FTI-277 
on vascular development in a mouse embryo (Fig. 9; Kawasaki et al., 2008). Concepti at 
embryonic day 6.75 (E 6.75) were picked out from the uteri of pregnant mice and cultured in 
vitro for three days, and, in the absence of further manipulation, PECAM1+ blood vessels 
formed in the yolk sac during this time. However, FTI-277 treatment led to a reduced 
number of PECAM1+ vessels, but the overall development of the yolk sac was not affected. 
Quantitative RT-PCR analysis also indicated that PECAM1 expression was decreased in the 
presence of FTI-277, while the expression of SMA was not affected. These findings suggest 
that FTI-277 selectively suppresses vascular development. Importantly, endothelial 
differentiation induced by constitutively active PalmPLC1 plus FGF-2 was inhibited by 
FTI-277, indicating that FTI-277 targets signaling pathway(s) downstream of PLC1.   
 
 
Fig. 9. FTI-277 inhibited ex vivo yolk sac vascularization (Kawasaki et al., 2008. Originally 
published in Journal of Cell Biology. doi: 10.1083/jcb.200709127). E6.75 concepti were picked 
out and cultured with or without FTI-277 (10 M) for three days and whole-mount stained 
for PECAM1. 
4.2 Loss of H-Ras attenuates endothelial differentiation of VEGFR2+ cells in vitro 
Because the principal targets of FTI-277 include H-Ras, we hypothesized that H-Ras 
signaling could be involved in the VEGF-Ainduced endothelial differentiation of vascular 
progenitor cells. To examine this possibility, we established an ES cell line based on 
MGZRTcH cells in which a pre-miRNA sequence targeting H-Ras is expressed under the 
control of Tc (Tc-miR-H-Ras). In Tc-miR-H-Ras cells, expression of endogenous H-Ras was 
efficiently knocked down in the absence of Tc (Tet-off system). A limiting dilution assay was 
performed using Tc-miR-H-Rasderived VEGFR2+ cells in the presence or absence of Tc. In 
the absence of Tc (H-Ras knocked-down condition), the number of VEGF-Ainduced 
PECAM1+ colonies was decreased while the number of SMA+ colonies was increased 
compared to cells grown in the presence of Tc (PECAM1:SMA=51.6%:48.4% to 
36.8%:63.2%). These findings suggest that H-Ras plays a role in the endothelial 
differentiation of VEGFR2+ progenitor cells.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 254 
constitutively localized at the plasma membrane. We then established a stable ES cell line 
harboring Tc-regulatable PalmPLC1 (Tc-PalmPLC1) or a negative control cell line (Tc-
empty) and examined the differentiation of VEGFR2+ cells derived from these cell lines.  
The induced expression of PalmPLC1 did not lead to the appearance of PECAM1+ cells 
from VEGFR2+ progenitor cells, and, after performing an endothelial survival assay, we 
found that PalmPLC1 did not transmit signals for cell survival in ESC-derived endothelial 
cells. We next examined endothelial differentiation of VEGFR2+ cells in the presence of a 
low dose of FGF-2 to support survival of endothelial cells. Stimulation with PalmPLC1 plus 
FGF-2 reconstituted signaling for endothelial differentiation although stimulation with only 
FGF-2 did not affect the number of differentiated endothelial cells. PalmPLC1-expressing 
progenitor cells treated with FGF-2 became positive for PECAM1, VE-cadherin, CD34, and 
endoglin, and these findings indicate that PLC1 signaling is involved in the endothelial 
specification of vascular progenitor cells but not in the survival of differentiated endothelial 
cells (Fig. 8). Consistent with this, VEGFR3, which transmits signals for endothelial survival 
but not endothelial specification, failed to activate PLC1 (Sase et al., 2009).  
At present, the signaling pathways downstream of Y1175 that mediate survival of 
endothelial cells remain to be elucidated. However, Shb may be a good candidate for a 
signaling effector because it activates the PI3K pathway. 
 
 
Fig. 8. Signaling from VEGFR2-Y1175 for induction of endothelial cells in vitro 
4. Ras signaling specifies endothelial lineage 
In addition to the chimeric receptor approach described above, we also used various 
pharmacological inhibitors to study endothelial differentiation (Kawasaki et al., 2008), and 
we found that temporally regulated Ras signaling plays a crucial role in endothelial 
specification downstream of PLC1. 
4.1 A farnesyltransferase inhibitor, FTI-277, inhibits VEGF-Ainduced endothelial 
differentiation of ESC-derived VEGFR2+ cells  
To determine the signaling components involved in VEGF-Ainduced endothelial 
differentiation from vascular progenitor cells, we screened various low molecular weight 
compounds targeting signaling molecules for their ability to inhibit endothelial 
differentiation in vitro. Among the compounds tested, we found that the farnesyltransferase 
inhibitor FTI-277 (Lerner et al., 1995) selectively affects endothelial differentiation. FTI-277 
interferes with the farnesylation of small G proteins and their subsequent association with 
the plasma membrane, thus abrogating their signaling functions. FTI-277 inhibited the 
appearance of VEGF-Ainduced PECAM1+ cells, but that of SMA+ was not. The effect of 
Dissecting the Signal Transduction Pathway that Directs Endothelial  
Differentiation Using Embryonic Stem Cell-Derived Vascular Progenitor Cells 255 
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4.3 Loss of H-Ras attenuates endothelial differentiation in mouse embryos  
To examine the importance of H-Ras signaling during vascular development in vivo, we 
investigated the vascular phenotype of H-ras knockout mice. Because heterozygous H-ras+/- 
mice produced homozygous H-ras/ offspring in the expected Mendelian ratio as 
previously reported (Ise et al., 2000), we focused on the vascular phenotype during early 
development. There were no clear differences in the vascular phenotypes of wild-type (WT) 
and H-ras+/- embryos. Vascular anomalies were found in the brain of 73% of H-ras-/- 
embryos examined at E9.5 although they contained similar numbers of somites as their WT 
littermates (Fig. 10; Kawasaki et al., 2008).  
We next double-stained the cephalic region of the embryos for PECAM1 and VEGFR2, the 
earliest marker of endothelial cell differentiation. In H-ras+/- embryos, numerous complex 
vascular networks were stained for both PECAM1 and VEGFR2, but vascular structures 
positive for either PECAM1 or VEGFR2 were strikingly reduced in H-ras-/- embryos. 
However, these defects were transient because no abnormalities were apparent in E10.5 H-
ras-/- embryos. Collectively, these data suggest that H-Ras signaling is involved in the in vivo 
differentiation of endothelial cells although it is not indispensable. 
 
 
Fig. 10. Whole-mount PECAM1 staining of E9.5 H-ras+/- and H-ras-/- mice (Kawasaki et al., 
2008. Originally published in Journal of Cell Biology. doi: 10.1083/jcb.200709127). 
Magnifications of the area marked with arrows in the top are shown in the bottom. 
4.4 A constitutively active G12V mutant of H-Ras induces PECAM1+ cells from 
VEGFR2+ progenitor cells 
We next established an ES cell line carrying a constitutively active form of H-Ras (Tc-H-
Ras[G12V]) under the control of Tc, and we examined the differentiation of VEGFR2+ cells 
derived from this cell line. When H-Ras[G12V] expression was suppressed by Tc treatment, 
the appearance of PECAM1+ cells was VEGF-Adependent. However, expression of H-
Ras[G12V] led to the VEGF-Aindependent induction of PECAM1+ cells. These PECAM1+ 
cells were also positive for other endothelial markers including CD34 and endoglin, and 
they incorporated AcLDL. Additionally, the aggregated VEGFR2+ cells derived from Tc-H-
Ras[G12V] cells formed tube-like structures even in the absence of VEGF-A when cultured 
in type I collagen gel for seven days, indicating that vascular formation by VEGFR2+ cells is 
dependent on H-Ras signaling. Furthermore, Tc-H-Ras[G12V] cells formed vascular 
structures when subcutaneously injected with Matrigel into the abdominal region of mice, 
dependent upon the expression of H-Ras[G12V]. These findings suggest that active Ras 
induces the differentiation of cells with characteristics of endothelial cells from VEGFR2+ 
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progenitor cells (Kawasaki et al., 2008). Additionally, data from a limiting dilution assay 
showed that expression of H-Ras[G12V] led to endothelial differentiation at the expense of 
mural differentiation. Thus, the fate of cell differentiation was altered by Ras signaling. 
Although Ras signaling induces the expression of VEGF-A (Rak et al., 1995; Gruger et al., 
1995), Ras-induced endothelial differentiation was not dependent on autocrine stimuation 
by induced VEGF-A.  Endothelial differentiation by H-Ras[G12V] proceeded normally in the 
presence of SU5614, an inhibitor of VEGFR2 kinase (Spiekermann et al., 2002), or VEGFR1 
(Flt1)-Fc chimeric protein which competes with VEGFR2 for binding to VEGF-A. 
Collectively, these findings suggest that differentiation depends on intracellular Ras 
signaling. 
4.5 Signaling for endothelial differentiation is mediated through the Ras-Erk pathway 
Ras proteins activate both the Raf/MEK/Erk and the PI3K/Akt pathways. To determine the 
signaling pathway(s) that mediate Ras-induced endothelial differentiation, we established 
ES cell lines in which H-Ras effector mutants H-Ras[G12V, T35S] or H-Ras[G12V, Y40C] can 
be inducibly expressed. The effector mutants H-Ras[G12V, T35S] and H-Ras[G12V, Y40C] 
preferentially activate the Raf/MEK/Erk and PI3K/Akt pathways, respectively (Joneson et 
al., 1996). When H-Ras[G12V, T35S] was expressed, PECAM1+ colonies increased in 
number, while SMA+ colonies were decreased as determined by limiting dilution assay. In 
contrast, when H-Ras[G12V, Y40C] was expressed, the numbers of PECAM1+ colonies and 
SMA+ colonies were unchanged. These findings suggest that the Ras-PI3K pathway does 
not affect the determination of cell fate, and we concluded that the Ras-Erk pathway 
specifies the endothelial fate of VEGFR2+ progenitor cells. 
4.6 Kinetics of Ras activation by VEGF-A 
Ras proteins are activated by extracellular stimuli including hormones, cytokines and 
growth factors. ESC-derived VEGFR2+ cells differentiate into endothelial cells upon 
stimulation with VEGF-A, but not upon stimulation with PDGF-BB, a known activator of 
Ras signaling. Thus, the activation statuses of Ras are different between that downsteam of 
VEGFR2 and that downstream of PDGF receptors.  
We examined the effects of FTI-277 treatment at different time points after VEGF-A 
stimulation. FTI-277 inhibited endothelial differentiation even when added 3 h after VEGF-
A stimulation, indicating that Ras activation later than 3 h after stimulation plays a role in 
endothelial differentiation. We hypothesized that the specificity of Ras signaling induced by 
VEGFR2 may be attributed to the timing of Ras activation, and we investigated the window 
within which Ras is specifically activated by VEGF-A, focusing on the period later than 3 h 
after VEGF-A stimulation.  
We examined the levels of phosphorylation of Erk, a downstream effector of Ras, 312 h 
after stimulation with VEGF-A. Erk phosphorylation peaked at 6 h and 9 h after stimulation, 
suggesting that Ras could be activated with a similar time course. We next examined the 
activation of Ras in cells stimulated with VEGF-A or PDGF-BB for 6 h, and the patterns of 
Ras activation in response to VEGF-A or PDGF-BB were markedly different. At 6 h after 
stimulation, VEGF-A caused intense activation of Ras and Erk, whereas PDGF-BB failed to 
activate both Ras and Erk. At 5 min after stimulation, both VEGF-A and PDGF-BB induced 
activation of Ras and Erk although to different extents. Activation of Ras and Erk by VEGF-
A was also observed at 9 h, but not at 3 h after stimulation (Fig. 11). Importantly, 
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embryos examined at E9.5 although they contained similar numbers of somites as their WT 
littermates (Fig. 10; Kawasaki et al., 2008).  
We next double-stained the cephalic region of the embryos for PECAM1 and VEGFR2, the 
earliest marker of endothelial cell differentiation. In H-ras+/- embryos, numerous complex 
vascular networks were stained for both PECAM1 and VEGFR2, but vascular structures 
positive for either PECAM1 or VEGFR2 were strikingly reduced in H-ras-/- embryos. 
However, these defects were transient because no abnormalities were apparent in E10.5 H-
ras-/- embryos. Collectively, these data suggest that H-Ras signaling is involved in the in vivo 
differentiation of endothelial cells although it is not indispensable. 
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derived from this cell line. When H-Ras[G12V] expression was suppressed by Tc treatment, 
the appearance of PECAM1+ cells was VEGF-Adependent. However, expression of H-
Ras[G12V] led to the VEGF-Aindependent induction of PECAM1+ cells. These PECAM1+ 
cells were also positive for other endothelial markers including CD34 and endoglin, and 
they incorporated AcLDL. Additionally, the aggregated VEGFR2+ cells derived from Tc-H-
Ras[G12V] cells formed tube-like structures even in the absence of VEGF-A when cultured 
in type I collagen gel for seven days, indicating that vascular formation by VEGFR2+ cells is 
dependent on H-Ras signaling. Furthermore, Tc-H-Ras[G12V] cells formed vascular 
structures when subcutaneously injected with Matrigel into the abdominal region of mice, 
dependent upon the expression of H-Ras[G12V]. These findings suggest that active Ras 
induces the differentiation of cells with characteristics of endothelial cells from VEGFR2+ 
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progenitor cells (Kawasaki et al., 2008). Additionally, data from a limiting dilution assay 
showed that expression of H-Ras[G12V] led to endothelial differentiation at the expense of 
mural differentiation. Thus, the fate of cell differentiation was altered by Ras signaling. 
Although Ras signaling induces the expression of VEGF-A (Rak et al., 1995; Gruger et al., 
1995), Ras-induced endothelial differentiation was not dependent on autocrine stimuation 
by induced VEGF-A.  Endothelial differentiation by H-Ras[G12V] proceeded normally in the 
presence of SU5614, an inhibitor of VEGFR2 kinase (Spiekermann et al., 2002), or VEGFR1 
(Flt1)-Fc chimeric protein which competes with VEGFR2 for binding to VEGF-A. 
Collectively, these findings suggest that differentiation depends on intracellular Ras 
signaling. 
4.5 Signaling for endothelial differentiation is mediated through the Ras-Erk pathway 
Ras proteins activate both the Raf/MEK/Erk and the PI3K/Akt pathways. To determine the 
signaling pathway(s) that mediate Ras-induced endothelial differentiation, we established 
ES cell lines in which H-Ras effector mutants H-Ras[G12V, T35S] or H-Ras[G12V, Y40C] can 
be inducibly expressed. The effector mutants H-Ras[G12V, T35S] and H-Ras[G12V, Y40C] 
preferentially activate the Raf/MEK/Erk and PI3K/Akt pathways, respectively (Joneson et 
al., 1996). When H-Ras[G12V, T35S] was expressed, PECAM1+ colonies increased in 
number, while SMA+ colonies were decreased as determined by limiting dilution assay. In 
contrast, when H-Ras[G12V, Y40C] was expressed, the numbers of PECAM1+ colonies and 
SMA+ colonies were unchanged. These findings suggest that the Ras-PI3K pathway does 
not affect the determination of cell fate, and we concluded that the Ras-Erk pathway 
specifies the endothelial fate of VEGFR2+ progenitor cells. 
4.6 Kinetics of Ras activation by VEGF-A 
Ras proteins are activated by extracellular stimuli including hormones, cytokines and 
growth factors. ESC-derived VEGFR2+ cells differentiate into endothelial cells upon 
stimulation with VEGF-A, but not upon stimulation with PDGF-BB, a known activator of 
Ras signaling. Thus, the activation statuses of Ras are different between that downsteam of 
VEGFR2 and that downstream of PDGF receptors.  
We examined the effects of FTI-277 treatment at different time points after VEGF-A 
stimulation. FTI-277 inhibited endothelial differentiation even when added 3 h after VEGF-
A stimulation, indicating that Ras activation later than 3 h after stimulation plays a role in 
endothelial differentiation. We hypothesized that the specificity of Ras signaling induced by 
VEGFR2 may be attributed to the timing of Ras activation, and we investigated the window 
within which Ras is specifically activated by VEGF-A, focusing on the period later than 3 h 
after VEGF-A stimulation.  
We examined the levels of phosphorylation of Erk, a downstream effector of Ras, 312 h 
after stimulation with VEGF-A. Erk phosphorylation peaked at 6 h and 9 h after stimulation, 
suggesting that Ras could be activated with a similar time course. We next examined the 
activation of Ras in cells stimulated with VEGF-A or PDGF-BB for 6 h, and the patterns of 
Ras activation in response to VEGF-A or PDGF-BB were markedly different. At 6 h after 
stimulation, VEGF-A caused intense activation of Ras and Erk, whereas PDGF-BB failed to 
activate both Ras and Erk. At 5 min after stimulation, both VEGF-A and PDGF-BB induced 
activation of Ras and Erk although to different extents. Activation of Ras and Erk by VEGF-
A was also observed at 9 h, but not at 3 h after stimulation (Fig. 11). Importantly, 
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phosphorylation of Erk around 6 h after VEGF-A stimulation was sensitive to FTI-277. 
Activation of the Ras-Erk pathway 69 h after stimulation with VEGF-A thus appears to 
direct endothelial differentiation of VEGFR2+ progenitor cells. These findings provide 
mechanistic insights into signaling events required for cell specification through widely-
shared effector molecules. 
4.7 VEGF-Aspecific Ras activation precedes the expression of endothelial markers 
We finally examined whether the expression of vascular markers is induced after the 
delayed activation of the Ras-Erk pathway during in vitro differentiation of vascular 
progenitor cells. The mRNA expression of the endothelial markers PECAM1 and VE-
cadherin increased from 12 h after VEGF-A stimulation. Intriguingly, the expression of 
VEGFR2 in VEGF-Astimulated cells was similar to that seen in non-stimulated cells up to 6 
h after treatment. However, at time points later than 12 h after stimulation, VEGFR2 
expression was up-regulated in VEGF-Astimulated cells, but it was down-regulated in 
non-stimulated cells. These observations suggest that specification to endothelial lineage 
occurs between 612 h after stimulation with VEGF-A, and this is preceded by the delayed 
activation of Ras (Fig. 11). We conclude that VEGF-A stimulation of VEGFR2+ vascular 
progenitor cells specifically induces Ras-Erk activation around 69 h after stimulation, and 
this event in turn specifies endothelial differentiation.  
 
 
Fig. 11. Kinetics of endothelial differentiation of vascular progenitor cells after VEGF-A 
stimulation. The link between PLC and Ras-Erk (the second double-headed arrow) remains 
to be elucidated. 
5. Unsolved questions in signaling for endothelial differentiation  
The development of multicellular organisms requires the orchestrated interactions of a wide 
variety of cells, including growth, migration, and differentiation. Extracellular factors as 
well as intracellular signaling molecules are involved in the regulation of cellular processes 
during development. Each signaling molecule appears to have defined functions that are 
dependent upon the appropriate cellular context. 
VEGFR2 signaling plays a central role in de novo blood vessel formation. In an in vitro 
embryoid body culture system, VEGFR2-/- ES cells still give rise to endothelial cells with low 
efficiency (Schuh et al., 1999). This may be due to an effects of FGF-2 included in the culture 
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medium (Schuh et al., 1999), because FGF-2 induces endothelial differentiation of ESC-
derived VEGFR2+ cells to a modest extent (Kano et al., 2005). VEGFR2 signaling appears to 
be the primary pathway for controlling endothelial specification with high efficiency, 
although it is not the sole pathway capable of mediating these effects. We found that 
activation of the Ras-Erk pathway 69 h after stimulation with VEGF-A plays a critical role 
in endothelial specification of vascular progenitor cells. The mechanism(s) regulating the 
delayed activation of Ras and the downstream signaling of the Ras-Erk pathway are the next 
questions to be solved.  
5.1 Upstream and downstream of the delayed Ras activation induced by VEGF-A   
In ESC-derived VEGFR2+ progenitor cells, the PKC-dependent pathway (Fig. 5) appears to 
be activated early, since phosphorylation of Erk was notably increased while activation of 
Ras was modest 5 min after VEGF-A stimulation (Kawasaki et al., 2008). In contrast, the Ras 
pathway strongly induced Erk phosphorylation 69 h after stimulation, a finding supported 
by the inhibition of Erk phosphorylation by FTI-277. The mechanism(s) controlling the 
delayed activation of Ras remain unclear. At present, we only know that PLC1 lies 
upstream of the delayed Ras activation. It is possible that Ras activation is mediated through 
the transcriptional induction of some signaling molecules and/or activation of other 
signaling receptor(s). It is also important to identify transcription factors that are 
phosphorylated by Erk to better understand the signaling specificity of early and late Erk 
activation. VEGFR2+ cells develop into mural cells in the absence of growth factor, and 
mural differentiation may be the default fate of VEGFR2+ cells. During the differentiation of 
vascular progenitor cells, induction of mural markers is delayed compared to the induction 
of endothelial markers by VEGF-A: expression of SMA was increased at 24 h while 
PECAM1 became expressed from 12 h after stimulation. It appears likely that VEGFR2+ cells 
in which the delayed Ras-Erk signaling is activated before the determination of cell fate to 
mural cells are differentiated into endothelial cells. However, it remains possible that VEGF-
A signaling merely suppresses mural differentiation, thus altering the default differentiation 
fate. Alternatively, it is possible that VEGF-A signaling not only induces endothelial 
differentiation but also suppresses mural differentiation. 
Although Ras appears to be activated downstream of PLC1 in vascular progenitor cells 
after stimulation with VEGF-A, constitutively active Ras transmits sufficient signals for full 
endothelial differentiation while constitutively active PLC1 transmits signals only for 
endothelial specification. This discrepancy remains unexplored. It is likely that 
constitutively active effector molecules may transmit artificial signals. In particular, G12V 
mutants of Ras proteins are resistant to intrinsic negative regulation through hydrolysis of 
GTP. H-Ras[G12V] may constitutively send strong signals that are sufficient to fully induce 
endothelial differentiation.   
5.2 Phenotypes of H-Ras knockout mice 
We examined vascular formation in H-ras-/- mice, and vascular anomalies were found in the 
brain of 73% of E9.5 H-ras-/- embryos. However, there were no obvious abnormalities in 
E10.5 H-ras-/- embryos, consistent with the previous report that H-ras knockout mice are 
born and grow normally (Ise et al., 2000). These findings suggest that H-ras-/- embryos catch 
up for the delay in vascular formation in the cephalic region until E10.5. It is possible that 
expression of other Ras family members, N-Ras and K-Ras, is upregulated, and these 
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phosphorylation of Erk around 6 h after VEGF-A stimulation was sensitive to FTI-277. 
Activation of the Ras-Erk pathway 69 h after stimulation with VEGF-A thus appears to 
direct endothelial differentiation of VEGFR2+ progenitor cells. These findings provide 
mechanistic insights into signaling events required for cell specification through widely-
shared effector molecules. 
4.7 VEGF-Aspecific Ras activation precedes the expression of endothelial markers 
We finally examined whether the expression of vascular markers is induced after the 
delayed activation of the Ras-Erk pathway during in vitro differentiation of vascular 
progenitor cells. The mRNA expression of the endothelial markers PECAM1 and VE-
cadherin increased from 12 h after VEGF-A stimulation. Intriguingly, the expression of 
VEGFR2 in VEGF-Astimulated cells was similar to that seen in non-stimulated cells up to 6 
h after treatment. However, at time points later than 12 h after stimulation, VEGFR2 
expression was up-regulated in VEGF-Astimulated cells, but it was down-regulated in 
non-stimulated cells. These observations suggest that specification to endothelial lineage 
occurs between 612 h after stimulation with VEGF-A, and this is preceded by the delayed 
activation of Ras (Fig. 11). We conclude that VEGF-A stimulation of VEGFR2+ vascular 
progenitor cells specifically induces Ras-Erk activation around 69 h after stimulation, and 
this event in turn specifies endothelial differentiation.  
 
 
Fig. 11. Kinetics of endothelial differentiation of vascular progenitor cells after VEGF-A 
stimulation. The link between PLC and Ras-Erk (the second double-headed arrow) remains 
to be elucidated. 
5. Unsolved questions in signaling for endothelial differentiation  
The development of multicellular organisms requires the orchestrated interactions of a wide 
variety of cells, including growth, migration, and differentiation. Extracellular factors as 
well as intracellular signaling molecules are involved in the regulation of cellular processes 
during development. Each signaling molecule appears to have defined functions that are 
dependent upon the appropriate cellular context. 
VEGFR2 signaling plays a central role in de novo blood vessel formation. In an in vitro 
embryoid body culture system, VEGFR2-/- ES cells still give rise to endothelial cells with low 
efficiency (Schuh et al., 1999). This may be due to an effects of FGF-2 included in the culture 
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medium (Schuh et al., 1999), because FGF-2 induces endothelial differentiation of ESC-
derived VEGFR2+ cells to a modest extent (Kano et al., 2005). VEGFR2 signaling appears to 
be the primary pathway for controlling endothelial specification with high efficiency, 
although it is not the sole pathway capable of mediating these effects. We found that 
activation of the Ras-Erk pathway 69 h after stimulation with VEGF-A plays a critical role 
in endothelial specification of vascular progenitor cells. The mechanism(s) regulating the 
delayed activation of Ras and the downstream signaling of the Ras-Erk pathway are the next 
questions to be solved.  
5.1 Upstream and downstream of the delayed Ras activation induced by VEGF-A   
In ESC-derived VEGFR2+ progenitor cells, the PKC-dependent pathway (Fig. 5) appears to 
be activated early, since phosphorylation of Erk was notably increased while activation of 
Ras was modest 5 min after VEGF-A stimulation (Kawasaki et al., 2008). In contrast, the Ras 
pathway strongly induced Erk phosphorylation 69 h after stimulation, a finding supported 
by the inhibition of Erk phosphorylation by FTI-277. The mechanism(s) controlling the 
delayed activation of Ras remain unclear. At present, we only know that PLC1 lies 
upstream of the delayed Ras activation. It is possible that Ras activation is mediated through 
the transcriptional induction of some signaling molecules and/or activation of other 
signaling receptor(s). It is also important to identify transcription factors that are 
phosphorylated by Erk to better understand the signaling specificity of early and late Erk 
activation. VEGFR2+ cells develop into mural cells in the absence of growth factor, and 
mural differentiation may be the default fate of VEGFR2+ cells. During the differentiation of 
vascular progenitor cells, induction of mural markers is delayed compared to the induction 
of endothelial markers by VEGF-A: expression of SMA was increased at 24 h while 
PECAM1 became expressed from 12 h after stimulation. It appears likely that VEGFR2+ cells 
in which the delayed Ras-Erk signaling is activated before the determination of cell fate to 
mural cells are differentiated into endothelial cells. However, it remains possible that VEGF-
A signaling merely suppresses mural differentiation, thus altering the default differentiation 
fate. Alternatively, it is possible that VEGF-A signaling not only induces endothelial 
differentiation but also suppresses mural differentiation. 
Although Ras appears to be activated downstream of PLC1 in vascular progenitor cells 
after stimulation with VEGF-A, constitutively active Ras transmits sufficient signals for full 
endothelial differentiation while constitutively active PLC1 transmits signals only for 
endothelial specification. This discrepancy remains unexplored. It is likely that 
constitutively active effector molecules may transmit artificial signals. In particular, G12V 
mutants of Ras proteins are resistant to intrinsic negative regulation through hydrolysis of 
GTP. H-Ras[G12V] may constitutively send strong signals that are sufficient to fully induce 
endothelial differentiation.   
5.2 Phenotypes of H-Ras knockout mice 
We examined vascular formation in H-ras-/- mice, and vascular anomalies were found in the 
brain of 73% of E9.5 H-ras-/- embryos. However, there were no obvious abnormalities in 
E10.5 H-ras-/- embryos, consistent with the previous report that H-ras knockout mice are 
born and grow normally (Ise et al., 2000). These findings suggest that H-ras-/- embryos catch 
up for the delay in vascular formation in the cephalic region until E10.5. It is possible that 
expression of other Ras family members, N-Ras and K-Ras, is upregulated, and these 
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proteins may compensate for the loss of H-Ras (Ise et al., 2000). Alternatively, a reduction of 
endothelial differentiation in the absence of H-Ras may be permissive for embryonic 
development. Compensatory growth of differentiated endothelial cells may offset the 
reduction in endothelial differentiation. It appears likely that N-Ras and K-Ras are also 
involved in endothelial specification because treatment with FTI-277 or knockdown of H-
Ras failed to completely inhibit endothelial specification induced by VEGF-A in the in vitro 
vascular differentiation system.  
5.3 Towards more efficient differentiation of endothelial cells 
In recent years, revascularization therapy using endothelial progenitor cells (EPCs) has been 
studied for the treatment of ischemic disorders and arteriosclerosis. In this therapy, EPCs 
implanted at sites of disease form new vascular structures. Identification of the signaling 
pathways required for endothelial differentiation could provide valuable information for 
establishing a highly efficient endothelial differentiation system. This would be a boon to 
the field of regenerative medicine. 
The efficiency of endothelial differentiation of vascular progenitor cells in vitro remains ~50%. 
Differentiating ES cells actively proliferate, indicating that they are going through cell cycles. 
Recent work revealed that Ras can efficiently transmit signals during G1 phase but not during 
G1/S or S/G2 (SakaueSawano et al., 2008). Signals for endothelial specification are likely 
successfully transmitted in vascular progenitor cells at G1 phase (Fig. 12). Manipulations that 
control the cell cycle status may improve the efficiency of specification of vascular progenitor 
cells to endothelial cells, which is transmitted principally through Ras proteins. 
 
 
Fig. 12. Possible cell cycledependent signaling for endothelial differentiation through Ras 
activation 
Modulation of the VEGFR2 signaling pathway at the level of receptorligand interaction 
may also improve the efficiency of endothelial differentiation in vitro. Recently, protein 
kinase A was found to induce expression of VEGFR2 and its co-receptor neuropilin-1, thus 
enhancing vascular progenitor potential (Yamamizu et al., 2009). 
6. Conclusions 
Vascular endothelial growth factor 2 (VEGFR2) is a critical signaling component controlling 
many aspects of vasculogenesis during embryonic development, including proliferation, 
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migration, and endothelial differentiation of vascular progenitor cells. However, the 
signaling pathways specifying endothelial differentiation downstream of VEGFR2 are 
poorly understood. We investigated these signaling pathways using an in vitro endothelial 
differentiation system (Kawasaki et al., 2008; Sase et al., 2009). Using a variety of different 
approaches including chimeric receptors, gene silencing, gain-of-function mutants, and 
pharmacological inhibitors, we dissected the signal transduction pathway that directs 
endothelial differentiation (Fig. 13). In response to VEGF-A stimulation, VEGFR2 transmits 
signals for specification of vascular progenitor cells and survival of endothelial cells through 
Y1175. PLC1, a downstream effector that is recruited to phosphorylated Y1175, relays 
endothelial specification signals. Activation of H-Ras that occurs at a delayed phase after 
VEGF-A stimulation triggers endothelial specification. The unique activation of signaling 
molecules downstream of VEGFR2/PLC/Ras is essential for transmitting signals 
controlling endothelial specification. At the present time, the link between PLC1 and H-Ras 
remains to be identified. Shb, another downstream effector recruited to phosphorylated 
Y1175, may be involved in the survival of endothelial cells through activation of the PI3K 
pathway. VEGFR3 lacks the ability to induce endothelial specification, and this may be due 
to its inability to activate PLC1, although it activates the PI3K pathway to support 
endothelial cell survival. It has previously been shown that Y1175 signaling is indispensable 
for migration of vascular progenitor cells to the site of their differentiation (Sakurai et al., 
2005). Therefore, Y1175 of VEGFR2 appears to be a central node transmitting signals 
required for endothelial differentiation including migration, specification, and subsequent 
cell survival.  
 
 
Fig. 13. Signal transduction pathways for endothelial differentiation from VEGFR2 
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proteins may compensate for the loss of H-Ras (Ise et al., 2000). Alternatively, a reduction of 
endothelial differentiation in the absence of H-Ras may be permissive for embryonic 
development. Compensatory growth of differentiated endothelial cells may offset the 
reduction in endothelial differentiation. It appears likely that N-Ras and K-Ras are also 
involved in endothelial specification because treatment with FTI-277 or knockdown of H-
Ras failed to completely inhibit endothelial specification induced by VEGF-A in the in vitro 
vascular differentiation system.  
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studied for the treatment of ischemic disorders and arteriosclerosis. In this therapy, EPCs 
implanted at sites of disease form new vascular structures. Identification of the signaling 
pathways required for endothelial differentiation could provide valuable information for 
establishing a highly efficient endothelial differentiation system. This would be a boon to 
the field of regenerative medicine. 
The efficiency of endothelial differentiation of vascular progenitor cells in vitro remains ~50%. 
Differentiating ES cells actively proliferate, indicating that they are going through cell cycles. 
Recent work revealed that Ras can efficiently transmit signals during G1 phase but not during 
G1/S or S/G2 (SakaueSawano et al., 2008). Signals for endothelial specification are likely 
successfully transmitted in vascular progenitor cells at G1 phase (Fig. 12). Manipulations that 
control the cell cycle status may improve the efficiency of specification of vascular progenitor 
cells to endothelial cells, which is transmitted principally through Ras proteins. 
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Vascular endothelial growth factor 2 (VEGFR2) is a critical signaling component controlling 
many aspects of vasculogenesis during embryonic development, including proliferation, 
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migration, and endothelial differentiation of vascular progenitor cells. However, the 
signaling pathways specifying endothelial differentiation downstream of VEGFR2 are 
poorly understood. We investigated these signaling pathways using an in vitro endothelial 
differentiation system (Kawasaki et al., 2008; Sase et al., 2009). Using a variety of different 
approaches including chimeric receptors, gene silencing, gain-of-function mutants, and 
pharmacological inhibitors, we dissected the signal transduction pathway that directs 
endothelial differentiation (Fig. 13). In response to VEGF-A stimulation, VEGFR2 transmits 
signals for specification of vascular progenitor cells and survival of endothelial cells through 
Y1175. PLC1, a downstream effector that is recruited to phosphorylated Y1175, relays 
endothelial specification signals. Activation of H-Ras that occurs at a delayed phase after 
VEGF-A stimulation triggers endothelial specification. The unique activation of signaling 
molecules downstream of VEGFR2/PLC/Ras is essential for transmitting signals 
controlling endothelial specification. At the present time, the link between PLC1 and H-Ras 
remains to be identified. Shb, another downstream effector recruited to phosphorylated 
Y1175, may be involved in the survival of endothelial cells through activation of the PI3K 
pathway. VEGFR3 lacks the ability to induce endothelial specification, and this may be due 
to its inability to activate PLC1, although it activates the PI3K pathway to support 
endothelial cell survival. It has previously been shown that Y1175 signaling is indispensable 
for migration of vascular progenitor cells to the site of their differentiation (Sakurai et al., 
2005). Therefore, Y1175 of VEGFR2 appears to be a central node transmitting signals 
required for endothelial differentiation including migration, specification, and subsequent 
cell survival.  
 
 
Fig. 13. Signal transduction pathways for endothelial differentiation from VEGFR2 
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1. Introduction 
Embryonic stem (ES) cells are a rich source of multiple different cell types of diverse 
lineages. Significant advances have recently been made in our understanding of the 
molecular mechanisms by which ES cells differentiate into endothelial cells. The 
differentiation of ES cells into endothelial cells can be enhanced by certain growth factors, 
environmental cues, cell-cell interactions, and extracellular matrix. A wide variety of signal 
transduction pathways and transcription factors have been shown to participate in this 
process. The use of ES cells for endothelial differentiation are not only of interest with 
respect to the molecular mechanisms but also for identifying sources of endothelial cells that 
can be used for a number of therapeutic purposes. The purpose of this chapter is to review 
recent advances in the molecular mechanisms underlying ES differentiation into endothelial 
cells and how endothelial cells derived from ES cells are being used therapeutically.  
2. Culture conditions 
ES cells are derived from the inner cell mass of a growing blastocyst 1. As such, they have 
the capacity to differentiate into all the cell types of an organism 2. To maintain their 
undifferentiated state ES cells are generally grown in the presence of feeder cells or 
leukemia inhibitory factor (LIF). In the absence of inhibitory factors ES cells can 
spontaneously differentiate into cells with characteristics of one of three germ layers; 
mesoderm, endoderm, or ectoderm.  A variety of approaches have been used to differentiate 
human and mouse ES cells that include: (1) aggregating ES cells into three-dimensional cell 
masses called embryoid bodies (EBs); (2) by co-culturing the ES cells with other cell types; 
and (3) by culturing the ES cells on specific matrix surfaces together with defined media.     
Murine ES cells have been used for several years to study differentiation along multiple 
lineages. Culturing ES cells into EBs has been the most frequently used model to study EC 
differentiation. The appearance of structures consisting of immature hematopoietic cells 
surrounded by endothelial cells and the formation of vascular-like channels suggests that 
the EBs produce factors necessary not only for endothelial differentiation but also for 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 266 
Zambrowicz, B.P., Imamoto, A., Fiering, S., Herzenberg, L.A., Kerr, W.G., Soriano, P. (1997) 
Disruption of overlapping transcripts in the ROSA  geo 26 gene trap strain leads 
to widespread expression of -galactosidase in mouse embryos and hematopoietic 
cells. Proc.Natl. Acad. Sci. USA 94, 3789-3794 
14 
Endothelial Differentiation of  
Embryonic Stem Cells 
Peter Oettgen 
Division of Cardiology,  
Division of Molecular and Vascular Medicine,  
Department of Medicine, and the Center for Vascular Biology Research,  
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA,  
USA  
1. Introduction 
Embryonic stem (ES) cells are a rich source of multiple different cell types of diverse 
lineages. Significant advances have recently been made in our understanding of the 
molecular mechanisms by which ES cells differentiate into endothelial cells. The 
differentiation of ES cells into endothelial cells can be enhanced by certain growth factors, 
environmental cues, cell-cell interactions, and extracellular matrix. A wide variety of signal 
transduction pathways and transcription factors have been shown to participate in this 
process. The use of ES cells for endothelial differentiation are not only of interest with 
respect to the molecular mechanisms but also for identifying sources of endothelial cells that 
can be used for a number of therapeutic purposes. The purpose of this chapter is to review 
recent advances in the molecular mechanisms underlying ES differentiation into endothelial 
cells and how endothelial cells derived from ES cells are being used therapeutically.  
2. Culture conditions 
ES cells are derived from the inner cell mass of a growing blastocyst 1. As such, they have 
the capacity to differentiate into all the cell types of an organism 2. To maintain their 
undifferentiated state ES cells are generally grown in the presence of feeder cells or 
leukemia inhibitory factor (LIF). In the absence of inhibitory factors ES cells can 
spontaneously differentiate into cells with characteristics of one of three germ layers; 
mesoderm, endoderm, or ectoderm.  A variety of approaches have been used to differentiate 
human and mouse ES cells that include: (1) aggregating ES cells into three-dimensional cell 
masses called embryoid bodies (EBs); (2) by co-culturing the ES cells with other cell types; 
and (3) by culturing the ES cells on specific matrix surfaces together with defined media.     
Murine ES cells have been used for several years to study differentiation along multiple 
lineages. Culturing ES cells into EBs has been the most frequently used model to study EC 
differentiation. The appearance of structures consisting of immature hematopoietic cells 
surrounded by endothelial cells and the formation of vascular-like channels suggests that 
the EBs produce factors necessary not only for endothelial differentiation but also for 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
268 
vasculogenesis. These structures closely resemble the so-called blood islands of the yolk sac. 
One of the major advantages of this culture method is the highly reproducible timing of 
molecular events that occurs during the process of differentiation. The induction of both 
hematopoietic and endothelial markers at precise time points during the differentiation has 
greatly facilitated investigation of factors that promote or inhibit EC differentiation or 
hematopoiesis. Their close association has also led to commonly held belief that the 
hematopoietic and endothelial lineages stem from a common precursor known as the 
hemangioblast. The markers of hematopoiesis and endothelial differentiation also permit 
the isolation of specific populations of cells at different stages of differentiation. An example 
of one of the earliest markers of the endothelial lineage is VE-cadherin, and of the 
hematopoietic lineage is CD41. One of the potential disadvantages of this model is that only 
a fraction of the cells, on the order of 5-10%, ultimately become endothelial cells.  
Human ES cells have also been used to generate EBs as a model of EC differentiation or 
hematopoiesis. endothelial cells can be isolated and propagated from human EBs at vary 
time points during differentiation. The EBs can also be used as a model of angiogenesis in 
addition to EC differentiation and vasculogenesis.  11-day old EBs are cultured within three 
dimensional type 1 collagen matrix gels that is supplemented with angiogenic growth 
factors including VEGF and FGF2 3.  The sprouting of new vessels can be observed radiating 
out from the EBs into the surrounding matrix.  
A second mouse model of ES cell differentiation is a two dimensional system that takes 
advantage of the calvaria stromal cell line OP9. ES cells are initially grown as EBs and then a 
subset of cells expressing VEGF-R2 are separated by flow cytometry. These VEGF-R2 cells 
are grown on the OP9 cells they gradually differentiate into endothelial cells expressing VE-
cadherin and CD31 (PECAM-1).  Interestingly, the endothelial cells exhibited two 
morphological characteristics. On the one hand endothelial cells grew as sheets of cells and 
on the other hand the cells coalesced into cord-like structures. It was determined that the 
sheet-like Endothelial cells were of lymphatic origin, whereas the other endothelial cells 
were more like blood endothelial cells. Two soluble factors made by the OP9 cells that 
contribute to the differentiation of these cells into lymphatic endothelial cells include 
Angiopoietin-1 and VEGF-C.  
A third method of culturing the murine ES cells into endothelial cells consists of isolating a 
subpopulation of ES cells that express the VEGF receptor 2 (VEGF-R2) and allowing them to 
differentiate on an acellular matrix such as type IV collagen 4. By adding growth factors to a 
serum free media it was determined that VEGF was a critical factor for differentiating 
VEGF-R2 expressing ES cells into endothelial cells.  
3. Markers of the endothelial lineage 
A critical determinant of endothelial differentiation is the identification of selective markers 
that separate the endothelial lineage from other lineages. Because of the close association 
between the hematopoietic and the endothelial lineage, the existence of a bipotent cell called 
the hemangioblast capable of differentiating into either the endothelial or hematopoietic 
lineages was suggested and identified 5,6. A commonly used marker to define this cell type is 
the VEGF receptor 2 (VEGF-R2). Using an embryoid body (EB) model of ES the temporal 
expression pattern of several endothelial markers was evaluated by PCR and 
immunohistochemistry 7. The expression of VEGF-R2 on day three of differentiation 
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preceded the expression of all of the endothelial markers. The expression of PECAM-1, Tie-
1, Tie2, and VE-cadherin, followed shortly thereafter on days 4 and 5 of differentiation. 
Furthermore, the number of cells expressing these EC-specific markers represented a small 
fraction of the overall number of ES cells that appeared to coalesce into discreet regions of 
the EBs and by day 12 of differentiation when they formed primitive vascular structures. 
The number of cells expressing the endothelial marker PECAM-1 was enhanced by adding 
the growth factor VEGF on day 6 of ES cell differentiation 7.  We have similarly used the 
embryoid body model to identify a population of VEGF-R2 expressing mouse embryonic 
stem cells that also express the endothelial marker VE-cadherin and that are distinct from 
those that express the hematopoietic marker CD41 8. 
The close association between the hematopoietic and endothelial lineages that is seen during 
ES cell differentiation has also been observed in a variety of different organisms including 
the mouse, chicken, zebrafish and humans during embryonic development. In the mouse for 
example, cells of the hematopoietic and endothelial lineages are first observed in the yolk 
sac in regions called blood islands. In addition to the yolk sac, the generation of blood is first 
observed in the developing embryo in a region called the aorta-gonad-mesonephros (AGM), 
in the vitelline and umbilical arteries, and in the allantois/placenta region 9 10,11. In the AGM 
region hematopoietic cells are found in close association with the endothelial wall of the 
aorta suggesting that these early hematopoietic cells are generated from an early 
intermediate called the hemogenic endothelium 9,12. Additional support for the hemogenic 
endothelium has come from in vitro studies of mouse embryonic stem cell differentiation. 
Blast colony-forming cells (BL-CFCs) were identified that can give rise to cells of both the 
endothelial and hematopoietic lineages 5,6. More recently, studies using time-lapse 
photography and FACS analysis of differentiating mouse embryonic stem cells, have 
demonstrated that the hemangioblast generates hematopoietic cells through the formation 
of a hemogenic endothelium intermediate 13. In particular, Tie2hic-Kit+CD41- expressing cells 
were identified as a population of cells that constitute the hemogenic endothelium. 
Further differentiation of endothelial cells into cells of arterial, venous, and lymphatic 
endothelium has also been shown to occur in ES cells and do so in the developing embryo 
prior to the development of blood flow. The differentiation of embryonic stem cells into 
arterial endothelial cells is dependent on the presence and concentration of VEGF. When 
mouse ES cells are cultured in the presence of lower molecular weight isoforms of VEGF 
(120 and 164) they differentiate into endothelial cells expressing arterial markers 14. The 
differentiation of ES cells into arterial versus venous endothelial cells is also dependent on 
the dose of VEGF. Whereas at low concentration of VEGF (2ng/ml) cultured VEGF-R2 
expressing mouse ES cells differentiate into endothelial cells expressing venous EC markers 
such as neuropilin-2 (NRP2), at higher concentrations of VEGF (50 ng/ml) the same cells 
will differentiate into EC expressing the arterial markers Ephrin B2 and neuropiin-1 (NRP1) 
15. ES cells have also been used study their differentiation into lymphatic endothelial cells. 
For example, murine ES cells were aggregated to form EBs and then were cultured in a 3-
dimensional collagen matrix for up to 18 days 16. Treatment with a combination of growth 
factors including VEGF-C and VEGF-A enhanced the formation of lymphatic endothelial 
cells in the EBs 17. An alternative approach of promoting the differentiating ES cell along the 
lymphatic lineage is to use VEGF-R2 expressing ES cells and to co-culture them with OP9 
stromal cells 18. The differentiation of the VEGF-R2 cells into lymphatic endothelial cells is 
dependent upon VEGF-C and angiopoietin-1. 
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4. Signal transduction pathways 
A variety of signal transduction pathways have been implicated during the process of 
endothelial differentiation. At the top of the hierarchy of signal transduction molecules are 
the hedgehog (HH) family of signaling proteins, which play a number of different roles in 
determination of cell fate, embryonic patterning, and morphogenesis 19.  HH signaling 
activates the transcription factor GLI.  Inhibition of Indian hedgehog (IHH) during the 
differentiation of mouse or human ES cells blocks their ability to differentiate along the 
endothelial and hematopoietic lineages 20 21.  In addition to IHH, several studies have 
suggested a role for sonic hedgehog (SHH) in endothelial differentiation. In the absence of 
SHH, angioblasts fail to form into EC tubes or vascular networks 22. Administration of SHH 
was able to promote the differentiation of human multipotent adult progenitor cells into 
arterial endothelial cells both in vivo and in vitro 23.  
Bone morphogenic proteins (BMPs) belong to the TGF-beta family of proteins that are 
involved in regulating cell proliferation, survival, and differentiation during embryogenesis 
24. In particular, BMP-2 and BMP-4 are known mediators of endothelial function and 
differentiation during embryogenesis and ES cell differentiation 25,26. BMP appears to 
function downstream of the HH proteins during the in vitro differentiation of ES cells along 
the EC lineage. Inhibition of EC differentiation by blocking the HH pathway can be rescued 
with BMP-4 20. Furthermore, when human ES cells are cultured in the presence of BMP-4, 
this augments their differentiation along the endothelial lineage 25.  
BMPs can also activate a number of downstream signal transduction pathways. For 
example, the induction of angiogenesis by BMP-2 is dependent upon activation of the 
canonical and non-canonical WNT pathways 26. BMPs can also activate the MAP kinase 
signaling pathways.  For example, BMP-4 activation of EC sprouting is dependent upon p38 
MAP kinase 27. Inhibition of EC migration by BMPs is dependent upon the JNK and ERK 
pathways 28. In contrast to BMP-2 and BMP-4, two BMPs, BMP-9 and BMP-10 inhibit the 
growth of endothelial cells and promote endothelial quiescence 29,30. The role of BMP-9 and 
BMP-10 in endothelial differentiation has not been studied, however in contrast to other 
endothelial cells, BMP-9 promotes the proliferation of mouse embryonic-stem cell derived 
endothelial cells 31. 
WNT signaling is involved in processes that determine cell fate, self-renewal of stem cells, 
polarity, and organogenesis.  There are three classical WNT pathways: (1) the canonical or 
WNT/-catenin pathway; (2) the planar cell polarity pathway; and (3) the WNT/Ca2+ 
pathway 32. WNT5A is a mediator of EC proliferation, survival, and differentiation. WNT5A 
is expressed in the developing vasculature of several organs including the skin, retina, 
stomach, and liver 33. WNT5A functions predominantly through the non-canonical WNT 
pathways. Signaling cascades activated by WNT5A include the protein kinase C (PKC) and 
c-Jun n-terminal kinase (JNK) pathways 34. WNT5A can also inhibit the activity of the 
canonical WNT/-catenin pathway 35. WNT5A contributes to the regulation of the 
differentiation of ES cells along the endothelial lineage 36. WNT5A deficient ES cells cannot 
differentiate into endothelial cells. In endothelial cells WNT5A can activate both the 
canonical and non-canonical WNT pathways. The WNT/Ca2+ pathway is the predominant 
WNT pathway activated in WNT5A deficient ES cells exposed to exogenous WNT5A.  A 
role for WNT signaling has also been evaluated during the differentiation of the 
hemangioblast in human ES cells 37.  Administration of the WNT inhibitor dickkopf1 
markedly inhibited the differentiation of ES cells towards the endothelial or hematopoietic 
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lineages. Likewise, when ES cells were cultured in the presence of WNT1, there was a marked 
increase in the number of hemangioblast like cells. In contrast, when ES cells were exposed to 
WNT5A, they did not have the same effect of increasing the number of hemangioblasts, 
suggesting that WNT5A principally acts at later stages of EC differentiation 38.  
5. Transcription factors 
A variety of transcription factors are known to play a critical role in cellular differentiation 
during embryonic development. In particular, selected transcription factors are known to 
regulate the differentiation of embryonic stem along the endothelial or hematopoietic 
lineages. As mentioned above, the hemangioblast is a bipotent cell capable of differentiating 
into either endothelial or hematopoietic cells. The basic helix-loop-helix (HLH) transcription 
factor SCL (Tal1) has been shown to be critical for blood and endothelial cell development 39. 
SCL is expressed early during embryogenesis in hematopoietic and endothelial cells and its 
disruption in either mouse or zebrafish leads to severe defects in vasculogenesis 40-42. SCL is 
also an early marker of the hemangioblast in embryonic stem cells during their 
differentiation towards the hematopoietic and endothelial lineages 43. In this model of ES 
cells were cultured in serum free conditions and sequentially exposed to BMP4, activin A, 
bFGF, and VEGF. As the mesodermal marker brachyury gradually decreases there is an 
increase in the expression of SCL together with two other transcription factors Runx1 and 
Hhex. SCL deficient ES cells are unable to generate either primitive or definitive 
hematopoietic cells 44. SCL also appears to be critical for the development of the hemogenic 
endothelium 13. SCL deficient ES cells failed to differentiate into Tie2hic-Kit+CD41- cells that 
constitute cells with the capacity to differentiate into hematopoietic and endothelial cells. 
Members of the ETS family of transcription factors have also been shown to play a role in 
the regulation of EC-specific gene expression and EC differentiation.  For example, ER71 has 
been shown to be critical for endothelial differentiation and vascular development in mice 
and zebrafish 45,46. In ES cells ER71 is critical for the expression of VEGF-R2 47.  ER71 appears 
to induce VEFGF-R2 downstream of BMP, Notch, and Wnt signaling. Another ETS factor 
that is expressed in the vasculature and regulates hematopoiesis is Fli-1. Fli-1 deficient mice 
die at embryonic day E12.5 of defective vasculogenesis leading to cerebral hemorrhage 48. 
Fli-1 deficient ES cells also exhibit defective hematopoiesis with a marked reduction in the 
number of blast colony forming cells. In contrast to most other ETS factors we and other 
groups have shown that the ETS factor ERG exhibits an EC-restricted expression pattern 49-
52. Furthermore, it has also been shown that several EC-restricted genes including VE-
cadherin, endoglin, and vWF, are regulated by ERG 53-55. In addition to its role in regulating 
EC-restricted genes we have recently shown that ERG is critical effector of EC differentiation 
of ES cells that appears to be independent of hematopoiesis 56. ERG was selectively 
expressed in VEGF-R2+VE-caherin+ cells and not in VEGF-R2+CD41+ cells. Suppression of 
ERG in ES cells by lentivirally delivery of shRNA resulted in a significant reduction in EC 
differentiation but not hematopoietic cells. 
There are several transcription factors that facilitate the differentiation of ES cells into 
arterial, venous, and lymphatic endothelial cells. The critical transcription factor that 
promotes the differentiation of the hemangioblast or VEGF-R2 expressing cells into venous 
endothelial cells is COUP-TFII 15. The differentiation of these cells was dependent upon the 
dose of VEGF. Whereas low doses of VEGF (2-10 ng/ml) induced the differentiation of 
VEGF-R2 cells into venous endothelial cells expressing high levels of COUP-TFII, high doses 
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4. Signal transduction pathways 
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differentiation of mouse or human ES cells blocks their ability to differentiate along the 
endothelial and hematopoietic lineages 20 21.  In addition to IHH, several studies have 
suggested a role for sonic hedgehog (SHH) in endothelial differentiation. In the absence of 
SHH, angioblasts fail to form into EC tubes or vascular networks 22. Administration of SHH 
was able to promote the differentiation of human multipotent adult progenitor cells into 
arterial endothelial cells both in vivo and in vitro 23.  
Bone morphogenic proteins (BMPs) belong to the TGF-beta family of proteins that are 
involved in regulating cell proliferation, survival, and differentiation during embryogenesis 
24. In particular, BMP-2 and BMP-4 are known mediators of endothelial function and 
differentiation during embryogenesis and ES cell differentiation 25,26. BMP appears to 
function downstream of the HH proteins during the in vitro differentiation of ES cells along 
the EC lineage. Inhibition of EC differentiation by blocking the HH pathway can be rescued 
with BMP-4 20. Furthermore, when human ES cells are cultured in the presence of BMP-4, 
this augments their differentiation along the endothelial lineage 25.  
BMPs can also activate a number of downstream signal transduction pathways. For 
example, the induction of angiogenesis by BMP-2 is dependent upon activation of the 
canonical and non-canonical WNT pathways 26. BMPs can also activate the MAP kinase 
signaling pathways.  For example, BMP-4 activation of EC sprouting is dependent upon p38 
MAP kinase 27. Inhibition of EC migration by BMPs is dependent upon the JNK and ERK 
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canonical WNT/-catenin pathway 35. WNT5A contributes to the regulation of the 
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canonical and non-canonical WNT pathways. The WNT/Ca2+ pathway is the predominant 
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role for WNT signaling has also been evaluated during the differentiation of the 
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markedly inhibited the differentiation of ES cells towards the endothelial or hematopoietic 
 
Endothelial Differentiation of Embryonic Stem Cells 
 
271 
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differentiation but not hematopoietic cells. 
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arterial, venous, and lymphatic endothelial cells. The critical transcription factor that 
promotes the differentiation of the hemangioblast or VEGF-R2 expressing cells into venous 
endothelial cells is COUP-TFII 15. The differentiation of these cells was dependent upon the 
dose of VEGF. Whereas low doses of VEGF (2-10 ng/ml) induced the differentiation of 
VEGF-R2 cells into venous endothelial cells expressing high levels of COUP-TFII, high doses 
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of VEGF (50 ng/ml) repressed COUP-TFII levels and induced the differentiation of VEGF-
R2 cells into endothelial cells expressing markers of arterial endothelial cells such as Ephrin 
B2. Transcription factors that are preferentially upregulated in arterial endothelial cells 
include the HLH factors Hey1 and Hey2. Notch signaling appears to be critical for 
promoting differentiation of ES cells into arterial endothelial cells. Inhibition of Notch 
signaling with a gamma secretase inhibitor preferentially leads to the expression of venous 
EC markers and a repression of arterial markers 15. An environmental stimulus that 
promotes the differentiation of ES cells into arterial endothelial cells is hypoxia. Exposure of 
ES cells to hypoxia was associated with an increase in the expression of the Notch ligand 
Dll4 and the transcription factors Hey1 and Hey2 57. 
The prototypic transcription factor that regulates the differentiation of ES cells into 
lymphatic endothelial cells is Prox1.  Prox1 expression can be induced by three-dimensional 
culture of murine ES cells into EBs in collagen matrices in the presence of VEGF-C and 
VEGF-A 16. Similarly when VEGF-R2 cells were co-cultured with OP9 cells expression of 
Prox1 was observed in lymphatic endothelial cells on day 3 18. Expression of Prox1 in blood 
endothelial cell leads expression of lymphatic markers and transdifferentiation into 
lymphatic endothelial cells 58. Another transcription factor that regulates the expression of 
the VEGF-R3, which binds to VEGF-C, is the T box transcription factor Tbx1 59. Although 
Tbx1 is not required for LEC differentiation it is required for the growth and maintenance of 
lymphatic vessels. A transcription factor that is involved in regulating later stages of 
lymphatic EC maturation is the forkhead transcription factor Foxc2 60,61. Foxc2 was shown to 
be important for the development of lymphatic valves and controlling interactions between 
lymphatic endothelial cells and mural cells.  
6. Therapeutic implications 
One of the ultimate goals of developing culture methods that promote the differentiation of 
stem cells into endothelial cell is to provide a source of cells for a variety of different 
therapeutic applications. One obvious application would be to generate new blood vessels 
or repair existing blood vessels in clinical settings where blood flow is compromised. As an 
initial proof of concept a population of VEGF-R2 expressing mouse ES cells were injected 
into chicken embryo hearts. These cells were shown to be able to integrate into the host 
vasculature and differentiate into two cellular components of the vasculature, endothelial 
cell and smooth muscle cells 62. Based on these promising studies embryonic stem cell 
derived endothelial cell have been used in animal models of human disease to promote 
angiogenesis and ultimately improve blood flow. For example, murine ES cell derived 
endothelial cell were injected either intramuscularly or intra-arterially in a hindlimb model 
of ischemia, and were shown to engraft at the site of ischemia and improve tissue perfusion 
63. One of the concerns of using ES cells for therapeutic purposes is the potential formation 
of teratomas from undifferentiated ES cells. In the hindlimb ischemia study no teratomas 
formed when ES cell derived endothelial cell were used compared to their uniform 
development within two weeks when undifferentiated ES cells were used. A similarly 
promising study was done using human ES cell (hESC) derived endothelial cells 64. The 
hESC derived endothelial cells were shown to engraft into blood vessels at sites of 
myocardial ischemia using a mouse myocardial infarction model. Together these exciting 
proof-of-concept studies provide evidence that ES cell derived endothelial cells can be used 
in a variety of settings to promote blood vessel growth at sites of ischemia. One of the major 
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challenges in using the currently available stem cells as a source of endothelial cells for 
therapeutic applications is the potential of significant immune responses to the engrafted 
cells. One potential mechanism of overcoming this hurdle more recently is the development 
of induced pluripotent stem (iPS) cells in which skin fibroblasts from any individual can be 
transformed into ES cells by introducing four transcription factors 65. These iPS cells have 
subsequently been cultured to promote their differentiation into vascular cells that are very 
similar to those obtained from human ES cells 66.  
7. Acknowledgements 
This work was supported by NIH grant PO1 HL76540. 
8. References 
[1] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse 
embryos. Nature. 1981;292:154-156. 
[2] Hwang NS, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv Drug 
Deliv Rev. 2008;60:199-214. 
[3] Feraud O, Cao Y, Vittet D. Embryonic stem cell-derived embryoid bodies development 
in collagen gels recapitulates sprouting angiogenesis. Lab Invest. 2001;81:1669-1681. 
[4] Hirashima M, Ogawa M, Nishikawa S, Matsumura K, Kawasaki K, Shibuya M. A 
chemically defined culture of VEGFR2+ cells derived from embryonic stem cells 
reveals the role of VEGFR1 in tuning the threshold for VEGF in developing 
endothelial cells. Blood. 2003;101:2261-2267. 
[5] Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis 
and definitive haematopoiesis. Nature. 1997;386:488-493. 
[6] Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for 
hematopoietic and endothelial cells. Development. 1998;125:725-732. 
[7] Vittet D, Prandini MH, Berthier R, et al. Embryonic stem cells differentiate in vitro to 
endothelial cells through successive maturation steps. Blood. 1996;88:3424-3431. 
[8] Nikolova-Krstevski V, Bhasin M, Otu HH, Libermann TA, Oettgen P. Gene expression 
analysis of embryonic stem cells expressing VE-cadherin (CD144) during 
endothelial differentiation. BMC Genomics. 2008;9:240. 
[9] de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells 
first develop within the major arterial regions of the mouse embryo. Embo J. 
2000;19:2465-2474. 
[10] Rhodes KE, Gekas C, Wang Y, et al. The emergence of hematopoietic stem cells is 
initiated in the placental vasculature in the absence of circulation. Cell Stem Cell. 
2008;2:252-263. 
[11] Zeigler BM, Sugiyama D, Chen M, Guo Y, Downs KM, Speck NA. The allantois and 
chorion, when isolated before circulation or chorio-allantoic fusion, have 
hematopoietic potential. Development. 2006;133:4183-4192. 
[12] Garcia-Porrero JA, Godin IE, Dieterlen-Lievre F. Potential intraembryonic hemogenic 
sites at pre-liver stages in the mouse. Anat Embryol (Berl). 1995;192:425-435. 
[13] Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The 
haemangioblast generates haematopoietic cells through a haemogenic endothelium 
stage. Nature. 2009;457:892-895. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
272 
of VEGF (50 ng/ml) repressed COUP-TFII levels and induced the differentiation of VEGF-
R2 cells into endothelial cells expressing markers of arterial endothelial cells such as Ephrin 
B2. Transcription factors that are preferentially upregulated in arterial endothelial cells 
include the HLH factors Hey1 and Hey2. Notch signaling appears to be critical for 
promoting differentiation of ES cells into arterial endothelial cells. Inhibition of Notch 
signaling with a gamma secretase inhibitor preferentially leads to the expression of venous 
EC markers and a repression of arterial markers 15. An environmental stimulus that 
promotes the differentiation of ES cells into arterial endothelial cells is hypoxia. Exposure of 
ES cells to hypoxia was associated with an increase in the expression of the Notch ligand 
Dll4 and the transcription factors Hey1 and Hey2 57. 
The prototypic transcription factor that regulates the differentiation of ES cells into 
lymphatic endothelial cells is Prox1.  Prox1 expression can be induced by three-dimensional 
culture of murine ES cells into EBs in collagen matrices in the presence of VEGF-C and 
VEGF-A 16. Similarly when VEGF-R2 cells were co-cultured with OP9 cells expression of 
Prox1 was observed in lymphatic endothelial cells on day 3 18. Expression of Prox1 in blood 
endothelial cell leads expression of lymphatic markers and transdifferentiation into 
lymphatic endothelial cells 58. Another transcription factor that regulates the expression of 
the VEGF-R3, which binds to VEGF-C, is the T box transcription factor Tbx1 59. Although 
Tbx1 is not required for LEC differentiation it is required for the growth and maintenance of 
lymphatic vessels. A transcription factor that is involved in regulating later stages of 
lymphatic EC maturation is the forkhead transcription factor Foxc2 60,61. Foxc2 was shown to 
be important for the development of lymphatic valves and controlling interactions between 
lymphatic endothelial cells and mural cells.  
6. Therapeutic implications 
One of the ultimate goals of developing culture methods that promote the differentiation of 
stem cells into endothelial cell is to provide a source of cells for a variety of different 
therapeutic applications. One obvious application would be to generate new blood vessels 
or repair existing blood vessels in clinical settings where blood flow is compromised. As an 
initial proof of concept a population of VEGF-R2 expressing mouse ES cells were injected 
into chicken embryo hearts. These cells were shown to be able to integrate into the host 
vasculature and differentiate into two cellular components of the vasculature, endothelial 
cell and smooth muscle cells 62. Based on these promising studies embryonic stem cell 
derived endothelial cell have been used in animal models of human disease to promote 
angiogenesis and ultimately improve blood flow. For example, murine ES cell derived 
endothelial cell were injected either intramuscularly or intra-arterially in a hindlimb model 
of ischemia, and were shown to engraft at the site of ischemia and improve tissue perfusion 
63. One of the concerns of using ES cells for therapeutic purposes is the potential formation 
of teratomas from undifferentiated ES cells. In the hindlimb ischemia study no teratomas 
formed when ES cell derived endothelial cell were used compared to their uniform 
development within two weeks when undifferentiated ES cells were used. A similarly 
promising study was done using human ES cell (hESC) derived endothelial cells 64. The 
hESC derived endothelial cells were shown to engraft into blood vessels at sites of 
myocardial ischemia using a mouse myocardial infarction model. Together these exciting 
proof-of-concept studies provide evidence that ES cell derived endothelial cells can be used 
in a variety of settings to promote blood vessel growth at sites of ischemia. One of the major 
 
Endothelial Differentiation of Embryonic Stem Cells 
 
273 
challenges in using the currently available stem cells as a source of endothelial cells for 
therapeutic applications is the potential of significant immune responses to the engrafted 
cells. One potential mechanism of overcoming this hurdle more recently is the development 
of induced pluripotent stem (iPS) cells in which skin fibroblasts from any individual can be 
transformed into ES cells by introducing four transcription factors 65. These iPS cells have 
subsequently been cultured to promote their differentiation into vascular cells that are very 
similar to those obtained from human ES cells 66.  
7. Acknowledgements 
This work was supported by NIH grant PO1 HL76540. 
8. References 
[1] Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse 
embryos. Nature. 1981;292:154-156. 
[2] Hwang NS, Varghese S, Elisseeff J. Controlled differentiation of stem cells. Adv Drug 
Deliv Rev. 2008;60:199-214. 
[3] Feraud O, Cao Y, Vittet D. Embryonic stem cell-derived embryoid bodies development 
in collagen gels recapitulates sprouting angiogenesis. Lab Invest. 2001;81:1669-1681. 
[4] Hirashima M, Ogawa M, Nishikawa S, Matsumura K, Kawasaki K, Shibuya M. A 
chemically defined culture of VEGFR2+ cells derived from embryonic stem cells 
reveals the role of VEGFR1 in tuning the threshold for VEGF in developing 
endothelial cells. Blood. 2003;101:2261-2267. 
[5] Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis 
and definitive haematopoiesis. Nature. 1997;386:488-493. 
[6] Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for 
hematopoietic and endothelial cells. Development. 1998;125:725-732. 
[7] Vittet D, Prandini MH, Berthier R, et al. Embryonic stem cells differentiate in vitro to 
endothelial cells through successive maturation steps. Blood. 1996;88:3424-3431. 
[8] Nikolova-Krstevski V, Bhasin M, Otu HH, Libermann TA, Oettgen P. Gene expression 
analysis of embryonic stem cells expressing VE-cadherin (CD144) during 
endothelial differentiation. BMC Genomics. 2008;9:240. 
[9] de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells 
first develop within the major arterial regions of the mouse embryo. Embo J. 
2000;19:2465-2474. 
[10] Rhodes KE, Gekas C, Wang Y, et al. The emergence of hematopoietic stem cells is 
initiated in the placental vasculature in the absence of circulation. Cell Stem Cell. 
2008;2:252-263. 
[11] Zeigler BM, Sugiyama D, Chen M, Guo Y, Downs KM, Speck NA. The allantois and 
chorion, when isolated before circulation or chorio-allantoic fusion, have 
hematopoietic potential. Development. 2006;133:4183-4192. 
[12] Garcia-Porrero JA, Godin IE, Dieterlen-Lievre F. Potential intraembryonic hemogenic 
sites at pre-liver stages in the mouse. Anat Embryol (Berl). 1995;192:425-435. 
[13] Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The 
haemangioblast generates haematopoietic cells through a haemogenic endothelium 
stage. Nature. 2009;457:892-895. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
274 
[14] Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ. Sensory nerves 
determine the pattern of arterial differentiation and blood vessel branching in the 
skin. Cell. 2002;109:693-705. 
[15] Lanner F, Sohl M, Farnebo F. Functional arterial and venous fate is determined by 
graded VEGF signaling and notch status during embryonic stem cell 
differentiation. Arterioscler Thromb Vasc Biol. 2007;27:487-493. 
[16] Kreuger J, Nilsson I, Kerjaschki D, Petrova T, Alitalo K, Claesson-Welsh L. Early lymph 
vessel development from embryonic stem cells. Arterioscler Thromb Vasc Biol. 
2006;26:1073-1078. 
[17] Liersch R, Nay F, Lu L, Detmar M. Induction of lymphatic endothelial cell 
differentiation in embryoid bodies. Blood. 2006;107:1214-1216. 
[18] Kono T, Kubo H, Shimazu C, et al. Differentiation of lymphatic endothelial cells from 
embryonic stem cells on OP9 stromal cells. Arterioscler Thromb Vasc Biol. 
2006;26:2070-2076. 
[19] Ingham PW. Transducing Hedgehog: the story so far. EMBO J. 1998;17:3505-3511. 
[20] Kelly MA, Hirschi KK. Signaling hierarchy regulating human endothelial cell 
development. Arterioscler Thromb Vasc Biol. 2009;29:718-724. 
[21] Maye P, Becker S, Kasameyer E, Byrd N, Grabel L. Indian hedgehog signaling in 
extraembryonic endoderm and ectoderm differentiation in ES embryoid bodies. 
Mech Dev. 2000;94:117-132. 
[22] Vokes SA, Yatskievych TA, Heimark RL, et al. Hedgehog signaling is essential for 
endothelial tube formation during vasculogenesis. Development. 2004;131:4371-4380. 
[23] Aranguren XL, Luttun A, Clavel C, et al. In vitro and in vivo arterial differentiation of 
human multipotent adult progenitor cells. Blood. 2007;109:2634-2642. 
[24] Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 
2004;22:233-241. 
[25] Goldman O, Feraud O, Boyer-Di Ponio J, et al. A boost of BMP4 accelerates the 
commitment of human embryonic stem cells to the endothelial lineage. Stem Cells. 
2009;27:1750-1759. 
[26] de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces 
pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J 
Cell Biol. 2009;184:83-99. 
[27] Zhou Q, Heinke J, Vargas A, et al. ERK signaling is a central regulator for BMP-4 
dependent capillary sprouting. Cardiovasc Res. 2007;76:390-399. 
[28] David L, Mallet C, Vailhe B, Lamouille S, Feige JJ, Bailly S. Activin receptor-like kinase 
1 inhibits human microvascular endothelial cell migration: potential roles for JNK 
and ERK. J Cell Physiol. 2007;213:484-489. 
[29] David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 
as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in 
endothelial cells. Blood. 2007;109:1953-1961. 
[30] Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits 
bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J 
Cell Sci. 2007;120:964-972. 
[31] Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. BMP-9 induces 
proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell 
Sci;123:1684-1692. 
 
Endothelial Differentiation of Embryonic Stem Cells 
 
275 
[32] Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4:68-75. 
[33] Masckauchan TN, Agalliu D, Vorontchikhina M, et al. Wnt5a signaling induces 
proliferation and survival of endothelial cells in vitro and expression of MMP-1 
and Tie-2. Mol Biol Cell. 2006;17:5163-5172. 
[34] Wright M, Aikawa M, Szeto W, Papkoff J. Identification of a Wnt-responsive signal 
transduction pathway in primary endothelial cells. Biochem Biophys Res Commun. 
1999;263:384-388. 
[35] Weidinger G, Moon RT. When Wnts antagonize Wnts. J Cell Biol. 2003;162:753-755. 
[36] Yang DH, Yoon JY, Lee SH, et al. Wnt5a is required for endothelial differentiation of 
embryonic stem cells and vascularization via pathways involving both Wnt/beta-
catenin and protein kinase Calpha. Circ Res. 2009;104:372-379. 
[37] Woll PS, Morris JK, Painschab MS, et al. Wnt signaling promotes hematoendothelial 
cell development from human embryonic stem cells. Blood. 2008;111:122-131. 
[38] Kim DJ, Park CS, Yoon JK, Song WK. Differential expression of the Wnt and Frizzled 
genes in Flk1+ cells derived from mouse ES cells. Cell Biochem Funct. 2008;26:24-32. 
[39] Bloor AJ, Sanchez MJ, Green AR, Gottgens B. The role of the stem cell leukemia (SCL) 
gene in hematopoietic and endothelial lineage specification. J Hematother Stem 
Cell Res. 2002;11:195-206. 
[40] Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein 
SCL/tal-1 in vascular development. Genes Dev. 1998;12:473-479. 
[41] Patterson LJ, Gering M, Patient R. Scl is required for dorsal aorta as well as blood 
formation in zebrafish embryos. Blood. 2005;105:3502-3511. 
[42] Patterson C, Ike C, Willis PWt, Stouffer GA, Willis MS. The bitter end: the ubiquitin-
proteasome system and cardiac dysfunction. Circulation. 2007;115:1456-1463. 
[43] Pearson S, Sroczynska P, Lacaud G, Kouskoff V. The stepwise specification of 
embryonic stem cells to hematopoietic fate is driven by sequential exposure to 
Bmp4, activin A, bFGF and VEGF. Development. 2008;135:1525-1535. 
[44] Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia 
oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. 
Cell. 1996;86:47-57. 
[45] Ferdous A, Caprioli A, Iacovino M, et al. Nkx2-5 transactivates the Ets-related protein 
71 gene and specifies an endothelial/endocardial fate in the developing embryo. 
Proc Natl Acad Sci U S A. 2009;106:814-819. 
[46] Sumanas S, Lin S. Ets1-related protein is a key regulator of vasculogenesis in zebrafish. 
PLoS Biol. 2006;4:e10. 
[47] Lee D, Park C, Lee H, et al. ER71 acts downstream of BMP, Notch, and Wnt signaling 
in blood and vessel progenitor specification. Cell Stem Cell. 2008;2:497-507. 
[48] Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired 
hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of 
the Fli1 transcription factor. Mol Cell Biol. 2000;20:5643-5652. 
[49] Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, Duterque-
Coquillaud M. The Ets family member Erg gene is expressed in mesodermal tissues 
and neural crests at fundamental steps during mouse embryogenesis. Mech Dev. 
2000;91:331-335. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
274 
[14] Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ. Sensory nerves 
determine the pattern of arterial differentiation and blood vessel branching in the 
skin. Cell. 2002;109:693-705. 
[15] Lanner F, Sohl M, Farnebo F. Functional arterial and venous fate is determined by 
graded VEGF signaling and notch status during embryonic stem cell 
differentiation. Arterioscler Thromb Vasc Biol. 2007;27:487-493. 
[16] Kreuger J, Nilsson I, Kerjaschki D, Petrova T, Alitalo K, Claesson-Welsh L. Early lymph 
vessel development from embryonic stem cells. Arterioscler Thromb Vasc Biol. 
2006;26:1073-1078. 
[17] Liersch R, Nay F, Lu L, Detmar M. Induction of lymphatic endothelial cell 
differentiation in embryoid bodies. Blood. 2006;107:1214-1216. 
[18] Kono T, Kubo H, Shimazu C, et al. Differentiation of lymphatic endothelial cells from 
embryonic stem cells on OP9 stromal cells. Arterioscler Thromb Vasc Biol. 
2006;26:2070-2076. 
[19] Ingham PW. Transducing Hedgehog: the story so far. EMBO J. 1998;17:3505-3511. 
[20] Kelly MA, Hirschi KK. Signaling hierarchy regulating human endothelial cell 
development. Arterioscler Thromb Vasc Biol. 2009;29:718-724. 
[21] Maye P, Becker S, Kasameyer E, Byrd N, Grabel L. Indian hedgehog signaling in 
extraembryonic endoderm and ectoderm differentiation in ES embryoid bodies. 
Mech Dev. 2000;94:117-132. 
[22] Vokes SA, Yatskievych TA, Heimark RL, et al. Hedgehog signaling is essential for 
endothelial tube formation during vasculogenesis. Development. 2004;131:4371-4380. 
[23] Aranguren XL, Luttun A, Clavel C, et al. In vitro and in vivo arterial differentiation of 
human multipotent adult progenitor cells. Blood. 2007;109:2634-2642. 
[24] Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 
2004;22:233-241. 
[25] Goldman O, Feraud O, Boyer-Di Ponio J, et al. A boost of BMP4 accelerates the 
commitment of human embryonic stem cells to the endothelial lineage. Stem Cells. 
2009;27:1750-1759. 
[26] de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces 
pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J 
Cell Biol. 2009;184:83-99. 
[27] Zhou Q, Heinke J, Vargas A, et al. ERK signaling is a central regulator for BMP-4 
dependent capillary sprouting. Cardiovasc Res. 2007;76:390-399. 
[28] David L, Mallet C, Vailhe B, Lamouille S, Feige JJ, Bailly S. Activin receptor-like kinase 
1 inhibits human microvascular endothelial cell migration: potential roles for JNK 
and ERK. J Cell Physiol. 2007;213:484-489. 
[29] David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 
as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in 
endothelial cells. Blood. 2007;109:1953-1961. 
[30] Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits 
bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J 
Cell Sci. 2007;120:964-972. 
[31] Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. BMP-9 induces 
proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell 
Sci;123:1684-1692. 
 
Endothelial Differentiation of Embryonic Stem Cells 
 
275 
[32] Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4:68-75. 
[33] Masckauchan TN, Agalliu D, Vorontchikhina M, et al. Wnt5a signaling induces 
proliferation and survival of endothelial cells in vitro and expression of MMP-1 
and Tie-2. Mol Biol Cell. 2006;17:5163-5172. 
[34] Wright M, Aikawa M, Szeto W, Papkoff J. Identification of a Wnt-responsive signal 
transduction pathway in primary endothelial cells. Biochem Biophys Res Commun. 
1999;263:384-388. 
[35] Weidinger G, Moon RT. When Wnts antagonize Wnts. J Cell Biol. 2003;162:753-755. 
[36] Yang DH, Yoon JY, Lee SH, et al. Wnt5a is required for endothelial differentiation of 
embryonic stem cells and vascularization via pathways involving both Wnt/beta-
catenin and protein kinase Calpha. Circ Res. 2009;104:372-379. 
[37] Woll PS, Morris JK, Painschab MS, et al. Wnt signaling promotes hematoendothelial 
cell development from human embryonic stem cells. Blood. 2008;111:122-131. 
[38] Kim DJ, Park CS, Yoon JK, Song WK. Differential expression of the Wnt and Frizzled 
genes in Flk1+ cells derived from mouse ES cells. Cell Biochem Funct. 2008;26:24-32. 
[39] Bloor AJ, Sanchez MJ, Green AR, Gottgens B. The role of the stem cell leukemia (SCL) 
gene in hematopoietic and endothelial lineage specification. J Hematother Stem 
Cell Res. 2002;11:195-206. 
[40] Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein 
SCL/tal-1 in vascular development. Genes Dev. 1998;12:473-479. 
[41] Patterson LJ, Gering M, Patient R. Scl is required for dorsal aorta as well as blood 
formation in zebrafish embryos. Blood. 2005;105:3502-3511. 
[42] Patterson C, Ike C, Willis PWt, Stouffer GA, Willis MS. The bitter end: the ubiquitin-
proteasome system and cardiac dysfunction. Circulation. 2007;115:1456-1463. 
[43] Pearson S, Sroczynska P, Lacaud G, Kouskoff V. The stepwise specification of 
embryonic stem cells to hematopoietic fate is driven by sequential exposure to 
Bmp4, activin A, bFGF and VEGF. Development. 2008;135:1525-1535. 
[44] Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia 
oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. 
Cell. 1996;86:47-57. 
[45] Ferdous A, Caprioli A, Iacovino M, et al. Nkx2-5 transactivates the Ets-related protein 
71 gene and specifies an endothelial/endocardial fate in the developing embryo. 
Proc Natl Acad Sci U S A. 2009;106:814-819. 
[46] Sumanas S, Lin S. Ets1-related protein is a key regulator of vasculogenesis in zebrafish. 
PLoS Biol. 2006;4:e10. 
[47] Lee D, Park C, Lee H, et al. ER71 acts downstream of BMP, Notch, and Wnt signaling 
in blood and vessel progenitor specification. Cell Stem Cell. 2008;2:497-507. 
[48] Spyropoulos DD, Pharr PN, Lavenburg KR, et al. Hemorrhage, impaired 
hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of 
the Fli1 transcription factor. Mol Cell Biol. 2000;20:5643-5652. 
[49] Vlaeminck-Guillem V, Carrere S, Dewitte F, Stehelin D, Desbiens X, Duterque-
Coquillaud M. The Ets family member Erg gene is expressed in mesodermal tissues 
and neural crests at fundamental steps during mouse embryogenesis. Mech Dev. 
2000;91:331-335. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
276 
[50] Baltzinger M, Mager-Heckel AM, Remy P. Xl erg: expression pattern and 
overexpression during development plead for a role in endothelial cell 
differentiation. Dev Dyn. 1999;216:420-433. 
[51] Hewett PW, Nishi K, Daft EL, Clifford Murray J. Selective expression of erg isoforms in 
human endothelial cells. Int J Biochem Cell Biol. 2001;33:347-355. 
[52] Yuan L, Nikolova-Krstevski V, Zhan Y, et al. Antiinflammatory effects of the ETS 
factor ERG in endothelial cells are mediated through transcriptional repression of 
the interleukin-8 gene. Circ Res. 2009;104:1049-1057. 
[53] Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates 
angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008;111:3498-
3506. 
[54] Liu J, Yuan L, Molema G, et al. Vascular bed-specific regulation of the von Willebrand 
factor promoter in the heart and skeletal muscle. Blood;117:342-351. 
[55] Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, Gottgens B. Endoglin 
expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the 
promoter and a -8-kb enhancer. Blood. 2006;107:4737-4745. 
[56] Nikolova-Krstevski V, Yuan L, Le Bras A, et al. ERG is required for the differentiation 
of embryonic stem cells along the endothelial lineage. BMC Dev Biol. 2009;9:72. 
[57] Diez H, Fischer A, Winkler A, et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 
signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell 
Res. 2007;313:1-9. 
[58] Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of 
vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J. 
2002;21:4593-4599. 
[59] Chen L, Mupo A, Huynh T, et al. Tbx1 regulates Vegfr3 and is required for lymphatic 
vessel development. J Cell Biol;189:417-424. 
[60] Dagenais SL, Hartsough RL, Erickson RP, Witte MH, Butler MG, Glover TW. Foxc2 is 
expressed in developing lymphatic vessels and other tissues associated with 
lymphedema-distichiasis syndrome. Gene Expr Patterns. 2004;4:611-619. 
[61] Petrova TV, Karpanen T, Norrmen C, et al. Defective valves and abnormal mural cell 
recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat 
Med. 2004;10:974-981. 
[62] Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic 
stem cells serve as vascular progenitors. Nature. 2000;408:92-96. 
[63] Huang NF, Niiyama H, Peter C, et al. Embryonic stem cell-derived endothelial cells 
engraft into the ischemic hindlimb and restore perfusion. Arterioscler Thromb Vasc 
Biol;30:984-991. 
[64] Li Z, Wilson KD, Smith B, et al. Functional and transcriptional characterization of 
human embryonic stem cell-derived endothelial cells for treatment of myocardial 
infarction. PLoS One. 2009;4:e8443. 
[65] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived 
from human somatic cells. Science. 2007;318:1917-1920. 
[66] Taura D, Sone M, Homma K, et al. Induction and isolation of vascular cells from 






Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
276 
[50] Baltzinger M, Mager-Heckel AM, Remy P. Xl erg: expression pattern and 
overexpression during development plead for a role in endothelial cell 
differentiation. Dev Dyn. 1999;216:420-433. 
[51] Hewett PW, Nishi K, Daft EL, Clifford Murray J. Selective expression of erg isoforms in 
human endothelial cells. Int J Biochem Cell Biol. 2001;33:347-355. 
[52] Yuan L, Nikolova-Krstevski V, Zhan Y, et al. Antiinflammatory effects of the ETS 
factor ERG in endothelial cells are mediated through transcriptional repression of 
the interleukin-8 gene. Circ Res. 2009;104:1049-1057. 
[53] Birdsey GM, Dryden NH, Amsellem V, et al. Transcription factor Erg regulates 
angiogenesis and endothelial apoptosis through VE-cadherin. Blood. 2008;111:3498-
3506. 
[54] Liu J, Yuan L, Molema G, et al. Vascular bed-specific regulation of the von Willebrand 
factor promoter in the heart and skeletal muscle. Blood;117:342-351. 
[55] Pimanda JE, Chan WY, Donaldson IJ, Bowen M, Green AR, Gottgens B. Endoglin 
expression in the endothelium is regulated by Fli-1, Erg, and Elf-1 acting on the 
promoter and a -8-kb enhancer. Blood. 2006;107:4737-4745. 
[56] Nikolova-Krstevski V, Yuan L, Le Bras A, et al. ERG is required for the differentiation 
of embryonic stem cells along the endothelial lineage. BMC Dev Biol. 2009;9:72. 
[57] Diez H, Fischer A, Winkler A, et al. Hypoxia-mediated activation of Dll4-Notch-Hey2 
signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp Cell 
Res. 2007;313:1-9. 
[58] Petrova TV, Makinen T, Makela TP, et al. Lymphatic endothelial reprogramming of 
vascular endothelial cells by the Prox-1 homeobox transcription factor. Embo J. 
2002;21:4593-4599. 
[59] Chen L, Mupo A, Huynh T, et al. Tbx1 regulates Vegfr3 and is required for lymphatic 
vessel development. J Cell Biol;189:417-424. 
[60] Dagenais SL, Hartsough RL, Erickson RP, Witte MH, Butler MG, Glover TW. Foxc2 is 
expressed in developing lymphatic vessels and other tissues associated with 
lymphedema-distichiasis syndrome. Gene Expr Patterns. 2004;4:611-619. 
[61] Petrova TV, Karpanen T, Norrmen C, et al. Defective valves and abnormal mural cell 
recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat 
Med. 2004;10:974-981. 
[62] Yamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic 
stem cells serve as vascular progenitors. Nature. 2000;408:92-96. 
[63] Huang NF, Niiyama H, Peter C, et al. Embryonic stem cell-derived endothelial cells 
engraft into the ischemic hindlimb and restore perfusion. Arterioscler Thromb Vasc 
Biol;30:984-991. 
[64] Li Z, Wilson KD, Smith B, et al. Functional and transcriptional characterization of 
human embryonic stem cell-derived endothelial cells for treatment of myocardial 
infarction. PLoS One. 2009;4:e8443. 
[65] Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived 
from human somatic cells. Science. 2007;318:1917-1920. 
[66] Taura D, Sone M, Homma K, et al. Induction and isolation of vascular cells from 






Stem Cells for HUMAN Hepatic  
Tissue Engineering 
Nativ, N.I.1, Ghodbane, M.A.1, Maguire, T.J.1,  
Berthiaume, F.1 and Yarmush, M.L.1,2 
1Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 
2Center for Engineering in Medicine, Massachusetts General Hospital 
USA 
1. Introduction  
1.1 Clinical implications 
End-stage liver disease is a life-threatening condition for which the only effective medical 
treatment available to date is orthotropic liver transplantation. Other approaches are needed 
because of the severe shortage of donors. These alternatives include cell transplantation and 
extracorporeal bioartificial livers. Since adult hepatocytes do not readily proliferate in 
culture, and healthy human livers are used to meet transplantation needs and are therefore 
not available for other purposes, a major challenge for these cell-based therapies is to 
identify a reliable hepatocyte source[1]. In the case of extracorporeal devices, many have 
suggested the use of animal sources (e.g. rat and pig), where immunoisolation may be 
possible. This is not likely to be a viable option for cell implantable modalities since these 
implants must be vascularized to function properly, and as a result would be exposed to 
xenogeneic immune rejection[2]. An increasingly plausible approach is the use of 
hepatocytes derived from embryonic stem cells (ESCs), as recent studies – reviewed in 
greater detail below – show that it is possible to differentiate ESCs into hepatocyte-like cells 
with high yields. Furthermore, recent developments with induced pluripotent stem cells 
(iPSCs) suggest that many of the procedures used to differentiate ESCs could be used on 
iPSCs, thus making it possible to derive patient-specific syngeneic hepatocytes. Besides 
therapeutic applications, hepatocytes derived from human ESCs can be used for a variety of 
other applications, such as toxicity drug screening, where the use of human cells is much 
preferred compared to animal cells that often vary in sensitivity and metabolism of 
xenobiotics and drugs. 
1.2 Industrial implications 
One of the fundamental challenges facing the development of new chemical entities within 
the pharmaceutical industry is the extrapolation of key in vivo parameters from in vitro cell 
culture assays and animal studies. Development of microscale devices and screening assays 
incorporating primary human cells can potentially provide better, faster and more efficient 
prediction of in vivo toxicity and clinical drug performance[3]. With this goal in mind, large 
strides have been made in the area of microfluidics to provide in vitro surrogates that are 
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designed to mimic the physiological architecture and dynamics. Current embodiments of 
this synergy cover various microelectromechanical (MEMs) devices that contain 
hepatocytes, for use in drug metabolism screening and toxicology assessment. 
1.3 Liver function and structure 
The liver, a key metabolic and detoxification center, contains parenchymal cells called 
hepatocytes (70%) and various nonparenchymal cell types such as sinusoidal endothelial 
cells, stellate (fat-storing, Ito) cells, Kupffer cells, and cholangiocytes (bile duct cells). 
Hepatocytes are responsible for most liver-specific functions, including albumin synthesis, 
detoxification of ammonia into urea and glutamine, bile and cholesterol production [4]. The 
liver is also critical for maintaining circulating glucose levels via gluconeogenesis during 
fasting. A large array of enzymes is responsible for the detoxification of organic compounds, 
either endogenous (such as many hormones) or exogenous (drugs and toxins) via two 
sequential mechanisms described as Phase I and Phase II biotransformations. There is an 
extensive body of literature that has shown that controlling environmental parameters, in 
other words the culture conditions, which consist of the type of substrate used, spatial 
orientation of the cultured cells, addition of growth factors, and the combinatorial effects of 
these parameters, is critically important to induce and maintain a high level of 
hepatocellular viability and function[5]. The functional and structural complexity of the 
liver organ has been very difficult to reproduce ex vivo in hepatocyte culture systems. Some 
of these challenges have been partially met using novel cell culture approaches as well as 
microfabrication techniques that can emulate the size scales of the liver sinusoid. While all 
of these studies describe various techniques to boost in vitro hepatocyte function, they do 
not resolve the limited access to primary hepatocytes, which do not proliferate to any 
significant degree outside of the liver[1]. This is crucial because despite modifications in the 
culture environment, large numbers of mature hepatocytes are needed, and yet, are not 
available, for clinical applicability. Herein, we focus primarily on the challenge of securing a 
sufficient supply of high functioning hepatocytes for clinical and industrial applications 
using a stem cell differentiation platform. 
1.4 Adult stem cells  
To address cell source issues more effectively, research into alternate hepatocyte precursor 
populations has been conducted. Unlike differentiated cells, hepatoblasts are not only 
capable of expressing differentiated function, but are also able to self-renew. A few 
hepatoblasts have been identified that have the capacity to differentiate into mature 
hepatocytes and include bipotential precursors for hepatocytes and biliary cells, and 
hematopoietic stem cells [6].  
In scenarios following severe hepatic injury, liver regeneration is attributed to a potential 
stem cell compartment located within the smallest branches of the intrahepatic biliary tree, 
which gives rise to the bipotential cells known as oval cells [7]; [8]. Oval cells are 
characterized as small cells with a high nucleus-to-cytoplasm ratio, oval shaped nucleus, 
and the ability to express markers of both fetal hepatocytes and biliary cells [9]; [10]. Oval 
cells have been shown to require growth factors such as transforming growth factor alpha 
(TGF, epidermal growth factor (EGF), and hepatocyte growth factor (HGF) for 
progression through the cell cycle as well and subsequent differentiation toward mature 
hepatocytes [11]. Despite the large number of observations describing liver growth 
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processes driven by oval cell proliferation and differentiation into hepatocytes, oval cells are 
difficult to isolate and the molecular mechanisms behind these processes must still be 
elucidated. 
Hematopoietic stem cells (HSCs) have also been induced to differentiate along hepatocyte 
specific pathways. For example, one experimental system utilized HSC transplantation to 
alleviate liver disease in fumarylacetoacetate hydrolase (FAH) deficient mice [12]. FAH 
deficiency leads to liver dysfunction and eventual lethality. Following HSC transplantation, 
liver function was reconstituted. However, it is unclear whether the HSCs or HSC progeny 
that repopulated the liver. In addition, the mechanism that induces differentiation toward 
mature hepatocytes is unclear. 
Despite the fact that hepatoblasts exhibit the potential to provide a renewable hepatocyte 
cell source, these cells are hard to isolate and exist in very low numbers [13]. In addition, the 
full efficacy of utilizing these precursor cells is questionable, since the long-term functional 
stability of hepatocytes obtained from these systems has yet to be assessed.  
2. Embryonic stem cells and induced pluripotent stem cells  
There are multiple stem cell starting paths for hepatocytes: 1. ESCs, 2. iPSCs, 3. Endoderm 
precursors and 4. Hepatic stem cells. However, due to their robust nature and large body of 
literature, we will focus on the first two. Furthermore these two cell types are readily 
abundant and have a higher proliferative capacity, thereby providing a strong potential 
starting point for the aforementioned applications. 
2.0.1 Embryonic stem cells (ES cells) 
Embryonic stem cells, derived from the inner cell mass of the blastocyst [14], have been 
proposed as another potential source for the generation of mature hepatocytes. ES cells are 
pluripotent and can be induced to differentiate into any cell type. When cultured in the 
presence of an anti-differentiation agent such as leukemia inhibitory factor (LIF) and with or 
without a feeder layer, these cells can proliferate while maintaining pluripotency [15]. Upon 
removal of the anti-differentiation agent, ES cells begin to spontaneously differentiate.  
2.0.2 Induced pluripotent stem cells (iPS cells) 
A new area of research has developed in recent years, majorly in part due to the legislative 
restrictions certain countries have placed on ES cell research. One area that has shown 
strong advancement is the area of induced pluripotent stem cells (iPS cells). iPS cells are the 
result of reprogramming somatic cells to a pluripotent state which resemble ES cells with 
respect to  morphology, proliferation (self- renewal), surface antigens, gene expression, 
epigenetic status of pluripotent cell-specific genes, epigenomics and telomerase activity [16, 
17]. Human iPS cells’ autologous nature offers several advantages over human ES cells in 
regards to potential patient specific therapeutics, the study of disease state, study of 
developmental processes, drug discovery as well as drug toxicity on differentiated 
hepatocytes while avoiding the ethical issues associated with isolation and the usage of 
human ES cells as illustrated in Figure 1.  
Yamanaka coined the term induced pluripotent stem cells in 2006 while inducing a 
pluripotent state in mouse somatic cells by direct reprogramming [16]. The same year, his 
lab demonstrated the generation of induced pluripotent stem cells from adult human  
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processes driven by oval cell proliferation and differentiation into hepatocytes, oval cells are 
difficult to isolate and the molecular mechanisms behind these processes must still be 
elucidated. 
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stability of hepatocytes obtained from these systems has yet to be assessed.  
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precursors and 4. Hepatic stem cells. However, due to their robust nature and large body of 
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starting point for the aforementioned applications. 
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proposed as another potential source for the generation of mature hepatocytes. ES cells are 
pluripotent and can be induced to differentiate into any cell type. When cultured in the 
presence of an anti-differentiation agent such as leukemia inhibitory factor (LIF) and with or 
without a feeder layer, these cells can proliferate while maintaining pluripotency [15]. Upon 
removal of the anti-differentiation agent, ES cells begin to spontaneously differentiate.  
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A new area of research has developed in recent years, majorly in part due to the legislative 
restrictions certain countries have placed on ES cell research. One area that has shown 
strong advancement is the area of induced pluripotent stem cells (iPS cells). iPS cells are the 
result of reprogramming somatic cells to a pluripotent state which resemble ES cells with 
respect to  morphology, proliferation (self- renewal), surface antigens, gene expression, 
epigenetic status of pluripotent cell-specific genes, epigenomics and telomerase activity [16, 
17]. Human iPS cells’ autologous nature offers several advantages over human ES cells in 
regards to potential patient specific therapeutics, the study of disease state, study of 
developmental processes, drug discovery as well as drug toxicity on differentiated 
hepatocytes while avoiding the ethical issues associated with isolation and the usage of 
human ES cells as illustrated in Figure 1.  
Yamanaka coined the term induced pluripotent stem cells in 2006 while inducing a 
pluripotent state in mouse somatic cells by direct reprogramming [16]. The same year, his 
lab demonstrated the generation of induced pluripotent stem cells from adult human  
 
 




Fig. 1. Applications of IPS Cell Technology 
Patient-derived iPS cells can produce various somatic cells with the same genetic 
information as the patient. These cells could be used to construct disease models and to 
screen for effective and safe drugs, as well as to treat patients through cell transplantation 
therapy. (Figure taken from [20], figure 1) 
fibroblasts by retroviral transfection of four factors: Oct3/4, Sox2, c-Myc and Klf4 [16, 18]. 
Since then, others have generated human iPS cells using different combination of factors 
while preserving Oct3/4 and Sox2 as the core factors needed for pluripotency 
reprogramming while Oct3/4 is the most important[19, 20]. The main risk associated with 
the use of human iPS derived cells for transplantation is directly influenced by the iPS 
generation methods which may involve risk of DNA modification (gene deletion, viral gene 
incorporating into the human genome and gene expression alterations) which may lead to 
insertional mutations that will affect iPS function, differentiation potential and 
tumorigenesis [20, 21]. The human iPS cells generated by the Yamanaka group, for example, 
had more than 20 retroviral integration sites in total which may increase tumor formation 
[16, 18]. That risk has accelerated the search for new methods for generating clinically safer 
iPS cells such as the use of non-integrating episomal vectors or the use of molecules that 
promote or enhance reprogramming of somatic cells to iPS cells to improve reprogramming 
efficiency and reduce genomic alterations due to viral integration [21, 22].  
2.0.3 Induced pluripotent stem cells are similar, but not identical to embryonic stem 
cells 
Although iPS cells share similar features with ES cells as mentioned above, they are not 
identical. The reprogramming process does not involve genetic transformation but rather an 
epigenomic one. Lister et al. have shown that iPSCs are not identical to ESCs with respect to 
epigenomic profile by profiling whole-genome DNA methylation at single-base resolution 
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in five human iPSC lines, along with methylomes of ES cells, somatic cells, and 
differentiated iPSCs and ES cells [17]. In addition, iPSCs maintain some epigenomic features 
which resemble the somatic cell they have been generated from [17]. Cell memory based on 
epigenomics may suggest that, for example, iPSCs which were generated from primary 
hepatocytes as a somatic cell source will yield more or better functioning iPSC derived 
hepatocytes compared to those generated from iPSCs which were generated from fibroblasts 
as a somatic cell source. These discrepancies between human ES and iPS cells led to the 
question of what is the difference between the two stem cell types in regards to pluripotency 
and differentiation potential? And what is the best method to assess it? The ultimate test for 
pluripotency in the mouse system is the generation of a chimeric mouse which was 
successfully generated by blastocyst microinjection of mouse ES and iPS cells. Obviously, 
this test is not applicable to human ES and iPS cells and, therefore, other methods are being 
used to determine the pluripotency of the cells such as teratoma formation. As in the case of 
human ES cells, human iPS cells have the potential to differentiate to any of the three germ 
layers and form teratomas when transplanted subcutaneously into a severe combined 
immunodefficient (SCID) mouse [16, 18]. Unfortunately, teratoma formation does not 
guarantee full reprogramming as many mouse ES cell-like cell lines form teratomas but fail 
to produce germline chimeras [20]. The ultimate method to assess the differentiation 
potential of human ES and iPS cells to mature and functional hepatocytes is to compare the 
two with respect to mature hepatocytes gene and protein expression profiles, as well as 
metabolic activity, drug clearance, glycogen storage, urea and albumin synthesis and 
secretion while using the same differentiation method. 
In addition to the functionality of the differentiated hepatocytes, the efficiency of the process 
is of high importance due to the potential of human ESCs and iPSCs to differentiate 
spontaneously into cells from the three germ layers. Complete differentiation of stem cells in 
vitro is especially important when used for cell based therapies. Heterogeneous populations 
at the end of the differentiation process composed of differentiated cells as well as stem cells 
may lead to teratoma formation at the site of transplantation as well at other locations to 
which the cells migrated.  
2.1 Traditional embryonic stem cell and induced pluripotent stem cell differentiation 
paradigms 
Many paradigms currently exist to specifically direct the differentiation of embryonic 
stem cells toward a hepatocyte lineage in vitro, while utilizing the knowledge of 
embryological pathways occurring in vivo during normal liver development. This process 
involves numerous stages and is influenced by cytokines as well as cell-matrix 
interactions in a temporal and spatial manner. When developing new paradigms for 
direct differentiation of human ES and iPS cells into mature and functional hepatocytes in 
vitro with high efficiency, one must refer to the developmental process of the liver during 
embryonic development. 
2.1.1 Hepatocyte differentiation during embryogenesis 
The main stages are illustrated in Figure 2A. In the first phase, ES cells differentiate to 
endodermal cells. ES and iPS cells are pluripotent and therefore can give rise to any of the 
three germ layers: ectoderm, mesoderm and endoderm where the latter, more specifically 
the anterior- ventral definitive endoderm, give rise to the cells of the liver. The expression of 
 




Fig. 1. Applications of IPS Cell Technology 
Patient-derived iPS cells can produce various somatic cells with the same genetic 
information as the patient. These cells could be used to construct disease models and to 
screen for effective and safe drugs, as well as to treat patients through cell transplantation 
therapy. (Figure taken from [20], figure 1) 
fibroblasts by retroviral transfection of four factors: Oct3/4, Sox2, c-Myc and Klf4 [16, 18]. 
Since then, others have generated human iPS cells using different combination of factors 
while preserving Oct3/4 and Sox2 as the core factors needed for pluripotency 
reprogramming while Oct3/4 is the most important[19, 20]. The main risk associated with 
the use of human iPS derived cells for transplantation is directly influenced by the iPS 
generation methods which may involve risk of DNA modification (gene deletion, viral gene 
incorporating into the human genome and gene expression alterations) which may lead to 
insertional mutations that will affect iPS function, differentiation potential and 
tumorigenesis [20, 21]. The human iPS cells generated by the Yamanaka group, for example, 
had more than 20 retroviral integration sites in total which may increase tumor formation 
[16, 18]. That risk has accelerated the search for new methods for generating clinically safer 
iPS cells such as the use of non-integrating episomal vectors or the use of molecules that 
promote or enhance reprogramming of somatic cells to iPS cells to improve reprogramming 
efficiency and reduce genomic alterations due to viral integration [21, 22].  
2.0.3 Induced pluripotent stem cells are similar, but not identical to embryonic stem 
cells 
Although iPS cells share similar features with ES cells as mentioned above, they are not 
identical. The reprogramming process does not involve genetic transformation but rather an 
epigenomic one. Lister et al. have shown that iPSCs are not identical to ESCs with respect to 
epigenomic profile by profiling whole-genome DNA methylation at single-base resolution 
 
Stem Cells for HUMAN Hepatic Tissue Engineering 
 
283 
in five human iPSC lines, along with methylomes of ES cells, somatic cells, and 
differentiated iPSCs and ES cells [17]. In addition, iPSCs maintain some epigenomic features 
which resemble the somatic cell they have been generated from [17]. Cell memory based on 
epigenomics may suggest that, for example, iPSCs which were generated from primary 
hepatocytes as a somatic cell source will yield more or better functioning iPSC derived 
hepatocytes compared to those generated from iPSCs which were generated from fibroblasts 
as a somatic cell source. These discrepancies between human ES and iPS cells led to the 
question of what is the difference between the two stem cell types in regards to pluripotency 
and differentiation potential? And what is the best method to assess it? The ultimate test for 
pluripotency in the mouse system is the generation of a chimeric mouse which was 
successfully generated by blastocyst microinjection of mouse ES and iPS cells. Obviously, 
this test is not applicable to human ES and iPS cells and, therefore, other methods are being 
used to determine the pluripotency of the cells such as teratoma formation. As in the case of 
human ES cells, human iPS cells have the potential to differentiate to any of the three germ 
layers and form teratomas when transplanted subcutaneously into a severe combined 
immunodefficient (SCID) mouse [16, 18]. Unfortunately, teratoma formation does not 
guarantee full reprogramming as many mouse ES cell-like cell lines form teratomas but fail 
to produce germline chimeras [20]. The ultimate method to assess the differentiation 
potential of human ES and iPS cells to mature and functional hepatocytes is to compare the 
two with respect to mature hepatocytes gene and protein expression profiles, as well as 
metabolic activity, drug clearance, glycogen storage, urea and albumin synthesis and 
secretion while using the same differentiation method. 
In addition to the functionality of the differentiated hepatocytes, the efficiency of the process 
is of high importance due to the potential of human ESCs and iPSCs to differentiate 
spontaneously into cells from the three germ layers. Complete differentiation of stem cells in 
vitro is especially important when used for cell based therapies. Heterogeneous populations 
at the end of the differentiation process composed of differentiated cells as well as stem cells 
may lead to teratoma formation at the site of transplantation as well at other locations to 
which the cells migrated.  
2.1 Traditional embryonic stem cell and induced pluripotent stem cell differentiation 
paradigms 
Many paradigms currently exist to specifically direct the differentiation of embryonic 
stem cells toward a hepatocyte lineage in vitro, while utilizing the knowledge of 
embryological pathways occurring in vivo during normal liver development. This process 
involves numerous stages and is influenced by cytokines as well as cell-matrix 
interactions in a temporal and spatial manner. When developing new paradigms for 
direct differentiation of human ES and iPS cells into mature and functional hepatocytes in 
vitro with high efficiency, one must refer to the developmental process of the liver during 
embryonic development. 
2.1.1 Hepatocyte differentiation during embryogenesis 
The main stages are illustrated in Figure 2A. In the first phase, ES cells differentiate to 
endodermal cells. ES and iPS cells are pluripotent and therefore can give rise to any of the 
three germ layers: ectoderm, mesoderm and endoderm where the latter, more specifically 
the anterior- ventral definitive endoderm, give rise to the cells of the liver. The expression of 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
284 
Wnt signaling inhibitors in the anterior endoderm represses the Wnt/ catenin pathway 
and was shown to be required for liver specification in the endoderm [23]. Signaling by the 
transforming growth factor beta (TGFβ) growth factor Nodal at relatively high 
concentrations initiates endoderm formation. Nodal signaling stimulates the expression of a 
core group of endoderm transcription factors including the HMG domain DNA-binding 
factor Sox17 and the fork head domain proteins Foxa1–3 (HNF3α/β/γ) which in turn 
regulate a cascade of genes committing cells to the endoderm lineage [24]. FoxA2 and 
GATA4 serve as transcription factors for the alb1 gene which encodes for serum albumin 
and appear early in the pre-liver hepatic domain of ventral foregut endoderm and later in 
liver [25, 26].     
 
  
                     (A)                                                                         (B) 
Fig. 2. Embryonic development of the liver. 
(A) Development of the liver is illustrated from the standpoint of cellular differentiation 
(red) from uncommitted endoderm to functional adult hepatocytes and biliary epithelium. 
(B) The schematic shows mouse embryos at different stages of development with the 
endoderm tissue highlighted in yellow, the liver in red, and the gall bladder in green. The 
major developmental events are listed below. The endoderm germ layer is formed during 
gastrulation (e6.5-e7.5). Throughout gastrulation and early somite stages of development 
(e7-e8.5) the endoderm is patterned along the A-P axis into foregut (fg) midgut (mg) and 
hindgut (hg) progenitor domains. Morphogenesis forms foregut and hindgut pockets as the 
endodermal cup is transformed into a gut tube. By e8.5 hepatic fate specified in a portion of 
the ventral foregut endoderm adjacent to the heart. As the embryo grows the endoderm 
forms a gut tube and the liver domain moves to the midgut. The liver diverticulum (ld) 
forms by e9 and expands into an obvious liver bud (lb) by e10. The liver grows, and by e15 
hepatoblasts are differentiating into hepatocyte and biliary cells. Final maturation of the 
liver is gradual and continues into the postnatal period. 
(Figure taken from[74], figures 1 and 2) 
In the second phase, we see the differentiation from definitive to hepatic endoderm. The 
onset of liver development is characterized by the commitment of midgut endoderm to 
become liver through interactions with cardiac mesoderm which secrete fibroblast growth 
factors (FGFs) [27]. FGFs signaling in the foregut endoderm activated the MAPK pathway is 
necessary for initiation and stabilization of hepatic differentiation [28]. Bone morphogenetic 
proteins (BMPs) (BMP2, BMP4, BMP5, and BMP7) signaling from the septum transversum 
mesenchyme also contributes to hepatic gene induction in the endoderm [29-32]. Wnt 
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signaling along this stage is suppressed but is required in the following stage where the 
hepatic endoderm outgrows into the liver bud[23]. In addition, HNF3 and activin A 
signaling are involved in the process of the specification from endodermal stem cells toward 
the hepatic epithelial lineages as indicated in Figures 2 and 3 [31, 32]. Under the influence of 
these signals, endodermal cells (the liver bud) migrate from the ventral foregut into the 
extracellular matrix (ECM) rich septum traversum, forming the primordial hepatoblasts. 
This migration is accompanied by major remodeling of the extracellular matrix surrounding 
the hepatic cells. Some investigators have tried to induce this process in vitro by 
differentiating ES and iPS cells using various types and configurations of ECM [33]. 
 
 
Fig. 3. Schematic presentation of fetal liver development. The establishment of a fully 
functional liver architecture is not accomplished before postnatal stages and follows upon a 
sequential array of tightly regulated intra- and extracellular signaling pathways, including 
liver-enriched transcription factors (LETFs) and growth factors, cytokines, glucocorticoids 
and hormones, respectively. To distinguish the level of expression and/or regulating role 
among diverse LETFs, different letter sizes are used. Abbreviations: ALB, albumin; AFP, 
alpha-fetoprotein, BMP, bone morphogenic proteins; C/EBP, CCAAT enhancer binding 
protein; CK, cytokeratin; CM, cardiogenic mesoderm; E, embryonic day in rodent liver 
development; FGF, fibroblast growth factors; GGT, c-glutamyltransferase; HGF, hepatocyte 
growth factor; HNF, hepatocyte nuclear factor; OC-2, Onecut transcription factor; ST, 
septum transversum; TGF, transforming growth factor. (Figure taken from[31], figure 2) 
In the third phase, the liver primordium is induced to invade the septum transversum, 
giving rise to fetal hepatocytes (primordial hepatoblasts) which are bi-potent and may 
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proliferate of later differentiate into hepatocytes and cholangiocytes (biliary cells). Markers 
of hepatoblasts inherent in this phase are GATA4, HNF4alpha, HNF6, hepatic alpha-
fetoprotein [AFP], albumin [ALB], and biliary cytokeratin (CK 17/CK19) [29, 30, 32].  
Hematopoietic stem cells (HSCs) colonize the liver bud, thereby emitting a growth signal for 
the liver. Hematopoietic tissue and hepatoplasts subsequently release additional growth 
factors to further develop both tissues. Hepatoblasts continue to proliferate and start 
expressing placental alkaline phosphatase, intermediate filament proteins (cytokeratins 
CK14, CK8, and CK18), c-glutamyltransferase, and later also alpha1-antitrypsin, glutathione 
S-transferase P, C/EBP, lactate dehydrogenase, and muscle pyruvate kinase [29-32].  
At this stage three cell populations exist: (a) hepatocyte-committed cells that exclusively 
express hepatocyte markers, such as AFP and ALB, (b) cholangiocyte-committed progenitor 
cells, expressing biliary cell markers such as CK19, and (c) a bipotential hepatoblast 
population, expressing both hepatic and biliary markers. Bipotential hepatoblasts then 
proceed through a series of maturation steps which entail proliferation, cellular growth, and 
functional maturation. These final in vivo steps are induced by various extracellular signals 
such as: (1) dexamethasone, which induces albumin production and downregulates alpha-
fetal protein production; (2) transforming growth factor beta, which inhibits hepatocyte 
proliferation and increases albumin production; (3) oncostatin M, mostly produced by 
HSCs, which induces tight cell-cell contacts, necessary for maximum differentiated 
hepatocyte function, maintenance of albumin production, and upregulation of other various 
hepatocyte functions; (4) HGF, excreted by mesenchymal cells or nonparenchymal liver 
cells, antagonizes the latter process, resulting in support of growth and differentiation of the 
fetal hepatocytes. The hormone insulin synergistically promotes this effect [27, 29, 31].  
In parallel, the percentage of bipotent cells is markedly reduced. At this point, although cells 
continue to proliferate, most of them are unipotent and irreversibly committed to either the 
hepatic or cholangic lineage [29-32]. Complete functional hepatic maturation ultimately 
takes place after birth upon coassistance of HGF, produced by the surrounding 
nonparenchymal liver cells (sinusoidal, stellate, and endothelial cells) [27, 31]. About half of 
the active genes tested in the liver are bound by the transcription factor HNF4 alpha and it is 
suggested that it directly regulates hepatic genes and is an important transcription factor 
during the differentiation process of ES and iPS cells into mature hepatocytes [34, 35].  
It is important to mention that mouse iPS cells exhibit full potential for fetal liver 
development in embryos derived solely from mouse iPS cells by tetraploid 
complementation compared to wild-type embryos as indicated by similar levels of 
hepatocyte marker mRNA and liver specific cell type protein expression levels. In addition, 
liver Hematoxylin and Eosin (H&E) stained sections presented a similarity in liver 
morphology between the two [36].  
2.1.2 Induction of ES and iPS cell differentiation into hepatocyte-like cells in vitro 
The resultant paradigms, taking these cues into account, can thus be broadly grouped in 
terms of temporal regulation through cytokine addition or spatial regulation using various 
extracellular matrix configurations. Various configurations for generating hepatocyte-like 
cells in vitro involve culturing human ES and iPS cells on extra cellular matrix and inducing 
differentiation with hepatocyte development stage specific factors in order to maximize the 
yield of cells at each stage which will determine the overall differentiation yield of the 
process.  
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As mentioned above, the first step involves the differentiation of pluripotent human ES into 
endodermal cells and most differentiation paradigms utilize Activin A which mimics Nodal 
signaling. At the end of this stage, most of the cells lost the expression of the pluripotent 
marker Oct4 while concomitantly gaining strong expression of definitive endoderm (DE) 
transcription factors Sox17, FoxA2 as well as GATA4 [36-38]. The later steps of 
differentiation induce endodermal like cells to differentiate into mature and fully functional 
hepatocytes while utilizing different ECMs and various factors for about 15 additional days 
[36-38]. 
The human ES cells exhibited a similar differentiation efficiency as human iPS cells while 
using the same differentiation procedure (about 81% albumin positive cells) as well as 
similar hepatocyte mRNA fingerprints [36] . In addition, cell properties of primary human 
hepatocytes such as albumin and urea secretion, as well as cytochrome CYP450 activity 
were similar in vitro between hepatocyte-like cells generated from human ES as well as 
those generated from human iPS cells, although lower compared to primary isolated 
hepatocytes (10 fold difference for urea and albumin secretion and 30 fold difference for 
CYP450 isozyme activities after phenobarbital induction) [38]. While comparing the 
expression of a series of genes encoding phase I and phase II hepatic enzymes between 
cadaveric liver samples and hepatocyte-like cells, it was indicated that the level of mRNA 
was similar between the ES and iPS derived hepatocyte-like cells while lower compared 
with adult liver samples in most cases [36]. This may indicate that differentiated cells are not 
mature enough and this step of the differentiation procedure demands further optimization 
[36, 38].  
Human ES and iPS cell derived hepatocytes were shown to contribute to the liver 
parenchyma in vivo and were stained positive for albumin 7 days after their injection to the 
right lateral liver lobe of newborn mice, which exemplifies the potential of human iPS cells 
in regenerative medicine therapeutics [36]. 
2.2 Differentiation paradigms utilizing tissue engineering 
A key requirement for effective tissue engineering is the cellular environment that allows 
the cells to maintain the functional capacity observed in the in vivo environment. Often the 
environment mimics some critical aspects of the in vivo setting through proper control of 
the materials and mechanical properties as well as the chemical milieu.  
A consideration with tissue-engineered constructs is the presence of exogenous chemical 
and mechanical stimuli such as soluble growth and differentiation factors as well as 
mechanical forces (e.g., cyclic mechanical loading, fluid shear).  
2.2.1 Matrix configuration 
Culturing cells in various controlled three-dimensional (3D) environments has proven to be 
a successful differentiation technique. This is thought to be a result of mimicking the in vivo 
histoarchitecture of liver, incorporating cell-matrix interactions as well as soluble cues.  
Several ECMs are present in liver development. One study compared the effect of using 
type I collagen, fibronectin, laminin, and MatrigelTM on directing hepatic differentiation. 
Cells were cultured for 7 days in embyoid bodies (EBs) before being transferred to one of the 
substrates. This mimics to some extent the liver development stage where endodermal cells 
migrate into the ECM rich septum transversum. Type I collagen was shown to cause the 
greatest increase in liver specific genes, with MatrigelTM also showing a beneficial effect[39].  
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proliferation and increases albumin production; (3) oncostatin M, mostly produced by 
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the active genes tested in the liver are bound by the transcription factor HNF4 alpha and it is 
suggested that it directly regulates hepatic genes and is an important transcription factor 
during the differentiation process of ES and iPS cells into mature hepatocytes [34, 35].  
It is important to mention that mouse iPS cells exhibit full potential for fetal liver 
development in embryos derived solely from mouse iPS cells by tetraploid 
complementation compared to wild-type embryos as indicated by similar levels of 
hepatocyte marker mRNA and liver specific cell type protein expression levels. In addition, 
liver Hematoxylin and Eosin (H&E) stained sections presented a similarity in liver 
morphology between the two [36].  
2.1.2 Induction of ES and iPS cell differentiation into hepatocyte-like cells in vitro 
The resultant paradigms, taking these cues into account, can thus be broadly grouped in 
terms of temporal regulation through cytokine addition or spatial regulation using various 
extracellular matrix configurations. Various configurations for generating hepatocyte-like 
cells in vitro involve culturing human ES and iPS cells on extra cellular matrix and inducing 
differentiation with hepatocyte development stage specific factors in order to maximize the 
yield of cells at each stage which will determine the overall differentiation yield of the 
process.  
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As mentioned above, the first step involves the differentiation of pluripotent human ES into 
endodermal cells and most differentiation paradigms utilize Activin A which mimics Nodal 
signaling. At the end of this stage, most of the cells lost the expression of the pluripotent 
marker Oct4 while concomitantly gaining strong expression of definitive endoderm (DE) 
transcription factors Sox17, FoxA2 as well as GATA4 [36-38]. The later steps of 
differentiation induce endodermal like cells to differentiate into mature and fully functional 
hepatocytes while utilizing different ECMs and various factors for about 15 additional days 
[36-38]. 
The human ES cells exhibited a similar differentiation efficiency as human iPS cells while 
using the same differentiation procedure (about 81% albumin positive cells) as well as 
similar hepatocyte mRNA fingerprints [36] . In addition, cell properties of primary human 
hepatocytes such as albumin and urea secretion, as well as cytochrome CYP450 activity 
were similar in vitro between hepatocyte-like cells generated from human ES as well as 
those generated from human iPS cells, although lower compared to primary isolated 
hepatocytes (10 fold difference for urea and albumin secretion and 30 fold difference for 
CYP450 isozyme activities after phenobarbital induction) [38]. While comparing the 
expression of a series of genes encoding phase I and phase II hepatic enzymes between 
cadaveric liver samples and hepatocyte-like cells, it was indicated that the level of mRNA 
was similar between the ES and iPS derived hepatocyte-like cells while lower compared 
with adult liver samples in most cases [36]. This may indicate that differentiated cells are not 
mature enough and this step of the differentiation procedure demands further optimization 
[36, 38].  
Human ES and iPS cell derived hepatocytes were shown to contribute to the liver 
parenchyma in vivo and were stained positive for albumin 7 days after their injection to the 
right lateral liver lobe of newborn mice, which exemplifies the potential of human iPS cells 
in regenerative medicine therapeutics [36]. 
2.2 Differentiation paradigms utilizing tissue engineering 
A key requirement for effective tissue engineering is the cellular environment that allows 
the cells to maintain the functional capacity observed in the in vivo environment. Often the 
environment mimics some critical aspects of the in vivo setting through proper control of 
the materials and mechanical properties as well as the chemical milieu.  
A consideration with tissue-engineered constructs is the presence of exogenous chemical 
and mechanical stimuli such as soluble growth and differentiation factors as well as 
mechanical forces (e.g., cyclic mechanical loading, fluid shear).  
2.2.1 Matrix configuration 
Culturing cells in various controlled three-dimensional (3D) environments has proven to be 
a successful differentiation technique. This is thought to be a result of mimicking the in vivo 
histoarchitecture of liver, incorporating cell-matrix interactions as well as soluble cues.  
Several ECMs are present in liver development. One study compared the effect of using 
type I collagen, fibronectin, laminin, and MatrigelTM on directing hepatic differentiation. 
Cells were cultured for 7 days in embyoid bodies (EBs) before being transferred to one of the 
substrates. This mimics to some extent the liver development stage where endodermal cells 
migrate into the ECM rich septum transversum. Type I collagen was shown to cause the 
greatest increase in liver specific genes, with MatrigelTM also showing a beneficial effect[39].  
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Therefore, one research group utilized a collagen scaffold as a 3D network for hepatic 
differentiation. Mouse ES cells were cultured in an EB configuration and implanted into a 
collagen scaffold and cultured in media containing aFGF, HGF, oncostatin M, 
dexamethasone, and insulin transferrin sodium selenite (ITS). Cells cultured in the 3D 
configuration showed gene expression of AFP, ALB, glucose 6-phosphate (G6P) and 
tyrosine aminotransferase (TAT) after 6 days in cultures as opposed to 12 days in an EB 
configuration alone. However, these cells stained positive for albumin protein, but not for 
the CK-18 protein. Following implantation into the median lobe of the liver of a nude mouse 
for 14 days, the cells stained positive for both CK-18 and albumin proteins. This result 
signifies that cells were not completely matured by the in vitro protocol [40]. While this 
study showed the advantages of 3D culture, most studies fail to demonstrate a genetic or 
functional advantage relative to standard monolayer differentiation protocols. Other groups 
have used 3D cultures to provide a configuration suitable for direct implantation, 
eliminating the need to remove cells from culture by using biodegradable and/or 
biocompatible materials. For example, one group used a polyurethane foam spheroid 
culture to direct differentiation of mouse ES cells. Embryoid bodies were inoculated into a 
block of polyurethane foam (PUF) to induce the formation of spheroids in the pores of the 
scaffold. Induction of hepatic differentiation was accomplished by supplementing the media 
with aFGF, HGF, oncostatin D, dexamethasone, and ITS. Analysis of gene expression 
showed the expression of endoderm markers transthyretin (TTR) and AFP as well as 
hepatocyte specific albumin, arginase, and tryptophan 2,3-dioxygenase (TDO) expression. 
Notably, ES cell derived hepatocyte like cells demonstrated ammonia clearance and albumin 
secretion rates within the range, albeit on the low end, of those seen for primary rat 
hepatocytes seeded in the PUF scaffold.   However, this method of differentiation is lengthy 
and immature endoderm markers were still present at the end of the 30 day protocol[41]. 
Biodegradable polymer scaffolds have also shown to be an effective three-dimensional 
environment for hepatic differentiation. One study allowed ES cells to form EBs for 5 days 
before being mixed them with Matrigel™. The cell suspension was then seeded into a rigid 
polymer network comprised of poly-L-lactic acid (PLLA) and polyglycolic acid (PGA). The 
cells formed spheroids along the polymer fibers and were cultured for 20 days with 
dexamethasone, dimethyl sulfoxide (DMSO), FGF4, HGF, oncostatin M, and ITS. After the 
culture period, the cells showed expression of AFP, ALB, G6P, TTR, and CK-18 and the 
ability to secrete albumin, uptake low-density lipoprotein (LDL) and store glycogen [42].  
Encapsulation of ES cells in alginate has been explored as a method for the control of hepatic 
differentiation. The capsules allow the diffusion of nutrient, oxygen, and growth factors into 
the capsules while sequestering the cells.  This technique has been widely used in the past to 
induce stem cell differentiation and maintain hepatocyte function, making it an ideal 
candidate for controlled hepatic differentiation. For instance, one group encapsulated 5-day-
old embryoid bodies derived from mouse ES cells in a 2% alginate solution. The media was 
supplemented with aFGF, HGF, oncostatin M, dexamethasone, and ITS, similar to those 
factors previously used by other research groups. RT-PCR analysis determined that this 
methods results in the expression of endoderm (AFP) and hepato-specific (ALB, Cyp7A1, 
TAT, TTR, and CK18) genes.  The cells produced albumin and urea, but only with growth 
factor supplementation. If one takes a closer look at the temporal addition of growth factors 
in these systems, several similarities exist. FGF is usually added at early time points in order 
to promote differentiation of definitive endodermal cells into hepatic endoderm cells. This is 
almost always followed by HGF supplementation, mimicking signaling from the 
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mesenchyme which promotes growth and differentiation of fetal hepatocytes. Lastly, 
oncostatin M, dexamethasone, and ITS are added, as these factors are known to promote 
hepatocyte maturation. Sequential supplementation therefore mimics in vivo development. 
In addition, ES cells are allowed to form embryoid bodies prior to being cultured in a 3D 
environment. This allows the formation cell-cell interactions known to increase hepatocyte 
function during development.  Although these aforementioned methods yield hepatocyte-
like cells from a functional perspective, growth factors are expensive and therefore these 
approaches are not amendable to scale up for clinical application.  
A different approach is the use of cellular encapsulation to control lineage commitment and 
final maturation of murine ES cells. The novelty of this method lies in the fact that no 
growth factor supplementation is required to direct hepatic differentiation. This was 
accomplished through the manipulation cell seeding density and alginate concentration. 
These two variables dictate the size of cellular aggregates that form within the capsule 
which in turn direct differentiation. It was found that a 2.0% w/v alginate concentration and 
a 5x106 cells/mL seeding density were the optimal parameters for hepatic differentiation 
[43, 44]. Genetic analysis showed the expression of a variety of Cyp450s as well as CK-18. In 
addition, albumin and urea secretion as well as glycogen storage were shown and reached a 
maximum around day 20 in culture. This method demonstrates a way to obtain a high yield 
of hepatocyte-like cells through inducing cell-cell interactions known to upregulate 
hepatocyte function during development, thus eliminating the need for growth factor 
supplementation. In addition, the cells can be recovered from the capsule through 
depolymerization without effecting cell viability.  Scalability is also significant, as 
generating large numbers of cells would simply involve producing large batches of 
capsules. With all these advantages taken into consideration, this technique is amenable to 
the mass production of hepatocyte like cells and thus has the potential for clinical utility. 
2.2.2 Coculture 
A co-culture of ES cells with another cell type present during hepatic development or in the 
adult liver cell has been shown to induce hepatic differentiation. The supporting cell type 
directs the ES cells towards the hepatic lineage by introducing cues resulting from soluble 
factors, cell-cell interactions, or a combination of the two. Thus, this approach is performed 
by separating the cells with a porous membrane or with the cells in direct contact with one 
another. Both methods have been shown to induce hepatic differentiation of embryonic 
stem cells with careful choice of feeder layers. In fact, investigators often develop their own 
cell lines optimized to drive hepatic differentiation. For example, one group first developed 
a protocol to differentiate endoderm cells by culturing the cells on Matrigel™ and 
supplementing the media with activin A and HGF [45]. The endoderm cells were separated 
by fluorescence-activated cell sorting (FACS), made possible by the transfection of enhanced 
GFP (EGFP) under the control of an AFP promoter. The purified cells were then further 
exposed to a co-culture with MLSgt20 cells, a cell line cloned from fetal murine stromal cells 
experimentally shown to promote hepatic differentiation in ES cells [46].  Combining the 
results of the two studies, the AFP positive endoderm cells were contact co-cultured with 
the MLSgt20 cells. The co-cultured cells expressed markers for both immature (GATA4, 
AFP) and mature (Alb, TAT, TO, CYP3a4/7) hepatocytes at the end of the culture period. 
The cells also showed the ability to clear ammonia and store glycogen. However, gene 
expression was not identical to that of adult human liver hepatocytes [47]. A drawback of 
contact co-culture is that the hepatocyte like cells must be separated from the supporting cell 
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Therefore, one research group utilized a collagen scaffold as a 3D network for hepatic 
differentiation. Mouse ES cells were cultured in an EB configuration and implanted into a 
collagen scaffold and cultured in media containing aFGF, HGF, oncostatin M, 
dexamethasone, and insulin transferrin sodium selenite (ITS). Cells cultured in the 3D 
configuration showed gene expression of AFP, ALB, glucose 6-phosphate (G6P) and 
tyrosine aminotransferase (TAT) after 6 days in cultures as opposed to 12 days in an EB 
configuration alone. However, these cells stained positive for albumin protein, but not for 
the CK-18 protein. Following implantation into the median lobe of the liver of a nude mouse 
for 14 days, the cells stained positive for both CK-18 and albumin proteins. This result 
signifies that cells were not completely matured by the in vitro protocol [40]. While this 
study showed the advantages of 3D culture, most studies fail to demonstrate a genetic or 
functional advantage relative to standard monolayer differentiation protocols. Other groups 
have used 3D cultures to provide a configuration suitable for direct implantation, 
eliminating the need to remove cells from culture by using biodegradable and/or 
biocompatible materials. For example, one group used a polyurethane foam spheroid 
culture to direct differentiation of mouse ES cells. Embryoid bodies were inoculated into a 
block of polyurethane foam (PUF) to induce the formation of spheroids in the pores of the 
scaffold. Induction of hepatic differentiation was accomplished by supplementing the media 
with aFGF, HGF, oncostatin D, dexamethasone, and ITS. Analysis of gene expression 
showed the expression of endoderm markers transthyretin (TTR) and AFP as well as 
hepatocyte specific albumin, arginase, and tryptophan 2,3-dioxygenase (TDO) expression. 
Notably, ES cell derived hepatocyte like cells demonstrated ammonia clearance and albumin 
secretion rates within the range, albeit on the low end, of those seen for primary rat 
hepatocytes seeded in the PUF scaffold.   However, this method of differentiation is lengthy 
and immature endoderm markers were still present at the end of the 30 day protocol[41]. 
Biodegradable polymer scaffolds have also shown to be an effective three-dimensional 
environment for hepatic differentiation. One study allowed ES cells to form EBs for 5 days 
before being mixed them with Matrigel™. The cell suspension was then seeded into a rigid 
polymer network comprised of poly-L-lactic acid (PLLA) and polyglycolic acid (PGA). The 
cells formed spheroids along the polymer fibers and were cultured for 20 days with 
dexamethasone, dimethyl sulfoxide (DMSO), FGF4, HGF, oncostatin M, and ITS. After the 
culture period, the cells showed expression of AFP, ALB, G6P, TTR, and CK-18 and the 
ability to secrete albumin, uptake low-density lipoprotein (LDL) and store glycogen [42].  
Encapsulation of ES cells in alginate has been explored as a method for the control of hepatic 
differentiation. The capsules allow the diffusion of nutrient, oxygen, and growth factors into 
the capsules while sequestering the cells.  This technique has been widely used in the past to 
induce stem cell differentiation and maintain hepatocyte function, making it an ideal 
candidate for controlled hepatic differentiation. For instance, one group encapsulated 5-day-
old embryoid bodies derived from mouse ES cells in a 2% alginate solution. The media was 
supplemented with aFGF, HGF, oncostatin M, dexamethasone, and ITS, similar to those 
factors previously used by other research groups. RT-PCR analysis determined that this 
methods results in the expression of endoderm (AFP) and hepato-specific (ALB, Cyp7A1, 
TAT, TTR, and CK18) genes.  The cells produced albumin and urea, but only with growth 
factor supplementation. If one takes a closer look at the temporal addition of growth factors 
in these systems, several similarities exist. FGF is usually added at early time points in order 
to promote differentiation of definitive endodermal cells into hepatic endoderm cells. This is 
almost always followed by HGF supplementation, mimicking signaling from the 
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mesenchyme which promotes growth and differentiation of fetal hepatocytes. Lastly, 
oncostatin M, dexamethasone, and ITS are added, as these factors are known to promote 
hepatocyte maturation. Sequential supplementation therefore mimics in vivo development. 
In addition, ES cells are allowed to form embryoid bodies prior to being cultured in a 3D 
environment. This allows the formation cell-cell interactions known to increase hepatocyte 
function during development.  Although these aforementioned methods yield hepatocyte-
like cells from a functional perspective, growth factors are expensive and therefore these 
approaches are not amendable to scale up for clinical application.  
A different approach is the use of cellular encapsulation to control lineage commitment and 
final maturation of murine ES cells. The novelty of this method lies in the fact that no 
growth factor supplementation is required to direct hepatic differentiation. This was 
accomplished through the manipulation cell seeding density and alginate concentration. 
These two variables dictate the size of cellular aggregates that form within the capsule 
which in turn direct differentiation. It was found that a 2.0% w/v alginate concentration and 
a 5x106 cells/mL seeding density were the optimal parameters for hepatic differentiation 
[43, 44]. Genetic analysis showed the expression of a variety of Cyp450s as well as CK-18. In 
addition, albumin and urea secretion as well as glycogen storage were shown and reached a 
maximum around day 20 in culture. This method demonstrates a way to obtain a high yield 
of hepatocyte-like cells through inducing cell-cell interactions known to upregulate 
hepatocyte function during development, thus eliminating the need for growth factor 
supplementation. In addition, the cells can be recovered from the capsule through 
depolymerization without effecting cell viability.  Scalability is also significant, as 
generating large numbers of cells would simply involve producing large batches of 
capsules. With all these advantages taken into consideration, this technique is amenable to 
the mass production of hepatocyte like cells and thus has the potential for clinical utility. 
2.2.2 Coculture 
A co-culture of ES cells with another cell type present during hepatic development or in the 
adult liver cell has been shown to induce hepatic differentiation. The supporting cell type 
directs the ES cells towards the hepatic lineage by introducing cues resulting from soluble 
factors, cell-cell interactions, or a combination of the two. Thus, this approach is performed 
by separating the cells with a porous membrane or with the cells in direct contact with one 
another. Both methods have been shown to induce hepatic differentiation of embryonic 
stem cells with careful choice of feeder layers. In fact, investigators often develop their own 
cell lines optimized to drive hepatic differentiation. For example, one group first developed 
a protocol to differentiate endoderm cells by culturing the cells on Matrigel™ and 
supplementing the media with activin A and HGF [45]. The endoderm cells were separated 
by fluorescence-activated cell sorting (FACS), made possible by the transfection of enhanced 
GFP (EGFP) under the control of an AFP promoter. The purified cells were then further 
exposed to a co-culture with MLSgt20 cells, a cell line cloned from fetal murine stromal cells 
experimentally shown to promote hepatic differentiation in ES cells [46].  Combining the 
results of the two studies, the AFP positive endoderm cells were contact co-cultured with 
the MLSgt20 cells. The co-cultured cells expressed markers for both immature (GATA4, 
AFP) and mature (Alb, TAT, TO, CYP3a4/7) hepatocytes at the end of the culture period. 
The cells also showed the ability to clear ammonia and store glycogen. However, gene 
expression was not identical to that of adult human liver hepatocytes [47]. A drawback of 
contact co-culture is that the hepatocyte like cells must be separated from the supporting cell 
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type after the culture period. To eliminate the need for purification of differentiated cells, 
one group co-cultured three human liver non-parenchymal cell lines with ES cells using a 
transwell membrane. Mouse ES cells containing a GFP gene with and albumin promoter 
were cultured in suspension for 2 days to facilitate embryoid body formation.   The EBs 
were then cultured on a poly-amino-urethane (PAU) coated non-woven 
polytetrafluoroethylene (PTFE) fabric that allowed the cells to adhere. The media was 
supplemented with basic FGF and activin A for 3 days. The ES cells were then co-cultured in 
Matrigel layered transwells with the human cells lines growth-arrested with mitomycin C. 
Cholangiocytes, liver endothelial, and hepatic stellate cell lines were chosen due to their 
secretion of soluble factors that have shown to be important for liver regeneration. 
Cholangiocytes generate IL-6 and TNF-, liver endothelial cells produce FGF4 and vascular 
endothelial growth factor (VEGF) and hepatic stellate cells produce HGF. The cells were co-
cultured with media supplementation of dHGF and DMSO for 8 days and dexamethasone 
for the final 3 days of culture. The differentiated GFP positive cells were separated by cell 
sorting and showed a yield of 70%. These cells expressed both hepatocyte markers as well as 
endoderm markers, demonstrating that the cells were not fully mature. They also stained 
positive for albumin and GFP, secreted albumin, and metabolized ammonia, lidocaine, and 
diazepam. However, albumin secretion and metabolic activity occurred at lower levels than 
primary mouse hepatocytes[48]. Another example of a non-contact co-culture was 
demonstrated using cynomolgus monkey ES cells with mouse fetal liver-derived cells to 
simulate the environment of the developing liver. The ES cells lost pluripotent markers and 
expressed AFP, ALB, CYP7A1, and HNF4, an important transcription factor for mature 
hepatocytes. The cells also stained positively for AFP, albumin, alpha1AT, and HNF4, as 
well as for Hep Par 1, an anti-hepatocyte antibody. Functional analysis also showed 
glycogen storage through Periodic acid-Schiff (PAS) staining as well as ammonia 
clearance[49]. 
While the aforementioned co-culture systems utilize non-parenchymal cells or fetal liver 
cells as a support cell type, the use of hepatocytes as the feeder cell type in co-culture 
differentiation schemes has also been attempted. Moore et al. examined the effects of co-
cultivated hepatocytes on the hepatospecific differentiation of murine ES cells[50]. 
Hepatocytes co-cultured with cadherin-expressing ES cells markedly enhanced ES cell 
differentiation toward the hepatic lineage, as demonstrated by hepatic-like cuboidal 
morphology, heightened gene expression of the late maturation marker G6P in relation to 
the early marker AFP, and the intracellular localization of albumin. The effect was mediated 
by cadherin, since it was reversed through E-cadherin blockage and inhibited in control ES 
cells with reduced cadherin expression. Direct contact co-cultures of hepatocytes and ES 
cells maximally promoted ES cell commitment towards hepato-differentiation. This study 
showed that both soluble signaling and cell-cell interaction creates a synergistic effect that 
drives hepatic differentiation.  
Cho et al. developed another co-culture method with hepatocytes[51]. A collagen gel was 
formed on tissue culture dishes and primary rat hepatocytes were plated after gelation. A 
thick collagen layer was then deposited on top of the hepatocytes. We have previously 
shown that this collagen sandwich hepatocyte culture maintains hepatocyte function in 
vitro. Murine ES cells were then seeded on the thick collagen layer and cultured in this 
configuration for 10 days. At this stage, the ES cells were removed from the collagen layer 
by dispase treatment while leaving the collagen sandwiched hepatocytes intact. RT-PCR 
demonstrated the presence of endoderm markers Foxa2, Sox17, and AFP and the absence of 
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mesoderm and ectoderm markers. The presence of Foxa2 and AFP were confirmed by 
immunostaining, and flow cytometry showed that they were expressed in 95% of cells. In 
addition, the cells proliferated and stopped expressing Oct4, a marker for pluripotency. 
These results showed that mouse ES cells cultured on top of collagen-sandwiched 
hepatocytes differentiated and proliferated into a uniform and homogeneous cell population 
of endoderm-like cells. However, the endoderm cells did not express albumin, signifying 
that they had not yet committed to the hepatic lineage. To further mature the cells, they 
were co-cultured for 20 days with fibroblasts due to the in vivo interactions of the endoderm 
with the mesenchyme during development. The media was supplemented with oncostatin 
M, ITS, and dexamethasone. The resulting hepatocyte like cells expressed hepatospecific 
genes albumin, alpha-1-antitrypsin (AAT), CK-8, CK-18, TTR, and CYP2A13 and displayed 
morphology similar to that of primary rat hepatocytes. Immunostaining demonstrated the 
presence of albumin and CK-18 while functional analysis showed the cells could synthesize 
urea. This study showed the generation of a homogeneous population of hepatocyte-like 
cells from ES cells[51]. However, the drawback of this method is that two separate co-
cultures are required to direct differentiation, with one feeder cell being the scarce cell type 
that we are trying to generate. 
2.2.3 Metabolic engineering 
A distinguishing feature of adult hepatocytes is the high content of mitochondria and high 
level of oxidative metabolism. On the contrary, ES cells contain a much smaller amount of 
mitochondria and produce energy mainly through the glycolytic pathway. Recent studies 
show that metabolic additives that promote carbon backbone oxidation can be used to help 
direct differentiation towards the hepatocyte lineage. One such method utilizes sodium 
butyrate treatment to generate an enriched population of hepatocyte-like cells from 
embryonic stem cell [52]. ES cells were plated on gelatin and the media was supplemented 
with DMSO for the first 5 days of culture. Sodium butyrate replaced DMSO for the next 6 
days, and cells were replated onto collagen coated or non-coated polystyrene at various time 
points in order to perform metabolic analysis. Significantly higher levels of urea secretion 
and albumin positive cells were observed in a 2.5 mM sodium butyrate condition on both 
substrates. It was also shown that mitochondrial mass increased from days 5-8 in culture, 
which is characteristic of hepatic differentiation. However, the percentage of albumin 
positive and high mitochondrial activity cells was still less than mouse hepatoma cells. 
These results imply that these cells represent an immature hepatocyte phenotype. A 
subsequent study was conducted in order to further differentiate the cells into  
mature hepatocyte-like cells [53]. The immature cells were treated with S-
NitrosoAcetylPenicillamine (SNAP), a nitric oxide donor. Nitric oxide is known to induce 
the synthesis of mitochondria, thus possibly facilitating a further increase of mitochondrial 
mass to levels seen in mature liver cells. After the 11 days of culture conditions that were 
found to induce partial differentiation using sodium butyrate, cells were replated on day 12 
and supplemented with various dilutions of SNAP in DMSO for the next 3 days. A 500 μM 
concentration of SNAP significantly increased glucose consumption, lactate production, and 
the percentage of albumin positive cells. From a functional perspective, SNAP treatment 
also increased urea and albumin secretion as well as cytochrome P4507a1 activity relative to 
the other culture conditions. These studies demonstrate that simply altering the ES cell’s 
metabolic activity to more closely resemble those of mature hepatocytes is an alternative 
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type after the culture period. To eliminate the need for purification of differentiated cells, 
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endoderm markers, demonstrating that the cells were not fully mature. They also stained 
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differentiation toward the hepatic lineage, as demonstrated by hepatic-like cuboidal 
morphology, heightened gene expression of the late maturation marker G6P in relation to 
the early marker AFP, and the intracellular localization of albumin. The effect was mediated 
by cadherin, since it was reversed through E-cadherin blockage and inhibited in control ES 
cells with reduced cadherin expression. Direct contact co-cultures of hepatocytes and ES 
cells maximally promoted ES cell commitment towards hepato-differentiation. This study 
showed that both soluble signaling and cell-cell interaction creates a synergistic effect that 
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formed on tissue culture dishes and primary rat hepatocytes were plated after gelation. A 
thick collagen layer was then deposited on top of the hepatocytes. We have previously 
shown that this collagen sandwich hepatocyte culture maintains hepatocyte function in 
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mesoderm and ectoderm markers. The presence of Foxa2 and AFP were confirmed by 
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NitrosoAcetylPenicillamine (SNAP), a nitric oxide donor. Nitric oxide is known to induce 
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strategy to developing hepatocyte-like cells. This novel method circumvents the need for 
media supplementation with expensive cocktails of growth factors or co-culture with 
another cell type. 
3. Utilizing hepatocyte-like cells 
Techniques aimed at obtaining a homogeneous population of hepatocyte-like cells with 
functional characteristics similar to native hepatocytes from ES cells are rapidly improving. 
As these methods progress, applications taking advantage of a constant supply of 
hepatocytes are being developed in parallel. One application is the use of hepatocytes for 
the treatment of liver failure. With the gap between those on the waiting list for a liver 
transplant and the organs available for transplantation growing every year, a renewable 
source of hepatocyte-like cells could potentially alleviate this problem. Bioartificial livers 
containing functional hepatocyte-like cells could be used to keep patients alive while 
waiting for a transplant. In addition, decellularizing livers unsuitable for transplant and 
reseeding them with functional cells could increase the donor pool. In conjunction, these 
two cutting-edge methods could reduce the number of patients who die on the waiting list. 
Finally, the important role the liver plays in the metabolic clearance of drugs makes 
hepatocytes an important research tool for the pharmaceutical industry. By including 
microfluidic technology, the number heaptocytes needed per assay can be greatly reduced, 
facilitating high-throughput screening of new chemical entities. This next section will 
discuss the current state of these applications of hepatocyte-like cells derived from ES cells. 
3.1 Decellularized liver scaffolds for implantation 
Using hepatocyte-like cells for transplantation is a potentially very exciting application. As 
mentioned earlier, a large gap exists between the number of patients waiting for a liver 
transplant and the number of available liver grafts. With this gap growing each year, an 
alternative source of transplantable livers is greatly needed. Although the differentiation of 
hepatocyte-like cells from embryonic stem cells has been accomplished through a variety of 
methods, creating a three-dimensional organ structure is challenging due to the nutrient and 
oxygen limitations that occur in the engineered tissue. The liver consists of a complex 
network of extracellular matrix proteins as well as microvasculature critical to organ 
function. One approach to provide the complex 3D environment of the liver is not to try to 
recreate it from scratch, but rather to use natural decellularized liver scaffolds. Data show 
that the native 3D matrix can promote cell engraftment, survival, and sustained hepatic 
function over time. In addition, by preserving the native microvasculature structure, the risk 
of ischemic damage or lack of perfusion is minimized. This approach has the potential of 
utilizing livers unsuitable for transplantation as a source of scaffolds to seed hepatocyte-like 
cells derived from ES cells, thereby increasing the number of livers available for 
transplantation. 
Using the liver as a scaffold requires that the organ be decellularized while leaving the 3D 
architecture intact. Following decellularization, the scaffold must be reseeded with the 
proper cell types engrafting to their appropriate locations within the tissue to promote 
function. This has been accomplished by perfusing sodium dodecyl sulfate (SDS) solutions 
through the portal vein of a rat liver for 72 hours [54]. The result was a translucent structure 
free of cells which preserved the 3D architecture of the liver, Figure 4a. Most notably, the 
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microvascular tree was preserved, as shown in Figure 4b. Using the scaffold, cells were 
seeded by injecting 12.5 million cells in 4 doses at 10-minute intervals. This approach 
resulted in a grafting efficiency greater than 90%, and perfusion of the recellularized 
scaffold showed 80% viability over 2 days. Since a liver consists of non-parenchymal cells as 
well as hepatocytes, epithelial cells were also seeded and engrafted in the lining of the 
vessel. Moreover, epithelial cell seeding did not affect hepatocyte viability, providing proof 
of concept that other cell types could also be successfully seeded. The scalability of the 
system was also tested, injecting a total of 200 million cells using the 4-dose approach. This 




Fig. 4a. Rat liver during the decellularization process. SDS was perfused through the portal 
vein, leaving a translucent, cell free structure which maintained native liver architecture. 
From left to right, the images show the liver at 0, 18, 48, 52, and 72 hours of the SDS 
perfusion, respectively. (Figure taken from [54], Figure 1) 
 
Fig. 4b. Portal (red) and venous (blue) corrosion cast of normal (left) and decellularized liver 
(right). Comparison of the two shows that the decellularization process preserves the native 
liver microvasculature. (Figure taken from [54], Figure 2) 
Analysis of the reseeded hepatocytes showed gene expression similar to that of long-term 
stable cultures (e.g. collagen sandwich) of hepatocytes. Immunohistochemical analysis of 
UGT1a, G6pc, and albumin showed staining at levels comparable to adult livers. Functional 
analysis showed urea synthesis significantly higher that hepatocyte sandwich and similar 
albumin secretion rates. However, albumin production was much lower than that of adult 
rat livers. The recellularized liver was then transplanted into a rat for 8 hours to investigate 
the effect of shear stress due to blood flow. Transplantation did not affect hepatic function, 
viability, or morphology in any significant way. Other investigators successfully 
decellularized a liver and seeded the matrix with both hepatocytes and other epithelial cells 
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[55]. These studies demonstrate the feasibility of using a decellularized liver matrix as a 
scaffold for hepatocytes. The inclusion of other non-parenchymal cells and evaluation of the 
transplant after long periods in vivo still needs to be performed prior to bringing this 
approach to the bedside. This may further require the development of techniques to derive 
hepatic nonparenchymal cells from ES cells. 
3.2 Bioartificial liver devices 
The shortage of donor livers has also prompted researchers to develop bioartificial liver 
(BAL) devices, Figure 5. These devices aim to provide temporary assistance to patients with 
liver failure while waiting for a donor organ. Early BAL concepts were modified dialysis 
systems which did not incorporate living cells, [56] and were found to be limited in efficacy. 
Since the liver provides a host of biochemical processing and detoxification functions that 
are essential to life, it was thought that an effective device should contain liver parenchymal 
cells (e.g. hepatocytes). Cells were added to the dialysis systems, and again poor results 
were obtained, in this case because the bioreactor design itself did not allow for sufficient 
metabolite transport (especially oxygen), and as a result the cells did not function properly 
or even survive. Next, a support structure was built that allows for the convective and 
diffusive transport of plasma metabolites to and from the cells in the device [57]. Many 
creative operational strategies and designs exist [58]; [59]; [60], ranging from packed bed 





Fig. 5. Schematic of a radial flow Bioartifical Liver Device. Red arrows show the direction 
of medium flow and in blue is the location of the seeded hepatocytes. The design includes 
patterned microgrooves to decrease shear stress on the seeded hepatocytes. (Figure taken 
from [67], Figure 1) 
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withstand low levels of fluid shear stress, therefore in a recent modification of the flat plate 
geometry, cells were seeded at the bottom of grooves to allow for higher flow rates, thus 
increasing mass transport within the device, while keeping shear stress at the cell surface to 
a low level [64, 65]. 
The high metabolic activity of hepatocytes makes the transport of oxygen a significant 
technical concern in BAL devices. In fact, transport limitations have led to the loss of hepatic 
function over time and the failure of many BAL devices based on hollow fiber technology 
that have undergone clinical trials. To alleviate this issue, semi-permeable membranes have 
been introduced into devices to increase the oxygen tension within the device. However, a 
device would require a surface area of approximately 10 m2 to provide therapeutic benefit 
[66]. Therefore, the incorporation of an internal membrane oxygenator would create scale up 
issues. To address these problems, a radial stacked plate bioreactor was developed to 
increase the surface area to volume ratio of the device. The design was devoid of a semi-
permeable membrane and therefore required perfusion at high volumetric flow rates in 
order to create the necessary oxygen tension to maintain hepatocyte function. Nevertheless, 
hepatocytes will also lose function above a critical shear stress. Therefore, 
photolithographically patterned microgrooves were incorporated to shield the cells from the 
resulting high shear rates required for sufficient convective oxygen transport. 
The requirement of high-flow rates and low shear stress is a non-trivial engineering 
problem. In order to examine the effect of microgrooves, computation fluid dynamics 
(CFD) was employed to characterize the device. CFD analysis showed that varying width 
of the microgrooves with the distance from the center of the bioreactor results shear 
stresses well below detrimental levels throughout the device. Incorporating an oxygenator 
within the perfusion circuit, design and operating parameters were optimized that 
provided sufficient convective oxygen delivery and acceptable shear stresses. These 
critical parameters resulted in 95% viability of hepatocytes under perfusion after 36 hours 
within the device. In addition, urea and albumin secretion levels were significantly higher 
than a flat plate bioreactor and comparable to hepatocytes co-cultures with fibroblasts. 
The device produced 2,100 μg of albumin per day, as compared to 19x105 μg/day 
required for a therapeutic effect. To be clinical useful, this device would need to be scaled 
by a factor of 905, which would allow the device to be operated without exceeding the 
recommended clinical priming volume[67]. 
As opposed to ex vivo bioartificial liver devices, an implantable liver assist device (LAD) has 
been developed by engineering a hepatic organoid.  The implantable construct comprised of 
a PAU-coated PTFE non-woven fabric covered with a polyethylene-vinyl alcohol membrane 
layered with a polyester supporting fabric. Based on the method described in Section 2.2.2, 
human cholangiocytes, liver endothelial cells, and hepatic stellate cells were injected into an 
LAD coated with FGF-2 to facilitate angiogenesis. The LAD performance was evaluated 
through implantation into mice after a 50% hepatectomy for 7 days. While LAD with only 
hepatocytes did not survive, devices with non-parenchymal cells exhibited the formation of 
organotypic structures in the LAD similar to the liver acinus. Additionally, in vitro analysis 
showed that the organoid significantly improved ammonia and lidociane clearance as well 
as albumin secretion relative to device with seeded with hepatocytes alone. This study 
showed that the inclusion of non-parenchymal cells in liver assist devices has the potential 
of improving in vivo performance. 
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withstand low levels of fluid shear stress, therefore in a recent modification of the flat plate 
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3.3 In vitro drug screening systems 
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) U.S. 
drug companies spent $62.4 billion on research and development in 2009. Studies indicate 
that it can cost more than $800 million, of which 80% is spent on clinical trials and 
development, and will take between 8 and 10 years of development to bring a new drug to 
market. Among candidate drugs that make it past Phase I clinical trials, 50% fail due to 
human toxicity and bioavailability issues. Moreover, of all candidate drugs, 90% do not 
make it through final stages of development. This tremendous attrition rate has not 
improved in recent years. To curb such costly failures, a significant amount of research has 
been dedicated to identifying in vitro screening systems; i.e., approaches that can be utilized 
in preclinical phases of discovery and development that offer greater utility in predicting in 
vivo subcellular and cellular physiological responses. 
Currently, a majority of hepatic in vitro screening assays employed within the field of drug 
metabolism and pharmacokinetics (DPMK) utilize hepatocytes cultured under fully static 
conditions. In such assays, hepatocytes are either adhered to the bottom of a microtiter well-
plate to which culture medium containing candidate drug(s) is subsequently added; or else 
the hepatocytes are maintained inside the microtiter well in suspension in the media. The 
microtiter plate is shaken to facilitate mixing and transport, but there is no means for 
providing a continuous flow of culture media over the cells. 
The lack of continuous flow produces functional limitations in these conventional static 
systems when compared to microfluidic systems. The presence of flow helps regulate the 
concentrations of both metabolites and cellular by-products in the immediate vicinity of the 
hepatocytes; whereas in a static system these concentrations are ever-changing until a 
saturation/depletion condition is attained through accumulation, uptake, and reaction. In a 
flow system it is possible to maintain a pseudo steady state (equilibrium) which results in 
optimal working characteristics. Furthermore, in a static well the system is usually mass 
transport limited; flow can remedy this by the addition of convective mode of mass 
transport.  
A variety of devices have been developed for this purpose [68-70], and in particular to 
determine parameters for multi-compartmental physiologically-based pharmacokinetic 
(PBPK) models, Figure 6. For example, a multi-tissue compartmental device has been 
developed that incorporates a large liver compartment for the assessment of drug 
absorption both in the liver as well as in other metabolizing tissue types [71-73]. More 
specifically, the Hμrel® Corporation has developed a liver-specific microfluidic chip that 
focuses on liver metabolism, with the possible application to liver toxicity assessment, 
Figure 7. The Hμrel®  device allows for the seeding of various cell types to emulate the in 
vivo components affecting pharmacokinetics. The device consists of separate chambers, each 
seeded with a specific cell type. Device testing demonstrated that the flow co-culture format 
in the device resulted in better predictions of in vivo clearance rates compared to static 
cultures and flow-based monoculture models, across a wide range of cytochrome P450s. The 
reason for increased hepatocyte function when flow is incorporated is not yet known for 
certain. One possibility is that increased mass transport in the system leads to a thinner 
boundary layer in addition to faster removal of unwanted by-products, together resulting in 
an observed increased clearance. Regardless of the mechanism, the Hμrel®  device yields an 
in vitro analogue to PBPK models utilizing minimal amounts of cells and drug, thus 
facilitating high-throughput screening of new chemical entities.  
 





Fig. 6. Example of multi-compartmental MEMs model utilized to determine PBPK values 
for use in in silico simulations. The new chemical entity is dosed on one side of the Caco-2 
cells, where it must be absorbed prior to reaching the microchannels. The absorbed drug 
then passes into the liver for metabolic clearance prior to being re-circulated and reaching 
the target tissue.  
 
Fig. 7. Geometry of the static and flow configurations in the HREL® system. The assembly 
of a HµREL® housing set with four biochips. The components of the chip housing and 
interface are, from the top – adapter, housing top, HµREL® biochips, housing bottom. The 
complete setup of the HµREL® prototype instrument then involves connecting inlet and outlet 
tubing to the adapter. The inlet tubing is then fed through a peristaltic pump, and connected to 
a reservoir that contains the media with the test compound of interest. The outlet tubing is also 
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boundary layer in addition to faster removal of unwanted by-products, together resulting in 
an observed increased clearance. Regardless of the mechanism, the Hμrel®  device yields an 
in vitro analogue to PBPK models utilizing minimal amounts of cells and drug, thus 
facilitating high-throughput screening of new chemical entities.  
 





Fig. 6. Example of multi-compartmental MEMs model utilized to determine PBPK values 
for use in in silico simulations. The new chemical entity is dosed on one side of the Caco-2 
cells, where it must be absorbed prior to reaching the microchannels. The absorbed drug 
then passes into the liver for metabolic clearance prior to being re-circulated and reaching 
the target tissue.  
 
Fig. 7. Geometry of the static and flow configurations in the HREL® system. The assembly 
of a HµREL® housing set with four biochips. The components of the chip housing and 
interface are, from the top – adapter, housing top, HµREL® biochips, housing bottom. The 
complete setup of the HµREL® prototype instrument then involves connecting inlet and outlet 
tubing to the adapter. The inlet tubing is then fed through a peristaltic pump, and connected to 
a reservoir that contains the media with the test compound of interest. The outlet tubing is also 






Lz =100 mm outlet 
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4. Future directions 
Considerable progress has been made in differentiating ESCs into liver cells; however, 
current protocols have not yet produced cells that express a completely adult-like mature 
hepatocyte. In fact, criteria that define what is an acceptable functional human stem cell-
derived hepatocyte will need to be established and standardized. ESC differentiation 
protocols typically do not yield a pure hepatocyte population, and often times sorting 
protocols are needed. Methods to scale-up such protocols to the therapeutic scale of a 
human patient will need to be developed. There remains safety concerns (e.g. 
tumoregenicity) when using ESCs and iPSC for cell transplantation which cannot easily 
investigated in rodent models and will require further analysis in more “human-like” 
systems, such as nonhuman primates. On a short-term basis, human hepatocytes derived 
from ESCs or iPSCs may be effectively used for toxicology studies on xenobiotics as well as 
drug safety screening. The development of devices that contain such cells for high 
throughput testing is an important avenue for the future in this area, and special 
consideration should be taken to make such systems easy to use at the point of care or in the 
field. The ability to derive cells that are patient-specific provides a unique opportunity to 
better understand patient variability in their sensitivity to drugs as well as potentially 
develop individualized patient-specific drug regimens. 
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1. Introduction 
A hepatocyte is one of the most desired cells for regenerative medicine as well as for 
pharmaco-toxicological testing. Hepatocytes, the parenchymal cells of the liver, possess a 
wide range of functions, including protein synthesis/storage, detoxification, transformation 
of carbohydrates, synthesis of cholesterol, bile salts and phospholipids, as well as the 
excretion of exogenous and endogenous substances (Blouin et al 1977).  
The various functions of the liver are essential for the maintenance of the human body and 
liver failure is often only treatable by organ liver transplantation (OLT). The shortage of 
donated organs, however, limits this treatment option available to patients. Since the Model 
for End-Stage Liver Disease and Pediatric End-Stage Liver Disease (MELD/PELD) liver 
allocation system was introduced in February 2002, the usage of borderline-quality donated 
livers for OLT has increased (Freeman et al 2002). As a result, the number of patients on 
waiting lists for OLT has stabilized; however, more than 15,000 patients await OLT annually 
in the United of States alone (Thuluvath et al 2010).  
Hepatocyte transplantation (HT), a cell-replacement therapy for liver disease, could decrease 
the number of the patients on the waiting list. HT is particularly useful for metabolic liver 
diseases that do not require whole organ replacement but rather a partial restoration of specific 
liver metabolic functions (Fox et al 1998, Strom et al 1997). The feasibility and the therapeutic 
efficacy of HT have been demonstrated in several clinical trials (Strom et al 2006). However, 
the limited availability of human hepatocytes due to organ shortage prohibits the provision of 
this promising therapy to patients as a standard option. Human hepatocytes can be isolated 
from cadaveric livers that are donated but not suitable for OLT (Strom et al 1982). The number 
of unused donated livers has decreased since the MELD liver allocation system was initiated. 
This dilemma has led to an urgent demand for developing stem cell-derived functional human 
hepatocytes as an alternative. Stem cell-derived hepatocytes could also be utilized in artificial 
liver bio-devices for patients with acute liver failure who may not need the OLT (Gerlach et al 
2010, Gerlach et al 2008, Soto-Gutierrez et al 2006a). An unlimited supply of stem cell-derived 
hepatocytes could facilitate the development of these cell-based therapies for treatment of life-
threatening liver diseases. 
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Moreover, these stem cell-derived hepatocytes could be utilized not only for therapeutic 
applications but also for pharmaco-toxicological testing (Davila et al 2004). It is anticipated 
that stem cell-derived hepatocytes will be important as in vitro tools for testing drug safety, 
thereby significantly facilitating drug development. Toxicity assessment for drug 
development could be conducted with phenotypically and genotypically standardized 
human hepatocytes. In this regard, genetically homogeneous stem cell-derived hepatocytes 
would be superior to primary human hepatocytes. Human stem cell-derived hepatocytes 
would be particularly useful for conducting some infectious disease research as well. As a 
case in point, hepatocytes derived from animals have been demonstrated to not be useful for 
the study of human hepatitis virus biology such as HCV (Cai et al 2007). 
A number of different stem/progenitor cells have been proposed as an alternative cell 
source for generation of functional hepatocytes – these include fetal hepatocytes (Suzuki et 
al 2000), adult hepatic progenitor/stem (epithelial) cells (Alison & Sarraf 1998), bone-
marrow derived-stem cells (Gilchrist & Plevris 2010), and adipose-derived stem cells 
(Schaffler & Buchler 2007). Although the biological potential of fetal hepatocytes and adult 
hepatic progenitor cells is promising, ethical issues and limited availability hampers 
development for use in the clinic. Relatively small numbers of stem/progenitor cells would 
be insufficient for use to generate stem cell-derived hepatocytes in the clinic, particularly for 
HT, as HT recipients require transplantations of more than a billion cells at a time (Fox et al 
1998). Some reports claimed that there was hepatic differentiation of mesenchymal stem 
cells from adipose tissue or bone marrow. However, the differentiation to functional 
hepatocytes, remains controversial (Goodell 2003, Wagers & Weissman 2004). Further 
research efforts are required to gain consensus for utilizing these adult stem cell-derived 
hepatocytes in the clinic.  
To date, pluripotent stem cells are the most realistic candidate for the generation of stem cell-
derived hepatocytes. Pluripotent stem cells possess nearly unlimited self-renewal capability in 
vitro and are able to differentiate into all three germ layers. Human embryonic stem cells 
(hESCs) are derived from blastocysts (Thomson et al 1998), and several protocols have been 
published for the differentiation of hESCs to functional hepatocytes. Additionally, recent 
breakthroughs in the field of induced pluripotent stem (iPS) cell technology (Takahashi & 
Yamanaka 2006) have provided yet another promising source to generate stem cell-derived 
hepatocytes. The human iPS cells may overcome the ethical concerns of utilizing blastocyst-
derived pluripotent stem cell and may provide patient specific immunotype cells so as to 
avoid the lifelong use of immunosuppressants (Takahashi et al 2007). Disease-specific iPS cells, 
derived from patients who suffer from various congenital liver diseases, such as alpha1-
antitrypsin deficiency, familial hypercholesterolemia, and glycogen storage disease, are 
anticipated to become important tools for studying the mechanisms underlying the 
pathogenesis of these diseases and investigations of new treatments (Ghodsizadeh et al 2010). 
Moreover, human iPS-derived hepatocytes would be an unlimited source for materials that are 
genetically homogeneous for conducting consistent pharmaco-toxicological evaluations. For 
example, an iPS-derived hepatocyte library could be established based upon single-nucleotide 
polymorphisms (SNPs) in drug metabolizing enzymes (eg. cytochrome P450s), and this could 
enable evaluation of drug metabolism with specific SNP-type hepatocytes. These data could be 
utilized to design personalized therapies for future “made-to-order” medicine (Medine et al 
2010). 
In this chapter, we describe the developmental progression from a pluripotent stem cell 
state to hepatocytes and provide an overview of protocols for hepatic differentiation of 
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pluripotent stem cells. Enrichment strategies of functional hepatocytes and functional 
evaluation methodologies are also discussed.  
2. Lessons from liver development 
A reasonable approach to induce hepatic differentiation from pluripotent stem cells is to 
recapitulate actual embryonic developmental events in vitro. Liver development occurs 
through a series of cell-to-cell interactions between the embryonic endoderm and its nearby 
mesoderm (Duncan 2003, Zaret 1996). A number of genes and signaling pathways that are 
involved in this process have been identified (Lemaigre & Zaret 2004). Understanding the 
molecular pathways controlling hepatogenesis is essential in designing protocols for 
inducing hepatic differentiation in vitro. Although our knowledge of embryonic liver 
development is based on studies from non-human embryos, it is anticipated that the 
fundamental processes are similar if not identical to those in human liver development. 
Studies from mouse, chicken, zebrafish and Xenopus have shown that much of 
hepatogenesis is evolutionarily conserved (Roberts 2000, Tian & Meng 2006). Numerous 
signals are required at each step of hepatogenic development (Lemaigre & Zaret 2004, Zhao 
& Duncan 2005). Here, we review these sequential events – we have divided them into four 
stages to highlight the crucial cues at each stage for a better understanding of hepatic 
differentiation protocols that will be described in subsequent sections.  
2.1 Stage 1. Toward definitive endoderm 
The earliest event of organogenesis during mouse embryonic development is gastrulation. At 
this phase (ED6.5-7.5), the definitive endoderm layer is formed from mesendoderm lineage 
cells (Tada et al 2005). The process begins with the migration of Brachyury (T) positive cells 
through the anterior region of the primitive streak and through the Node, located at the 
anterior-most position of the streak (Vincent et al 2003). It has been shown that signaling by a 
member of the transforming growth factor (TGF)-β superfamily, specifically Nodal, initiates 
both endoderm and mesoderm formation (Vincent et al 2003). The epidermal growth factor 
family molecule, Cripto-1/FRL1/cryptic, plays a central role as a co-receptor for Nodal. 
Nodal/ALK signaling in conjunction with Cripto contributes to generate endoderm precursor 
cells and for the subsequent specification of definitive endoderm (DE) (Strizzi et al 2005). The 
duration and magnitude of Nodal signaling influence the specification of mesoderm or 
endoderm. The physical position of cells relative to the Node also seems to control this 
specification. Exposure to longer and higher levels of Nodal signaling induce endoderm 
specification, whereas lower stimulation of Nodal signaling promotes differentiation into the 
mesoderm (Schier 2003). Nodal signaling targets a core group of endoderm transcription 
factors genes expression including Sox17, Foxa2 (HNF3) (Shen 2007). 
2.2 Stage 2. Influence from cardiogenic mesodermal cells and septum transversum 
mesenchyme 
Following gastrulation, the definitive endoderm is patterned along the A-P axis into foregut, 
midgut and hindgut progenitor domains (Dessimoz et al 2006). Morphogenesis forms 
foregut and hindgut pockets as the endodermal cup is transformed into a gut tube. At ED8 
the definitive endoderm cells occupy a portion of the ventral foregut adjacent to the heart. 
Signaling cues from cardiogenic mesodermal cells such as fibroblast growth factors (FGFs) 
(Jung et al 1999) and cues from the septum transversum mesenchyme (STM), such as bone 
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morphogenic proteins 2 and 4 (BMP2, BMP4) are essential to direct cell fate to a hepatic 
lineage (Rossi et al 2001). It has been demonstrated that mouse embryonic foregut explants 
express albumin when co-cultured with cardiac mesoderm (Calmont et al 2006, Rossi et al 
2001). Studies using explant systems have shown that the cardiac mesoderm can be replaced 
by exogenous FGF1 or FGF2 supplementation (Jung et al 1999). BMP signaling is required, 
but not sufficient, for hepatic induction in explants (Rossi et al 2001).  
2.3 Stage 3. Hepatoblast proliferation  
The domain that eventually becomes the liver moves to the midgut, and the liver 
diverticulum forms by ED9 (Rifkind et al 1969). By ED9.5, the basal lamina breaks down and 
hepatoblasts delaminate and migrate into the STM. The liver diverticulum expands into a 
pronounced liver bud by ED10. The liver bud then undergoes tremendous growth and 
becomes the major site of fetal hematopoiesis. The massive proliferation and protection from 
apoptosis are regulated by paracrine signals from adjacent mesenchyme. These signals are 
including the FGFs, BMPs, Wnts, and the TGFβ signaling pathways. Hepatocyte Growth 
Factor (HGF) signaling is also required for hepatoblast migration and proliferation 
(Birchmeier et al 2003). 
Although Wnt/-catenin signaling appears to repress liver fate during earlier endoderm 
patterning stages of development, -catenin has the opposite effect and promotes hepatic 
growth in the liver bud at this stage (ED10) (McLin et al 2007, Micsenyi et al 2004, Monga et 
al 2003). Immunohistochemical studies showed TGF-3 expression in the liver bud 
mesenchyme at ED13.5 (Pelton et al 1991). Similarly, Stenvers et al showed a predominant 
expression of the TGF- receptor III (TbetaRIII) mRNA in liver at midgestation. They also 
demonstrated that TbetaRIII gene disruption induced apoptosis in the liver at ED13.5 
(Stenvers et al 2003).  
2.4 Stage 4. A bifurcation point to hepatocyte or cholangiocyte 
The differentiation of bi-potential hepatoblasts into hepatocytes or cholangiocytes begins 
around ED13 of mouse development. Hepatoblasts, adjacent to the portal vein, transform 
into cuboidal cells, which eventually forms the intrahepatic bile ducts during the prenatal 
period through the ductal plate remodeling process (Lemaigre 2003, Raynaud et al 2011), 
while other hepatoblasts gradually differentiate into mature hepatocytes. It has been shown 
that oncostatin M (OSM) promotes hepatic maturation (Kamiya et al 2001) During this 
phase, the liver bud transitions from a hematopoietic organ to a metabolic organ. Coexisting 
hematopoietic cells also play a significant role in the hepatic maturation process. For 
example, OSM is released from the hematopoietic cells and activates a JAK/Stat3 signaling 
pathway via the gp130 receptor (Ito et al 2000, Kamiya et al 1999), and intrahepatic 
structures are organized by ED15. The final maturation of the liver is a gradual process and 
continues into the postnatal period. Many hepatic enzymes such as cytochrome P450s shift 
from a fetal form to a mature form during the postnatal period. 
3. Hepatic differentiation of pluripotent stem cells 
Currently hepatic differentiation strategies from pluripotent stem cells can be classified into 
three approaches; 1) via formation of spontaneous embryoid body (EB), 2) co-culture with 
supporter cells, and 3) directed hepatic differentiation via stepwise stimulation by defined 
growth factors.  
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3.1 Embryoid body formation and spontaneous hepatic differentiation 
Mouse ESCs aggregate in suspension to form spheroid clumps of cells called embryoid 
bodies (EBs). Removal of leukemia inhibitory factor (LIF) induces spontaneous 
differentiation into three germ layers (Itskovitz-Eldor et al 2000). Chinzei et al reported that 
AFP and albumin gene expressions were detected in EBs after 9 days and 12 days, 
respectively, without additional exogenous growth factors (Chinzei et al 2002). However, 
the spontaneous differentiation of hepatocytes in EBs is inefficient (usually under 10%) and 
is highly cell line dependent (Lavon & Benvenisty 2005, Schwartz et al 2005, Shirahashi et al 
2004). To increase the ratio of hepatic cells in the EBs, differentiation can be directed by 
exposure to exogenous growth factors. Hamazaki and colleagues demonstrated that the 
combination and consecutive supplementation of FGF, HGF, OSM, and dexamethasone 
efficiently induced hepatic differentiation (Hamazaki et al 2001). In regards to human ESCs, 
hepatic induction using the EB formation approach was reported by Schuldiner and 
colleagues (Schuldiner et al 2000). These studies with EB formation provided evidence that 
mouse and human pluripotent stem cells were able to differentiate to the hepatic lineage in 
vitro. The 3D structure of EBs has an advantage over the 2D culture system in further 
inducing functional maturation. However, the uncontrolled heterogeneous cell populations 
in EBs and the variation in size and morphology prohibit further clinical applications. 
3.2 Co-culture of pluripotent stem cells with supporter cells 
Another approach for hepatic differentiation is providing in vivo-like supplements including 
cytokines, growth factors, and extracellular matrixes. These elements can be provided by co-
culturing appropriate supporter cells, such as hepatic mesenchymal cells. A co-culture strategy 
for hepatic differentiation was first applied using Thy1-positive mesenchymal cells derived 
from mouse fetal liver (Ishii et al 2005). An enhanced green fluorescent protein (EGFP)-AFP 
labeling system was used to isolate hepatic lineage committed ES-derived cells, which were 
subsequently co-cultured with the Thy1 positive mesenchymal cells. Several late-phase hepatic 
markers such as tyrosine amino transferase, tryptophan 2,3-dioxygenase, and glucose-6-
phosphatase were expressed in the co-cultured ES-derived hepatocytes. Fair et al reported that 
co-cultured mESCs with chick embryonic cardiac mesoderm cells expressed mesendoderm 
genes, Sox17, HNF3, GATA4, after 24 hours (Fair et al 2003). They also demonstrated that 
the xenogeneic cell-to-cell contact between mESCs and the chick cells, apart from providing 
cytokines/growth factors, may also provide signals via direct cell-to-cell interaction. In 
contrast, Saito et al demonstrated that diffusible factors from mouse fetal liver-derived cells 
were sufficient to stimulate hepatic differentiation of cynomolgus monkey ES cells (Saito et al 
2006). They also demonstrated that induction of hepatic differentiation utilizing the co-culture 
system was faster than chemical/growth factor induction. Soto-Gutierrez et al combined a co-
culture system of human liver nonparenchymal cell lines with growth factors. This protocol 
resulted in the successful derivation of 70% albumin positive cells from mESCs (Soto-Gutierrez 
et al 2007). These data indicate the feasibility of the co-culture system for inducing hepatic 
differentiation from pluripotent stem cells. However, it might be difficult to reproduce hepatic 
differentiation by co-culturing with primary cells as the quality and the secreted factors are 
uncertain. Moreover, the contamination of the supporter cells and the difficulty in the scale-up 
of hepatocyte production are issues that hamper clinical applications. 
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The in vitro developmental capability of ES cells has been shown with spontaneous 
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morphogenic proteins 2 and 4 (BMP2, BMP4) are essential to direct cell fate to a hepatic 
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3.1 Embryoid body formation and spontaneous hepatic differentiation 
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could induce hepatic differentiation. As described in section 2, extensive developmental 
biology studies have uncovered the pathways controlling hepatogenesis. To mimic the 
sequential stimulation of in vivo hepatogenesis, various combinations of stepwise growth 
factor stimulation strategies have been tested.  
The critical first step is to efficiently induce definitive endoderm (DE) commitment of ESCs. 
Based on researches of mesendoderm and definitive endoderm differentiation in rodent and 
Xenopus, it was reasonable to expect that a high concentration of Nodal is key to the 
induction of definitive endoderm differentiation (Schier 2003). In most studies, a high dose 
of Activin A was used as a substitute for Nodal. Activin shares the same receptors (ActRII 
and ALK4) with Nodal but does not require the association of Cripto to initiate the 
Nodal/Smad2 signaling pathway (Strizzi et al 2005). After a few days of Activin treatment, 
most of the ES cells express definitive endoderm genes (Sox17 and Foxa2), while mesoderm, 
pluripotency and the extraembryonic endoderm genes are down regulated (D'Amour et al 
2005, Kubo et al 2004). Further studies indicate that generation of hESC-DE requires two 
conditions: signaling by Activin/Nodal family members and the release from inhibitory 
signals generated by PI3K through insulin/IGF (McLean et al 2007). In this approach, using 
a high-density monolayer culture, pluripotent stem cells are cultured in a feeder cell-free 
system and mesendoderm differentiation is induced by a defined serum-free medium, 
supplemented with high-dose of Activin A (e.g. 100ng/ml) (Yoshie et al 2010).  
The signaling pathways regulating foregut formation can be recapitulated in cell culture by 
the addition of specific growth factors such as FGFs and BMPs. A number of groups have 
used this combination to generate hepatic cells (Dan & Yeoh 2008, Ochiya et al 2009). The 
endoderm specification stage is followed by HGF stimulation to expand the hepatoblast 
population (LaBrecque 1994). Hepatic maturation is normally regulated and promoted by 
some combination of OSM and Dexamethasone. (Agarwal et al 2008, Baharvand et al 2008, 
Cai et al 2007, Soto-Gutierrez et al 2006b, Teratani et al 2005).  
Hay and colleagues introduced a similar stepwise induction concept, except using chemicals 
to induce hepatic differentiation in ES and iPS cells (Hay et al 2008a, Hay et al 2008b, 
Sullivan et al 2010). A combination of Activin A and the histone deacetylase inhibitors 
(HDI), sodium butyrate, were utilized for the definitive endoderm induction and 1% DMSO 
for further hepatic specification (Hay et al 2008b). Although the effect of butyrate for 
inducing differentiation has been known for a long time (Leder & Leder 1975), the role of 
HDI in the hepatic differentiation process was not totally elucidated. McLean showed that a 
combination of Activin and a PI3K inhibitor is more efficient to induce DE differentiation 
(McLean et al 2007). Recent progress on studies in signal transduction pathways has led 
researchers to control not only the initiation of signal transduction by adding exogenous 
growth factors, but also the regulation of intracellular signaling to induce hepatic 
differentiation in a more precise and efficient manner. Touboul et al used the PI3K inhibitor, 
LY294002, for DE induction and activin receptor-like kinase (ALK) 5 inhibitor, SB431542, for 
hepatic specification. Currently, these protocols still require combinations with recombinant 
growth factors. Since mass production of these recombinant proteins are cost prohibitive, a 
totally defined chemical protocol would be ideal for a large-scale hepatocyte production.  
Although hepatic differentiation protocols are now more sophisticated, fully differentiated 
stem cell-derived hepatocytes that possess identical hepatic functions to primary adult 
hepatocytes have yet to be produced. Using a unique primary hepatocyte culture system, 
Michalopoulos's group demonstrated that a combination of dexamethasone, HGF, and EGF 
was required for formation of liver-like tissue. Dexamethasone induces expression of both 
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HNF4 and C/EBP-, essential transcription factors for hepatocyte differentiation, while 
HGF and EGF induce members of the TGF- family and HNF6, which are essential for 
maintenance of hepatic functions (Michalopoulos et al 2003). Although this unique culture 
system has not been tested with stem cell-derived hepatic cells, this combination and culture 
system may be essential to achieve further hepatic maturation.  
4. Enrichment strategies of stem cell derived hepatocytes 
Despite utilizing these well-designed differentiation protocols on mouse and human ES 
cells, hepatic induction from pluripotent stem cells results in mixtures with non-hepatic 
cells. Generally speaking, in the areas of stem cell-derived cell studies, there has not been a 
differentiation protocol that is able to induce 100% of this desired target cells based upon 
current technologies. This is one of the issues that is hindering further clinical development. 
Particularly in the use of pluripotent stem cells, contamination with undifferentiated cells is 
one of the biggest concerns due to their tumorigenic potential (Ben-David & Benvenisty 
2011, Dressel et al 2008). Therefore, further investigations will be necessary to obtain 
clinically applicable stem cell-derived hepatocytes. One of the approaches is to develop 
techniques that allow for isolation and purification of specific hepatic subtypes.  
For basic research, it is common to use genetic selection techniques. Under this strategy, 
undifferentiated pluripotent stem cells are genetically modified to carry either a reporter 
gene, usually a green fluorescence protein (EGFP) gene or an antibiotic resistance gene 
under the transcriptional control of a hepatic-promoter such as alpha-fetoprotein (Yin et al 
2002). The transgenic cells are then induced to differentiate and subsequently selected based 
on the activation of the hepatocyte-specific promoter. The major disadvantage of this 
approach is the risks associated with the genetic modification which may lead to insertional 
oncogenesis. In addition, these transcriptional markers are also common to immature 
hepatocytes. It is, therefore difficult to designate one gene as a definitive single marker of 
hepatic differentiation.  
An endogenously expressed surface marker, asialoglycoprotein receptor (ASGPR), has been 
proposed as a cell surface marker for functional hepatocytes (Li et al 2008, Treichel et al 
1995). Recent studies have utilized ASGPR to identify mature hepatic cells from a mixed 
population of fetal hepatocytes (Ring et al 2010). ASGPR is a transmembrane hepatocellular 
surface carbohydrate binding glycoprotein that lacks terminal sialic acid residues 
(=asialoglycoproteins). Characterization of the ASGPR has revealed its functional role in the 
binding, internalization and transport of a wide range of glycoproteins in a selective manner 
via the process of receptor-mediated endocytosis. The expression of the ASGPR has been 
clinically correlated to loss of hepatic functions in liver diseases associated with cancer, viral 
hepatitis, and cirrhosis. Basma et al enriched hESC-derived hepatic cells using the ASGPR 
marker (Basma et al 2009). Although the G6Pase, albumin, and TAT mRNA expressions 
were dramatically improved by this enrichment step, mRNA expression of both Oct4 and 
AFP were still detectable. This data indicates that a single enrichment step could not 
completely eliminate the undifferentiated stem cell or the progenitor cell contamination. 
Kumashiro et al used a silica-based colloidal medium (Percoll) and PECAM-1 antibodies to 
separate mESCs-derived hepatocytes from Oct4 positive undifferentiated cells. The ES-
derived hepatocytes were transplanted into the CCl4-injured mouse liver and this led to 
improved liver function. Importantly, unlike unselected ES-derived hepatocytes, the 
enriched ES-derived hepatocytes did not develop teratomas in the recipients’ liver 
(Kumashiro et al 2005).  
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totally defined chemical protocol would be ideal for a large-scale hepatocyte production.  
Although hepatic differentiation protocols are now more sophisticated, fully differentiated 
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2002). The transgenic cells are then induced to differentiate and subsequently selected based 
on the activation of the hepatocyte-specific promoter. The major disadvantage of this 
approach is the risks associated with the genetic modification which may lead to insertional 
oncogenesis. In addition, these transcriptional markers are also common to immature 
hepatocytes. It is, therefore difficult to designate one gene as a definitive single marker of 
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An endogenously expressed surface marker, asialoglycoprotein receptor (ASGPR), has been 
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binding, internalization and transport of a wide range of glycoproteins in a selective manner 
via the process of receptor-mediated endocytosis. The expression of the ASGPR has been 
clinically correlated to loss of hepatic functions in liver diseases associated with cancer, viral 
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marker (Basma et al 2009). Although the G6Pase, albumin, and TAT mRNA expressions 
were dramatically improved by this enrichment step, mRNA expression of both Oct4 and 
AFP were still detectable. This data indicates that a single enrichment step could not 
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enriched ES-derived hepatocytes did not develop teratomas in the recipients’ liver 
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Conclusively, the hepatic enrichment studies demonstrate the advantages of selecting 
hepatic cells from mixed ES-derived cell population. However, there is to date, no single 
standard technology to achieve sufficient hepatocyte enrichment or non-hepatic cell 
exclusion. The influence of other cell types on hepatic differentiation is one aspect that 
requires further studies. Non-hepatic cells such as cholangiocyte contamination may have a 
positive influence for further maturation in stem cell-derived hepatic cells. For future 
clinical applications, genetic modification of stem cell will not be acceptable. Although the 
ASGPR enrichment protocol is promising, the need for a large quantity of antibody remains 
a substantial financial burden for large-scale production of stem cell-derived hepatocytes. 
Thus, additional investigations are needed to find novel strategies to enrich clinically viable 
stem cell-derived hepatocytes.  
5. Characteristics of pluripotent stem cell derived hepatocytes 
One of the difficulties for stem cell research is the interpretation of in vitro data on the extent 
of terminal differentiation. Since human primary hepatocytes lose their hepatic functions in 
vitro within a week after their isolation, it is clearly a challenge to induce full maturation 
status equivalent to that of adult hepatocytes in stem cell-derived hepatocytes in vitro. With 
this in mind, the in vitro evaluation for hepatic differentiation has to be undertaken very 
carefully using multi-pronged approaches. The evaluation should be conducted at 1) the 
transcription level, 2) the translation level, 3) performing biochemical (in vitro) functional 
tests, as well as 4) in vivo functional assays. 
5.1 Transcriptional evaluation. Hepatic marker genes expression 
Many genes have been proposed as hepatocyte-specific genes. The most commonly cited 
genes are; albumin, alpha-fetoprotein (AFP), cytokeratin-18, glucose-6-phosphatase (G6P), 
phosphoenolpyruvate carboxykinase (PEPCK), alpha-1-antitrypsin (A1AT), bilirubin, 
uridine diphosphate-glucuronosyltransferase, coagulation factor VII. However, some of 
these are also expressed in other tissues such as extra-embryonic yolk sac. AFP, for example, 
is expressed in both the liver and the yolk sac. Therefore, AFP expression needs to be 
demonstrated along with definitive endoderm marker genes, Sox17 and CXCR4. 
Transcriptome studies on mouse liver development have revealed that the expression 
patterns of these hepatic markers are dramatically altered during hepatogenesis. For 
instance, Jochheim et al. demonstrated that HNF4 gene expression peaked on ED11.5 and 
decreased until ED13.5, after which, it gradually increased but its levels were not as high as 
at ED11.5 (Jochheim et al 2003). Therefore, quantitative RT-PCR data must be carefully 
interpreted, as a downregulation of HNF4 mRNA expression could still be an indication of 
increased hepatocyte maturation. Genes encoding cytochrome P-450 (CYP)-7A1, bilirubin, 
uridine diphosphate-glucuronosyltransferase, coagulation factor VII, and asialoglycoprotein 
receptors are considered late phase hepatic marker genes and are not expressed in the yolk 
sac. Therefore, these genes could be useful as markers for mature hepatocytes. In contrast, 
G6P, CYP3A4 and PEPCK are also deemed late-phase marker genes, however, their 
expression is not liver specific. CYP7A1 is a member of the cytochrome P450 superfamily of 
enzymes. This liver specific endoplasmic reticulum membrane protein is involved in the 
cholesterol catabolic pathway, which converts cholesterol to bile acids. Other CYP enzymes 
are responsible for oxidative metabolism of most therapeutic drugs. Therefore, it is 
important to demonstrate the expression of these genes in the stem cell-derived hepatic cells 
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for drug testing. Among the CYP enzymes, 3A4, 1A2, 2C19, 2D6, are dominant players for 
drug metabolism in human liver. 
Ideally the gene expression levels in stem cell-derived hepatic cell at the end of the 
differentiation protocol should be comparable to that of an adult hepatocyte. Concurrently, 
evaluations for non-hepatocyte specific genes to determine the extent of differentiation to 
specific hepatic lineage should also be performed.  
With regards to the development of drug metabolizing enzymes such as CYP genes, both 
the pattern and the level of expressions are important. Many metabolic and detoxifying 
enzymes are expressed at significant levels only after birth. Therefore, the gene expression 
ratio of the fetal form to the adult form could be used as a determinant of the status of 
hepatic maturation. For example, fetal liver cells express CYP3A7, a fetal form of CYP3A4. 
Higher 3A4/3A7 ratio indicates increased hepatic maturation of stem cell-derived hepatic 
cells (Ek et al 2007, Miki et al 2011).  
5.2 Translational evaluation. Hepatic marker proteins expression 
Gene expression does not necessarily translate to protein production and activity. Using a 
hepatic differentiation protocol, Hay et al demonstrated that Oct4 protein was undetectable 
after the second day, while Oct4 mRNA remains detectable until day 11 of the protocol. 
Along the same vein, albumin mRNA expression was observed at day 11 but albumin 
protein was detected only starting at day 15 (Hay et al 2008b). Therefore, 
immunohistochemistry and/or Western blot analyses must be performed to verify the 
expression of key proteins at the end of any differentiation protocol. AFP, Albumin, A1AT, 
and cytokeratins (8, 18, 19) are common proteins that were used in many reports. As 
mentioned in section 4, some cell surface marker proteins (e.g. ASGPR) are also important. 
5.3 Biochemical functional assay 
Demonstration of albumin production and secretion from stem cell-derived hepatic cells is 
the gold standard assay to demonstrate functional protein synthesis. In the human body, 
albumin is the most abundant protein in serum and is produced specifically by the liver. 
Therefore, serum albumin has been used as an indicator to evaluate liver function in a 
clinical setting. Although albumin production and secretion are essential, it is however 
insufficient to use this as a marker for stem cell-derived hepatic cells. It has been shown the 
albumin gene is expressed at a relatively early stage of hepatogenesis, and furthermore, 
visceral endoderm cells such as yolk sac cells also produce albumin (Meehan et al 1984). 
Therefore, albumin production from stem cell-derived hepatic cells must be further 
supported through a combination of other assays.  
The ability to metabolize ammonia is also a standard assay to evaluate hepatic detoxification 
function. In vivo, ammonia is a metabolic product generated from dietary amino acids, and 
80-90% of ammonia is converted into urea by hepatocytes through the urea cycle. To test 
this function in vitro, excess amount of ammonium chloride is added to the culture medium 
(ammonia challenge). Ammonia clearance or urea production can then be measured as 
functional readout of the assay. Since precise parameter adjustment for measuring ammonia 
level in culture media is difficult, the standard protocol is measuring urea concentration in 
the supernatant via the enzymatic urease method. A pitfall in this assay is the possibility of 
arginase leakage from damaged cells due to the excess ammonium chloride, which could 
produce urea independently from the urea cycle activity. Therefore, the acquisition of urea 
metabolism function should be further confirmed by the expression of key enzymes in the 
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for drug testing. Among the CYP enzymes, 3A4, 1A2, 2C19, 2D6, are dominant players for 
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this function in vitro, excess amount of ammonium chloride is added to the culture medium 
(ammonia challenge). Ammonia clearance or urea production can then be measured as 
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urea cycle, such as arginase I (ARG1), argininosuccinate lyase (ASL), argininosuccinate 
synthetase 1 (ASS1), carbamoyl-phosphate synthetase 1 (CPS1), and ornithine 
carbamoyltransferase (OTC) (Mavri-Damelin et al 2008, Miki et al 2011). 
To meet the demand for pharmaco-toxicological applications, demonstration of activities of 
xenobiotic-metabolizing phase I and phase II enzymes and phase III transporters must be 
satisfied (Xu et al 2005). To evaluate phase I activities, CYP-dependent monooxygenase 
activity assays; 7-ethoxycoumarin-O-deethylase (ECOD assay) (Lubet et al 1985), 7-
ethoxyresorufin-O-deethylase (EROD assay), and specific oxidation of testosterone are 
commonly used. In measuring phase II activities, glucuronosyltransferase activity and 
sulfotransferase activity toward p-nitrophenol, and glutathione S-transferase activity are 
commonly used. Functional assays for phase III transporters have yet to be standardized. 
Measurement of fluorescent protein conjugated bile acid could be useful to evaluate one of 
the phase III transporters, i.e. the bile salt export pump (BSEP/ABCB11), for activity in stem 
cell-derived hepatocytes (Yamaguchi et al 2010).  
5.4 In vivo analysis 
These in vitro hepatic functional assays are essential and useful. However, the most 
definitive proof for the functionality of stem cell-derived hepatic cells would be the 
demonstration of hepatic engraftment in vivo using animal models (Soto-Gutierrez et al 
2006a, Yamamoto et al 2003). It would be ideal if stem cell-derived hepatic cells could 
improve survival rates in lethal disease models. Transgenic mouse models of congenital 
liver diseases would be candidates for such assays. The fumarylacetoacetate hydrolase 
(FAH) deficiency mouse model (Lagasse et al 2000) and urokinase-type plasminogen 
activator-transgenic SCID mice (Tateno et al 2004) have been previously and provide a 
means to test stem cell-derived hepatocytes in a liver transplantation setting. Unfortunately 
such animal models are not widely available and also require significant technical expertise 
to perform hepatocyte transplantation in neonatal animals. 
Nevertheless, whether human or rodent, primary hepatocytes tend to lose their 
differentiated characteristics in culture. One question that arises is whether the stem cell-
derived hepatic cells have to be fully differentiated in vitro. It is anticipated that stem cell-
derived hepatic progenitor cells spontaneously differentiate to fully mature hepatocytes in 
their correct endogenous environment. Once hepatic lineage commitment is confirmed, stem 
cell-derived hepatic progenitor cells could be an acceptable source for cell replacement 
therapy. The endogenous mouse liver environment is suitable to test this hypothesis. It is 
therefore extremely important to establish standard animal models that are easy to 
experiment with, and also widely available for stem cell-derived hepatic cell 
transplantation.  
6. Conclusion and future perspectives 
Hepatic differentiation is a sequential dynamic event that involves various types of cells and 
complex signaling networks. Although the signaling pathways and growth factors that are 
involved in definitive endoderm specification have been well documented, only portions of 
the mechanisms involved in the human hepatogenic development have been defined. 
Therefore, the goal of inducing directed differentiation of pluripotent stem cells toward 
hepatocytes remains a big challenge. A number of differentiation protocols have been 
described to generate hepatocytes from pluripotent stem cells. Collectively, various hepatic 
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differentiation studies demonstrate how the exposure of various growth factors to 
pluripotent stem cells, with the appropriate timing and doses, is essential for directing the 
differentiation process from early mesendoderm via definitive endoderm towards more 
functionally mature hepatocytes. Based on the recent advances in the field of developmental 
biology, hepatic differentiation protocols have been modified to provide more than 70% 
albumin positive cells from mESCs (Soto-Gutierrez et al 2007) and 35% of ASGPR positive 
cells from hESCs (Touboul et al 2010). It appears that iPS cells possess a similar capacity to 
hES cells to generate hepatocytes using similar differentiation protocols (Sullivan et al 2010).  
It must be noted that the stem cell-derived hepatocytes described to date generally exhibit 
fetal hepatocyte-like gene expression profiles and immature functional characteristics 
compared to authentic adult primary hepatocytes. Recent finding suggested that a 3D 
dynamic bioreactor culture system which provides an in vivo-like culture environment 
induced teratoma-like multi-directional differentiation of human ESCs (Gerlach et al 2010). 
When a hepatic differentiation protocol was applied in this system, the 3D dynamic culture 
system induced further hepatic maturation, including tissue-like structure formation (Miki 
et al 2011). Although the superiority of the culture conditions in the 3D dynamic culture 
system has been clearly demonstrated, it is difficult to determine which parameters are 
critical for this advantage in hepatic maturation. Using matrigel or collagen gel, it has been 
shown that static 3D culture conditions prolong hepatic function of primary hepatocytes 
(Kono et al 1997). It has been proposed that the 3D structure allows more physiological cell-
to-cell interactions, and induces polarity in hepatocytes (Haouzi et al 2005). Baharvand et al 
demonstrated that hESCs are more efficiently differentiated to hepatic cells under static 3D 
culture conditions than conventional 2D culture conditions (Baharvand et al 2008).  
Dynamic culture conditions are, not surprisingly, more advantageous than static culture 
conditions (Vinci et al 2011). Unlike static cultures, the dynamic culture system provides 
continuous and gradual medium change under controlled oxygen tension and temperature. 
Taken together, the dynamic 3D culture system can provide a more physiological and 
homeostatic environment that could be favorable for stem cell-derived hepatocyte 
maturation. The continuous supply of fresh medium via nano-size porous hollow fibers also 
provides micro steady flow around the cells (Gerlach et al 2010) and low shear stress that 
could further stimulate maturation signals through sensory systems (e.g. cilia) on the 
polarized hepatic cells (Decaens et al 2008). Furthermore, it is noteworthy that in the human 
body, the liver passively but dynamically moves with the movements of diaphragm. In 
addition to the oxygen concentration in the blood flow, such movement could be a factor to 
induce rapid postnatal hepatic maturation events such as cytochrome isotype switching 
from CYP3A7 to 3A4.  
As reviewed, the current differentiation protocols demonstrated the feasibility of hepatic cell 
production from pluripotent stem cells. Further optimization will be required to better 
define hepatic differentiation protocols and improved culture conditions to obtain fully 
differentiated functional hepatocytes in vitro. On the other hand, for cell replacement 
therapy applications, such in vitro full maturation may not be essential. Both fetal and adult 
hepatocytes demonstrated bilirubin conjugating activity in the Gunn rat after cell 
transplantation (Borel-Rinkes et al 1992). Hepatic progenitor cells could mature in the 
endogenous hepatic environment and thereby provide therapeutic effects to patients. The 
direction of research for this goal will be generating hepatic lineage committed cells in vitro, 
establishing an appropriate enrichment protocol, and critically evaluating the efficacy and 
safety of these cells in animal models.  
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In conclusion, the promise of pluripotent stem cells for the generation of hepatocytes and 
with further investigations will eventually lead us to a more in-depth understanding of 
mechanisms of hepatogenesis and hepatic maturation. The widespread utility of pluripotent 
stem cell-derived functional hepatocytes for basic research and pharmaceutical applications, 
could also become a reality. In the future, stem cell-derived hepatocytes are anticipated to 
have an enormous impact on the treatment of liver disease. 
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1. Introduction   
Research in stem cell biology has the potential to dramatically alter the way we understand 
the vast complexity and coordination that is required for an organism to develop and 
function. The creation of therapeutic tools that will inevitably accompany these discoveries 
in this field of research may completely revolutionize our approach to medicine in the 21st 
century.  
In this chapter we will examine one facet of stem cell research that holds great potential to 
improve the quality of life for millions of individuals; the study of osteogenesis from 
pluripotent stem cells. Despite its overt rigid structure, which provides mechanical support 
and protective functions, bone is a highly dynamic tissue that is tightly regulated to serve 
multiple roles in the body. Bone tissue is constantly being remodeled by the actions of the 
osteoblasts, the bone forming cells, and the osteoclasts, the bone resorbing cells. The 
improper balance of these cells can result in a number of bone-related and 
osteodegenerative diseases. Osteoporosis, for example, is estimated to effect 75 million 
individuals in Europe, Japan and the US alone, and thus the potential benefits of 
understanding the processes regulating osteogenesis may be quite far reaching.  
Despite the similarity of the bone tissues found in the adult mammalian skeleton, there are 
three different sources from which bone is derived in the developing embryo (Fig. 1). Two 
of these bone origins are from mesodermal progenitors, where cells from either the lateral 
plate or paraxial mesoderm contribute to the appendicular or axial skeleton, respectively. 
The third origin of bone tissue can be traced back to ectodermal cells where neural crest 
progenitors differentiate into many of the bones within the craniofacial region. Differences 
in the origin in bone are also paralleled in differences seen in the bone formation process. 
Most bones of mesodermal origin develop via the process of endochondral bone formation, 
whereas the bones of ectodermal origin form by a process called intramembranous bone 
formation. These processes differ most generally in the series of cell differentiations that 
lead to the mature tissue. In endochondral bone formation the mesenchymal progenitors 
differentiate into chondrocytes, which lay down the cartilaginous framework that is 
eventually replaced by the mineralized matrix of invading osteoblasts, while the 
chondrocytes undergo apoptosis. In intramembranous bone formation, the progenitors 
differentiate directly into osteoblasts. In addition, mature bone tissues house adult stem cell 
niches, such as those composed of mesenchymal or hematopoietic stem cells. These cells are 
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the source for diverse cell types throughout the life of the organism and are critical for 
normal maintenance and overall physiology.  
 
 
Fig. 1. Embryonic origins of bone tissue 
While it is widely accepted that pluripotent stem cells have the capability to give rise to 
osteoblasts, it has only recently been examined whether they do so through a mesodermal 
route or through progenitors with neural crest characteristics. This chapter will provide a 
review of the current understanding of the different progenitors that contribute to the 
aforementioned bone formation processes and regulatory networks known to play critical 
roles in these cells. It will further examine the experimental manipulations in stem cell 
culture systems that have allowed us to derive neural crest and mesodermal type 
osteoprogenitors in vitro. However, it remains elusive whether a neural crest type progenitor 
and a mesodermal progenitor will have the same capacity to repair bone when transplanted 
or whether one will be superior to the other in a certain transplantation site. In order to 
systematically assess the influence of the type of progenitor and the transplantation site as 
well as the process of bone formation that is typically used as repair mechanism in a 
particular transplantation site, this chapter therefore also summarizes bone tissue 
engineering studies that have been undertaken using these diverse progenitors and that will 
bring us closer to eventual clinical applications that this exciting field of research will 
provide.   
2. Pluripotent stem cells to bone 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states. One such program is the 
development of bone tissue; and research in this field has already made a positive impact on 
the lives of individuals in various clinical trials (Giordano et al., 2007). However, before 
these applications become commonplace in the medical field, further study is required to 
improve both our understanding and methodologies. This chapter seeks to give a broad 
overview of a diverse range of topics, from differentiation of pluripotent stem cells along 
osteogenic lineages, some current approaches in applying stem cell based bone engineering 
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for potential clinical applications, and concluding with a discussion of different bone origins 
and their respective developmental pathways.  
2.1 Embryonic stem cells 
Pluripotent stem cells can be distinguished from adult stem cells based on their nature of 
origin, but first and foremost based on their more versatile differentiation capability. This 
unsurpassed differentiation capability is known as pluripotency, the potential to generate 
cell types from the three embryonic germ layers: the mesoderm, the ectoderm and the 
endoderm. One class of pluripotent stem cells, the embryonic stem cells (ESCs) have been 
under fervent ethical debate since their initial derivation. The crux of this debate can be 
attributed to their source being a cluster of cells found in the blastocyst, an early pre-
implantation embryonic stage. This cluster of cells, the inner cell mass (ICM), is established 
directly after the developing embryo has gone through the first fate decision, in which the 
trophoectoderm secedes from the ICM. While this outer trophoectodermal layer of the 
blastocyst eventually gives rise to the placenta, the in vivo fate of the ICM is to develop into 
the embryo proper, which contains cell types of the three germ layers. Mirroring this 
capability of the ICM, isolated ESCs also have the capacity to give rise to cell types of all 
three germ layers when differentiated in vitro (Itskovitz-Eldor et al., 2000).  
ESCs were first derived from mouse blastocysts (Evans and Kaufman, 1981; Martin, 1981) 
and since then their derivation has been reported from a number of mammals including: 
hamster, rabbit and rat (Doetschman et al., 1988; Giles et al., 1993; Iannaccone et al., 1994).  
Although these alternative rodent ESC lines have never gained recognition as model 
systems, their utilization continues to provide insights into stem cell biology. As for primate 
ESC derivation, the initial challenges that plagued the field for years were finally overcome 
by Thomson et al. (1995), and this study laid the ground for the establishment of human 
ESCs by the same team just shortly before the turn of the century (Thomson et al., 1998).  
In addition to the pluripotent nature, it is their second characteristic of being capable of 
unlimited proliferation that ESCs first became an attractive cell source for regenerative 
therapies. This propagation in the undifferentiated state can be supported in culture with 
the addition of leukemia inhibitory factor (LIF) (Williams et al., 1988). Since LIF is inefficient 
in maintaining the undifferentiated state in human ESCs, the molecular cues needed maybe 
released by murine embryonic fibroblast feeder layers, which both human ESCs and murine 
ESCs can be grown on (Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). In 
feeder-independent conditions, basic fibroblast growth factor (bFGF) is able to maintain the 
pluripotent state of human ESCs (Amit et al., 2003).  
2.2 Differentiation of ESCs into bone cells  
Historically the developmental program that pluripotent stem cells take to form bone tissue 
was first elucidated using murine ESCs. Buttery and coworkers were the first to show that 
mESCs maintained in medium supplemented with beta-glycerophosphate and ascorbic acid 
had mineralized in culture, a hallmark feature of bone tissue formation (Buttery et al., 2001). 
In the past decade, numerous protocols have then been established that allow ESC 
differentiation into bone and cartilage and their characteristic cell types, the osteoblasts and 
osteoclasts as well as the chondocytes. The studies that describe formation of osteoblasts 
typically all assess the ability of the cells to secrete an organic matrix composed of collagen 
type I (COL I) and proteoglycans, the deposition of inorganic hydroxyapatite and the 
expression of osteoblast-specific genes (Davis et al., 2011; Handschel et al., 2008; Shimko et 
al., 2004).  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
324 
the source for diverse cell types throughout the life of the organism and are critical for 
normal maintenance and overall physiology.  
 
 
Fig. 1. Embryonic origins of bone tissue 
While it is widely accepted that pluripotent stem cells have the capability to give rise to 
osteoblasts, it has only recently been examined whether they do so through a mesodermal 
route or through progenitors with neural crest characteristics. This chapter will provide a 
review of the current understanding of the different progenitors that contribute to the 
aforementioned bone formation processes and regulatory networks known to play critical 
roles in these cells. It will further examine the experimental manipulations in stem cell 
culture systems that have allowed us to derive neural crest and mesodermal type 
osteoprogenitors in vitro. However, it remains elusive whether a neural crest type progenitor 
and a mesodermal progenitor will have the same capacity to repair bone when transplanted 
or whether one will be superior to the other in a certain transplantation site. In order to 
systematically assess the influence of the type of progenitor and the transplantation site as 
well as the process of bone formation that is typically used as repair mechanism in a 
particular transplantation site, this chapter therefore also summarizes bone tissue 
engineering studies that have been undertaken using these diverse progenitors and that will 
bring us closer to eventual clinical applications that this exciting field of research will 
provide.   
2. Pluripotent stem cells to bone 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states. One such program is the 
development of bone tissue; and research in this field has already made a positive impact on 
the lives of individuals in various clinical trials (Giordano et al., 2007). However, before 
these applications become commonplace in the medical field, further study is required to 
improve both our understanding and methodologies. This chapter seeks to give a broad 
overview of a diverse range of topics, from differentiation of pluripotent stem cells along 
osteogenic lineages, some current approaches in applying stem cell based bone engineering 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
325 
for potential clinical applications, and concluding with a discussion of different bone origins 
and their respective developmental pathways.  
2.1 Embryonic stem cells 
Pluripotent stem cells can be distinguished from adult stem cells based on their nature of 
origin, but first and foremost based on their more versatile differentiation capability. This 
unsurpassed differentiation capability is known as pluripotency, the potential to generate 
cell types from the three embryonic germ layers: the mesoderm, the ectoderm and the 
endoderm. One class of pluripotent stem cells, the embryonic stem cells (ESCs) have been 
under fervent ethical debate since their initial derivation. The crux of this debate can be 
attributed to their source being a cluster of cells found in the blastocyst, an early pre-
implantation embryonic stage. This cluster of cells, the inner cell mass (ICM), is established 
directly after the developing embryo has gone through the first fate decision, in which the 
trophoectoderm secedes from the ICM. While this outer trophoectodermal layer of the 
blastocyst eventually gives rise to the placenta, the in vivo fate of the ICM is to develop into 
the embryo proper, which contains cell types of the three germ layers. Mirroring this 
capability of the ICM, isolated ESCs also have the capacity to give rise to cell types of all 
three germ layers when differentiated in vitro (Itskovitz-Eldor et al., 2000).  
ESCs were first derived from mouse blastocysts (Evans and Kaufman, 1981; Martin, 1981) 
and since then their derivation has been reported from a number of mammals including: 
hamster, rabbit and rat (Doetschman et al., 1988; Giles et al., 1993; Iannaccone et al., 1994).  
Although these alternative rodent ESC lines have never gained recognition as model 
systems, their utilization continues to provide insights into stem cell biology. As for primate 
ESC derivation, the initial challenges that plagued the field for years were finally overcome 
by Thomson et al. (1995), and this study laid the ground for the establishment of human 
ESCs by the same team just shortly before the turn of the century (Thomson et al., 1998).  
In addition to the pluripotent nature, it is their second characteristic of being capable of 
unlimited proliferation that ESCs first became an attractive cell source for regenerative 
therapies. This propagation in the undifferentiated state can be supported in culture with 
the addition of leukemia inhibitory factor (LIF) (Williams et al., 1988). Since LIF is inefficient 
in maintaining the undifferentiated state in human ESCs, the molecular cues needed maybe 
released by murine embryonic fibroblast feeder layers, which both human ESCs and murine 
ESCs can be grown on (Evans and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). In 
feeder-independent conditions, basic fibroblast growth factor (bFGF) is able to maintain the 
pluripotent state of human ESCs (Amit et al., 2003).  
2.2 Differentiation of ESCs into bone cells  
Historically the developmental program that pluripotent stem cells take to form bone tissue 
was first elucidated using murine ESCs. Buttery and coworkers were the first to show that 
mESCs maintained in medium supplemented with beta-glycerophosphate and ascorbic acid 
had mineralized in culture, a hallmark feature of bone tissue formation (Buttery et al., 2001). 
In the past decade, numerous protocols have then been established that allow ESC 
differentiation into bone and cartilage and their characteristic cell types, the osteoblasts and 
osteoclasts as well as the chondocytes. The studies that describe formation of osteoblasts 
typically all assess the ability of the cells to secrete an organic matrix composed of collagen 
type I (COL I) and proteoglycans, the deposition of inorganic hydroxyapatite and the 
expression of osteoblast-specific genes (Davis et al., 2011; Handschel et al., 2008; Shimko et 
al., 2004).  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
326 
One difference between these protocols however, is the choice of additional osteogenic 
inducers. While beta-glycerophosphate and ascorbic acid are absolutely necessary for the 
cells to calcify, the additional supplementation of either dexamethasone, retinoic acid or 
1,25alpha (OH)2 vitamin D3 (VD3) each can significantly increase the amount of bone 
nodules and expression of osteogenic markers in both mouse and human ESC cultures 
(Buttery et al., 2001; Phillips et al., 2001; Sottile et al., 2003; zur Nieden et al., 2003).  
Similar to endochondral bone formation in the embryo, osteogenesis from ESCs in vitro can 
be direct or the future bone can at first undergo a chondrocyte phase. Both processes have 
been described for ESCs. For example, during ESC in vitro intramembranous ossification, 
osteoblasts would be specified through a mesenchymal precursor and then directly into the 
osteoblastic fate. In this case, markers for hypertrophic chondrocytes should be absent or 
should only be minimally expressed. In turn, ESC differentiation would model embryonal 
endochondral ossification when ESCs would first differentiate into chondrocytes, then 
undergo hypertrophy and give way to osteoprogenitors that calcify. Hegert and colleagues, 
supported by data from our group, have shown that chondrogenic ESC cultures indeed can 
be manipulated to calcify, whereby such ossification results in a lower calcium content of 
the matrix then the direct (non chondrocyte-mediated) differentiation (Hegert et al., 2002; 
zur Nieden et al., 2005). This direct chondrocytic differentiation is mediated by growth 
factors of the transforming growth factor family, including bone morphogenic proteins and 
TGF1 (Kramer et al., 2000; Hegert et al.,  2002; zur Nieden et al., 2005; Toh et al., 2007). 
Under such treatment the cartilage-specific transcription factors Sox9 and scleraxis are up-
regulated at early stages of differentiation (Kramer et al., 2002, 2005; zur Nieden et al., 2005). 
The addition of BMP also increased the formation of cartilaginous matrix, comprised of 
collagen, proteoglycans and ECM proteins and expression of collagen mRNAs found in 
cartilage, such as collagen type II and collagen type X, the latter being indicative of 
chondrocytes undergoing hypertrophy (Kielty et al., 1985). ESC cultures containing such 
hypertrophic chondrocytes also initiate expression of osteoblast-specific mRNAs. This 
overlap of the chondrocyte-specific and the osteoblast- specific differentiation program 
suggest that ESCs may be undergoing the endochondral bone formation process.  
In addition to growth factors and chemicals that direct differentiation through the 
endochondral or intramembranous route, different physical means have also been utilized to 
induce ESC differentiation into bone. While murine ESCs are typically grown into small (i.e. 
approximately 300-400 µm) agglomerates of differentiating cells called embryoid bodies (EBs) 
(Trettner et al., 2011), as the first stage of differentiation, human ESCs can alternatively be 
induced to differentiate by overgrowing colonies on a plate (Karp et al., 2006). Further 
osteogenic differentiation can be observed when intact EBs or dissociated EB cells are cultured 
in the presence of osteogenic supplements (Buttery et al., 2001; Cao et al., 2005; Chaudhry et 
al., 2004; zur Nieden et al., 2003). Woll and coworkers trypsinized mouse EBs into single cell 
suspensions and plated those at very low clonal density (Woll et al., 2006). They reported that 
approximately 60-80% of single-cell derived colony formation exhibited matrix mineralization 
as determined by von Kossa staining. Further qPCR analysis of osteoblast markers supported 
the potential of these cells to undergo osteogenesis, although there was heterogeneity between 
colonies in expression of these specific markers. Despite this heterogeneity between these 
individual colonies, the clonal expansion from a single cell offers an easy approach to dissect 
the differentiation pathway leading to bone cell formation. 
This seems to be of particular importance as ESCs can be lead to differentiate from 
pluripotency into mesenchyme and subsequently bone, whereby mesenchyme may be 
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specified either from a mesodermal or neural crest derived origin. More recent studies have 
indeed reported the generation of mesenchymal stem cell like cells from ESCs as well as the 
isolation of progenitors with osteogenic properties that were mesoderm or neural crest 
derived (Aihara et al., 2010; Olivier et al., 2006; Sakurai et al., 2006; Trivedi and Hematti, 
2007).  
A few days into the differentiation, ESCs will express T-Brachyury, a gene that is typically 
transcribed in the primitive streak when the early embryo undergoes gastrulation to 
establish the three germ layers (Beddington et al., 1992). The primitive streak contains cells 
with mesendodermal character, a subpopulation of cells that can later become osteoblasts. 
T-Brachyury expression is often used to characterize the output of differentiating 
mesendoderm (Gadue et al., 2006; Nakanishi et al., 2009) and is thus also informative to the 
very early differentiation events of osteogenesis. Similarly, modeled after the early lineage 
decisions in vivo, activin and nodal induction may be used to enhance the percentage of 
mesendodermal cells positive for Goosecoid (Gsc), E-cadherin, and platelet-derived growth 
factor receptor alpha (PDGFR) (Tada et al., 2005), which are a combination of markers 
expressed by organizer cells in the primitive streak region. During subsequent development, 
this triple-positive cell population diverges to Gsc+ and either E-cadherin or PDGFR 
positive intermediates that later differentiate into definitive endoderm and mesodermal 
lineages, including calcified osteopontin expressing osteoblasts (Tada et al., 2005). 
While the mesendodermal progenitors are being established in the process of gastrulation in 
vivo, neurulation has already initiated in the anterior part of the embryo. Therefore, 
specification of neural crest populations may occur in vitro during ESC differentiation at 
around the same time or slightly after T-Brachyury+ or Gsc+ populations are found. In the 
embryo, neural crest cells emerge from the dorsal epithelium of the neural tube after it has 
formed, undergo epithelial-to-mesenchymal transitions and become highly migratory.  
These cells later disperse to and incorporate within skin tissue (i.e. melanocytes) as well as 
neurons and glia in the peripheral nervous system (Chung et al., 2009; Dupin et al., 2007; 
Weston, 1991). Due to the multitude of cell types that arise from the highly specific 
population of neural crest cells, it is sometimes regarded as the fourth germ layer.  In 
addition, the neural crest is generally considered to be the source of a population of cells 
deemed the ectomesenchyme, which produces a variety of mesenchymal tissues including 
craniofacial cartilage and bone (Morrisskay et al., 1993; Smith and Hall, 1990). More recently 
however, the view that mesenchymal cell types are established from progenitor populations 
of neural crest origin was challenged by Weston and colleagues, who suggest that neural 
crest and ectomesenchyme are developmentally distinct progenitor populations, possibly 
distinguishable by the expression of E-cadherin and PDGFR (Weston et al., 2004). 
While it seems widely established that ESCs have the capacity to differentiate into 
osteoblasts from these various origins, other questions related to the feasibility of their 
clinical use are still under investigation. As pluripotent cells, ESCs are particularly attractive 
for the treatment of critical size bone defects that require large numbers of cells as an 
illimitable source of progenitors, be it mesoderm or neural crest derived MSCs or even more 
committed osteoprogenitors. More recently, a new less ethically controversial source of 
pluripotent cells has been discovered in the artificial creation of induced pluripotent stem 
cells (iPSCs). In this method mature, fully differentiated cells are reprogrammed to a 
pluripotent state. Explicitly, pluripotency-associated genes are shuttled into somatic cells, 
e.g. fibroblasts or keratinocytes (Aasen et al., 2008; Okita et al., 2007; Takahashi and 
Yamanaka, 2006), and brought to expression before they are silenced, which is just enough 
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vivo, neurulation has already initiated in the anterior part of the embryo. Therefore, 
specification of neural crest populations may occur in vitro during ESC differentiation at 
around the same time or slightly after T-Brachyury+ or Gsc+ populations are found. In the 
embryo, neural crest cells emerge from the dorsal epithelium of the neural tube after it has 
formed, undergo epithelial-to-mesenchymal transitions and become highly migratory.  
These cells later disperse to and incorporate within skin tissue (i.e. melanocytes) as well as 
neurons and glia in the peripheral nervous system (Chung et al., 2009; Dupin et al., 2007; 
Weston, 1991). Due to the multitude of cell types that arise from the highly specific 
population of neural crest cells, it is sometimes regarded as the fourth germ layer.  In 
addition, the neural crest is generally considered to be the source of a population of cells 
deemed the ectomesenchyme, which produces a variety of mesenchymal tissues including 
craniofacial cartilage and bone (Morrisskay et al., 1993; Smith and Hall, 1990). More recently 
however, the view that mesenchymal cell types are established from progenitor populations 
of neural crest origin was challenged by Weston and colleagues, who suggest that neural 
crest and ectomesenchyme are developmentally distinct progenitor populations, possibly 
distinguishable by the expression of E-cadherin and PDGFR (Weston et al., 2004). 
While it seems widely established that ESCs have the capacity to differentiate into 
osteoblasts from these various origins, other questions related to the feasibility of their 
clinical use are still under investigation. As pluripotent cells, ESCs are particularly attractive 
for the treatment of critical size bone defects that require large numbers of cells as an 
illimitable source of progenitors, be it mesoderm or neural crest derived MSCs or even more 
committed osteoprogenitors. More recently, a new less ethically controversial source of 
pluripotent cells has been discovered in the artificial creation of induced pluripotent stem 
cells (iPSCs). In this method mature, fully differentiated cells are reprogrammed to a 
pluripotent state. Explicitly, pluripotency-associated genes are shuttled into somatic cells, 
e.g. fibroblasts or keratinocytes (Aasen et al., 2008; Okita et al., 2007; Takahashi and 
Yamanaka, 2006), and brought to expression before they are silenced, which is just enough 
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to turn the differentiated cells into ESC-like cells with a pluripotent pheno- and genotype. 
Only five years after their discovery, iPSCs have been recently exploited to study 
osteogenesis and have already been shown to possess comparable differentiation capacity 
(Bilousova et al., 2011). 
3. Bone tissue engineering 
The current gold standard for bone tissue replacement is the autologous graft, which utilizes 
bone tissue that has been extracted from another site within the patient’s own body. 
However, there is only a limited amount of bone tissue that can feasibly be harvested 
without inducing considerable donor site morbidity (Rose and Oreffo, 2002). On the other 
hand, surgical procedures using an allograft, where the bone is harvested from a cadaver, 
can provide enough material to correct large-scale bone defects. However, this approach 
carries its own disadvantages including potential immunorejection and pathogen 
transmission.  Techniques involving synthetic materials such as metals and ceramics are 
continually being used and explored as alternatives to these approaches, but these 
substitutes continually fall short of bone grafts in areas such as host site integration and 
tensile strength (Rezwan et al., 2006; Yaszemski et al., 1996). Thus, the attractive features and 
potential versatility of stem cells offers the investigator an exciting source to improve and 
develop new technologies that may significantly enhance the efficacy of these procedures.  
Currently a popular approach in applying stem cells to de novo bone synthesis is the in vitro 
culturing or ‘seeding’ of cells onto scaffolding materials that can be used for subsequent 
implantation. In order for this approach to be successful there are a number of essential 
properties that a researcher must keep in mind when designing the appropriate scaffolding 
material. These properties will have a direct effect on both the colonization of the scaffold 
and its successful incorporation into host bone tissue. To achieve an optimal scaffold design 
a number of considerations such as biocompatibility, porosity, pore size, osteoinductivity 
and conductivity (including biomolecule incorporation), biodegradability, and mechanical 
properties must be accounted for (Salgado et al., 2004). Thus, reaching this goal will be a 
challenge that requires the coordinated efforts of researches across the diverse disciplines of 
material and biological sciences. 
3.1 Mesenchymal stem cells in bone tissue engineering 
Beyond the type of scaffold used in a particular study, the choice of seeded cell type will 
also play a critical role in the creation of de novo bone tissue. Starting with the most 
differentiated cell type, seeding a scaffold with harvested autologous osteoblasts 
superficially seems attractive because of their inherent cellular program to develop new 
bone. However, using this cell type is problematic because of low initial concentrations 
following harvest and relatively poor proliferation capacity in vitro. Also, if these treatments 
are designed to not only amend bone defects, but also to alleviate bone disorders, it is 
unlikely that harvested osteoblasts will have the suitable characteristics to be effective. 
Another possible cell type is the multipotent adult mesenchymal stem cell.   
Mesenchymal stem cells (MSCs) are unspecialized adult stem cells that reside in mature 
somatic tissues, predominantly the bone marrow in the long bones. There they share the 
niche with hematopoietic stem cells, but differ from them in the array of specialized 
daughter cells that they can generate. MSCs were first described forty five years ago by 
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Friedenstein and colleagues, when they first found this heterogeneity in differentiation 
capacity between cells isolated from bone marrow. While they described the cells as ossific 
progenitor cells of stromal origin in rats in this first study, subsequent studies proved the 
multilineage differentiation potential of these cells into fibroblasts, chondrocytes and other 
cells of connective tissue coining the term mesenchymal stem cell (Friedenstein et al., 1966, 
1976, 1987; Tondreau et al., 2004a, b; Johnstone et al., 1998; Young et al., 1998; Niemeyer et 
al., 2004).  
Despite the fact that the scientific community has long exploited MSCs to understand the 
processes of osteogenic and chondrogenic differentiation as well as for the study of adult 
stem cell maintenance (Bruder et al., 1990; Gazit et al., 1993; Grayson et al., 2006; Hong and 
Yaffe, 2006), the isolation of the non-hematopoietic mesenchymal stem cell from bone 
marrow or other tissue sources remains complex. Initially, Friedenstein isolated the MSCs 
by their tight adherence to plastic (Friedenstein et al. 1976). Yet, newer studies suggest that 
by isolating MSCs based on their plastic adherence, a portion of mesenchymal stem cells are 
lost (Zhang et al. 2009). Unfortunately, the fibroblast-like MSCs show a variable profile of 
surface marker expression (Simmons und Torok-Storb, 1991; Jiang et al. 2002; Vogel et al. 
2003), which makes it difficult to isolate them based on a specific marker set. A few years 
ago, a group of investigators with extensive track records in MSC research has agreed on 
specific characteristics that need to be met by a cell in order to be called an MSC (Dominici 
et al., 2006, the International Society for Cellular Therapy position statement). For example, 
CD14, CD34 or CD45 mark hematopoietic cells and are therefore considered negative 
markers for MSCs. The most commonly used markers for the detection and purification of 
MSCs are CD90 (Thy-1 cell surface antigen), CD105 (endoglin) and CD73 (ecto-5’-
nucleotidase) (Pittenger et al., 1999; Dominici et al., 2006). Both CD105 and CD73 are 
constitutively expressed by MSCs, however are also expressed by endothelial cells (Gougos 
und Letarte, 1988; Airas et al., 1995). Therefore, a combinatorial approach using CD106 
(vascular cell adhesion molecule 1) is also recommended in the literature to identify MSCs, 
as CD106 is only expressed on the MSC surface, but not on endothelial cells (Pittenger et al., 
1999; Osborn et al., 1989). Stro1 (Stenderup et al., 2001), glycophorin A (Pittenger et al., 1999; 
Reyes et al., 2001; Jones et al., 2006), D7-fib (Jones et al., 2002) and p75 (Quirici et al., 2002) 
have also been associated with MSCs recently, but are not contained in the International 
Society for Cellular Therapy position statement.  
Currently, the use of bone marrow derived mesenchymal stem cells (BDMSCs) to study 
bone tissue generation is popular because these can be harvested from the patient’s own 
body, thereby removing concerns of immunorejection and disease transmission. Because the 
transition of BDMSC studies to clinical applications is currently more direct, and not 
enveloped in ethical considerations, there have been many studies looking at the 
differentiation capacity of BDMSCs in vivo (Arinzeh et al., 2003; Bruder et al., 1998; Gao et 
al., 2001; Kotobuki et al., 2008). BDMSCs are already used in preclinical trials for treatment 
of osteogenesis imperfecta and non-union bone fractures (Le Blanc et al., 2005; Tuch, 2006). 
However, this does not exclude the necessity to examine ESCs as a potential source of bone 
engineered cells. In fact, improvements in the techniques of somatic nuclear transfer (Byrne 
et al., 2007) and creating iPSCs (Nakagawa et al., 2008; Yu et al., 2007), make it quite 
plausible that the protocols derived from the study of ESCs may someday become more 
applicable to the future of regenerative medicine than their adult stem cell counterparts. In 
addition, there are drawbacks from using BDMSCs, including the limited number that can 
be obtained, more restricted proliferation and differentiation capacities when compared to 
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to turn the differentiated cells into ESC-like cells with a pluripotent pheno- and genotype. 
Only five years after their discovery, iPSCs have been recently exploited to study 
osteogenesis and have already been shown to possess comparable differentiation capacity 
(Bilousova et al., 2011). 
3. Bone tissue engineering 
The current gold standard for bone tissue replacement is the autologous graft, which utilizes 
bone tissue that has been extracted from another site within the patient’s own body. 
However, there is only a limited amount of bone tissue that can feasibly be harvested 
without inducing considerable donor site morbidity (Rose and Oreffo, 2002). On the other 
hand, surgical procedures using an allograft, where the bone is harvested from a cadaver, 
can provide enough material to correct large-scale bone defects. However, this approach 
carries its own disadvantages including potential immunorejection and pathogen 
transmission.  Techniques involving synthetic materials such as metals and ceramics are 
continually being used and explored as alternatives to these approaches, but these 
substitutes continually fall short of bone grafts in areas such as host site integration and 
tensile strength (Rezwan et al., 2006; Yaszemski et al., 1996). Thus, the attractive features and 
potential versatility of stem cells offers the investigator an exciting source to improve and 
develop new technologies that may significantly enhance the efficacy of these procedures.  
Currently a popular approach in applying stem cells to de novo bone synthesis is the in vitro 
culturing or ‘seeding’ of cells onto scaffolding materials that can be used for subsequent 
implantation. In order for this approach to be successful there are a number of essential 
properties that a researcher must keep in mind when designing the appropriate scaffolding 
material. These properties will have a direct effect on both the colonization of the scaffold 
and its successful incorporation into host bone tissue. To achieve an optimal scaffold design 
a number of considerations such as biocompatibility, porosity, pore size, osteoinductivity 
and conductivity (including biomolecule incorporation), biodegradability, and mechanical 
properties must be accounted for (Salgado et al., 2004). Thus, reaching this goal will be a 
challenge that requires the coordinated efforts of researches across the diverse disciplines of 
material and biological sciences. 
3.1 Mesenchymal stem cells in bone tissue engineering 
Beyond the type of scaffold used in a particular study, the choice of seeded cell type will 
also play a critical role in the creation of de novo bone tissue. Starting with the most 
differentiated cell type, seeding a scaffold with harvested autologous osteoblasts 
superficially seems attractive because of their inherent cellular program to develop new 
bone. However, using this cell type is problematic because of low initial concentrations 
following harvest and relatively poor proliferation capacity in vitro. Also, if these treatments 
are designed to not only amend bone defects, but also to alleviate bone disorders, it is 
unlikely that harvested osteoblasts will have the suitable characteristics to be effective. 
Another possible cell type is the multipotent adult mesenchymal stem cell.   
Mesenchymal stem cells (MSCs) are unspecialized adult stem cells that reside in mature 
somatic tissues, predominantly the bone marrow in the long bones. There they share the 
niche with hematopoietic stem cells, but differ from them in the array of specialized 
daughter cells that they can generate. MSCs were first described forty five years ago by 
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Friedenstein and colleagues, when they first found this heterogeneity in differentiation 
capacity between cells isolated from bone marrow. While they described the cells as ossific 
progenitor cells of stromal origin in rats in this first study, subsequent studies proved the 
multilineage differentiation potential of these cells into fibroblasts, chondrocytes and other 
cells of connective tissue coining the term mesenchymal stem cell (Friedenstein et al., 1966, 
1976, 1987; Tondreau et al., 2004a, b; Johnstone et al., 1998; Young et al., 1998; Niemeyer et 
al., 2004).  
Despite the fact that the scientific community has long exploited MSCs to understand the 
processes of osteogenic and chondrogenic differentiation as well as for the study of adult 
stem cell maintenance (Bruder et al., 1990; Gazit et al., 1993; Grayson et al., 2006; Hong and 
Yaffe, 2006), the isolation of the non-hematopoietic mesenchymal stem cell from bone 
marrow or other tissue sources remains complex. Initially, Friedenstein isolated the MSCs 
by their tight adherence to plastic (Friedenstein et al. 1976). Yet, newer studies suggest that 
by isolating MSCs based on their plastic adherence, a portion of mesenchymal stem cells are 
lost (Zhang et al. 2009). Unfortunately, the fibroblast-like MSCs show a variable profile of 
surface marker expression (Simmons und Torok-Storb, 1991; Jiang et al. 2002; Vogel et al. 
2003), which makes it difficult to isolate them based on a specific marker set. A few years 
ago, a group of investigators with extensive track records in MSC research has agreed on 
specific characteristics that need to be met by a cell in order to be called an MSC (Dominici 
et al., 2006, the International Society for Cellular Therapy position statement). For example, 
CD14, CD34 or CD45 mark hematopoietic cells and are therefore considered negative 
markers for MSCs. The most commonly used markers for the detection and purification of 
MSCs are CD90 (Thy-1 cell surface antigen), CD105 (endoglin) and CD73 (ecto-5’-
nucleotidase) (Pittenger et al., 1999; Dominici et al., 2006). Both CD105 and CD73 are 
constitutively expressed by MSCs, however are also expressed by endothelial cells (Gougos 
und Letarte, 1988; Airas et al., 1995). Therefore, a combinatorial approach using CD106 
(vascular cell adhesion molecule 1) is also recommended in the literature to identify MSCs, 
as CD106 is only expressed on the MSC surface, but not on endothelial cells (Pittenger et al., 
1999; Osborn et al., 1989). Stro1 (Stenderup et al., 2001), glycophorin A (Pittenger et al., 1999; 
Reyes et al., 2001; Jones et al., 2006), D7-fib (Jones et al., 2002) and p75 (Quirici et al., 2002) 
have also been associated with MSCs recently, but are not contained in the International 
Society for Cellular Therapy position statement.  
Currently, the use of bone marrow derived mesenchymal stem cells (BDMSCs) to study 
bone tissue generation is popular because these can be harvested from the patient’s own 
body, thereby removing concerns of immunorejection and disease transmission. Because the 
transition of BDMSC studies to clinical applications is currently more direct, and not 
enveloped in ethical considerations, there have been many studies looking at the 
differentiation capacity of BDMSCs in vivo (Arinzeh et al., 2003; Bruder et al., 1998; Gao et 
al., 2001; Kotobuki et al., 2008). BDMSCs are already used in preclinical trials for treatment 
of osteogenesis imperfecta and non-union bone fractures (Le Blanc et al., 2005; Tuch, 2006). 
However, this does not exclude the necessity to examine ESCs as a potential source of bone 
engineered cells. In fact, improvements in the techniques of somatic nuclear transfer (Byrne 
et al., 2007) and creating iPSCs (Nakagawa et al., 2008; Yu et al., 2007), make it quite 
plausible that the protocols derived from the study of ESCs may someday become more 
applicable to the future of regenerative medicine than their adult stem cell counterparts. In 
addition, there are drawbacks from using BDMSCs, including the limited number that can 
be obtained, more restricted proliferation and differentiation capacities when compared to 
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ESCs, and they may also harbor undesirable characteristics when harvested from unhealthy 
bone. So although the use of MSCs has progressed further in clinical applications of bone 
tissue engineering, the examination of ESCs as a potential source for repairing bone defects 
and disorders still merits a great deal of attention. 
3.2 Embryonic stem cells for bone tissue engineering 
Since Levenberg and colleagues (2003) demonstrated the potential to create complex tissue 
structures on 3D scaffolds using differentiating human ESCs, a number of investigations 
sought to refine and optimize the conditions required to engineer specific tissue types 
within 3D scaffolds. In 2004, Chaudhry and colleagues (2004) were the first to demonstrate 
the feasibility of inducing mineralization of murine ESC derived cells within 3D poly L-
lactic acid (PLLA) scaffolds. To accomplish this goal the team initially differentiated murine 
ESCs into osteoblast progenitor cells in 2D culture. EBs were initially formed, which were 
then subsequently transferred into suspension dishes for 3 days in the presence of retinoic 
acid, and then were grown in the presence of -glycerophosphate and ascorbic acid. EBs 
were trypsinized and seeded onto PLLA scaffolds. After four weeks of subsequent culture in 
osteogenic media, the scaffolds showed extensive bone nodule formation on the surface of 
the scaffold and evidence of cell invasion/mineralization with the interior, as demonstrated 
by electron microscopy and von Kossa staining. Molecular characterization of the cells that 
had colonized the scaffold also revealed expression of the osteoblast specific markers 
osteocalcin, osteopontin and alkaline phosphatase (Alk Phos).  
When discussing synthetic scaffolds for tissue engineering it is important to realize that not 
only the composition of the material itself is important, but that the nano-scale architecture 
can also play a critical role in the successful colonization of the material.  Smith and colleagues 
(2009) developed a fabrication method of producing a nanofibrous PLLA scaffold in an 
attempt to mimic a collagen matrix. These were compared to traditional ‘solid-walled’ PLLA 
scaffolds in both 2D and 3D osteogenic culture systems. It was found that the 3D nanofibrous 
matrices expedited differentiation of mouse ESCs as revealed by markers runx2, an osteoblast-
specific transcription factor (5 times greater), bone sialoprotein (8.5 times greater) and 
osteocalcin (2.9 times greater). These scaffolds were also found to contain greater amounts of 
COL I (5.5 times) and calcium (3 times) when cultured for 28 days. Another point of interest 
from this study showed that the nanofibrous scaffold, unlike all the other materials tested, was 
also able to support osteogenesis without the addition of osteogenic supplements. Although, 
the osteogenic output was not as robust as when cultured with media supplemented with 
ascorbic acid, -glycerophosphate, and dexamethasone. Thus, it appears that the nano-scaled 
architecture of these scaffolds mimics the endogenous ECM. 
These differences in geometry presumably create a more appropriate spatial context to 
facilitate cell-cell interactions and communication for bone tissue development. In addition, 
it was previously found  that this nanofibrous scaffold absorbed four times the amount of 
serum proteins than their traditional solid walled counterparts (Woo et al., 2003). Thus, the 
ability of this nano-scaled architecture to both improve the spatial arrangement of cells and 
to absorb more growth factors, demonstrates how attention to microscopic manufacturing of 
materials can greatly enhance the potential and success of these scaffolds.   
The availability of a blood supply, especially to large bone grafts, is critical for engineered 
tissue transplant efficacy. The creation of a flap for transplantation is one surgical approach 
to address this issue. A flap is tissue that already has a vasculature system in place to 
support nutrient and gas exchange. Although not explored in ESC-derived grafts, studies 
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performed with BDMSCs demonstrate the feasibility of this approach. Warnke and 
colleagues performed an interesting clinical demonstration of this technique in 2004. Here, a 
seeded scaffold intended to repair a large resection of the patient’s mandible was first 
implanted within the patient’s latissimus dorsi muscle. This in vivo incubation period 
allowed time for the graft, a titanium mesh cage filled with hydroxyapatite blocks coated 
with recombinant human BMP7, to develop vasculature. The graft was initially seeded with 
solution containing autologous bone and natural bovine bone-mineral extract. After seven 
weeks the implant was removed along with the muscle tissue containing the thoracodorsal 
artery and vein, which had provided the circulation to the implant, and was transplanted 
into the patient’s jaw. Bone mineral density was measured using non-invasive 3D 
chromatography and revealed continuous improvement for the duration of 38 weeks 
(Warnke et al., 2004). Due to ethical considerations, a biopsy of the implant was not 
undertaken. However, mineralized scar tissue in areas of implant overgrowth was 
histologically examined and showed young cancellous bone formation containing viable 
osteoblasts and osteocytes. The patient’s continual smoking and alcohol abuse compromised 
the initial favorable prognosis of the treatment, and unfortunately the patient had passed 
away 15 months following the operation (Warnke et al., 2006). Also due to the nature of the 
procedure, which precluded the use of control implants, statistical analyses were not 
performed. However this study provides at least an initial demonstration of principle within 
a human subject, and may eventually serve as a model to vascularize engineered bone tissue 
in vivo.   
To examine the differences in the in vivo osteogenic capacity of between BDMSCs and ESCs, 
Tremoleda and colleagues (2008) implanted chambers that were cell-impermeable. These 
chambers contained either BDMSCs or ESCs that had been cultured in vitro for 4 days in 
standard osteogenic media. Since the pore size of these chambers precluded the passage of 
cells but allowed the diffusion of growth factors and other macromolecules, comparison of 
the intrinsic capacity for differentiation of these cell types became more straightforward. 
After 79 days post-implantation within nude mice, the authors reported no qualitative 
differences between the bone tissue formation between the BDMSCs, H7, and H9 embryonic 
stem cells. Although an interesting finding revealed that the ESC lines used did not require 
the in vitro osteogenic culture prior to implantation to form de novo bone tissue, which was 
unlike the BDMSCs, which required this pretreatment. Thus, although a significant 
difference between these cell types with the same osteogenic treatment was not uncovered 
in this study, the fact that ESCs required less coaxing and were more primed to respond to 
the bone tissue environment may be capitalized upon in future studies. 
However, one of the major concerns when using ESCs for reparative medicine is the 
potential for residual undifferentiated cells to form teratomas following in vivo introduction. 
As such, undifferentiated murine ESCs form teratomas when injected into a healthy knee 
joint (Wakitani et al., 2003). The rate at which the teratomas grew in the knee joint however 
was slower than upon subcutaneous injection, suggesting that the microenvironment in the 
knee joint is not as favorable for ESC proliferation as for example a subcutaneous injection 
site. Surprisingly, if cells were injected into an inflammatory environment caused by a full-
thickness osteochondral defect, the cells integrated and repaired the defect even in an 
allogenic setting (Wakitani et al., 2004).  
Also, our group was recently able to show that ESCs lose their teratoma formation capacity 
with progressing osteogenic differentiation and maturation in vitro, whereby the in vitro 
microenvironment used to steer differentiation influences their teratoma formation capacity 
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ESCs, and they may also harbor undesirable characteristics when harvested from unhealthy 
bone. So although the use of MSCs has progressed further in clinical applications of bone 
tissue engineering, the examination of ESCs as a potential source for repairing bone defects 
and disorders still merits a great deal of attention. 
3.2 Embryonic stem cells for bone tissue engineering 
Since Levenberg and colleagues (2003) demonstrated the potential to create complex tissue 
structures on 3D scaffolds using differentiating human ESCs, a number of investigations 
sought to refine and optimize the conditions required to engineer specific tissue types 
within 3D scaffolds. In 2004, Chaudhry and colleagues (2004) were the first to demonstrate 
the feasibility of inducing mineralization of murine ESC derived cells within 3D poly L-
lactic acid (PLLA) scaffolds. To accomplish this goal the team initially differentiated murine 
ESCs into osteoblast progenitor cells in 2D culture. EBs were initially formed, which were 
then subsequently transferred into suspension dishes for 3 days in the presence of retinoic 
acid, and then were grown in the presence of -glycerophosphate and ascorbic acid. EBs 
were trypsinized and seeded onto PLLA scaffolds. After four weeks of subsequent culture in 
osteogenic media, the scaffolds showed extensive bone nodule formation on the surface of 
the scaffold and evidence of cell invasion/mineralization with the interior, as demonstrated 
by electron microscopy and von Kossa staining. Molecular characterization of the cells that 
had colonized the scaffold also revealed expression of the osteoblast specific markers 
osteocalcin, osteopontin and alkaline phosphatase (Alk Phos).  
When discussing synthetic scaffolds for tissue engineering it is important to realize that not 
only the composition of the material itself is important, but that the nano-scale architecture 
can also play a critical role in the successful colonization of the material.  Smith and colleagues 
(2009) developed a fabrication method of producing a nanofibrous PLLA scaffold in an 
attempt to mimic a collagen matrix. These were compared to traditional ‘solid-walled’ PLLA 
scaffolds in both 2D and 3D osteogenic culture systems. It was found that the 3D nanofibrous 
matrices expedited differentiation of mouse ESCs as revealed by markers runx2, an osteoblast-
specific transcription factor (5 times greater), bone sialoprotein (8.5 times greater) and 
osteocalcin (2.9 times greater). These scaffolds were also found to contain greater amounts of 
COL I (5.5 times) and calcium (3 times) when cultured for 28 days. Another point of interest 
from this study showed that the nanofibrous scaffold, unlike all the other materials tested, was 
also able to support osteogenesis without the addition of osteogenic supplements. Although, 
the osteogenic output was not as robust as when cultured with media supplemented with 
ascorbic acid, -glycerophosphate, and dexamethasone. Thus, it appears that the nano-scaled 
architecture of these scaffolds mimics the endogenous ECM. 
These differences in geometry presumably create a more appropriate spatial context to 
facilitate cell-cell interactions and communication for bone tissue development. In addition, 
it was previously found  that this nanofibrous scaffold absorbed four times the amount of 
serum proteins than their traditional solid walled counterparts (Woo et al., 2003). Thus, the 
ability of this nano-scaled architecture to both improve the spatial arrangement of cells and 
to absorb more growth factors, demonstrates how attention to microscopic manufacturing of 
materials can greatly enhance the potential and success of these scaffolds.   
The availability of a blood supply, especially to large bone grafts, is critical for engineered 
tissue transplant efficacy. The creation of a flap for transplantation is one surgical approach 
to address this issue. A flap is tissue that already has a vasculature system in place to 
support nutrient and gas exchange. Although not explored in ESC-derived grafts, studies 
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performed with BDMSCs demonstrate the feasibility of this approach. Warnke and 
colleagues performed an interesting clinical demonstration of this technique in 2004. Here, a 
seeded scaffold intended to repair a large resection of the patient’s mandible was first 
implanted within the patient’s latissimus dorsi muscle. This in vivo incubation period 
allowed time for the graft, a titanium mesh cage filled with hydroxyapatite blocks coated 
with recombinant human BMP7, to develop vasculature. The graft was initially seeded with 
solution containing autologous bone and natural bovine bone-mineral extract. After seven 
weeks the implant was removed along with the muscle tissue containing the thoracodorsal 
artery and vein, which had provided the circulation to the implant, and was transplanted 
into the patient’s jaw. Bone mineral density was measured using non-invasive 3D 
chromatography and revealed continuous improvement for the duration of 38 weeks 
(Warnke et al., 2004). Due to ethical considerations, a biopsy of the implant was not 
undertaken. However, mineralized scar tissue in areas of implant overgrowth was 
histologically examined and showed young cancellous bone formation containing viable 
osteoblasts and osteocytes. The patient’s continual smoking and alcohol abuse compromised 
the initial favorable prognosis of the treatment, and unfortunately the patient had passed 
away 15 months following the operation (Warnke et al., 2006). Also due to the nature of the 
procedure, which precluded the use of control implants, statistical analyses were not 
performed. However this study provides at least an initial demonstration of principle within 
a human subject, and may eventually serve as a model to vascularize engineered bone tissue 
in vivo.   
To examine the differences in the in vivo osteogenic capacity of between BDMSCs and ESCs, 
Tremoleda and colleagues (2008) implanted chambers that were cell-impermeable. These 
chambers contained either BDMSCs or ESCs that had been cultured in vitro for 4 days in 
standard osteogenic media. Since the pore size of these chambers precluded the passage of 
cells but allowed the diffusion of growth factors and other macromolecules, comparison of 
the intrinsic capacity for differentiation of these cell types became more straightforward. 
After 79 days post-implantation within nude mice, the authors reported no qualitative 
differences between the bone tissue formation between the BDMSCs, H7, and H9 embryonic 
stem cells. Although an interesting finding revealed that the ESC lines used did not require 
the in vitro osteogenic culture prior to implantation to form de novo bone tissue, which was 
unlike the BDMSCs, which required this pretreatment. Thus, although a significant 
difference between these cell types with the same osteogenic treatment was not uncovered 
in this study, the fact that ESCs required less coaxing and were more primed to respond to 
the bone tissue environment may be capitalized upon in future studies. 
However, one of the major concerns when using ESCs for reparative medicine is the 
potential for residual undifferentiated cells to form teratomas following in vivo introduction. 
As such, undifferentiated murine ESCs form teratomas when injected into a healthy knee 
joint (Wakitani et al., 2003). The rate at which the teratomas grew in the knee joint however 
was slower than upon subcutaneous injection, suggesting that the microenvironment in the 
knee joint is not as favorable for ESC proliferation as for example a subcutaneous injection 
site. Surprisingly, if cells were injected into an inflammatory environment caused by a full-
thickness osteochondral defect, the cells integrated and repaired the defect even in an 
allogenic setting (Wakitani et al., 2004).  
Also, our group was recently able to show that ESCs lose their teratoma formation capacity 
with progressing osteogenic differentiation and maturation in vitro, whereby the in vitro 
microenvironment used to steer differentiation influences their teratoma formation capacity 
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in vivo. Whereas spontaneously differentiated cells formed teratomas in 16% of the cases 
when taken from day 10 old cultures, 30-day osteogenic cultures did not show any sign of 
teratoma formation upon subcutaneous injection (Taiani et al., 2009).  
Highlighting the concern of teratoma formation further, Nakajima and colleagues (2008) 
seeded mouse ESCs embedded in a collagen matrix into osteochondral defects within the 
knee joints of mice. Their investigation focused on the differentiation potential of these cells 
when the joint was either free to move or physically immobilized. They revealed that the 
mechanical environment appears to have a dramatic effect on the differentiation outcome of 
these implanted cells. Three weeks post operation, the defects were examined and the free-
moving joints were shown to contain cartilaginous tissue formation with favorable 
histological characteristics. Surprisingly, when the joint was immobilized a teratoma formed 
in every instance of study. Thus, considering the close link between chondrogenesis and 
osteogenesis (to be discussed further in next section), it is important to note the results here 
and recognize that the mechanical environment into which undifferentiated stem cells are 
placed can have important consequences. 
3.3 ESC-derived MSCs 
Another cell type that has been recently gained attention as a possible therapeutic source is the 
embryonic stem cell-derived mesenchymal stem cell (ESC-MSC) in which ESCs are induced 
along the mesenchymal stem cell lineage. For a more detailed overview of the markers and 
techniques used to isolate such mesenchymal stem cell like cells from ESCs, the reader is 
referred to two recent reviews by Hematti (2011) and zur Nieden (2011). In one study of this 
cell type Barberi and colleagues (2005) demonstrated that cells initially differentiated along a 
paraxial mesoderm lineage were able to undergo osteogenesis in vitro. They found that this 
induced and sorted cell type (i.e. using the mesenchymal stem cell marker CD73) was able to 
undergo osteogenesis, by various staining assays and expression of bone specific markers. 
Similarly, Hu and colleagues derived human ESC-MSCs, and examined their capacity to 
differentiate into bone forming cells (Hu et al., 2010). When these cells were cultured in the 
presence of dexamethasone and BMP-7, they found that both Alk Phos levels and calcium 
deposition was statistically higher in dishes containing both supplements. This improvement 
found with both supplements was a synergistic one, as revealed through the modest effect 
when BMP-7 was used independently. When these cells were grown on 3D PLLA nanofibrous 
scaffolds, similar to that of Smith and colleagues (2009) discussed earlier, they exhibited 
growth throughout the scaffold and demonstrated extensive mineralization.   
The in vitro osteogenic capacity between isolated human MSCs and derived human ESC-
MSCs, was directly compared by de Peppo and others (2010). In this study they designated 
human ESC-MSCs as human embryonic stem cell-derived mesodermal progenitors hES-
MPs and used a similar approach to that of Hu et al. (2010) to derive this cell type (Karlsson 
et al., 2009). Here they demonstrated that in vitro culture of hES-MPs resulted in faster ECM 
mineralization as compared to human MSCs. These results were contrary to their Alk Phos 
assays, which showed significantly greater activity of Alk Phos in human MSCs at every 
point during the first five weeks of differentiation. This apparent discrepancy may reflect a 
differential dependence of Alk Phos to mineralize the ECM between these cell types. In 
addition, this study examined the osteogenic capacity of cells in relation to their passage 
number. In every assay performed the osteogenic capacity decreased as passage number 
increased for all cell types examined. Although they reported that the hES-MPs were more 
buffered against this diminishing capacity, it brings attention to the problem with serial 
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passages, which are inexorably tied to the requirements of tissue engineering, and their 
resulting potential to undergo osteogenesis.  
The apparent discrepancy in relative Alk Phos activity was also found by Bigdeli and others 
(2010) when they compared the osteogenic capacity of human MSCs and a derived human 
ESC line (Bigdeli et al., 2008), which could be expanded on culture plastic without the 
support of feeder layers or other dish coatings such as Matrigel. Utilizing this cell line 
allowed the investigators to perform more direct comparison of the two cell types, since the 
typical differences between culture conditions were eliminated. Like the aforementioned 
study (de Peppo et al., 2010), they found that although Alk Phos expression was 
significantly lower at each time point examined, the derived human ESC line was better able 
to mineralize the extracellular matrix when compared to human MSCs. These results were 
further supported by ion mass spectrometry of the mineralized ECM, which demonstrated 
the signature of natural hydroxyapatite.  
A study comparing osteogenesis of murine MSCs and murine ESCs derived from the same 
mouse strain (Shimko et al., 2004) also revealed this pattern where the mineral content was 
not directly correlated to Alk Phos activity. Thus, although Alk Phos activity is used 
frequently in studies of osteogenic differentiation, the level of enzyme activity may not 
directly correspond to the potential of the cells to mineralize the extracellular matrix. In 
addition, diverse Alk Phos levels may not necessarily suggest that more or less osteoblasts 
were formed, but may simply reflect different maturation kinetics of the different cell types.  
Shimko et. al, (2004) went further in characterizing the mineralized matrix between murine 
MSCs and murine ESCs derived from the same mouse strain and cultured in the same 
conditions. As compared to natural hydroxyapatite found in bone, where the ratio of 
calcium to phosphorous is: 1.67:1; murine ESCs exhibited a ratio far closer (1.26:1) than 
murine MSCs (0.29:1). Mouse ESC cultures also contained, on average, a mineral content 50 
times greater than mouse MSCs. However, once again reflecting distinct differentiation 
kinetics, pathways, or inherent differences in mineralization capacity, Alk Phos activity was 
significantly higher in MSCs throughout the course of the experiment. In addition, 
expression of osteocalcin and COL I in mouse ESCs was delayed relative to mouse MSCs. 
Thus, murine MSC differentiation appeared to be more reflective of natural osteogenesis, 
when examining organic matrix components and gene expression. On the other hand, the 
quantity and quality of the mineralization found in murine ESCs significantly surpassed 
what was exhibited by murine MSCs.   
Although transferring the techniques of osteogenic induction of ESCs from flat culture 
dishes towards 3D scaffolds have demonstrated initial success, there continues to be the 
need for method refinement in order for these approaches to bone engineering become 
widely accepted. One such area of study where current knowledge is lacking is an 
understanding of the possible differentiation pathways that are normally found in 
vertebrate development these cells take in attempts at bone tissue engineering. 
4. Different embryonic bone origins 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states, among them the osteoblast. 
Because of their capacity to differentiate into any cell type of the body, pluripotent stem cells 
may differentiate through the neural crest route or the mesodermal route, followed by 
mesenchymal specification. Similarly, ossification from pluripotent stem cells may occur 
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in vivo. Whereas spontaneously differentiated cells formed teratomas in 16% of the cases 
when taken from day 10 old cultures, 30-day osteogenic cultures did not show any sign of 
teratoma formation upon subcutaneous injection (Taiani et al., 2009).  
Highlighting the concern of teratoma formation further, Nakajima and colleagues (2008) 
seeded mouse ESCs embedded in a collagen matrix into osteochondral defects within the 
knee joints of mice. Their investigation focused on the differentiation potential of these cells 
when the joint was either free to move or physically immobilized. They revealed that the 
mechanical environment appears to have a dramatic effect on the differentiation outcome of 
these implanted cells. Three weeks post operation, the defects were examined and the free-
moving joints were shown to contain cartilaginous tissue formation with favorable 
histological characteristics. Surprisingly, when the joint was immobilized a teratoma formed 
in every instance of study. Thus, considering the close link between chondrogenesis and 
osteogenesis (to be discussed further in next section), it is important to note the results here 
and recognize that the mechanical environment into which undifferentiated stem cells are 
placed can have important consequences. 
3.3 ESC-derived MSCs 
Another cell type that has been recently gained attention as a possible therapeutic source is the 
embryonic stem cell-derived mesenchymal stem cell (ESC-MSC) in which ESCs are induced 
along the mesenchymal stem cell lineage. For a more detailed overview of the markers and 
techniques used to isolate such mesenchymal stem cell like cells from ESCs, the reader is 
referred to two recent reviews by Hematti (2011) and zur Nieden (2011). In one study of this 
cell type Barberi and colleagues (2005) demonstrated that cells initially differentiated along a 
paraxial mesoderm lineage were able to undergo osteogenesis in vitro. They found that this 
induced and sorted cell type (i.e. using the mesenchymal stem cell marker CD73) was able to 
undergo osteogenesis, by various staining assays and expression of bone specific markers. 
Similarly, Hu and colleagues derived human ESC-MSCs, and examined their capacity to 
differentiate into bone forming cells (Hu et al., 2010). When these cells were cultured in the 
presence of dexamethasone and BMP-7, they found that both Alk Phos levels and calcium 
deposition was statistically higher in dishes containing both supplements. This improvement 
found with both supplements was a synergistic one, as revealed through the modest effect 
when BMP-7 was used independently. When these cells were grown on 3D PLLA nanofibrous 
scaffolds, similar to that of Smith and colleagues (2009) discussed earlier, they exhibited 
growth throughout the scaffold and demonstrated extensive mineralization.   
The in vitro osteogenic capacity between isolated human MSCs and derived human ESC-
MSCs, was directly compared by de Peppo and others (2010). In this study they designated 
human ESC-MSCs as human embryonic stem cell-derived mesodermal progenitors hES-
MPs and used a similar approach to that of Hu et al. (2010) to derive this cell type (Karlsson 
et al., 2009). Here they demonstrated that in vitro culture of hES-MPs resulted in faster ECM 
mineralization as compared to human MSCs. These results were contrary to their Alk Phos 
assays, which showed significantly greater activity of Alk Phos in human MSCs at every 
point during the first five weeks of differentiation. This apparent discrepancy may reflect a 
differential dependence of Alk Phos to mineralize the ECM between these cell types. In 
addition, this study examined the osteogenic capacity of cells in relation to their passage 
number. In every assay performed the osteogenic capacity decreased as passage number 
increased for all cell types examined. Although they reported that the hES-MPs were more 
buffered against this diminishing capacity, it brings attention to the problem with serial 
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passages, which are inexorably tied to the requirements of tissue engineering, and their 
resulting potential to undergo osteogenesis.  
The apparent discrepancy in relative Alk Phos activity was also found by Bigdeli and others 
(2010) when they compared the osteogenic capacity of human MSCs and a derived human 
ESC line (Bigdeli et al., 2008), which could be expanded on culture plastic without the 
support of feeder layers or other dish coatings such as Matrigel. Utilizing this cell line 
allowed the investigators to perform more direct comparison of the two cell types, since the 
typical differences between culture conditions were eliminated. Like the aforementioned 
study (de Peppo et al., 2010), they found that although Alk Phos expression was 
significantly lower at each time point examined, the derived human ESC line was better able 
to mineralize the extracellular matrix when compared to human MSCs. These results were 
further supported by ion mass spectrometry of the mineralized ECM, which demonstrated 
the signature of natural hydroxyapatite.  
A study comparing osteogenesis of murine MSCs and murine ESCs derived from the same 
mouse strain (Shimko et al., 2004) also revealed this pattern where the mineral content was 
not directly correlated to Alk Phos activity. Thus, although Alk Phos activity is used 
frequently in studies of osteogenic differentiation, the level of enzyme activity may not 
directly correspond to the potential of the cells to mineralize the extracellular matrix. In 
addition, diverse Alk Phos levels may not necessarily suggest that more or less osteoblasts 
were formed, but may simply reflect different maturation kinetics of the different cell types.  
Shimko et. al, (2004) went further in characterizing the mineralized matrix between murine 
MSCs and murine ESCs derived from the same mouse strain and cultured in the same 
conditions. As compared to natural hydroxyapatite found in bone, where the ratio of 
calcium to phosphorous is: 1.67:1; murine ESCs exhibited a ratio far closer (1.26:1) than 
murine MSCs (0.29:1). Mouse ESC cultures also contained, on average, a mineral content 50 
times greater than mouse MSCs. However, once again reflecting distinct differentiation 
kinetics, pathways, or inherent differences in mineralization capacity, Alk Phos activity was 
significantly higher in MSCs throughout the course of the experiment. In addition, 
expression of osteocalcin and COL I in mouse ESCs was delayed relative to mouse MSCs. 
Thus, murine MSC differentiation appeared to be more reflective of natural osteogenesis, 
when examining organic matrix components and gene expression. On the other hand, the 
quantity and quality of the mineralization found in murine ESCs significantly surpassed 
what was exhibited by murine MSCs.   
Although transferring the techniques of osteogenic induction of ESCs from flat culture 
dishes towards 3D scaffolds have demonstrated initial success, there continues to be the 
need for method refinement in order for these approaches to bone engineering become 
widely accepted. One such area of study where current knowledge is lacking is an 
understanding of the possible differentiation pathways that are normally found in 
vertebrate development these cells take in attempts at bone tissue engineering. 
4. Different embryonic bone origins 
Both in vitro and in vivo studies continue to elucidate the developmental program that 
pluripotent stem cells take to their eventual differentiated states, among them the osteoblast. 
Because of their capacity to differentiate into any cell type of the body, pluripotent stem cells 
may differentiate through the neural crest route or the mesodermal route, followed by 
mesenchymal specification. Similarly, ossification from pluripotent stem cells may occur 
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through intramembranous bone formation or endochondral bone formation. In regard to the 
in vivo source of mesenchymal cells, which differentiate into bone in the appropriate 
developmental context, there also appears to be multiple developmental origins. The earliest 
MSCs appear to arise from Sox1+ neuroepithelium through a neural crest intermediate stage 
(Takashima et al., 2007) and not from mesoderm progenitors as previously believed.   
The process of fracture healing also occurs through both intramembranous and 
endochondral means, which is dependent on the mechanical conditions at the fractured site 
(Claes et al., 1998). When dissecting the steps of bone development, far more is known about 
the endochondral pathway than the intramembranous process. The most overt difference 
between these two pathways is that either chondrocytes will arise from mesenchymal 
condensations, which subsequently apoptose and are replaced by invading osteoblasts, or 
there is a direct differentiation into osteoblasts themselves. Thus the differential influence 
and the necessity of chondrocytes highlight the most apparent differences between these 
bone-forming pathways. Thus, in order to optimize bone tissue-engineering procedures 
there is a need to understand the molecular basis underlying different bone formation 
processes. However, a current review of the literature demonstrates large holes in our 
understanding of these multiple routes in which bone naturally forms and how they are 
recapitulated in experimental systems. The remaining part of this chapter will be devoted 
towards our preliminary understanding of these processes with particular emphasis to their 
roles in bone tissue engineering.  
4.1 Endochondral ossification 
In the endochondral process mesenchymal cells condense and differentiate into proliferating 
chondrocytes, which take on the general shape of the future bone. These chondrocytes 
eventually fall out of the cell cycle and these post-mitotic chondrocytes undergo 
hypertrophy. In this stage of development the mature hypertrophic chondrocytes lay down 
cartilage-specific proteins into the surrounding matrix. This cartilaginous framework 
provides molecular cues, which attracts invading vasculature along with osteoblasts, which 
will replace the cartilage intermediate. Osteogenesis occurs directly adjacent to hypertrophic 
chondrocytes. It appears that both the parathyroid hormone (PTH)-related peptide (PTHrP) 
and its receptor PPR are critical in the process osteogenesis via the endochondral pathway. 
In mice, upon disruption of the either PTHrP or PPR, the formation of ectopic hypertrophic 
chondrocytes is accompanied by ectopic bone collar formation (Karaplis et al., 1994). To 
determine if the hypertrophic chondrocytes induce osteogenesis in adjacent cells and is not a 
spatial/temporal coincidence, Chung and colleagues (2001) studied transgenic mice that 
express constitutively active PPR under the control of a chondrocyte specific promoter. This 
constitutive action resulted in suppression of hypertrophic chondrocyte formation and 
concurrent suppression of bone collar and primary spongiosa development. In addition, 
when these transgenic mice were mated to PTHrP-/- mice the resulting rescue of the ectopic 
bone formation, supported the conclusion that hypertrophic chondrocytes are responsible 
for the induction of osteogenesis in adjacent tissue. 
Regulation of the PTHrP/PPR signal appears to be controlled by one of the members of the 
hedgehog family of paracrine factors, Indian hedgehog (Ihh). Members of this signaling 
family are found throughout the animal kingdom and take on a number of critical roles in 
the developing organism. Here, Ihh is expressed by both prehypertrophic and hypertrophic 
chondrocytes. This signal mediates the expression of PTHrP by cells of the perichondrium, 
which in turn binds to PPR on chondrocytes. Ihh and PTHrP signaling thereby creates a 
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negative feedback loop which suppresses differentiation of the proliferating chondrocytes 
into hypertrophic ones (Lanske et al., 1996; Vortkamp et al., 1996). Thus, this balance of 
signals dictates the spatial positioning of the hypertrophic chondrocytes. However, the role 
of Ihh appears to have a broader impact on osteogenesis than its PTHrP-dependent 
regulation of chondrocyte maturation.  
St-Jacques and colleagues (1999) demonstrated that Ihh also plays a role in chondrocyte 
proliferation and the direct development of osteoblasts in endochondral bones. Previous 
studies have demonstrated a critical role of Wnt signaling and -catenin localization as well 
(Gong et al., 2001; Kato et al., 2002). Hu and others (2005) found nuclear -catenin 
localization within the cells of perichondrium indicating an upstream role of Ihh signaling 
to facilitate proper Wnt signaling. Furthermore, Ihh null mice do not exhibit osteocalcin 
expression within endochondral bones, whereas this expression is readily detected within 
the intramembranous bones of the skull and clavicle. This differential dependence of Ihh 
signaling underscores one of the differences between endochondral and intramembranous 
bone formation.   
When assessing the role of local synthesis of VD3 in transgenic mice that exhibited a 
chondrocyte-specific loss-of-function Cyp27b1, the enzyme that converts 25-hydroxyvitamin 
D3 into the active form VD3, it was found that the hypertrophic zone was expanded (Naja et 
al., 2009), thereby increasing both bone mass and trabecular size and number. The classical 
view that VD3 synthesis (active form) was restricted to the kidneys and that this hormone’s 
influence on bone tissue regulation was an indirect consequence of altering calcium and 
phosphate homeostasis had to be reevaluated. The authors suggest their results can be 
explained by a reduced osteoclast recruitment, which follows from a reported delay of 
vascularization that may be attributed to a reduction of VEGF found.  Conversely, 
overexpression of Cyp27b1 under a chondrocyte-specific promoter resulted in the opposite 
expression profile and phenotype. These results are in accordance with chondrocyte specific 
VD3 receptor ablation experiments, which showed impaired vascularization and osteoclast 
number in endochondral bone (Masuyama et al., 2006). As opposed to the traditional view of 
the role of VD3 in bone biology as an indirect mediator of mineral uptake, these experiments 
demonstrate a functional role of this metabolite in regulating endochondral bone formation. 
Some investigators have explored an approach to bone tissue-engineering by mimicking the 
development of mammalian long bones, where the creation of cartilage scaffolds in vitro are 
implanted in vivo. This approach hinges on the idea that the body will recognize this 
cartilage scaffold as an intermediate step in the endochondral bone formation process and 
will then proceed to ossify this construct. In the formation of endochondral bone, 
chondrocytes are exposed to very low oxygen levels and their survival is dependent on the 
expression of the transcription factor hypoxia-inducible factor-1 (For review see: Pfander 
and Gelse, 2007). Thus, the natural ability of chondrocytes to withstand the low oxygen 
supply can provide the time needed for new vasculature to develop and reach the core of 
the implant before widespread cell necrosis.  
Jukes et al. (2008) tested whether in vitro differentiation of ESCs along chondrocyte lineages 
on scaffolds could improve in vivo osteogenesis following implantation. ESCs were initially 
induced along a chondrogenic pathway for 21 days on ceramic scaffolds. These 
chondrogenically-primed scaffolds were then subsequently implanted in immunodeficient 
mice and were found to exhibit nascent bone tissue formation when examined 21 days post-
operatively. For comparison, primary chondrocytes and adult MSCs of human, goat, and 
bovine origin were used in lieu of the chondrocyte-induced ESCs. It was found that each cell 
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through intramembranous bone formation or endochondral bone formation. In regard to the 
in vivo source of mesenchymal cells, which differentiate into bone in the appropriate 
developmental context, there also appears to be multiple developmental origins. The earliest 
MSCs appear to arise from Sox1+ neuroepithelium through a neural crest intermediate stage 
(Takashima et al., 2007) and not from mesoderm progenitors as previously believed.   
The process of fracture healing also occurs through both intramembranous and 
endochondral means, which is dependent on the mechanical conditions at the fractured site 
(Claes et al., 1998). When dissecting the steps of bone development, far more is known about 
the endochondral pathway than the intramembranous process. The most overt difference 
between these two pathways is that either chondrocytes will arise from mesenchymal 
condensations, which subsequently apoptose and are replaced by invading osteoblasts, or 
there is a direct differentiation into osteoblasts themselves. Thus the differential influence 
and the necessity of chondrocytes highlight the most apparent differences between these 
bone-forming pathways. Thus, in order to optimize bone tissue-engineering procedures 
there is a need to understand the molecular basis underlying different bone formation 
processes. However, a current review of the literature demonstrates large holes in our 
understanding of these multiple routes in which bone naturally forms and how they are 
recapitulated in experimental systems. The remaining part of this chapter will be devoted 
towards our preliminary understanding of these processes with particular emphasis to their 
roles in bone tissue engineering.  
4.1 Endochondral ossification 
In the endochondral process mesenchymal cells condense and differentiate into proliferating 
chondrocytes, which take on the general shape of the future bone. These chondrocytes 
eventually fall out of the cell cycle and these post-mitotic chondrocytes undergo 
hypertrophy. In this stage of development the mature hypertrophic chondrocytes lay down 
cartilage-specific proteins into the surrounding matrix. This cartilaginous framework 
provides molecular cues, which attracts invading vasculature along with osteoblasts, which 
will replace the cartilage intermediate. Osteogenesis occurs directly adjacent to hypertrophic 
chondrocytes. It appears that both the parathyroid hormone (PTH)-related peptide (PTHrP) 
and its receptor PPR are critical in the process osteogenesis via the endochondral pathway. 
In mice, upon disruption of the either PTHrP or PPR, the formation of ectopic hypertrophic 
chondrocytes is accompanied by ectopic bone collar formation (Karaplis et al., 1994). To 
determine if the hypertrophic chondrocytes induce osteogenesis in adjacent cells and is not a 
spatial/temporal coincidence, Chung and colleagues (2001) studied transgenic mice that 
express constitutively active PPR under the control of a chondrocyte specific promoter. This 
constitutive action resulted in suppression of hypertrophic chondrocyte formation and 
concurrent suppression of bone collar and primary spongiosa development. In addition, 
when these transgenic mice were mated to PTHrP-/- mice the resulting rescue of the ectopic 
bone formation, supported the conclusion that hypertrophic chondrocytes are responsible 
for the induction of osteogenesis in adjacent tissue. 
Regulation of the PTHrP/PPR signal appears to be controlled by one of the members of the 
hedgehog family of paracrine factors, Indian hedgehog (Ihh). Members of this signaling 
family are found throughout the animal kingdom and take on a number of critical roles in 
the developing organism. Here, Ihh is expressed by both prehypertrophic and hypertrophic 
chondrocytes. This signal mediates the expression of PTHrP by cells of the perichondrium, 
which in turn binds to PPR on chondrocytes. Ihh and PTHrP signaling thereby creates a 
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negative feedback loop which suppresses differentiation of the proliferating chondrocytes 
into hypertrophic ones (Lanske et al., 1996; Vortkamp et al., 1996). Thus, this balance of 
signals dictates the spatial positioning of the hypertrophic chondrocytes. However, the role 
of Ihh appears to have a broader impact on osteogenesis than its PTHrP-dependent 
regulation of chondrocyte maturation.  
St-Jacques and colleagues (1999) demonstrated that Ihh also plays a role in chondrocyte 
proliferation and the direct development of osteoblasts in endochondral bones. Previous 
studies have demonstrated a critical role of Wnt signaling and -catenin localization as well 
(Gong et al., 2001; Kato et al., 2002). Hu and others (2005) found nuclear -catenin 
localization within the cells of perichondrium indicating an upstream role of Ihh signaling 
to facilitate proper Wnt signaling. Furthermore, Ihh null mice do not exhibit osteocalcin 
expression within endochondral bones, whereas this expression is readily detected within 
the intramembranous bones of the skull and clavicle. This differential dependence of Ihh 
signaling underscores one of the differences between endochondral and intramembranous 
bone formation.   
When assessing the role of local synthesis of VD3 in transgenic mice that exhibited a 
chondrocyte-specific loss-of-function Cyp27b1, the enzyme that converts 25-hydroxyvitamin 
D3 into the active form VD3, it was found that the hypertrophic zone was expanded (Naja et 
al., 2009), thereby increasing both bone mass and trabecular size and number. The classical 
view that VD3 synthesis (active form) was restricted to the kidneys and that this hormone’s 
influence on bone tissue regulation was an indirect consequence of altering calcium and 
phosphate homeostasis had to be reevaluated. The authors suggest their results can be 
explained by a reduced osteoclast recruitment, which follows from a reported delay of 
vascularization that may be attributed to a reduction of VEGF found.  Conversely, 
overexpression of Cyp27b1 under a chondrocyte-specific promoter resulted in the opposite 
expression profile and phenotype. These results are in accordance with chondrocyte specific 
VD3 receptor ablation experiments, which showed impaired vascularization and osteoclast 
number in endochondral bone (Masuyama et al., 2006). As opposed to the traditional view of 
the role of VD3 in bone biology as an indirect mediator of mineral uptake, these experiments 
demonstrate a functional role of this metabolite in regulating endochondral bone formation. 
Some investigators have explored an approach to bone tissue-engineering by mimicking the 
development of mammalian long bones, where the creation of cartilage scaffolds in vitro are 
implanted in vivo. This approach hinges on the idea that the body will recognize this 
cartilage scaffold as an intermediate step in the endochondral bone formation process and 
will then proceed to ossify this construct. In the formation of endochondral bone, 
chondrocytes are exposed to very low oxygen levels and their survival is dependent on the 
expression of the transcription factor hypoxia-inducible factor-1 (For review see: Pfander 
and Gelse, 2007). Thus, the natural ability of chondrocytes to withstand the low oxygen 
supply can provide the time needed for new vasculature to develop and reach the core of 
the implant before widespread cell necrosis.  
Jukes et al. (2008) tested whether in vitro differentiation of ESCs along chondrocyte lineages 
on scaffolds could improve in vivo osteogenesis following implantation. ESCs were initially 
induced along a chondrogenic pathway for 21 days on ceramic scaffolds. These 
chondrogenically-primed scaffolds were then subsequently implanted in immunodeficient 
mice and were found to exhibit nascent bone tissue formation when examined 21 days post-
operatively. For comparison, primary chondrocytes and adult MSCs of human, goat, and 
bovine origin were used in lieu of the chondrocyte-induced ESCs. It was found that each cell 
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type demonstrated differential abilities to form bone tissue in vivo. Interestingly, the goat 
MSCs resulted in the highest degree of bone tissue formation, and it appeared that this 
formation occurred via an intramembranous pathway.  
Farrell et al. (2009) further examined the in vitro chondrogenic-priming of scaffolds using 
human MSCs and reported limited success. After the cells were cultured on collagen–GAG 
scaffolds for three weeks in chondrogenic media, the scaffolds were implanted 
subcutaneously in nude mice. Although cell survival and angiogenesis was found higher in 
the chondrogenically-primed scaffolds, as opposed to scaffolds that were osteogenically-
primed, there appeared to be no de novo osteogenesis. The authors reported the 
chondrogenically-primed scaffolds showed evidence of the initial progression of 
endochondral ossification, yet were unable to proceed through the later stages of osteoblast-
induced mineralization. When mineralization was induced in vitro prior to implantation, the 
nascent angiogenesis that was previously obtained was compromised. Thus, it appears that 
for this approach to be successful, the timed release of additional factors in vivo is needed to 
promote the osteogenic replacement of the cartilaginous scaffold.   
When examining the developmental pathway of bone-tissue engineered constructs, by 
either endochondral or intramembranous routes, it makes sense that different cell types will 
mature along different pathways even when presented to the same conditions. Tortelli and 
others (2010) revealed how the differentiated state of implanted cells affects subsequent 
ossification and host cell recruitment to the graft site. They seeded hydroxyapatite scaffolds 
with either human MSCs or osteoblasts. When differentiated osteoblasts were used to seed 
the scaffolds, ossification occurred through an intramembranous pathway, as revealed by 
the lack of cartilage markers by immunohistological examination. This intramembranous 
ossification appeared to be more rapid and thus accounted for more bone deposition within 
the same time period when compared to the MSC-seeded scaffolds. However, MSC 
scaffolds, which ossified in an endochondral fashion, were able to facilitate nascent 
vascularization of the graft. This highlights the fact that engineered bone grafts may one day 
be tailored to a patient’s need depending on factors such as speed of graft ossification and 
site incorporation. In addition this study shows that implanted MSCs can progress through 
the endochondral pathway, but as the aforementioned study by Farrell et al. (2009) 
demonstrates this process currently cannot be split into an early in vitro stage that can be 
‘picked up’ later in vivo. However, if the process of endochondral bone formation is 
elucidated further and applied to tissue engineering, then it is feasible that this approach 
may one day become a viable avenue to repair large bone defects. 
Although mimicking the development of long bone through endochondral ossification of 
scaffolds maybe appropriate in some contexts, intramembranous ossification may be 
suitable for other applications in regenerative medicine. The body utilizes both of these 
systems in different contexts depending on certain conditions whose reasons remain to be 
fully characterized. Nonetheless, it appears quite probable that bone tissue engineering need 
not only be tailored to the individual but also the specific bone defect or disease in order to 
be completely effective.  
4.2 Intramembranous ossification 
As for intramembranous bone formation, not only is little known about the process itself, 
but the developmental pathway of the cells leading to the formation of the tissues within the 
cranial skeleton is still not well understood.  
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4.2.1 Neural crest cells  
As incipiently indicated, the migrating cranial neural crest cells form bone mostly through 
intramembranous ossification. Initially neural crest cells become committed to either an 
ectomesenchymal (i.e. producing tissues such as cartilage, bone and connective tissue) or a 
non-ectomesenchymal (i.e. producing neurons, glia and pigment cells) lineage. The 
ectomesenchymal tissue is also referred to in the literature as mesectoderm. Blentic and 
others (2008) describe how migrating neural crest cells in chick and zebrafish embryos 
commit to either fate.  Cells that migrate into the pharyngeal arches are induced to respond 
to FGF signaling within these embryonic structures, resulting in the expression of the 
homeobox gene Dlx2. Concurrently, early neural crest markers Sox10 and FoxD2 are 
downregulated, which are still expressed in the neural crest cells that have not invaded the 
pharyngeal arches and thus are fated to become non-ectomesenchyme. Whether or not 
neural cells migrate into the pharyngeal arches appears to be determined by the timing of 
their emergence from the neural tube. Although not fully understood, it appears that early 
migrating cells ‘fill up’ the pharyngeal arches and the cells that migrate later are thus more 
likely to find residence outside of the arches and become non-ectomesenchyme (Blentic et 
al., 2008). 
4.2.2 Neural crest and mesodermal progenitors in intramembranous bone formation 
The parietal bone, which is of paraxial mesoderm origin and the frontal bone, which is of 
neural crest origin, both form via intramembranous ossification, thus making the study of 
calvarial bones an attractive platform to study the possible differences in bones of different 
embryonic origins.  Quarto et al. (2010) examined the osteogenic capacity of first passage 
osteoblasts that were obtained from these respective bones in mice. Frontal bone-derived 
osteoblasts from post-natal day 7 and day 60 mice were found to exhibit greater 
mineralization capacity, as revealed by Alk Phos activity, von Kossa and Alizarin Red S 
staining. This was also supported by expression data of the bone-specific markers 
osteocalcin and runx2. These in vitro observations were reinforced by the relative healing 
capacity of these two bones. The successful healing of 2mm defects was found within the 
frontal bone in the majority of mice at 8 weeks post-injury, whereas complete healing was 
not typically found in same sized injuries of the parietal bones within the same time period.  
The investigators uncovered a higher level of endogenous canonical Wnt signaling in frontal 
bone osteoblasts as compared to parietal bone osteoblasts that may be responsible for this 
differential regenerative propensity. By modulating Wnt signaling through exogenous 
addition of Wnt3a or transfecting osteoblasts with constructs that increase -catenin 
signaling in parietal bones to frontal bone levels, and vice versa, the authors showed a 
reversal of osteogenic potential of these cells. Thus, providing strong evidence that that the 
enhanced osteogenic potential of frontal bone osteoblasts can be at least be partially 
attributed to these differences in endogenous Wnt signaling.  
Xu and colleagues (2007) found that osteoblasts derived from the frontal bone proliferated 
faster and attached to culture dishes better than osteoblasts that were harvested from 
parietal bone. This may be linked to the fourfold greater expression of osteoblast-specific 
cadherin that they found within frontal bone osteoblasts. The parietal bone osteoblasts did 
however show double the Alk Phos activity at the time points examined. When cultured in 
the presence of osteogenic inducing factors, such as VD3, the frontal bone osteoblasts 
showed a much more robust bone nodule formation. However, expression of osteogenic 
differentiation markers, such as osteopontin, Col1, and Wnt5a was significantly greater in 
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type demonstrated differential abilities to form bone tissue in vivo. Interestingly, the goat 
MSCs resulted in the highest degree of bone tissue formation, and it appeared that this 
formation occurred via an intramembranous pathway.  
Farrell et al. (2009) further examined the in vitro chondrogenic-priming of scaffolds using 
human MSCs and reported limited success. After the cells were cultured on collagen–GAG 
scaffolds for three weeks in chondrogenic media, the scaffolds were implanted 
subcutaneously in nude mice. Although cell survival and angiogenesis was found higher in 
the chondrogenically-primed scaffolds, as opposed to scaffolds that were osteogenically-
primed, there appeared to be no de novo osteogenesis. The authors reported the 
chondrogenically-primed scaffolds showed evidence of the initial progression of 
endochondral ossification, yet were unable to proceed through the later stages of osteoblast-
induced mineralization. When mineralization was induced in vitro prior to implantation, the 
nascent angiogenesis that was previously obtained was compromised. Thus, it appears that 
for this approach to be successful, the timed release of additional factors in vivo is needed to 
promote the osteogenic replacement of the cartilaginous scaffold.   
When examining the developmental pathway of bone-tissue engineered constructs, by 
either endochondral or intramembranous routes, it makes sense that different cell types will 
mature along different pathways even when presented to the same conditions. Tortelli and 
others (2010) revealed how the differentiated state of implanted cells affects subsequent 
ossification and host cell recruitment to the graft site. They seeded hydroxyapatite scaffolds 
with either human MSCs or osteoblasts. When differentiated osteoblasts were used to seed 
the scaffolds, ossification occurred through an intramembranous pathway, as revealed by 
the lack of cartilage markers by immunohistological examination. This intramembranous 
ossification appeared to be more rapid and thus accounted for more bone deposition within 
the same time period when compared to the MSC-seeded scaffolds. However, MSC 
scaffolds, which ossified in an endochondral fashion, were able to facilitate nascent 
vascularization of the graft. This highlights the fact that engineered bone grafts may one day 
be tailored to a patient’s need depending on factors such as speed of graft ossification and 
site incorporation. In addition this study shows that implanted MSCs can progress through 
the endochondral pathway, but as the aforementioned study by Farrell et al. (2009) 
demonstrates this process currently cannot be split into an early in vitro stage that can be 
‘picked up’ later in vivo. However, if the process of endochondral bone formation is 
elucidated further and applied to tissue engineering, then it is feasible that this approach 
may one day become a viable avenue to repair large bone defects. 
Although mimicking the development of long bone through endochondral ossification of 
scaffolds maybe appropriate in some contexts, intramembranous ossification may be 
suitable for other applications in regenerative medicine. The body utilizes both of these 
systems in different contexts depending on certain conditions whose reasons remain to be 
fully characterized. Nonetheless, it appears quite probable that bone tissue engineering need 
not only be tailored to the individual but also the specific bone defect or disease in order to 
be completely effective.  
4.2 Intramembranous ossification 
As for intramembranous bone formation, not only is little known about the process itself, 
but the developmental pathway of the cells leading to the formation of the tissues within the 
cranial skeleton is still not well understood.  
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4.2.1 Neural crest cells  
As incipiently indicated, the migrating cranial neural crest cells form bone mostly through 
intramembranous ossification. Initially neural crest cells become committed to either an 
ectomesenchymal (i.e. producing tissues such as cartilage, bone and connective tissue) or a 
non-ectomesenchymal (i.e. producing neurons, glia and pigment cells) lineage. The 
ectomesenchymal tissue is also referred to in the literature as mesectoderm. Blentic and 
others (2008) describe how migrating neural crest cells in chick and zebrafish embryos 
commit to either fate.  Cells that migrate into the pharyngeal arches are induced to respond 
to FGF signaling within these embryonic structures, resulting in the expression of the 
homeobox gene Dlx2. Concurrently, early neural crest markers Sox10 and FoxD2 are 
downregulated, which are still expressed in the neural crest cells that have not invaded the 
pharyngeal arches and thus are fated to become non-ectomesenchyme. Whether or not 
neural cells migrate into the pharyngeal arches appears to be determined by the timing of 
their emergence from the neural tube. Although not fully understood, it appears that early 
migrating cells ‘fill up’ the pharyngeal arches and the cells that migrate later are thus more 
likely to find residence outside of the arches and become non-ectomesenchyme (Blentic et 
al., 2008). 
4.2.2 Neural crest and mesodermal progenitors in intramembranous bone formation 
The parietal bone, which is of paraxial mesoderm origin and the frontal bone, which is of 
neural crest origin, both form via intramembranous ossification, thus making the study of 
calvarial bones an attractive platform to study the possible differences in bones of different 
embryonic origins.  Quarto et al. (2010) examined the osteogenic capacity of first passage 
osteoblasts that were obtained from these respective bones in mice. Frontal bone-derived 
osteoblasts from post-natal day 7 and day 60 mice were found to exhibit greater 
mineralization capacity, as revealed by Alk Phos activity, von Kossa and Alizarin Red S 
staining. This was also supported by expression data of the bone-specific markers 
osteocalcin and runx2. These in vitro observations were reinforced by the relative healing 
capacity of these two bones. The successful healing of 2mm defects was found within the 
frontal bone in the majority of mice at 8 weeks post-injury, whereas complete healing was 
not typically found in same sized injuries of the parietal bones within the same time period.  
The investigators uncovered a higher level of endogenous canonical Wnt signaling in frontal 
bone osteoblasts as compared to parietal bone osteoblasts that may be responsible for this 
differential regenerative propensity. By modulating Wnt signaling through exogenous 
addition of Wnt3a or transfecting osteoblasts with constructs that increase -catenin 
signaling in parietal bones to frontal bone levels, and vice versa, the authors showed a 
reversal of osteogenic potential of these cells. Thus, providing strong evidence that that the 
enhanced osteogenic potential of frontal bone osteoblasts can be at least be partially 
attributed to these differences in endogenous Wnt signaling.  
Xu and colleagues (2007) found that osteoblasts derived from the frontal bone proliferated 
faster and attached to culture dishes better than osteoblasts that were harvested from 
parietal bone. This may be linked to the fourfold greater expression of osteoblast-specific 
cadherin that they found within frontal bone osteoblasts. The parietal bone osteoblasts did 
however show double the Alk Phos activity at the time points examined. When cultured in 
the presence of osteogenic inducing factors, such as VD3, the frontal bone osteoblasts 
showed a much more robust bone nodule formation. However, expression of osteogenic 
differentiation markers, such as osteopontin, Col1, and Wnt5a was significantly greater in 
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the parietal bone derived cells. Members of the FGF signaling cascade were also 
differentially expressed between these two cell types. Thus, the frontal and parietal bones 
appear superficially similar yet exhibit an number of different characteristics such as growth 
kinetics, regulation by signaling cascades and varying marker expression, all of which 
demonstrate that these bones are not as similar as they initially appear to be.  
To further examine the regenerative osteogenic capacity of cells from different embryonic 
origins Leucht and others (2008) engineered mice in which developing cells of neural crest 
origin would irreversibly express GFP. Tissues from mesodermal origin were also induced 
to express β-galactosidase. Following skeletal injury in either the mandible or the tibia 
resulted in natural bone regeneration where the progenitor pool which became new bone 
tissue was derived from the same embryonic origin of the injured bone itself (i.e. cells from 
neural crest origin repaired mandible defects, and cells of mesodermal origin repaired tibia 
defects). The investigators then performed a number of transplant experiments where 
skeletal progenitor cells were implanted into bone of different embryonic origin. 
Interestingly neural crest derived progenitors were able to form more new bone when 
implanted ectopically into tibia injury sites, than if they were implanted back into their 
endogenous environment within mandible injuries. Conversely, when mesoderm derived 
progenitors were implanted into mandible injuries, an abundance of cartilage formed, 
which over time ossified via an endochondral pathway.  
These results suggest a difference in the underlying reparative plasticity of cells from 
different origins. In vitro analysis demonstrated that mesoderm osteoprogenitors 
proliferated faster than the corresponding neural crest osteoprogenitors. However, the cells 
of neural crest origin were able to differentiate faster based on Alizarin Red S staining and 
qPCR of osteogenic markers. The authors went further to try to understand the possible 
molecular mechanisms underlying this difference (Leucht et al., 2008). They found that in 
the adult mice Hoxa11 expression was maintained in the tibia and was absent in the 
mandible. For neural crest osteoprogenitors, which originally lack Hoxa11 expression, they 
began to express Hoxa11 when ectopically placed in the tibia. This switch in expression was 
not found in the mesodermal osteoprogenitors, which continued to express Hoxa11 even 
when placed in the Hoxa11-negative environment of the mandible. This study once again 
reiterates how the molecular identity of cells used for transplantations can be a crucial factor 
in determining the success of a stem cell based bone graft. In addition, it may be true that 
osteoprogenitors of neural crest origin may be best suited as the stem cell source of bone 
grafts because of their greater plasticity to adapt to local environments.   
4.2.3 ESC-derived neural crest stem cells 
When ESC cultures are osteogenically induced following standard differentiation 
procedures, it is seldom examined which developmental progenitors are responsible for the 
terminally differentiated osteoblasts. Although some studies have differentiated ESCs along 
defined lineages and then determined their osteogenic capacity, Lee et al. (2008) reported 
the isolation and propagation of human neural crest cells from human ESCs. Initially they 
cultured human ESCs in neural induction media and then mechanically removed and 
replated the resulting neural rosettes. Cells that were doubly positive for the neural crest 
markers p75 and HNK-1 were further cultured and revealed a CD73 positive population. 
This marker expression indicates the presence of neural crest-derived mesenchymal stem 
cells. This CD73+ population could be osteogenically induced as revealed by Alizarin Red S, 
and Alk Phos staining, and bone sialoprotein expression.  
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In a similar study Jiang and colleagues (2008) also used a FACS enrichment strategy for p75 
and HNK-1 positive neural crest cells after co-culture of human ESCs with PA6 stromal 
cells, although the osteogenic differentiation potential of such isolated neural crest cells was 
not determined. In another study cranial neural crest-like cells were derived from human 
ESCs, not by co-culture but instead though EB formation (Zhou and Snead, 2008). Here, 
FACS purification of neural crest cells was performed based on the expression of Frizzled3, 
a Wnt receptor, and cadherin11, a cadherin specifically expressed in the gastrulating embryo 
and migrating neural crest cells (Kimura et al., 1995). Only about 1% of cells were double 
positive for these selected markers and were able to self-renew and maintain multipotent 
differentiation potential, including runx2 positive osteoblasts with the capability to calcify. 
Although not definitive demonstrations of the isolation of osteoprogenitor stem cells from 
different germ layer-derived populations, these studies offer compelling evidence that cells 
existing in in vitro culture conditions can recapitulate the neural crest osteogenic pathways 
found in the developing embryo.  
5. Conclusion 
In summation, pluripotent stem cells are a particularly attractive source to develop new 
technologies and techniques to address many debilitating bone disorders and defects, and 
we have come far in the understanding and characterization of osteogenesis. Although more 
investigations and innovations are needed before regenerative bone biology becomes 
commonplace, the future holds great promise in this field of research.   
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the parietal bone derived cells. Members of the FGF signaling cascade were also 
differentially expressed between these two cell types. Thus, the frontal and parietal bones 
appear superficially similar yet exhibit an number of different characteristics such as growth 
kinetics, regulation by signaling cascades and varying marker expression, all of which 
demonstrate that these bones are not as similar as they initially appear to be.  
To further examine the regenerative osteogenic capacity of cells from different embryonic 
origins Leucht and others (2008) engineered mice in which developing cells of neural crest 
origin would irreversibly express GFP. Tissues from mesodermal origin were also induced 
to express β-galactosidase. Following skeletal injury in either the mandible or the tibia 
resulted in natural bone regeneration where the progenitor pool which became new bone 
tissue was derived from the same embryonic origin of the injured bone itself (i.e. cells from 
neural crest origin repaired mandible defects, and cells of mesodermal origin repaired tibia 
defects). The investigators then performed a number of transplant experiments where 
skeletal progenitor cells were implanted into bone of different embryonic origin. 
Interestingly neural crest derived progenitors were able to form more new bone when 
implanted ectopically into tibia injury sites, than if they were implanted back into their 
endogenous environment within mandible injuries. Conversely, when mesoderm derived 
progenitors were implanted into mandible injuries, an abundance of cartilage formed, 
which over time ossified via an endochondral pathway.  
These results suggest a difference in the underlying reparative plasticity of cells from 
different origins. In vitro analysis demonstrated that mesoderm osteoprogenitors 
proliferated faster than the corresponding neural crest osteoprogenitors. However, the cells 
of neural crest origin were able to differentiate faster based on Alizarin Red S staining and 
qPCR of osteogenic markers. The authors went further to try to understand the possible 
molecular mechanisms underlying this difference (Leucht et al., 2008). They found that in 
the adult mice Hoxa11 expression was maintained in the tibia and was absent in the 
mandible. For neural crest osteoprogenitors, which originally lack Hoxa11 expression, they 
began to express Hoxa11 when ectopically placed in the tibia. This switch in expression was 
not found in the mesodermal osteoprogenitors, which continued to express Hoxa11 even 
when placed in the Hoxa11-negative environment of the mandible. This study once again 
reiterates how the molecular identity of cells used for transplantations can be a crucial factor 
in determining the success of a stem cell based bone graft. In addition, it may be true that 
osteoprogenitors of neural crest origin may be best suited as the stem cell source of bone 
grafts because of their greater plasticity to adapt to local environments.   
4.2.3 ESC-derived neural crest stem cells 
When ESC cultures are osteogenically induced following standard differentiation 
procedures, it is seldom examined which developmental progenitors are responsible for the 
terminally differentiated osteoblasts. Although some studies have differentiated ESCs along 
defined lineages and then determined their osteogenic capacity, Lee et al. (2008) reported 
the isolation and propagation of human neural crest cells from human ESCs. Initially they 
cultured human ESCs in neural induction media and then mechanically removed and 
replated the resulting neural rosettes. Cells that were doubly positive for the neural crest 
markers p75 and HNK-1 were further cultured and revealed a CD73 positive population. 
This marker expression indicates the presence of neural crest-derived mesenchymal stem 
cells. This CD73+ population could be osteogenically induced as revealed by Alizarin Red S, 
and Alk Phos staining, and bone sialoprotein expression.  
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In a similar study Jiang and colleagues (2008) also used a FACS enrichment strategy for p75 
and HNK-1 positive neural crest cells after co-culture of human ESCs with PA6 stromal 
cells, although the osteogenic differentiation potential of such isolated neural crest cells was 
not determined. In another study cranial neural crest-like cells were derived from human 
ESCs, not by co-culture but instead though EB formation (Zhou and Snead, 2008). Here, 
FACS purification of neural crest cells was performed based on the expression of Frizzled3, 
a Wnt receptor, and cadherin11, a cadherin specifically expressed in the gastrulating embryo 
and migrating neural crest cells (Kimura et al., 1995). Only about 1% of cells were double 
positive for these selected markers and were able to self-renew and maintain multipotent 
differentiation potential, including runx2 positive osteoblasts with the capability to calcify. 
Although not definitive demonstrations of the isolation of osteoprogenitor stem cells from 
different germ layer-derived populations, these studies offer compelling evidence that cells 
existing in in vitro culture conditions can recapitulate the neural crest osteogenic pathways 
found in the developing embryo.  
5. Conclusion 
In summation, pluripotent stem cells are a particularly attractive source to develop new 
technologies and techniques to address many debilitating bone disorders and defects, and 
we have come far in the understanding and characterization of osteogenesis. Although more 
investigations and innovations are needed before regenerative bone biology becomes 
commonplace, the future holds great promise in this field of research.   
6. Acknowledgment 
N.zN. acknowledges support from the German Federal Ministry of Education and Research 
(BEO31/0312314 and 0315121A), the Tobacco-Related Disease Research Program (19KT-
0017) and the Alberta Heritage Foundation for Medical Research. The authors offer sincere 
apologies to the many colleagues whose work could not be cited because of space 
limitations.  
7. References 
Aasen, T.; Raya, A.; Barrero, M. J.; Garreta, E.; Consiglio, A.; Gonzalez, F.; Vassena, R.; Bilic, 
J.; Pekarik, V.; Tiscornia, G.; Edel, M.; Boué, S. & Izpisúa Belmonte, J.C. (2008). 
Efficient and rapid generation of induced pluripotent stem cells from human 
keratinocytes. Nat Biotechnol 26, 1276-1284. 
Aihara, Y.; Hayashi, Y.; Hirata, M.; Ariki, N.; Shibata, S.; Nagoshi, N.; Nakanishi, M.; 
Ohnuma, K.; Warashina, M.; Michiue, T.; Uchiyama, H.; Okano, H.; Asashima, M. 
& Furue, M.K. (2010). Induction of neural crest cells from mouse embryonic stem 
cells in a serum-free monolayer culture. Int J Dev Biol 54, 1287-1294. 
Airas, L.; Hellman, J.; Salmi, M.; Bono, P.; Puurunen, T.; Smith, D.J. & Jalkanen, S. (1995). 
CD73 is involved in lymphocyte binding to the endothelium: characterization of 
lymphocyte-vascular adhesion protein 2 identifies it as CD73. J Exp Med 182(5), 
1603-1608. 
Amit, M. , Shariki, C. , Margulets, V. & Itskovitz-Eldor, J. (2004) Feeder layer- and serum-
free culture of human embryonic stem cells. Biol Reprod 70(3), 837-345.  
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
340 
Arinzeh, T. L.; Peter, S. J.; Archambault, M. P.; van den Bos, C.; Gordon, S.; Kraus, K.; Smith, 
A. & Kadiyala, S. (2003). Allogeneic mesenchymal stem cells regenerate bone in a 
critical-sized canine segmental defect. J Bone Joint Surg Am 85-A, 1927-1935. 
Barberi, T.; Willis, L. M.; Socci, N. D. & Studer, L. (2005). Derivation of multipotent 
mesenchymal precursors from human embryonic stem cells. Plos Med 2, 554-560. 
Beddington, R. S. P.; Rashbass, P. & Wilson, V. (1992). Brachyury - a Gene Affecting Mouse 
Gastrulation and Early Organogenesis. Dev Suppl, 157-165. 
Bigdeli, N.; Andersson, M.; Strehl, R.; Emanuelsson, K.; Kilmare, E.; Hyllner, J. & Lindahl, A. 
(2008). Adaptation of human embryonic stem cells to feeder-free and matrix-free 
culture conditions directly on plastic surfaces. J Biotechnol 133, 146-153. 
Bigdeli, N.; de Peppo, G. M.; Lenneras, M.; Sjovall, P.; Lindahl, A.; Hyllner, J. & Karlsson, C. 
(2010). Superior osteogenic capacity of human embryonic stem cells adapted to 
matrix-free growth compared to human mesenchymal stem cells. Tissue Eng Part A 
16, 3427-3440. 
Bilousova, G.; Jun, D. H.; King, K. B.; De Langhe, S.; Chick, W. S.; Torchia, E. C.; Chow, K. S.; 
Klemm, D. J.; Roop, D. R. & Majka, S. M. (2011). Osteoblasts Derived from Induced 
Pluripotent Stem Cells Form Calcified Structures in Scaffolds Both in Vitro and in 
Vivo. Stem Cells 29, 206-216. 
Blentic, A.; Tandon, P.; Payton, S.; Walshe, J.; Carney, T.; Kelsh, R. N.; Mason, I. & Graham, 
A. (2008). The emergence of ectomesenchyme. Dev Dynam 237, 592-601. 
Bruder, S.P.; Gazit, D.; Passi-Even, L.; Bab, I. & Caplan, A.I. (1990). Osteochondral 
differentiation and the emergence of stage-specific osteogenic cell-surface 
molecules by bone marrow cells in diffusion chambers. Bone Miner 11(2), 141-151. 
Bruder, S. P.; Kurth, A. A.; Shea, M.; Hayes, W. C.; Jaiswal, N. & Kadiyala, S. (1998). Bone 
regeneration by implantation of purified, culture-expanded human mesenchymal 
stem cells. J Orthop Res 16, 155-162. 
Buttery, L. D. K.; Bourne, S.; Xynos, J. D.; Wood, H.; Hughes, F. J.; Hughes, S. P. F.; 
Episkopou, V. & Polak, J. M. (2001). Differentiation of osteoblasts and in vitro bone 
formation from murine embryonic stem cells. Tissue Eng 7, 89-99. 
Byrne, J. A.; Pedersen, D. A.; Clepper, L. L.; Nelson, M.; Sanger, W. G.; Gokhale, S.; Wolf, D. 
P. & Mitalipov, S. M. (2007). Producing primate embryonic stem cells by somatic 
cell nuclear transfer. Nature 450, 497-502. 
Cao, T.; Heng, B. C.; Ye, C. P.; Liu, H.; Toh, W. S.; Robson, P.; Li, P.; Hong, Y. H. & Stanton, 
L. W. (2005). Osteogenic differentiation within intact human embryoid bodies 
result in a marked increase in osteocalcin secretion after 12 days of in vitro culture, 
and formation of morphologically distinct nodule-like structures. Tissue Cell 37, 
325-334. 
Chaudhry, G. R.; Yao, D.; Smith, A. & Hussain, A. (2004). Osteogenic cells derived from 
embryonic stem cells produced bone nodules in three-dimensional scaffolds. J 
Biomed Biotechnol, 203-210. 
Chung, I. H.; Yamaza, T.; Zhao, H.; Choung, P. H.; Shi, S. & Chai, Y. (2009). Stem Cell 
Property of Postmigratory Cranial Neural Crest Cells and Their Utility in Alveolar 
Bone Regeneration and Tooth Development. Stem Cells 27, 866-877. 
Chung, U. I.; Schipani, E.; McMahon, A. P. & Kronenberg, H. M. (2001). Indian hedgehog 
couples chondrogenesis to osteogenesis in endochondral bone development. J Clin 
Invest 107, 295-304. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
341 
Claes, L. E.; Heigele, C. A.; Neidlinger-Wilke, C.; Kaspar, D.; Seidl, W.; Margevicius, K. J. & 
Augat, P. (1998). Effects of mechanical factors on the fracture healing process. Clin 
Orthop Relat R, S132-S147. 
Davis, L. A.; Dienelt, A. & zur Nieden, N. I. (2011). Absorption-based assays for the analysis 
of osteogenic and chondrogenic yield. Methods Mol Biol 690, 255-272. 
Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, 
R.; Keating, A.; Prockop, D.j. & Horwitz, E. (2006). Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular 
Therapy position statement. Cytotherapy 8(4), 315-317. 
de Peppo, G. M.; Sjovall, P.; Lenneras, M.; Strehl, R.; Hyllner, J.; Thomsen, P. & Karlsson, C. 
(2010). Osteogenic potential of human mesenchymal stem cells and human 
embryonic stem cell-derived mesodermal progenitors: a tissue engineering 
perspective. Tissue Eng Part A 16, 3413-3426. 
Doetschman, T.; Williams, P. & Maeda, N. (1988). Establishment of Hamster Blastocyst-
Derived Embryonic Stem (ES) Cells. Dev Biol 127, 224-227. 
Dupin, E.; Calloni, G.; Real, C.; Gongalves-Trentin, A. & Le Douarin, N. M. (2007). Neural 
crest progenitors and stem cells. Cr Biol 330, 521-529. 
Evans, M. J. & Kaufman, M. H. (1981). Establishment in Culture of Pluripotential Cells from 
Mouse Embryos. Nature 292, 154-156. 
Farrell, E.; van der Jagt, O. P.; Koevoet, W.; Kops, N.; van Manen, C. J.; Hellingman, C. A.; 
Jahr, H.; O'Brien, F. J.; Verhaar, J. A. N.; Weinans, H. & van Osch, G. J. V. M. (2009). 
Chondrogenic Priming of Human Bone Marrow Stromal Cells: A Better Route to 
Bone Repair? Tissue Eng Part C-Meth 15, 285-295. 
Friedenstein, A.J.; Piatetzky-Shapiro, I.I. & Petrakova, K.V. (1966). Osteogenesis in 
transplants of bone marrow cells. J Embryol Exp Morphol 16(3), 381-390. 
Friedenstein, A.J.; Gorskaja, J.F. & Kulagina, N.N. (1976). Fibroblast precursors in normal 
and irradiated mouse hematopoietic organs. Exp Hematol 4(5), 267-274. 
Friedenstein, A.J.; Chailakhyan, R.K. & Gerasimov, U.V. (1987). Bone marrow osteogenic 
stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue 
Kinet 20(3), 263-272. 
Gadue, P.; Huber, T. L.; Paddison, P. J. & Keller, G. M. (2006). Wnt and TGF-beta signaling 
are required for the induction of an in vitro model of primitive streak formation 
using embryonic stem cells. P Natl Acad Sci USA 103, 16806-16811. 
Gao, J. Z.; Dennis, J. E.; Solchaga, L. A.; Awadallah, A. S.; Goldberg, V. M. & Caplan, A. I. 
(2001). Tissue-engineered fabrication of an osteochondral composite graft using rat 
bone marrow-derived mesenchymal stem cells. Tissue Eng 7, 363-371. 
Gazit, D.; Ebner, R.; Kahn, A.J. & Derynck, R. (1993). Modulation of expression and cell 
surface binding of members of the transforming growth factor-beta superfamily 
during retinoic acid-induced osteoblastic differentiation of multipotential 
mesenchymal cells. Mol Endocrinol 7(2), 189-198. 
Giles, J. R.; Yang, X.; Mark, W. & Foote, R. H. (1993). Pluripotency of cultured rabbit inner 
cell mass cells detected by isozyme analysis and eye pigmentation of fetuses 
following injection into blastocysts or morulae. Mol Reprod Dev 36, 130-138. 
Giordano, A., Galderisi, U., Marino, I.R. (2007). From the laboratory bench to the patient's 
bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 
211(1), 27-35. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
340 
Arinzeh, T. L.; Peter, S. J.; Archambault, M. P.; van den Bos, C.; Gordon, S.; Kraus, K.; Smith, 
A. & Kadiyala, S. (2003). Allogeneic mesenchymal stem cells regenerate bone in a 
critical-sized canine segmental defect. J Bone Joint Surg Am 85-A, 1927-1935. 
Barberi, T.; Willis, L. M.; Socci, N. D. & Studer, L. (2005). Derivation of multipotent 
mesenchymal precursors from human embryonic stem cells. Plos Med 2, 554-560. 
Beddington, R. S. P.; Rashbass, P. & Wilson, V. (1992). Brachyury - a Gene Affecting Mouse 
Gastrulation and Early Organogenesis. Dev Suppl, 157-165. 
Bigdeli, N.; Andersson, M.; Strehl, R.; Emanuelsson, K.; Kilmare, E.; Hyllner, J. & Lindahl, A. 
(2008). Adaptation of human embryonic stem cells to feeder-free and matrix-free 
culture conditions directly on plastic surfaces. J Biotechnol 133, 146-153. 
Bigdeli, N.; de Peppo, G. M.; Lenneras, M.; Sjovall, P.; Lindahl, A.; Hyllner, J. & Karlsson, C. 
(2010). Superior osteogenic capacity of human embryonic stem cells adapted to 
matrix-free growth compared to human mesenchymal stem cells. Tissue Eng Part A 
16, 3427-3440. 
Bilousova, G.; Jun, D. H.; King, K. B.; De Langhe, S.; Chick, W. S.; Torchia, E. C.; Chow, K. S.; 
Klemm, D. J.; Roop, D. R. & Majka, S. M. (2011). Osteoblasts Derived from Induced 
Pluripotent Stem Cells Form Calcified Structures in Scaffolds Both in Vitro and in 
Vivo. Stem Cells 29, 206-216. 
Blentic, A.; Tandon, P.; Payton, S.; Walshe, J.; Carney, T.; Kelsh, R. N.; Mason, I. & Graham, 
A. (2008). The emergence of ectomesenchyme. Dev Dynam 237, 592-601. 
Bruder, S.P.; Gazit, D.; Passi-Even, L.; Bab, I. & Caplan, A.I. (1990). Osteochondral 
differentiation and the emergence of stage-specific osteogenic cell-surface 
molecules by bone marrow cells in diffusion chambers. Bone Miner 11(2), 141-151. 
Bruder, S. P.; Kurth, A. A.; Shea, M.; Hayes, W. C.; Jaiswal, N. & Kadiyala, S. (1998). Bone 
regeneration by implantation of purified, culture-expanded human mesenchymal 
stem cells. J Orthop Res 16, 155-162. 
Buttery, L. D. K.; Bourne, S.; Xynos, J. D.; Wood, H.; Hughes, F. J.; Hughes, S. P. F.; 
Episkopou, V. & Polak, J. M. (2001). Differentiation of osteoblasts and in vitro bone 
formation from murine embryonic stem cells. Tissue Eng 7, 89-99. 
Byrne, J. A.; Pedersen, D. A.; Clepper, L. L.; Nelson, M.; Sanger, W. G.; Gokhale, S.; Wolf, D. 
P. & Mitalipov, S. M. (2007). Producing primate embryonic stem cells by somatic 
cell nuclear transfer. Nature 450, 497-502. 
Cao, T.; Heng, B. C.; Ye, C. P.; Liu, H.; Toh, W. S.; Robson, P.; Li, P.; Hong, Y. H. & Stanton, 
L. W. (2005). Osteogenic differentiation within intact human embryoid bodies 
result in a marked increase in osteocalcin secretion after 12 days of in vitro culture, 
and formation of morphologically distinct nodule-like structures. Tissue Cell 37, 
325-334. 
Chaudhry, G. R.; Yao, D.; Smith, A. & Hussain, A. (2004). Osteogenic cells derived from 
embryonic stem cells produced bone nodules in three-dimensional scaffolds. J 
Biomed Biotechnol, 203-210. 
Chung, I. H.; Yamaza, T.; Zhao, H.; Choung, P. H.; Shi, S. & Chai, Y. (2009). Stem Cell 
Property of Postmigratory Cranial Neural Crest Cells and Their Utility in Alveolar 
Bone Regeneration and Tooth Development. Stem Cells 27, 866-877. 
Chung, U. I.; Schipani, E.; McMahon, A. P. & Kronenberg, H. M. (2001). Indian hedgehog 
couples chondrogenesis to osteogenesis in endochondral bone development. J Clin 
Invest 107, 295-304. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
341 
Claes, L. E.; Heigele, C. A.; Neidlinger-Wilke, C.; Kaspar, D.; Seidl, W.; Margevicius, K. J. & 
Augat, P. (1998). Effects of mechanical factors on the fracture healing process. Clin 
Orthop Relat R, S132-S147. 
Davis, L. A.; Dienelt, A. & zur Nieden, N. I. (2011). Absorption-based assays for the analysis 
of osteogenic and chondrogenic yield. Methods Mol Biol 690, 255-272. 
Dominici, M.; Le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, 
R.; Keating, A.; Prockop, D.j. & Horwitz, E. (2006). Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular 
Therapy position statement. Cytotherapy 8(4), 315-317. 
de Peppo, G. M.; Sjovall, P.; Lenneras, M.; Strehl, R.; Hyllner, J.; Thomsen, P. & Karlsson, C. 
(2010). Osteogenic potential of human mesenchymal stem cells and human 
embryonic stem cell-derived mesodermal progenitors: a tissue engineering 
perspective. Tissue Eng Part A 16, 3413-3426. 
Doetschman, T.; Williams, P. & Maeda, N. (1988). Establishment of Hamster Blastocyst-
Derived Embryonic Stem (ES) Cells. Dev Biol 127, 224-227. 
Dupin, E.; Calloni, G.; Real, C.; Gongalves-Trentin, A. & Le Douarin, N. M. (2007). Neural 
crest progenitors and stem cells. Cr Biol 330, 521-529. 
Evans, M. J. & Kaufman, M. H. (1981). Establishment in Culture of Pluripotential Cells from 
Mouse Embryos. Nature 292, 154-156. 
Farrell, E.; van der Jagt, O. P.; Koevoet, W.; Kops, N.; van Manen, C. J.; Hellingman, C. A.; 
Jahr, H.; O'Brien, F. J.; Verhaar, J. A. N.; Weinans, H. & van Osch, G. J. V. M. (2009). 
Chondrogenic Priming of Human Bone Marrow Stromal Cells: A Better Route to 
Bone Repair? Tissue Eng Part C-Meth 15, 285-295. 
Friedenstein, A.J.; Piatetzky-Shapiro, I.I. & Petrakova, K.V. (1966). Osteogenesis in 
transplants of bone marrow cells. J Embryol Exp Morphol 16(3), 381-390. 
Friedenstein, A.J.; Gorskaja, J.F. & Kulagina, N.N. (1976). Fibroblast precursors in normal 
and irradiated mouse hematopoietic organs. Exp Hematol 4(5), 267-274. 
Friedenstein, A.J.; Chailakhyan, R.K. & Gerasimov, U.V. (1987). Bone marrow osteogenic 
stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell Tissue 
Kinet 20(3), 263-272. 
Gadue, P.; Huber, T. L.; Paddison, P. J. & Keller, G. M. (2006). Wnt and TGF-beta signaling 
are required for the induction of an in vitro model of primitive streak formation 
using embryonic stem cells. P Natl Acad Sci USA 103, 16806-16811. 
Gao, J. Z.; Dennis, J. E.; Solchaga, L. A.; Awadallah, A. S.; Goldberg, V. M. & Caplan, A. I. 
(2001). Tissue-engineered fabrication of an osteochondral composite graft using rat 
bone marrow-derived mesenchymal stem cells. Tissue Eng 7, 363-371. 
Gazit, D.; Ebner, R.; Kahn, A.J. & Derynck, R. (1993). Modulation of expression and cell 
surface binding of members of the transforming growth factor-beta superfamily 
during retinoic acid-induced osteoblastic differentiation of multipotential 
mesenchymal cells. Mol Endocrinol 7(2), 189-198. 
Giles, J. R.; Yang, X.; Mark, W. & Foote, R. H. (1993). Pluripotency of cultured rabbit inner 
cell mass cells detected by isozyme analysis and eye pigmentation of fetuses 
following injection into blastocysts or morulae. Mol Reprod Dev 36, 130-138. 
Giordano, A., Galderisi, U., Marino, I.R. (2007). From the laboratory bench to the patient's 
bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 
211(1), 27-35. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
342 
Gong, Y.; Slee, R. B.; Fukai, N.; Rawadi, G.; Roman-Roman, S.; Reginato, A. M.; et al. 
Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001). LDL receptor-
related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-
523. 
Gougos, A. & Letarte, M. (1988). Identification of a human endothelial cell antigen with 
monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 
141(6), 1925-1933. 
Grayson, W.L.; Zhao, F.; Izadpanah, R.; Bunnell, B. & Ma, T. (2006). Effects of hypoxia on 
human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell 
Physiol 207(2), 331-339. 
Handschel, J.; Berr, K.; Depprich, R. A.; Kubler, N. R.; Naujoks, C.; Wiesmann, H. P.; 
Ommerborn, M. A. & Meyer, U. (2008). Induction of osteogenic markers in 
differentially treated cultures of embryonic stem cells. Head Face Med 4, 10. 
Hegert, C.; Kramer, J.; Hargus, G.; Muller, J.; Guan, K.; Wobus, A.M.; Müller, P.K. & 
Rohwedel, J. (2002). Differentiation plasticity of chondrocytes derived from mouse 
embryonic stem cells. J Cell Sci 115(Pt 23), 4617-4628. 
Hematti, P. (2011). Human embryonic stem cell-derived mesenchymal progenitors: an 
overview. Methods Mol Biol 690, 163-174. 
Hong, J.H. & Yaffe, M.B. (2006). TAZ: a beta-catenin-like molecule that regulates 
mesenchymal stem cell differentiation. Cell Cycle 5(2), 176-179.  
Hu, H.; Hilton, M. J.; Tu, X.; Yu, K.; Ornitz, D. M. & Long, F. (2005). Sequential roles of 
Hedgehog and Wnt signaling in osteoblast development. Development 132, 49-60. 
Hu, J.; Smith, L. A.; Feng, K.; Liu, X.; Sun, H. & Ma, P. X. (2010). Response of human 
embryonic stem cell-derived mesenchymal stem cells to osteogenic factors and 
architectures of materials during in vitro osteogenesis. Tissue Eng Part A 16, 3507-
3514. 
Iannaccone, P. M.; Taborn, G. U.; Garton, R. L.; Caplice, M. D. & Brenin, D. R. (1994). 
Pluripotent Embryonic Stem-Cells from the Rat Are Capable of Producing 
Chimeras. Dev Biol 163, 288-292. 
Itskovitz-Eldor, J.; Schuldiner, M.; Karsenti, D.; Eden, A.; Yanuka, O.; Amit, M.; Soreq, H. & 
Benvenisty, N. (2000). Differentiation of human embryonic stem cells into embryoid 
bodies comprising the three embryonic germ layers. Mol Med 6, 88-95. 
Jiang, Y.; Jahagirdar, B.N.; Reinhardt, R.L.; Schwartz, R.E.; Keene, C.D.; Ortiz-Gonzalez, 
X.R.; Reyes, M.; Lenvik, T.; Lund, T.; Blackstad, M.; Du, J.; Aldrich, S.; Lisberg, A.; 
Low, W.C.; Largaespada, D.A. & Verfaillie, C.M. (2002). Pluripotency of 
mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49.  
Jiang, X.; Gwye, Y.; McKeown, S.J.; Bronner-Fraser, M.; Lutzko, C. & Lawlor, E.R. (2009). 
Isolation and characterization of neural crest stem cells derived from in vitro-
differentiated human embryonic stem cells. Stem Cells Dev 18(7), 1059-1070. 
Johnstone, B.; Hering, T.M.; Caplan, A.I.; Goldberg, V.M. & Yoo, J.U.  (1998). In vitro 
chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell 
Res 238(1), 265-272. 
Jukes, J. M.; Both, S. K.; Leusink, A.; Sterk, L. M. T.; Van Blitterswijk, C. A. & De Boer, J. 
(2008). Endochondral bone tissue engineering using embryonic stem cells. P Natl 
Acad Sci USA 105, 6840-6845. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
343 
Jones, E.A.; Kinsey, S.E.; English, A.; Jones, R.A.; Straszynski, L.; Meredith, D.M.; Markham, 
A.F.; Jack, A.; Emery, P. & McGonagle D. (2002). Isolation and characterization of 
bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46(12), 
3349-3360. 
Jones, E.A.; English, A.; Kinsey, S.E.; Straszynski, L.; Emery, P.; Ponchel, F. & McGonagle, D. 
(2006). Optimization of a flow cytometry-based protocol for detection and 
phenotypic characterization of multipotent mesenchymal stromal cells from human 
bone marrow. Cytometry B Clin Cytom 70(6), 391-399. 
Karaplis, A. C.; Luz, A.; Glowacki, J.; Bronson, R. T.; Tybulewicz, V. L. J.; Kronenberg, H. M. 
& Mulligan, R. C. (1994). Lethal Skeletal Dysplasia from Targeted Disruption of the 
Parathyroid Hormone-Related Peptide Gene. Genes Dev 8, 277-289. 
Karlsson, C.; Emanuelsson, K.; Wessberg, F.; Kajic, K.; Axell, M. Z.; Eriksson, P. S.; Lindahl, 
A.; Hyllner, J. & Strehl, R. (2009). Human embryonic stem cell-derived 
mesenchymal progenitors-Potential in regenerative medicine. Stem Cell Res 3, 39-50. 
Karp, J. M.; Ferreira, L. S.; Khademhosseini, A.; Kwon, A. H.; Yeh, J. & Langer, R. S. (2006). 
Cultivation of human embryonic stem cells without the embryoid body step 
enhances osteogenesis in vitro. Stem Cells 24, 835-843. 
Kato, M.; Patel, M. S.; Levasseur, R.; Lobov, I.; Chang, B. H.; Glass, D. A., 2nd; Hartmann, C.; 
Li, L.; Hwang, T. H.; Brayton, C. F., Lang, R.A.; Karsenty, G. & Chan, L. (2002). 
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent 
embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell 
Biol 157, 303-314. 
Kielty, C.M.; Kwan, A.P.; Holmes, D.F.; Schor, S.L. & Grant, M.E. (1985). Type X collagen, a 
product of hypertrophic chondrocytes. Biochem J 227(2), 545-554. 
Kimura, Y.; Matsunami, H.; Inoue, T.; Shimamura, K.; Uchida, N.; Ueno, T.; Miyazaki, T. & 
Takeichi, M. (1995). Cadherin-11 expressed in association with mesenchymal 
morphogenesis in the head, somite, and limb bud of early mouse embryos. Dev Biol 
169, 347–358. 
Kotobuki, N.; Katsube, Y.; Katou, Y.; Tadokoro, M.; Hirose, M. & Ohgushi, H. (2008). In vivo 
survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal 
stem cells (MSCs). Cell Transplant 17, 705-712. 
Kramer, J; Hegert, C.; Guan, K.; Wobus, A.M.; Müller, P.K. & Rohwedel, J. (2000). 
Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by 
BMP-2 and BMP-4. Mech Dev 92(2), 193-205.  
Kramer, J.; Hegert, C.; Hargus, G. & Rohwedel, J. (2005). Mouse ES cell lines show a variable 
degree of chondrogenic differentiation in vitro. Cell Biol Int 29(2), 139-146.  
Lanske, B.; Karaplis, A. C.; Lee, K.; Luz, A.; Vortkamp, A.; Pirro, A.; Karperien, M.; Defize, L. 
H. K.; Ho, C.; Mulligan, R. C.; Abou-Samra, A.B.; Jüppner, H.; Segre, G.V. & 
Kronenberg HM. (1996). PTH/PTHrP receptor in early development and Indian 
hedgehog-regulated bone growth. Science 273, 663-666. 
Le Blanc, K.; Gotherstrom, C.; Ringden, O.; Hassan, M.; McMahon, R.; Horwitz, E.; Anneren, 
G.; Axelsson, O.; Nunn, J.; Ewald, U.; Nordén-Lindeberg, S.; Jansson, M.; Dalton, 
A.; Aström, E. & Westgren, M. (2005). Fetal mesenchymal stem-cell engraftment in 
bone after in utero transplantation in a patient with severe osteogenesis imperfecta. 
Transplantation 79(11), 1607-1614. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
342 
Gong, Y.; Slee, R. B.; Fukai, N.; Rawadi, G.; Roman-Roman, S.; Reginato, A. M.; et al. 
Osteoporosis-Pseudoglioma Syndrome Collaborative Group (2001). LDL receptor-
related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-
523. 
Gougos, A. & Letarte, M. (1988). Identification of a human endothelial cell antigen with 
monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 
141(6), 1925-1933. 
Grayson, W.L.; Zhao, F.; Izadpanah, R.; Bunnell, B. & Ma, T. (2006). Effects of hypoxia on 
human mesenchymal stem cell expansion and plasticity in 3D constructs. J Cell 
Physiol 207(2), 331-339. 
Handschel, J.; Berr, K.; Depprich, R. A.; Kubler, N. R.; Naujoks, C.; Wiesmann, H. P.; 
Ommerborn, M. A. & Meyer, U. (2008). Induction of osteogenic markers in 
differentially treated cultures of embryonic stem cells. Head Face Med 4, 10. 
Hegert, C.; Kramer, J.; Hargus, G.; Muller, J.; Guan, K.; Wobus, A.M.; Müller, P.K. & 
Rohwedel, J. (2002). Differentiation plasticity of chondrocytes derived from mouse 
embryonic stem cells. J Cell Sci 115(Pt 23), 4617-4628. 
Hematti, P. (2011). Human embryonic stem cell-derived mesenchymal progenitors: an 
overview. Methods Mol Biol 690, 163-174. 
Hong, J.H. & Yaffe, M.B. (2006). TAZ: a beta-catenin-like molecule that regulates 
mesenchymal stem cell differentiation. Cell Cycle 5(2), 176-179.  
Hu, H.; Hilton, M. J.; Tu, X.; Yu, K.; Ornitz, D. M. & Long, F. (2005). Sequential roles of 
Hedgehog and Wnt signaling in osteoblast development. Development 132, 49-60. 
Hu, J.; Smith, L. A.; Feng, K.; Liu, X.; Sun, H. & Ma, P. X. (2010). Response of human 
embryonic stem cell-derived mesenchymal stem cells to osteogenic factors and 
architectures of materials during in vitro osteogenesis. Tissue Eng Part A 16, 3507-
3514. 
Iannaccone, P. M.; Taborn, G. U.; Garton, R. L.; Caplice, M. D. & Brenin, D. R. (1994). 
Pluripotent Embryonic Stem-Cells from the Rat Are Capable of Producing 
Chimeras. Dev Biol 163, 288-292. 
Itskovitz-Eldor, J.; Schuldiner, M.; Karsenti, D.; Eden, A.; Yanuka, O.; Amit, M.; Soreq, H. & 
Benvenisty, N. (2000). Differentiation of human embryonic stem cells into embryoid 
bodies comprising the three embryonic germ layers. Mol Med 6, 88-95. 
Jiang, Y.; Jahagirdar, B.N.; Reinhardt, R.L.; Schwartz, R.E.; Keene, C.D.; Ortiz-Gonzalez, 
X.R.; Reyes, M.; Lenvik, T.; Lund, T.; Blackstad, M.; Du, J.; Aldrich, S.; Lisberg, A.; 
Low, W.C.; Largaespada, D.A. & Verfaillie, C.M. (2002). Pluripotency of 
mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49.  
Jiang, X.; Gwye, Y.; McKeown, S.J.; Bronner-Fraser, M.; Lutzko, C. & Lawlor, E.R. (2009). 
Isolation and characterization of neural crest stem cells derived from in vitro-
differentiated human embryonic stem cells. Stem Cells Dev 18(7), 1059-1070. 
Johnstone, B.; Hering, T.M.; Caplan, A.I.; Goldberg, V.M. & Yoo, J.U.  (1998). In vitro 
chondrogenesis of bone marrow-derived mesenchymal progenitor cells. Exp Cell 
Res 238(1), 265-272. 
Jukes, J. M.; Both, S. K.; Leusink, A.; Sterk, L. M. T.; Van Blitterswijk, C. A. & De Boer, J. 
(2008). Endochondral bone tissue engineering using embryonic stem cells. P Natl 
Acad Sci USA 105, 6840-6845. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
343 
Jones, E.A.; Kinsey, S.E.; English, A.; Jones, R.A.; Straszynski, L.; Meredith, D.M.; Markham, 
A.F.; Jack, A.; Emery, P. & McGonagle D. (2002). Isolation and characterization of 
bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46(12), 
3349-3360. 
Jones, E.A.; English, A.; Kinsey, S.E.; Straszynski, L.; Emery, P.; Ponchel, F. & McGonagle, D. 
(2006). Optimization of a flow cytometry-based protocol for detection and 
phenotypic characterization of multipotent mesenchymal stromal cells from human 
bone marrow. Cytometry B Clin Cytom 70(6), 391-399. 
Karaplis, A. C.; Luz, A.; Glowacki, J.; Bronson, R. T.; Tybulewicz, V. L. J.; Kronenberg, H. M. 
& Mulligan, R. C. (1994). Lethal Skeletal Dysplasia from Targeted Disruption of the 
Parathyroid Hormone-Related Peptide Gene. Genes Dev 8, 277-289. 
Karlsson, C.; Emanuelsson, K.; Wessberg, F.; Kajic, K.; Axell, M. Z.; Eriksson, P. S.; Lindahl, 
A.; Hyllner, J. & Strehl, R. (2009). Human embryonic stem cell-derived 
mesenchymal progenitors-Potential in regenerative medicine. Stem Cell Res 3, 39-50. 
Karp, J. M.; Ferreira, L. S.; Khademhosseini, A.; Kwon, A. H.; Yeh, J. & Langer, R. S. (2006). 
Cultivation of human embryonic stem cells without the embryoid body step 
enhances osteogenesis in vitro. Stem Cells 24, 835-843. 
Kato, M.; Patel, M. S.; Levasseur, R.; Lobov, I.; Chang, B. H.; Glass, D. A., 2nd; Hartmann, C.; 
Li, L.; Hwang, T. H.; Brayton, C. F., Lang, R.A.; Karsenty, G. & Chan, L. (2002). 
Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent 
embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell 
Biol 157, 303-314. 
Kielty, C.M.; Kwan, A.P.; Holmes, D.F.; Schor, S.L. & Grant, M.E. (1985). Type X collagen, a 
product of hypertrophic chondrocytes. Biochem J 227(2), 545-554. 
Kimura, Y.; Matsunami, H.; Inoue, T.; Shimamura, K.; Uchida, N.; Ueno, T.; Miyazaki, T. & 
Takeichi, M. (1995). Cadherin-11 expressed in association with mesenchymal 
morphogenesis in the head, somite, and limb bud of early mouse embryos. Dev Biol 
169, 347–358. 
Kotobuki, N.; Katsube, Y.; Katou, Y.; Tadokoro, M.; Hirose, M. & Ohgushi, H. (2008). In vivo 
survival and osteogenic differentiation of allogeneic rat bone marrow mesenchymal 
stem cells (MSCs). Cell Transplant 17, 705-712. 
Kramer, J; Hegert, C.; Guan, K.; Wobus, A.M.; Müller, P.K. & Rohwedel, J. (2000). 
Embryonic stem cell-derived chondrogenic differentiation in vitro: activation by 
BMP-2 and BMP-4. Mech Dev 92(2), 193-205.  
Kramer, J.; Hegert, C.; Hargus, G. & Rohwedel, J. (2005). Mouse ES cell lines show a variable 
degree of chondrogenic differentiation in vitro. Cell Biol Int 29(2), 139-146.  
Lanske, B.; Karaplis, A. C.; Lee, K.; Luz, A.; Vortkamp, A.; Pirro, A.; Karperien, M.; Defize, L. 
H. K.; Ho, C.; Mulligan, R. C.; Abou-Samra, A.B.; Jüppner, H.; Segre, G.V. & 
Kronenberg HM. (1996). PTH/PTHrP receptor in early development and Indian 
hedgehog-regulated bone growth. Science 273, 663-666. 
Le Blanc, K.; Gotherstrom, C.; Ringden, O.; Hassan, M.; McMahon, R.; Horwitz, E.; Anneren, 
G.; Axelsson, O.; Nunn, J.; Ewald, U.; Nordén-Lindeberg, S.; Jansson, M.; Dalton, 
A.; Aström, E. & Westgren, M. (2005). Fetal mesenchymal stem-cell engraftment in 
bone after in utero transplantation in a patient with severe osteogenesis imperfecta. 
Transplantation 79(11), 1607-1614. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
344 
Lee, G.; Kim, H.; Elkabetz, Y.; Al Shamy, G.; Panagiotakos, G.; Barberi, T.; Tabar, V. & 
Studer, L. (2008). Corrigendum: Isolation and directed differentiation of neural 
crest stem cells derived from human embryonic stem cells (vol 25, pg 1468, 2007). 
Nat Biotechnol 26, 831-831. 
Leucht, P.; Kim, J. B.; Amasha, R.; James, A. W.; Girod, S. & Helms, J. A. (2008). Embryonic 
origin and Hox status determine progenitor cell fate during adult bone 
regeneration. Development 135, 2845-2854. 
Levenberg, S.; Huang, N. F.; Lavik, E.; Rogers, A. B.; Itskovitz-Eldor, J. & Langer, R. (2003). 
Differentiation of human embryonic stem cells on three-dimensional polymer 
scaffolds. Proc Natl Acad Sci U S A 100, 12741-12746. 
Martin, G. R. (1981). Isolation of a Pluripotent Cell-Line from Early Mouse Embryos 
Cultured in Medium Conditioned by Teratocarcinoma Stem-Cells. P Natl Acad Sci 
USA 78, 7634-7638. 
Masuyama, R.; Stockmans, I.; Torrekens, S.; Van Looveren, R.; Maes, C.; Carmeliet, P.; 
Bouillon, R. & Carmeliet, G. (2006). Vitamin D receptor in chondrocytes promotes 
osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116, 
3150-3159. 
Morrisskay, G.; Ruberte, E. & Fukiishi, Y. (1993). Mammalian Neural Crest and Neural Crest 
Derivatives. Ann Anat 175, 501-507. 
Naja, R. P.; Dardenne, O.; Arabian, A. & St Arnaud, R. (2009). Chondrocyte-specific 
modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-
dihydroxyvitamin D3 in growth plate development. Endocrinology 150, 4024-4032. 
Nakagawa, M.; Koyanagi, M.; Tanabe, K.; Takahashi, K.; Ichisaka, T.; Aoi, T.; Okita, K.; 
Mochiduki, Y.; Takizawa, N. & Yamanaka, S. (2008). Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat 
Biotechnol 26, 101-106. 
Nakajima, M.; Wakitani, S.; Harada, Y.; Tanigami, A. & Tomita, N. (2008). In vivo 
mechanical condition plays an important role for appearance of cartilage tissue in 
ES cell transplanted joint. J Orthopaed Res 26, 10-17. 
Nakanishi, M.; Kurisaki, A.; Hayashi, Y.; Warashina, M.; Ishiura, S.; Kusuda-Furue, M. & 
Asashima, M. (2009). Directed induction of anterior and posterior primitive streak 
by Wnt from embryonic stem cells cultured in a chemically defined serum-free 
medium. Faseb J 23, 114-122. 
Niemeyer, P.; Mehlhorn, A.; Jaeger, M.; Kasten, P.; Simank, H.G.; Krause, U. & Südkamp, 
N.P. (2004). Adult mesenchymal stem cells for the regeneration of musculoskeletal 
tissue. MMW Fortschr Med 146(51-52), 45. 
Okita, K.; Ichisaka, T. & Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313-U311. 
Olivier, E. N.; Rybicki, A. C. & Bouhassira, E. E. (2006). Differentiation of human embryonic 
stem cells into bipotent mesenchymal stem cells. Stem Cells 24, 1914-1922. 
Osborn, L.; Hession, C.; Tizard, R.; Vassallo, C.; Luhowskyj, S.; Chi-Rosso, G. & Lobb, R. 
(1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-
induced endothelial protein that binds to lymphocytes. Cell 59(6), 1203-1211. 
Pfander, D. & Gelse, K. (2007). Hypoxia and osteoarthritis: how chondrocytes survive 
hypoxic environments. Curr Opin Rheumatol 19, 457-462. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
345 
Phillips, B. W.; Belmonte, N.; Vernochet, C.; Ailhaud, G. & Dani, C. (2001). Compactin 
enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res 
Commun 284, 478-484. 
Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, 
M.A.; Simonetti, D.W.; Craig, S. & Marshak, D.R. (1999). Multilineage potential of 
adult human mesenchymal stem cells. Science 284(5411), 143-147. 
Quarto, N.; Wan, D. C.; Kwan, M. D.; Panetta, N. J.; Li, S. & Longaker, M. T. (2010). Origin 
matters: differences in embryonic tissue origin and Wnt signaling determine the 
osteogenic potential and healing capacity of frontal and parietal calvarial bones. J 
Bone Miner Res 25, 1680-1694. 
Quirici, N.; Soligo, D.; Bossolasco, P.; Servida, F.; Lumini, C. & Deliliers, G.L. (2002). 
Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor 
receptor antibodies. Exp Hematol 30(7), 783-791. 
Reyes, M.; Lund, T.; Lenvik, T.; Aguiar, D.; Koodie, L. & Verfaillie, C.M. (2001). Purification 
and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. 
Blood 98(9), 2615-2625.  
Rezwan, K.; Chen, Q. Z.; Blaker, J. J. & Boccaccini, A. R. (2006). Biodegradable and bioactive 
porous polymer/inorganic composite scaffolds for bone tissue engineering. 
Biomaterials 27, 3413-3431. 
Rose, F. R. & Oreffo, R. O. (2002). Bone tissue engineering: hope vs hype. Biochem Biophys Res 
Commun 292, 1-7. 
Sakurai, H.; Era, T.; Jakt, L. M.; Okada, M.; Naki, S.; Nishikawa, S. & Nishikawa, S. I. (2006). 
In vitro Modeling of paraxial and lateral mesoderm differentiation reveals early 
reversibility. Stem Cells 24, 575-586. 
Salgado, A. J.; Coutinho, O. P. & Reis, R. L. (2004). Bone tissue engineering: state of the art 
and future trends. Macromol Biosci 4, 743-765. 
Shimko, D. A.; Burks, C. A.; Dee, K. C. & Nauman, E. A. (2004). Comparison of in vitro 
mineralization by murine embryonic and adult stem cells cultured in an osteogenic 
medium. Tissue Eng 10, 1386-1398. 
Simmons, P.J. & Torok-Storb, B. (1991). CD34 expression by stromal precursors in normal 
human adult bone marrow. Blood 78(11), 2848-2853. 
Smith, L. A.; Liu, X. H.; Hu, J. & Ma, P. X. (2009). The influence of three-dimensional 
nanofibrous scaffolds on the osteogenic differentiation of embryonic stem cells. 
Biomaterials 30, 2516-2522. 
Smith, M. M. & Hall, B. K. (1990). Development and Evolutionary Origins of Vertebrate 
Skeletogenic and Odontogenic Tissues. Biol Rev 65, 277-373. 
Sottile, V.; Thomson, A. & McWhir, J. (2003). In vitro osteogenic differentiation of human ES 
cells. Cloning Stem Cells 5, 149-155. 
Stenderup, K.; Justesen, J.; Eriksen, E.F.; Rattan, S.I. & Kassem, M. (2001). Number and 
proliferative capacity of osteogenic stem cells are maintained during aging and in 
patients with osteoporosis. J Bone Miner Res 16(6), 1120-1129. 
St-Jacques, B.; Hammerschmidt, M.; & McMahon, A. P. (1999). Indian hedgehog signaling 
regulates proliferation and differentiation of chondrocytes and is essential for bone 
formation. Genes Dev 13, 2617-2617. 
Tada, S.; Era, T.; Furusawa, C.; Sakurai, H.; Nishikawa, S.; Kinoshita, M.; Nakao, K.; Chiba, 
T. & Nishikawa, S. I. (2005). Characterization of mesendoderm: a diverging point of 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
344 
Lee, G.; Kim, H.; Elkabetz, Y.; Al Shamy, G.; Panagiotakos, G.; Barberi, T.; Tabar, V. & 
Studer, L. (2008). Corrigendum: Isolation and directed differentiation of neural 
crest stem cells derived from human embryonic stem cells (vol 25, pg 1468, 2007). 
Nat Biotechnol 26, 831-831. 
Leucht, P.; Kim, J. B.; Amasha, R.; James, A. W.; Girod, S. & Helms, J. A. (2008). Embryonic 
origin and Hox status determine progenitor cell fate during adult bone 
regeneration. Development 135, 2845-2854. 
Levenberg, S.; Huang, N. F.; Lavik, E.; Rogers, A. B.; Itskovitz-Eldor, J. & Langer, R. (2003). 
Differentiation of human embryonic stem cells on three-dimensional polymer 
scaffolds. Proc Natl Acad Sci U S A 100, 12741-12746. 
Martin, G. R. (1981). Isolation of a Pluripotent Cell-Line from Early Mouse Embryos 
Cultured in Medium Conditioned by Teratocarcinoma Stem-Cells. P Natl Acad Sci 
USA 78, 7634-7638. 
Masuyama, R.; Stockmans, I.; Torrekens, S.; Van Looveren, R.; Maes, C.; Carmeliet, P.; 
Bouillon, R. & Carmeliet, G. (2006). Vitamin D receptor in chondrocytes promotes 
osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116, 
3150-3159. 
Morrisskay, G.; Ruberte, E. & Fukiishi, Y. (1993). Mammalian Neural Crest and Neural Crest 
Derivatives. Ann Anat 175, 501-507. 
Naja, R. P.; Dardenne, O.; Arabian, A. & St Arnaud, R. (2009). Chondrocyte-specific 
modulation of Cyp27b1 expression supports a role for local synthesis of 1,25-
dihydroxyvitamin D3 in growth plate development. Endocrinology 150, 4024-4032. 
Nakagawa, M.; Koyanagi, M.; Tanabe, K.; Takahashi, K.; Ichisaka, T.; Aoi, T.; Okita, K.; 
Mochiduki, Y.; Takizawa, N. & Yamanaka, S. (2008). Generation of induced 
pluripotent stem cells without Myc from mouse and human fibroblasts. Nat 
Biotechnol 26, 101-106. 
Nakajima, M.; Wakitani, S.; Harada, Y.; Tanigami, A. & Tomita, N. (2008). In vivo 
mechanical condition plays an important role for appearance of cartilage tissue in 
ES cell transplanted joint. J Orthopaed Res 26, 10-17. 
Nakanishi, M.; Kurisaki, A.; Hayashi, Y.; Warashina, M.; Ishiura, S.; Kusuda-Furue, M. & 
Asashima, M. (2009). Directed induction of anterior and posterior primitive streak 
by Wnt from embryonic stem cells cultured in a chemically defined serum-free 
medium. Faseb J 23, 114-122. 
Niemeyer, P.; Mehlhorn, A.; Jaeger, M.; Kasten, P.; Simank, H.G.; Krause, U. & Südkamp, 
N.P. (2004). Adult mesenchymal stem cells for the regeneration of musculoskeletal 
tissue. MMW Fortschr Med 146(51-52), 45. 
Okita, K.; Ichisaka, T. & Yamanaka, S. (2007). Generation of germline-competent induced 
pluripotent stem cells. Nature 448, 313-U311. 
Olivier, E. N.; Rybicki, A. C. & Bouhassira, E. E. (2006). Differentiation of human embryonic 
stem cells into bipotent mesenchymal stem cells. Stem Cells 24, 1914-1922. 
Osborn, L.; Hession, C.; Tizard, R.; Vassallo, C.; Luhowskyj, S.; Chi-Rosso, G. & Lobb, R. 
(1989). Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-
induced endothelial protein that binds to lymphocytes. Cell 59(6), 1203-1211. 
Pfander, D. & Gelse, K. (2007). Hypoxia and osteoarthritis: how chondrocytes survive 
hypoxic environments. Curr Opin Rheumatol 19, 457-462. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
345 
Phillips, B. W.; Belmonte, N.; Vernochet, C.; Ailhaud, G. & Dani, C. (2001). Compactin 
enhances osteogenesis in murine embryonic stem cells. Biochem Biophys Res 
Commun 284, 478-484. 
Pittenger, M.F.; Mackay, A.M.; Beck, S.C.; Jaiswal, R.K.; Douglas, R.; Mosca, J.D.; Moorman, 
M.A.; Simonetti, D.W.; Craig, S. & Marshak, D.R. (1999). Multilineage potential of 
adult human mesenchymal stem cells. Science 284(5411), 143-147. 
Quarto, N.; Wan, D. C.; Kwan, M. D.; Panetta, N. J.; Li, S. & Longaker, M. T. (2010). Origin 
matters: differences in embryonic tissue origin and Wnt signaling determine the 
osteogenic potential and healing capacity of frontal and parietal calvarial bones. J 
Bone Miner Res 25, 1680-1694. 
Quirici, N.; Soligo, D.; Bossolasco, P.; Servida, F.; Lumini, C. & Deliliers, G.L. (2002). 
Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor 
receptor antibodies. Exp Hematol 30(7), 783-791. 
Reyes, M.; Lund, T.; Lenvik, T.; Aguiar, D.; Koodie, L. & Verfaillie, C.M. (2001). Purification 
and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. 
Blood 98(9), 2615-2625.  
Rezwan, K.; Chen, Q. Z.; Blaker, J. J. & Boccaccini, A. R. (2006). Biodegradable and bioactive 
porous polymer/inorganic composite scaffolds for bone tissue engineering. 
Biomaterials 27, 3413-3431. 
Rose, F. R. & Oreffo, R. O. (2002). Bone tissue engineering: hope vs hype. Biochem Biophys Res 
Commun 292, 1-7. 
Sakurai, H.; Era, T.; Jakt, L. M.; Okada, M.; Naki, S.; Nishikawa, S. & Nishikawa, S. I. (2006). 
In vitro Modeling of paraxial and lateral mesoderm differentiation reveals early 
reversibility. Stem Cells 24, 575-586. 
Salgado, A. J.; Coutinho, O. P. & Reis, R. L. (2004). Bone tissue engineering: state of the art 
and future trends. Macromol Biosci 4, 743-765. 
Shimko, D. A.; Burks, C. A.; Dee, K. C. & Nauman, E. A. (2004). Comparison of in vitro 
mineralization by murine embryonic and adult stem cells cultured in an osteogenic 
medium. Tissue Eng 10, 1386-1398. 
Simmons, P.J. & Torok-Storb, B. (1991). CD34 expression by stromal precursors in normal 
human adult bone marrow. Blood 78(11), 2848-2853. 
Smith, L. A.; Liu, X. H.; Hu, J. & Ma, P. X. (2009). The influence of three-dimensional 
nanofibrous scaffolds on the osteogenic differentiation of embryonic stem cells. 
Biomaterials 30, 2516-2522. 
Smith, M. M. & Hall, B. K. (1990). Development and Evolutionary Origins of Vertebrate 
Skeletogenic and Odontogenic Tissues. Biol Rev 65, 277-373. 
Sottile, V.; Thomson, A. & McWhir, J. (2003). In vitro osteogenic differentiation of human ES 
cells. Cloning Stem Cells 5, 149-155. 
Stenderup, K.; Justesen, J.; Eriksen, E.F.; Rattan, S.I. & Kassem, M. (2001). Number and 
proliferative capacity of osteogenic stem cells are maintained during aging and in 
patients with osteoporosis. J Bone Miner Res 16(6), 1120-1129. 
St-Jacques, B.; Hammerschmidt, M.; & McMahon, A. P. (1999). Indian hedgehog signaling 
regulates proliferation and differentiation of chondrocytes and is essential for bone 
formation. Genes Dev 13, 2617-2617. 
Tada, S.; Era, T.; Furusawa, C.; Sakurai, H.; Nishikawa, S.; Kinoshita, M.; Nakao, K.; Chiba, 
T. & Nishikawa, S. I. (2005). Characterization of mesendoderm: a diverging point of 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
346 
the definitive endoderm and mesoderm in embryonic stem cell differentiation 
culture. Development 132, 4363-4374. 
Taiani, J.; Krawetz, R.J.; zur Nieden, N.I.; Wu, E.Y.; Kallos, M.S.; Matyas, J.R. & Rancourt, 
D.E. (2010). Reduced differentiation efficiency of murine embryonic stem cells in 
stirred suspension bioreactors. Stem Cells Dev 19(7), 989-998. 
Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Takashima, Y.; Era, T.; Nakao, K.; Kondo, S.; Kasuga, M.; Smith, A. G. & Nishikawa, S. I. 
(2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. 
Cell 129, 1377-1388. 
Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. 
S. & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. 
Science 282, 1145-1147. 
Thomson, J. A.; Kalishman, J.; Golos, T. G.; Durning, M.; Harris, C. P.; Becker, R. A. & Hearn, 
J. P. (1995). Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A 
92, 7844-7848. 
Toh, W.S.; Yang, Z.; Liu, H.; Heng, B.C.; Lee, E.H. & Cao, T. (2007). Effects of culture 
conditions and bone morphogenetic protein 2 on extent of chondrogenesis from 
human embryonic stem cells. Stem Cells 25(4), 950-960.  
Tondreau, T.; Lagneaux, L.; Dejeneffe, M.; Delforge, A.; Massy, M.; Mortier, C. & Bron, D. 
(2004a). Isolation of BM mesenchymal stem cells by plastic adhesion or negative 
selection: phenotype, proliferation kinetics and differentiation potential. 
Cytotherapy 6(4), 372-379. 
Tondreau, T.; Lagneaux, L.; Dejeneffe, M.; Massy, M.; Mortier, C.; Delforge, A. & Bron, D. 
(2004b). Bone marrow-derived mesenchymal stem cells already express specific 
neural proteins before any differentiation. Differentiation 72(7), 319-312. 
Tortelli, F.; Tasso, R.; Loiacono, F. & Cancedda, R. (2010). The development of tissue-
engineered bone of different origin through endochondral and intramembranous 
ossification following the implantation of mesenchymal stem cells and osteoblasts 
in a murine model. Biomaterials 31, 242-249. 
Tremoleda, J. L.; Forsyth, N. R.; Khan, N. S.; Wojtacha, D.; Christodoulou, I.; Tye, B. J.; 
Racey, S. N.; Collishaw, S.; Sottile, V.; Thomson, A. J.; Simpson, A.H.; Noble, B.S. & 
McWhir, J. (2008). Bone tissue formation from human embryonic stem cells in vivo. 
Cloning Stem Cells 10, 119-132. 
Trettner, S.; Seeliger, A. & zur Nieden, N. I. (2011). Embryoid body formation: recent 
advances in automated bioreactor technology. Methods Mol Biol 690, 135-149. 
Trivedi, P. & Hematti, P. (2007). Simultaneous generation of CD34(+) primitive 
hematopoietic cells and CD73(+) mesenchymal stem cells from human embryonic 
stem cells cocultured with murine OP9 stromal cells. Exp Hematol 35, 146-154. 
Tuch, B.E. (2006) Stem cells--a clinical update. Aust Fam Physician 35(9), 719-721. 
Vogel, W.; Grünebach, F.; Messam, C.A.; Kanz, L.; Brugger, W. & Bühring, H.J. (2003). 
Heterogeneity among human bone marrow-derived mesenchymal stem cells and 
neural progenitor cells. Haematologica 88(2), 126-133. 
Vortkamp, A.; Lee, K.; Lanske, B.; Segre, G. V.; Kronenberg, H. M. & Tabin, C. J. (1996). 
Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related 
protein. Science 273, 613-622. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
347 
Wakitani, S.; Takaoka, K.; Hattori, T.; Miyazawa, N.; Iwanaga, T.; Takeda, S.; Watanabe, T.K. 
& Tanigami, A. (2003). Embryonic stem cells injected into the mouse knee joint 
form teratomas and subsequently destroy the joint. Rheumatology 42(1), 162-165. 
Wakitani, S.; Aoki, H.; Harada, Y.; Sonobe, M.; Morita, Y.; Mu, Y.; Tomita, N.; Nakamura, Y.; 
Takeda, S.; Watanabe, T.K. & Tanigami, A. (2004). Embryonic stem cells form 
articular cartilage, not teratomas, in osteochondral defects of rat joints. Cell 
Transplant 13(4), 331-336. 
Warnke, P. H.; Springer, I. N. G.; Wiltfang, J.; Acil, Y.; Eufinger, H.; Wehmoller, M.; Russo, 
P. A. J.; Bolte, H.; Sherry, E.; Behrens, E. & Terheyden, H. (2004). Growth and 
transplantation of a custom vascularised bone graft in a man. Lancet 364, 766-770. 
Warnke, P. H.; Wiltfang, J.; Springer, I.; Acil, Y.; Bolte, H.; Kosmahl, M.; Russo, P. A. J.; 
Sherry, E.; Lutzen, U.; Wolfart, S. & Terheyden, H. (2006). Man as living bioreactor: 
Fate of an exogenously prepared customized tissue-engineered mandible. 
Biomaterials 27, 3163-3167. 
Weston, J. A. (1991). Sequential Segregation and Fate of Developmentally Restricted 
Intermediate Cell-Populations in the Neural Crest Lineage. Curr Top Dev Biol 25, 
133-153. 
Weston, J. A.; Yoshida, H.; Robinson, V.; Nishikawa, S.; Fraser, S. T. & Nishikawa, S. (2004). 
Neural crest and the origin of ectomesenchyme: Neural fold heterogeneity suggests 
an alternative hypothesis. Dev Dynam 229, 118-130. 
Williams, R. L.; Hilton, D. J.; Pease, S.; Willson, T. A.; Stewart, C. L.; Gearing, D. P.; Wagner, 
E. F.; Metcalf, D.; Nicola, N. A. & Gough, N. M. (1988). Myeloid-Leukemia 
Inhibitory Factor Maintains the Developmental Potential of Embryonic Stem-Cells. 
Nature 336, 684-687. 
Woll, N. L.; Heaney, J. D. & Bronson, S. K. (2006). Osteogenic nodule formation from single 
embryonic stem cell-derived progenitors. Stem Cells Dev 15, 865-879. 
Woo, K. M.; Chen, V. J. & Ma, P. X. (2003). Nano-fibrous scaffolding architecture selectively 
enhances protein adsorption contributing to cell attachment. J Biomed Mater Res A 
67A, 531-537. 
Xu, Y.; Malladi, P.; Zhou, D. & Longaker, M. T. (2007). Molecular and cellular 
characterization of mouse calvarial osteoblasts derived from neural crest and 
paraxial mesoderm. Plast Reconstr Surg 120, 1783-1795. 
Yaszemski, M. J.; Payne, R. G.; Hayes, W. C.; Langer, R. & Mikos, A. G. (1996). Evolution of 
bone transplantation: molecular, cellular and tissue strategies to engineer human 
bone. Biomaterials 17, 175-185. 
Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; 
Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; Slukvin, I.I. & Thomson, J.A. (2007). 
Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 
1917-1920. 
Young, R.G.; Butler, D,L.; Weber, W.; Caplan, A.I.; Gordon, S.L. & Fink, D.J. (1998). Use of 
mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 
16(4), 406-413. 
Zhang, Z.L.; Tong, J.; Lu, R.N.; Scutt, A.M.; Goltzman, D. & Miao, D.S. (2009). Therapeutic 
potential of non-adherent BM-derived mesenchymal stem cells in tissue 
regeneration. Bone Marrow Transplant 43(1), 69-81. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
346 
the definitive endoderm and mesoderm in embryonic stem cell differentiation 
culture. Development 132, 4363-4374. 
Taiani, J.; Krawetz, R.J.; zur Nieden, N.I.; Wu, E.Y.; Kallos, M.S.; Matyas, J.R. & Rancourt, 
D.E. (2010). Reduced differentiation efficiency of murine embryonic stem cells in 
stirred suspension bioreactors. Stem Cells Dev 19(7), 989-998. 
Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse 
embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676. 
Takashima, Y.; Era, T.; Nakao, K.; Kondo, S.; Kasuga, M.; Smith, A. G. & Nishikawa, S. I. 
(2007). Neuroepithelial cells supply an initial transient wave of MSC differentiation. 
Cell 129, 1377-1388. 
Thomson, J. A.; Itskovitz-Eldor, J.; Shapiro, S. S.; Waknitz, M. A.; Swiergiel, J. J.; Marshall, V. 
S. & Jones, J. M. (1998). Embryonic stem cell lines derived from human blastocysts. 
Science 282, 1145-1147. 
Thomson, J. A.; Kalishman, J.; Golos, T. G.; Durning, M.; Harris, C. P.; Becker, R. A. & Hearn, 
J. P. (1995). Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A 
92, 7844-7848. 
Toh, W.S.; Yang, Z.; Liu, H.; Heng, B.C.; Lee, E.H. & Cao, T. (2007). Effects of culture 
conditions and bone morphogenetic protein 2 on extent of chondrogenesis from 
human embryonic stem cells. Stem Cells 25(4), 950-960.  
Tondreau, T.; Lagneaux, L.; Dejeneffe, M.; Delforge, A.; Massy, M.; Mortier, C. & Bron, D. 
(2004a). Isolation of BM mesenchymal stem cells by plastic adhesion or negative 
selection: phenotype, proliferation kinetics and differentiation potential. 
Cytotherapy 6(4), 372-379. 
Tondreau, T.; Lagneaux, L.; Dejeneffe, M.; Massy, M.; Mortier, C.; Delforge, A. & Bron, D. 
(2004b). Bone marrow-derived mesenchymal stem cells already express specific 
neural proteins before any differentiation. Differentiation 72(7), 319-312. 
Tortelli, F.; Tasso, R.; Loiacono, F. & Cancedda, R. (2010). The development of tissue-
engineered bone of different origin through endochondral and intramembranous 
ossification following the implantation of mesenchymal stem cells and osteoblasts 
in a murine model. Biomaterials 31, 242-249. 
Tremoleda, J. L.; Forsyth, N. R.; Khan, N. S.; Wojtacha, D.; Christodoulou, I.; Tye, B. J.; 
Racey, S. N.; Collishaw, S.; Sottile, V.; Thomson, A. J.; Simpson, A.H.; Noble, B.S. & 
McWhir, J. (2008). Bone tissue formation from human embryonic stem cells in vivo. 
Cloning Stem Cells 10, 119-132. 
Trettner, S.; Seeliger, A. & zur Nieden, N. I. (2011). Embryoid body formation: recent 
advances in automated bioreactor technology. Methods Mol Biol 690, 135-149. 
Trivedi, P. & Hematti, P. (2007). Simultaneous generation of CD34(+) primitive 
hematopoietic cells and CD73(+) mesenchymal stem cells from human embryonic 
stem cells cocultured with murine OP9 stromal cells. Exp Hematol 35, 146-154. 
Tuch, B.E. (2006) Stem cells--a clinical update. Aust Fam Physician 35(9), 719-721. 
Vogel, W.; Grünebach, F.; Messam, C.A.; Kanz, L.; Brugger, W. & Bühring, H.J. (2003). 
Heterogeneity among human bone marrow-derived mesenchymal stem cells and 
neural progenitor cells. Haematologica 88(2), 126-133. 
Vortkamp, A.; Lee, K.; Lanske, B.; Segre, G. V.; Kronenberg, H. M. & Tabin, C. J. (1996). 
Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related 
protein. Science 273, 613-622. 
 
Osteogenesis from Pluripotent Stem Cells: Neural Crest or Mesodermal Origin? 
 
347 
Wakitani, S.; Takaoka, K.; Hattori, T.; Miyazawa, N.; Iwanaga, T.; Takeda, S.; Watanabe, T.K. 
& Tanigami, A. (2003). Embryonic stem cells injected into the mouse knee joint 
form teratomas and subsequently destroy the joint. Rheumatology 42(1), 162-165. 
Wakitani, S.; Aoki, H.; Harada, Y.; Sonobe, M.; Morita, Y.; Mu, Y.; Tomita, N.; Nakamura, Y.; 
Takeda, S.; Watanabe, T.K. & Tanigami, A. (2004). Embryonic stem cells form 
articular cartilage, not teratomas, in osteochondral defects of rat joints. Cell 
Transplant 13(4), 331-336. 
Warnke, P. H.; Springer, I. N. G.; Wiltfang, J.; Acil, Y.; Eufinger, H.; Wehmoller, M.; Russo, 
P. A. J.; Bolte, H.; Sherry, E.; Behrens, E. & Terheyden, H. (2004). Growth and 
transplantation of a custom vascularised bone graft in a man. Lancet 364, 766-770. 
Warnke, P. H.; Wiltfang, J.; Springer, I.; Acil, Y.; Bolte, H.; Kosmahl, M.; Russo, P. A. J.; 
Sherry, E.; Lutzen, U.; Wolfart, S. & Terheyden, H. (2006). Man as living bioreactor: 
Fate of an exogenously prepared customized tissue-engineered mandible. 
Biomaterials 27, 3163-3167. 
Weston, J. A. (1991). Sequential Segregation and Fate of Developmentally Restricted 
Intermediate Cell-Populations in the Neural Crest Lineage. Curr Top Dev Biol 25, 
133-153. 
Weston, J. A.; Yoshida, H.; Robinson, V.; Nishikawa, S.; Fraser, S. T. & Nishikawa, S. (2004). 
Neural crest and the origin of ectomesenchyme: Neural fold heterogeneity suggests 
an alternative hypothesis. Dev Dynam 229, 118-130. 
Williams, R. L.; Hilton, D. J.; Pease, S.; Willson, T. A.; Stewart, C. L.; Gearing, D. P.; Wagner, 
E. F.; Metcalf, D.; Nicola, N. A. & Gough, N. M. (1988). Myeloid-Leukemia 
Inhibitory Factor Maintains the Developmental Potential of Embryonic Stem-Cells. 
Nature 336, 684-687. 
Woll, N. L.; Heaney, J. D. & Bronson, S. K. (2006). Osteogenic nodule formation from single 
embryonic stem cell-derived progenitors. Stem Cells Dev 15, 865-879. 
Woo, K. M.; Chen, V. J. & Ma, P. X. (2003). Nano-fibrous scaffolding architecture selectively 
enhances protein adsorption contributing to cell attachment. J Biomed Mater Res A 
67A, 531-537. 
Xu, Y.; Malladi, P.; Zhou, D. & Longaker, M. T. (2007). Molecular and cellular 
characterization of mouse calvarial osteoblasts derived from neural crest and 
paraxial mesoderm. Plast Reconstr Surg 120, 1783-1795. 
Yaszemski, M. J.; Payne, R. G.; Hayes, W. C.; Langer, R. & Mikos, A. G. (1996). Evolution of 
bone transplantation: molecular, cellular and tissue strategies to engineer human 
bone. Biomaterials 17, 175-185. 
Yu, J.; Vodyanik, M. A.; Smuga-Otto, K.; Antosiewicz-Bourget, J.; Frane, J. L.; Tian, S.; Nie, J.; 
Jonsdottir, G. A.; Ruotti, V.; Stewart, R.; Slukvin, I.I. & Thomson, J.A. (2007). 
Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 
1917-1920. 
Young, R.G.; Butler, D,L.; Weber, W.; Caplan, A.I.; Gordon, S.L. & Fink, D.J. (1998). Use of 
mesenchymal stem cells in a collagen matrix for Achilles tendon repair. J Orthop Res 
16(4), 406-413. 
Zhang, Z.L.; Tong, J.; Lu, R.N.; Scutt, A.M.; Goltzman, D. & Miao, D.S. (2009). Therapeutic 
potential of non-adherent BM-derived mesenchymal stem cells in tissue 
regeneration. Bone Marrow Transplant 43(1), 69-81. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
348 
Zhou, Y. & Snead, M.L. (2008). Derivation of cranial neural crest-like cells from human 
embryonic stem cells. Biochem Biophys Res Commun 376(3), 542-547. 
zur Nieden, N. I. (2011). Embryonic stem cells for osteo-degenerative diseases. Methods Mol 
Biol 690, 1-30. 
zur Nieden, N. I.; Kempka, G. & Ahr, H. J. (2003). In vitro differentiation of embryonic stem 
cells into mineralized osteoblasts. Differentiation 71, 18-27. 
zur Nieden, N.I.; Kempka, G.; Rancourt, D.E. & Ahr, H.J. (2005). Induction of chondro-, 
osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: 
effect of cofactors on differentiating lineages. BMC Dev Biol 5(1), 1. 
Part 7 
Pluripotent Alternatives –  
Induced Pluripotent Stem Cells (iPSCs) 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 
 
348 
Zhou, Y. & Snead, M.L. (2008). Derivation of cranial neural crest-like cells from human 
embryonic stem cells. Biochem Biophys Res Commun 376(3), 542-547. 
zur Nieden, N. I. (2011). Embryonic stem cells for osteo-degenerative diseases. Methods Mol 
Biol 690, 1-30. 
zur Nieden, N. I.; Kempka, G. & Ahr, H. J. (2003). In vitro differentiation of embryonic stem 
cells into mineralized osteoblasts. Differentiation 71, 18-27. 
zur Nieden, N.I.; Kempka, G.; Rancourt, D.E. & Ahr, H.J. (2005). Induction of chondro-, 
osteo- and adipogenesis in embryonic stem cells by bone morphogenetic protein-2: 
effect of cofactors on differentiating lineages. BMC Dev Biol 5(1), 1. 
Part 7 
Pluripotent Alternatives –  
Induced Pluripotent Stem Cells (iPSCs) 
18 
The Past, Present and Future of 
Induced Pluripotent Stem Cells 
Koji Tanabe and Kazutoshi Takahashi 
Center for iPS Cell Research and Application 
Japan 
1. Introduction 
Our body is derived from only one cell, a fertilized egg. At the birth, the body consists of 220 
kinds of somatic cells. The fertilized egg divides many times during development. The resulting 
cells differentiate into many kinds of somatic cells, and a fertilized egg can differentiate into all 
of the different types of cells, including intraembryonic and extraembryonic tissues. This ability 
is called totipotency. Fertilized eggs differentiate into various kinds of somatic cells. However, 
somatic cells do not divide and differentiate into other types of somatic cells after differentiation 
in a disorderly manner. There are two possibilities to explain this. First, somatic cells can 
completely lose their potential to differentiate into other kinds of cells during development, or 
second, they may retain their potential, but such potential may be suppressed after 
development. The studies to elucidate how these processes occur were the origin of 
reprogramming science and regenerative medicine. 
In 1938, Spemann was the first person to carry out nuclear transplantation, but the experiment 
failed (Spemann, 1938). In 1952, Briggs and King transplanted the nucleus of a frog blastula 
into enucleated unfertilized eggs. The eggs developed into tadpoles. This was the first cloned 
animal with nuclear transplantation, and the origin of the cloning technique. An interesting 
discovery was that the later the nucleuses were taken during the developmental stage, the 
lower the efficiency of generating clone frogs. It was impossible to produce a cloned frog using 
the nucleus from a stage later than the development of a tailbud. At that time, they thought the 
information in the nucleus changed during development (Brigge & King, 1952). However, 
Gurdon arrived at a different conclusion from Briggs and King. He transplanted the nuclei of 
small intestinal epithelial cells into enucleated unfertilized eggs and obtained tadpoles 
(Gurdon, 1962). His data suggested that the nucleus of a somatic cell could be reprogrammed, 
and thereby regain the ability to differentiate into many kinds of cells. In 1997, the cloning of a 
sheep demonstrated that mammalian somatic cells could also be reprogrammed (Wilmut, 
1997). These data suggested that the information in the nucleus did not change irreversibly 
during development, and indicated that somatic cells have the potentially ability to 
differentiate into other kinds of cells after development. 
2. What are ES cells? 
It was necessary for the growth of developmental engineering and reprogramming science 
to make cells that can easily expand and maintain the ability to differentiate into many kinds 
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of cells in a cell culture system. Embryonic stem (ES) cells fulfilled these characteristics. ES 
cells have two important abilities, self-renewal and pluripotency. The ability for self-renewal 
allows these cells to grow semipermanently. Pluripotency, as described above, is the 
potential for differentiation into many kinds of cells which make up the body, such as 
muscle cells, neural cells and so on. Mouse ES cells injected into mouse blastocysts 
contribute to the formation of all tissues in the body. The mice generated from embryos 
injected with ES cells are called chimeric mice. These abilities of the ES cells made it possible 
to generate a large number of any type of cells that is desired.  
ES cells are established from fertilized eggs. The inner cell mass of blastocyst-stage embryos 
are transformed into ES cells. The fertilized egg is first cultured on feeder cells, which 
provide several necessary factors to the egg and ES cells. A few days later, the cells of the 
inner cell mass start to grow under culture conditions. ES cells are established from these 
growing cells. In 1981, mouse ES cells were established (Evans & Kaufman, 1981), and 
human ES cells were established in 1998 (Thomson et al 1998). Interestingly, the 
characteristics of human ES cells are different from those of mouse ES cells. The morphology 
of human ES cells was more like that of cynomolgus ES cells, which had been established 
several years before the mouse ES cells. Moreover, the optimal culture conditions differ 
between human ES cells and mouse ES cells. For example, leukemia inhibitory factor (LIF) 
and bone morphogenic protein (BMP) are important for maintaining the abilities of mouse 
ES cells in vitro. On the other hand, basic fibroblast growth factor (bFGF) and Activin A are 
required for the maintenance of human ES cells (Boiani & Schöler 2005).  
Mouse ES cells are commonly used as a tool to generate transgenic and gene-targeted 
animals. These animal models have controbuted to the progress made in basic and medical 
sciences. Human pluripotent stem cells, including ES cells, are expected to be a good source 
of regenerative medicine, because of their outstanding capacities such as self-renewal and 
pluripotency. 
3. Why generate artificial pluripotent stem cells? 
There are several outstanding issues surrounding the use of ES cells for clinical applications. 
One of them is immunological rejection. ES cells are generated from fertilized eggs, which 
can have different immunizing antigens from the recipient who received the regenerative 
medicine developed using these cells. If the somatic cells from ES cells are transplanted into 
recipients, then the cells are rejected by the patient’s own immune system. To overcome this 
problem, a new technique was developed. In this technique, the nuclei of an individual’s 
somatic cells are transplanted into enucleated unfertilized eggs. The eggs can then be used 
to make ES cells expressing the individual’s own immunizing antigens. These ES cells were 
called nuclear transfer ES cells (ntES cell), and the somatic cells derived from ntES cells are 
not rejected by the recipient after transplantation. These ntES cells have been established 
from not only mouse, but also from monkey cells (Rideout et al., 2000; Byrne et al., 2007). 
However, there have been no reports of human ntES cells. A likely reason for this is that the 
efficiency of generating ntES cells is very low, thus requiring a lot of embryos. This is not 
only a technical challange but also poses ethical problems. Generating human embryos for 
research is questionable and in case human nuclear transplanted embryos are implanted in a 
uterus, a cloned human would be generated. 
Another ethical problem is the use of ES cells for clinical applications. To generate ES cells, it 
is necessary to either injure or break up embryos, which are the origin of human life. To 
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avoid these problems, ES cells were generated from embryos which arrested their own 
development or from poor-quality embryos generated for in vitro fertilization treatments. 
The embryos which would be discarded as of low quality for fertilization treatment are used 
to make ES cells. Moreover, ES cells can be generated from single blastomers of embryos, 
and the biopsied embryos still can grow normally (Chung et al., 2006; Klimanskaya et al., 
2006; Chung et al., 2008). That is, ES cells can be generated without embryonic destruction. 
However, there are still discussions ongoing about how these “origins of human life” are 
handled by humans, and many countries have legislation preventing the development and 
use of ES cells. Therefore, it is necessary to be able to make pluripotent stem cells artificially 
for clinical applications. One of the major goals of nuclear reprogramming research is to 
generate ES-like cells by the conversion of somatic cells. 
4. The search for reprogramming factors 
One of the most difficult points for finding ways to convert somatic cells to pluripotent stem 
cell was to identify reprogramming factors. There had been hints based on the previous 
research on ES cells. For example, it was known that ES cells could induce pluripotency in 
somatic cells. When mouse somatic cells were hybridized with mouse ES cells, the nuclei of 
the somatic cells were reprogrammed. The genes which were normally expressed 
specifically in ES cells started to be expressed from the genome of somatic cells after 
hybridization. These hybridized somatic cells could differentiate into all three germ layers. 
When human ES cells were used for hybridization, the nuclei of human somatic cells were 
also reprogrammed. These data demonstrated that there were factors (reprogramming 
factors) which could induce pluripotency in somatic cells that were present not only in 
oocytes, but also in ES cells.  
It was hypothesized that tsuch reprogramming factors would be important factors for 
maintaining pluripotency in ES cells, and that the identification of the factors required by ES 
cells would also indicate the factors required for the reprogramming of somatic cells. These 
factors would be expressed highly and specifically in ES cells. Next, Then gene expression 
pattern was compared between ES cells and somatic cells to narrow down the candidates of 
reprogramming factors using a computer database. The selected genes were named ES cell 
associated transcripts (ECATs). These ECATs were expressed highly and specifically in ES 
cells. They also were shown to play important roles in maintaining the properties of ES cells. 
For example, Nanog is one of the ECATs. In the absence of Nanog, mouse ES cells 
differentiate into visceral or parietal endoderm, and do not maintain the properties of ES 
cells. An overexpression of Nanog also maintains the self-renewal of ES cells, independent 
of LIF (Mitsui, et al., 2003; Chambers, et al., 2003). 
In the 1990s, the transcription network involved in maintaining the pluripotency and self-
renewal of ES cells gradually started to become clearer. Oct3/4 was discovered to be one of 
key factors that make ES cells unique. Oct3/4 is expressed in ES cells, germ cells and also 
differentiated cells. However, the expression level of Oct3/4 is strictly regulated strictly by 
the transcription network in ES cells. A mere 1.5-fold increase in the expression of Oct3/4 
induces the differentiation of ES cells to primitive endoderm. A reduction in the expression 
of Oct3/4 by half leads ES cells to generate trophectoderm (Niwa et al, 2000). 
Moreover, several oncogenes were also shown to be important for maintaining ES cells. The 
Myc family of genes plays an important role in maintaining ES cells. Max is an important 
partner required for the functions of Myc. If max is knocked out, Myc family genes such as 
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c-Myc, L-Myc and N-Myc cannot exert their effects. Max knockout ES cells cannot survive. 
Several genes were selected from the ECATs, important transcripts for ES cells and 
oncogenes as candidates of reprogramming factors. It was necessary to create an assay 
system which evaluated candidates reprogramming factors for their ability to reprogram 
somatic cells. Fbx15 is another of the ECATs. That is, Fbx15 is expressed specifically in ES 
cells, and not in somatic cells. Fibroblasts with a G418 antibiotic resistance gene in the Fbx15 
locus were used for the assay system. Normal cells cannot survive in the presence of G418. If 
the fibroblasts are reprogrammed by the candidates, their Fbx15 locus is activated, the G418 
resistance genes are expressed, and the fibroblasts are resistant to G418. The cells that were 













A - An illustration of the Fbx15 reporter system. Fbx15 is a marker gene of ES cells which is specifically 
expressed in ES cells. Fbx15 is not expressed in fibroblasts. If fibroblasts are reprogrammed by 
reprogramming factors, then the Fbx15 locus is activated in the cells. These reprogrammed cells 
thereafter demonstrate resistance for G418; a tocix antibiotic to mammalian cells. 
B - An illustration of the Nanog reporter system. The Nanog locus is inactivated in somatic cells. On the 
other hand, the Nanog locus is activated in reprogrammed cells. The reprogrammed cells are positive 
for GFP (green fluorescent protein) and also show resistance for Puromycin ,  
C- MEFs and iPS cells carrying the Nanog reporter system. The iPS cells are positive for GFP driven by 
the Nanog reporter system. 
Fig. 1. Reporter system 
5. Creating the world’s first iPS cells  
Candidate reprogramming genes were introduced into mouse embryonic fibroblasts (MEF) 
carrying a Fbx15 reporter system. When 24 candidates were introduced into MEF at the 
same time, G418 resistant mouse ES-like colonies appeared about 2 weeks later. The 24 
candidates were narrowed down to just 4 factors: Oct3/4, Sox2, klf4 and c-Myc. The cells 
reprogrammed from somatic cells by these four factors were named “induced pluripotent 
stem cells” (iPS cells). Their global gene expression patterns were similar to those of mouse 
ES cells. The proliferation of iPS cells was also similar to ES cells. The iPS cells can 
differentiate into all 3 germ layers in vitro and in vivo. The iPS cells generated using the 
Fbx15 reporter system could also contribute to mouse embryos, but the chimeric embryos 
did not survive until birth (Takahashi & Yamanaka, 2006). These data indicated that these 
first iPS cells had many features like ES cells, but were not completely ES cell like. These iPS 
cells were considered to be only partially reprogrammed, so the reporter system was 
improved to facilitate the development of completely reprogrammed iPS cells. Nanog and 
Oct3/4 are more tightly associated with pluripotency in ES cells than Fbx15. The iPS cells 
established using a Nanog or Oct3/4 reporter system (Fig1.B,C) contributed to chimeric 
mouse embryos which survived beyond birth, and these improved iPS cells contribute to the 
germline of chimeric mice (Okita et al.,2007; Wernig et al.,2007; Maherali et al., 2007) (Fig,2). 
Moreover, it was reported that cloned live pups could be generated using iPS cells by 
tetraploid complementation (Kang et al., 2009). These studies strongly suggest that mouse 
iPS cells are substantially comparable to mouse ES cells, at least in terms of their 
differentiation potential.   
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A - iPS cells are injected into blastocysts to make chimera mice. iPS cells are injected into mouse 
blastocysts (middle) using a micro manipulation system consisting of a holding- (left) and a transfer 
pipette (right)  
B, C - Mouse iPS cells expressing red fluorescent proteins are injected into mouse blastocysts. The 
mouse iPS cells contribute to all tissues in the mice bodies. The right mouse pup is the chimera.  





Fig. 3. Comparing the morphologies among the mouse, rat and human. 
The mouse, rat and human morphologies of fibroblasts, iPS cells and ES cells. Mouse, rat 
and human iPS cell colonies are morphologically very similar to ES cell colonies. Mouse and 
at iPS and ES cell colonies are round shaped. On the other hand, human iPS and ES cell 
colonies are flat shaped and different for many properties compared to mouse and rat. 
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In 2007, Human iPS cells were established (Takahashi et al., 2007; Yu et al., 2007). This was 
only one year after the establishment of mouse iPS cells, which is remarkable considering 
that it took about 15 years to establish human ES cells after establishing mouse ES cells. The 
establishment of the human iPS cells was the result of the accumulation of knowledge 
regarding human ES cells and mouse iPS cell induction. Human iPS cells were established 
using two different combinations of reprogramming factors. Our group used Oct3/4, Sox2, 
and Klf4 with or without c-Myc. Another group used Oct3/4, Sox2, and Nanog, with or 
without Lin28 (Takahashi et al., 2007; Yu et al., 2007). Therefore, Oct3/4 and Sox2 were 
common between our combinations and the other group’s combinations. Human iPS cells 
can differentiate into all 3 germ layers in vitro (Fig.4) and in vivo (Fig.5). Up to now, rat, 
monkey, pig, dog and rabbit iPS cells have been established, however, the germline 
transmission of these iPS cells has not yet been reported (Liu et al., 2008; Jing et al., 2008; 
Wenlin etal., 2008; Esteban et al.,2009; Zhao et al.,2009; Shimada et al,. 2009; Wu et al., 2010; 





A - In vitro differentiation of human iPS cells into neurons (Red). 
B - In vitro differentiation of human iPS cells into smooth (Red) and striated muscles 
(Green).  





Fig. 5. In vivo differentiation of human iPS cells. 
Human iPS cells are transplanted into testes of immunocompromised mice. After about 10 
weeks, human iPS cells form teratomas. The teratomas are analysed histologically with 
haematoxylin and eosin staining. iPS cells are differentiated into all three germ layers. 
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6. Increasing the efficiency of generating iPS cells 
In the beginning of iPS cell research, the generation efficiency was very low, when Oct3/4, 
Sox2 and klf4 were used. It was found that the addition of c-Myc increased the efficiency 
more than 100-fold. Although c-Myc is not essential for iPS cell induction, it is a very 
effective factor for increasing the efficiency. The stability of c-Myc is regulated by the 
glycogen synthase kinase 3 (GSK3), which negatively regulates the Wnt pathway. 
Phosphorylated c-Myc is rapidly degraded by the ubiquitin-proteosome pathway. 
Therefore, Wnt may enhance the generation efficiency of iPS cells with Oct3/4, Sox2 and 
klf4 (Marson et al., 2008). However, precisely role of c-Myc during iPS cell induction is still 
unclear. Even when iPS cells were induced with c-Myc, the overall efficiency calculated 
from the number of potentially reprogrammable cells was less than 1%. Therefore, further 
improvements in the reprogramming efficiency were needed. There are three main ways to 
increase this efficiency: inducing iPS cells with the help of chemicals, adding more 
reprogramming factors, and changing the combination of reprogramming factors.  
6.1 Increasing the efficiency with chemical compounds 
6.1.1 Chemicals affecting DNA and histone modifications  
DNA and histone modifications regulate the gene expression patterns in cells. These 
modifications stably maintain the gene expression pattern to ensure the proper characteristics 
of the cells. During iPS cell generation, these modifications are changed dramatically (Deng et 
al., 2009). One of DNA methyltransferase inhibitors, 5-azacytidine, improved the efficiency of 
reprogramming by nuclear transfer. Several inhibitors of DNA methyltransferase, such as 5-
azacytidine, BIX-01294, RG108, etc. improved the efficiency of iPS cell generation. Inhibitors of 
histone deacetylases, for example valproic acid (VPA), butyrate, and trichostatin A, also 
increased the iPS cell generation efficiency. iPS cells could be induced using just Oct3/4 and 
Sox2 with VPA (Xu et al., 2008; Shi et al., 2008; Huangfu et al., 2008; Danwei et al., 2008; Mali et 
al., 2010; Zhou et al., 2010). It was thought that the effects of these chemicals which change 
DNA and histone modifications was due to inhibition of genes expressed in somatic cells and 
the induction of those expressed in ES cells. However, these chemicals have low specificity. 
They change the global DNA and histone modifications. Therefore, they inhibit not only the 
expression of genes which define somatic cells, but also those which are important for ES and 
iPS cells. As a result, if the concentration of these chemicals, the length of the treatment, or the 
original somatic cells are different, these chemicals may either have no effect or may even 
decrease the efficiency of iPS cell generation. 
6.1.2 Chemicals affecting molecular signaling pathways 
The inhibition of the Tgf- (transforming growth factor-) pathway increases the efficiency 
of mouse iPS cell generation. This inhibition is effective during the early stage of iPS cell 
induction. It is thought that the mechanism of Tgf- inhibition is as follows: Fibroblasts are 
mesenchymal cells, while iPS cells are epithelial cells. Fibroblasts need to be converted to 
epithelial cells during iPS cell induction (Payman et al., 2010). The Tgf- pathway 
accelerates the epithelial-to-mesenchymal transition. Therefore, the inhibition of the Tgf- 
pathway improves the iPS cell generation efficiency by accelerating the mesenchymal-to-
epithelial transition (Maherali et al., 2009). The combined inhibition of the MAPK pathway 
and the Tgf- pathway has a synergistic effect (Tongxiang et al., 2009) to generate human 
iPS cells. Moreover, using just an Oct3/4 transgene, mouse iPS cells can be generated from 
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neonatal human epithelial keratinocytes with a combination of compounds including 
sodium butyrate (a histone deacetylase inhibitor), PS48 (an activator of 3’-phosphoinositide-
dependent kinase-1), A-83-01 (a TGF-β inhibitor) and PD0325901 (a MAPK inhibitor) (Zhou 
et al., 2011). The use of 8-bromoadenosine 3', 5'-cyclic monophosphate (8-Br-cAMP), a cyclic 
AMP analog, also improves human iPS cell induction efficiency (Wang & Adjaye, 2010). It is 
thought that 8-Br-cAMP exerts its pro-induction effect by decreasing the expression of p53 
and increasing the expression of Cyclins. 
6.2 Promoting the efficiency by adding more reprogramming factors 
Suppressing p53 gene (TP53) expression enhances the efficiency of generating both mouse 
and human iPS cells (Kawamura et al., 2009;  Rowland et al., 2009; Hong et al., 2009; Li et al., 
2009; Marión et al., 2009; Utikal Banito et al., 2009). The p21 gene is one of the p53 
downstream targets. The p21 protein binds and inactivates the G1/S-cyclin dependent 
kinase (cdk) and S-Cdk complexes to stop the cell cycle. Overexpression of p21 negated the 
amplifying effect of p53 suppression during iPS cell transduction. Inhibition of the 
retinoblastoma protein (RB) also improves the efficiency of iPS cell generation. RB inhibits E2F, 
which accelerates the transcription of S-phase genes such as Cyclin E and Cyclin A. The 
complex of G1-cdk and Cyclin D1 phosphorylate RB. Phosphorylated RB cannot bind and 
inhibit E2F, allowing the cell cycle to progress from the G1 phase to the S phase. Cyclin D1 also 
increases the iPS cell generation efficiency. Rem2 GTPase is one of the suppressors of the p53 
pathway. Rem2 is an important player to maintain human ES cells. Rem2 enhances the 
reprogramming by regulating p53 and cyclinD1 (Edel et al., 2010). These data suggest that 
accelerating cell proliferation enhances the iPS cell generation efficiency. Promoting cell 
proliferation accelerates the stochastic process of reprogramming. However it is thought that 
the amplifying effect of p53 inhibition does not only result from the acceleration of cell cycle. It 
is known that p53 directly binds to the promoter region of the Nanog gene and suppresses its 
expression in mouse ES cells (Sabapathy et al., 1997; Qin et al., 2007). There is a possibility that 
p53 directly regulates the gene expression pattern during iPS cell generation. 
Lin28 is also effective for increasing the efficiency of reprogramming. Lin28 was used to 
generate some of the first human iPS cells. Like c-Myc, Lin28 is effective, but not essential, 
for the generation of human iPS cells. Lin28 is also effective in combination with Oct3/4, 
Sox2, Klf4 and c-Myc. Lin28 can interfere with the maturation of miRNA and promote their 
degradation by uridylation of miRNA (Heo et all., 2008 2009).  Let-7 is one of the Lin28-
associated miRNAs, and regulates the translation of several genes including c-Myc, K-Ras, 
Cyclin D1 and Hmga2. However, the mechanism(s) underlying the effects of Lin28 are still 
unclear (Kim et al., 2009; Viswanathan et al., 2009). 
Tbx3 also improves the efficiency of mouse iPS cell generation. The association between 
Tbx3, Nanog and Tcf3 is important for pluripotency and self-renew of ES cells. Moreover, 
the efficiency of germline transmission of mouse iPS cells with Tbx-3 is higher than that with 
just Oct3/4, Sox2 and Klf4 (Jianyong et al ., 2010).  
E-Cadherin also enhanced the mouse reprogramming efficiency in combination with 
Oct3/4, Sox2 and Klf4 or Oct3/4, Sox2, Klf4 and c-Myc. E-Cadherin is a molecule that 
mediates cell-cell interactions, and is upregulated during iPS cell induction. An antibody 
against the extracellular domain of E-cadherin reduced the efficiency of iPS cell generation. 
These data indicated that the cell-cell contact mediated by E-cadherin plays an important 
role in reprogramming (Chen et al., 2010). 
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In addition, some micro RNAs also enhance the efficiency of iPS cell generation. The mir-290 
cluster is highly expressed in mouse ES cells. The efficiency of mouse iPS cell generation 
with Oct3/4, Sox2 and klf4 was improved by miR-291-3p, miR-294, miR-295, which are 
included in the cluster of mir-290. However, they are not effective with c-Myc. While c-Myc 
binds to the promoter of the mir-290 cluster, introducing c-Myc could not induce the 
expression of the mir-290 cluster in fibroblasts. The promoter of the mir-290 cluster is 
regulated negatively by histone modifications in fibroblasts. These data suggest that the mir-
290 cluster is one of targets which are regulated by histone modification (Robert et al., 2009). 
6.3 Promoting the efficiency by using different combinations of reprogramming 
factors 
L-Myc is one of Myc family members. L-Myc is more effective for iPS cell induction than c-
Myc. Moreover, mouse iPS cells established with L-Myc contribute to the germline more 
efficiently than iPS cells with c-Myc (Nakagawa et al., 2010). 
Utf1 also improves the efficiency of mouse iPS cell generation. The number of mouse iPS 
colonies generated using a combination of Oct3/4, Sox2, klf4 and Utf1 was 10 times higher 
than that with Oct3/4, Sox2, Klf4 and c-Myc (Zhao et al., 2008). 
Recently, both human and mouse iPS cells were established using just the miR-302/367 cluster 
in the absence of any other reprogramming factors. The miR-302/367 cluster is highly 
expressed in ES and iPS cells, and is one of the target of Oct3/4 and Sox2. The use of just the 
miR302/367 cluster reprogrammed both human and mouse cells more efficiently and rapidly 
than the combination of Oct3/4, Sox2, Klf4 and c-Myc (Anokye-Danso et al., 2011).  
7. The methods for generating iPS cells  
There are two main methods to generate iPS cells. These are the genomic integration method 
and the genomic integration-free method. 
7.1 The Genomic integration method 
7.1.1 Retrovirus systems 
Retrovirus systems were used to generate the world’s first mouse and human iPS cells 
(Takahashi et al., 2006, 2007). The reprogramming factors introduced by a retrovirus system 
are strongly and stably expressed in somatic cells. The retrovirus system can efficiently 
introduce several reprogramming factors into cells at the same time. For these reasons, a 
retrovirus system efficiently generates iPS cells. Therefore, retrovirus systems are suitable 
for investigating the mechanism of iPS cell induction. Moreover, reprogramming factors 
introduced into somatic cells by the retrovirus system are gradually silenced during the 
reprogramming progress (Okita et al., 2007). This is good for iPS cell generation, because the 
expression of reprogramming factors in reprogrammed cells sometimes induces 
differentiation and cell death. Moreover, expressing transgenic reprogramming factors into 
reprogrammed cells can induce tumorigenicity. 
7.1.2 Lentivirus systems  
Lentiviral vectors were also used to generate some of the first human iPS cells (Yu et al., 
2007). Lentivirus can infect not only the dividing cells, but also non-dividing cells. 
Lentivirus infection therefore occurs independent of cell division. The reprogramming 
factors introduced by lentiviruses are stably expressed and less silenced than those 
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introduced by retroviruses. Thus, drug-inducible transgene expression systems were made 
because of these characteristics of lentiviral vectors to investigate the mechanism of iPS cell 
induction (Hockemeyer et al., 2008; Maherali et al., 2008). 
7.2 Genomic integration-free method  
The genes introduced by either retroviral or lentiviral vectors permanently integrate into the 
genome. Such integration increases the risk of tumorigenicity for two reasons: the first 
reason is that the integration can interrupt genes and gene promoters; the second reason is 
that the integrated factors could be reactivated unexpectedly by nearby promoters.  For 
clinical applications, these issues will need to be overcome. Recently, two principal ways to 
generate iPS cells without genomic integration were developed. One of them is removing 
the genomic integration after establishing iPS cells. The other is establishing iPS cells 
without integration vectors. 
7.2.1 Removing genomic integration after establishing iPS cells  
Cre-mediated recombination can be used to remove transgenes from the iPS cell genome.  
Human iPS cells have been established using lentiviral constructs including loxP sequences 
in their long terminal repeat (LTR). Established iPS cells can be treated with Cre 
recombinase in order to excise the lentiviral cassettes. However, the LTR sequence still 
remains in the genome (Soldner et al., 2009).  
A “piggybac” transposon vector system can also solve this problem. Using this system, the 
integrated reprogramming factor can be removed seamlessly. Transposase has activities for 
both the insertion and excision of transposon vectors by recognizing the TTAA tetra-
nucleotide sequence in the host genome ( Kaji et al., 2009  Woltjen et al., 2009 Yusa et al., 
2009). 
7.2.2 Generating iPS cells without genomic integration of reprogramming factors  
The first integration-free iPS cells were generated from mouse somatic cells with adenoviral 
vectors or conventional expression vectors (Okita et al, 2008; Stadtfeld et al, 2008). Recently, 
episomal vectors were used to generate human iPS cells (Yu et al., 2009). Episomal vectors 
consist of the replication origin and an Epstein-Barr nuclear antigen (EBNA). The EBNA 
vector can self-replicate and maintain the expression of transgenic reprogramming factors 
without genomic integration. However, the efficiency of reprogramming with episomal 
vectors was 10 times less than that with integration vectors. However, the efficiency was 
recently improved using episomal vectors encoding Oct3/4, Sox2, Klf4, L-Myc, Lin28 and a 
short hairpin RNA against p53 (Okita et al., 2011). This method is very promising for clinical 
application because the possibility of episomal vector genomic integration is very low, 
although it is still not zero. There is a little possibility that this vector may accidentally 
integrate into the genome accidentally. This possibility should be kept in mind when 
planning trial for clinical application. 
The Sendai RNA virus is also a promising vector that can be used to generate clinical-grade 
iPS cells. This virus does not enter into the nucleus for replication, transcription or 
translation. Therefore, there are no risks of insertion of reprogramming factors introduced 
by this virus. The transduction efficiency using this virus is comparable to that using 
retrovirus system. iPS cells were also established from less than 1 ml of peripheral blood 
using this system(Seki et al. 2010). If deficient sendai viral vectors are used for iPS induction, 
the vectors can be removed by siRNA (Nishimura et al., 2011). 
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introduced by retroviruses. Thus, drug-inducible transgene expression systems were made 
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There are also other ways to establish iPS cells virus-free. In one study, the Oct3/4, Sox2, 
Klf4 and c-Myc proteins were modified so that they could easily pass through the cell 
membrane. Both human and mouse iPS cells were established using these proteins 
(Hongyan et al., 2009; Dohoon et al., 2009). Another recent method used synthetic modified 
mRNA to generate iPS cells. RNA usually is unstable, and cells with foreign RNA are 
usually destroyed by the interferon response. The authors modified the medium and RNA 
to reduce the interferon response and improve RNA stability. The reprogramming factor 
from the introduced RNA was expressed stably and highly in the cells. Using this method, 
the possibility of genomic integration is very low, because of the nature of RNA. However, 
the possibility of cell damage in iPS cells generated using this method is slightly increased 
through the stressful induction method that  requires  consecutive introduction of RNA into 
cells for 2 weeks and artificial inhibition of the cell interferon response. A newer method to 
establish both human and mouse iPS cells used just miRNA, miR-200c, 302 and 369. These 
iPS cells were named mi-iPS cells (Miyoshi et al., 2011).  
Regardless of the method used to generate iPS cells, the quality of the cells should be 
examined from various points of view and in depth before using the iPS cells for clinical 
applications. 
8. Applications of iPS cells  
The major benefit of iPS cells is that they make it possible to obtain differentiated cells in the 
required quantities. It is expected that iPS cells can be used for regenerative medicine and 
drug discovery (Fig. 6). 
 
 
Fig. 6. A Schematic illustration for the application of iPS cells 
iPS cells derived from patients are useful for regenerative medicine and drug discovery. 
Somatic cells are taken by biopsy from patients. Patient specific iPS cells are then established 
from the somatic cells and differentiated into targeted cells. If the targeted cells are 
transplanted into a disease site, then this would bethat is very promising for regenerative 
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medicine. Moreover, if disease phenotypes are reproduced using patient specific iPS cells in 
vitro, patient specific responses to drugs could be evaluated for individual therapies. 
8.1 Using iPS cells for regenerative medicine 
Differentiated cells from iPS cells derived from the recipients are not rejected by the immune 
system upon transplantation, because they have the same immune markers as the recipient. 
Hence, it is expected that it will be possible to use iPS cells for cell therapy and regenerative 
medicine. Under this scheme, iPS cells are differentiated into the targeted cells, and the 
differentiated cells are then implanted into the diseased area where they can improve the 
patient’s symptoms. Experiment procedures utilizing lab animals have already proven the 
effectiveness of this scheme for cell therapy. For example, in a rat model of Parkinson’s 
disease, the implantation of dopamine-producing neurons that were differentiated from iPS 
cells led to a clear improvement in the symptoms (Hargus et al., 2010).  
It is also possible to use an approach which is a combination of cell therapy and gene 
therapy. Sickle cell anemia is a genetic blood disorder. The patient’s red blood cells are 
abnormally sickle-shaped, thus decreasing the oxygen transport ability of these patients’ red 
blood cells compared to unaffected individuals. This abnormality is caused by a mutation in 
one gene. The mutation was repaired using gene therapy technology in iPS cells derived 
from model mice. The repaired iPS cells were differentiated into hematopoietic stem cells. 
The hematopoietic stem cells transplanted into the model mice started to generate normal 
red blood cells and cure the disease (Hanna et al., 2007). The effectiveness of these 
procedures has not yet been examined in humans. However, Geron and Advanced Cell 
Technology announced that they plan to start clinical trials of transplantation of cells 
derived from ES cells for spinal cord injury and muscular degeneration, respectively. The 
current advances in the differentiation induction technology are likely to facilitate human 
studies. For example, the three dimensional structure of the neural retina differentiated from 
mouse ES cells was recently demonstrated (Eiraku et al., 2011). The combinations of the 
various differentiation technologies will likely provide new sources and methods for 
regenerative medicine. 
8.2 Concerns about using iPS cells for regenerative medicine 
Before using iPS cells for clinical applications, the safety of iPS cells should be sufficiently 
verified. In the paper introduced previously about curing Parkinson disease model mice, the 
authors suggested several problems that need to be overcome before this strategy can be 
clinically used. The major problem was that the model mice transplanted with the cells 
differentiated from iPS cells eventually developed teratomas (Hargus et al., 2010). The 
formation of teratomas in donor mice was caused by the undifferentiated cells that were 
present in the differentiated cells used for transplantation. It will therefore be necessary to 
develop an efficient differentiation system that allows for the invariably selection of targeted 
somatic cells and complete removal of all residual undifferentiated cells. In fact, attempts 
have already been made to select or generate iPS cells which can easily be differentiated into 
targeted cells. Recently, our group demonstrated that iPS cells have various differentiation 
potentials, and we found that several iPS cell clones were highly resistant to neural 
differentiation (Miura et al., 2009). Additional, studies to identify the genes responsible for 
the resistance are currently underway.  
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In addition, it was reported iPS cells carry epigenetic memory of the original somatic cells 
during early passages. This memory affects their differentiation potential. For example, iPS 
cells from B cells differentiated into blood progenitor cells more efficiently than iPS cells 
derived from fibroblasts (Kim et al., 2010; Polo et al., 2010). The origin of iPS cells was 
therefore reflected in the differentiation potential of the iPS cells. Further accumulation of 
this knowledge will help create smooth path toward the clinical application of iPS cells. 
8.3 Using iPS cells to understand pathological conditions and for drug discovery 
Utilizing the advantages provided by the iPS cell technology, differentiated cells which are 
difficult to harvest from patients and culture in vitro can now be obtained in sufficient 
quantities for researchers to study the pathogenesis of diseases and to perform drug 
screening. 
The first disease-specific iPS cells were established from patients with familial amyotrophic 
lateral sclerosis (ALS). However, the authors could not reproduce disease phenotypes using 
differentiated cells from ALS-iPS cells in vitro (Dimos et al., 2008). The first in vitro 
reproduction of a disease phenotype was achieved with iPS cells derived from a spinal 
muscular atrophy (SMA) patient. The motor neurons differentiated from SMA iPS cells 
exhibited the specific phenotype, such as a decreased number and size of neurons (Ebert et 
al., 2009). Recently, many disease models have been generated in vitro with iPS cells from 
patients with Familial dysautonomia (FD), myeloproliferative disorders, Dyskeratosis 
congenital, Leopard syndrome, Rett syndrome (REFS) and further diseases (Lee et al., 2009; 
Ye et al., 2009; Suneet et al., 2010; Carvajal et al., 2010; Marchetto et al., 2010 ).  
The effects and side effects of drugs are generally tested using laboratory animals, primarily 
rodents. However, the effects of drugs are different between humans and animals, and such 
studies were one of obstacle to developing new therapeutic agents. Moreover, using 
laboratory animals is cost- and time-intensive. The ability to test new agents on specific 
types of cells will greatly facilitate research on drug effects and toxicity. 
It was previously very difficult to collect sufficient amounts of targeted cells from patients 
for analyses until the iPS cell breakthrough. Many disease models using iPS cells will likely 
be established in the near future, because the safety of iPS cells (with regard to teratoma 
formation) is not an issue affecting basic research involving these cells. Therefore, iPS cell 
technologies will greatly facilitate our understanding of the pathogenesis of various diseases 
and will help in the development of novel treatments. 
9. Conclusion 
About sixty years ago, humans started to deeply and systematically investigate living things 
from a molecular point of view. The major purposes were to achieve a better understanding 
of the basic function of living things and to try to regulate and use these findings to enhance 
human lives. The biological systems improved by nature for several billion years are much 
more efficient than the engineered systems developed by humans. For example, fireflies 
emit thermal free light  while producing their fluorescence, while electric lights produce 
heat. This indicates that biological systems are very efficient.  Understanding and using 
these biological systems can therefore have a major impact on the quality of human life. 
The development of iPS cells is a prime example of using such biological systems for human 
benefit. The development of iPS cells has demonstrated that the characteristics of 
differentiated cells could be changed artificially by employing appropriate factors and 
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methods. Recently, new direct reprogramming technologies have been developed, which 
allowed somatic cells to be directly reprogrammed into targeted somatic cells without 
involving iPS cells.  
However, precisely what occurs during iPS cell inductionstill remains unclear. Human 
fertilized eggs differentiate into somatic cells for several months in the mother’s womb. 
During the induction of iPS cells, the somatic cells are artificially induced to regress into 
pluripotent stem cells within just a few weeks. There is a possibility that abnormalities are 
accumulated in iPS cells due to artificial reprogramming stresses. It will be necessary to 
uncover the full mechanism of iPS cell induction, and many questions remain to be 
answered, including: Exactly what is happening during iPS cell induction? Can 
abnormalities of cells be caused by what is happening during iPS induction? Moreover, it is 
also important to evaluate the established iPS cells in comparison to ES cells. Such research 
will help pave the way for iPS cells to move from a scientific finding to a medical revolution.  
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1. Introduction 
Pluripotent stem cells have the ability to differentiate into cells of the three primary germ 
layer lineages, ectoderm, mesoderm and endoderm. The most studied type of pluripotent 
stem cells are embryonic stem cells (ESC), cells derived from the inner cell mass of embryos 
at the blastocyst stage of development (Evans and Kaufman, 1981; Martin, 1981; Thomson et 
al., 1998). The pluripotent property of human embryonic stem cells (hESC) makes them 
useful for the development of cellular therapies to replace diseased or degenerated cells in 
the body. Moreover, hESC also possess the ability to propagate indefinitely in vitro while 
maintaining a normal karyotype, and thus can provide an unlimited source of cells for the 
development of cell replacement therapies (Pera et al., 2000). However, one of the major 
hurdles in hESC research has been the ethical implications of using stem cells derived from 
embryos. Furthermore, generation of patient-specific stem cell lines may overcome some of 
the issues associated with immuno-compatibility in cell replacement therapy.  
The breakthrough studies conducted by Shinya Yamanaka’s group demonstrated direct 
reprogramming of mouse or human fibroblasts back to pluripotent cells, creating so-called 
induced pluripotent stem cells (iPSC) (Takahashi et al., 2007; Takahashi and Yamanaka, 
2006). Studies of iPSC revolutionized stem cell research by creating a more reproducible 
method to generate sufficient amounts of patient-specific pluripotent cells and bypassing 
the ethical implications surrounding research utilizing human embryos. iPSC also provide 
an alternative approach to generate disease-specific lines for mechanistic studies in disease 
modeling, as well as high throughput screening for drug discovery or toxicology studies 
(Amabile and Meissner, 2009). As the area of iPSC research is rapidly evolving, this review 
aims to summarize and discuss the current techniques used for the generation of iPSC.  
2. Reprogramming factors used in generation of induced pluripotent stem 
cells (iPSC) 
The initial derivation of iPSC by Shinya Yamanaka’s group was achieved by overexpressing 
four transcription factors first in mouse and then human fibroblasts, namely Octamer-
binding transcription factor 4 (Oct4), Sex-determining region Y HMG box 2 (Sox2), Krüppel-
like factor 4 (Klf4) and v-myc myelocytomatosis viral oncogene homolog (c-Myc), often 
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the issues associated with immuno-compatibility in cell replacement therapy.  
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induced pluripotent stem cells (iPSC) (Takahashi et al., 2007; Takahashi and Yamanaka, 
2006). Studies of iPSC revolutionized stem cell research by creating a more reproducible 
method to generate sufficient amounts of patient-specific pluripotent cells and bypassing 
the ethical implications surrounding research utilizing human embryos. iPSC also provide 
an alternative approach to generate disease-specific lines for mechanistic studies in disease 
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The initial derivation of iPSC by Shinya Yamanaka’s group was achieved by overexpressing 
four transcription factors first in mouse and then human fibroblasts, namely Octamer-
binding transcription factor 4 (Oct4), Sex-determining region Y HMG box 2 (Sox2), Krüppel-
like factor 4 (Klf4) and v-myc myelocytomatosis viral oncogene homolog (c-Myc), often 
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referred to as the ‘Yamanaka factors’ (Takahashi et al., 2007; Takahashi and Yamanaka, 
2006). Alternatively, a study from James Thomson’s lab identified a different combination of 
factors for the generation of human iPSC, using Oct4, Sox2, Nanog and Lin28 (Yu et al., 
2007). Subsequent reports from many labs have contributed to a growing list of 
reprogramming factors used for iPSC generation, including Estrogen-related receptor beta 
(Esrrb), Sal-like 4 (Sall4), microRNAs (miRNA), simian virus 40 large-T (SV40LT) antigen 
and human telomerase reverse transcriptase (hTERT). This section will provide a 
background of our understanding of these reprogramming factors in regulating the cell fate 
of pluripotent stem cells and discuss their role during direct somatic cell reprogramming. 
Other strategies to enhance reprogramming efficiency will also be discussed, such as 
supplementation with small molecules as well as knockdown of p53, p21 and p16.  
2.1 Oct4 
Oct4 was one of the first transcription factors identified to be a master regulator of cellular 
pluripotency (Okamoto et al., 1990; Rosner et al., 1990; Scholer et al., 1989). During mouse 
development in vivo, Oct4 expression is restricted to the inner cell mass, primitive ectoderm 
and primordial germ cells (Pesce and Scholer, 2001). Similarly in vitro, ESC and embryonal 
carcinoma cells (ECC) have high expression of Oct4, which is reduced upon their 
differentiation (Assou et al., 2007; Rosner et al., 1990).  
Although expression of Oct4 is fundamental for the maintenance of pluripotency and 
development of the inner cell mass in mice (Nichols et al., 1998), complex regulation of its 
precise level is required to prevent cells from differentiating into other lineages. A transient 
increase in endogenous Oct4 levels has been observed upon mesodermal differentiation of 
mouse embryonic stem cells (mESC) (Zeineddine et al., 2006). Furthermore in various over-
expression studies, an increase in Oct4 expression can cause mESC to differentiate into 
endoderm, mesoderm and neuroectoderm lineages (Niwa et al., 2000; Shimozaki et al., 2003; 
Zeineddine et al., 2006). On the other hand, repression of Oct4 levels results in a loss of 
pluripotency and promotes trophectodermal differentiation in mESC and hESC (Matin et al., 
2004; Niwa et al., 2000). Consistent with these studies, Oct4 has been shown to directly 
inhibit the expression of major trophectoderm differentiation regulators such as caudal type 
homeobox 2 (Cdx2) and Eomesdermin (Eomes) (Liu et al., 1997; Liu and Roberts, 1996; Niwa 
et al., 2005). Together these studies highlight the significance of the critical range of Oct4 
level required to maintain ESC pluripotency (Niwa et al., 2000).  
As a master regulator of pluripotency, Oct4 was one of the original four factors utilized by 
Yamanaka and colleagues in the generation of iPSC in both mouse and human (Takahashi et 
al., 2007; Takahashi and Yamanaka, 2006). As seen in Oct4 over-expression and down-
regulation experiments in ESC, the precise level of Oct4 in combination with other 
reprogramming factors is also essential for efficient generation of iPSC (Papapetrou et al., 
2009). Using bicistronic vectors, Papapetrou et al. (2009) showed that a 3-fold higher 
expression of Oct4 compared to Sox2, Klf4 and c-Myc enhanced iPSC generation 
(Papapetrou et al., 2009). Interestingly, overexpression of Oct4 alone was sufficient to induce 
reprogramming in neural stem cells that already express high endogenous level of Sox2, c-
Myc and Klf4  (Kim et al., 2009b; Kim et al., 2009c). To date, most protocols for generation of 
iPSC require ectopic expression of Oct4, underlying the important role of Oct4 during direct 
somatic cell reprogramming (Feng et al., 2009b). Recently, Heng et al. (2010) demonstrated 
that an orphan nuclear receptor Nr5a2 can functionally replace Oct4 in the generation of 
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mouse iPSC (Heng et al., 2010). However, the precise role of Nr5a2 in regulating cell fate in 
pluripotent stem cells remains unclear. Further research is also needed to confirm the ability 
of Nr5a2 to replace Oct4 in human iPSC generation. 
2.2 Sox2 
Sox2 is an important transcription factor in pluripotent stem cells as well as precursor cells 
of the neural compartment. It is expressed in the inner cell mass, epiblast and 
extraembryonic ectodermal cells during mouse embryo development (Avilion et al., 2003; 
Miyagi et al., 2004). Unlike Oct4, Sox2 expression is maintained in neural stem cells (Ellis et 
al., 2004; Graham et al., 2003) and over-expression of Sox2 favors neural differentiation in 
mESC (Kopp et al., 2008; Zhao et al., 2004). Sox2 is known to interact with several binding 
partners, including Oct4 in the maintenance of pluripotency (Yuan et al., 1995). In a genome-
wide chromatin immunoprecipitation study in hESC, Sox2 and Oct4 were found to share 
many target genes, many of which are transcription factors important in development 
(Boyer et al., 2005).  
Importantly, Sox2 was shown to be indispensable for maintaining pluripotency. Sox2 
knockout mouse embryos are unable to form an epiblast and fail to develop past the 
implantation stage (Avilion et al., 2003). Down-regulation of Sox2 in mESC and hESC results 
in loss of pluripotency and differentiation towards the trophectoderm cell lineage (Adachi et 
al., 2010; Fong et al., 2008; Li et al., 2007; Masui et al., 2007). Somewhat surprising was the 
finding that expression of many Sox2 target genes were not affected by the loss of Sox2 
(Masui et al., 2007). The authors in this study suggested potential compensation of Sox2 
function by other members of the Sox family. Consistent with this idea, Nakagawa et al. 
(2008) demonstrated that Sox1, Sox3, Sox15 and Sox18 have the ability to replace Sox2 to 
some extent in iPSC generation (Nakagawa et al., 2008). To date, Sox2 and Oct4 remain to be 
the two fundamental reprogramming factors and are widely used in various protocols to 
generate iPSC. Similar to Oct4, it should be noted that ectopic expression of Sox2 can be 
omitted in the generation of iPSC, if the starting cell type expresses substantial levels of Sox2  
(Utikal et al., 2009a). 
2.3 Nanog 
Nanog is a homeodomain protein that is widely considered as a master regulator for stem 
cell pluripotency (Chambers et al., 2003; Mitsui et al., 2003). Nanog expression is restricted 
to the inner cell mass, epiblast and primordial germ cells in the early embryo, as well as a 
number of pluripotent cells lines such as ESC, ECC and embryonic germ cells (Chambers et 
al., 2003). During embryo development, Nanog plays a role in suppressing Cdx2, a master 
regulator of trophectoderm differentiation, and in turn suppression of Cdx2 specifies the 
inner cell mass fate (Chen et al., 2009). Moreover, Nanog can also physically interact with 
Oct4 (Wang et al., 2006) and cooperates extensively with Oct4 and Sox2 to form an 
autoregulated core-transcriptional network that maintain stem cell pluripotency (Boyer et 
al., 2005; Chen et al., 2008; Kim et al., 2008).  
Unlike Oct4 or Sox2, sustained expression of Nanog renders mESC and hESC resistant to 
differentiation (Chambers et al., 2003; Darr et al., 2006; Ivanova et al., 2006). However in the 
absence of Oct4, Nanog alone is not sufficient to maintain mESC self-renewal, suggesting 
that Nanog plays a subservient role in maintaining self-renewal (Chambers et al., 2003). This 
is also supported by evidence from Nanog knockdown studies. Although early studies 
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suggested that a reduction of Nanog resulted in differentiation of mESC and hESC (Fong et 
al., 2008; Hyslop et al., 2005; Ivanova et al., 2006; Mitsui et al., 2003), it was later discovered 
that transient down-regulation of Nanog can be reversible and does not necessarily mark 
commitment to differentiation (Chambers et al., 2007). In this respect, mESC can remain 
undifferentiated in the absence of Nanog, but are more prone to differentiation (Chambers 
et al., 2007). 
Given the important role of Nanog in establishing cell pluripotency, it was somewhat 
surprising that the initial derivation of iPSC could be achieved without the ectopic 
expression of Nanog (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). However, 
Nanog has proved to be a valuable marker for identification of fully reprogrammed iPSC 
that are germline competent (Maherali et al., 2007; Okita et al., 2007; Wernig et al., 2007). 
Furthermore, ectopic expression of Nanog in combination with Oct4, Sox2, Klf4 and c-Myc 
seems to accelerate the reprogramming kinetics of somatic cells to iPSC, but has no effect on 
the overall reprogramming efficiency (Hanna et al., 2009).  
2.4 Klf4 
Klf4 and its family members have emerged as important regulators for maintaining 
pluripotency. Klf4 belongs to the Krüppel-like factor (Klf) family of zinc finger transcription 
factors. Klf4 can act as an oncogene or a tumor suppressor gene depending on the 
physiological context (McConnell et al., 2007; Rowland and Peeper, 2006). Klf4 is usually 
expressed in adult tissues that possess some degree of regenerative capability, including 
intestine, gut, skin and testis (Nandan and Yang, 2009). Li et al. (2005) provided the first 
evidence that Klf4 plays a role in regulating stem cell pluripotency, by showing that 
overexpression of Klf4 prevents differentiation of mESC into erythroid progenitors (Li et al., 
2005). In conjunction with Oct4, Sox2 and c-Myc, Klf4 was among the first factors to be used 
to generate iPSC (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). However, the 
current view is that Klf4 acts only as a secondary factor to enhance somatic cell 
reprogramming, as iPSC can be generated without Klf4 using a different combination of 
reprogramming factors (Yu et al., 2007). Klf4 was later discovered to be an important 
component of the core transcriptional network that regulates expression of Oct4, Sox2, 
Nanog, Myc and also Klf4 itself (Chen et al., 2008; Kim et al., 2008). Furthermore, Klf4 can 
directly interact and cooperate with Oct4 and Sox2 to activate a subset of ESC specific genes, 
including Nanog and Lefty1 (Nakatake et al., 2006; Wei et al., 2009). Klf4 also acts to inhibit 
apoptosis by suppressing p53 (Rowland et al., 2005), which helps to reprogram somatic cells 
to a pluripotent state (See discussion below).  
Importantly, other Klf family members including Klf1, Klf2 or Klf5, can substitute for Klf4 in 
iPSC generation (Nakagawa et al., 2008), which suggests that functional redundancies exist 
among the Klf family members in establishing cell pluripotency. This also explains the 
observation that Klf4 knockdown in mESC exhibited no obvious phenotype (Jiang et al., 
2008; Nakatake et al., 2006), whereas triple knockdown of Klf2, Klf4 and Klf5 resulted in 
rapid differentiation of mESC (Jiang et al., 2008). However, isoform-specific functions of Klf4 
and Klf5 are also observed. Previous studies showed that Klf5 knockout mice result in 
embryo lethality and defects in implantation (Ema et al., 2008), whereas Klf4 knockout mice 
are normal during early embryo development but die soon after birth due to loss of skin 
barrier function (Segre et al., 1999). Furthermore, Ema et al. (2008) demonstrated that 
knocking out Klf5 in mESC results in spontaneous differentiation. Although introduction of 
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Klf4 can rescue the spontaneous differentiation phenotype, proliferation is significantly 
decreased (Ema et al., 2008). Further studies are needed to dissect the precise roles of 
different Klf members in regulating cell pluripotency.  
2.5 Lin28 
Lin28 encodes for a cytoplasmic RNA binding protein that acts as a translational enhancer 
(Polesskaya et al., 2007). It was first identified as a heterochronic gene that regulates the 
developmental timing pathway in Caenorhabditis elegans (Moss et al., 1997). A previous 
transcriptome study has shown that Lin28 is a hESC-specific gene, suggesting that it may 
play a role in regulating stem cell pluripotency (Richards et al., 2004). However, functional 
studies of Lin28 in hESC and mESC yielded opposing results. In mESC, Lin28 knockdown 
resulted in decreased cell proliferation while overexpression of Lin28 enhanced cell 
proliferation (Xu et al., 2009a). In sharp contrast, Lin28 knockdown in hESC had no obvious 
phenotype, whereas Lin28 overexpression reduced proliferation and promoted 
extraembryonic endoderm differentiation (Darr and Benvenisty, 2009). Further studies are 
clearly needed to elucidate whether Lin28 has a different role in maintenance of pluripotent 
stem cells in mice and humans.  
Lin28 was first used in combination with Nanog, Oct4 and Sox2 to generate human iPSC, 
acting as an enhancer for somatic cell reprogramming much like Klf4 (Yu et al., 2007). 
However, it remains unclear how Lin28 contributes to induction of pluripotency. It was 
demonstrated that Lin28 can block the processing of let7 microRNA family members, a 
group of pro-differentiation microRNA that also act as tumor suppressors (Melton et al., 
2010; Viswanathan et al., 2008). Members of the let7 microRNA family have been shown to 
repress expression of oncogenes such as c-Myc and Ras. Hence, down-regulation of let7 by 
Lin28 could increase cell proliferation and drive cellular transformation (Viswanathan et al., 
2009). Consistent with this idea, a recent study in mice demonstrated that Lin28 accelerates 
reprogramming kinetics by enhancing cell proliferation (Hanna et al., 2009). Another 
proposed mechanism of Lin28 action is that it can selectively regulate gene expression at a 
post-transcriptional level, enhancing translation of anti-differentiation mRNAs while 
degrading pro-differentiation mRNAs to maintain pluripotency. A previous study 
demonstrated that Lin28 can reside in polysomal ribosome fractions, in which mRNAs are 
translated (Balzer and Moss, 2007). Indeed, Lin28 has been shown to bind directly to Oct4 
mRNA in hESC to facilitate translation via interaction with RNA helicase A (Qiu et al., 
2010). Lin28 can also reside in P-bodies, in which mRNAs are degraded (Balzer and Moss, 
2007). Therefore, it remains speculative that Lin28 may be able to selectively degrade certain 
pro-differentiation mRNA to support stem cell pluripotency. Further studies are needed to 
confirm this hypothesis.  
2.6 c-Myc 
The basic helix–loop–helix/leucine zipper transcription factor c-Myc has a well documented 
role in cellular transformation and tumor progression, by controlling cell cycle, apoptosis, 
protein biosynthesis and metabolism (Kendall et al., 2006; Patel et al., 2004). c-Myc has been 
shown to regulate its target genes through interactions with the transcription machinery, as 
well as exerting epigenetic regulation via interactions with chromatin remodeling 
complexes, DNA methyltransferases and histone modifying enzymes (Eilers and Eisenman, 
2008). Subsequent studies also identified a critical role of c-Myc in mESC maintenance. 
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Overexpression of c-Myc enables mESC to be resistant to differentiation, whereas expression 
of a dominant negative form of c-Myc promotes differentiation (Cartwright et al., 2005). 
However, a functional study of c-Myc in hESC yielded rather different results. 
Overexpression of c-Myc drives hESC to apoptosis and differentiation into extraembryonic 
endoderm and trophectoderm (Sumi et al., 2007).  
c-Myc was identified as one of the four ‘Yamanaka factors’ initially used to generate both 
mouse and human iPSC (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). Other 
reports have also shown that c-Myc can be substituted by two other related family members, 
N-Myc and L-Myc, during somatic cell reprogramming (Blelloch et al., 2007; Nakagawa et 
al., 2008). Subsequent studies demonstrated that somatic cell reprogramming can be 
achieved without c-Myc, albeit with significantly reduced efficiency and slower kinetics 
(Nakagawa et al., 2008; Wernig et al., 2008). Furthermore, reactivation of c-Myc has been 
observed in iPSC following blastocyst incorporation, resulting in tumor formation in the 
chimeric mice (Okita et al., 2007). This finding raises concerns about the safety of using iPSC 
generated with c-Myc for clinical applications. Understanding the molecular mechanism of 
c-Myc contributions during somatic cell reprogramming may help identify alternative 
enhancers for iPSC generation that are less tumorigenic.  
Recent studies have shed light on the function of c-Myc during somatic cell reprogramming. 
Genome-wide analysis of promoter binding demonstrated that c-Myc regulates a different 
set of target genes compared to other pluripotency factors Oct4, Sox2 and Klf4 in mESC and 
iPSC (Chen et al., 2008; Kim et al., 2008; Sridharan et al., 2009). This suggests that c-Myc may 
have a very different function than the other transcription factors associated with induction 
of pluripotency. One proposed function is that c-Myc acts to repress expression of somatic 
genes during the early reprogramming stage, a process that is necessary before the 
activation of pluripotency gene networks (Sridharan et al., 2009). Another proposed 
mechanism of action of c-Myc is that it may induce a cell cycle program that is necessary for 
self-renewal of stem cells, activating genes which promote proliferation (i.e. cyclin A, cyclin 
E or E2F) and repressing genes associated with growth arrest (i.e. p21, p27) (Vermeulen et 
al., 2003). Finally, c-Myc may exert epigenetic control by modifying the chromatin structure 
to become suitable for activation of the self-renewal gene program, thus allowing somatic 
cells to revert back to a pluripotent state (Knoepfler et al., 2006).  
2.7 Esrrb 
Esrrb belongs to a subfamily of orphan nuclear receptors that are closely related to estrogen 
receptors  (Giguere, 2002). The natural ligands for Esrrb are currently unknown. 
Nevertheless, Esrrb and its family members can bind to DNA and function as 
transcriptional activators without exogenous ligands (Giguere, 2002). Most of our 
knowledge of the role of Esrrb in regulating self-renewal comes from studies in mice. 
Overexpression of Esrrb is sufficient to maintain self-renewal of mESC in conditions that 
favour differentiation, possibly by maintaining the level of Oct4 expression (Zhang et al., 
2008). Also, knockdown of Esrrb level in mESC induces differentiation (Ivanova et al., 2006; 
Loh et al., 2006). These results identify Esrrb as a positive regulator of ESC pluripotency.  
Indeed, Esrrb has been used as a factor to reprogram somatic cells back to a pluripotent 
state. In the presence of Oct4 and Sox2, Feng et al. (2009) demonstrated that Esrrb could 
replace Klf4 as an enhancer to reprogram mouse fibroblasts into iPSC, albeit with lower 
reprogramming efficiency (Feng et al., 2009a). Furthermore, another family member Esrrg 
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also possesses a similar reprogramming ability when used in conjunction with Oct4 and 
Sox2 (Feng et al., 2009a). Genome-wide analysis of promoter binding suggested that Essrb 
shares many target genes with Oct4 and Sox2. Further studies demonstrated that Esrrb is a 
binding partner for Oct4 and Nanog in mESC (van den Berg et al., 2010; Wang et al., 2006), 
but whether it physically interacts with Sox2 remains to be determined. In summary, Esrrb 
was found to have a partially overlapping role with Klf4 in enhancing somatic cell 
reprogramming in mice, by cooperating with other pluripotency factors Oct4 and Nanog. To 
date, it has not yet been determined whether Esrrb plays a similar role in human cells.  
2.8 Sall4 
Sall4 belongs to the family of Spalt transcription factors that are characterized by highly 
conservative C2H2 zinc-finger domains (Sweetman and Munsterberg, 2006). Mutations of 
Sall4 in humans results in Okihiro syndrome, a disease characterized by limb deformities 
and eye movement deficits (Kohlhase et al., 2002). Sall4 is highly enriched in ESC, and is one 
of the ‘embryonic cell associated transcripts’ identified by Shinya Yamanaka’s group. A 
previous study indicated that knockdown of Sall4 promoted mESC differentiation, most 
notably into the trophectoderm lineage (Zhang et al., 2006). However, follow-up reports 
showed that Sall4-null mESC are able to remain pluripotent, albeit with impaired 
proliferation (Tsubooka et al., 2009; Yuri et al., 2009). A study by Yuri et al. (2009) also 
demonstrated high expression of trophectoderm markers in Sall4-null mESC (Yuri et al., 
2009). These results suggest that Sall4 is not essential to maintain pluripotency in mESC, but 
rather functions to stabilize the stem cell phenotype by promoting proliferation and possibly 
repressing trophectoderm differentiation. Furthermore, it is becoming clear that Sall4 is an 
integral part of the autoregulatory transcriptional network of Oct4, Sox2 and Nanog in 
mESC (Lim et al., 2008; Yang et al., 2008). These results suggest Sall4 is a possible candidate 
reprogramming factor for induced pluripotency.  
Recently, Wong et al. (2008) discovered that Sall4 can enhance the efficiency of 
reprogramming mouse fibroblasts through fusion with mESC (Wong et al., 2008). Sall4 also 
increases the reprogramming efficiency of mouse fibroblasts when used in combination with 
Oct4, Sox2 and Klf4 (Tsubooka et al., 2009). However, this enhancing effect of Sall4 in 
reprogramming is inconsistent in different human fibroblast cell types, possibly due to 
variations in endogenous levels of Sall4 in different samples (Tsubooka et al., 2009). Further 
studies of Sall4 in human pluripotent stem cells will clarify whether the role of Sall4 in 
regulating cell pluripotency is conserved between mouse and human.  
2.9 miRNA 
miRNA are small RNAs that provide post-transcriptional control of gene regulation. Once 
transcribed, primary miRNA undergo multiple processing steps to become mature miRNA 
that promote degradation or repress translation of target mRNA (Siomi and Siomi, 2010). A 
previous report provided evidence that miRNA play an important role in the inter-
connected transcriptional network regulated by pluripotency factors Oct4, Sox2 and Nanog 
in mESC (Marson et al., 2008). The pluripotency factors Oct4, Sox2 and Nanog are able to 
bind and regulate expression of specific miRNA, activating ESC specific miRNA while 
repressing those associated with differentiation (Barroso-delJesus et al., 2008; Marson et al., 
2008). It is believed that miRNA serve as a mechanism for Oct4, Sox2 and Nanog to fine-
tune the expression level of their target genes.  
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Recently, Robert Blelloch’s group described a subset of miRNA that play an important role 
in regulating the cell cycle of mESC, termed ESC-specific cell cycle regulatory miRNA 
(ESCC miRNA) (Wang et al., 2008b). These ESCC miRNA promote G1 to S transition in 
mESC by repressing expression of various cyclin E-Cdk2 inhibitors (Wang et al., 2008b). In a 
follow-up study, the same group demonstrated that ESCC miRNA, in particular mir-291-3p, 
mir-294 and mir-295, are able to enhance reprogramming efficiency when used in 
combination with Oct4, Sox2 and Klf4. These ESCC miRNA are found to be downstream 
effectors of c-Myc, and thus are able to act as substitutes for c-Myc albeit to a lesser extent 
(Judson et al., 2009). Another set of ESCC miRNA, the mir-302 cluster, is able to reprogram 
human melanoma and prostate cancer cells to ESC-like cells in the absence of any other 
reprogramming factors (Lin et al., 2008). However, it remains unclear whether miRNA on 
their own can reprogram normal human primary cells to obtain genuine iPSC, as the 
effectiveness of miRNA-based reprogramming strategies may be cell-type dependent. 
Alternatively, others have shown that suppression of pro-differentiation let-7 miRNA can 
also enhance reprogramming efficiency in mouse fibroblasts when used in combination with 
the Yamanaka factors (Melton et al., 2010). This result is consistent with the previous 
identification of Lin28 as a reprogramming factor for iPSC generation, which presumably 
acts by blocking the processing of the let-7 family of miRNA (see discussion above). 
Together, these results demonstrate opposing roles played by different miRNA in somatic 
cell reprogramming and identify miRNA as important regulators of cell pluripotency. 
Future research to screen for reprogramming effects of other miRNA members will prove 
helpful in deriving a more efficient somatic cell reprogramming method. For instance, a 
recent report showed that miRNA-145 can regulate expression of Oct4, Sox2 and Klf4 and 
represses pluripotency in hESC (Xu et al., 2009b). Therefore, it will be interesting to see 
whether miRNA-145 can contribute to somatic cell reprogramming. 
2.10 SV40 LT antigen and hTERT 
The SV40LT antigen and the catalytic subunit of hTERT are well documented for their roles 
in establishing immortalized cells. Overexpression of SV40LT and hTERT along with 
another oncogene Ras are sufficient to confer tumorigenic transformation of normal human 
cells (Hahn et al., 1999). One proposed mechanism by which SV40 functions in 
tumorigenesis is by perturbing cellular senescence pathways through suppression of p53 
activity. As discussed below, reduced p53 activity during reprogramming has been shown 
to improve the efficiency. On the other hand, reduction in telomere length during the 
normal aging process results in replicative senescence and limits the cellular lifespan of 
human cells. Studies have shown that this can be prevented by ectopic expression of hTERT 
to drive cellular immortalization (Bodnar et al., 1998). High telomerase activity is observed 
in the vast majority of tumors and is vital for the progression of malignant tumor cells (Kim 
et al., 1994). Interestingly, a previous study has also shown that c-Myc overexpression can 
activate hTERT activity (Wu et al., 1999). Therefore, SV40LT and hTERT may be able to 
contribute to somatic cell reprogramming by activating a cell cycle program that is required 
for pluripotent cells, much like the role of c-Myc in induced pluripotency.  
Two recent studies sought to enhance the efficiency of generating human iPSC by 
supplementing reprogramming factors with hTERT and/or SV40LT (Mali et al., 2008; Park 
et al., 2008). In the study by Mali et al. (2008), the reprogramming cocktails were 
supplemented with the SV40LT transgene and resulted in accelerated reprogramming 
kinetics and up to a 70-fold increase in reprogramming efficiency, depending on the 
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combination of reprogramming factors used (Mali et al., 2008). Similar results were obtained 
by Park et al. (2008) when hTERT and SV40LT were included in their reprogramming 
strategy (Park et al., 2008). Interestingly, while the addition of both SV40LT and hTERT was 
reported to increase cell proliferation, there were no viral integrations of either transgene in 
the genomes of the iPSC derived by this method (Park et al., 2008). This suggests that 
SV40LT and hTERT might be acting indirectly on supportive cells to enhance 
reprogramming. However, concerns remain about the safety of using SV40LT and hTERT in 
somatic cell reprogramming for clinical purposes. In this regard, future research studying 
whether iPSC generated using these two factors are more tumorigenic will help address this 
issue. 
2.11 Silencing of the p53/p21/p16 pathway 
One of the major roadblocks in iPSC generation is overcoming cellular senescence. p53 is 
known as the guardian of the genome and deregulation of p53 function promotes cell 
immortalization and bypasses cell senescence (Bond et al., 1994). Recent discoveries 
suggested that high-passage somatic cells with short telomeres show a dramatic decrease in 
the efficiency for iPSC generation (Marion et al., 2009; Utikal et al., 2009b). In this regard, 
bypassing cellular senescence may help improve the reprogramming efficiency of iPSC 
generation.  
Key studies have shown that knockdown of senescence factors like p53, p21CIP1 or p16INK4a 
enhances the efficiency of generating iPSC (Banito et al., 2009; Hanna et al., 2009; Hong et al., 
2009; Kawamura et al., 2009; Marion et al., 2009). Furthermore, p53 knockdown can be used 
to replace c-Myc and/or Klf4 in the Yamanaka factors (Hong et al., 2009; Kawamura et al., 
2009). When used in combination with UTF1, a chromatin bound factor highly expressed in 
pluripotent stem cells, the addition of p53  further enhanced reprogramming efficiency by 
100-fold when used with the Yamanaka factors (Zhao et al., 2008). Together these studies 
show that the p53 pathway not only acts as a roadblock for cancer but also for iPSC 
generation. As p53 is a major tumor suppressor, further studies will be required to evaluate 
the safety of p53 knockdown in iPSC generation before these iPSC can be used in clinical 
applications.  
2.12 Small molecules used to enhance somatic cell reprogramming 
It is becoming clear that reversion of somatic cells to a pluripotent state involves epigenetic 
changes to chromatin that allow different sets of genes to be expressed (Feng et al., 2009b). 
Several reports have investigated the use of small molecules to enhance current cellular 
reprogramming methods towards developing a completely transgene-free strategy. 
Huangfu et al. (2008) discovered that the addition of valproic acid (VPA), a histone 
deacetylase (HDAC) inhibitor, can increase the efficiency and kinetics of reprogramming 
(Huangfu et al., 2008a). Moreover, two other HDAC inhibitors, suberoylanilide hydroxamic 
acid (SAHA) and trichostatin A (TSA), can also improve the reprogramming efficiency, 
albeit to a lesser extent. This provides supporting evidence for the notion that chromatin 
modifiers can help to overcome the epigenetic barrier to achieving complete 
reprogramming. Furthermore, addition of VPA was also able to substitute for c-Myc and 
Klf4 during reprogramming, thus reducing the number of reprogramming factors required 
to derive iPSC (Huangfu et al., 2008b). Similar effects on enhancing reprogramming 
efficiency were also observed with DNA methyltransferase inhibitors, including azacytidine 
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(AZA) (Huangfu et al., 2008a) and RG108 (Shi et al., 2008a), as well as a histone 
methyltransferase inhibitor, BIX-01294 (Shi et al., 2008b). In addition, a calcium channel 
agonist, BayK864, was shown to enhance the effect of BIX-01294 and further improve the 
efficiency of reprogramming (Shi et al., 2008a). However, it remains unclear whether or not 
the enhancing effect of these small molecules is dependent on the cell type used for iPSC 
generation. Altogether, it is thought that histone deacetylase inhibitors (VPA, TSA, SAHA), 
methyltransferase inhibitors (AZA, RG108, BIX-01294) and possibly other, yet to be 
identified, chromatin modifiers may function by relaxing chromatin to allow ectopically 
expressed transcription factors to bind. 
Other researchers have screened small molecule libraries to identify chemical compounds 
that can directly substitute for the known reprogramming factors. This led to the discovery 
of RepSox (replacement of Sox2), a small molecule used to substitute for Sox2 in the 
reprogramming strategy (Ichida et al., 2009). RepSox acts by inhibiting transforming growth 
factor-ß (TGF-ß) signaling, in turn increasing Nanog expression that ultimately promotes 
partially reprogrammed cells to become fully reprogrammed (Ichida et al., 2009). However, 
future research will need to address the specificity of RepSox in order to fulfill its potential 
in generating iPSC for clinical purposes.  
Finally, an interesting study by Esteban et al. (2010) demonstrated that antioxidants, in 
particular vitamin C, also help to enhance somatic cell reprogramming when used in 
combination with Oct4, Sox2 and Klf4 (Esteban et al., 2010). During early stages of 
reprogramming, vitamin C is able to overcome, at least partially, the cellular senescence 
roadblock by down-regulating p53 to allow the conversion of partially reprogrammed cells 
into fully reprogrammed iPSC (Esteban et al., 2010). This study provides a natural alternative 
to synthesized small molecules and may be easier to obtain approval for clinical usage.  
3. Techniques for delivery of reprogramming factors 
Since the seminal iPSC work by Shinya Yamanaka and colleagues, the field has moved 
forward at a rapid pace. Significant progress has been made in identifying new strategies to 
enhance the reprogramming efficiency and new methods to improve clinical safety. In this 
section, we will discuss the current techniques employed to introduce the reprogramming 
factors required for iPSC generation. It is important to note that the reprogramming 
efficiencies discussed in this section are only subject to the context described in the 
particular studies. Actual efficiency can be highly affected by many factors including the cell 
type of origin, the reprogramming factors and enhancer molecules used, as well as the 
methods to calculate reprogramming efficiencies.  
3.1 Integrating Viral Vectors 
3.1.1 Retroviral vectors 
Retroviruses are efficient gene delivery vectors widely used in a broad range of dividing cell 
types. They can integrate into the host cell genome to produce continuous transgene 
expression. However, slow dividing or non-dividing cells are extremely resistant to 
retroviral transduction and the random sites of transgene integration can lead to 
unpredicatable genetic mutations within the genome and aberrant transgene expression. 
The initial derivation of iPSC utilized retroviral-mediated introduction of Oct4, Sox2, Klf4 
and c-Myc to convert mouse fibroblasts back to a pluripotent state (Takahashi and 
Yamanaka, 2006), and subsequently human iPSC derived from adult dermal fibroblasts, 
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fetal and neonatal cells (Lowry et al., 2008; Park et al., 2008; Takahashi et al., 2007). Also, it 
was observed that retroviral mediated expression of transgenes were silenced during the 
iPSC reprogramming process (Hotta and Ellis, 2008). Even with a low efficiency (0.001%-
0.5%), these pioneering studies revealed a potential alternative to the controversial use of 
ESC as a cell source for cellular transplantation therapies.  
3.1.2 Lentiviral vectors 
At the same time Yamanaka and colleagues reported the generation of human iPSC by 
retroviral transduction, Yu et al. (2007) demonstrated successful derivation of human iPSC 
using lentiviral methods to deliver a different set of factors Oct4, Sox2, Nanog and Lin28 (Yu 
et al., 2007). Lentiviruses, a subclass of retroviruses, offer the capability of high-efficiency 
infection in both dividing and non-dividing cells with stable expression of the transgenes 
and low immunogenicity. These distinguishing characteristics allow lentiviral vectors to be 
used for reprogramming a broader range of somatic cell types. However, lentiviruses 
integrate randomly into the host genome, similar to other retroviruses, which may hinder 
the use of iPSC generated using these methods for clinical applications. Initial derivation of 
human iPSC using lentiviral transduction yielded reprogramming efficiencies of 0.01%, 
significantly lower than previous retroviral methods (Yu et al., 2007). Subsequent 
improvements have been made by using lentiviral vectors to deliver SV40T, UTF1 or p53 
shRNA to supplement the reprogramming cocktails, resulting in a 70-100 fold increase in 
reprogramming efficiency (Mali et al., 2008; Zhao et al., 2008). Moreover, reporter and 
antibiotic selection casettes have also been incorporated into lentiviral vectors to aid in the 
isolation of iPSC (Hotta et al., 2009a; Hotta et al., 2009b).  
Previous studies indicated that transient expression of reprogramming factors is sufficient to 
activate the endogenous pluripotent gene program to allow for direct cell reprogramming 
(Takahashi et al., 2007; Takahashi and Yamanaka, 2006). This led to the development of 
inducible lentiviral vectors for direct cell reprogramming. Inducible lentiviral methods 
provide for improved temporal control over the levels of reprogramming factor expression 
and have been used to study the timing of reprogramming as well as the molecular changes 
that occur during the process. This system relies on inclusion of an additional vector that 
constitutively expresses the reverse tetracycline transactivator (rtTA). In the presence of the 
drug doxycycline, the rtTA functions to drive expression of the reprogramming factors, 
while in the absence of doxycycline the reprogramming transgenes are not expressed. 
Utilizing this type of inducible system, it has been established that exogenous transgene 
expression is necessary for 8-12 days to induce reprogramming of mouse fibroblasts and 
dispensable thereafter (Brambrink et al., 2008; Maherali et al., 2008; Stadtfeld et al., 2008a). 
Moreover, when doxycycline was removed eight days after initial transduction, the partially 
reprogrammed cells were unable to survive in the ESC growth conditions due to incomplete 
reactivation of their self-renewal programs. This provides a useful system to select for cells 
that have completely reverted back to a pluripotent stem cell state.  
A major obstacle encountered when attempting to transduce cells with multiple viruses is 
that only a small proportion of the total cells will become infected with all the viruses. 
During reprogramming of somatic cells, those cells infected with few viruses may fail to 
become reprogrammed; leading to a low reprogramming efficiency. In this regard, 
development of a system to express the transgenes from a single vector may substantially 
improve the efficiency. One method to express the four transgenes from a single promoter is 
to insert the self-cleaving 2A and 2A-like sequences between each cDNA sequence 
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(Donnelly et al., 1997). These 2A sequences act by triggering ribosomal skipping that result 
in expression of each sequence in a stoichiometric fashion. Importantly, efficient 
polycistronic expression by 2A-mediated separation of transgenes was achieved in hESC 
(Hasegawa et al., 2007). This strategy was recently applied to derive mouse and human iPSC 
using a single lentiviral vector expressing Oct4, Sox2, Klf4, and c-Myc (Carey et al., 2009; 
Shao et al., 2009; Sommer et al., 2009). One of the advantages of using polycistronic vectors 
is that it reduces the difficulty of handling multiple lentiviral vectors for different 
reprogramming factors. Moreover, the mouse and human iPSC generated using this method 
had less viral integration sites compared to those developed using lentiviral delivery with 
individual gene. Indeed, the results showed as few as a single viral integration was 
sufficient for reprogramming (Carey et al., 2009; Shao et al., 2009). Minimizing the number 
of viral integrations reduces the risk of tumorigenesis and genomic instability. Also, the use 
of polycistronic vectors ensures expression of all four factors in the transduced cells. 
However, reprogramming efficiencies using this method were significantly lower (0.05%) 
than previous methods and reprogramming kinetics were also notably slower. One possible 
explanation for this low reprogramming efficiency is that the reprogramming factors are 
required to be expressed at an optimal stoichiometry in order to achieve efficient direct cell 
reprogramming (Papapetrou et al., 2009). Further studies are needed to clarify if the use of 
polycistronic vectors is an ideal technique to generate iPSC.  
3.2 Non-integrating and excisable approaches 
A major concern with employing retroviral or lentiviral-based methods to derive iPSC is 
random, uncontrollable integrations of the foreign transgenes into the host chromosomes. 
While many of these integrations prove harmless to the cells, residual viral portions have 
been shown to contribute to tumor formation. Moreover, it has been suggested that viral 
integrations may be a possible cause for some of the gene expression and differentiation 
potential differences observed between blastocyst-derived ESC and iPSC. These differences 
could affect the interpretation of results during mechanistic studies and, due to the safety 
concerns, severely limit the clinical applicability of these genetically modified cells. The 
previous approaches were extremely inefficient processes and most required multiple 
integration sites to induce reprogramming. Therefore, many groups have focused on 
developing novel, non-integrating methods for deriving iPSC. Some of these methods 
include the use of non-integrating vectors, excisable vectors, as well as RNA- or protein-
based reprogramming. 
3.2.1 Adenoviral vectors 
The use of adenoviral vectors is advantageous for somatic cell reprogramming as they lack 
the machinery to integrate into the host’s genome. This allows for high-level expression of 
exogenous genes with a low risk of integration of viral transgenes into the host genome. The 
viral titer becomes diluted after every cell division, which allows transient expression of the 
transgenes. On the other hand, multiple rounds of infections can achieve prolonged 
expression of transgenes, but it can be difficult to control gene expression levels. 
Reprogramming somatic cells with adenoviral vectors was first reported by Stadtfeld et al 
(Stadtfeld et al., 2008b). Using adenoviral vectors, mouse and human iPSC were generated 
using the Yamanaka factors in various donor cell types, albeit with a low reprogramming 
efficiency as compared to integrating viral vectors (0.0001%-0.001%) (Stadtfeld et al., 2008b; 
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Zhou and Freed, 2009). Similarly, a low reprogramming efficiency was also observed using 
polycistronic adenoviral vectors (Okita et al., 2008). One explanation for this is that it is 
difficult to maintain high enough transgene levels for multiple days to allow for 
reprogramming in many of the cells. Also, roughly 20% of the transduced cells were 
tetraploid, a phenomenon which was not seen in retroviral or lentiviral induced iPSC 
(Stadtfeld et al., 2008b). The reason for this observed tetraploidy is not clear, but it was 
suggested that cellular fusion or the presence of a rare aneuploid cell population in the 
starting culture may account for this result. Therefore, further research is needed to refine 
the use of adenoviral vectors in reprogramming somatic cells back to pluripotency.  
3.2.2 Plasmids 
Another non-integrating approach to transiently express reprogramming factors is the use 
of conventional plasmids. Previous reports have successfully generated integration-free 
mouse iPSC using polycistronic plasmids to express the Yamanaka factors (Gonzalez et al., 
2009; Okita et al., 2008). However, a substantial amount of iPSC colonies contained 
integration of the transgenes. Therefore, screening of transgene integration sites is still 
necessary for iPSC generated using this technique to ensure their safety for clinical 
purposes. Furthermore, multiple rounds of transfection are required to sustain transgene 
expression at the level required to induce reprogramming and the observed reprogramming 
efficiency remained significantly lower than seen with the retroviral vectors (Gonzalez et al., 
2009; Okita et al., 2008). Improvements to this plasmid-based method were made by the use 
of a polycistronic nonviral minicircle plasmid to reprogram human adult adipose stem cells 
(Jia et al., 2010). Minicircle DNA offers a higher transfection rate and is diluted at a slower 
rate than conventional plasmids when the cells divide. As a result, fewer rounds of 
transfections are required to generate iPSC. Using this method, Jia et al. (2010) generated 
integration-free human iPSC with a reprogramming efficiency of 0.005%, an efficiency still 
much lower than the integrating viral methods (Jia et al., 2010).  
Episomal plasmids are another non-integrating method used to reprogram somatic cells into 
iPSC. Unlike conventional plasmids where transient transgene expression is gradually 
depleted after each cell division, episomal plasmids can be stably established in a number of 
cell types by drug selection and removed when the drug selection is withdrawn. Using this 
technique, Yu et al. (2009) generated a polycistronic episomal vector to co-express seven 
transgenes to reprogram human foreskin fibroblasts into iPSC (Yu et al., 2009). It was 
observed that different positioning of the transgene in the polycistronic vector resulted in 
varying reprogramming efficiencies, with the highest efficiency achieved being 0.006%. In 
summary, these studies provide proof-of-principle of the derivation of human iPSC free of 
genomic integration. However, all plasmid-based methods used to date yield a lower 
reprogramming efficiency compared to integrative viral methods, possibly due to 
difficulties in sustaining high transgene expression. Further research combining enhancing 
factors, such as small molecules, may help improve the reprogramming efficiency of these 
plasmid-based methods.  
3.2.3 Cre recombinase /loxP system 
Early non-integrating methods, such as those utilizing adenoviral and plasmid introduction 
of reprogramming factors, were substantially less efficient than the retroviral methods. 
Excisable integrating vectors offer a plausible reprogramming strategy to overcome the 
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shortcomings of both the integrating retroviral and the transient expression methods. These 
excisable systems allow high initial transgene expression followed by subsequent removal of 
exogenous factors. Soldner et al. (2009) used inducible lentiviral vectors to derive human iPSC 
from fibroblasts collected from Parkinson’s disease patients followed by Cre-recombinase 
mediated excision of the viral transgenes (Soldner et al., 2009). In this study, a constitutively 
active reverse tetracycline transactivator lentivirus was infected along with doxycycline-
inducible lentiviruses for expression of the reprogramming factors, Oct4, Sox2, Klf4 and c-
Myc. The inducible lentiviruses were engineered to contain a loxP site in the 3’ LTR that 
becomes duplicated into the 5’ LTR during viral replication, producing loxP sites flanking 
the transgenes. Subsequent expression of Cre-recombinase by electroporation allows the 
transgenes to be excised. Using this technique, the authors reported successful derivation of 
integration-free human iPSC (Soldner et al., 2009). Interestingly, the authors also 
demonstrated that the gene expression profile of these iPSC are more similar to hESC 
following transgene excision, suggesting that residual integrated reprogramming factors 
perturb the transcriptional profile of human iPSC (Soldner et al., 2009). Although the Cre-
loxP system is the most efficient recombination system known, screening of integration-free 
iPSC clones is still required, as the authors reported that only sixteen out of 180 clones 
analyzed were integration-free following excision of transgene. Moreover, Cre-mediated 
excision of the transgenes does not remove the loxP sites, which raises concern of the 
possibility of disruption of endogenous gene expression. In this regard, a recent report by 
Chang et al. (2009) demonstrated successful generation of integration-free human iPSC 
where residual loxP sites did not interrupt expression of any genes or other functional 
sequences (Chang et al., 2009).  
3.2.4 piggyBac transposon-based system  
Unlike the Cre-loxP system, the advantage of transposon-based system is that transposases can 
remove all exogenous transposon elements from the host DNA. In particular, the piggyBac 
transposons have been demonstrated to be an efficient system for excisable gene delivery, 
delivering up to 10kb DNA fragments (Ding et al., 2005). Following transfection of the 
piggyBac transposons, transient expression of the transposase enzyme catalyzes the insertion 
or the excision event (Fraser et al., 1996). The advantage of the piggyBac transposon system is 
that it can be completely removed from the host genomes without altering the DNA sequences 
at the integration sites (Wang et al., 2008a). This led to the development of piggyBac-based 
reprogramming strategy that allowed generation of mouse and human iPSC using 
tetracycline-inducible or polycistronic expression of reprogramming factors (Kaji et al., 2009; 
Woltjen et al., 2009; Yusa et al., 2009). A high reprogramming efficiency of 2.5% was reported 
in the generation of mouse iPSC using this technique (Kaji et al., 2009). Furthermore, the 
integration sites were sequenced to confirm that excision of transgenes did not alter the host 
genome. Therefore, the piggyBac transposon system represents an efficient non-integrative 
approach to generate iPSC. However, excision of the transgenes by the transposase may still 
lead to micro-deletions of the genomic DNA (Wang et al., 2008a), which could hinder the 
clinical application of iPSC generated using this method.  
3.2.5 RNA and protein-based reprogramming  
Since all of the reprogramming strategies highlighted above create the risk of unexpected 
genetic modifications, many groups have begun to devise ways to reprogram somatic cells 
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in the absence of genetic modification. Yakubov et al. (2010) recently developed a 
reprogramming technique by transfecting RNA synthesized in vitro from cDNA of Oct4, 
Lin28, Sox2, and Nanog to generate iPSC from human fibroblasts (Yakubov et al., 2010). This 
method harnesses the power of the endogenous translational machinery for proper protein 
folding and post-translational modifications. Also, this method of generating iPSC 
eliminates the risks associated with the use of viruses and DNA transfection methods. 
However, at least five consecutive transfections were necessary to reprogram these human 
fibroblasts as the transfected RNAs have a limited half-life. Finally, the reprogramming 
efficiency (0.05%) remained lower than those observed for integrating viral methods. 
Further characterization is also needed to confirm the pluripotency of the iPSC-like cells 
generated using this method and to prove the feasibility of RNA-based reprogramming. 
An alternate approach to somatic cell reprogramming without genetic modification is using 
protein transduction. Importantly, a previous study demonstrated that protein tagged with 
a C-terminus poly-arginine domain allows efficient protein transduction through the cell 
membrane (Matsushita et al., 2001). Using direct protein delivery of reprogramming factors, 
two groups have report successful derivation of iPSC with the Yamanaka factors (Kim et al., 
2009a; Zhou et al., 2009). Zhou et al. (2009) was the first to use recombinant reprogramming 
factors tagged with the poly-arginine domain to generate mouse iPSC. This virus-free and 
DNA-free method yielded a reprogramming efficiency of 0.006% with the use of an 
enhancer molecule VPA (Zhou et al., 2009). In addition, Kim et al. (2009) used whole cell 
extract from human embryonic kidney cells overexpressing the Yamanaka factors for the 
generation of human iPSC, yielding a reprogramming efficiency of 0.001% (Kim et al., 
2009a). Both studies generated iPSC without any genetic modification, making them suitable 
for clinical applications. This direct protein transduction method also eradicates the need to 
screen for integration-free iPSC, thus shortening the time required for generating clinical 
grade iPSC. However, the reprogramming efficiency achieved with this method is still far 
lower than those obtained with viral mediated reprogramming. Moreover, multiple rounds 
of treatment are required during the reprogramming process as the recombinant proteins 
become degraded overtime. Nevertheless, these studies proved the feasibility of protein-
based reprogramming methods and improvements to this technique could be important for 
final clinical application of iPSC.  
4. Conclusions 
The clinical potential of hESC for cell replacement therapies and for studying human 
diseases is undeniable. However, the use of these cells has been constantly burdened by 
both ethical (destruction of human embryos) and practical concerns (lack of available 
embryos, difficulties with generation of histo-compatible hESC). The conversion of somatic 
cells into pluripotent cells may overcome many of these roadblocks. Large numbers of 
embryos are no longer needed to create banks of patient-matched lines, since cells can now 
be harvested directly from each patient to create iPSC that are genetically identical and 
immune-compatible. Since the initial derivation of iPSC using the four Yamanaka factors, a 
growing list of reprogramming factors have been identified that either permit or enhance 
the reprogramming process. Moreover, researchers have begun to study other ways to 
improve the reprogramming efficiency, including the use of miRNA, small molecules, and 
several different methods to overcome barriers that prevent direct somatic cell 
reprogramming.  
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The first generation iPSC methods involved integration of viral transgenes, but the clinical 
necessity for deriving iPSC without these viral transgenes has pushed many researchers to 
develop alternative methods. The use of inducible polycistronic lentiviral vectors has 
already evolved to the utilization of excisable Cre-loxP and piggyBac expression systems, 
non-integrating plasmids, and recombinant proteins and RNA transfection as tools for 
generating iPSC. Advances in these non-viral, non-integrating methods will presumably 
continue until a method is discovered that can, with high efficiency, be used to derive 
patient-specific iPSC lines in a technically simple manner which can be adopted by many 
researchers and clinicians. In this regard, pursuing the development of protein-based and 
small molecule-based reprogramming methods may be most beneficial. However, these 
methods are still at an early stage and further improvements are needed to achieve high 
reprogramming efficiencies. Interestingly, a recent report utilized lentiviral vectors to 
deliver three transgenes and demonstrated direct conversion of mouse fibroblasts into 
neuronal like cells, bypassing the need of reprogramming back to a pluripotent state 
(Vierbuchen et al., 2010). Further research is needed to develop similar non-viral methods 
and to translate these techniques to human cells for clinical applications. Many 
methodologies used in the derivation of iPSC can be applied to study direct conversion of a 
somatic cell into another cell type of interest. However, the disadventagous of such direct 
reprogramming of a somatic cell into another lineage is that the reprogrammed cells are 
terminally differentiated and are not proliferating. Therefore, this reprogramming strategy 
is not ideal for large scale production to yield cells for the development of cell replacement 
therapies. In this regard, direct reprogramming of a somatic cell to a progenitor stage, where 
the progenitor cells remain proliferative, may prove advantageous. Recent studies also 
showed that iPSC retain an ‘epigenetic memory’ of their origins, where differentiation of 
iPSC to their tissue of origin is more efficient than other lineages (Kim et al., 2010; Polo et al., 
2010). This could be used as a strategy to derive efficient protocols for differentiating iPSC to 
a particular cell type of interest. In summary, the field of stem cell biology was radically 
altered by the derivation of iPSC. Since their generation, the field has moved forward at a 
staggering speed, in large part due to the potential of iPSC to transform modern medicine as 
well as our understanding of human development.  
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1. Introduction 
One of the major technical hurdles for clinical application of embryonic stem (ES) cells or 
induced pluripotent stem (iPS) cells is formation of teratomas by undifferentiated cells after 
transplantation. In addition, iPS cells have their own safety concerns such as an increased 
chance of tumorigenicity caused by chromosomal instability or alteration during the 
reprogramming process (1). Since the first report of mouse iPS cell generation by retroviral 
vectors (2), several non-integrating vector systems have been examined in pursuit of “safer” 
iPS cell generation methods. These approaches include adenoviruses (3), Sendai viruses 
(SeV) (4, 5), Cre-excisable viruses (6), the piggyBac transposition system (7, 8) conventional 
plasmids (9), the oriP/EBNA1-episomal vector (10), direct protein delivery methods (11, 12) 
or small molecule delivery methods (13, 14).  
A number of cell sources for generating human iPS cells have been reported, including 
dermal fibroblasts (15), keratinocytes (16), peripheral blood cells (17), adipose tissue (18), 
and cord blood (CB) cells (19). The three germ layer differentiation potential of these 
established iPS cells has been demonstrated. However, it is not clear which cell source is 
best for generating “standard” iPS cells, as differentiation preferences of established iPS cells 
reflect the epigenetic status of the original cells (called “epigenetic memory”) (20).  
Recently, several groups reported new insights into two distinct stages of pluripotency in ES 
cells. These stem cell stages consist of the inner cell mass (ICM) of blastocyst type (ICM 
type-cells or naïve cells), and epiblast type stem cells (EpiSCs or prime cells) (21). Mouse 129 
or C57/BL6 mouse ES cells are the ICM type: “true” pluripotent stem cells representing pre-
implantation blastocysts that contribute to chimerism and demonstrate germ line 
transmission when placed back into blastocysts. They can also be grown in single cell 
suspension. In contrast, the “EpiSCs” or “prime” ES cells represent post-implantation stage 
epiblasts. They retain the potential of three germ line differentiation in vitro, but are 
incapable of contributing to chimerism and cannot survive after single cell cloning. Human 
ES cells or iPS cells seem to correspond to the EpiSCs with respect to colony morphology 
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established iPS cells has been demonstrated. However, it is not clear which cell source is 
best for generating “standard” iPS cells, as differentiation preferences of established iPS cells 
reflect the epigenetic status of the original cells (called “epigenetic memory”) (20).  
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suspension. In contrast, the “EpiSCs” or “prime” ES cells represent post-implantation stage 
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and gene expression prolife (22, 23), but can be converted to the naïve stem cell stage by 
cultivation (24) or constitutive activation of KLF2/KLF4 genes (25). In this report, we 
demonstrate an easier and safer reprogramming method for the direct establishment of 
ICM-type human iPS cells from fresh or frozen CB cells using temperature-sensitive SeV 
vectors, which facilitates confirmation of removal of the SeV construct at a single cell level.  
2. Experimental procedures, materials, and methods 
All experimental protocols were reviewed and approved by the ethical committee of the 
Riken Center for Developmental Biology (CDB), the Foundation for Biomedical Research 
and Innovation (FBRI), Asagiri Hospital, and the animal experiment committee of FBRI. 
Fresh CB was supplied by Asagiri Hospital. CD34+ cells were purified from mononuclear cells 
(isolated from fresh CB with Lymphoprep TM (Cosmo Bio Co., Tokyo, Japan)) using a human 
CD34 Micro Bead kit and Auto Macs columns (Miltenyi Biotec) in accordance with the 
manufacturer’s instruction. We also used frozen CD34+ CB cells obtained from Riken RBC 
(Tsukuba, Japan). CD34+ cells were cultured in hematopoietic culture medium (HC media) 
[serum free X-VIVO 10 (Lonza, Basel Switzerland) containing 50 ng/mL IL-6 (Peprotech, 
London UK), 50 ng/mL sIL-6R (Peprotech), 50 ng/mL SCF (Peprotech), 10 ng/mL TPO 
(Peprotech), 20 ng/mL Flt3-ligand (R&D system, MN)] (4) for one day prior to viral infection. 
SNL76/7 feeder cells (European Collection of Cell Culture, Salisbury, UK) were treated with 
100 L of mitomycin C solution (1 mg/mL) (Nacalai Tesque, Kyoto, Japan) in 10 cm dishes for 
three hours to generate mitomycin C treated-SNL 76/7 feeder cells (MMC-SNL). They were 
seeded on 24-well plates (Becton Dickinson, Tokyo, Japan), or in six-well plates, or in 60 mm 
dishes in naïve human ES cell culture medium. Fifty mL of naïve human ES cell medium was 
prepared by mixing 24 mL DMEM/F12 (Invitrogen; 11320), 24 mL Neurobasal (Invitrogen; 
21103), 0.5 mL of x100 nonessential amino acids (Invitrogen), 1 mL B27 supplement 
(Invitrogen; 17504044), and 0.5 mL N2 supplement (Invitrogen; 17502048). The medium also 
contained 0.5 mg/mL of BSA Fraction V (Sigma), penicillin-streptomycin (final x 1, 
Invitrogen), 1 mM glutamine (Invitrogen), 0.1 mM β-mercaptoethanol (Invitrogen), 1.0 M 
PD0325901 (Stemgent), 3.0 M CHIR99021 (Stemgent), 10 M forskolin (Sigma) and 20 ng/mL 
of recombinant human LIF (Millipore; LIF1005). Prime human iPS cells were cultured with 
prime human ES cell medium [DMEM/F-12 (SIGMA) containing 20% KSR (Invitrogen), 2 mM 
L-glutamine (Invitrogen), 1% NEAA (Invitrogen), 0.1 mM 2-ME (Invitrogen), and 4 ng/mL 
bFGF (Peprotech)]. The medium was changed every day. Passage of human ES cell-like cells 
was previously described (26). The split ratio was routinely 1:3 or 1:4.  
2.1 Viral infection and generation of ICM-type iPS cells 
Temperature-sensitive Sendai viral vector constructs integrating the four Yamanaka factors 
(SeV18+OCT3/4/TS7, SeV18+SOX2/TS7, SeV18+KLF4/TS7, and SeV(HNL)c-MYC/TS7) were 
supplied by DNAVEC Corp. The CD34+ cells were thawed and cultured for one day in HC 
media in six-well plates at a density of 2 x 104 cells/two mL/well before the infection with 
SeV. The thawed CD34+ cells (1 x 104), or an equivalent number of freshly isolated CD34+ 
cells, were transferred to 96-well plates in 180 L of hematopoietic cell culture medium with 
20 L of viral supernatant containing two m.o.i. each of the five SeV constructs (SeVTS7-
OCT3/4, -SOX2, -KLF4, -c-MYC, -GFP). The medium was replaced by fresh medium the 
following day and infected cells were cultured another four days. At this point, 1 x 104 
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infected CB cells were seeded and cultured on confluent MMC-SNL cells in six-well plates 
in human naïve ES cell medium supplemented with PD0325901, CHIR99021, recombinant 
human LIF (rhLIF) and forskolin under hypoxic conditions (MCO-5M, SANYO Japan, 5% 
O2, 5% CO2 at 37o C). Dome-shaped naive ES cell like-colonies were picked up between 
fourteen and nineteen days, suspended as single cells, seeded on MMC-SNL and cultured 
with naïve ES cell medium. The second passage colonies were subjected to heat treatment 
(38o C for three days) and then passaged again for detection of remaining SeV constructs by 
RT-PCR and immunostaining with anti-SeV (HN) antibody. SeV-free colonies were 
transferred to a normal oxygen environment (MCO-5M, SANYO Japan, 20% O2, 5% CO2 at 
37o C) and cultured on MMC-SNL cells with prime human ES cell medium shown in Fig 1.  
 
 
Fig. 1. Schema for generating naive and prime iPS cell from CB cells with SeV vectors.  
2.1.1 Optimized culture conditions for naïve iPS cells 
1X104 SeV-infected CD34+ CB cells were transferred onto various numbers of pre-seeded 
MMC-SNL cells in 60 mm dishes (from 1.0 x 105 to 2.0 x 106). Cells were cultured for 14 days 
in naïve human ES cell medium either under hypoxic or normoxic conditions. The emergent 
colonies were fixed and stained for ALP activities. The number of colonies stained positively 
for ALP activities was scored. 
The naïve ES cell-like colonies were picked up 14 to 19 days after seeding on SNL in naïve 
ES cell medium under 5% O2 culture conditions. These cells were subjected to heat 
treatment at 38 oC for three days at passage two in the naive state. After heat treatment, 
prime ES cell-like colonies were passaged (passage three) and checked for residual SeV 
constructs by RT-PCR and immunostaining with anti-SeV antibody. Then, the virus-free cell 
clumps from passage three were cultured in prime human ES cell medium under 20% O2 
culture conditions. Viral-Free (VF) iPS cell colonies were passaged two or three times and 
then tested for further appraisal of differentiation potential of the reprogrammed cell clones. 
We tried to induce pluripotency in adherent cells derived from CD34+ cells in Table 1. 
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(isolated from fresh CB with Lymphoprep TM (Cosmo Bio Co., Tokyo, Japan)) using a human 
CD34 Micro Bead kit and Auto Macs columns (Miltenyi Biotec) in accordance with the 
manufacturer’s instruction. We also used frozen CD34+ CB cells obtained from Riken RBC 
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London UK), 50 ng/mL sIL-6R (Peprotech), 50 ng/mL SCF (Peprotech), 10 ng/mL TPO 
(Peprotech), 20 ng/mL Flt3-ligand (R&D system, MN)] (4) for one day prior to viral infection. 
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three hours to generate mitomycin C treated-SNL 76/7 feeder cells (MMC-SNL). They were 
seeded on 24-well plates (Becton Dickinson, Tokyo, Japan), or in six-well plates, or in 60 mm 
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PD0325901 (Stemgent), 3.0 M CHIR99021 (Stemgent), 10 M forskolin (Sigma) and 20 ng/mL 
of recombinant human LIF (Millipore; LIF1005). Prime human iPS cells were cultured with 
prime human ES cell medium [DMEM/F-12 (SIGMA) containing 20% KSR (Invitrogen), 2 mM 
L-glutamine (Invitrogen), 1% NEAA (Invitrogen), 0.1 mM 2-ME (Invitrogen), and 4 ng/mL 
bFGF (Peprotech)]. The medium was changed every day. Passage of human ES cell-like cells 
was previously described (26). The split ratio was routinely 1:3 or 1:4.  
2.1 Viral infection and generation of ICM-type iPS cells 
Temperature-sensitive Sendai viral vector constructs integrating the four Yamanaka factors 
(SeV18+OCT3/4/TS7, SeV18+SOX2/TS7, SeV18+KLF4/TS7, and SeV(HNL)c-MYC/TS7) were 
supplied by DNAVEC Corp. The CD34+ cells were thawed and cultured for one day in HC 
media in six-well plates at a density of 2 x 104 cells/two mL/well before the infection with 
SeV. The thawed CD34+ cells (1 x 104), or an equivalent number of freshly isolated CD34+ 
cells, were transferred to 96-well plates in 180 L of hematopoietic cell culture medium with 
20 L of viral supernatant containing two m.o.i. each of the five SeV constructs (SeVTS7-
OCT3/4, -SOX2, -KLF4, -c-MYC, -GFP). The medium was replaced by fresh medium the 
following day and infected cells were cultured another four days. At this point, 1 x 104 
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infected CB cells were seeded and cultured on confluent MMC-SNL cells in six-well plates 
in human naïve ES cell medium supplemented with PD0325901, CHIR99021, recombinant 
human LIF (rhLIF) and forskolin under hypoxic conditions (MCO-5M, SANYO Japan, 5% 
O2, 5% CO2 at 37o C). Dome-shaped naive ES cell like-colonies were picked up between 
fourteen and nineteen days, suspended as single cells, seeded on MMC-SNL and cultured 
with naïve ES cell medium. The second passage colonies were subjected to heat treatment 
(38o C for three days) and then passaged again for detection of remaining SeV constructs by 
RT-PCR and immunostaining with anti-SeV (HN) antibody. SeV-free colonies were 
transferred to a normal oxygen environment (MCO-5M, SANYO Japan, 20% O2, 5% CO2 at 
37o C) and cultured on MMC-SNL cells with prime human ES cell medium shown in Fig 1.  
 
 
Fig. 1. Schema for generating naive and prime iPS cell from CB cells with SeV vectors.  
2.1.1 Optimized culture conditions for naïve iPS cells 
1X104 SeV-infected CD34+ CB cells were transferred onto various numbers of pre-seeded 
MMC-SNL cells in 60 mm dishes (from 1.0 x 105 to 2.0 x 106). Cells were cultured for 14 days 
in naïve human ES cell medium either under hypoxic or normoxic conditions. The emergent 
colonies were fixed and stained for ALP activities. The number of colonies stained positively 
for ALP activities was scored. 
The naïve ES cell-like colonies were picked up 14 to 19 days after seeding on SNL in naïve 
ES cell medium under 5% O2 culture conditions. These cells were subjected to heat 
treatment at 38 oC for three days at passage two in the naive state. After heat treatment, 
prime ES cell-like colonies were passaged (passage three) and checked for residual SeV 
constructs by RT-PCR and immunostaining with anti-SeV antibody. Then, the virus-free cell 
clumps from passage three were cultured in prime human ES cell medium under 20% O2 
culture conditions. Viral-Free (VF) iPS cell colonies were passaged two or three times and 
then tested for further appraisal of differentiation potential of the reprogrammed cell clones. 
We tried to induce pluripotency in adherent cells derived from CD34+ cells in Table 1. 
 












iPS cell clones 
characterized 
Fresh 
CD34+ CB SeV 1.0x10
4 20 MMC-SNL cells 5 5 
 
Clone # RT-PCT (undifferentiation) 
RT-PCT  
(differentiation) IHC Teratoma Karyotype 
#24   
#30    
#35     
#36  
#37      
: performed 
Table 1. Efficiency of induction of iPSC clones from cord blood cells with SeV vectors. 
2.1.2 Alkaline phosphatase and immunohistological staining 
Naive ES cell like- and prime ES cell like-colonies were stained with leukocyte alkaline 
phosphatase kit (VECTOR, Burlingame, CA) in accordance with the manufacturer’s 
instructions. Cells were fixed with 4% paraformaldehyde followed by immunostaining with 
a series of antibodies. Nuclei were stained with DAPI (1:1000, SIGMA). Photomicrographs 
were taken with a fluorescent microscope (Olympus BX51, IX71, Tokyo) and a visible light 
microscope (Olympus CKX31). 
Expression of CD34 and CD45 in mononuclear cells (MNC) from CB was determined by 
flow cytometry (middle). CD34+CD45low+ cells (0.2%) and CD34- CD45+ cells were 
fractionated by cell sorting and both were infected with SeV carrying four factors and GFP. 
Phase contrast microscopic and fluorescence photographs of CD34+ cells (right) and CD34- 
mononuclear cells (left) the day after infection are shown in lower panels.  
We found that the GFP+ population was selectively found in the CD34+ fraction the day after 
SeV infection (Fig. 2). This fraction corresponds to hematopoietic stem cells or progenitors, 
as reported elsewhere (27).  
2.1.3 Determination of SeV construct in naïve ES cell-like cells 
The remaining SeV constructs in naïve ES cell-like colonies were determined by RT-PCR and 
immunostaining. Using four temperature-sensitive Sendai viral constructs (SeV TS7) 
integrating Yamanaka’s transcription factor quartet (c-MYC, KLF4, OCT3/4 and SOX2), we 
were able to generate ES cell-like colonies from CD34+ CD45low+ CB cells. The protocol for 
generating iPS cells from CB cells with temperature-sensitive SeV vector is shown in Fig. 1. 
Naïve ES cell-like colonies were generated by culturing cells in naïve human ES cell medium 
under hypoxic conditions (5% O2). Merged dome-like colonies were picked up three weeks 
after SeV infection and subjected to heat treatment at 38oC to reduce the amount of residual 
SeV constructs. Remaining SeV constructs were detected by RT-PCR and immunostaining 
with anti-SeV antibody. Then, the cell clumps of “naïve" virus-free cell clones were 
transferred to conventional prime human ES cell medium and cultured under normoxic 
 
 




Fig. 2. SeV selectively infects the CD34+ fraction of CB cells. 
conditions (20% O2) to convert cells to “prime” virus-free ES cell-like cells. We cannot 
maintain the naïve state for more than five passages due to the instability of pluripotency in 
naïve culture conditions and the tendency for spontaneous differentiation. In contrast, 
pluripotency in the prime state (like conventional human ES cells) was stable and we could 
maintain prime ES or iPS cells for more than 50 passages. Therefore, further appraisal of the 
differentiation potential of the reprogrammed cells was done in the prime state (Fig. 4A,B). 
Naïve ES cell-like clones from a single cell suspension were examined. Like mouse ES cells, 
emergent dome-like  colonies (P = 1) started to express SSEA-1 in the naïve stage (Fig. 3C, 
lower left ), but its expression ceased after shifting to the prime state (Fig. 3C, lower right). 
Expression of pluripotency-related molecules in the prime state was examined by 
immunostaining with a set of antibodies (Table 2). The presence of SeV constructs in the 
naïve reprogrammed cells was examined by RT-PCR at the single cell level (Fig. 3D). Heat-
treated naïve clones that were free of SeV constructs under hypoxic conditions (5% O2) were 
transferred to prime culture with a normoxic atmosphere (20% O2). These virus-free ES cell 
like-clones were expanded in conventional prime human ES cell culture for further 
appraisal of the differentiation potential.  
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conditions (20% O2) to convert cells to “prime” virus-free ES cell-like cells. We cannot 
maintain the naïve state for more than five passages due to the instability of pluripotency in 
naïve culture conditions and the tendency for spontaneous differentiation. In contrast, 
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differentiation potential of the reprogrammed cells was done in the prime state (Fig. 4A,B). 
Naïve ES cell-like clones from a single cell suspension were examined. Like mouse ES cells, 
emergent dome-like  colonies (P = 1) started to express SSEA-1 in the naïve stage (Fig. 3C, 
lower left ), but its expression ceased after shifting to the prime state (Fig. 3C, lower right). 
Expression of pluripotency-related molecules in the prime state was examined by 
immunostaining with a set of antibodies (Table 2). The presence of SeV constructs in the 
naïve reprogrammed cells was examined by RT-PCR at the single cell level (Fig. 3D). Heat-
treated naïve clones that were free of SeV constructs under hypoxic conditions (5% O2) were 
transferred to prime culture with a normoxic atmosphere (20% O2). These virus-free ES cell 
like-clones were expanded in conventional prime human ES cell culture for further 
appraisal of the differentiation potential.  
 








Fig. 3. Elimination of SeV constructs as determined by RT-PCR and generation of naïve or 
prime iPS cells. 
A: Emerging naïve ES cell–like colony. Dome-like colonies emerged and were picked up 
(top left). Naïve ES cell-like colonies were seeded on MMC-SNL cells (passage one:  P = 1, 
top right). Naïve ES cell-like colony (P = 2, lower left). Cells in the center of the naïve colony 
(white arrow) started to differentiate at later passages (P = 6, lower right). B: The efficiency 
of generation of naïve ES cell-like colonies under hypoxic (black) and normoxic (white) 
conditions. The number of MMC-SNL cells seeded on 60 mm dishes and the number of ES 
cell-like colonies which emerged are scored on the X-axis and Y-axis, respectively. C: 
Staining of naïve ES cell-like colonies (left panels) and prime ES cell-like colonies (right 
panels). ALP staining of colonies on MMC-SNL (top left and right), phase contract 
observations of colonies on MMC-SNL (middle left) or Matrigel (middle right), colonies 
stained with DAPI (lower left) or immunostained with anti-SSEA-1 antibody (lower right). 
D: Detection of SeV construct in heat-treated clones by PCR. Picked colonies #24, #35, and 
#37 were subject to heat treatment (passage 2: P = 2) and subcloned. Subclones were named 
#24VF, #35VF, or #37VF (passage 3: P = 3). iPS cells generated from CB by retrovirus (ReV) 
and parent CD34+ CB cell were used as negative controls. % SeV+ in colony is the area 
positively stained with anti-SeV antibody divided by the total area of the colony calculated 
by two value recognition software (Adobe Photoshop). There was no difference in the 
frequency of emerging dome-shaped ES cell-like colonies in the naïve state from freshly 
isolated CD34+ cells and from frozen CD34+ cells.  
 




Fig. 4. Expression of pluripotency-associated genes and molecules in established SeV-free 
iPS cell clones. 
A: Phase contrast images of a representative naive ES cell-like colony on MMC-SNL (P = 1: top 
left), after heat-treatment and recloning of a prime clone (SeV iPS #37VF, top middle) and its 
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ALP staining (top right). The expression of SSEA-4, Oct3/4, TRA-1-60, SSEA-3, Nanog and 
TRA-1-81 in the same prime clone (SeV iPS #37VF) was detected by immunohistochemistry. 
Alexa 594 (red) and Alexa 488 (green) conjugated secondary antibodies were used to visualize 
expression. B: Endogenous gene expression determined by RT-PCR. Sample description, 
pluripotency-associated genes, and lanes are indicated. CD34+ and CD34- CB cells were used 
for controls. C: Gene expression comparison of SeV iPS #37VF vs CD34+ CBC (upper panel) 
and SeV iPS #37VF vs human ES cell line KhES-3 (lower panel). Expression levels of 
pluripotency-related genes are marked in the panels. D: Karyotyping of SeV iPS #37VF. 
 
Antibodies supplier Cat No Dilution 
anti-Oct4 Santa Cruz sc-5279 1/ 100 
anti-TRA-1-81 Chemicon  MAB4381 1/ 200 
anti-TRA-1-60 Chemicon MAB4360 1/ 200 
anti-SSEA-3 Chemicon MAB4303 1/ 200 
anti-SSEA-4 Chemicon MAB4304 1/ 200 
anti-Nanog  Reprocell RCAB0003P 1/ 1000 
-fetoprotein(AFP)  R&D MAB1368 1/ 100 
vimentin Santa Cruz sc-5565 1/ 200 
-smooth muscle actin(SMA) SIGMA A-2547 1/ 400 
desmin  Dako  M0760 1/ 50 
beta-III tubulin  SIGMA T4026 1/ 200 
GFAP Santa Cruz sc-6170 1/ 50 
anti-SSEA-1  Santa Cruz sc-21702 1/100 
anti SeV HN DNAVEC IL4.1 1/100 
Alexa Fluor 488 goat anti mouse  Invitrogen A11001 1/ 1000 
Alexa Fluor 594 rabbit anti mouse  Invitrogen A11005 1/ 1000 
Alexa Fluor 594 goat anti rabbit   Invitrogen A11037 1/ 1000 
DAPI  Invitrogen D1306 5ug/ml 
Table 2. List of antibodies used for immunostaining 
2.2 Characterization of virus-free ES cell-like clones  
2.2.1 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Total RNA was purified with RNeasy Mini kit (QIAGEN), according to the manufacturer’s 
instructions. One g of total RNA was used for reverse transcription reactions with 
PrimeScript RT reagent kit (TAKARA, Japan). PCR was performed with EXTaq (TAKARA, 
Japan). Total RNA from cell clones was extracted with the RNeasy minikit (QIAGEN). q-RT-
PCR was performed with an ABI PRISM 7000 (Life Technologies Japan) using SYBR Premix 
EX TaqTM (TAKARA, RR041A) in accordance with the manufacturer’s instructions. Primers 
are listed in Table 3.  
2.2.2 Gene Chip analysis and karyotyping 
Total RNAs from several established iPS cell clones, human ES cell line KhES-1, CD34- CB 
cells and CD34+ CB cells were purified with RNeasy Mini kit (QIAGEN) and hybridized 
with human Gene Chip (U133 plus 2.0 Array Affymetrix) according to the manufacturer’s  
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Primers   Size (bp) 
hOCT3/4-F1165  GAC AGG GGG AGG GGA GGA GCT AGG undifferentiated 
ES cell (endo) 144 hOCT3/4-R1283 CTT CCC TCC AAC CAG TTG CCC CAA AC 
hSOX2-F1430 GGG AAA TGG GAG GGG TGC AAA AGA GG undifferentiated 
ES cell (endo) 151 hSOX2-R1555 TTG CGT GAG TGT GGA TGG GAT TGG TG 
hMYC-F253 GCG TCC TGG GAA GGG AGA TCC GGA GC undifferentiated 
ES cell (endo) 328 hMYC-R555 TTG AGG GGC ATC GTC GCG GGA GGC TG 
hKLF4-F1128 ACG ATC GTG GCC CCG GAA AAG GAC C undifferentiated 
ES cell (endo) 397 hKLF4-R1826 TGA TTG TAG TGC TTT CTG GCT GGG CTC C 
DPPA4-F  GGAGCCGCCTGCCCTGGAAAATTC undifferentiated 
ES cell 408 DPPA4-R  TTT TTC CTG ATA TTC TAT TCC CAT 
REX1-F  CAG ATC CTA AAC AGC TCG CAG AAT undifferentiated 
ES cell 306 REX1-R  GCG TAC GCA AAT TAA AGT CCA GA 
NANOG-F  CAG CCC CGA TTC TTC CAC CAG TCC C undifferentiated 
ES cell 391 NANOG-R CGG AAG ATT CCC AGT CGG GTT CAC C 
hGAPDH F AAC AGC CTC AAG ATC ATC AGC control  337 hGAPDH R TTG GCA GGT TTT TCT AGA CGG 
hBRACHYURY-
F1292 GCC CTC TCC CTC CCC TCC ACG CAC AG mesoderm 274 hBRACHYURY-
R1540 CGG CGC CGT TGC TCA CAG ACC ACA GG 
hPAX6-F1206 ACC CAT TAT CCA GAT GTG TTT GCC CGA G ectoderm 317 hPAX6-R1497  ATG GTG AAG CTG GGC ATA GGC GGC AG 
hSOX17-F423  CGC TTT CAT GGT GTG GGC TAA GGA CG endoderm 608 hSOX17-R583  TAG TTG GGG TGG TCC TGC ATG TGC TG 
SeV vector F15204 GGATCACTAGGTGATATCGAGC SeV vectors 193 SeV vector R15397e CATATGGACAAGTCCAAGACTTC 
Table 3. List of primers used to detect pluripotency-associated genes in reprogrammed cells. 
instructions. Karyotyping of established iPS cells was reported by Nihon Gene Research 
Laboratories, Inc. (Sendai, Japan). 
The expression of pluripotency-related molecules in the prime stage such as SSEA-4, SSEA-
3, TRA-1-60, TRA-1-81, Oct3/4 and Nanog were detected by immunostaining (Fig. 4A). 
Endogenous expression of pluripotency-related genes was determined by RT-PCR (Fig. 4B). 
Total gene expression profiles of the established iPS clone SeV iPS #37VF are compared with 
human ES cell line KhES-3 or CD34+ cord blood cells (Fig. 4C). Karyotype of the established 
iPS cell clone SeV iPS #37VF is presented (Fig. 4D). 
2.3  Differentiation assays of virus-free iPS cells in vitro and in vivo  
2.3.1 In vitro differentiation assay 
Established human ES cell-like clones were harvested using collagenase IV. Cells were 
transferred to six-well ultra-low attachment plates (Corning) and cultured in human prime ES 
cell medium without bFGF to form embryoid bodies (EB). The medium was changed every 
other day. The resulting EBs were transferred to gelatin-coated plates after eight days and 
cultured in the same fresh medium for another eight days. Three cell lines were tested for 
differentiation potential on gelatin coated dishes after EB formation (Fig. 5a). All of these 
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F1292 GCC CTC TCC CTC CCC TCC ACG CAC AG mesoderm 274 hBRACHYURY-
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SeV vector F15204 GGATCACTAGGTGATATCGAGC SeV vectors 193 SeV vector R15397e CATATGGACAAGTCCAAGACTTC 
Table 3. List of primers used to detect pluripotency-associated genes in reprogrammed cells. 
instructions. Karyotyping of established iPS cells was reported by Nihon Gene Research 
Laboratories, Inc. (Sendai, Japan). 
The expression of pluripotency-related molecules in the prime stage such as SSEA-4, SSEA-
3, TRA-1-60, TRA-1-81, Oct3/4 and Nanog were detected by immunostaining (Fig. 4A). 
Endogenous expression of pluripotency-related genes was determined by RT-PCR (Fig. 4B). 
Total gene expression profiles of the established iPS clone SeV iPS #37VF are compared with 
human ES cell line KhES-3 or CD34+ cord blood cells (Fig. 4C). Karyotype of the established 
iPS cell clone SeV iPS #37VF is presented (Fig. 4D). 
2.3  Differentiation assays of virus-free iPS cells in vitro and in vivo  
2.3.1 In vitro differentiation assay 
Established human ES cell-like clones were harvested using collagenase IV. Cells were 
transferred to six-well ultra-low attachment plates (Corning) and cultured in human prime ES 
cell medium without bFGF to form embryoid bodies (EB). The medium was changed every 
other day. The resulting EBs were transferred to gelatin-coated plates after eight days and 
cultured in the same fresh medium for another eight days. Three cell lines were tested for 
differentiation potential on gelatin coated dishes after EB formation (Fig. 5a). All of these 
 
 




Fig. 5.  In vitro and in vivo differentiation potentials of established iPS cell lines. 
(a-g) Embryoid body-mediated differentiation of established iPS cells. All images shown are 
from cells derived from clone SeV iPS #35VF. Bright field images of embryoid bodies 
generated after eight days of culture (a). Embryoid bodies were transferred to gelatin dishes 
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and differentiated for a further eight days to induce either un-directed or guided 
differentiation (b-g). Phase contrast images of neuron-like cells (b) after differentiation on 
gelatin. Cells were fixed and stained with antibodies against GFAP (c), desmin (d), AFP (e), 
III-tubulin (f), and vimentin (g) to determine lineage-specific differentiation potential. (h) 
RT-PCR for lineage-specific differentiation of established iPS cell lines, SeV clones #35VF 
and #37VF. Retrovirally generated iPS cell clone R#23 from CD34+ CB cells was used for a 
control. (i) Teratoma formed from SeV iPS #35VF was injected into testis capsule. Teratoma 
had a cystic structure. The content of cysts is shown in the 1 mL syringe. (j) Hematoxylin 
and eosin staining of teratoma derived from iPS cells at low magnification. Histology 
showed derivatives of all three embryonic germ layers including bone-like (k: mesoderm), 
cartilage-like (l: mesoderm), gut-like epithelium (m: endoderm) and neural rosette-like (n: 
ectoderm) tissue. 
clones were able to give rise to cells from all three germ layers as evidenced by cell 
morphology (Fig. 5b) and immunocytochemistry (Fig. 5c-g). Upon differentiation, the presence 
of gene expression characteristic of all three germ layers was determined by RT-PCR (Fig. 5h). 
2.3.2 In vivo differentiation assay 
One million iPS cells were injected beneath the testicular capsule of SCID mice (SLC Japan) 
for teratoma formation. Tumor formation was observed 60 - 80 days after cell 
transplantation. Tumor tissues were fixed with 4% formalin followed by hematoxylin and 
eosin staining. Two lines were tested for teratoma formation and both cell lines formed 
teratomas with a cystic structure (Fig. 5i). HE staining of teratoma tissues (Fig. 5j - 5n) 
showed differentiated tissues corresponding to all three germ layers.  
3. Conclusions 
Reprogramming of somatic cells with SeV vector without DNA integration is advantageous, 
as it reduces the chance for tumorigenicity caused by random genomic integration. 
Advantages of using SeV vector over other non-integrating reprogramming methods such 
as using adenovirus, episomal plasmid vectors, conventional plasmid vectors, or small 
molecule delivery systems include superior reprogramming capability with potent protein 
expression potential (13). The remaining concern in using SeV vector is how we can confirm 
the removal of potent SeV vectors from reprogrammed cells. In this report, we used the 
temperature-sensitive SeV vector TS7 to reduce the number of SeV-infected cells. In 
addition, we made use of a single cell cloning technique in the naïve state to confirm the 
absence of SeV vector constructs in the reprogrammed cells at a single cell level. Therefore, 
this cloning technique provides an ultimate solution for RNA virus vector-based 
reprogramming methodology. 
The benefits of reprogramming somatic cells in the naïve state are not limited to a single cell 
cloning technology. It may provide answers to interesting questions like whether 
“standard” human iPS cells, having the correct epigenetic memory, can be generated by 
reprogramming somatic cells in the naïve state. Accumulation of epigenetic information 
before and after transferring to the naïve state would provide an answer to this question. 
Several reports showed that iPS cells can be preferentially generated from the CD34+ 
fraction of CB cells and peripheral blood cells with retroviral vectors (19, 26). In our 
experiment, we also showed that the SeV TS7-GFP vector selectively infects freshly isolated 
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CD34+ CD45low+ cells and is able to reprogram this fraction. These data suggested that the 
use of SeV would facilitate the effective generation of iPS cells from CB cells. However, the 
molecule(s) responsible for SeV viral entry into the cell is elusive. Hemagglutinin-
neuraminidase (HN), an envelope protein of Sev is reported to bind to sialomucin (28) and 
facilitate the cellular entry of virus. CD34 belongs to the sialomucin family. Although SeV is 
not able to infect CD34- cells from freshly isolated (non-cultured) CB cells, SeV is able to 
infect CD34- cells that have differentiated from CD34+ CB cells after seven days of culture in 
hematopoietic cell culture media. With limited information, we cannot conclude that CD34 
is the SeV entry molecule. Rather, it appears that a set of molecules other than CD34, 
expressed in CD45low+ cells, might be responsible for it.  
As a cell source for generating iPS cells, CB cells have certain advantages over other somatic 
cells. Unlike cultured cells or those obtained by biopsy from a variety of tissues at various 
ages, freshly isolated (non-cultured) CD34+ CB cells are the youngest stem cell population 
available following birth. They also have distinct genetic and epigenetic profiles as 
hematopoietic stem cells and progenitors and lack genetic alternations like rearrangements 
or possible post-natal genomic damage caused by UV irradiation or chemical irritants. 
Furthermore, generating iPS cells from this fraction would facilitate our understanding of 
the reprogramming process, since the genetic profiles of the cell source and the 
reprogrammed cells are known. Another advantage of using cord blood cells would be the 
possibility of collaborating with the existing world-wide network of public cord blood 
banks. Extensive discussions concerning the conditions and ethical issues are necessary 
before such clinical applications are pursued. Nonetheless, the use of CB as a source for iPS 
cells is a realistic option for generating “bona fide” iPS cells for future clinical use.  
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derived by transfecting somatic cells (e.g. skin fibroblasts) with a select group of 
transcription factors; Sox2, Oct4, Myc and Klf4 to induce reprogramming of the genome 
over a period of 3-4 weeks. This breakthrough by Yamanaka and colleagues enables the 
modelling of human disease by, for example, taking a patient’s skin cells, converting them 
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system that have been modelled using iPSC which includes; RETT syndrome (RTT), Familial 
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stepwise change of culture medium components followed by expansion of neural 
progenitors (Reubinoff et al., 2001). This protocol involves the long-term culture (3 weeks) of 
hESCs without replenishing the mouse embryonic fibroblast layer. These cells rapidly 
undergo morphological changes, forming neural rosettes. They are subsequently dissociated 
and replated in medium permissive for the growth and maintenance of NSCs (DMEM/F12, 
B27 supplement, EGF [epidermal growth factor], bFGF [basic fibroblast growth factor]). 
Similar to mouse ESCs, hESCs can also be differentiated as suspension cultures where they 
form cystic embryoid bodies (EBs).  Formation of these three-dimensional spheres can 
recapitulate the microenvironment during embryo development, and are preferred over 
monolayer formats because it allows for up-scaling of differentiation cultures to a greater 
extent. However, differentiation of hESCs in this sphere format gives rise to issues such as 
heterogeneity (containing cell types pertaining to the three germ layers) and differential 
access to soluble factors, which translates to difficulties in optimizing the purity of the 
desired differentiated progenitors. 
The second approach to induce neural lineage cells, is to co-culture hESCs with a variety of 
stromal cell types, such as the PA6 and MS5 (Kawasaki et al., 2000, Hong et al., 2008, 
Chimge and Bayarsaihan, 2010). Both PA6 and MS5 stromal cells  were derived from murine 
bone marrow. This induction method is based on the knowledge that signals from 
mesodermal cells of the Spemann organizer (which develop into the notochord) can induce 
overlying ectoderm to neuroectodermal fate (Harland and Gerhart, 1997, Londin et al., 
2005). This neural induction protocol was reported to generate up to 92% NCAM [neural cell 
adhesion molecule]–positive cells in 12 days. Given the ease and efficiency of this protocol it 
is not surprising that it is widely used. However, the neural-inducing effect of the stromal 
cells is not fully understood. PA6 cells can induce neural differentiation of hESCs in the 
absence of physical contact, but the conditioned medium of PA6 cells was unable to induce 
neural differentiation (Kawasaki et al., 2000). In addition, paraformalydehye-treated PA6 
cells continued to exhibit neural-inducing activity, suggesting that the viability of these cells 
is not vital. In order to fine-tune the procedure to exclude animal products, a matrix material 
from the human amniotic membrane was found to support neural induction of hESCs with 
similar efficiencies to that of the mouse stromal cells (Ueno et al., 2006). 
Given the caveats in the EB and co-culture methods, strategies were developed to maximize 
the induction of hESCs into neural lineage, using differentiating factors and monolayer 
subculture systems. The secretion of the bone morphogenic protein (BMP) antagonists,  
noggin and chordin, from the epidermal ectoderm of the Xenopus embryo was demonstrated 
to be essential for neural induction (Sasai et al., 1996). In addition, follistatin, an inhibitor of 
Activin signaling, was found to promote neural induction (Hemmati-Brivanlou and Melton, 
1994). Hence, strategies used for increasing the yield of neural derivatives from hESCs 
include using inhibitors of BMP signaling such as Noggin (Itsykson et al., 2005), and the 
inhibitors of Activin/Nodal signaling such as the pharmacological inhibitor of Nodal 
signaling, SB431542 (Smith et al., 2008). Since both signaling pathways converge to 
downstream SMAD proteins, subsequent work further optimized the induction of neural 
lineage cells by using the inhibitors of both BMP and Nodal signaling (Chambers et al., 
2009). However, Noggin, as a protein is expensive and may exhibit batch-to-batch 
variability. Recent findings report that substituting noggin with a small-molecule inhibitor 
of BMP, Dorsomorphin, can efficiently promote neural differentiation of hESCs and iPSCs 
(Morizane et al., 2010, Zhou et al., 2010). Other methods rely on genetic manipulations such 
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as generating nestin-EGFP hESC reporter lines  to allow purification of hESC-derived neural 
progenitors (Noisa et al., 2010).  
 
 
Fig. 1. Schematic representation of neural induction and patterning in in vivo and in vitro. 1) 
At early gastrulation, the notochord (orange) secretes BMP-antagonists, such as Noggin and 
Chordin to create a gradient of BMP activity (yellow).   2) Neuroepithelial (NE) cells that are 
proximal to the notochord become neural precursors (grey) as a consequence of low BMP 
activity; and the rest of the ectoderm becomes epithelial (yellow) or neural crest (not 
shown). The NE is patterned by many signals including Shh, RA, Noggin and Chordin 
(orange) that are secreted from the notochord; BMP (yellow) from the epithelium and FGF 
(blue) from the somites. 3) The cells in the NE differentiate to specific subtypes of neurons 
depending on the location in the neural tube and the factors that influence the 
differentiation.  Neural induction and patterning of human ESCs can be induced in vitro as 
shown in the right panels (bright field micrograph or GFP labeled neuronal sub type). 
The next aim, upon obtaining neural progenitors/stem cells, is to coax these cells into 
differentiation of various neuronal subtypes including the cholinergic neurons, 
dopaminergic neurons, motorneurons, and peripheral sensory neurons. Several  methods 
using various combination of protein factors, co-culture systems and small molecules 
have successfully been utilized to obtain  individual neuronal subtypes. The basic strategy 
for developing culture cocktails to obtain neuronal subtypes is to mimic signals from early 
developmental events during specification of the body axis of the embryo. Factors 
frequently used to induce neural progenitor differentiation include retinoic acid (RA), 
FGFs and Wingless-Int (Wnts) that can poise cells to differentiate to the neural lineage 
along the the anterior/posterior (A-P) axis (Hendrickx et al., 2009, Onai et al., 2009). 
Similarly, Sonic Hedgehog (Shh) and BMPs secreted from the ventral and dorsal neural 
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tube respectively are important for the precise patterning of multiple neuronal 
progenitors (Furuta et al., 1997, Litingtung and Chiang, 2000). Hence, the efficiency of 
deriving specific neuronal subtypes can be influenced by the mode of neural induction. 
The selection of the appropriate neural differentiation protocol is pertinent for the 
maximization of desired neuronal subtype. 
2.2 Neuronal differentiation of human ESCs 
Many neuronal subtypes have successfully been derived from hESCs (Fig1). Amongst them 
are the dopaminergic neurons, serotonergic neurons, peripheral sensory neurons, and 
cholinergic neurons (Bissonnette et al., 2011). Dopaminergic neurons are progressively lost 
in Parkinson’s disease (PD), while the motorneurons are lost in amyotrophic lateral sclerosis 
(ALS). The factors and conditions used for successful derivation of dopaminegic neurons, 
motoneurons as well as other neuronal subtypes can be found in Table 1.  
Shh and FGF8 were identified to be crucial for the specification of dopaminergic neurons in 
vivo (Ye et al., 1998) but were not directly effective in vitro (Stull and Iacovitti, 2001). This led 
to the search for other signals in promoting dopaminergic neuron differentiation. Currently, 
differentiation of human ESCs into midbrain dopaminergic neurons can be achieved 
through the formation of EBs and the use of various factors such as serum-free conditioned-
medium from human hepatocarcinoma cell line HepG2, brain-derived neurotrophic factor 
(BDNF), ascorbic acid, transforming growth factor (TGF), and glial cell line-derived  
Neurotrophic factor (GDNF)  (Cho et al., 2008a, Cho et al., 2008b, Park et al., 2004, Schulz et 
al., 2004, Yan et al., 2001). Particularly, TGFß can cooperate with Shh and FGF8 to increase 
the yield of dopaminergic neurons by enhancing their survival (Roussa et al., 2004); and 
GDNF was found to be important for the maintenance of motoneurons in the striatum 
proper (Nevalainen et al., 2010). Large-scale production of dopaminergic neurons from 
hESC was reported using the EB format with addition of Shh, FGF8 and ascorbic acid. 86% 
of totally differntiated cells were dopaminergic neurons. Secretion of factors by PA6 cells is 
important for dopaminergic differentiation (Vazin et al., 2008). PA6 secreted factors include 
stromal cell-derived factor 1 (SDF-1/CXCL12), pleiotrophin (PTN), insulin-like growth 
factor 2 (IGF2), and ephrin B1 (EFNB1). 
The protocols used for the specification of spinal motoneurons from hESCs were derived from 
developmental studies. Here motoneurons were found to be induced by signals such as 
retionic acid from the caudal paraxial mesoderm (Guidato et al., 2003). Shh signaling from the 
notochord is also required for the induction of motoneurons (Lewis and Eisen, 2001). Neural 
induction is predominantly performed through the formation of EBs, using defined medium 
conditions. Because neuroectodermal cells differentiated from hESCs generally have a rostral 
character, motoneuron differentiation is then achieved by the caudalizing factor retinoic acid 
followed by the ventralizing factor Shh (Li et al., 2005). Small molecules that can activate the 
Shh signaling, purmorphamine and SAG (a chlorobenzothiophene-containing Hh pathway 
agonist), have been shown to be effective as substitutes of Shh in motoneuron differentiation 
(Li et al., 2008, Hu and Zhang, 2009, Wada et al., 2009). The use of Hb9 (homeobox gene 
selectively expressed in motoneurons)  promoter driven GFP hESCs allows isolation of a fairly 
pure population of motoneurons (Singh Roy et al., 2005). Enrichment of derived motoneurons, 
up to 80%, was also shown to be achieved by gradient centrifugation in Biocoll (Wada et al., 
2009), alleviating the need for genetic manipulations. 
 





Subtypes Neural Induction Method 










bFGF or DMEM/N2 
DMEM/N2, GDNF, 
BDNF, 5% serum  
(Schulz et al., 
2004) 
EB with RA and bFGF BDNF, TGF-α  (Park et al., 2004) 
EB, followed by bFGF and 
N2 supplement Shh, FGF8  
(Cho et al., 
2008) 
PA6 co-culture PA6, Shh, FGF8, GDNF  (Vazin et al., 2008) 
PA6 co-culture 
PA6 co-culture or  
SDF-1/CXCL12, PTN, 
IGF2, EFNB1 
 (Vazin et al., 2009) 
MS5 co-culture RA, Shh, FGF8, Wnt1 √ (Cooper et al., 2010) 
Motoneurons 
EB, then adherent in  
F12/DMEM, N2 
supplement, heparin and 
bFGF 
RA, then Shh  (Li et al., 2005) 
 EB, bFGF 
RA in DMEM/F12,N2, 
heparin, cAMP. Then 
Shh/purmorphamine, 
then GDNF, BDNF, 
IGF1 




then BDNF, GDNF, 
IGF, cAMP 




PA6 co-culture Co-culture with PA6 stromal cells  
(Pomp et al., 
2008) 
MS-5 co-culture, followed 
by  Shh, FGF8, BDNF, 
ascorbic acid 
BDNF, GDNF, NGF 
(nerve growth factor), 
Dibutyryl-cAMP 
√ (Lee et al., 2009) 
Cholinergic 
neurons Free-floating aggregates 




 RA, followed by free-floating aggregates FGF8, Shh, BMP9  
(Bissonnette 
et al., 2011) 
Serotonergic 
neurons RA with EB formation 
5-HT, forskolin, acidic 
FGF, BDNF, GDNF  
(Kumar et al., 
2009) 
Table 1. Factors used in differentiation of hESC-induced NSCs into the various neuronal 
subtypes.  
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N2 supplement Shh, FGF8  
(Cho et al., 
2008) 
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(Bissonnette 
et al., 2011) 
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2.3 Glial differentiation of hESCs 
The two glial cell types of the nervous system, the astrocytes and oligodendrocytes, play 
supporting roles in the brain and peripheral nervous system. Astrocytes secrete various 
neurotrophic factors, are known to modulate oligodendrocyte myelination of neuronal 
axons (Moore et al., 2011), and modulate neurotransmitter levels through re-uptake and 
release mechanisms (Voutsinos-Porche et al., 2003). Evidence is emerging that implicates 
astrocytes in the pathogenesis of neurological disorders such as Rett syndrome (Maezawa et 
al., 2009) and ALS (Nagai et al., 2007). A protocol to obtain astrocytes includes exposure of 
adherent hESCs to cyclopamine, an inhibitor of hedgehog signaling, and subsequent culture 
in human astrocyte medium to generate a high percentage of nestin and glial fibrillary 
acidic protein (GFAP)-expressing cells (Lee et al., 2006).  
Oligodendrocytes are cells that produce myelin sheaths that insulate axons of neurons, 
enabling saltatory conduction between the Nodes of Ranvier for rapid propogation of action 
potential. These cells are targets of severe developmental diseases such as Pelizaeus- 
Merzbacher disease, and demyelinating diseases such as multiple sclerosis and Charcot-
Marie-Tooth (Bramow et al., 2010, Garbern, 2007, Sargiannidou et al., 2009). Dysfunctional 
oligodendrocytes in these diseases lead to disruptions in axonal transport. In spinal cord 
injury, demyelination of nerve fibres attributes to functional loss of neurons. So, myelin 
formation and insulation of neurons is crucial to restore functional network. Hence, it  is 
important to source for pure poulation of glial (oligodendrocyte precursor) cells that can 
restore function of neurons by remyelination. A few reports and studies from Geron trial 
have shown the feasibility of using functional OPCs or neurotrophin expressing GRPs from 
directed differentiation of hESCs and their therapeutic potential at early time points after 
spinal cord injury (Keirstead et al., 2005, Cao et al., 2005).  
Oligodendrocytes undergo multiple stages of differentiation, from oligodendrocyte 
progenitors, to pro-oligodendrocytes, to non-myelinating oligodendrocytes, and finally 
myelinating oligodendrocytes (Reviewed in Miller, 2000). A protocol by Hu et al. 2009 
provides an excellent example of the procedure for obtaining oligodendrocyte progenitors. 
Briefly, hESC-derived neural progenitors are treated with RA and Shh for patterning into 
the ventral spinal progenitors, followed by FGF2 for inhibition of differentiation into 
motoneurons. Oligodendrocyte progenitors were induced with the addition of factors 
promoting for survival and proliferation of oligodendrocytes – transferrin, progesterone, 
sodium selenite, putrescine, triiodothyronine (T3), neurotrophin 3 (NT3), platelet-derived 
growth factor (PDGF), cyclic adenosine-monophosphate (cAMP), insulin growth factor-1 
(IGF-1) and biotin. Other factors shown to promote oligodendrocyte differentiation of hESCs 
include hepatocyte growth factor (Hu et al., 2009) and extracellular matrix protein 
vitronectin (Gil et al., 2009). Oligodendrocytes have also been shown to be derived from iPS 
cells (Czepiel et al., 2011). 
3. iPSC technology and implications for neurodegenerative diseases  
Neurological diseases are conditions that affect the central and peripheral nervous 
system.  At present pharmacological interventions for many neurological diseases, 
especially the degenerative conditions, are limited and predominantly restricted to 
alleviation of symptoms. Finding drugs for treatment of neurological disorders represents 
one of the critical goals of medical research today. The recent discovery of iPSC 
technology (Takahashi and Yamanaka, 2006) opens the possibility to generate patient 
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specific models of human disease. The generation of patient specific cells using iPSC 
technology will be a powerful resource for both cell therapy and drug screening (Fig2). 
iPSC is particulary important for neurological diseases as there are limited cellular models 
of the nervous system. 
3.1 X-linked diseases 
A disproportionately large number of disease conditions have been associated with the X 
chromosome because the phenotypic consequence of a recessive mutation is revealed 
directly in males for any gene that has no active counterpart on the Y chromosome. Thus, 
although the X chromosome contains only 4% of all human genes, almost 10% of diseases 
with a mendelian pattern of inheritance have been assigned to the X chromosome (307 out of 
3,199). 168 X-link diseases have been explained by mutations in 113 X-linked genes(Ross et 
al., 2005).  
While males carry a single X chromosome, females have two and hence two copies of each 
gene. Yet, as one of their X chromosomes is inactive in each cell, females also have only one 
working X chromosome in each cell. Thus, females havea mosaic of cells that express either 
the paternal X allele or the maternal X allele. This cellular mosaicism gives females a big 
advantage over males in the context of X-linked diseases. When an X-linked gene is 
mutated, the normal cells can partly compensate for the cells that express the mutant allele 
as a result from cell elimination or by functional compensation (Migeon, 2007).  In males, on 
the other hand, all cells express the mutant gene and therefore usually show much more 
severe symptoms.  
Because the process that inactivates X chromosomes is random with respect to parental 
origin of the X, usually half of the female cells contain a working X chromosome from the 
father while the other half contain a working X chromosome from the mother. By 
reprogramming fibroblasts from female with X-linked disease one can generate both the 
perfect pair of control (expressing the normal allele) and experimental (expressing the 
mutant allele) cell types for investigation of the disease phenotype (see schematic Fig. 3). 
These isogenic control and mutant iPS-derived neurons represent a promising source for 
modelling X-linked diseases.  
3.2 Rett syndrome (RTT) 
RTT is one of the most common causes for mental retardation in females, affecting 1 in 10000 
live female births. It was first reported in 1966 by the neurophysiologist Dr. Andreas Rett 
(Rett, 1966). The large majority of RTT cases are caused by sporadic or from germline 
mutations within the coding sequence of the X-linked methyl CpG binding protein 2 
(MeCP2) gene (Amir et al., 1999) and therefore the mutation cannot be detected by simple 
screening of the parents. Females with classic RTT appear normal from birth until 6–18 
months of age, but then they fail to acquire new milestones and enter a period of regression 
during which motor and language skills are lost. These females show a large diversity of 
symptoms, that appear progressively (reviewed in Chahrour and Zoghbi, 2007) until they 
reach a plateau, suggesting that the condition does not involve progressive 
neurodegeneration (Sun and Wu, 2006). The postnatal onset of symptoms might be 
explained by the increase in MeCP2 levels in cortical neurons throughout normal 
development (Akbarian et al., 2001, Balmer et al., 2003, Jung et al., 2003).  
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Fig. 2. The potential of iPSCs technology. Cell sample can be easily obtained from patients 
and cultured in vitro. These cells can then be reprogrammed into iPSCs and further be 
differentiated into the afflicted cells. Cellular phenotype is assessed by measuring cell 
properties (i.e. neural morphology, maturation of synapses, cell survival under stress, etc). 
Once a distinct disease related phenotype is identified, drug screening platform can be 
developed to test their potential to reverse these  phenotypes (in this example, component 
‘c’ is a potential candidate (see Fig. 3) and can be used for further tests in vivo). Another 
usage for this technology is cell therapy - transplantation of the cells back to the patient.   
 
 
Fig. 3. In vitro disease modeling for X-linked diseases. Schematic explaining reprogramming 
of mosaic cell population from a female with X-linked disease, such as RTT, both iPSC 
clones expressing the mutant allele (Xamut Xiwt) and iPSC clones expressing the wild-type 
(Xawt Ximut)  can be expanded and further differentiated into the afflicted cells (i.e. neurons). 
The wild type neurons, can be used as a perfect control for the mutant neurons for further 
studies, such as screening of molecules that might potentially reverse the symptoms. 
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Although MeCP2 is expressed in a large variety of cells, the most afflicted cells in RTT are 
neurons. In agreement, a specific knockout in the central nervous system revealed the same 
spectrum of symptoms as the full mouse knockout. Several specific neurons were studied in 
the context of RTT. For example, pyramidal glutaminergic neurons, which show obvious 
morphological differences when they express the mutation (see Fig. 3), can account for the 
mental retardation seen in RTT; dopaminergic  neurons can account for the motor function; 
neurons in the Amygdala can affect learning and memory; and hypothalamus neurons can 
affect feeding, aggression and stress.  
In females, the major source for phenotypic variability is the pattern of X chromosome 
inactivation (XCI) (Bourdon et al., 2001). Females with classical RTT are usually a balanced 
mosaic with regard to MeCP2 expression (Adler et al., 1995), whereby half of their cells 
express the wild-type MeCP2 allele and the other half express the mutant MeCP2 allele 
(Shahbazian et al., 2002). However, sometimes, by chance, the XCI pattern favors expression 
of the wild-type allele. Such ‘lucky’ females might show milder symptoms and even to be 
asymptomatic(Sirianni et al., 1998). Another source for phenotypic variability is the type of 
mutation in the MeCP2 gene. Over 300 different mutations in the gene MeCP2 were 
identified, which are the major source of the phenotypic variability in males with RTT. Thus 
generation of iPSCs from multiple patients might shed more light on the correlation 
between mutation type and symptoms as well as the function of different domains in 
MeCP2 protein. In addition, there are important implications for drug screening, as some 
drugs might treat patients with certain mutations but not others. For example, 
aminoglycosides antibiotics, such as gentamicin, can increase wild type MeCP2 expression 
levels in affected neurons by skipping a premature stop codon by bind to the 16S rRNA, 
impairing ribosomal proofreading (Kellermayer, 2006, Marchetto et al., 2010). Thus, disease 
modeling for multiple patients will allow us to tailor specific drugs for each patient.  
Initially, RTT was thought to be a neurodegenerative disease, however, the decrease in 
axondendritic arborization and impaired development of dendrites (Fig. 4) suggest that RTT 
is a disorder featuring an arrest in neuronal development (Hagberg, 1985, Belichenko et al., 
1994, Armstrong, 1992, Armstrong, 2001). Furthermore, no obvious cell death is seen in RTT, 
and this therefore begs the question of whether restoring MeCP2 expression would restore 
normal neuronal function and reverse the resulting disease phenotypes. In a seminal work, 
Guy et al (2007) provide evidence supporting the feasibility of disease reversibility in mouse 
models of RTT (Guy et al., 2007). They created a mouse in which endogenous MeCP2 is 
silenced by insertion of a Lox-Stop cassette and can be conditionally activated through Cre-
mediated deletion of the cassette. The MeCP2 lox-Stop allele behaved as a null mutation, 
and its activation was controlled by a tamoxifen-inducible Cre transgene. Gradual tamoxifen 
injection reversed the late-onset neurological phenotype of adult  MeCP2-lox-Stop/+; cre 
heterozygotes, indicating that MeCP2-deficient neurons are not permanently damaged, 
since MeCP2 activation leads to robust abrogation of advanced neurological defects in both 
young and adult animals. This work establish that consequences of MeCP2 loss of function 
are reversible, and suggest that the neurological defects in RTT, and other MeCP2 disorders, 
are not impervious to therapeutic possibilities. Indeed, several molecules, have delayed the 
onset of RTT-like symptoms in animal models, and enhanced survival rates (Chang et al., 
2006, Ogier et al., 2007). Potential molecules for treatment of RTT are BDNF, IGF-1 and NGF. 
A molecule with promise in RTT therapy is BDNF. There are phenotypic similarities 
between MeCP2- and BDNF-null mice, including a reduction in brain weight and hindlimb 
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clasping. Over expression of BDNF in  MeCP2-null mouse brains delayed the onset of RTT-
like symptoms, and enhanced survival rates (Chang et al., 2006, Ogier et al., 2007). More 
specifically, BDNF overexpression rescued the hypoactivity in wheel running exhibited by 
MeCP2 knockout mouse, and the low frequency of action potential firing observed in their 
cortical neurons (Chang et al., 2006); and treatment of MeCP2 null mice with AMPAkines 
(which increases BDNF mRNA and protein levels) rescued the irregular respiratory patterns 
exhibited by MeCP2. However, the therapeutic utility of BDNF is hampered by its poor 
efficiency at crossing the blood–brain barrier. Nevertheless, a therapeutic intervention in 
humans might thus arise from identifying an agent similarly capable of stimulating synaptic 
maturation.  
An in vitro disease modeling for RTT was established by Marchetto et al (2010). In this study 
they reprogrammed fibroblasts from RTT patients into iPSCs, and further differentiated 
them into neurons. When analyzed, these neurons showed lower synaptic density, simpler 
morphology with less branching and smaller cell body. Furthermore, by using 
electrophysiological methods they showed that RTT neurons have a significant decrease in 
frequency and amplitude. This is in agreement with studies on RTT mice models and on 
postmortem brain tissues from patients. This RTT disease model was used to screen 
molecules, such as IGF-1. Like BDNF, IGF-1 is widely expressed in the CNS during normal 
development (D'Ercole et al., 1996), strongly promotes neuronal cell survival and synaptic 
connections. Indeed, IGF-1 treatment leads to a partial rescue of RTT (Tropea et al., 2009).  
In their study, Marchetto et al (2010) investigated the use of IGF1 and gentamicin in iPSC-
derived neurons carrying a MeCP2 mutation. While IGF1 treatment increased synapse 
number in some clones, it stimulated glutamatergic RTT neurons above normal levels. 
Gentamicin was used to rescue neurons derived from iPSCs carrying a nonsense MeCP2 
mutation by increasing full-length MeCP2 levels in RTT neurons, rescuing glutamatergic 
synapses. Thus, this in vitro disease model can be used to screen therapeutic candidate 
molecules.   
 
 
Fig. 4. Schematic representation of drug screening for pyramidal neurons carrying MeCP2 
mutation. In RTT, the cell body is small and there is reduced dendritic branching 
(Armstrong 1995), fewer synapses, and reduced spine density compared to the control. 
These morphological differences can be an indicator for drug screening. In this example, 
component ‘C’ reverses the impaired morphology of the RTT neurons and therefore can be 
further studied in RTT animal models as a potential drug to reverse the RTT symptoms.    
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3.3 Familial dysautonomia 
Familial dysautonomia (FD), also known as Riley–Day syndrome or HSAN-III is a 
neurodevelopmental disorder, caused by a mutation in the I-k-B kinase complex-associated 
protein (IKBKAP) gene on chromosome 9. This condition is affects 1 in 3,700 Eastern 
European Jewish ancestry (Ashkenazi Jews), but rare in the general population. The disease 
was first reported by Conrad Milton Riley and Richard Lawrence. It is a fatal autosomal 
recessive disease characterized by the degeneration of sensory and autonomic neurons 
(Slaugenhaupt et al., 2001, Axelrod et al., 2002), resulting in variable symptoms including: 
insensitivity to pain, inability to produce tears, poor growth, and labile blood pressure 
(episodic hypertension and postural hypotension). Future parents can be screened for the 
mutation and if both parents are shown to be carriers by genetic testing, there is a 25% 
chance that the child will produce FD. The point mutation in the IKBKAP gene results in a 
tissue-specific splicing defect with various levels of exon 20 skipping and reduced levels of 
normal IKBAP protein (Slaugenhaupt et al., 2001, Anderson et al., 2001). The ratio between 
the normal and mutant transcripts affects the severity of the disease. 
An iPSC-based model for FD was established by Lee et al (Lee et al., 2009). FD-iPSC-derived 
neural crest showed reduced migration as well as decreased rate of neurogenesis. 
Furthermore, when they screened the afflicted cells with candidate drugs, they found that 
kinetin resulted in a marked reduction of the mutant IKBKAP splice form, associated with 
an increase in normal IKBKAP levels. This treatment increased the percentage of 
differentiating neurons but it did not affect the migration potential of the neural crest. Thus 
FD-iPSC model is an example of gaining insight about early progession of a neuro-
developmental disease. 
3.4 Parkinson’s disease 
Parkinson’s disease (PD) is one of the most widely studied neurodegenerative disease 
caused by the progressive degeneration of midbrain dopaminergic neurons. Although the 
aetiology of PD remains enigmatic, partially attributed to complex environmental factors, 
and mutations in several genes (LRRK-2, Parkin, DJ-1, PINK1, ATP13A2, alpha-synuclein, 
GBA) have been found to give rise to PD-like pathogenesis. However, these genetic factors 
contribute to only a small fraction of PD cases, impeding significant progress in 
understanding PD pathogenesis completely. Moreover, it was found in PD patients who had 
received neuronal grafts through transplantation that the cells which were previously young 
and healthy developed α–synuclein and ubiquitin-positive Lewy bodies after more than a 
decade. This led to the proposal of several mechanisms such as inflammation, oxidative 
stress, excitotoxicity and growth-factor deprivation that may have substantial impact on the 
propagation of PD (Brundin et al., 2008). Thus, it would be necessary to re-examine the 
disease pathology by mimicking characteristics of the disease under these varied conditions 
or in combination with known genetic defects since the benefits of cell transplantation in PD 
trials is still uncertain. This objective may soon be achievable as Soldner et al (2009) 
demonstrated that iPSCs could be derived from patients with idiopathic PD. Furthermore, 
the iPSCs could be directed to differentiate into dopaminergic neurons through EB 
formation in the presence of FGF2, FGF8 and Shh. Coupled with the possibility of deriving 
large-scale functional dopaminergic neurons; via the generation of homogenous spherical 
neural masses (Cho et al., 2008), the ultimate goal of creating patient-specific neuronal cells 
for transplantation therapy may soon be in the pipeline. It is reassuring to note that neurons 
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clasping. Over expression of BDNF in  MeCP2-null mouse brains delayed the onset of RTT-
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understanding PD pathogenesis completely. Moreover, it was found in PD patients who had 
received neuronal grafts through transplantation that the cells which were previously young 
and healthy developed α–synuclein and ubiquitin-positive Lewy bodies after more than a 
decade. This led to the proposal of several mechanisms such as inflammation, oxidative 
stress, excitotoxicity and growth-factor deprivation that may have substantial impact on the 
propagation of PD (Brundin et al., 2008). Thus, it would be necessary to re-examine the 
disease pathology by mimicking characteristics of the disease under these varied conditions 
or in combination with known genetic defects since the benefits of cell transplantation in PD 
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large-scale functional dopaminergic neurons; via the generation of homogenous spherical 
neural masses (Cho et al., 2008), the ultimate goal of creating patient-specific neuronal cells 
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reprogrammed from mouse fibroblasts were able to integrate functionally into the fetal 
brain and improve the locomotor behavior in at least a rat model of PD upon 
transplantation into the adult brain (Wernig et al., 2008). However, whether these 
transplanted cells will succumb to the same fate in the long-term as observed in the post-
mortem human PD trails remains to be investigated. 
3.5 Huntington’s disease 
Huntington’s disease (HD) is caused by CAG repeats in the N-terminus of the gene 
encoding Huntingtin protein. Like Lewy proteins in Parkinson’s disease patients,  the 
expression of aberrant polyglutamine-containing molecules in HD leads to massive loss of 
medium spiny neurons in the striatum and neurons in the cortex as the disease progresses. 
Despite substantial efforts invested in various cellular and animal models to understand the 
disease, the mechanisms implicated in the selective cell death of neurons remains unclear 
and there is no cure at present. One major hurdle is the lack of appropriate human samples 
carrying the genetic mutation for HD which would offer the most ideal system for 
investigating the process of neurodegeneration. With the advent of iPSC technology, HD-
specific iPSCs were generated (Park et al., 2008). Thereafter, HD specific NSCs 
(nestin+/PAX6+/SOX1+/OCT4-) were obtained and these were subjected to differentiation 
conditions combining morhogens (SHH and DKK1) and neurotrophins (BDNF) to induce 
neurons of the striatal lineages (Zhang et al.). Importantly, these neurons contained the 
same CAG expansion as the mutation in the HD patient in which the iPSC line was 
established. Thus, a valuable resource is now available to search for drugs that can reduce 
the toxicity of polyglutamine. 
3.6 Amyotrophic lateral sclerosis 
Another seminal study to interrogate a deliberating disease, arising from the progressive 
degeneration of motor neurons of the spinal cord using the iPSC technology is amyotrophic 
lateral sclerosis (ALS) (Dimos et al., 2008). In this landmark study, skin fibroblasts produced 
directly from an 82-year-old elderly woman patient, diagnosed clinically with ALS and a 
SOD1 mutation were reprogrammed successfully into the pluripotent state. These patient-
specific iPSCs showed strong alkaline phosphatase activity and exhibited markers (SSEA-3, 
SSEA-4, TRA1-60 and TRA1-81) and a transcriptional profile (REX1, FOXD3, TERT, NANOG 
and CRIPTO) that are comparable to pluripotent hESCs. Furthermore, these cells could form 
EBs and were capable of differentiating into cells of the germ layers. Most importantly the 
iPSCs were directed specifically towards both motor neurons and glia fates, enabling further 
exploration of either a cell autonomous (such as the amount of SOD1 in motor neurons) or 
non-cell-autonomous (such as the role of neighboring astrocytes, microglia and 
oligodendrocytes) function of the disease as implicated in rodent models (Boillee et al., 2006, 
Yamanaka et al., 2008). Thus, the iPSC technology essentially reversed the patient’s history 
to allow the onset and progression of ALS to be captured in culture for drawing mechanistic 
insights.  
In addition to ALS, Park and co-workers (Park et al., 2008) managed to single-handedly 
generate reprogrammed cells from patients with a range of genetic diseases that were either 
Mendelian or complex in inheritance. The diseases in which iPSCs were derived include: 
adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), 
Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne 
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(DMD) and Becker muscular dystrophy (BMD), Parkinson disease, Huntington disease, 
juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21 and the 
carrier state of Lesch-Nyhan syndrome. Similar to the set of assays used in the 
characterization of the ALS iPSCs, these disease-associated iPSC lines were all confirmed to 
be pluripotent and capable of multi-lineage differentiation. Moreover, these human iPSCs 
produced teratomas in immunodeficient Rag2−/−γC−/− mice, the golden standard for 
testing pluripotency. Taken together, these efforts undoubtedly demonstrated the feasibility 
of the iPSC technology to reprogram somatic cells from a variety of diseased patients. And 
in the process, provided valuable source of material that pave the way for unraveling 
disease mechanisms and customized cellular therapies tailored for the individual.     
4. Conclusion 
Research on hESCs has allowed the development of specific protocols for generation of 
neural progenitors and differentiated neural lineages. These protocols can now be applied to 
iPSCs to enable the generation of specific neurons, astrocytes and oligodendrocytes. The 
availability of samples from relevant donors carrying different mutations will also facilitate 
modelling of neuronal diseases by reprogramming somatic cells. A ‘mutation library’ for a 
particular disease can then serve as a platform for the tailoring of specific drugs for specific 
patients. Furthermore, disease modelling from multiple patients might provide additional 
insights on the pathogenesis of the disease; particularly RTT in which specific mutations are 
associated with variable severity in clinical symptoms. Another advantage in 
reprogramming is that the clinical history of every donor is known. This will allow us to 
model diseases in which the genetic component is not known such as Alzheimer and 
Parkinson’s.  Thus the use of iPSCs technology will herald a new era in the study of 
neurological diseases. 
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1. Introduction 
Embryonic development and later rejuvenation of adult tissues are regulated by a 
population of stem cells (SCs) that, by undergoing self-renewal, maintain their own pool 
and, by giving rise to differentiated progenitors, replace cells used up during life (Ratajczak 
et al., 2007). Thus, SCs are guardians of tissue/organ integrity and regulate the life span of 
an adult organism. The most important SCs, from a regenerative potential point of view, are 
pluripotent stem cells (PSCs). According to their definition, such cells must meet certain in 
vitro and in vivo criteria. PSCs must: i) give rise to cells from all three germ layers; ii) 
complete blastocyst development; and iii) form teratomas after inoculation into 
experimental animals.  
The SC compartment shows a high degree of hierarchy (Hayashi & Surani, 2009). In 
embryonic development, the most primitive stem cells are the fertilized oocyte (zygote) and 
the first blastomers in the morula. These cells are called totipotent, possessing the ability to 
give rise to both embryo and placenta. The developing morula gives rise to the blastocyst, 
where PSCs are found in the inner cell mass (ICM).  These cells may give rise to all three 
germ layers of the developing embryo; however, they have lost the ability to differentiate 
into placenta. The PSCs at this stage can be expanded ex vivo as immortalized embryonic 
stem cell (ESC) lines (Evans & Kaufman, 1981).  
After implantation of the blastocyst, PSCs from the blastocyst ICM give rise to pluripotent 
epiblast stem cells (EpiSCs) that will form  the entire embryo proper (Brons et al., 2007; Tesar 
et al., 2007). During the gastrulation process, cell lineage determination programs are  
initiated and EpiSCs respond to the signals from surrounding extra-embryonic tissues, 
which leads to their differentiation into several types of tissue-committed stem cells (TCSCs) 
(Ratajczak et al., 2007). TCSCs are monopotent (unipotent), which means they are restricted 
in their differentiation potential to cells for one tissue only (e.g., epidermis, intestinal 
epithelium, liver, skeletal muscles, or lympho-hematopoietic). TCSCs terminate expression 
of pluripotent genes and, at the same time, turn on lineage-specific molecular programs.  
The first population of SCs, which at around embryonic day 7.25 (E7.25) become specified in 
the proximal epiblast, are primordial germ cells (PGCs), and alkaline phosphatase (AP)-
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positive PGCs grow into extra-embryonic mesoderm at the base of the allantois as an 
appendage arising from around the posterior primitive streak (Surani et al., 2007). These 
cells transcribe pluripotency-related genes, such as Oct-4, Nanog, and Sox2, and are the only 
population of SCs that maintains expression of these genes during gastrulation. When PGCs 
are cultured over murine embryonic fibroblasts and exposed ex vivo to three growth factors 
(kit ligand, leukemia inhibitory factor, and basic fibroblast growth factor), they continue to 
proliferate and form large colonies of embryonic germ cells (EGCs), which, like ESCs, can be 
expanded indefinitely (Matsui et al., 1992). At around E12.5, PGCs arrive at the genital 
ridges, lose their markers of pluripotency, and initiate their commitment to becoming 
gametes (oocytes and sperm).  
As mentioned above, SCs show a developmental hierarchy (Hayashi & Surani, 2009), and 
PSCs that emerge during embryogenesis give rise to more differentiated SC populations 
with the ability to self renew, but with a more limited ability for multilineage differentiation 
(Surani et al., 2007). Evidence is accumulating that differentiation potential is regulated by 
epigenetic reprogramming (Surani et al., 2007). PSCs from the ICM show global DNA 
demethylation, which results in i) activation of the X chromosome, ii) expression of germ-
line, lineage-characteristic genes (e.g Stella, Mvh, Dazl, and Sycp3), and iii) expression of 
repetitive sequence families (e.g. LINE1, SINE, and IAP). After implantation of the blastocyst 
in the uterus, ICM-derived PSCs give rise to EpiSCs and again methylate  i) the X 
chromosome, ii) promoters for genes characteristic of PSCs in the ICM (Rex-1 and Stella), 
and iii) repetitive sequences (Hayashi et al., 2008). Whereas most  EpiSCs undergo further 
differentiation into TCSCs by stable repression of promoters for pluripotent-specific genes, 
some EpiSCs in the proximal epiblast (precursors of PGCs) revert to a state that resembles 
ICM PSCs by undergoing genome-wide DNA demethylation (Hayashi & Surani, 2009). This 
leads to re-activation of the X chromosome and promoters for germline-lineage genes and 
repetitive sequences.  
Unlike differentiated somatic cells, PSCs commonly express the pluripotency core 
transcription factors (TFs) such as Oct-4, Nanog, and Sox2 (Kim et al., 2008). These TFs form 
the pluripotency core circuitry by reinforcing the expression of genes involved in keeping 
PSCs in an undifferentiated state and, at the same time, repressing their differentiation. The 
biological significance of these core TFs has been experimentally proven by the generation of 
inducible pluripotent stem cells (iPSCs), in which fully differentiated somatic cells can be 
reprogrammed into ESC-like stem cells after transduction by so-called Yamanaka factors 
(Oct-4, Sox2, Klf4, and cMyc) (Takahashi & Yamanaka, 2006; Wernig et al., 2007).  
Another hallmark of pluripotency is the presence of transcriptionally active chromatin 
structures at the promoters of core TFs due to methylation and histone modifications of 
promoter DNA (Cedar & Bergman, 2009). Thus, promoters for core TFs in PSCs are de-
methylated and highly enriched for histone codes associated with active transcription, such 
as acetylated histones and trimethylation on lysine 4 of histone 3 (H3K4me3). In addition to 
the expression of pluripotency core TFs, undifferentiated PSCs also exhibit specific 
epigenetic marks called bivalent domains (BDs) (Azuara et al., 2006; Boyer et al., 2006; Lee et 
al., 2006; Stock et al., 2007).  In BDs, the transcriptionally active H3K4me3 code coexists with 
repressive histone codes, such as trimethylated lysine 27 in histone 3 (H3K27me3). The BDs 
are mainly detected in the promoter regions of homeodomain-containing developmental 
master TFs, such as Dlx-, Irx-, Lhx-, Pou-, Pax-, and Six-family proteins. Due to the 
overwhelming effect of the transcription-repressive activity of H3K27me3, the transcription 
of BD-controlled  genes is transiently repressed to prevent premature differentiation. 
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However, in response to developmental stimuli, BDs in promoters of these genes are 
switched into the monovalent type that promotes transcription. Therefore, both positive 
(expression of Oct-4-Nanog-Sox2) and negative (repression of differentiation-inducing TFs 
by bivalent domains) mechanisms are indispensable for controlling the pluripotent state of 
PSCs. 
As mentioned before, PSCs are detected only during very early embryonic development and 
they disappear after differentiation into TCSCs and germline cells (Niwa, 2007). However, 
recent evidence has accumulated demonstrating that PSCs may reside in adult tissues and 
are able to differentiate into TCSCs (Ratajczak et al., 2007). These cells have been variously 
described in the literature as i) multipotent adult progenitor cells (MAPCs), ii) marrow-
isolated adult multilineage-inducible (MIAMI) cells, iii) multipotent adult (MA) SCs, or iv) 
OmniCytes (Beltrami et al., 2007; D'Ippolito et al., 2004; Jiang et al., 2002; Pochampally et al., 
2004). Thus, the physical presence of PSCs in adult tissues may better explain stem cell 
plasticity, according to which TCSCs are purportedly plastic and can trans-dedifferentiate 
into SCs for other tissues.  
However, several questions remain to be addressed regarding these rare PSCs. First, the 
developmental origin of these cells is unresolved. As shown in Figure 1, PSCs during 
embryogenesis/gastrulation may become eliminated after giving rise to TCSCs, or 
conversely, they may survive among TCSCs and serve as a back-up/reserve source for these 
cells. Thus, it is important to elucidate whether PSCs found in adult tissue cells are 
functional under steady-state conditions or are merely remnants from developmental 
embryogenesis that reside in a dormant state in adult tissues. Second, is the question of 
  
 
Fig. 1. Developmental specification of PSCs into TCSCs. Scenario I: During 
embryogenesis/gastrulation, PSCs  are eliminated after giving rise to TCSCs and PGCs. 
Scenario II: PSCs survive and serve as a back-up/reserve source of TCSCs.  
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whether the dormant state of these cells is regulated by cell-intrinsic epigenetic 
reprogramming similar to other PSCsduring embryogenesis. Finally, there is the question of 
whether their dormant state is influenced by microenvironmental cues, such as their  (i) 
location in non-physiological niches, (ii) exposure to inhibitors, or  (iii) deprivation of 
appropriate stimulatory signals. The answer to these questions could be key to successful 
application of these adult-tissue-derived PSCs in the clinical setting. In this chapter, we will 
discuss these issues in more detail. 
2. Very small embryonic-like stem cells (VSELs) residing in adult tissues 
Recently, our group purified a population of very small embryonic-like stem cells (VSELs) 
from BM by employing a multiparameter fluorescence-activated cell sorter (FACS) (Kucia et 
al., 2006b). These rare Sca-1+Lin–CD45– cells reside in several adult murine organs (e.g., 
brain, liver, skeletal muscles, heart, and kidney) (Zuba-Surma et al., 2008) and recently were 
detected also in human umbilical cord-blood and mobilized peripheral-blood (Kucia et al., 
2006a; Paczkowska et al., 2009; Wojakowski et al., 2009). VSELs are very small in size (~3–6 
m) and express pluripotent markers, such as Oct-4, Nanog, Rex-1, and SSEA-1 (Kucia et al., 
2006b). They are morphologically, similarly to ESCs, possessing large nuclei containing 
unorganized chromatin (euchromatin) and exhibiting a significantly higher 
nuclear/cytoplasm (N/C) ratio and a lower cytoplasmic area than hematopoietic stem cells 
(HSCs). The true expression of Oct-4 and Nanog in BM-derived murine VSELs was recently 
confirmed by demonstrating transcriptionally active chromatin structures for both Oct-4 and 
Nanog promoters (Shin et al., 2009).  If cultured under a C2C12 myoblast feeder layer, 
freshly isolated VSELS form spheres corresponding to embryoid bodies (EBs). These VSEL-
derived spheres (VSEL-DSs) contain primitive SCs that, after replating into tissue-specific 
differentiation media, are induced to differentiate into cells from all three germ layers (Kucia 
et al., 2008a). From experiments with mouse models, it has been proposed that VSELs are 
mobilized into peripheral blood in response to injury and circulate to the organ of injury in 
an attempt to enrich and regenerate damaged tissues (e.g., following heart infarct or stroke) 
(Kucia et al., 2008b; Paczkowska et al., 2009; Wojakowski et al., 2009). This physiological 
mechanism probably plays a significant role in the regeneration of some small tissue and 
organ injuries; however, further studies are needed to demonstrate that these cells do in fact 
home to the damaged organs. 
3. Molecular signature of VSELs residing in BM 
To investigate the relationship between VSELs and embryonic PSCs (e.g. embryonic stem 
cells [ESCs], epiblast stem cells [EpiSCs], primordial germ cells [PGCs], and embryonic germ 
cells [EGs]), we employed several molecular strategies to evaluate VSEL molecular 
signatures (Figure 2). Highly purified Sca-1+Lin–CD45– VSELs from murine BM were 
evaluated for i) expression of pluripotent genes, epiblast/germ line markers, and 
developmentally crucial imprinted genes; ii) the presence of BDs; and iii) reactivation of the 
X chromosome in female VSELs.  
3.1 VSELs express PSC genes 
PSCs express the essential pluripotency TF Oct-4. The importance of this TF is well-
established by the fact that transduction with Oct-4 is obligatory in several protocols for 
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generating iPSCs. We found that VSELs express Oct-4 at both the mRNA and protein level 
(Kucia et al., 2006a). However, recently some doubts have been raised about whether cells 
isolated from adult tissues express these embryonic genes, and it has been suggested that 
positive PCR data showing Oct-4 expression may be due to amplification of Oct-4 
pseudogenes (Lengner et al., 2007; Liedtke et al., 2007). Thus, to prove true expression of the 
Oct-4 gene in VSELs, we investigated the epigenetic state of the Oct-4 promoter. Our DNA 
methylation studies of the Oct-4 promoter using bisulfite sequencing revealed that it is 
hypomethylated in highly purified Sca-1+Lin–CD45– VSELs, similarly to cells isolated from 
ESC-derived EBs (28% and 13.2%, respectively) (Shin et al., 2009). Next, to evaluate the state 
of histone codes for the Oct-4 promoter, we performed the chromatin-immunoprecipitation 
(ChIP) assay to verify its association with acetylated histone 3 (H3Ac) and dimethylated 
lysine 9 of histone 3 (H3K9me2), the molecular marks for open- and closed-type chromatin, 
respectively. By employing the carrier-ChIP assay (using the human hematopoietic cell-line 
THP-1 as carrier) we found that Oct-4 promoter chromatin is associated with H3Ac and its 
association with H3K9me2 is relatively low (Shin et al., 2009). We also evaluated the 
epigenetic state of another core TF,  Nanog, and observed that its promoter has a higher level 
of methylation in VSELs (50%). However, in quantitative ChIP experiments performed in 
parallel,  it was confirmed that the H3Ac/H3K9me2 ratio favors transcription and supports 
its active state (Shin et al., 2009). Based on these results, we conclude that VSELs truly 
express Oct-4 and Nanog. Of note, we also reported that VSELs express several  
other markers of PSCs, such as SSEA-1 antigen, as well as Sox2 and Klf4 TFs (Shin et al., 
2010b). 
3.2 Expression of epiblast markers 
As a result of the epigenetic reprogramming that occurs during implantation of the 
blastocyst, EpiSCs exhibit transcription profiles different from ESCs. For example, the 
expression of Nanog, Sox2, and Stella is reduced in EpiSCs through DNA methylation of 
their promoters (Surani et al., 2007). In functional assays, EpiSCs, unlike ESCs, show a 
highly restricted capacity to complement blastocyst development (Brons et al., 2007; Tesar et 
al., 2007). However, pluripotent EpiSCs may differentiate in vivo into TCSCs, which during 
embryogenesis orchestrate organogenesis and later in adult life are involved in rejuvenation 
of tissues and organs. Like EpiSCs, highly purified BM-derived Oct-4+ VSELs do not 
complement blastocyst development and therefore cannot enable in vitro differentiation into 
cells from all three germ layers. Therefore, we have hypothesized that VSELs may be 
epiblast-derived precursors of TCSCs (Ratajczak et al., 2010). To investigate the similarity 
between VSELs and EpiSCs, we examined  the expression of genes that are characteristic of 
EpiSCs (Gbx2, Fgf5, and Nodal) and ESCs from the blastocyst ICM (Rex-1) in adult BM-
derived VSELs.  It is known that Gbx2, Fgf5, and Nodal are upregulated in EpiSCs, but are 
expressed at lower levels in ESCs isolated from the ICM (Hayashi et al., 2008). In contrast, 
the level of Rex-1 transcripts is highly expressed in ICM cells. We found that VSELs highly 
express Gbx2, Fgf5, and Nodal, but express the Rex-1 transcript at a low level compared to the 
established murine ESC cell line, ESC-D3. This suggests that VSELs are more differentiated 
than ICM-derived ESCs and share several markers with more differentiated EpiSCs (Shin et 
al., 2010b). 
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whether the dormant state of these cells is regulated by cell-intrinsic epigenetic 
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Fig. 2. Epigenetic modification of VSELs during embryogenesis and aging. Epigenetic 
modifications control the differentiation potential of SCs during embryogenesis and aging. 
The DNA methylation processes during development of ICM-derived epiblast SCs specify 
them to TCSCs. However, at the beginning of gastrulation, the proximal epiblast-specified 
PGCs can reset their epigenetic profile to one that characterizes ICM-derived PSCs. 
Subsequently, during PGC migration to the genital ridges, global DNA demethylation leads 
to the erasure of genomic imprints. Consistent with the hypothesis that VSELs originate 
from an epiblast-derived PGC population, they show a PGC-like epigenetic profile, 
including partial DNA demethylation of several pluripotency, germ-line, and genomic 
imprints. These epigenetic profiles of developing VSELs are retained after their deposition 
into adult tissues. This parent-specific reprogramming of the genomic imprinting of VSELs 
deposited in adult tissues (e.g., BM) functions as i)  a “lock-in mechanism” to prevent their 
inappropriate proliferation and ii) a mechanism to restrict their sensitivity to Ins/Igf 
signaling. During the aging process, while residing in adult tissues, VSELs exposed  to 
oxidative stress or chronic Ins/Igf signaling de-repress locked-in genomic imprints and 
progressively methylate DNA in the Oct-4 promoter (Ratajczak et al 2011a). As a result of 
these epigenetic changes, the total number and pluripotency of VSELs decreases with age 
(Ratajczak et al. 2008), which leads to impaired tissue regeneration and rejuvenation. 
3.3 Expression of germline markers 
During gastrulation, EpiSCs lose expression of core pluripotency TFs. On the other hand, 
during specification of proximal epiblast EpiSCs into PGCs, the expression of these early 
embryonic genes is re-activated by resetting epigenetic programs in these cells (Hayashi & 
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Surani, 2009). Thus, PGCs reset epigenetic marks to an ICM-like state, which results in re-
activation of pluripotency and germline-related genes (Hayashi & Surani, 2009). The 
specification of PGCs is initiated at E7.25 by expression of germline master regulators, such 
as Fragilis, Blimp1, and Stella, in response to signals from extra-embryonic tissues (Surani et 
al., 2007). At this time, around 40 proximal epiblast-derived PGCs are detected. At E8.5, 
PGCs enter back into the embryo proper through the primitive streak and start migration 
through the hindgut endoderm and mesentry to the aorta-gonads-mesonephros (AGM) 
region, and at around E11.5 they reach the genital ridge in which PGCs differentiate into 
monopotent gametes (sperm and egg). Our data indicate some relationship between VSELs 
and PGCs (Shin et al., 2010b). Accordingly, VSELs are reported to highly express genes that 
are involved in germ-line specification of the epiblast (e.g., Stella, Prdm14, Fragilis, Blimp1, 
Nanos3, and Dnd1). The expression of Stella, Blimp1, and Mvh has been confirmed at the 
protein level by immunostaining. Furthermore, the Stella promoter in VSELs is partially 
demethylated and displays transcriptionally active histone modifications (H3Ac and 
H3K4me3) and is less enriched for transcriptionally repressive histone marks (H3K9me2 
and H3K27me3) (Shin et al., 2010b). It can be concluded that VSELs express several 
germline-specific genes and display a Stella promoter chromatin structure that is 
characteristics of germline specification. VSELs also highly express Dppa2, Dppa4, and Mvh, 
which characterize late migratory PGCs; however, they do not express Sycp3, Dazl, and 
LINE1 genes that are expressed in post-migratory PGCs (Maatouk et al., 2006; Maldonado-
Saldivia et al., 2007). Thus, our results in toto support the conclusion that VSELs deposited 
into murine BM show some similarities in gene expression and epigenetic signatures to 
epiblast-derived migratory PGCs (at ~E10.5–E11.5). 
3.4 VSELs are marked by BDs 
As mentioned above, in undifferentiated ESCs, most of the homeodomain-containing 
developmental TFs are repressed by BDs (Bernstein et al., 2006), which are chromatin 
structures in which transcriptionally opposite histone codes physically co-exist in the same 
promoter. In undifferentiated ESCs, BD epigenetic codes at the promoters of these TFs are 
temporarily repressed, preventing their premature differentiation. During differentiation, 
the transient repressive epigenetic marks in these TFs become monovalent and thereafter 
activate or repress expression of the appropriate TFs. Our preliminary data indicate that 
murine VSELs display BDs in the promoters of several homeodomain-containing 
developmental TFs (Sox21, Nkx2.2, Dlx1, Lbx1h, Hlxb9, Pax5, and HoxA3). The presence of 
transcriptionally active histone codes, such as H3K4me3, physically coexisting with 
repressive histone codes, such as H3K27me3, was confirmed by employing the carrier-ChIP 
assay (submitted for publication). 
3.5 VSELs from female mice partially activate an X chromosome 
The process of X-chromosome inactivation is mediated by expression of the large noncoding 
RNA Xist, which is transcribed on the inactivated X chromosome. Coating of the X 
chromosome to be inactivated by spreading of Xist RNA induces the silenced chromatin 
structure (Payer & Lee, 2008). As already mentioned above, it is well known that female 
PSCs (e.g., murine and human ESCs isolated from the blastocyst ICM, as well as PGCs) 
reactivate  the X chromosome that was inactivated after fertilization, and, as a result, female 
PSCs display two equivalently activated X chromosomes (Surani et al., 2007). Our initial 
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studies in murine female VSELs show that these cells partially reactivate the inactivated X 
chromosome. As mentioned above, female murine VSELs partially hypermethylate the Xist 
promoter (~80%), unlike somatic cells which show 50% DNA methylation. This result 
strongly suggests that murine VSELs, like ESCs and PGCs, can undergo the process of X 
chromosome reactivation (submitted for publication).  
4. Developmental origin of VSELs 
Taking into consideration all the molecular signatures characteristic of  VSELs, we propose 
that VSELs are epiblast-derived PSCs deposited early during embryogenesis in developing 
organs as a potential reserve pool of precursors for TCSCs. Thus, VSELs have an important 
role in tissue rejuvenation and regeneration (Shin et al., 2010a). Because of the gene 
expression profile and epigenetic state of the core TFs, expression of epiblast and germline 
genes suggests that VSELs deposited in adult BM originate from migratory PGCs that have 
gone astray from the “orthodox” migration route.  
From the second trimester on, VSELs are easily found as a Sca-1+Lin–CD45– population in 
murine fetal liver, which  is the main embryonic hematopoietic tissue. VSELs that emerge in 
fetal liver (FL-VSELs) follow the developmental route of hematopoietic stem cells (HSCs)  and 
subsequently colonize BM together with HSCs (Zuba-Surma et al., 2009).  FL-VSELs and their 
BM-derived counterparts express a similar pattern of pluripotent and epiblast/germline genes 
at the mRNA and protein levels. Accordingly, the promoters for Oct-4, Nanog, and Stella show 
significant DNA demethylation and enriched histone modifications for an open, 
transcriptionally active structure in these promoters (Shin et al., 2010a).  
Mounting evidence also indicates that PGCs could be related to HSCs, another population 
of highly migratory SCs (De Miguel et al., 2009). In support of this notion, the first primitive 
HSCs appear in the extra-embryonic tissues in yolk sac blood islands at the time when 
proximal epiblast-specified PGCs enter the extra-embryonic mesoderm (Mikkola & Orkin, 
2006). In addition, the appearance of definitive HSCs in the AGM region of the embryo 
proper coincides with migration of PGCs to the genital ridges through the AGM (De Miguel 
et al., 2009). Furthermore, PGCs isolated from murine embryos have been proven to be able 
to grow HSC colonies while, on the other hand, robust hematopoietic differentiation has 
been observed in some classical germline tumors (Kritzenberger & Wrobel, 2004; Ohtaka et 
al., 1999; Rich, 1995; Saito et al., 1998; Woodruff et al., 1995). All this suggests developmental 
overlap between PGCs and HSCs. 
On the other hand, VSELs share several characteristics with both PGCs and HSCs.  In 
particular, VSELS i) share several  BM- and FL-derived markers characteristic of the 
epiblast/germ line (Shin et al., 2010b), ii)  follow the developmental route of HSCs (Zuba-
Surma et al., 2009), and iii), in appropriate culture conditions, can also be differentiated 
toward the hematopoietic lineage. All of this suggests that VSELs are the most primitive 
murine BM-residing population of SCs and function as precursors for long-term 
repopulating HSCs (Ratajczak et al., 2011b).  
Thus, PGCs, HSCs , and VSELs together form a unique highly migratory population of 
interrelated SCs that may be envisioned as  a kind of 4th (highly migratory) germ layer. Due 
to this unique developmental origin, VSELs show characteristic epigenetic reprogramming 
and gene expression in stemness, germline, and imprinted genes (as described below) that 
maintain their pluripotency, but also prevent inappropriate proliferation and teratoma 
formation (Shin et al., 2009). 
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5. Epigenetic changes of imprinted genes that regulate VSEL pluripotency 
Unlike ESCs, highly purified BM-derived Oct-4+ VSELs do not proliferate in vitro if cultured 
alone and do not grow teratomas in vivo. On the other hand, cells from VSEL-DSs have 
restored their proliferation potential, demonstrating that their quiescent state can be 
modulated. This suggests that VSELs are a quiescent cell population and that some 
mechanisms must exist to prevent their unleashing of proliferation and teratoma formation. 
Like VSELs, PGCs in cultures freshly isolated from embryos proliferate only for a few days 
before disappearing, either because they differentiate or die (De Felici & McLaren, 1983). 
They also neither grow teratomas nor complement blastocyst development (Surani et al., 
2007). However, when PGCs are cultured over a feeder layer supplemented by a specific  
combination of growth factors, they continue to proliferate and can be reprogrammed into 
EGCs (Shamblott et al., 1998; Turnpenny et al., 2003). Therefore, it is possible that these two 
SC populations employ a similar molecular mechanism to regulate their pluripotency and to 
prevent cell proliferation. 
The hallmark of epigenetic reprogramming during PGC development is erasure of genomic 
imprinting (Surani et al., 2007), which is an epigenetic process ensuring paternal-specific, 
mono-allelic expression of imprinted genes (Reik & Walter, 2001). Around 80 imprinted 
genes (expressed from maternal or paternal chromosomes only) have been reported in the 
mouse genome and their proper mono-allelic expression regulates totipotency and 
pluripotency of the zygote and developmentally early SCs, respectively. Furthermore, most 
imprinted genes, such as insulin-like growth factor 2 (Igf2), H19, Igf2 receptor (Igf2R), and 
p57KIP2 (also known as Cdkn1c) are directly involved in embryo development. Since the 
majority of imprinted genes exist as gene clusters enriched for CpG islands, their expression 
is coordinately regulated by the DNA methylation state of CpG-rich cis-elements known as 
differentially methylated regions (DMRs) (Delaval & Feil, 2004). The differential 
methylation state of DMRs is mediated by DNA methyltransferases (Dnmts), depending on 
the parental allele of origin. Depending on the developmental period of methylation, there 
are two types of DMRs: “primary DMRs” are differentially methylated during 
gametogenesis and “secondary DMRs” acquire allele-specific methylation after fertilization. 
So far, 15 primary DMRs have been identified in the mouse genome. Interestingly, most 
DMRs are methylated at the maternal allele and only three DMRs (at Igf2-H19, Rasgrf1, and 
Meg3 loci) are paternally methylated (Kobayashi et al., 2006). In addition to DNA 
methylation of DMRs, histone modifications also contribute to monoallelic expression of 
imprinted genes (Fournier et al., 2002; Mager et al., 2003). 
Shortly after PGC specification at E7.25, PGCs initiate epigenetic reprogramming programs, 
resulting in global DNA demethylation and changes in histone modifications (Seki et al., 
2007). As a result, epigenetic marks for genomic imprinting in both parental chromosomes 
are erased during migration into the genital ridge and new genomic imprints are established 
during differentiation into gametes in a sex-dependent manner. The erasure of genomic 
imprints could be a mechanism to protect the Oct-4-expressing germline SCs from 
uncontrolled expansion and teratoma formation. For example, while the nuclei of early 
migrating PGCs at E8.5–9.5 can be successfully used as donors for nuclear transfer, nuclei 
from post-migratory PGCs after E11.5 are incompetent to support full-term development 
(Yamazaki et al., 2003). 
Since VSELs, as discussed above, share similar molecular signatures as PGCs, we have 
proposed that VSELs, like PGCs, modify methylation of imprinted genes, which prevents 
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studies in murine female VSELs show that these cells partially reactivate the inactivated X 
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them from unleashing proliferation and may explain their quiescent state in adult tissues. 
Indeed, as shown in Figure 3 and Table 1, VSELs freshly isolated from murine BM erase the 
paternally methylated imprints (e.g., Igf2-H19 and Rasgrf1 loci), while they hypermethylate 
the maternally methylated ones (e.g., Igf2 receptor (Igf2R), Kcnq1-p57KIP2, and  Peg1 loci). 
Because paternally expressed imprinted genes (Igf2 and Rasgrf1) enhance embryo growth 
and maternally expressed genes (H19, p57KIP2, and Igf2R) inhibit cell proliferation (Reik & 
Walter, 2001), the unique genomic imprinting pattern observed in VSELs demonstrates 
growth-repressive imprinting in these cells. As coordinated with genomic imprinting 
reprogramming programs, VSELs highly express growth-repressive imprinted gene 
transcripts (H19, p57KIP2, and Igf2R) and downregulate growth-promoting ones (Igf2 and 
Rasgrf1), which explains the quiescent state of VSELs (Shin et al., 2009). Importantly, all the 
growth-repressive patterns of genomic imprinting are progressively recovered during the 
formation of VSEL-DSs, in which SCs proliferate and differentiate. These results suggest that 
epigenetic reprogramming of genomic imprinting should maintain the quiescence of Oct-4+ 
VSELs deposited in the adult body and protect them from premature aging and tumor 
formation. Therefore, the modulation of mechanisms controlling genomic imprinting in 
VSELs is crucial for developing more powerful strategies to unleash the regenerative 
potential of these cells for efficient employment in the clinical setting. 
6. VSELs and ageing 
Tissue regeneration depends on the  proper function of SCs, and we envision that aging can 
be partially explained by a decline in the regenerative potential of VSELs (Ratajczak et al., 
2008). In support of this notion, the number of VSELs in murine BM gradually declines with 
age, ranging from 0.052 ± 0.018% at 2 months to 0.003 ± 0.002% at  3 years of age (Kucia et 
al., 2008a). Furthermore, the frequency of VSEL-DS formation decreases with age, thus little 
VSEL-DS formation was observed in cells isolated from older mice (>2 years). Accordingly, 
VSELs from older mice (2 years) also show lower expression of pluripotency master 
regulators, such as Oct-4, Nanog, Sox2, Klf4, and cMyc, while the Oct-4 promoter in VSELs 
becomes hypermethylated with age and shows a closed chromatin structure (Ratajczak et 
al., 2011a). The age-dependent decrease of the pool size and function of VSELs in BM may 
explain the decline of regeneration potential during aging. This hypothesis has been further 
corroborated by looking for differences in the content of these cells among BM mononuclear 
cells (BMMNCs) in long- and short-lived mouse strains. The concentration of VSELs was 
much higher in the BM of long-lived (e.g., C57B6) compared to short-lived (DBA/2J) mice 
(Kucia et al., 2006b).  
We have also reported that while long-lived Laron dwarf mice, with low levels of circulating 
Igf1, have a higher number of VSELs in BM compared to normal littermates (Ratajczak et al. 
2011a), short-lived bovine-growth-hormone-expressing transgenic mice, with high 
circulating Igf1 levels, prematurely deplete this population of PSCs (submitted for 
publication). These observations suggest interesting links between high caloric uptake, 
increases in chronic insulin/insulin growth factor signaling, and premature depletion of 
VSELs.     
In support of this linkage, it is well known that changes in insulin/insulin-like growth 
factors (Ins/Igf) signaling molecules play a crucial role in aging. In particular, insulin-like 
growth factor 1 (Igf1) signaling negatively regulates the life span of animals, from worms 
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and flies to mammals (Russell & Kahn, 2007), whileIgf1 and insulin level in blood is 
regulated positively by caloric uptake (Piper & Bartke, 2008). Overall, the genomic 
imprinting reprogramming in VSELs leads to impaired Ins/Ingf signaling due to i) 
downregulation of expression of Igf2, ii) upregulation of expression of Igf2R, which serves as 
a molecular sink for Igf2, and iii) a decrease in expression of Rasgrf1, which is a small GTP 
exchange factor (GEF) for Ins/Igf signal transduction. This suggests that the epigenetic 
mechanism governing the VSEL quiescent state regulates the sensitivity to Ins/Igf signaling 
and could, if overactivated, lead to premature depletion of primitive VSELs in tissues 
(Ratajczak et al., 2011a). 
Thus, high chronic calorie uptake, followed by high plasma insulin and Igf-1 levels may, 




Fig. 3. The unique DNA methylation pattern and expression of imprinted genes in 
VSELs. Arrows in the schematic diagram of paternally (Igf2-H19 and Rasgrf1) or maternally 
(Igf2R and Kcnq1) methylated loci indicate the transcriptional activity of the indicated gene. 
Red (up) and blue (down) arrows indicate upregulated and downregulated gene expression, 
respectively. M = maternal chromosome, P = paternal chromosome. DMR1, IG-DMR, 
KvDMR, DMR2 = DMRs for Igf2-H19, Rasgrf1, Kcnq1, and Igf2R loci, respectively. 
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Table 1 . Expression profiles of crucial imprinted genes in murine VSELs. 
The expression level of paternally (pat) or maternally (mat) expressed imprinted genes in 
murine BM-derived VSELs is indicated by red-up (up-regulated) and blue-down (down-
regulated) arrows. The effect of the indicated imprinted genes on cell proliferation is 
marked as '+' (proliferation promoting) or '–' (repressing). 
7. Regeneration potential of VSELs in vivo 
To address the most important question of whether these primitive VSELs could be 
efficiently employed in the clinic, we have tested their potential role in several in vivo tissue-
regeneration animal models. First, VSELs can be specified in vivo into mesenchymal stem 
cells (MSCs). Accordingly, in the first study by Taichman et al, VSELs isolated  from GFP+ 
mice were implanted into SCID mice, and 4 weeks later the formation of  bone-like tissues 
was observed (Taichman et al., 2010). Second, freshly isolated BM-derived VSELs from GFP+ 
mice were injected into the hearts of mice that had undergone ischemia/reperfusion injury. 
After 35 days of follow-up, VSEL-treated mice exhibited improved global and regional left 
ventricular (LV) systolic function (as determined by echocardiography) and attenuated 
myocyte hypertrophy in surviving tissue (as determined by histology and 
echocardiography) when compared with vehicle-treated controls (Zuba-Surma et al., 2010). 
Finally, we observed that VSELs, if plated over the supportive OP9 cell line, give rise to 
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colonies of CD45+CD41+Gr-1–Ter119– cells that, when transplanted into wild-type animals, 
protected them from lethal irradiation and differentiated in vivo into all  major 
hematopoietic lineages (e.g., Gr-1+, B220+ and CD3+ cells) (Ratajczak et al., 2011b). Thus, we 
propose that VSELs are a population of BM-residing PSCs that give rise to long-term- 
engrafting hematopoietic SCs.     
8. Conclusion 
In the past few years, several attempts have been made to purify a population of PSCs from 
adult tissues. We propose that the VSELs described by our team play a physiological role in 
rejuvenation of the pool of TCSCs under steady-state conditions. VSELs developmentally 
originate from epiblast-derived migrating PGCs and they could be deposited in adult 
organs early in development as a reserve pool of primitive SCs for tissue repair and 
regeneration. Therefore, VSELs share several molecular signatures with epiblast and 
migrating PGCs with respect to gene expression and epigenetic programs. Based on the 
developmental origin of VSELs, their proliferation, like PGCs, is controlled by the DNA 
methylation state of some of the developmentally crucial imprinted genes (e.g. H19, Igf2, 
and Rasgrf1). During the ageing process, proliferation-repressive epigenetic marks 
progressively disappear, resulting in the increased sensitivity to Ins/Igf signaling and, 
concomitantly, to depletion of the primitive VSEL population. The decrease in the number 
and pluripotency of these cells will affect pools of TCSCs and have an impact on tissue 
rejuvenation and life span. Furthermore, VSELs can be specified into several tissue-residing 
TCSCs (e.g. MSCs, HSCs, and cardiac SCs) in response to tissue/organ injury. Therefore, 
VSELs isolated from adult tissues are an alternative and ethically uncontroversial source of 
SCs for regenerative medicine. However, to successfully employ VSELs for this purpose, it 
is very important to establish experimental protocols for reprogramming of the growth-
repressive genomic imprinted state of VSELs into the regular somatic pattern to unleash 
their regenerative potential. 
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1. Introduction  
The pluripotent nature of embryonic stem cells (ESCs) makes them amenable for 
regenerative therapies because they can differentiate into cells that form all tissue types 
within the body (Zandstra and Nagy, 2001). The potential drawbacks to the use of ESCs for 
cellular therapies include the obvious ethical dilemmas of obtaining ESCs, the potential of 
cancer or tumor formation and the risk of immunogenic rejection (Wobus and Boheler, 
2005). Therefore adult stem cell sources with multipotent and pluripotent potential have 
been sought as an alternative for ESCs including mesenchymal stem cell (MSCs) and tissue-
derived specific stem cells. 
Interestingly, the isolation of a population of dental stem cells derived ectodermally from 
the neural crest (NC) have been shown to be multipotent and give rise to multifarious cell 
types that result in the development of many of the body’s organs or tissues (Huang et al., 
2009a; Huang et al., 2009b). Stem cells extracted from dental tissues including dental pulp, 
periodontal ligament, apical papilla and dental follicle precursor cells have an expansive 
differentiation potential with respect to mesodermal and ectodermal lineages.  Currently 
there are six types of dental stem cells that are well characterized and described both in vitro 
and in vivo (Gronthos et al., 2000; Huang et al., 2009a; Karaöz et al., 2010; Miura et al., 2003; 
Morsczeck et al., 2005; Seo et al., 2004; Sonoyama et al., 2006). 
Some dental stem cells lines have been shown to express ESC markers Oct4, Nanog, Sox2 
and Klf4 and NC markers p75, Sox10, Slug and Nestin suggesting that dental stem cells may 
be able to become many of the same tissues as ESCs (Huang et al., 2009a). Further, dental 
stem cells have been shown to differentiate into neurogenic, adipogenic, cardiomyogenic, 
chondrogenic, myogenic and osteogenic lineages (Huang et al., 2009a; Karaöz et al., 2010; 
Miura et al., 2003; Seo et al., 2004; Sonoyama et al., 2006; Zhang et al., 2006). Since dental 
stem cells have been shown to differentiate into a multitude of cell types, their potential for 
use in tissue regeneration may be boundless.  
We are currently using dental stem cells to investigate the mechanisms of 
mechanotransduction elicited during dynamic cyclic compression for chondrogenesis. Our 
long term goal is to develop technology and protocols utilizing dental stem cells and 
biomechanical force for reparative medicine and tissue regeneration of cartilage. This review 
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will discuss the most current findings in tissue engineering with respect to dental stem cells 
both for whole tooth regeneration and potential use in future stem cell therapies. 
2. Characteristics and sources of stem cells 
2.1 What is a stem cell?  
The general properties that define a stem cells are:  1. Stem cells are cells that are clonogenic 
and have the ability for self-renewal; 2. Stem cells are unspecialized cells that when correctly 
stimulated have the ability to differentiate into specialized cell types (Blau et al., 2001; 
Bongso and Fong, 2009). 
There are two broader categories of stem cells: embryonic stem cells (ESCs) and adult stem 
cells. Embryonic stem cells are derived from the blastocyst stage of a developing embryo 
(Fortier, 2005; Thomson et al., 1998) and are capable of forming all three germ layers 
(ectoderm, endoderm, and mesoderm)(Bongso and Fong, 2009). Harvesting ESCs requires 
the destruction of the embryo (Lanzendorf et al., 2001) which leads to ethical dilemmas 
when obtaining these cells. The use of adult stem cells avoids these ethical issues. Adult 
stem cells have been obtained from multiple tissues including bone marrow (Pittenger et al., 
1999), adipose tissue (Zuk et al., 2001), muscle (Deasy et al., 2001), umbilical cord tissue 
(Schugar et al., 2009), intestine (Wong, 2004), and skin (Blanpain et al., 2004). While most of 
this book focuses on the embryonically derived stem cells, this chapter focuses on the adult 
or postnatal stem cells with special emphasis on those derived from dental tissues.  
2.2 Stem cell potency  
Stem cell potency refers to the ability of the cell to differentiate into specific tissue type(s). 
Totipotent is defined as the ability to differentiate into any of the cell types of the entire 
organism, both embryonic and adult cell types (Dannan, 2009; Mummery et al., 2011; Smith, 
2006). An example of a totipotent cell is a fertilized egg cell because it is able to differentiate 
into embryonic, extra-embryonic (ie. placenta) and adult tissues of the entire organism 
(Alison et al., 2002; Dannan, 2009; Mummery et al., 2011).  Pluripotent stem cells have the 
potential to differentiate into all cell lineages including the three germ layers: ectoderm, 
mesoderm, or endoderm but not the extra-embryonic tissues (Alison et al., 2002; Dannan, 
2009; Fortier, 2005; Mummery et al., 2011; Smith, 2006). ESCs are considered the gold 
standard of stem cells because of their pluripotency and their ability to be maintained 
indefinitely in culture (Thomson et al., 1998). Pluripotency has also been demonstrated in 
adult stem cells including bone marrow mesenchymal stem cells (BMMSCs) (Jiang et al., 
2002). Multipotent stem cells have the ability to differentiate into multiple cell lineages that 
can form more than one tissue type (Alison et al., 2002; Mummery et al., 2011; Smith, 2006). 
Mesenchymal stem cells (MSCs) derived from adipose tissue are an example of a 
multipotent stem cell and are able to differentiate into multiple tissues of the mesodermal 
lineage including bone, fat and cartilage (Zuk et al., 2002). 
2.3 Bone marrow mesenchymal stem cells  
Stem cells obtained from bone marrow are a major source of adult MSCs and are widely 
studied. Bone marrow stromal cells can be harvested from bone marrow by mechanical 
disruption, but the cell suspension will contain both hematopoietic stem cells and BMMSCs 
(Bianco et al., 2001). BMMSCs are isolated as colony forming unit-fibroblasts (CFU-Fs) from 
the bone marrow cell suspension. In order to separate the two types of stem cells, the cell 
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suspension is cultured in vitro at low density. A small number of BMMSCs will adhere to 
the plate and begin to form colonies while the non-adherent hematopoietic cells are then 
removed by repeat washings (Bianco et al., 2001; Chamberlain et al., 2007). BMMSCs 
isolated in this manner are capable of 20–25 passages in vitro without significant changes to 
the cell phenotype (Bianco et al., 2001; Conget and Minguell, 1999). Gronthos et al. (2003) 
further showed that BMMSCs could be isolated from bone marrow aspirates by determining 
which CFU-F colonies were highly reactive to the antibody STRO-1 (STRO-1Bright) and also 
reactive to the antibody VCAM-1 (VCAM-1+). These new studies isolated BMMSCs in bone 
marrow aspirates based on STRO-1Bright/ VCAM-1+ cell surface markers by florescence 
activated cell sorting (FACS) and were capable of proliferating up to 40 population 
doublings (Gronthos et al., 2003).   
BMMSCs show a great level of plasticity and have shown the potential to differentiate into 
multiple tissue types in vitro including muscle, adipose, cartilage, bone, connective tissue, 
neurons and endothelial cells (Gronthos et al., 2003; Pittenger et al., 1999; Woodbury et al., 
2000; Young and Black, 2004). Interestingly, when transplanted into immunodeficient mice, 
BMMSCs undergo osteogenic differentiation in vivo and form bone (Kuznetsov et al., 1997).  
In 2006, the minimum criteria to define human multipotent mesenchymal stromal cells was 
established as: Cells that are plastic adherent in standard culture; Cells that have the ability 
to differentiate in vitro into osteoblasts, adipocytes and chondroblasts;  Cells that express 
the cell surface markers CD73, CD90 and CD105 in 95% of the cell population as determined 
by flow cytometry and lack the expression ( ≤ 2% positive) of CD14, CD34, CD45 or CD11b, 
CD79a or CD19 and HLA class II (Dominici et al., 2006).  
2.4 Dental stem cells 
Dental stem cells are an alternative source of adult stem cells that are easily accessible by 
tooth extraction with a local anesthetic or when a primary tooth is replaced. This section 
discusses where dental stem cells arise during tooth formation and the types of tissue they 
form. We also characterize the many types of the dental stem cells utilized in research today 
and compare the utility of dental stem cells versus BMMSCs.  
There are six types of human dental stem cells that have been well described in the 
literature: 1. Dental pulp stem cells (DPSCs) (Gronthos et al., 2000); 2. Stem cells isolated 
from human exfoliated deciduous teeth (SHEDs) (Miura et al., 2003); 3. Stem cells derived 
from human natal dental pulp (hNDPs) (Karaöz et al., 2010); 4. Periodontal ligament stem 
cells (PDLSCs) (Seo et al., 2004); 5. Stem cells isolated from the apical papilla (SCAPs) 
(Sonoyama et al., 2008); 6. Stem cells isolated from dental follicle precursor cells (DFPCs) 
(Morsczeck et al., 2005). 
Within the body, MSCs have been localized to perivascular niches (Crisan et al., 2009; Kolf et 
al., 2007) and recent studies have also shown that dental stem cells are also localized to 
perivascular niches within the tooth structure (Chen et al., 2006; Shi and Gronthos, 2003). 
Dental stem cells arise from dental mesenchyme which has early interaction with the neural 
crest during normal tooth development (Huang et al., 2009b). Therefore, dental stem cells 
may display characteristics of both mesoderm and ectoderm due to their ectomesenchymal 
origins (Huang et al., 2009b). 
2.4.1 Mammalian tooth formation  
A mature tooth is comprised externally of hard structures of enamel, dentin and cementum 
and internally possesses a soft dental pulp (Figure 1). Tooth formation or odontogenesis is a 
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will discuss the most current findings in tissue engineering with respect to dental stem cells 
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2009; Fortier, 2005; Mummery et al., 2011; Smith, 2006). ESCs are considered the gold 
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suspension is cultured in vitro at low density. A small number of BMMSCs will adhere to 
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A mature tooth is comprised externally of hard structures of enamel, dentin and cementum 
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complex process involving multiple tooth-associated cell types. Odontogenesis occurs as a 
tooth bud is formed from an aggregation of embryonic cells. These cells have ectodermal 
and ectomesodermal origins from the first branchial arch and the neural crest respectively 
(Ten Cate, 1998; Tucker and Sharpe, 2004). Tooth development has three stages. 1. The bud 
stage, where epithelial cells begin to proliferate into ectomesenchyme and condense in the 
jaw forming the tooth bud. 2. The cap stage, where ectomesenchmyal cells aggregate and 
begin to surround and enclose the epithelial cells which invaginate further into the 
mesenchyme and form the dental follicle, the enamel organ or cap and the dental papilla 
(Slatter, 2002; Ten Cate, 1998; Tucker and Sharpe, 2004). The dental follicle is of 
ectomesodermal origins and forms a sac surrounding the developing tooth that supports the 
tooth prior to eruption. The enamel organ is of ectodermal origins and eventually forms the 
enamel, whereas the dental papilla is of mesodermal origins and eventually forms the 
primary dentin and the pulp. 3. The bell stage, where the tooth undergoes extensive 
differentiation with the epithelial cells differentiating into ameloblasts and mesenchymal 
cells differentiating into odontoblasts. After the bell stage, the hard structures are formed 
with ameloblasts forming enamel while odontoblasts form dentin (Figure 1). Secondary 
dentin aids in root formation. Later in tooth development further differentiation of the 
dental follicle occurs with the formation of cementoblasts, fibroblasts and osteoblasts to 
form the cementum, the periodontal ligament and bone respectively (Figure 1).  
2.4.2 Sources of dental stem cells 
2.4.2.1 Dental Pulp Tissue  
The soft dental pulp is located in the middle of the tooth surrounded by the harder 
structures of the tooth including dentin, cementum and enamel (Figure 1). The dental pulp 
contains a mix of cell types including fibroblasts which form the extracellular matrix and 
collagen and odontoblasts that form reparative dentin (Gronthos et al., 2002; Liu et al., 2006). 
The dental pulp region also contains nerve fibers and blood vessels and is accessible to 
external stimuli through the apical foramen (Figure1). Three types of stem cells have been 
identified from dental pulp tissue: DPSCs, SHEDs and hNDPs. DPSCs are present in the 
pulp of the adult tooth, whereas SHEDs are only present in the pulp of primary teeth or 
“baby teeth.”  Lastly, hNDPs are a unique type of dental pulp stem cells isolated only from 
the pulp of newborn teeth. Very few newborns are born with teeth, approximately one in 
every two to three thousand births (Leung and Robson, 2006), so hNDPs are very rare. 
2.4.2.1.1 Dental Pulp Stem Cells  
DPSCs are a heterogeneous population of cells that were first isolated by Gronthos et al. 
(2000) and exhibited some characteristics of BMMSCs, including the production of 
fibroblast-like cells that were clonogenic and had a high proliferation rate. Interestingly,  
DPSCs had a higher proliferation rate than BMMSCs (Gronthos et al., 2000) . DPSCs also 
had a similar protein expression pattern to BMMSCs in vitro including vascular adhesion 
molecule 1, alkaline phosphatase, collagen I, collagen III, osteonectin, osteopontin, 
osteocalcin, bone sialoprotein, α-smooth muscle actin, fibroblast growth factor 2 and the cell 
surface marker CD 146 (Gronthos et al., 2000). Immunohistochemistry staining further 
showed that like BMMSCs, primary cultures of DPSCs did not stain for the cell surface 
markers CD14, CD34, and CD45 or other markers including MyoD, neurofilament, collagen 
II , and peroxisome-proliferator activated receptor γ-2 (Gronthos et al., 2000). 
Multipotent Dental Stem Cells: 










Fig. 1. Mature tooth anatomy. Image copied with permission from Dr. Martin S. Spiller, 
D.M.D. from DoctorSpiller.com. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 454 
complex process involving multiple tooth-associated cell types. Odontogenesis occurs as a 
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cells differentiating into odontoblasts. After the bell stage, the hard structures are formed 
with ameloblasts forming enamel while odontoblasts form dentin (Figure 1). Secondary 
dentin aids in root formation. Later in tooth development further differentiation of the 
dental follicle occurs with the formation of cementoblasts, fibroblasts and osteoblasts to 
form the cementum, the periodontal ligament and bone respectively (Figure 1).  
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“baby teeth.”  Lastly, hNDPs are a unique type of dental pulp stem cells isolated only from 
the pulp of newborn teeth. Very few newborns are born with teeth, approximately one in 
every two to three thousand births (Leung and Robson, 2006), so hNDPs are very rare. 
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(2000) and exhibited some characteristics of BMMSCs, including the production of 
fibroblast-like cells that were clonogenic and had a high proliferation rate. Interestingly,  
DPSCs had a higher proliferation rate than BMMSCs (Gronthos et al., 2000) . DPSCs also 
had a similar protein expression pattern to BMMSCs in vitro including vascular adhesion 
molecule 1, alkaline phosphatase, collagen I, collagen III, osteonectin, osteopontin, 
osteocalcin, bone sialoprotein, α-smooth muscle actin, fibroblast growth factor 2 and the cell 
surface marker CD 146 (Gronthos et al., 2000). Immunohistochemistry staining further 
showed that like BMMSCs, primary cultures of DPSCs did not stain for the cell surface 
markers CD14, CD34, and CD45 or other markers including MyoD, neurofilament, collagen 
II , and peroxisome-proliferator activated receptor γ-2 (Gronthos et al., 2000). 
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Recently FACS has been used to sort DPSCs based on cell surface markers which found that 
in addition to the markers identified above, DPSCs expressed the following: CD9, CD10, 
CD13, CD29, CD44, CD49d, CD59, CD73, CD90, CD105, CD106, CD166 and STRO-
1(Lindroos et al., 2008; Nam and Lee, 2009). Further, DPSC did not express CD14, CD 31, CD 
45 (Nam and Lee, 2009) (Summarized in Table 1). 
When cultured under osteogenic conditions DPSCs were capable of forming calcified 
deposits sparsely throughout the culture;  these results were unlike BMMSCs which formed 
sheets of calcium deposits (Gronthos et al., 2000). In vivo transplantation of DPSCs into 
immunocompromised mice resulted in the production of a dentin-pulp-like complex with a 
collagen matrix containing blood vessels and lined with odontoblasts (Gronthos et al., 2000) 
suggesting that DPSCs are multipotent. Further studies also found DPSCs to be multipotent, 
capable of differentiating into myoblasts, osteoblasts, odontoblast-like cells, chondrocytes, 
adipocytes and neural cells (Gronthos et al., 2002; Liu et al., 2006; Pierdomenico et al., 2005; 
Zhang et al., 2006). 
 
Letter 
name BMMSCs DPSCs SHEDs hNDPs PDLSCs SCAPs DFPCs 
CD9 + +   +  + 
CD 10  +  - +  + 
CD 13 + + + + + + + 
CD 14 - - -  - -  
CD 18      -  
CD 19  -      
CD 24  -   - +  
CD 29  + +  + + + 
CD 34 - - - - - - - 
CD 44 + + + + + + + 
CD 45 - - - - - - - 
CD 53       + 
CD 59  +   +  + 
CD73 + + + + + + + 
CD 90 + + + + + + + 
CD 105 + + +  + + + 
CD 106 + + +  + + + 
CD 146 + + + + + + + 
CD 150      -  
CD 166  + + + +  + 
STRO-1 + + +  + + + 
 
Table 1. Cell surface markers expressed in dental stem cells compared to bone marrow 
mesenchymal stem cells as determined by flow cytometry. Table adapted from Karaöz et al. 
2011, Rodriguez-Lozano et al. 2011, Huang, G.T. et al. 2009, Nam and Lee 2009, Lindroos et 
al. 2008 and Shi et al. 2005. BMMSCs, bone marrow mesenchymal stem cells; DPSCs, dental 
pulp stem cells; SHEDs, stem cells from human exfoliated deciduous teeth; SCAPs, stem 
cells from apical papilla; DFPCs, dental follicle precursor cells; hNDPs, stem cells derived 
from human natal dental pulp; + = marker present; - = marker absent. 
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2.4.2.1.2 Stem Cells from Human Exfoliated Deciduous Teeth  
SHEDs are found in the pulp of the naturally exfoliated deciduous teeth or “baby teeth.”  
When the permanent tooth erupts from the gums the deciduous tooth in displaced. SHED 
cells were first isolated by Miura et al. (2003) from the remnant pulp in the crown of human 
deciduous incisors of children 7-8 years old.  
Similar to DPSCs, SHEDs met the criteria to be defined as a stem cell population as they 
were highly proliferative, capable of self-renewal and had the ability to differentiate into 
multiple cell types (Miura et al., 2003).  SHEDs also had a fibroblast-like morphology similar 
to DPSCs. However, SHEDs were capable of a greater number of population doublings and 
had a higher proliferation rate than both BMMSCs and DPSCs (Miura et al., 2003). SHEDs 
have also been isolated and identified as immature dental pulp stem cells (IDPSCs) (Kerkis 
et al., 2006) and found to express embryonic stem cell markers Oct-4 (POU transcription 
factor), Nanog, stage specific embryonic antigens (SSEA-3, SSEA-4), and tumorigenic 
recognition antigens (TRA-1-60, TRA-1-81). SHEDs have also been shown to express neural 
stem cell markers SRY (sex determining region  Y)-box 2 (Sox-2), nestin, and ATP-binding 
cassette, subfamily G, member 2 (ABCg2)(Morsczeck et al., 2010).  
SHEDs were further characterized using FACS as having the following cell surface markers: 
CD13, CD29, CD31, CD44, CD73, CD90, CD105, CD146, CD166, and STRO-1 and similar to 
BMMSCs and DPSCs, SHEDs did not express CD14, CD34 or CD45 (Kerkis et al., 2006; 
Morsczeck et al., 2010; Pivoriuunas et al., 2010; Shi et al., 2005; Wang et al., 2010) 
(Summarized in Table 1). 
A distinguishing feature of SHEDs not demonstrated for DPSCs is SHEDs formed sphere-
like clusters when cultured in neuronal differentiation media (Miura et al., 2003). While 
Miura et al. (2003) demonstrated that SHEDs could differentiate into neural cells, adipocytes 
and odontoblasts, Kerkis et al. (2006) showed that SHEDs also had chondrogenic and 
myogenic potential. SHEDs were shown to express chondrogenic markers Sox-9, type II 
collagen and type X collagen when cultured for 14 days with bone morphogenic protein 2 
(BMP2), a chondrogenic signaling protein in the TGFβ family (Koyama et al., 2009). 
Interestingly, Koyama et al. (2009) did not find any expression of the chondrogenic markers 
in their untreated populations of SHED cultures.  
When SHED were transplanted into immunocompromised mice they exhibited an 
osteoinductive capacity in vivo but were not able to regenerate the dentin-pulp-like complex 
that DPSCs cells were able to form (Miura et al., 2003). Kerkis et al. (2006) also showed that 
when SHEDs were transplanted into immunocompromised mice via intraperitoneal 
injection they engrafted into the lungs, liver, spleen, brain and kidney and the tissue formed 
by the SHEDs was indistinguishable from the host tissue for liver, spleen, brain and kidney 
(Kerkis et al., 2006).  
2.4.2.1.3 Stem Cells Derived from Human Natal Dental Pulp 
Natal teeth are deciduous teeth that arise in newborns that are smaller than primary teeth 
and have little or no root development (Leung and Robson, 2006). Karaöz et al. (2010) 
isolated and characterized hNDPs from the remnant pulp of natal teeth. A small number of 
hNDPs adhered to plastic in culture and displayed a fibroblast-like spindle shaped 
morphology that eventually became flattened in later passages (Karaöz et al., 2010). Similar 
to DPSCs, hNDPs had a higher proliferation rate the BMMSCs, were clonogenic, and had 
the ability to differentiate into multiple cell types, satisfying the criteria to be classified as a 
stem cell population.  
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in addition to the markers identified above, DPSCs expressed the following: CD9, CD10, 
CD13, CD29, CD44, CD49d, CD59, CD73, CD90, CD105, CD106, CD166 and STRO-
1(Lindroos et al., 2008; Nam and Lee, 2009). Further, DPSC did not express CD14, CD 31, CD 
45 (Nam and Lee, 2009) (Summarized in Table 1). 
When cultured under osteogenic conditions DPSCs were capable of forming calcified 
deposits sparsely throughout the culture;  these results were unlike BMMSCs which formed 
sheets of calcium deposits (Gronthos et al., 2000). In vivo transplantation of DPSCs into 
immunocompromised mice resulted in the production of a dentin-pulp-like complex with a 
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2011, Rodriguez-Lozano et al. 2011, Huang, G.T. et al. 2009, Nam and Lee 2009, Lindroos et 
al. 2008 and Shi et al. 2005. BMMSCs, bone marrow mesenchymal stem cells; DPSCs, dental 
pulp stem cells; SHEDs, stem cells from human exfoliated deciduous teeth; SCAPs, stem 
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2.4.2.1.2 Stem Cells from Human Exfoliated Deciduous Teeth  
SHEDs are found in the pulp of the naturally exfoliated deciduous teeth or “baby teeth.”  
When the permanent tooth erupts from the gums the deciduous tooth in displaced. SHED 
cells were first isolated by Miura et al. (2003) from the remnant pulp in the crown of human 
deciduous incisors of children 7-8 years old.  
Similar to DPSCs, SHEDs met the criteria to be defined as a stem cell population as they 
were highly proliferative, capable of self-renewal and had the ability to differentiate into 
multiple cell types (Miura et al., 2003).  SHEDs also had a fibroblast-like morphology similar 
to DPSCs. However, SHEDs were capable of a greater number of population doublings and 
had a higher proliferation rate than both BMMSCs and DPSCs (Miura et al., 2003). SHEDs 
have also been isolated and identified as immature dental pulp stem cells (IDPSCs) (Kerkis 
et al., 2006) and found to express embryonic stem cell markers Oct-4 (POU transcription 
factor), Nanog, stage specific embryonic antigens (SSEA-3, SSEA-4), and tumorigenic 
recognition antigens (TRA-1-60, TRA-1-81). SHEDs have also been shown to express neural 
stem cell markers SRY (sex determining region  Y)-box 2 (Sox-2), nestin, and ATP-binding 
cassette, subfamily G, member 2 (ABCg2)(Morsczeck et al., 2010).  
SHEDs were further characterized using FACS as having the following cell surface markers: 
CD13, CD29, CD31, CD44, CD73, CD90, CD105, CD146, CD166, and STRO-1 and similar to 
BMMSCs and DPSCs, SHEDs did not express CD14, CD34 or CD45 (Kerkis et al., 2006; 
Morsczeck et al., 2010; Pivoriuunas et al., 2010; Shi et al., 2005; Wang et al., 2010) 
(Summarized in Table 1). 
A distinguishing feature of SHEDs not demonstrated for DPSCs is SHEDs formed sphere-
like clusters when cultured in neuronal differentiation media (Miura et al., 2003). While 
Miura et al. (2003) demonstrated that SHEDs could differentiate into neural cells, adipocytes 
and odontoblasts, Kerkis et al. (2006) showed that SHEDs also had chondrogenic and 
myogenic potential. SHEDs were shown to express chondrogenic markers Sox-9, type II 
collagen and type X collagen when cultured for 14 days with bone morphogenic protein 2 
(BMP2), a chondrogenic signaling protein in the TGFβ family (Koyama et al., 2009). 
Interestingly, Koyama et al. (2009) did not find any expression of the chondrogenic markers 
in their untreated populations of SHED cultures.  
When SHED were transplanted into immunocompromised mice they exhibited an 
osteoinductive capacity in vivo but were not able to regenerate the dentin-pulp-like complex 
that DPSCs cells were able to form (Miura et al., 2003). Kerkis et al. (2006) also showed that 
when SHEDs were transplanted into immunocompromised mice via intraperitoneal 
injection they engrafted into the lungs, liver, spleen, brain and kidney and the tissue formed 
by the SHEDs was indistinguishable from the host tissue for liver, spleen, brain and kidney 
(Kerkis et al., 2006).  
2.4.2.1.3 Stem Cells Derived from Human Natal Dental Pulp 
Natal teeth are deciduous teeth that arise in newborns that are smaller than primary teeth 
and have little or no root development (Leung and Robson, 2006). Karaöz et al. (2010) 
isolated and characterized hNDPs from the remnant pulp of natal teeth. A small number of 
hNDPs adhered to plastic in culture and displayed a fibroblast-like spindle shaped 
morphology that eventually became flattened in later passages (Karaöz et al., 2010). Similar 
to DPSCs, hNDPs had a higher proliferation rate the BMMSCs, were clonogenic, and had 
the ability to differentiate into multiple cell types, satisfying the criteria to be classified as a 
stem cell population.  
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Using flow-cytometry Karaöz et al. (2010) showed that like BMMSCs, hNDPs expressed 
CD13, CD44, CD73, CD90, CD146, and CD166 but did not express CD14, CD31 or CD45 
(Summarized in Table 1). Stem cells derived from human natal dental pulp expressed many 
of the same cell surface markers seen in DPSCs and SHEDs (Table 1).   
Cultures of NDPs with chondrogenic, osteogenic, adipogenic, myogenic and neurogenic 
media expressed the appropriate differentiation markers associated with their culture 
media. Further, the multipotent nature of hNDPs was demonstrated by their differentiation  
in vitro into chondroblasts, osteoblasts, adipocytes, myoblasts and neuro-glial-like cells 
respectively (Karaöz et al., 2010). Interestingly, hNDPs expressed detectable levels of the 
embryonic stem cell markers Rex-1, Oct4 and Nanog as well as the transcription factors Sox-
2 and FoxD3 suggesting that these cells display some of the characteristics for pluripotency 
(Karaöz et al., 2010).  
2.4.2.2 Periodontal Ligament Stem Cells 
The periodontal ligament is the part of the tooth derived from the neural crest and made of 
soft connective tissue that resides between the cementum and the alveolar bone of the jaw 
(Figure 1). It is responsible for anchoring and supporting the tooth within the tooth socket. 
The periodontal ligament is composed of a heterogeneous population of cells containing 
fibroblasts, osteoblasts and cementoblasts (Bartold et al., 2000; Gay et al., 2007; Lekic et al., 
2001; Seo et al., 2004; Shimono et al., 2003). Early studies have suggested that the PDL tissue 
had regenerative or repair abilities when an injury was incurred by the periodontal tissue 
(Reviewed in Bartold et al. (2005) and Shimono et al. (2003)). 
Periodontal ligament stem cells were first isolated by Seo et al. (2004) from impacted third 
molar adult teeth. Immunohistochemical staining of PDLSCs stained positive for early 
mesenchymal stem cell markers STRO-1 and CD146 suggesting that these cells has similar 
stem cell characteristics to BMMSCs (Seo et al., 2004). PDLSCs demonstrated other 
characteristics of BMMSCs and DPSCs including fibroblastic-like cell morphology that 
adhered to plastic and formed clonogenic cell clusters with the ability to differentiate into 
multiple cell types (Seo et al., 2004). PDLSCs had a higher proliferation rate than BMMSCs, 
but similar rate to DPSCs after 24 hours in culture (Seo et al., 2004). 
Multipotent human PDLSCs cells have been characterized using FACS sorting and were 
shown to express the following cell surface markers: CD9, CD10, CD13, CD29, CD44, CD59, 
CD73, CD90, CD105, CD106, CD146, CD166 and STRO-1 (Feng et al., 2010; Lindroos et al., 
2008; Shi et al., 2005; Wada et al., 2009). Like BMMSCs, DPSCs and SHEDs, PDLSCs do not 
express CD14, CD31 or CD45 (Shi et al., 2005)(Summarized in Table 1). PDLSCs have also 
been shown to express the embryonic stem cell markers Oct4, Sox-2, Nanog and Klf-4 and 
neural crest markers Nestin, Slug, p75 and Sox-10 (Huang et al., 2009a). 
Like BMMSCs and DPSCs, PDLSC’s formed calcium deposits when cultured in osteogenic 
media, however, unlike BMMSCs and DPSCs these deposits were sparsely distributed 
though out the culture (Gay et al., 2007; Seo et al., 2004). Increased protein expression of 
osteoblastic/cementoblastic markers alkaline phosphatase, bone sialoprotein, matrix 
extracellular protein, osteocalcin and TGFβ receptor 1 was observed after osteogenic 
induction (Seo et al., 2004). PDLSCs were also capable of differentiation into adipocytes as 
demonstrated by the formation of oil red O positive droplets and the upregulation of 
adipocyte specific transcripts after 21-25 days of culture in adipogenic inducing media (Gay 
et al., 2007; Seo et al., 2004). Gay et al. (2007) showed that PDLSCs could undergo 
chondrogenic differentiation in vitro after 21 days culture.  
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When transplanted into immunocompromised mice PDLSCs formed a cementum/PDL-like 
structure with attached collagen fibers (Seo et al., 2004). However, despite the expression of 
osteogenic / cementoblastic markers in vitro (Gay et al., 2007; Seo et al., 2004), PDLSCs were 
unable to form dentin or bone in vivo (Seo et al., 2004). By implanting PDLSCs into 
immunocompromised rats with periodontal defects, Seo et al. (2004) were able to show that 
PDLSCs were capable of periodontal tissue repair. 
2.4.2.3 Stem Cells from the Apical Papilla  
SCAPs were first isolated by Sonoyama et al. (2006) from impacted wisdom teeth of adults 
aged 18-20. The apical papilla is a part of the soft tissue found at the apices of the immature 
permanent tooth that eventually becomes the pulp tissue in the mature tooth (Huang et al., 
2009b; Sonoyama et al., 2006; Sonoyama et al., 2008). Histological characterization of the 
apical papilla by Sonoyama et al. (2008) showed that the apical papilla is separate from the 
pulp canal and apical cell rich zone of the immature tooth. 
SCAPs expressed the early mesenchymal stem cell markers STRO-1 and CD146 suggesting 
that these cells were a stem cell population. Further characterization of this cell population 
showed that SCAPs formed adherent fibroblastic cell cultures that were clonogenic and 
capable of over 70 population doublings with the ability to transform into odontoblastic/ 
osteoblastic, adipogenic, chondrogenic and neural cell types (Abe et al., 2007; Sonoyama et 
al., 2006; Sonoyama et al., 2008). Sonoyama et al. (2006) also showed that SCAPs had a 
greater proliferation rate and population doubling than DPSCs isolated from the same tooth. 
SCAPs were also distinct from DPSCs with respect to expression levels of survivin, 
telomerase and the cell surface marker CD24, all which are thought to be associated with 
cell proliferation (Sonoyama et al., 2006).  
Analysis of cell surface markers by flow cytometry showed that SCAPs expressed CD13, 
CD24, CD29, CD73, CD90, CD105, CD106, CD146, CD166 and STRO-1 but did not express 
CD14, CD18, CD34, CD45, or CD150 (Abe et al., 2007; Sonoyama et al., 2006) (Summarized 
in Table1). 
In vitro culture of SCAPs, DPSCs and BMMSCs showed that SCAPs and DPSCs had similar 
osteo/dentinogenic potential to BMMSCs, but had a weaker response to adipogenic 
differentiation than BMMSCs (Sonoyama et al., 2008). After neural induction, 
immunostaining showed that SCAPs expressed the following neuronal markers: βIII 
tubulin, glial fibrillary acid protein, glutamic acid decarboxylase, nestin, neuronal nuclear 
antigen, neuronal filament M, neuron-specific enolase and 2′, 3′-cyclic nucleotide 3′-
phosphodiesterase (Abe et al., 2007; Sonoyama et al., 2008). When transplanted into 
immunocompromised mice SCAPs underwent in vivo differentiation into odontoblasts 
which regenerated the dentin-pulp-like structure and connective tissue (Sonoyama et al., 
2006). 
2.4.2.4 Dental Follicle Progenitor Cells  
As described above, the dental follicle is the ectomesodermal tissue surrounding the 
developing tooth that leads to the formation of cementoblasts, periodontal ligament and 
osteoblasts. Morsczeck et al. (2005) isolated human DFPCs from the dental follicle area of 
impacted wisdom teeth and noted that a small number had stem cell characteristics. DFPCs 
formed clonogenic, fibroblastic-like colonies in culture that adhered to plastic (Morsczeck et 
al., 2005). Like SHEDs, DFPCs expressed neural stem cell associated markers Sox-2, nestin, 
and ABCg2 (Morsczeck et al., 2010).  
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Like BMMSCs and DPSCs, PDLSC’s formed calcium deposits when cultured in osteogenic 
media, however, unlike BMMSCs and DPSCs these deposits were sparsely distributed 
though out the culture (Gay et al., 2007; Seo et al., 2004). Increased protein expression of 
osteoblastic/cementoblastic markers alkaline phosphatase, bone sialoprotein, matrix 
extracellular protein, osteocalcin and TGFβ receptor 1 was observed after osteogenic 
induction (Seo et al., 2004). PDLSCs were also capable of differentiation into adipocytes as 
demonstrated by the formation of oil red O positive droplets and the upregulation of 
adipocyte specific transcripts after 21-25 days of culture in adipogenic inducing media (Gay 
et al., 2007; Seo et al., 2004). Gay et al. (2007) showed that PDLSCs could undergo 
chondrogenic differentiation in vitro after 21 days culture.  
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When transplanted into immunocompromised mice PDLSCs formed a cementum/PDL-like 
structure with attached collagen fibers (Seo et al., 2004). However, despite the expression of 
osteogenic / cementoblastic markers in vitro (Gay et al., 2007; Seo et al., 2004), PDLSCs were 
unable to form dentin or bone in vivo (Seo et al., 2004). By implanting PDLSCs into 
immunocompromised rats with periodontal defects, Seo et al. (2004) were able to show that 
PDLSCs were capable of periodontal tissue repair. 
2.4.2.3 Stem Cells from the Apical Papilla  
SCAPs were first isolated by Sonoyama et al. (2006) from impacted wisdom teeth of adults 
aged 18-20. The apical papilla is a part of the soft tissue found at the apices of the immature 
permanent tooth that eventually becomes the pulp tissue in the mature tooth (Huang et al., 
2009b; Sonoyama et al., 2006; Sonoyama et al., 2008). Histological characterization of the 
apical papilla by Sonoyama et al. (2008) showed that the apical papilla is separate from the 
pulp canal and apical cell rich zone of the immature tooth. 
SCAPs expressed the early mesenchymal stem cell markers STRO-1 and CD146 suggesting 
that these cells were a stem cell population. Further characterization of this cell population 
showed that SCAPs formed adherent fibroblastic cell cultures that were clonogenic and 
capable of over 70 population doublings with the ability to transform into odontoblastic/ 
osteoblastic, adipogenic, chondrogenic and neural cell types (Abe et al., 2007; Sonoyama et 
al., 2006; Sonoyama et al., 2008). Sonoyama et al. (2006) also showed that SCAPs had a 
greater proliferation rate and population doubling than DPSCs isolated from the same tooth. 
SCAPs were also distinct from DPSCs with respect to expression levels of survivin, 
telomerase and the cell surface marker CD24, all which are thought to be associated with 
cell proliferation (Sonoyama et al., 2006).  
Analysis of cell surface markers by flow cytometry showed that SCAPs expressed CD13, 
CD24, CD29, CD73, CD90, CD105, CD106, CD146, CD166 and STRO-1 but did not express 
CD14, CD18, CD34, CD45, or CD150 (Abe et al., 2007; Sonoyama et al., 2006) (Summarized 
in Table1). 
In vitro culture of SCAPs, DPSCs and BMMSCs showed that SCAPs and DPSCs had similar 
osteo/dentinogenic potential to BMMSCs, but had a weaker response to adipogenic 
differentiation than BMMSCs (Sonoyama et al., 2008). After neural induction, 
immunostaining showed that SCAPs expressed the following neuronal markers: βIII 
tubulin, glial fibrillary acid protein, glutamic acid decarboxylase, nestin, neuronal nuclear 
antigen, neuronal filament M, neuron-specific enolase and 2′, 3′-cyclic nucleotide 3′-
phosphodiesterase (Abe et al., 2007; Sonoyama et al., 2008). When transplanted into 
immunocompromised mice SCAPs underwent in vivo differentiation into odontoblasts 
which regenerated the dentin-pulp-like structure and connective tissue (Sonoyama et al., 
2006). 
2.4.2.4 Dental Follicle Progenitor Cells  
As described above, the dental follicle is the ectomesodermal tissue surrounding the 
developing tooth that leads to the formation of cementoblasts, periodontal ligament and 
osteoblasts. Morsczeck et al. (2005) isolated human DFPCs from the dental follicle area of 
impacted wisdom teeth and noted that a small number had stem cell characteristics. DFPCs 
formed clonogenic, fibroblastic-like colonies in culture that adhered to plastic (Morsczeck et 
al., 2005). Like SHEDs, DFPCs expressed neural stem cell associated markers Sox-2, nestin, 
and ABCg2 (Morsczeck et al., 2010).  
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Interestingly, multipotent DFPCs have been reported in mice and rats that are capable of 
undergoing osteogenic, adipogenic, chondrogenic and neurogenic differentiation (Luan et 
al., 2006; Yao et al., 2008). However, only osteogenic differentiation has been demonstrated 
consistently for human DFPCs in vitro (Honda et al.; Kémoun et al., 2007; Lindroos et al., 
2008; Morsczeck et al., 2005). For human DFPCs neural induction has also been 
demonstrated by Morsczeck et al. (2010) but conflicting results for adipogenic and 
chondrogenic differentiation have been observed (Honda et al.; Kémoun et al., 2007; 
Lindroos et al., 2008). 
Immunohistochemistry and FACS sorting have shown that DFPCs express the following cell 
surface markers: CD9, CD10, CD13, CD29, CD44, CD53, CD59, CD73, CD90, CD105, CD106, 
CD146, CD166 and STRO-1 but do not express CD34 or CD45 (Lindroos et al., 2008; 
Morsczeck et al., 2010; Yagyuu et al., 2010). 
When Morsczeck et al. (2005) transplanted human DFPCs into severe combined 
immunodeficiency (SCID) mice they saw an increase in bone sialoprotein, osteocalcin and 
collagen I expression in vivo but did not see any evidence of cementum or bone 
formation. However, transplantation of mouse DFPCs into SCID mice demonstrated that 
DFPCs were capable of regenerating the PDL in vivo (Yokoi et al., 2007). Recently, when 
cryopreserved DFPCs were transplanted into immunocompromised rats, a mineralized 
tissue structure was formed in vivo containing cementocyte/osteocyte cells, but the exact 
identity of the tissue type could not be determined as dentin, cementum or bone (Yagyuu 
et al., 2010). 
3. Tissue engineering 
3.1 Dental stem cells in tissue engineering and regenerative medicine  
When tissues become damaged or non-functional tissue engineering is used to replace, 
repair or restore damaged tissue in the body (Levenberg and Langer, 2004). Tissue 
engineering and regenerative medicine requires an abundant cell source capable of 
differentiation into the required tissue.  Therefore, stem cells with their ability to self-renew, 
proliferate and differentiate make an ideal cell source for this type of tissue repair and 
replacement (Barrilleaux et al., 2006).  
Whole tooth regeneration is the goal of many researchers and much of tissue engineering 
involving dental stem cells is used to reconstruct or repair damaged and diseased dental 
tissue (Dannan, 2009; Huang et al., 2009b; Shi et al., 2005; Sonoyama et al., 2006; Yen and 
Sharpe, 2008; Yokoi et al., 2007).  When a patient’s dental pulp cavity becomes infected or 
diseased, often the entire pulp is removed and replaced with a filling. Due to the ability of 
DPSCs to form the dentine-pulp-like complex in vivo, it has been suggested that this may 
soon be an option for regenerative therapy of teeth (Caton et al., 2010). SHEDs also have 
shown potential for regenerating the dental-pulp-like tissue in vivo when transplanted into 
immunocompromised mice (Cordeiro et al., 2008) and therefore may be useful for future 
regenerative endodontic procedures. Further, Seo et al. (2004) showed that PDLs 
participated in periodontal tissue repair and formed a PDL/cementum-like complex when 
transplanted into immunocompromised mice suggesting that we will soon be able to 
regenerate tissues surrounding the teeth. Unfortunately one of the challenges remaining for 
whole tooth regeneration is that we are currently unable to regenerate human enamel 
(Mitsiadis and Papagerakis, 2011).  
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Two significant advancements in the area of whole tooth engineering are the ability to 
generate dental tissue structures in vitro and the ability to deliver these dental stem cells in 
vivo (Cordeiro et al., 2008; Yen and Sharpe, 2008). An important development in tissue 
engineering is the use of hydroxyapatite/ tricalcium phosphate (HA/TCP) particles and 
other carrier particles that allow dental stem cells cultured  in vitro and delivered in vivo 
(Caton et al., 2010; Sharma et al., 2010). Also important to for dental tissue engineering is 
developing appropriate biodegradable scaffolds that can be seeded with stem cells for use in 
transplants and that provide the correct 3D space for differentiation (Caton et al., 2010; 
Dannan, 2009; Huang, 2009; Sharma et al., 2010; Yen and Sharpe, 2008). Scaffolds are made 
from both synthetic polymers like polylactic acid (PLA), polyglycolic acid (PGA), 
polylacticco-glycolic acid (PLGA), and polycaprolactone (PCL)) or natural polymers like 
collagen, fibrin, polysaccharides and alginates (Sharma et al., 2010).  PGA fibers have been 
shown to be useful for engineering dental pulp-like tissue (Bohl et al., 1998).  
Dental stem cells are also used to repair or supplement other types of tissues including 
bone, heart and neuronal tissue (d'Aquino et al., 2009; Gandia et al., 2008; Huang et al., 
2009b; Wang et al., 2010). The potential of stem cells to regenerate bone tissue was 
demonstrated in a study by d’Aquino et al. (2007). These researchers showed that in vivo 
transplantation of human DPSCs in woven bone chips or polymer scaffolds into 
immunocompromised rats resulted in adult bone formation complete with de novo 
synthesis of blood vessels (d'Aquino et al., 2007). Potential treatment with DPSCs has also 
been tested using cardiac tissue in rats that have been subjected to a myocardial infarction. 
After transplanting DPSCs into the site of infarction via injection, there was a decrease in the 
size of the infarct and increased vessel formation near the infarct (Gandia et al., 2008). 
Interestingly, SHED cells have been used by researchers to produce dopaminergic neuron 
cells (Wang et al., 2010) to alleviate the effects of Parkinson’s disease in rats.  Wang et al. 
(2010) used a two-step induction protocol to stimulate SHED cells to form neurospheres 
which were then treated with a neurogenic cocktail to stimulate their differentiation into 
dopaminergic neurons. The formation of neurons by SHED cells suggests that dental cells 
may become an invaluable resource for neurodegenerative disease therapies. Another 
suggested application of stem cell therapy for SHEDs is for the treatment of wound healing 
(Nishino et al., 2011). Using a mouse model, SHEDs were transplanted into an excisional 
wound and were found to accelerate healing after 5 days when compared to control 
(Nishino et al., 2011). The potential use of dental stem cells has become even more viable for 
tissue regeneration and other therapies with the recent advances in cryopreservation. These 
advances allow proliferation and long term storage of these cells for future cell therapy 
treatments while maintaining their differentiation potential (Ding et al., 2010; Papaccio et al., 
2006; Seo et al., 2005; Woods et al., 2009; Zhang et al., 2006).   
3.2 Dental stem cells and dynamic compression  
Our lab is exploring the area of cellular based tissue engineering and in particular the effects 
of dynamic cyclic compression on chondrogenesis in two types of human dental stem cells, 
PDLSCs and SHEDs.  
Earlier work in our lab on biomechanical force has shown that short intervals of cyclic 
compression cause rabbit BMMSCs to up-regulate TGFβ (Huang et al., 2005). TGFβ3 has 
been shown to induce chondrogenic differentiation of BMMSCs in vitro (Barry et al., 2001) 
and the extracellular signal-related kinase (ERK) 1/2 signal transduction pathway of 
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Interestingly, multipotent DFPCs have been reported in mice and rats that are capable of 
undergoing osteogenic, adipogenic, chondrogenic and neurogenic differentiation (Luan et 
al., 2006; Yao et al., 2008). However, only osteogenic differentiation has been demonstrated 
consistently for human DFPCs in vitro (Honda et al.; Kémoun et al., 2007; Lindroos et al., 
2008; Morsczeck et al., 2005). For human DFPCs neural induction has also been 
demonstrated by Morsczeck et al. (2010) but conflicting results for adipogenic and 
chondrogenic differentiation have been observed (Honda et al.; Kémoun et al., 2007; 
Lindroos et al., 2008). 
Immunohistochemistry and FACS sorting have shown that DFPCs express the following cell 
surface markers: CD9, CD10, CD13, CD29, CD44, CD53, CD59, CD73, CD90, CD105, CD106, 
CD146, CD166 and STRO-1 but do not express CD34 or CD45 (Lindroos et al., 2008; 
Morsczeck et al., 2010; Yagyuu et al., 2010). 
When Morsczeck et al. (2005) transplanted human DFPCs into severe combined 
immunodeficiency (SCID) mice they saw an increase in bone sialoprotein, osteocalcin and 
collagen I expression in vivo but did not see any evidence of cementum or bone 
formation. However, transplantation of mouse DFPCs into SCID mice demonstrated that 
DFPCs were capable of regenerating the PDL in vivo (Yokoi et al., 2007). Recently, when 
cryopreserved DFPCs were transplanted into immunocompromised rats, a mineralized 
tissue structure was formed in vivo containing cementocyte/osteocyte cells, but the exact 
identity of the tissue type could not be determined as dentin, cementum or bone (Yagyuu 
et al., 2010). 
3. Tissue engineering 
3.1 Dental stem cells in tissue engineering and regenerative medicine  
When tissues become damaged or non-functional tissue engineering is used to replace, 
repair or restore damaged tissue in the body (Levenberg and Langer, 2004). Tissue 
engineering and regenerative medicine requires an abundant cell source capable of 
differentiation into the required tissue.  Therefore, stem cells with their ability to self-renew, 
proliferate and differentiate make an ideal cell source for this type of tissue repair and 
replacement (Barrilleaux et al., 2006).  
Whole tooth regeneration is the goal of many researchers and much of tissue engineering 
involving dental stem cells is used to reconstruct or repair damaged and diseased dental 
tissue (Dannan, 2009; Huang et al., 2009b; Shi et al., 2005; Sonoyama et al., 2006; Yen and 
Sharpe, 2008; Yokoi et al., 2007).  When a patient’s dental pulp cavity becomes infected or 
diseased, often the entire pulp is removed and replaced with a filling. Due to the ability of 
DPSCs to form the dentine-pulp-like complex in vivo, it has been suggested that this may 
soon be an option for regenerative therapy of teeth (Caton et al., 2010). SHEDs also have 
shown potential for regenerating the dental-pulp-like tissue in vivo when transplanted into 
immunocompromised mice (Cordeiro et al., 2008) and therefore may be useful for future 
regenerative endodontic procedures. Further, Seo et al. (2004) showed that PDLs 
participated in periodontal tissue repair and formed a PDL/cementum-like complex when 
transplanted into immunocompromised mice suggesting that we will soon be able to 
regenerate tissues surrounding the teeth. Unfortunately one of the challenges remaining for 
whole tooth regeneration is that we are currently unable to regenerate human enamel 
(Mitsiadis and Papagerakis, 2011).  
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Two significant advancements in the area of whole tooth engineering are the ability to 
generate dental tissue structures in vitro and the ability to deliver these dental stem cells in 
vivo (Cordeiro et al., 2008; Yen and Sharpe, 2008). An important development in tissue 
engineering is the use of hydroxyapatite/ tricalcium phosphate (HA/TCP) particles and 
other carrier particles that allow dental stem cells cultured  in vitro and delivered in vivo 
(Caton et al., 2010; Sharma et al., 2010). Also important to for dental tissue engineering is 
developing appropriate biodegradable scaffolds that can be seeded with stem cells for use in 
transplants and that provide the correct 3D space for differentiation (Caton et al., 2010; 
Dannan, 2009; Huang, 2009; Sharma et al., 2010; Yen and Sharpe, 2008). Scaffolds are made 
from both synthetic polymers like polylactic acid (PLA), polyglycolic acid (PGA), 
polylacticco-glycolic acid (PLGA), and polycaprolactone (PCL)) or natural polymers like 
collagen, fibrin, polysaccharides and alginates (Sharma et al., 2010).  PGA fibers have been 
shown to be useful for engineering dental pulp-like tissue (Bohl et al., 1998).  
Dental stem cells are also used to repair or supplement other types of tissues including 
bone, heart and neuronal tissue (d'Aquino et al., 2009; Gandia et al., 2008; Huang et al., 
2009b; Wang et al., 2010). The potential of stem cells to regenerate bone tissue was 
demonstrated in a study by d’Aquino et al. (2007). These researchers showed that in vivo 
transplantation of human DPSCs in woven bone chips or polymer scaffolds into 
immunocompromised rats resulted in adult bone formation complete with de novo 
synthesis of blood vessels (d'Aquino et al., 2007). Potential treatment with DPSCs has also 
been tested using cardiac tissue in rats that have been subjected to a myocardial infarction. 
After transplanting DPSCs into the site of infarction via injection, there was a decrease in the 
size of the infarct and increased vessel formation near the infarct (Gandia et al., 2008). 
Interestingly, SHED cells have been used by researchers to produce dopaminergic neuron 
cells (Wang et al., 2010) to alleviate the effects of Parkinson’s disease in rats.  Wang et al. 
(2010) used a two-step induction protocol to stimulate SHED cells to form neurospheres 
which were then treated with a neurogenic cocktail to stimulate their differentiation into 
dopaminergic neurons. The formation of neurons by SHED cells suggests that dental cells 
may become an invaluable resource for neurodegenerative disease therapies. Another 
suggested application of stem cell therapy for SHEDs is for the treatment of wound healing 
(Nishino et al., 2011). Using a mouse model, SHEDs were transplanted into an excisional 
wound and were found to accelerate healing after 5 days when compared to control 
(Nishino et al., 2011). The potential use of dental stem cells has become even more viable for 
tissue regeneration and other therapies with the recent advances in cryopreservation. These 
advances allow proliferation and long term storage of these cells for future cell therapy 
treatments while maintaining their differentiation potential (Ding et al., 2010; Papaccio et al., 
2006; Seo et al., 2005; Woods et al., 2009; Zhang et al., 2006).   
3.2 Dental stem cells and dynamic compression  
Our lab is exploring the area of cellular based tissue engineering and in particular the effects 
of dynamic cyclic compression on chondrogenesis in two types of human dental stem cells, 
PDLSCs and SHEDs.  
Earlier work in our lab on biomechanical force has shown that short intervals of cyclic 
compression cause rabbit BMMSCs to up-regulate TGFβ (Huang et al., 2005). TGFβ3 has 
been shown to induce chondrogenic differentiation of BMMSCs in vitro (Barry et al., 2001) 
and the extracellular signal-related kinase (ERK) 1/2 signal transduction pathway of 
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mitogen activated protein kinases (MAPKs) has been implicated in this process (Lee et al., 
2004). The application of dynamic mechanical compression has been shown to induce 
chondrogenic differentiation of stem cells via an autocrine signaling pathway (Huang et al., 
2005). Interestingly, just two hours of cyclic compression applied to BMMSCs stimulated 
TGFβ gene expression and the expression of both of its receptors (Huang et al., 2005). This 
stimulation in turn resulted in an up-regulation of the early response genes c-Fos and c-Jun 
as well as chondrogenic specific genes Sox-9, aggrecan and collagen type II (Huang et al., 
2005). 
Our lab has developed a line of adult dental stem cells derived from the PDL that are 
multipotent and express some ESC markers (Huang et al., 2009a). Using in vitro cultures in 
chondrogenic media we were able to show that after two weeks in culture with TGFβ3, 
PDLSCs increased expression of the chondrogenic markers collagen II and aggrecan (Huang 
et al., 2009a). Further, we see that PDLSCs express chondrogenic markers when subject to 
dynamic cyclic compression in a custom built bioreactor. After applying 15% strain at 1 
Hertz for four hours we see a two to three fold increase in PDLSCs chondrogenic gene 
expression of Sox-9 and aggrecan as well as a 50% increase in ERK1/2 activity (Fritz, 2009). 
These results suggest that human PDLSCs, like BMMSCs, subject to dynamic cyclic 
compression require the ERK1/2 signaling pathway for chondrogenic expression (Fritz, 
2009).  
Recently we examined the effects of shorter durations of dynamic cyclic compression on 
SHEDs. As in previous experiments (Fritz, 2009; Pelaez et al., 2009), fibrin gel constructs 
were cast into 1.5-mm deep and 8-mm diameter Teflon molds set on top of a clean 
microscope slide. We loaded 1 X 107 SHEDs into 85 µL fibrin gel mixture containing 5 U/mL 
thrombin in PBS and 40 mg/mL fibrinogen in high-glucose DMEM. The fibrin gel constructs 
were allowed to solidify for one hour before removing from the Teflon mold and then 
placed in fibrin gel media containing high-glucose DMEM, 1% penicillin/streptomycin and 
1× ITS supplement (BD Biosciences, San Jose, CA) and 0.0875 IU/mL aprotinin from bovine 
lung (Sigma-Aldrich, St. Louis, MO) for 24 hours in a water-jacketed incubator at 37°C and 
5% CO2. The compression chambers were loaded with the fibrin gel constructs and 650 µL of 
fibrin gel media. Fibrin gel constructs were then subjected them to 1Hertz dynamic cyclic 
compression with 15% strain in a custom built bioreactor placed in a water-jacketed 
incubator at 37°C and 5% CO2. Twelve samples for each treatment were subjected to 0 
minutes, 15 minutes, 30 minutes, 60 minutes and 240 minutes of compression. Fibrin gel 
constructs were removed from the bioreactor and flash frozen in liquid nitrogen.  
Messenger RNA expression was determined using methods similar to Fritz (2009) and 
Pelaez et al. (2009). Briefely, fibrin gel constructs were homogenized using a IKA Ultra 
Turrax® T8 Homogenizer in 1 mL TRIzol (Invitrogen, Carlsbad, CA) and RNA was 
extracted according to manufacturers recommended protocol. Purified RNA concentration 
was quantified on a NanoDrop ND-1000 spectrophotometer. Reverse transcription of 
mRNA was performed using MultiScribe™ Reverse Transcriptase (Applied Biosciences, 
Foster City, CA) according to the manufacturer’s suggested protocol. Quantitative real-time 
PCR was performed in a MxPro 3005P machine (Stratagene) using SYBR® Green PCR 
Master Mix (Applied Biosciences, Foster City, CA) according to manufacturer’s suggested 
protocols. All samples were run in triplicate.  GADPH was used as a reference gene. Fold 
changes of the chondrogenic genes (Sox-9, c-fos, and TGFβ3) were calculated from the log-
transformed CT values and expressed relative to the No Compression treatment group using 
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a modification of the delta-delta CT method (Livak and Schmittgen, 2001; Vandesompele et 
al., 2002).  
Protein was extracted from the fibrin gel scaffolds and levels of p-ERK assessed using the 
methods described in Fritz (2009). Briefly, fibrin gel constructs were homogenized in 1 mL 
of RIPA cell lysis buffer 2 (Enzo Life Sciences Int’l, Inc., Plymouth Meeting, PA) plus 0.5 
μL/mL protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and 1 mM 
phenymethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, MO). The homogenate was kept 
on ice for 40 minutes and vortexed every 10 minutes. The homogenate centrifuged and the 
remaining supernatant was saved for protein analyses. The level of p-ERK 1/2 in each 
sample was determined using [pThr202/Tyr204]Erk1/2 EIA kit (Enzo Life Sciences Int’l, Inc., 
Plymouth Meeting, PA). Manufacturer suggested protocols were performed for the EIA 
assays and all samples were analyzed in duplicates.  
All data are reported as mean ± S.E.M. (N=number of samples). 0 minutes, 15 minutes, 30 
minutes, 60 minutes and 240 minutes of compression were compared level of p-ERK 1/2 
and for mRNA expression of Sox-9, c-fos, and TGFβ3. Significant differences were 
determined by using a One-way ANOVA in Sigma Stat 3.00 (SPSS Inc.). 
The effects of dynamic compression on chondrogenesis and ERK 1/2 signal transduction 
was observed (Figure 2). As expected, we saw an increase in the levels of the early response 
gene c-fos after 60 minutes of dynamic compression (Figure 2). Surprisingly, we did not see 
any change in the other early response gene c-jun (Data not shown) as seen in BMMSCs 
described above. We also saw an increase in the gene expression of both TGFβ3 and Sox-9 
after 30 minutes of dynamic compression which lasted for at least 60 minutes of 
compression (Figure 2). Unlike the PDLSCs response to dynamic compression, SHEDs did 
not express Sox-9 after four hours. Further, we noticed and increase in the phosphorylation 
of ERK 1/2 as early as 15 minutes which was sustained for at least 60 minutes, but was no 
longer elevated after 4 hours (Figure 2). 
SHEDs clearly have a different response to dynamic compression than PDLSCs. Like 
PDLSCs we see an early rise in the phosphorylation of ERK 1/2 suggesting that this signal 
transduction pathway is responding to compressive forces in SHEDS. The rise in TGFβ3 
likely triggers the chondrogenic differentiation. Similar to PDLSCs, we see an increase in 
Sox-9, a transcription factor for chondrocyte differentiation, suggesting that SHEDs are 
indeed beginning to undergo chondrogenic differentiation. However, unlike PDLSCs, we 
did not see any aggrecan expression in our experiment which arises later in chondrogenic 
differentiation. Therefore we can suggest that SHEDs, like PDLSCs, respond to compressive 
force by undergoing chondrogenic differentiation and this is likely mediated though the 
ERK 1/2 signal transduction pathway. However, although chondrogenic differentiation is 
triggered within 30 minutes by dynamic compression, it is not completed during these short 
time intervals. This may be due to the decrease in TGFβ3 gene expression after 4 hours, 
which may be required to maintain chondrogenic differentiation in the dynamically 
compressed constructs as there was no supplementation of TGFβ3 in the media. 
Interestingly, the control samples did not show any gene expression for aggrecan but these 
samples were maintained in media without any supplemental TGFβ3. Koyama et al. (2009) 
did not show any chondrogenic gene expression in control cultures of SHEDs, but felt it 
may be due to the fact that some of their cultures were infected. We would suggest 
repeating that experiment to determine if SHEDs cultures express any of the chondrogenic 
markers without TGFβ3 supplementation. 
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mitogen activated protein kinases (MAPKs) has been implicated in this process (Lee et al., 
2004). The application of dynamic mechanical compression has been shown to induce 
chondrogenic differentiation of stem cells via an autocrine signaling pathway (Huang et al., 
2005). Interestingly, just two hours of cyclic compression applied to BMMSCs stimulated 
TGFβ gene expression and the expression of both of its receptors (Huang et al., 2005). This 
stimulation in turn resulted in an up-regulation of the early response genes c-Fos and c-Jun 
as well as chondrogenic specific genes Sox-9, aggrecan and collagen type II (Huang et al., 
2005). 
Our lab has developed a line of adult dental stem cells derived from the PDL that are 
multipotent and express some ESC markers (Huang et al., 2009a). Using in vitro cultures in 
chondrogenic media we were able to show that after two weeks in culture with TGFβ3, 
PDLSCs increased expression of the chondrogenic markers collagen II and aggrecan (Huang 
et al., 2009a). Further, we see that PDLSCs express chondrogenic markers when subject to 
dynamic cyclic compression in a custom built bioreactor. After applying 15% strain at 1 
Hertz for four hours we see a two to three fold increase in PDLSCs chondrogenic gene 
expression of Sox-9 and aggrecan as well as a 50% increase in ERK1/2 activity (Fritz, 2009). 
These results suggest that human PDLSCs, like BMMSCs, subject to dynamic cyclic 
compression require the ERK1/2 signaling pathway for chondrogenic expression (Fritz, 
2009).  
Recently we examined the effects of shorter durations of dynamic cyclic compression on 
SHEDs. As in previous experiments (Fritz, 2009; Pelaez et al., 2009), fibrin gel constructs 
were cast into 1.5-mm deep and 8-mm diameter Teflon molds set on top of a clean 
microscope slide. We loaded 1 X 107 SHEDs into 85 µL fibrin gel mixture containing 5 U/mL 
thrombin in PBS and 40 mg/mL fibrinogen in high-glucose DMEM. The fibrin gel constructs 
were allowed to solidify for one hour before removing from the Teflon mold and then 
placed in fibrin gel media containing high-glucose DMEM, 1% penicillin/streptomycin and 
1× ITS supplement (BD Biosciences, San Jose, CA) and 0.0875 IU/mL aprotinin from bovine 
lung (Sigma-Aldrich, St. Louis, MO) for 24 hours in a water-jacketed incubator at 37°C and 
5% CO2. The compression chambers were loaded with the fibrin gel constructs and 650 µL of 
fibrin gel media. Fibrin gel constructs were then subjected them to 1Hertz dynamic cyclic 
compression with 15% strain in a custom built bioreactor placed in a water-jacketed 
incubator at 37°C and 5% CO2. Twelve samples for each treatment were subjected to 0 
minutes, 15 minutes, 30 minutes, 60 minutes and 240 minutes of compression. Fibrin gel 
constructs were removed from the bioreactor and flash frozen in liquid nitrogen.  
Messenger RNA expression was determined using methods similar to Fritz (2009) and 
Pelaez et al. (2009). Briefely, fibrin gel constructs were homogenized using a IKA Ultra 
Turrax® T8 Homogenizer in 1 mL TRIzol (Invitrogen, Carlsbad, CA) and RNA was 
extracted according to manufacturers recommended protocol. Purified RNA concentration 
was quantified on a NanoDrop ND-1000 spectrophotometer. Reverse transcription of 
mRNA was performed using MultiScribe™ Reverse Transcriptase (Applied Biosciences, 
Foster City, CA) according to the manufacturer’s suggested protocol. Quantitative real-time 
PCR was performed in a MxPro 3005P machine (Stratagene) using SYBR® Green PCR 
Master Mix (Applied Biosciences, Foster City, CA) according to manufacturer’s suggested 
protocols. All samples were run in triplicate.  GADPH was used as a reference gene. Fold 
changes of the chondrogenic genes (Sox-9, c-fos, and TGFβ3) were calculated from the log-
transformed CT values and expressed relative to the No Compression treatment group using 
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a modification of the delta-delta CT method (Livak and Schmittgen, 2001; Vandesompele et 
al., 2002).  
Protein was extracted from the fibrin gel scaffolds and levels of p-ERK assessed using the 
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of RIPA cell lysis buffer 2 (Enzo Life Sciences Int’l, Inc., Plymouth Meeting, PA) plus 0.5 
μL/mL protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and 1 mM 
phenymethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, MO). The homogenate was kept 
on ice for 40 minutes and vortexed every 10 minutes. The homogenate centrifuged and the 
remaining supernatant was saved for protein analyses. The level of p-ERK 1/2 in each 
sample was determined using [pThr202/Tyr204]Erk1/2 EIA kit (Enzo Life Sciences Int’l, Inc., 
Plymouth Meeting, PA). Manufacturer suggested protocols were performed for the EIA 
assays and all samples were analyzed in duplicates.  
All data are reported as mean ± S.E.M. (N=number of samples). 0 minutes, 15 minutes, 30 
minutes, 60 minutes and 240 minutes of compression were compared level of p-ERK 1/2 
and for mRNA expression of Sox-9, c-fos, and TGFβ3. Significant differences were 
determined by using a One-way ANOVA in Sigma Stat 3.00 (SPSS Inc.). 
The effects of dynamic compression on chondrogenesis and ERK 1/2 signal transduction 
was observed (Figure 2). As expected, we saw an increase in the levels of the early response 
gene c-fos after 60 minutes of dynamic compression (Figure 2). Surprisingly, we did not see 
any change in the other early response gene c-jun (Data not shown) as seen in BMMSCs 
described above. We also saw an increase in the gene expression of both TGFβ3 and Sox-9 
after 30 minutes of dynamic compression which lasted for at least 60 minutes of 
compression (Figure 2). Unlike the PDLSCs response to dynamic compression, SHEDs did 
not express Sox-9 after four hours. Further, we noticed and increase in the phosphorylation 
of ERK 1/2 as early as 15 minutes which was sustained for at least 60 minutes, but was no 
longer elevated after 4 hours (Figure 2). 
SHEDs clearly have a different response to dynamic compression than PDLSCs. Like 
PDLSCs we see an early rise in the phosphorylation of ERK 1/2 suggesting that this signal 
transduction pathway is responding to compressive forces in SHEDS. The rise in TGFβ3 
likely triggers the chondrogenic differentiation. Similar to PDLSCs, we see an increase in 
Sox-9, a transcription factor for chondrocyte differentiation, suggesting that SHEDs are 
indeed beginning to undergo chondrogenic differentiation. However, unlike PDLSCs, we 
did not see any aggrecan expression in our experiment which arises later in chondrogenic 
differentiation. Therefore we can suggest that SHEDs, like PDLSCs, respond to compressive 
force by undergoing chondrogenic differentiation and this is likely mediated though the 
ERK 1/2 signal transduction pathway. However, although chondrogenic differentiation is 
triggered within 30 minutes by dynamic compression, it is not completed during these short 
time intervals. This may be due to the decrease in TGFβ3 gene expression after 4 hours, 
which may be required to maintain chondrogenic differentiation in the dynamically 
compressed constructs as there was no supplementation of TGFβ3 in the media. 
Interestingly, the control samples did not show any gene expression for aggrecan but these 
samples were maintained in media without any supplemental TGFβ3. Koyama et al. (2009) 
did not show any chondrogenic gene expression in control cultures of SHEDs, but felt it 
may be due to the fact that some of their cultures were infected. We would suggest 
repeating that experiment to determine if SHEDs cultures express any of the chondrogenic 
markers without TGFβ3 supplementation. 
 
Embryonic Stem Cells – Differentiation and Pluripotent Alternatives 464 
 
 
Fig. 2. The effects of different durations of dynamic cyclic compression (15% strain) on 
relative messenger RNA expression of c-fos, TGFβ3 and Sox-9 and on the phosphorylation 
level of ERK 1/2. All treatments N=6. Values are means ± S.E.M.; *P < 0.05, significantly 
different from No Compression treatment. 
4. Dental stem cells versus embryonic stem cells  
There are advantages and disadvantages for using dental stem cells compared to the using 
embryonic stem cells for tissue engineering and regenerative medicine. One advantage of 
using dental stem cells compared to ESCs is in the ease of obtaining these cells as they can 
be obtained from tissue during a standard tooth extraction or through loss of primary teeth 
(Huang et al., 2009b). ESCs are obtained from the inner cell mass of the embryoblast (Biswas 
and Hutchins, 2007) which requires access to the early embryo.  An advantage of using 
embryonic stem cells is their pluripotent potential and their ability to differentiate into all 
three germ layers (Alison et al., 2002; Mummery et al., 2011; Thomson et al., 1998). Studies 
on dental stem cells have only shown them to only be multipotent (Gronthos et al., 2000; 
Karaöz et al., 2010; Miura et al., 2003; Morsczeck et al., 2005; Seo et al., 2004; Sonoyama et al., 
2006). Interestingly, one PDL cell line has shown a broad differentiation potential and 
expresses some of the pluripotent markers expressed by ESCs (Huang et al., 2009a). A 
previous disadvantage of culturing ESCs is that they require a mouse embryonic feeder 
layer but recent studies have shown that ESCs can be cultured using human serum and 
human feeder cells and these cultures can be maintained for an extensive period of time 
(Ellerström et al., 2006).  Dental stem cells do not require a feeder layer but only have a 
limited number of passages (See above).   
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Many of the problems encountered with stem cells delivery and scaffold choice are the same 
for both dental stem cells and ESCs. The use of dental stem cells or ESCs for tissue 
engineering or regenerative repair often produce similar results and many of the same types 
of problems arise. Currently whole tooth regeneration is not possible using ESCs or dental 
stem cells. Similar to dental stem cells, human ESCs have been used to form osteoblasts both 
in vitro and in vivo and had the capacity to form mineralized tissue (Bielby et al., 2004).  
Like DPSCs, ESCs have been used to repair cardiac function in infarcted myocardium. 
Human ESCs were injected into an infarcted mouse myocardium and were shown to 
improve cardiac function after four weeks but this improvement was not maintained after 
three months (van Laake et al., 2008).  ESCs have also been used to explore neuronal 
regeneration for patients affected with Parkinson disease. Using the monkey as a primate 
model, ESCs have been used to generate dopaminergic neurons to aid in the relief of 
Parkinson disease (Takagi et al., 2005).  
5. Concluding remarks  
This review shows that dental stem cells are a viable alternative to embryonic stem cells for 
regenerative medicine. Dental stem cells are easily obtainable from the dental pulp of teeth 
and from other dental tissues which are often discarded as waste. Further,  dental stem cells, 
like BMMSCs, form  clonogenic, highly proliferative, multipotent cell populations in vitro 
and maintain their differentiation potential in vivo. Dental stem cells also show potential for 
cell therapy with respect to whole tooth regeneration. More work needs to be done to 
optimize the use of dental stem cells for use in cell therapies of other tissue types in the 
future including bone and cartilage formation. The potential of dental stem cells as an 
alternative choice to embryonic stem cells seems realistic for future stem cell therapies and 
regenerative medicine.  
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1.1 Importance of Spermatogonial Stem Cells (SSCs) 
Spermatogonial stem cells (SSCs) are undifferentiated germ cells that balance self-renewing 
and differentiating divisions to maintain spermatogenesis throughout adult life. This is a 
productive stem cell system that produces millions of spermatozoa each day while also 
maintaining rigorous quality control to safeguard germline integrity. SSCs are the only adult 
stem cells that are capable of self renewal and that differentiate to produce haploid cells 
transmitting genes to next generation. In the recent years, derivation of multipotent 
embryonic stem (ES)-like cells, which are capable of differentiating to three germinal layers, 
from SSCs in the testis, has been reported. This is of immense importance in medicine, basic 
science and animal reproduction and overcomes ethical issues pertaining to the use of 
human embryos for research. Since the population of SSCs in the testis is very low (< 1%), 
the identification of markers that are specifically expressed in SSCs aids in their efficient 
isolation. The characteristics of SSCs and ES-like cells in culture, and differential expression 
of genes in both these cell types can provide better understanding. In the present chapter, 
we would describe and compare the expression of SSC-specific markers in vivo and in vitro. 
We will also review the in vitro culture conditions of SSCs and characteristics of ES-like cells 
that differentiate from SSCs. This would enhance our perceptive of these special cells that 
has opened new avenues for stem cell researchers.  
1.2 Origin of Spermatogonial Stem Cell pool 
SSCs arise from gonocytes in the postnatal testis, which originally derive from primordial 
germ cells (PGCs) during foetal development. PGCs are a transient cell population that is 
first observed as a small cluster of alkaline phosphatase-positive cells in the epiblast stage 
embryo at about 7–7.25 days post psot coitum (dpc) in mice (Phillips et al., 2010). The 
specification of PGC is dependent on the expression of BMP4 and BMP8b from the 
extraembryonic ectoderm (Ginsburg et al., 1990; Lawson et al., 1999; Ying et al., 2001). 
During the formation of the allantois, the PGCs are passively swept away from the original 
position before they start migrating via the hindgut to arrive at the indifferent gonad 
(genital ridge) between 8.5 and 12.5 dpc in mice. PGCs replicate during the migratory phase 
and approximately 3000 PGCs colonize the genital ridges (Bendel-Stenzel et al., 1998). In the 
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male gonad at about 13.5 dpc, PGCs give rise to gonocytes, which become enclosed in 
testicular cords formed by Sertoli precursor cells and peritubular myoid cells. Gonocyte is a 
general term that can be subcategorized into mitotic (M)-prospermatogonia, T1-
prospermatogonia and T2-propsermatogonia (McCarrey 1993). M-prospermatogonia are 
located in the centre of the testicular cords, away from the basal membrane and continue 
proliferating until about 16.5 dpc of mouse development when they become T1-
prospermatogonia and enter the G0 stage of  mitotic arrest (McLaren 2003; Tohonen et al., 
2003). Gonocytes resume proliferation during the first week after birth (marking their 
transition to T2-prospermatogonia), concomitant with migration to the seminiferous tubules 
basement membrane (Clermont & Perey 1957). T2-prospermatogonia that colonize the 
basement membrane give rise to the first round of spermatogenesis as well as establish the 
initial pool of SSCs that maintains spermatogenesis throughout postpubertal life (Kluin & de 
Rooij 1981; McCarrey 1993; Yoshida et al., 2006). 
1.3 Dynamics of SSCs 
The kinetics of sperm production were first described in rodents (Oakberg 1956) with the 
knowledge of the presence of adult stem cells, such as hematopoietic stem cells (HSCs), 
researchers hypothesized that germ cell differentiation in the testis required a stem cell 
population. The presence of a stem cell population responsible for continual sperm 
production in the testis was demonstrated in 1994 (Brinster & Zimmermann). They 
documented the first successful spermatogonial stem cell (SSC) transplantation in mice 
resulting in donor-derived spermatogenesis. SSCs are part of a subset of male germ cells 
called undifferentiated spermatogonia (Caires et al., 2010). This subset includes Asingle (As) 
spermatogonia that are thought to be the SSCs and their progeny cells Apaired (Apr) and 
Aaligned (Aal) spermatogonia (figure 1). SSCs are a self-renewing population of adult stem 
cells capable of producing progeny for a continual production of sperm by sexually mature 
males. They help in maintaining a constant supply of undifferentiated spermatogonia, 
which are critical to the initiation of spermatogenesis and the long-term production of 
sperm. One must be careful to distinguish between spermatogonial stem cells (SSC) and 
spermatogonia in general. The term “spermatogonia” is used collectively to refer to a 
continuum of cells ranging from those resting on the basement membrane (known as either 
Aisolated or Asingle spermatogonia), to proliferating sub-populations (Apaired to Aaligned, 
spermatogonia) to differentiating sub-populations [A1-4, Intermediate and Type B 
spermatogonia]. The differentiating stages are committed to enter spermatogenesis, but 
whether the Aisolated cells represent the only spermatogonia with a true stem cell nature is 
not yet fully clear. The differentiation of germ cells from diploid undifferentiated 
spermatogonia to mature and haploid spermatozoa is supported by the Sertoli cells of the 
seminiferous epithelium. The formation of the SSC population is dependent on the 
associated niche in the microenvironment in the seminiferous tubules of the testis. This 
niche environment supplies factors and provides interactions crucial for the survival and 
development of SSCs. It is usually composed of adjacent differentiated cells, the stem cells 
themselves, and the extracellular matrix surrounding these cells. The somatic cells produce 
factors, which aid in the extrinsic regulation of the SSC self-renewal/differentiation process. 
SSCs represent a model for the investigation of adult stem cells because they can be 
maintained in culture, and the presence, proliferation and the loss of SSCs in a cell 
population can be determined with the use of a transplantation assay. 
 









Fig. 1. Adult pig testis section stained with anti-UCHL-1 antibody. Spermatogonia are 
present as, Asingle (As), Apaired (Apr) and Aaligned (Aal) at the basement membrane of 
seminiferous tubule. The As spermatogonia are thought to be the spermatogonial stem cells 
(SSCs).  
2. Identification of SSCs 
2.1 Markers of SSCs 
Exploring markers for spermatogonia help to identify the stem cell pool in the testis. Certain 
rodent markers for germ cells and SSCs such as VASA, DAZL, PLZF, and GFR1are also of 
monkey (Hermann et al., 2007) and in other species. VASA expression marks spermatogonia 
in sheep (Borjigin et al., 2010), buffalo (Goel et al., 2010b) and bull (Fujihara et al., 2011) 
testis. It has been demonstrated that GFR1 is a marker for mouse SSCs and probably their 
progeny (Meng et al., 2000; Buageaw et al., 2005; Hofmann et al., 2005; Naughton et al., 2006; 
He et al., 2007), and that  KIT is a characteristic for the more differentiated spermatogonia, 
including type A1-4 spermatogonia (Yoshinaga et al., 1991). KIT expression is shown to mark 
pig gonocytes (Goel et al., 2007) and spermatogonia (Dirami et al., 1999). PLZF marks pig 
(Goel et al., 2007) and sheep (Borjigin et al., 2010) gonocytes and type-A spermatogonia. 
Because there is not a unique marker available to distinguish the SSCs and other 
undifferentiated spermatogonia, called Apr and Aal, it is helpful to use two or three 
antibodies to characterize their phenotypes. The GFR1 and POU5F1 antibodies stain the 
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same subset of mouse spermatogonia (He et al., 2007). POU5F1 also marks spermatogonia in 
buffalo (Goel et al., 2010b) and bull (Fujihara et al., 2011). GPR125 is also believed to be a 
marker for mouse spermatogonial stem/progenitor cells (Seandel et al., 2007). It is 
speculated that some of these markers as mentioned above will also be applicable to human 
spermatogonia. It has been recently shown that GPR125 may be a marker for human SSCs, 
as it is for mouse SSCs (He et al., 2010).  
A comparison of the markers for spermatogonia and their progenitors in human and 
rodents indicates that these spermatogonia share many but not all phenotypes. In rodents, 
α6-integrin (CD49f), β1-integrin (CD29), and Thy-1 (CD90) are surface markers for mouse 
spermatogonial stem/progenitor cells (Shinohara et al., 1999; Kubota et al., 2003). THY-1 
also marks bovine spermatogonia (Reding et al., 2010). CD9 is a surface marker for mouse 
and rat spermatogonial stem/progenitor cells (Kanatsu-Shinohara et al., 2004a). GFRα1 and 
RET are co-receptors for GDNF and markers for spermatogonial stem/progenitor cells 
(Buaas et al., 2004; Costoya et al., 2004; Buageaw et al., 2005; Hofmann et al., 2005; Naughton 
et al., 2006). In human, α6-integrin is expressed in spermatogonia and their progenitors and 
was used to isolate and purify human spermatogonial cells by magnetic-activated cell 
separation (Conrad et al., 2008). Other rodent surface markers, such as CD90, GFRα1, and 
CD133, were also used to select human spermatogonia by magnetic-activated cell separation 
(MACS) and comparable results to α6-integrin were obtained (Conrad et al., 2008). PLZF is 
characterized as a hallmark for mouse spermatogonial stem/progenitor cells (Buaas et al., 
2004; Costoya et al., 2004). In adult monkey, the expression of PLZF is confined to the Adark 
and/or Apale spermatogonia (Hermann et al., 2007). GPR125 has been demonstrated to be 
expressed in mouse spermatogonia and their progenitors (Seandel et al., 2007), and it is 
recently reported that GPR125 is also present in human spermatogonia (Dym et al., 2009). 
UCHL-1 is known to express in spermatogonia of mice (Kwon et al., 2004), monkey 
(Tokunaga et al., 1999) and humans (He et al., 2010). UCHL-1 protein expression is present 
specifically in the spermatogonia of domestic animal testes such as bull (Wrobel et al., 1995; 
Herrid et al., 2009), pig (Luo et al., 2006; Goel et al., 2007), sheep (Rodriguez-Sosa et al., 2006) 
and buffalo (Goel et al., 2010b). UCHL-1 protein expression is also specific to spermatogonia 
of wild bovids (Goel et al., 2010a). UCHL-1 also marks spermatogonia in the testis of Indian 
mouse deer (Moschiola indica) and slender loris (Loris tardigradus) (unpublished data). It is 
therefore likely that the expression of UCHL-1 is conserved in a variety of species. 
Collectively, the above studies suggest that some spermatogonial markers are conserved 
between rodents and humans and other species. In contrast, some other rodent markers for 
spermatogonia and their progenitors are not applicable to human and other species. This 
can be illustrated by the fact that α1-integrin (CD29), a marker for rodent spermatogonial 
stem/progenitor cells, is not expressed in human spermatogonia but present in 
spermatocytes, spermatids, and spermatozoa in normal human testis (Schaller et al., 1993). 
Another example is that POU5F1 (Oct-4), a marker for mouse spermatogonial 
stem/progenitor cells (Ohbo et al., 2003; Ohmura et al., 2004; Hofmann et al., 2005), is not 
detected in adult human spermatogonia (Looijenga et al., 2003). POU5F1 shows a rather 
unique expression pattern in pig testis where spermatogonia show a weak staining, 
however, strong expression is present in differentiating germ cells such as spermatocytes 
and spermatids (Goel et al., 2008). Similarly, KIT is regarded as a marker for mouse 
differentiating spermatogonia (Yoshinaga et al., 1991; Schrans-Stassen et al., 1999; Dolci et 
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al., 2001), but it is undetected in human spermatogonia (Rajpert-De Meyts et al., 2003). 
Notably, some human markers for spermatogonia are also not applicable to rodents. As an 
example, the TSPY protein is preferentially expressed in elongated spermatids but not in 
spermatogonia of adult rat testis (Kido and Lau, 2006), unlike the expression pattern of the 
TSPY in adult human spermatogonia (Schnieders et al., 1996). Other rodent markers, 
including CD9 (Kanatsu- Shinohara et al., 2004b), CDH1 (Tokuda et al., 2007), neurogenin3 
(Yoshida et al., 2004, 2007), RET (Naughton et al., 2006), and STRA8 (Giuili et al., 2002), were 
demonstrated to be expressed in spermatogonia and their progenitors; however, whether 
these rodent markers are present in human spermatogonia remains to be clarified. Similarly, 
some human markers, such as CD133 (Conrad et al., 2008), CHEK2 (also known as chk2 
tumor suppressor protein) (Bartkova et al., 2001; Rajpert-De Meyts et al., 2003), and NSE 
(Neurone-specific enolase) (Rajpert-De Meyts et al., 2003), are also awaiting further studies 
to explore whether they are present in rodent spermatogonia and their progenitors. Such 
investigations would uncover further similarities and/or differences in spermatogonial 
phenotypes between human and rodents. 
2.2 Functional assay of SSCs 
Transplantation of isolated germ cells from a fertile donor male into the seminiferous 
tubules of infertile recipients can result in donor-derived sperm production. Therefore, 
this system represents a major development in the study of spermatogenesis and a 
unique functional assay to determine the developmental potential and relative 
abundance of spermatogonial stem cells in a given population of testis cells. The 
application of this method in farm animals has been the subject of an increasing number 
of studies, mostly because of its potential as an alternative strategy in producing 
transgenic livestock with higher efficiency and less time and capital requirement than 
the current methods such as microinjection of genes into fertilized eggs and somatic cell 
nuclear transfer.  
Germ cell transplantation (GCT), also referred to as spermatogonial stem cell (SSC) 
transplantation, is a powerful technology first introduced in 1994 by Brinster and colleagues. 
Although initially developed using a mouse model, GCT has important applications in the 
study and manipulation of spermatogenesis in many species. In this method, testis cells 
obtained from a fertile donor male are transferred into the seminiferous tubules of infertile 
recipient testes, where donor-derived sperm production can occur, allowing the recipient to 
sire progeny (Brinster & Avarbock, 1994; Brinster & Zimmermann, 1994). In essence, donor 
SSCs deposited in the lumen of the recipient seminiferous tubules are allowed by the Sertoli 
cells to migrate to the basolateral compartment of the tubule, to proliferate, form new 
colonies and initiate donor-derived spermatogenesis (Nagano et al., 1999; Ohta et al, 2000). 
Following the original introduction of GCT in mice (Brinster & Avarbock, 1994; Brinster & 
Zimmermann, 1994), the technique was also successful in rats (Jiang & Short, 1995;Ogawa et 
al., 1999b), monkey (Schlatt et al., 2000a) and goat (Honaramooz et al., 2003). In laboratory 
rodents, GCT not only provides a unique opportunity for gaining a new insight into 
spermatogenesis and the biology of the stem cell niche, but also presents a unique functional 
bioassay to test the competence of putative SSCs. Furthermore, GCT also offers a new 
strategy for preservation of male fertility and an alternative approach for generation of 
transgenic animals (Brinster 2002, 2007). 
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al., 2001), but it is undetected in human spermatogonia (Rajpert-De Meyts et al., 2003). 
Notably, some human markers for spermatogonia are also not applicable to rodents. As an 
example, the TSPY protein is preferentially expressed in elongated spermatids but not in 
spermatogonia of adult rat testis (Kido and Lau, 2006), unlike the expression pattern of the 
TSPY in adult human spermatogonia (Schnieders et al., 1996). Other rodent markers, 
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al., 1999b), monkey (Schlatt et al., 2000a) and goat (Honaramooz et al., 2003). In laboratory 
rodents, GCT not only provides a unique opportunity for gaining a new insight into 
spermatogenesis and the biology of the stem cell niche, but also presents a unique functional 
bioassay to test the competence of putative SSCs. Furthermore, GCT also offers a new 
strategy for preservation of male fertility and an alternative approach for generation of 
transgenic animals (Brinster 2002, 2007). 
 




Fig. 2. Germ cell transplantation (GCT) in mice. (A) Germ cell depleted mice testes are 
extoriated through a ventral incision. (B) The testicular cell suspension is injected into 
seminiferous tubules through the efferent duct using a fine glass capillary.   
Rather surprisingly, cross-species (xenogeneic/heterologous) transplantation of testis cells 
from donor rats and hamster into recipient mice resulted in complete rat (Clouthier et al., 
1996) and hamster (Ogawa et al., 1999a) spermatogenesis. This development sparked an 
interest in the idea of using the laboratory mouse as a universal recipient model for testis 
cells from different donor species. However, GCT from genetically more distant donor 
species, including farm animals, into mice only resulted in colonization or proliferation of 
SSCs but not in complete spermatogenesis (Nagano et al., 2001, 2002; Dobrinski et al., 2000; 
Kim et al., 2006). We have recently shown that spermatogonia from endangered wild bovid 
(the Indian black buck; Antelope cervecapra L.) were able to colonize the recipient mice testis 
following GCT, however, showed no signs of proliferation or differentiation (Goel et al., 
2011). This block in differentiation of donor germ cells is believed to be due to the 
incompatibility of donor germ cells and mouse Sertoli cells (Shinohara et al., 2003). 
Although GCT from nonrodent species into the mouse testis did not result in complete 
spermatogenesis, it is still the only available bioassay for detecting the colonization potential 
of SSCs in a given population of donor testis cells from any species (Dobrinski et al., 1999a, 
b, 2000). Interestingly, when (rather than transferring isolated testis cells into the 
seminiferous tubules) small fragments of testis tissue were transplanted under the back skin 
of recipient mice, complete donor-derived spermatogenesis was observed from a wide range 
of donor species, including farm animal species (Honaramooz et al., 2002, 2004; Schlatt et al., 
2002b; Oatley et al., 2005; Rathi et al., 2006, 2008; Arregui et al., 2008; Ehmcke et al., 2008; 
Nakie et al., 2010).  
3. Pluripotential ability of germ stem cells in testis 
3.1 Introduction  
In the years 2006 and 2007, many articles were published, where somatic skin cells could be 
reprogrammed to ES-like cells, the so-called induced pluripotent stem (iPS) cells. Each 
report on the induction of pluripotency in mouse and human skin fibroblasts used retroviral 
delivery of key pluripotent stem cell genes such as, Oct-4 (Pou5f1), Sox2, c-Myc, and Klf4 
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(Takahashi and Yamanaka, 2006; Hanna et al., 2007; Meissner et al., 2007; Okita et al., 2007; 
Takahashi et al., 2007; Wernig et al., 2007). In the second step, transformed iPS cells were 
identified and selected by expression of pluripotent markers including Nanog (Okita et al., 
2007; Wernig et al., 2007) or Oct-4 (Wernig et al., 2007), or by ES-specific morphology 
(Meissner et al., 2007). These iPS cells had unique characteristics as they were germ-line 
competent and indistinguishable from ES cells derived from the embryo at the epigenetic 
level. Additionally, recent work has demonstrated that patient-autologous skin iPS cells can 
be genetically modified and used after differentiation by induction to cure a mouse model of 
sickle cell anemia (Hanna et al., 2007). Although this research paves the way toward stem 
cell therapy, it seems to be impractical for the iPS cells to be used in clinical application 
because of their instability and potential retroviral infections (Dym et al., 2009). 
As a result, it is essential and necessary to figure out more physiological methods to induce 
pluripotency from adult somatic cells or adult stem cells. More recent efforts have been 
taken to generate iPS cells from neural stem cells using only two transcription factors, Oct-4 
and either c-Myc or Klf4 (Kim et al., 2008). It has also been demonstrated that iPS cells can 
be produced from adult cells by non-integrating adenoviruses transiently expressing Oct-4, 
Sox2, Klf4, and c-Myc (Stadtfeld et al., 2008). However, it is still possible that these factors 
could somehow find their way into the genome of the iPS cells. Therefore, reprogramming 
of adult cells without the use of oncogenes would be very useful and safer as a means to 
produce ES-like cells. The proof of principle that spermatogonial stem cells/progenitor cells 
could be reprogrammed to pluripotent cells by biochemical means alone was first shown by 
Shinohara and colleagues (Kanatsu-Shinohara et al., 2004b). However, they could not derive 
ES-like cells from SSCs of adult mice. Guan et al. (2006) demonstrated that mouse adult 
spermatogonia, possibly the spermatogonial stem cells and/or their progeny, were able to 
reprogram biochemically to pluripotent ES-like cells. This was confirmed in mouse by 
(Seandel et al., 2007) showing that adult spermatogonia and/or their progenitors could 
indeed form pluripotent ES-like cells. Golestaneh and others (Conrad et al., 2008; Kossack et 
al., 2008; Golestaneh et al., 2009) have recently demonstrated a similar phenomenon in male 
germ cells and spermatogonia in the human testis. It is important to note that the 
SSCs/progenitor cells appear to reprogram spontaneously to pluripotency when  the cells 
are removed from their niche and when ES cell media is added. Thus, SSCs/progenitor cells 
have a great potential to be used as a safe means to generate ES-like cells that eventually can 
be used for clinical therapies of human diseases. Human ES cells are pluripotent stem cells 
that have the potential to differentiate into all the types of cell lineages and tissues in the 
body, and thus they are ideal cell sources for cell transplantation and gene therapy. 
However, the major concern is the ethical issues associated with obtaining human ES cells 
from IVF clinics. The human iPS cells have major advantages over human ES cells because 
there are no ethical issues involved and, more importantly, the iPS cells appear to be similar 
to ES cells in morphology, proliferation, and pluripotency, as evaluated by teratoma 
formation and chimera contribution. In contrast, the iPS cells have some disadvantages, e.g., 
safety is a major concern due to the potential of cell transformation or tumor formation 
because of the oncogenes from the transfected iPS. It may be possible to overcome these 
issues by generating pluripotent stem cells without oncogene transfer directly from 
spermatogonial stem cells by testicular biopsy. Thus, the generation of human ES-like cells 
from SSCs may offer a safer means of obtaining pluripotent stem cells than from the iPS 
cells. The identification of human SSCs is now especially important in view of the 
discrepancy between the Skutella report (Conrad et al., 2008) and the report by the Reijo-
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Pera group (Kossack et al., 2008). The Skutella group concluded that the ES-like cells derived 
from human spermatogonia (Spga) were in fact as pluripotent as true embryonic stem (ES) 
cells. The Reijo-Pera group noted that their cells differ from true ES cells in gene expression, 
methylation, and in their ability to form teratomas. Comparisons are difficult because the 
Skutella group used isolated Spga to get their ES-like cells, whereas the Reijo-Pera group 
used the entire testis biopsy without separating the Spga. It is possible that ES-like cells 
derived from isolated spermatogonial stem cells yield superior ES-like cells compared to 
using whole testis, but this remains to be determined. There are now three means to 
generate human pluripotent stem cells: (1) from a fertilized embryo as the traditional 
method; (2) from adult somatic cells through iPS technology; and (3) from adult SSCs 
and/or their progeny. One major advantage of the third approach is that the production of 
the ES-like cells is spontaneous, unlike method 2, where several genes, some cancer causing, 
is employed. Thus, human SSCs and/or their progeny have a great potential for cell- and 
tissue engineering-based medical regeneration for various human diseases. It is possible that 
in the near future men could be cured of their diseases using a biopsy from their own testes 
(Dym et al., 2009). 
3.2 Culture of SSCs and induction of ES-like colonies 
Kanatsu-Shinohara et al. (2004b) cultured SSCs in such a way that these cells propagated 
themselves, while retaining their capacity to repopulate a recipient mouse testis upon 
transplantation. A special medium, which was designed to culture hematopoietic stem cells, 
has been used for culture and contained several growth factors, including GDNF. In this 
culture system, a feeder layer is first formed that is composed of the contaminating somatic 
cells of the neonatal testis. Then, after 2 weeks and two passages, mitomycin-treated mouse 
embryonic fibroblasts (MEFs) are used as a feeder layer. During the first weeks of culture, 
the formed colonies consisted of SSCs, but, within 4-7 weeks, colonies that morphologically 
resembled ES cell colonies formed. Further work indicated that these colonies were indeed 
composed of multipotent ES-like cells. In order to maintain the multipotent character of 
these ES-like cells, they were subsequently cultured under a standard ES cell culture 
conditions in medium containing 15% fetal calf serum and LIF. Under these conditions, the 
cultured SSCs could not be propagated because of the lack of GDNF. ES-like colonies could 
only be obtained when the starting population of SSCs was derived from neonatal mice; 
when it was derived from older mice, ES-like colonies did not appear. However, cultures of 
SSCs derived from adult p53 (Trp53)-null mice did produce ES-like colonies. P53 is involved 
in the cellular response to DNA damage and a lack of P53 increases the chances of teratoma 
development. Possibly, P53-deficient SSCs are more capable of undergoing the transition 
into ES-like cells.  
An essentially similar protocol was followed by Seandel et al. (2007), except that this group 
used inactivated testicular stromal cells consisting of a mixture of CD34+ peritubular cells, α 
-smooth-muscle-actin-positive peritubular cells and cells positive for the Sertoli cell marker 
vimentin, as a feeder layer because they had less success using MEFs. By this method, ES-
like colonies only appeared after more than 3 months in culture, more slowly than reported 
by Kanatsu-Shinohara et al. (2004b). A substantially different approach was taken by Guan 
et al. (2006). Their starting material was derived from 4- to 6-week-old mice and they did not 
use the stem cell medium described by Kanatsu-Shinohara et al. (2004b) but simply 
Dulbecco's Modified Eagle's Medium (DMEM) with serum and added GDNF, in which 
testicular cells were initially cultured for 4 to 7 days. These cells were then sorted for the 
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expression of STRA8 and subsequently cultured in DMEM under various conditions, but 
without adding GDNF. Colonies of ES-like cells formed when LIF was added to the medium 
and/or when the cells were cultured on a feeder layer of MEFs. The ES-like cells were 
further expanded by culture on MEFs and the addition of LIF.  
Hu et al. (2007) cultured germ cells of prepubertal mice under conditions that favour 
osteoblast differentiation and reported the emergence of cells that had characteristics of 
osteoblasts after several weeks in culture. In this system, there was no period of culture with 
added GDNF. Finally, Boulanger et al. (2007) employed no culture step at all. This group 
transplanted cells isolated from adult mouse seminiferous tubules, together with mammary 
cells, into mammary fat pads to obtain the differentiation of SSCs into mammary epithelial 
cells.  
We have shown that gonocytes from neonatal pig testis can attain multipotency during 
short-term culture (Goel et al., 2009). Freshly isolated gonocytes were found to have either 
weak or no expression of pluripotency determining transcription factors, such as POU5F1, 
SOX2 and C-MYC. Interestingly, the expression of these transcription factors, as well as 
other vital transcription factors, such as NANOG, KLF4 and DAZL, were markedly 
upregulated in cultured cells. The formation of teratomas with tissues originating from the 
three germinal layers following the subcutaneous injection of cells into nude mice from 
primary cultures confirmed their multipotency. 
Taken together, it does not seem that a very specific approach is required to obtain the 
transformation of SSCs into ES-like cells. This transformation can occur on different feeder 
layers and even without a feeder layer, if LIF is added to the culture medium. Furthermore, 
the culture medium also does not seem to play a decisive role in the transformation of SSCs 
into ES-like cells, as the groups of Kanatsu-Shinohara et al. (2004b) and Seandel et al. (2007) 
used a specific stem cell medium, whereas Guan et al. (Guan et al., 2006) used DMEM. All 
three groups added GDNF to the culture, either continuously (Kanatsu-Shinohara et al., 
2004b; Seandel et al., 2007) or only at the start (Guan et al., 2006). However, to obtain the 
transformation of SSCs into cells of another lineage, it might not be necessary for them to 
become ES-like cells first. Putting the SSCs in an osteoblast-inductive environment in culture 
(Hu et al., 2007) or transplanting them into a mammary gland-inductive environment in 
vivo (Boulanger et al., 2007) might be enough for these cells to change their lineage. This 
rather suggests that SSCs are restricted to the spermatogenic lineage owing to the 
seminiferous tubular environment in which they reside. Once outside of this environment, 
they can switch to another lineage depending on the particular niche in which they are 
placed.  
3.3 Gene expression in SSCs and ES-like cells 
A crucial question is what changes in gene expression accompany the transition from a 
cultured SSC to an ES-like cell? In this respect, it is interesting to study the possible changes 
in the expression of those genes that can transform a fibroblast into an ES-like cell, that is 
Myc, Oct4 (Pou5f1), Sox2 and Klf4 (Takahashi and Yamanaka, 2006; Wernig et al., 2007), in 
SSCs and in the ES-like cells derived from them. Kanatsu-Shinohara et al. (2008b) found that 
all four pluripotency genes are already expressed at low levels in cultured SSCs, although 
no NANOG (Kanatsu-Shinohara et al., 2004b) or SOX2 protein expression was found in 
these cells. In ES-like cells, the expression of these four genes is much increased. In addition 
to these pluripotency genes, the ES cell markers such as stage-specific embryonic antigen-1 
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expression of STRA8 and subsequently cultured in DMEM under various conditions, but 
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(SSEA-1; FUT4) and, to a low level, Forssman antigen (GBGT1), were induced in the ES-like 
cells and, as in ES cells, high levels of alkaline phosphatase (AP) were also found (Kanatsu-
Shinohara et al., 2004b). Guan et al. (2006) assayed expression patterns in SSCs cultured 
under conditions that induced these cells to become ES-like cells. In this situation, it is 
difficult to categorize these cells as being either SSCs or ES-like cells as they might be in an 
in-between state. In these SSCs/early ES-like cells, Oct4, Nanog and SSEA1 were expressed 
(Guan et al., 2006). Indeed, the level of expression of Nanog and SSEA1 suggests that these 
cells were already on their way to becoming ES-like cells. Seandel et al. (2007) also studied 
gene expression levels before and after the transition of cultured SSCs to ES-like cells. Oct4 
was present in both cell types, but Nanog and Sox2 were strongly induced in ES-like cells, 
whereas the early spermatogonial markers Stra8, Plzf (Zbtb16), c-Ret and Dazl became 
inhibited. Besides these specific studies, Kanatsu-Shinohara et al. (2008b) also carried out a 
microarray study and found that a great many genes changed their expression levels during 
the transition from being a cultured SSC to an ES-like cell. Among these genes, over a 100 
were induced more than 5-fold in ES-like cells as compared with cultured SSCs, and another 
100 were inhibited more than 5-fold in ES-like cells. Clear differences between the patterns 
of genomic imprinting are also seen between cultured SSCs and ES-like cells. Kanatsu-
Shinohara et al. (2004b) studied the imprinting pattern of three paternally (H19, Meg3 and 
Rasgrf1) and two maternally (Igf2r and Peg10) imprinted regions in cultured SSCs and in the 
ES-like cells derived from them. Cultured SSCs show a completely androgenetic (paternal) 
imprinting pattern at the differentially methylated regions (DMRs) of these genes and loci; 
the DMRs of H19 and Meg3 are completely methylated and that of Igf2r is demethylated. By 
contrast, in the ES-like cells, the paternally imprinted regions are methylated to different 
degrees and the maternally imprinted regions (Igf2r and Peg10) are rarely methylated. 
Interestingly, the methylation patterns that are seen in the ES-like cells are not the same as 
those seen in proper ES cells, as the DMRs in ES cells are generally more methylated than 
those in ES-like cells, including the maternally imprinted regions. Furthermore, both 
Kanatsu-Shinohara et al. (2004b) and Seandel et al. (2007) reported that most of the ES-like 
cells obtained had a normal karyotype and that there was no evidence of clonal cytogenetic 
abnormalities. However, recently, Takahashi et al. (2007) did find some SSC-derived ES-like 
cells that were trisomic for chromosomes 8 or 11, which is a common chromosomal 
abnormality in ES cells. 
In conclusion, the transition from cultured SSCs to ES-like cells is accompanied by extensive 
changes in gene expression, during which three of the four pluripotency genes (the 
exception being Oct4, which is already expressed in mouse SSCs) become expressed at 
higher levels, along with many other genes. Furthermore, changes occur in the genomic 
imprinting patterns of these cells as they undergo this transition. Although the ES-like cells 
acquire the expression of ES cell-specific genes, the expression pattern of these genes in ES-
like cells is not identical to that seen in normal ES cells, with differences evident, for 
example, in the expression of brachyury, Gdf3, Forssman antigen, Nog and Stra8. 
4. Applications of SSCs 
4.1 Restoration of fertility 
SSC transplantation may have application for treating male infertility in some cases. For 
example, high-dose chemotherapy and total body radiation treatment of cancer can cause 
permanent infertility. While adult men can cryopreserve a semen sample prior to their 
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oncologic treatment, this is not an option for pre-adolescent boys who are not yet making 
sperm. Using methods similar to those already established for other species, it may be 
possible for these young cancer patients to cryopreserve testis cells or tissue prior to cancer 
treatment and use those tissues to achieve fertility after they are cured (Orwig & Schlatt, 
2005; Goossens et al., 2008; Hermann et al., 2009). Recently, a non-human primate model of 
cancer survivorship to test the safety and feasibility of SSC transplantation in a species that 
is relevant to human physiology has been established (Hermann et al., 2007). Although SSC 
transplantation is not yet ready for the human fertility clinic, it may be reasonable for young 
cancer patients, with no other options to preserve their fertility, to cryopreserve testicular 
cells (Schlatt et al., 2009). Ginsberg and co-workers have been cryopreserving testicular 
tissue for young cancer patients since 2008 and report that this intervention is acceptable to 
parents and that testicular biopsies caused no acute adverse effects (Ginsberg et al., 2010). A 
human SSC culture system would be particularly useful in this setting because a few SSCs 
could be obtained in a small biopsy and expanded to a number sufficient for transplantion 
therapy. 
4.2 Genetic modification 
4.2.1 Genetic modification of rodents  
The establishment of SSCs led to the development of a new strategy for generating a 
genetically modified animal as an alternative or a potentially superior method to the 
conventional ES-based technology. First, SSCs are infected or transfected with a viral or 
plasmid vector carrying a drug-resistant gene. Individual clones of drug-resistant SSCs cells 
are selected and expanded in vitro. After DNA analysis, genetically modified SSCs are 
transplanted to infertile mice. In theory, half of spermatozoa that developed from the SSCs 
carry the transgene. Finally, recipient male mice are crossed with female mice to yield 
heterozygous transgenic mice with a theoretical success rate of 50%. In the conventional ES 
cell-based technology, the frequency of heterozygous transgenic mice depends on the 
properties of chimera mice. In some cases, no germline chimera can be found in the chimera 
population. In this respect, SSCs which are committed to spermatogenesis are 
advantageous. When SSCs were transfected with a plasmid vector bearing a drugresistant 
gene and used for the production of transgenic mice based on this method, approximately 
50% of offspring derived from a drug-resistant clone maintained a transgene (Kanatsu-
Shinohara et al., 2005). Mice lacking a specific gene (i.e. occludin) by homologous DNA 
recombination was then successfully produced (Kanatsu-Shinohara et al., 2006). 
Homozygous mutant mice showed signs of chronic gastritis, osteoporosis and a loss of 
acidic granule in the salivary glands, similar to the occludin knockout mice generated using 
ES cells (Saitou et al., 2000). From these finding, it was demonstrated that SSCs can be used 
for gene targeting in a similar manner to ES cells. 
4.2.2 Application to generation of knockout animals in domestic species 
The method for generating genetically modified mice based on ES cell technology has 
become a conventional experimental technique, and contributed to the functional analyses 
of many genes. Under current culture conditions, SSCs grow slower than ES cells. For 
example, clonal expansion from a single transfected SSCs requires mixing with non-
transfected SSCs to maintain cell densities during drug selection. Thus, SSC-based 
transgenic technology is not yet useful as ES cell-based technology. However, SSC-based 
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technology is potentially applicable to animal species other than mouse, and this is the 
greatest advantage of this technology. At present, ES cell-based transgenesis is feasible only 
in mice, and cloning by somatic cell nuclear transfer is extremely difficult or impossible due 
to the low proliferation potential of somatic cells and the poor success rates of nuclear 
transfer. If SSC culture conditions specific for animal species are established, animal 
transgenesis may become feasible in other species. Specifically, SSCs are derived from the 
testes of rat, hamster and cattle (Hamra et al., 2005; Ryu et al., 2005; Aponte et al., 2008; 
Kanatsu- Shinohara et al., 2008c). Hamsters have been historically difficult to manipulate 
genetically; however, the SSC technology may provide a good animal model. Bovine SSCs 
may be useful for the cattle industry as an important application. In particular, rats are 
important experimental animals that are larger than mice and have been used in various 
research areas. Therefore, SSC technology will be highly beneficial if it allows unlimited 
transgenesis in rats. Transplantation of SSCs is an essential step in SSC-based animal 
transgenesis and is technically challenging. The efficiency of this method is low in large 
animals (Ogawa et al., 1999b). Development of technologies for xenogeneic transplantation 
and in vivo spermatogenesis, in addition to the determination of culture conditions, are 
anticipated for universal application to various species in the future. With regard to 
xenogeneic transplantation from rats to mice, normal rat offspring were successfully born 
after transferring rat spermatids and spermatozoa developed in the mouse testes into rat 
oocytes by in vitro microinsemination (Shinohara et al., 2006; Kanatsu-Shinohara et al., 
2008a). 
4.3 Regenerative therapy 
Recent advances in cellular therapies have led to the emergence of a multidisciplinary 
scientific approach to developing therapeutics for a wide variety of diseases and genetic 
disorders. Although most cell-based therapies currently consist of heterogeneous cell 
populations, it is anticipated that the standard of care needs well-characterized stem cell 
lines that can be modified to meet the individual needs of the patient. Extensive research in 
the area of regenerative medicine is focused on the development of cells, tissues and organs 
for the purpose of restoring function through transplantation. The general belief is that 
replacement, repair and restoration of function is best accomplished by cells, tissues or 
organs that can provide the appropriate physiological/metabolic functions more efficiently 
than any mechanical devices, recombinant proteins or chemical compounds. Several cell-
based strategies are currently being investigated, including cell preparations from 
autologous parenchyma or established cell lines, as well as cell therapies derived from a 
variety of stem cell sources such as bone marrow or cord blood stem cells, embryonic stem 
cells, as well as cells, tissues and organs from genetically modified animals. Several lines of 
evidence have suggested extensive proliferation activity and pluripotency of germline stem 
cells, including SSCs. These characteristics provide new and unprecedented opportunities 
for the therapeutic use of SSCs for regenerative medicine. 
Guan et al. (2006) succeeded in developing a procedure for the isolation and purification of 
SSCs from adult mouse testis. They were able to isolate and culture these cells in culture 
medium containing the precise combination of cellular growth factors needed for the cells to 
reproduce themselves in vitro. These cells were characterized with regard to their molecular 
profiles and these were compared via molecular profiling of embryonic stem cells using a 
stem cell array which contains relevant genes related to stem cell metabolism. The results 
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indicate that SSCs share many molecular characteristics with embryonic stem cells. On the 
cellular level, SSCs resemble embryonic stem cells; they form an embryoid body structure 
after 2 weeks of culture. Stem cell potential of isolated SSCs was examined using the 
transplantation technique. This method allowed SSCs to recolonize the seminiferous tubules 
of germ cell-depleted mice and regenerate spermatogenesis. These cells are able to 
differentiate into various cell types of three germ layers in vitro (Guan et al., 2006, 2007). In 
contrast to ESCs, the use of SSCs for cell transplantation will allow establishment of 
individual cell-based therapy, because the donor and recipient are identical. In addition, any 
ethical problems are avoided.This approach provides an accessible in vitro model system for 
studies of mammalian gametogenesis, as well as for developing new strategies for 
reproductive engineering, infertility treatment and establishment of regenerative therapy.  
4.4 Conservation biology  
Thus far, most works on technologies of assisted reproduction in males have focused on 
mature spermatozoa. Successful semen collection, cryopreservation, and thawing techniques 
have been determined for a number of species. Advancements in the handling and storage 
of mature sperm have revolutionized the practice of both human and veterinary clinical 
reproductive medicine. In addition, these innovations have changed the nature of 
agriculture and agricultural economics, as artificial insemination has often supplanted 
natural breeding in intensive production regimens. Research on mature sperm is limited in 
that there are no cell culture systems that support spermatogenesis in vitro; therefore, sperm 
can only be obtained as primary cells from reproductively mature individuals. The stem 
cells that will produce sperm, on the other hand, are present in early neonates. Soon after 
birth in most species, gonocytes migrate to the basement membrane of the seminiferous 
cords; at this point in time the gonocytes transition into spermatogonia.  
The development of reproductive technologies based on SSCs could preserve the breeding 
potential of males that die prior to puberty. This can be of great importance when the 
genetic contribution of a single individual could have significant impact on a long-term 
viability of a population. Examples of this would include attempts to preserve the genetic 
information represented in offspring of founder individuals in captive breeding programs, 
or attempts to propagate individuals with diseases that preclude natural mating. In 
addition, because SSCs can be maintained in culture, these cells are similar to ESCs in 
providing an opportunity for genetic manipulation that is not present in the terminally-
differentiated spermatozoa. Efforts to take advantage of the attributes of SSCs have thus far 
focused on two technologies: spermatogonial stem cell transplantation (SSCT) and testis 
xenografting. 
5. Conclusions 
SSCs are the novel source of pluripotent stem cells that have an advantage over the iPS cells 
in numerous ways. Firstly, pluripotent cells from SSCs do not require the addition of any 
foreign genes as they are spontaneously generated in culture. Secondly, since pluripotent 
cells from SSCs are derived without viral transduction, they provide a safer alternative to 
iPS cells. Finally, SSCs and SSC-derived pluripotent cells can find immediate application in 
the field of regenerative medicine, fertility restoration, and genetic modification of mice and 
large animals and in the conservation of endangered species.  
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reproductive medicine. In addition, these innovations have changed the nature of 
agriculture and agricultural economics, as artificial insemination has often supplanted 
natural breeding in intensive production regimens. Research on mature sperm is limited in 
that there are no cell culture systems that support spermatogenesis in vitro; therefore, sperm 
can only be obtained as primary cells from reproductively mature individuals. The stem 
cells that will produce sperm, on the other hand, are present in early neonates. Soon after 
birth in most species, gonocytes migrate to the basement membrane of the seminiferous 
cords; at this point in time the gonocytes transition into spermatogonia.  
The development of reproductive technologies based on SSCs could preserve the breeding 
potential of males that die prior to puberty. This can be of great importance when the 
genetic contribution of a single individual could have significant impact on a long-term 
viability of a population. Examples of this would include attempts to preserve the genetic 
information represented in offspring of founder individuals in captive breeding programs, 
or attempts to propagate individuals with diseases that preclude natural mating. In 
addition, because SSCs can be maintained in culture, these cells are similar to ESCs in 
providing an opportunity for genetic manipulation that is not present in the terminally-
differentiated spermatozoa. Efforts to take advantage of the attributes of SSCs have thus far 
focused on two technologies: spermatogonial stem cell transplantation (SSCT) and testis 
xenografting. 
5. Conclusions 
SSCs are the novel source of pluripotent stem cells that have an advantage over the iPS cells 
in numerous ways. Firstly, pluripotent cells from SSCs do not require the addition of any 
foreign genes as they are spontaneously generated in culture. Secondly, since pluripotent 
cells from SSCs are derived without viral transduction, they provide a safer alternative to 
iPS cells. Finally, SSCs and SSC-derived pluripotent cells can find immediate application in 
the field of regenerative medicine, fertility restoration, and genetic modification of mice and 
large animals and in the conservation of endangered species.  
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1. Introduction 
The amniotic fluid or liquor amnii, was first isolated and studied during the beginning of 
the 20th century (Brace et al., 1989).  More recently, in the 1960s and 1970s there was an 
increased interest in characterization and culture of the cells contained in the amniotic fluid 
(Huisjes HJ, 1970; Marchant GS, 1971).  Nevertheless, most all of these studies were directed 
at using amniotic fluid, and the cells contained within, for determining the health of the 
fetus during development, or to provide a general characterization of the amniotic fluid. 
Although the discovery of stem cells, in particular bone marrow stem cells, occurred in the 
1960’s, it was not until recently that the possibility of isolating stem cells from the amniotic 
fluid was investigated.  Amniotic fluid stem cell isolation and characterization is therefore 
fairly recent, dating back to the early 1990’s (Torricelli et al., 1993).  
The study of amniotic fluid-derived stem cells (AFDSCs) has captured the attention of 
researchers and clinicians for several reasons. First, AFDSCs can be collected during 
amniocentesis and isolated from material that would be otherwise discarded.  Therefore, 
their use is not subject to the ethical debate that surrounds the use of embryonic stem cells. 
Second, like other fetal derived stem cells, storage of AFDSCs is easy and achieved at 
minimal costs.   AFDSC populations can be easily expanded, and have shown the capability 
of being stored over long periods of time with no adverse effects (Da Sacco et al., 2010).  
Furthermore, the “banking” of AFDSCs from developing fetuses, may guarantee a source of 
stem cells with a matching immune profile to that of the recipient.  Most importantly, the 
extensive characterization of a specific subset of AFDSCs positive for the marker c-Kit+ (De 
Coppi et al., 2007), have displayed no tumor formation following transplant into an animal 
model, even after several months. These cells, known simply as amniotic fluid stem cells 
(AFSC) have been at the forefront of AFDSC research and will be discussed in depth later.  
Finally, as a source of stem cells collected before birth AFDSCs may become an invaluable 
source of stem cells for direct treatment of various genetic disorders treatable in utero 
(Turner CG et al., 2009). 
The potential applications and implications of AFDSCs in regenerative medicine and 
therapeutic treatments are significant, however; AFDSCs research is still in its infancy and 
much work is required to properly characterize AFDSCs and determine their effectiveness.  
In this chapter, we describe the different AFDSCs that have been isolated to date, list their 
characteristics, and provide an overview of the different organs in which AFDSCs have been 
used in vitro or in vivo to develop this stem cell population into a viable therapeutic 
strategy. 
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2. The amniotic cavity 
The amniotic fluid is contained in the amniotic cavity that, in humans, starts forming as 
early as seven days post fertilization, and is delimited by a membrane called amnion. The 
formation of the amniotic cavity is a result of the cavitation of the epiblast.  The amnion is 
formed by the cells of the epiblast, by the side facing the cytotrophoblast. This is the first 
appearance of the amniotic ectoderm, and at this stage it is still a continuum of the portion 
of the epiblast that will form the embryo.  The amnion formation is completed at fourteen 
days post fertilization and is constituted of two layers: the amniotic ectoderm (inner layer 
facing the amniotic fluid) and the amniotic mesoderm (outer layer).  The amnion has the 
important function of protecting the embryo and controlling the composition and the 
volume of the amniotic fluid. In humans, after seventeen weeks of gestation the amnion 
becomes surrounded and fused with another membrane, the chorion, and is therefore 
incorporated into the placenta.  At the beginning of the formation of the amniotic cavity, 
active transport of solutes from the amnion, followed by passive movement of water, 
comprise the amniotic fluid.  
In mice the amniotic cavity starts forming at embryonic stage E0.5 as a result of apoptotic 
events in the epiblast. At this stage, there is still the presence of a proamniotic cavity and the 
amnion that will start forming during gastrulation, is not yet defined. At approximately day 
E7.5 the amniotic cavity is formed and one day later the embryo starts the rotation process. 
At the end of the rotation, the embryo will be surrounded by the amnion. Surrounding the 
amnion are two more membranes, the visceral yolk sac and most externally the parietal yolk 
sac (Kaufman MH, 1992). These membranes represent three distinct layers surrounding the 
mouse embryo. Differently from human, in mice, the amnion does not fuse with the chorion 
and is not included in the placenta. 
 
 
Fig. 1. Amniotic cavity formation 
Twelve days post fertilization the human amniotic cavity is delimitated by the amnion (that 
at this stage is composed by the amniotic ectoderm) and the embryonic ectoderm (left). In 
the 7.5-day mouse embryo (right) the amnion is formed by the amniotic mesoderm and the 
amniotic ectoderm. 
In mammals the embryo is immersed in the amniotic fluid contained inside the amniotic 
cavity. In human (left) the cavity is delimited by the amniotic ectoderm and the amniotic 
mesoderm that constitute the amnion, and by the chorion. The amniotic ectoderm is in 
direct contact with the amniotic fluid. In mouse (right) the amnion is surrounded by two 
extra membranes, the visceral and parietal yolk sac. 
 




Fig. 2. Extra-embryonic membranes 
3. The amniotic fluid 
The amniotic fluid is the liquid present in the amniotic cavity and is constituted of about 
98% water.  This volume and composition change continuously during the different 
gestational stages. The volume of the amniotic fluid at the beginning of the pregnancy is 
multiple times the volume of the fetus, but at the end of gestation, at forty weeks, it will 
represent only a quarter of the volume of the fetus. Early during development, when the 
fetus has not yet started urination and deglutition, the plasma from the mother is surmised 
to play an important role in the composition of the amniotic fluid, and even though the 
mechanism is not completely understood, active transport of solutes is probably present 
between the amnion into the amniotic cavity, therefore creating a gradient for water 
recruitment (Bacchi Modena A and Fieni S, 2004).  The exchange of fluid through the skin 
that occurs until keratinization is also an important contributor to the osmolarity of the 
amniotic fluid. After keratinization, urination, swallowing and secretion due to breathing 
events also contributes to the composition of the amniotic fluid. Urine start to be part of the 
composition of the amniotic fluid at about eight weeks and its amount will increase during 
gestation, reaching a flow rate of up to 900 ml/day at the end of gestation (Lotgering FK et 
al., 1986).  Similarly, at approximately eight weeks, the fetus begins swallowing and 
secreting material including lung fluid and urine. Secretion of lung fluid is due to an active 
transport of chloride through the epithelium of the lung (Adamson TM et al., 1973).  
Sampling of amniotic fluid at later stages of the pregnancy is used to monitor lung 
development via the presence or absence of surfactant lipids and proteins secreted into the 
amniotic fluid. 
The cells present in the amniotic fluid have both embryonic and extraembryonic origins.  
Approximately forty years ago, researchers attempted to characterize these cells by 
cytological and biochemical parameters (Morris HHB et al., 1974). Early characterization 
distinguished four epithelial cell types in the amniotic fluid: large eosinophilic cells, large 
cyanophilic cells, small round cyanophilic cells, and polygonal eosinophilic cells (Huisjes 
HJ, 1970). Today we know that most of the cells of the amniotic fluid are derived from the 
skin, digestive, urinary (Fig. 3) and pulmonary tracts of the fetus and from the surrounding 
amnion.  We also know that the proportion and type of cells changes continuously during 
the different gestational stages. Some cells may also be derived from the mother, passing 
through the placenta into the fluid itself. The size of the cells contained in the fluid can 
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range from 6um to 50um and the shape can vary notably from round to squamous in 
morphology (Siddiqui and Atala, 2004).  
 
 
Fig. 3. Kidney amniotic fluid cells 
Amniotic fluid contains cell populations derived from several different tissues. Pictured 
above is a population of cells isolated using kidney specific markers (40X magnification). 
4. Amniotic fluid-derived stem cells 
AFDSCs belong to the group of stem cells present in extra embryonic tissues; all sharing the 
feature of belonging to material that is discarded after birth or that can be collected during 
amniocentesis. Besides the amniotic fluid, the amnion, umbilical cord and placenta have 
shown to contain stem cells that can be isolated at birth (Bailo M et al., 2004; Banas RA et al, 
2008; Brunstein CG et al., 2006; Fukuchi Y et al., 2004). 
The first studies of AFDSCs, were completed using mesenchymal amniocytes isolated from 
sheep.  These cells showed the ability to expand in vitro and to integrate into a scaffold 
(Kaviani A et al., 2001). In the following years, the identification of cells expressing the 
marker Oct4 (Prusa et al., 2003), or co-expressing Oct4, CD44 and CD105 (Tsai et al., 2004) 
were discovered in amniotic fluid. More recently a clonal population of AFDSCs derived 
from human and mouse were isolated and characterized (De Coppi P et al., 2007). These 
cells named AFSCs, were isolated through positive selection for the marker CD117 (or c-Kit), 
and represented 1% of cells derived from amniocentesis. AFSCs express the marker of 
“stemness”, Oct4, and the embryonic stem cell (ESC) marker SSEA-4. Furthermore AFSCs 
express markers characteristic of mesenchymal and neural stem cells such as CD29, CD44, 
CD73, CD90, and CD105.  Interestingly, these cells are negative for markers of 
hematopoietic stem cells such as CD34 and CD133. 
Recently, a screen for the expression profile of cells present in the amniotic fluid was 
reported (Da Sacco S et al., 2010).  This screening analyzed cells obtained from human 
amniotic fluid between gestational weeks 15 to 20 and showed that markers such as Oct4 
and CD117 are stably expressed during gestation. Furthermore, while markers for ectoderm 
are stably expressed during gestation, markers for the early endoderm and mesoderm are 
more abundant during early gestation and tend to disappear after 17 to 18 weeks.  During 
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the same time, organ specific markers start to become highly expressed. A full proteome 
analysis (Tsangaris G et al., 2005) using bi-dimensional gel electrophoresis and mass 
spectrometry, has allowed the identification of specific proteins expressed in the cells 
present in the amniotic fluid. This analysis has confirmed that amniotic fluid contains a 
heterogeneous population of cells, both differentiated and with characteristics of stem cells.  
In the following paragraphs a detailed description of the approaches used to differentiate 
AFDSCs into various lineages is presented. 
When considering the use of amniotic fluid stem cells for regenerative medicine and various 
therapeutic interventions, clinicians and researchers agree that the ease of amniotic fluid 
stem cell isolation and culture make them attractive candidates for further research and 
development.  As mentioned previously, amniotic fluid stem cells are isolated from samples 
of amniotic fluid collected during routine amniocentesis.  This routine procedure (Fig. 4.) 
occurs during weeks 16-20 of a pregnancy, where approximately 10-20 milliliters of amniotic 
fluid is collected and split into two samples (Trounson, 2007).  One sample serves as the test 
sample to screen for genetic and gestational abnormalities, while the other sample serves as 
a back up.  When the back-up sample is no longer needed, some diagnostic laboratories 
donate this “medical waste” to research laboratories for stem cell isolation and further 
research.  Throughout this entire process, neither the mother, nor the fetus is harmed, 
making the collection of these cells ethically neutral. 
 
 
Fig. 4. Diagram for Amniotic Fluid-Derived Stem Cells isolation 
The use of AFDSCs for the treatment of congenital anomalies has great potential, but in 
most cases is still far from clinical applications. Nerveless there is at least one case in which 
cells derived from amniotic fluid have been successfully used for tissue engineering. 
Mesenchymal cells isolated from amniotic fluid have been expanded in vitro using a 
chondrogenic medium and than seeded into a biodegradable scaffold and maintained in a 
rotating bioreactor (Kunisaki SM et al., 2006). The cells used in this report were not 
specifically analyzed for pluripotency or selected for specific markers, and were considered 
progenitor cells by the authors. Being a mixed population of cells they likely contained both 
committed lineages and AFDSCs, but most importantly they were able to differentiate into 
cartilage in vitro into a three-dimensional scaffold and maintain these characteristics for as 
long as fifteen weeks.  
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range from 6um to 50um and the shape can vary notably from round to squamous in 
morphology (Siddiqui and Atala, 2004).  
 
 
Fig. 3. Kidney amniotic fluid cells 
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the same time, organ specific markers start to become highly expressed. A full proteome 
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Fig. 4. Diagram for Amniotic Fluid-Derived Stem Cells isolation 
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5. Amniotic fluid stem cells 
Within amniotic fluid are a menagerie of cells previously described as AFDSCs, however 
approximately 1% of the cells contained within the fluid have been identified and 
designated as amniotic fluid stem cells (AFSC). AFSCs represent the most characterized 
clonal population of pluripotent stem cells isolated from amniotic fluid. AFSCs can be 
isolated by immunoselection with magnetic microsphere or FACS for the receptor for stem 
cell factor (c-Kit or CD117). The clonal origin of these cells was tested by integration of a 
single provirus (CMMP-eGFP) and analysis of subclones. Analysis of the subclones grown 
at limiting dilution maintained the signature integration at the same position (a 4 kilobase 
BamH1 fragment). The sublones were able to differentiate into lineages representative of the 
three embryonic germ layers. After isolation AFSCs will grow slowly for about one week 
(this phenomenon differs in AFSCs isolated at different gestational stages), and will then 
start to proliferate faster following this initial ‘lag-phase’ (Siddiqui MM and Atala A, 2004). 
AFSCs grow in absence of feeder layer when plated on Petri dishes and have a doubling 
time of about 36 hours (De Coppi et al, 2007).   The isolated population can then be cultured 
quite readily on plastic or glass.  If maintained at a sub-confluent state, AFSCs do not 
differentiate. Clones should be cultured in medium containing -minimal essential medium 
supplemented with 20% Chang-B and 2% Chang-C solutions, 20% fetal bovine serum (FBS), 
1% L-glutamine, and 1% antibiotics. Clones should be periodically monitored for the 
presence of a correct karyotype, and for the expression of specific markers such as Oct4, 
SSEA4, CD29, CD44, and the absence of markers such as CD45, CD34, and CD133 (see De 
Coppi et al., 2007 for a complete list of specific markers). AFSCs are pluripotent and can be 
differentiate in vitro into several lineages (De Coppi et al., 2007; Siddiqui MM and Atala A, 
2004).  Numerous groups have reported the high renewal capacity of these cells without 
differentiation or loss of telomere length (Da Sacco et al., 2010). 
 
 
Fig. 5. Amniotic Fluid Stem Cells 
Human amniotic fluid stem cells (left) and mouse amniotic fluid stem cells (right) that were 
isolated via selection for the surface marker CD117.  Both cells have similar phenotypes (40X 
magnification). 
5.1 Differentiation of amniotic fluid stem cells 
C-kit positive amniotic fluid stem cells are pluripotent and have been successfully 
differentiated into all three germ layer cell types: endoderm, ectoderm and mesoderm.  
 
Amniotic Fluid Stem Cells 
 
499 
From these pluripotent cells, various phenotypes have been derived in vitro.  Osteogenic, 
endotheilial, hepatic, neurogenic, adipogenic and myogenic progenitor cell lines are a few of 
the lineages derived to date. Derivation of these lines has been verified by morphogenesis, 
phenotypic analysis and a litany of biochemical assays for characteristic of each cell type.  
Culture and manipulation of these cells into various progenitors has become so streamlined, 
that various standard protocols have been established (Delo et al., 2006). Although a 
significant milestone, differentiation of AFSC into various lineages in vitro is quite distinct 
from the in vivo potential, use and efficacy of these cells.  Transplantation of these cells into 
a living system, or the use of these cells to create a functional organ hinge on the ability of 
these cells not simply to survive in vivo, however; success is dependant on the physiological 
functionality of these cells to perform within the anatomy.  The future of regenerative 
medicine and cellular therapy hinges on this principle, and not surprisingly, AFSC have also 
shown remarkable capabilities in vivo in numerous organs. 
5.1.1 Hematopoietic system 
AFSC expressing CD117+ and Lin-, derived from both human and mouse, have been shown 
to have hematopoietic potential (Ditadi A et al., 2010). These cells were capable of 
differentiating into erythroid, myeloid, and lymphoid lineages in vitro as well as in vivo, in 
the peripheral blood of irradiated mice. Furthermore, single cells analysis was able to assess 
the expression of several genes important during different stages of hematopoietic 
differentiation.  
5.1.2 Brain 
A fully mature neural differentiation remains to be tested for cells derived from amniotic 
fluid. Neural differentiation was fist reported during the initial identification of AFSCs (De 
Coppi et al., 2007). Subsequently, a study for the differentiation of AFSCs into dopamine 
neurons (Donaldson AE et al., 2009), showed that AFSCs express specific markers of neural 
progenitors and immature dopamine neurons, but were unable to fully differentiate in vitro 
or in vivo. Analyzing other cell lines isolated from amniotic fluid (McLaughlin D et al., 2006) 
it was shown that phenotypic characteristics of dopaminergic neurons are present, while 
markers for other neurons, like cholinergic, GABAergic, and adrenergic were absent or had 
a weak expression.  
5.1.3 Bone 
AFSC cultured with an osteogenic medium, can secrete alkaline phosphatase and produce 
mineralized calcium, characteristic of functional osteoblasts. Furthermore, when implanted 
into an immunodeficient mouse, AFSC where able to produce mineralized tissue in vivo (De 
Coppi et al., 2007). A comparison between AFDSCs and bone morrow-derived stem cells 
(MSCs), has shown that while MSCs undergo a faster differentiation, AFDSCs can maintain 
and increase the mineralization for a longer period (Peister A et al., 2011). 
5.1.4 Kidney 
AFSC therapy in the kidney is progressing quickly and is arguably at the forefront of AFSC 
research.  Research groups using AFSC in kidney have not only been able to demonstrate 
the ability of AFSC to populate the kidney and form renal structures, but also to protect the 
kidney during injury and aid in the regeneration of renal tissue.  The groundbreaking 
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studies, which follow, paved the way for much of the other organ specific experimentation, 
in particular, that of the lung.  
In the embryonic kidney, AFSC have been shown to differentiate into tubular and 
glomerular structures and express characteristic kidney cell markers and genes (Perin et al., 
2007).  In this study, metanephric kidneys were isolated from embryonic mice, microinjected 
with approximately 1000 CM-dil labeled c-kit positive AFSC and placed on a membrane for 
cultivation in an incubator.  What is remarkable is that even though the embryonic kidney 
was not fully formed at the beginning of the experiment, labeled AFSC were seen to 
integrate into developing C and S-shaped structures at day 5, and at day 6, integrated into 
tubular and glomerular structures.  Reverse transcriptase-PCR for human kidney specific 
genes, not previously expressed by the AFSC, identified expression of ZO-1, claudin and 
glial-derived neurotrophic factor were detected.  This experiment showed the ability of 
AFSC to survive within developing tissue, engraft into that tissue, differentiate into the 
appropriate cell type and aid in the population of an organ.  
Furthermore, it has recently been discovered that AFSC injected into the acutely injured 
kidney stimulate the release of anti-inflammatory cytokines and attenuate pro-inflammatory 
signaling greatly reducing apoptosis and allowing for proliferation and repopulation of 
injured epithelia (Perin L. et al., 2011).  In this study, nude mice, deprived of water for a 
period of 22 hours, were given an intramuscular injection of a 50% hypertonic glycerol 
solution in water.  This type of injury induces rhabdomyolysis-related acute tubular necrosis 
(ATN) ultimately resulting in renal dysfunction.  Following intrarenal injection of 1.2x106 
cells, AFSC were observed, via luciferase, to persist at the site of injury most notably at 48 
and 72 hours, with persistence in the kidneys for up to 6 days.  Additionally, analysis of the 
cytokine milieu showed the markedly different expression patterns of cytokines at 14 days 
post transplant. Mice with ATN only, and no AFSC transplant, showed a general trend of 
increased pro-inflammatory cytokines and decreased anti-inflammatory cytokine 
expression.  On the other hand, mice with ATN and intra-renal injection of AFSC 
demonstrated that the anti inflammatory cytokines increased over the 14 day study period, 
while pro-inflammatory cytokines decreased. In another study after glycerol-induced acute 
kidney injury (Hauser PV et al., 2010) a comparison between mesenchymal stem cells 
(MSCs) and AFSCs has shown that while MSCs where mainly inducing proliferation, AFSCs 
had an antiapoptotic effect. Thus, these data suggests that AFSCs responds in a paracrine 
manner in response to injury and/or stress, and modulation of immune signaling is what 
contributes to the alleviation of symptoms associated with the injury.   
5.1.5 Lung 
In utero, the developing lungs of the fetus are filled with fetal lung liquid which is actively 
secreted into the amniotic fluid.  In the late gestational period, surfactant produced by the 
fetal lungs contributes to the composition of amniotic fluid and can be measured to 
determine the developmental stage of the surfactant system within the fetal lungs.  Thus, it 
makes sense that when looking for regenerative therapies for lung tissue, AFSC are a logical 
source. 
In our preliminary transplantation studies, it was found that c-kit positive AFSC can 
incorporate into mouse embryonic lung and express human lung epithelial cell markers 
(Carraro, et al., 2008).  In the same study, following naphthalene injury in nude mice, and 
intravenous transplantation of 1x106  AFSC, cells were observed to preferentially remain at 
the site of injury when compared to uninjured controls when visualized via luciferase assay.  
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Additionally, following oxygen injury in the lung it was observed that AFSC appear to 
exhibit alveolar epithelial type II phenotypes, widely surmised to be a lung epithelial stem 
cell, suggesting that once in the lung these cells are stimulated to differentiate in response to 
injury.  Furthermore, in vivo, the efficiency of AFSC diapedesis, integration and expression 
in upper and lower airway epithelia is increased following injury.  After oxygen injury, 
AFSC were observed to be taken into the SP-C positive alveolar epithelial lineage, whereas 
after naphthalene injury AFSC are taken up into the CC10-positive Clara cell lineage.  AFSC 
presence persisted in the lung after injury, but decreased over time.  Although integration 
into the adult lung following injury is a relatively rare event, additional therapeutic 
mechanisms displayed by these cells, such as the modulation of the inflammatory milieu 
and their differentiation into type II lineages demonstrate great potential in the stimulation 
of lung repair mechanisms.  
Lung researchers have also begun investigating the potential of seeding AFSC on a scaffold 
to regenerate tissue for transplantation.  Due to the overwhelming shortage of donor lungs, 
and the inability of modern medicine to effectively treat or halt many progressive lung 
diseases such as idiopathic pulmonary fibrosis, research focus has shifted to the 
bioengineering of functional lung tissue.  Decellularization of lungs, where all cells are 
removed from the extracellular matrix of an organ, has become an investigational target.  In 
2010 a whole lung decellularization method and tissue engineering study using neonatal 
lung epithelia was reported (Peterson et al., 2010).  What is remarkable about this study is 
that while it has long been known that epithelial cells seeded on a decellularized lung 
matrix were capable of forming alveolar epithelia, this study demonstrated the functionality 
of the regenerated tissue.  The decellularized, repopulated and regenerated lungs were 
transplanted into a rat and were able to support short-term perfusion and gas exchange.  In 
another study, researchers were able to seed not only epithelium, but also endothelium as 
well on a decellularized rat lung.  Following transplantation, blood gas analysis of the 
engineered lung demonstrated that the lung was capable of gas exchange (Ott et al., 2010).  
Thus decellularized lung matrix seems currently to be the most promising scaffold for 
whole lung regeneration and the possibility of using an autologous source of stem cells such 
as AFSC to repopulate the scaffold could have great potential in the future. 
5.1.6 Heart  
The use of AFSC as a regenerative therapy for cardiac disease and congenital disorders has 
shown the efficacy of transplanted cells providing both cardio protective potential, as well 
as the engineering of various cardiac components such as valves and tissue (Bollini et al., 
2011; Schmidt et al., 2007; & Hilkfer et al., 2011).  
The engineering of heart valves, obtained from normal human amniotic fluid samples, 
sorted via positive selection for the CD133 molecule, was elegantly demonstrated in 2007 
(Schmidt et al., 2007). Both CD 133 positive and negative cell populations were cultured in 
media that caused differentiation towards endothelial phenotypes. CD133+ cell 
populations showed the ability to produce functional endothelial cells indicated by the 
expression of eNOS and CD141, while CD133- cells displayed a more mesenchymal 
phenotype.  CD133- cells were then seeded on biodegradable PGA leaflets that were 
positioned within a mold to form a valve structure.  After 14 days, CD133+ cells were 
seeded onto the scaffold as well. While regeneration of both extracellular matrix and 
endothelial layers were generated, functional testing revealed that the heart valves were 
sufficiently functional only under low-pressure conditions.  This failure to perform at 
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physiological levels was not due to the scaffold material, which displayed linear 
properties prior to being seeded with cells, but instead was a result of the incomplete 
formation of collagen suggesting that the method of seeding and culture upon the 
biodegradable scaffolding needs to be optimized further to be able to transplant these 
engineered valves into patients. In an acute myocardial infarction model, ischemia, 
produced via ligation of the left anterior descending coronary artery, was followed with 
intravenous transplantation of AFSC and reperfusion of the heart for 2 hours.  Animals 
treated with 5x106 cells intravenously, showed a significant decrease in infarct size and 
number of apoptotic cardiomyocityes when compared to control animals administered 
saline alone (Bollini et al., 2011).  Staining to determine the localization and viability of 
transplanted AFSC showed that two hours post transplant, cells localized to the lung, 
spleen and heart.  AFSC within the heart co-stained for epithelia vWf and -SMA, 
suggestive of the potential of these cells to commit to endothelium and smooth muscle 
following transplant.  Long term retention and engraftment in the injured myocardial 
tissue did not occur however.  The secretion of thymosin beta 4 in vitro, a cardio 
protective factor, suggests that the transplantation of AFSC in this model exert a paracrine 
effect. 
5.2 Why use AFSC in regenerative medicine? 
When selecting a stem cell population for use in a regenerative or therapeutic capacity, there 
are a myriad of factors that need to be considered.  The pluripotentiality, the ability of the 
cells to differentiate into different germ layers and tissue types, is of fundamental 
importance if one is isolating cells to treat diseases or developmental deficiencies in which 
progenitor cells within the patient are compromised or overwhelmed.  Additionally, the 
plasticity of the cells and their ability to differentiate to repopulate different populations 
within an organ, and repopulate them correctly is crucial.  Furthermore, the behavior of the 
cells after injection must be carefully studied and characterized. Tumorogenicity, 
immunogenicity and the propensity to form teratomas and further exacerbate a disease state 
can rule out various cellular therapies simply due to risk.  To date, amniotic fluid stem cells 
have demonstrated the ability to meet all of these criteria and behave remarkably well in a 
regenerative and therapeutic capacity.  Amazingly pluripotent, less immunogenic, and not 
prone to teratoma formation, AFSCs have quickly risen near the top of the list of stem cell 
therapies to continue developing. 
Furthermore, recently induced pluripotent stem (iPS) cells have been prepared from cells 
derived from amniotic fluid (AF-iPS), and have shown high efficiency of transformation and 
colony formation after just six days (Li C et al., 2009). Although not fully understood, this is 
probably due to the presence of an epigenetic status closer to the embryonic state (Galende E 
et al., 2010). Reprogramming of somatic cells using the four specific factors, Oct4, Sox2, Klf4, 
and c-Myc has the potential to provide pluripotent stem cells specific for patients, thus AF-
iPS seem to be more easily reprogrammed to pluripotency compared to adult cells or cells 
from neonates.  
6. Conclusion 
The studies outlined in this chapter demonstrating the capability that AFSC have shown in 
vitro and in vivo show that AFSC are viable targets for regenerative medicine and for future 
therapeutic treatment strategies.  Although the relatively early stage of AFSC research limits 
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a full understanding of the behaviors, properties and characteristics of these fascinating 
cells, research to date demonstrates two important mechanisms of action that need to be 
investigated further.   
First, AFSC have the potential to serve as an in vivo treatment to stimulate endogenous cell 
populations, repopulate injured tissue or ameliorate inflammatory or disease states.  These 
properties are advantageous when dealing with disease or injury states in which there is 
enough functional tissue remaining in an organ to drive repopulation.  The only caveat to 
endogenous cellular stimulation is that the remaining tissue (that is being stimulated) must 
be functional, meaning that it is free of genetic disorders or mutations.  If remaining tissue 
within an organ meets these standards, exogenous AFSC transplantation can be used to 
stimulate endogenous progenitors to repopulate, protect progenitor or other cell types from 
further injury, or AFSC may be driven to differentiate to repopulate this tissue, as was 
indicated in the aforementioned embryonic studies.   
Second, AFSC have the potential to engineer whole organs in vitro to be transplanted into a 
recipient.  This strategy is advantageous in situations where, for whatever reason, enough 
functional tissue does not remain to repopulate with a cell transplant.  Whole organ re-
engineering, perhaps the holy grail of regenerative medicine, involves a symphony of 
factors, events and coordinated expression patterns to form intricate niche structures 
including endothelium, epithelium, extracellular matrix and so on.  The engineering of a 
whole organ will in fact require a much deeper understanding of these cells as signaling 
cascades and response elements need to be coordinated to engineer every cell type within a 
specific organ. However the recent findings of Kajtsura et al (2011) support the our notiion 
that the genome within a single stem cell type may prove to be sufficiently plastic to 
simultaneously derive all of the cell lineages required for complex organ repair or 
engineering. 
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